EANM'22

WORLD LEADING MEETING

BARCELONA

Oct 15 - 19, 2022



FINAL PROGRAMME

35th Annual Congress of the European Association of Nuclear Medicine

TABLE OF CONTENTS

WORDS OF WELCOME 4

GENERAL INFORMATION

» Board & Scientific Programme Council 6
» Session Coordinators 7
» EANM'22 Reviewers 8
» EANM'22 Chairpersons 12
» EANM National Societies: Delegates / Deputies 16
» UEMS/EBNM National Societies: Delegates / Deputies 18
» UEMS/EBNM Committees 21
» General Information 22
» About Barcelona 28
» Airport / Travel Information 32
» Programme Overview 37

SCIENTIFIC & TECHNOLOGISTS' PROGRAMME

» Plenary Sessions 46
» Continuing Medical Education/CME Sessions 48
» Technologists' Track 50
» Special Track 52
» Joint Symposia 53
» Special Sessions 53
» Learn & Improve Professional Skills (LIPS) Tracks 54
» Clinical Oncology Track 55
» Cutting Edge Science Track 56
» M2M - The 9th "From Molecule to Man" Track 57
» Further Oral Presentations 58
» e-Poster Presentations 60
» Awards 61

ORAL PRESENTATIONS 62

e-POSTER PRESENTATIONS 135

e-POSTER PRESENTATIONS e-POSTER SESSIONS 158

INDUSTRY EXHIBITION

» Satellite Symposia 211
» List of Exhibitors (A-Z) 219
» List of Exhibitors (Booth number) 225
» Exhibition Hall 231
» Company Profiles 233

CORPORATE MEMBERS 305

USEFUL CONTACTS 310

IMPRINT 310

EANM'22 WORLD LEADING MEETING
OCTOBER 15 - 19, 2022

TABLE OF CONTENTS | FINAL PROGRAMME

WORDS OF WELCOME

BY THE CONGRESS CHAIR



STEFANO FANTI

CONGRESS CHAIR 2020-2022

On behalf of the European Association of Nuclear Medicine, it is my great honour to invite you to the 35th Annual EANM Congress. The event will finally be held in person from October 15-19, 2022 in Barcelona, Spain. After two years of virtual events, we are now incredibly happy to be hosting the Congress in its usual and much missed onsite format.

The last two years have been challenging for the entire world due to the pandemic. This has been especially true for those who work in healthcare, as we all do. Nevertheless, nuclear medicine has experienced incredible growth, both in diagnostic imaging and therapy. We have seen exciting innovations in every area of our specialist field: new whole-body PET tomographs are now being used clinically, PSMA tracers have been incorporated into clinical guidelines and excellent trials of theranostic radiopharmaceuticals were presented and published. Furthermore, many other new radiopharmaceuticals, which facilitate the study and treatment of new targets, are being introduced, with more and more protocols addressing unmet clinical needs and new applications. This success remains related to that very peculiar characteristic of our specialist field, namely its functional approach to medicine, and we really feel the need to celebrate all such achievements and innovations with a real congress as we used to do.

We proudly celebrated the status of the EANM Congress as the world's leading meeting for nuclear medicine when we reached almost 7000 participants in 2019. The high early registration numbers for 2022 prove that the 'in-person' Congress was missed very much and that the opportunities to interact and network were not comparable online. So, take the chance to meet your colleagues around the world as well as our industry partners. The exhibition is sold out, and the participating companies are looking forward to finally meeting you in person again. Take your time and stroll through the stands of both familiar and new companies.

We will be returning to the usual format this year at one of our favourite venues – Barcelona. We decided to implement many new interactive features, including a completely new room setup, called "the Arena". Here, the participants are close to the speakers and are invited to interactively participate during our two new session formats: "the Debate" and "Challenge the Expert". Other innovations were already introduced last year and are now ready to be experienced live: the Highlights Lecture during the Opening Ceremony and the new Plenaries format, with many, short focused lectures led by key opinion leaders on the hottest topics. We also have special sessions dedicated to the Best Trials and Case Reports submitted from around the world. A completely new feature is the "Battle and Win!" session, in which six selected participants will battle for the Sam Gambhir Award. Don't miss it!

In summary, we are planning a great live event for October where we will finally come together again, and delight you with a well-orchestrated balance of science, education and entertainment. We have been working hard to provide you with a Congress filled with superb and comprehensive scientific content as well as numerous other innovative features to make your participation truly memorable.

Stefano Fanti

BOARD & SCIENTIFIC PROGRAMME COUNCIL

EANM BOARD

President 2021 - 2022
Jolanta Kunikowska (Poland)

President Elect 2021 - 2022
Rudi A.J.O. Dierckx (Netherlands)

Committee Coordinator 2021 - 2022
Roland Hustinx (Belgium)

Congress Chair 2020 – 2022
Stefano Fanti (Italy)

Education Chair 2020 – 2022
Paola A. Erba (Italy)

Secretary/Treasurer 2021 - 2022
Wolfgang Wadsak (Austria)

Scientific Liaison Officer 2021 - 2022
Michael Lassmann (Germany)

SCIENTIFIC PROGRAMME COUNCIL

Congress Chair 2020 – 2022
Stefano Fanti (Italy)

Bone & Joint Committee
Salvatore Annunziata (Italy), Tim Van Den Wyngaert (Belgium)

Cardiovascular Committee
Mark Lubberink (Sweden), Fabien Hyafil (France)

Dosimetry Committee
Frederik Verburg (Netherlands), Silvano Gnesin (Switzerland)

Inflammation & Infection Committee
Giorgio Treglia (Switzerland), Olivier Gheysens (Belgium)

Neuroimaging Committee
Diego Cecchin (Italy), Silvia Morbelli (Italy)

Oncology & Theranostics Committee
Ken Herrmann (Germany), Matthias Eiber (Germany)

Paediatrics Committee
Pinar O. Kiratli (Türkiye), Pietro Zucchetta (Italy)

Physics Committee
John Dickson (United Kingdom), Dimitris Visvikis (France)

Radiation Protection Committee
Lidia Cunha (Portugal), Francois Jamar (Belgium)

Radiopharmaceutical Sciences Committee
Peter Laverman (Netherlands), Johnny Vercouillie (France)

Technologists Committee
Andrea Santos (Portugal), Agata Pietrzak (Poland)

Thyroid Committee
Alfredo Campenni (Italy), Michael Kreissl (Germany)

Translational Molecular Imaging & Therapy Committee
Margret Schottelius (Switzerland), Felix Motthagy (Germany)

SESSION COORDINATORS

SESSION COORDINATORS

EANM thanks all Session Coordinators for their huge engagement in organizing the session details and speakers.

Ambrosini, V. (Italy)
Brendel, M. (Germany)
Camoni, L. (Italy)
Carrilho Vaz, S. (Portugal)
Cicone, F. (Italy)
de Geus-Oei, L.-F. (Netherlands)
de Keizer, B. (Netherlands)
Denis-Bacelar, A. (United Kingdom)
Deroose, C. (Belgium)
Eiber, M. (Germany)
Fanti, S. (Italy)
Fragoso Costa, P. (Germany)
Gnanasegaran, G. (United Kingdom)
Gnesin, S. (Switzerland)
Gotthardt, M. (Netherlands)
Herrmann, K. (Germany)
Jamar, F. (Belgium)
Kedves, A. (Hungary)
Kreissl, M. (Germany)
Kurth, J. (Germany)
Laverman, P. (Netherlands)
Leccisotti, L. (Italy)
Luporsi, M. (France)
Massalha, S. (Israel)
Morbelli, S. (Italy)
Morland, D. (France)
Mottaghy, F. (Germany)
Nanni, C. (Italy)
Olsen, R. (Denmark)
Oprea-Lager, D. (Netherlands)
Pereira, L. (United Kingdom)
Pietrzak, A. (Poland)
Rbah-Vidal, L. (France)
Rischpler, C. (Germany)
Rogasch, J. (Germany)
Santos, A. (Portugal)
Saraste, A. (Finland)
Terwinghe, C. (Belgium)
Testanera, G. (United Kingdom)
Tuncel, M. (Türkiye)
Turco, P. (Italy)
Visvikis, D. (France)
Wadsak, W. (Austria)

EANM'22 REVIEWERS

Abgral, R. (France)
Acampa, W. (Italy)
Adam, J. (Netherlands)
Ahmadzadehfar, H. (Germany)
Akdemir, U. Ö. (Türkiye)
Albano, D. (Italy)
Aloj, L. (United Kingdom)
Altini, C. (Italy)
Ambrosini, V. (Italy)
Ametamey, S. (Switzerland)
Annunziata, S. (Italy)
Antunovic, L. (Italy)
Atay Kapucu, L. Ö. (Türkiye)
Balkay, L. (Hungary)
Bar-Sever, Z. (Israel)
Bardiès, M. (France)
Barthel, H. (Germany)
Bauckneht, M. (Italy)
Beer, A. (Germany)
Beheshti, M. (Germany)
Bergström, K. (Finland)
Bernsen, M. (Netherlands)
Berti, V. (Italy)
Bilgin, B. E. (Türkiye)
Bogović Crnčić, T. (Croatia)
Booij, J. (Netherlands)
Botelho, M. F. R. (Portugal)
Bozkurt, M. F. (Türkiye)
Brendel, M. (Germany)
Brouwers, A. H. (Netherlands)
Buchert, R. (Germany)
Burroni, L. (Italy)
Buvat, I. (France)
Cai, W. (United States Of America)
Camoni, L. (Italy)
Caobelli, F. (Switzerland)
Carrilho Vaz, S. (Portugal)
Castellucci, P. (Italy)
Ceci, F. (Italy)
Cerci, J. (Brazil)
Cermik, T. F. (Türkiye)
Chiesa, C. (Italy)
Chiti, A. (Italy)
Chouin, N. (France)
Cicone, F. (Switzerland)
Cook, G. J.R. (United Kingdom)
Cornelissen, B. (United Kingdom)
Costa, G. M. L. M. (Portugal)
Cremonesi, M. (Italy)
Crivellaro, C. (Italy)
Dalm, S. (Netherlands)
Daou, D. (France)
De Geus-Oei, L.-F. (Netherlands)
de Keizer, B. (Netherlands)
De Palma, D. (Italy)
de Swart, J. (Netherlands)
de Vries, E. F. J. (Netherlands)
Deandreis, D. (Italy)
Decristoforo, C. (Austria)
Delgado-Bolton, R. C. (Spain)
Derlin, T. (Germany)
Deroose, C. (Belgium)
Deuther-Conrad, W. (Germany)
Dickson, J. (United Kingdom)
Drzezga, A. (Germany)
Eberlein, U. (Germany)
Eiber, M. (Germany)
Ellis, B. (United Kingdom)
Evangelista, L. (Italy)
Farolfi, A. (Italy)
Fendler, W. (Germany)
Fernández Léon, A. (Spain)
Ferrari, C. (Italy)
Flux, G. (United Kingdom)
Forrer, F. (Switzerland)
Forsback, S. (Finland)
Fragoso Costa, P. A. (Germany)
Fraioli, F. (United Kingdom)
Frangos, S. (Cyprus)
Gafita, A. (Germany)
Gallowitsch, H.-J. (Austria)
Geliashvili, T. (Russia)
Georgoulias, P. (Greece)
Gheysens, O. (Belgium)
Giammarile, F. (France)
Gillings, N. (Denmark)
Gimelli, A. (Italy)
Giovanella, L. (Switzerland)
Girotto, N. (Croatia)
Glatting, G. (Germany)
Glaudemans, A. (Netherlands)
Gnanasegaran, G. (United Kingdom)
Goffin, K. (Belgium)
Gotthardt, M. (Netherlands)
Gourni, E. (Switzerland)
Graf, S. (Austria)
Graham, R. (United Kingdom)
Grana, C. M. (Italy)
Gratz, S. (Germany)
Grötzinger, C. (Germany)
Guedj, E. (France)
Haberkorn, U. (Germany)
Halldin, C. (Sweden)
Hany, T. (Switzerland)
Hartman, N. (United Kingdom)
Herrmann, K. (Germany)
Hess, S. (Denmark)
Hesse, S. (Germany)
Hicks, R. (Australia)
Hindorf, C. (Sweden)
Hofman, M. (Australia)
Holm, S. (Denmark)
Howell, R. (United States Of America)
Hubalewska-Dydejczyk, A. (Poland)
Hyafil, F. (France)
Iagaru, A. (United States Of America)
Jamar, F. (Belgium)
Kirac, S. (Türkiye)
Kirienko, M. (Italy)
Kirjavainen, A. (Finland)
Kiss, O. (Germany)
Kluge, R. (Germany)
Kolenc Peitl, P. (Slovenia)
Konijnenberg, M. W. (Netherlands)
Koranda, P. (Czech Republic)
Koutsikos, J. (Greece)
Kráčmerova, T. (Czech Republic)
Kraeber-Bodéré, F. (France)
Krämer, S. (Switzerland)
Kreissl, M. (Germany)
Kresnik, E. (Austria)
Kucuk, Nuriye O. (Türkiye)

EANM'22 REVIEWERS

Kurch, L. (Germany)
Kurth, J. (Germany)
Lairez, O. (France)
Langbein, T. (Germany)
Langer, O. (Austria)
Lasnon, C. (France)
Lavelli, V. (Italy)
Laverman, P. (Netherlands)
Leccisotti, L. (Italy)
Lemos Pereira, E. A. (Portugal)
Lewington, V. (United Kingdom)
Lindner, O. (Germany)
Lodi, F. (Italy)
Lubberink, M. (Sweden)
Luporsi, M. (France)
Maes, A. (Belgium)
Maldonado, A. (Spain)
Manevska, N. (North Macedonia)
Marcassa, C. (Italy)
Marengo, M. (Italy)
Massalha, S. (Israel)
Mihailovic, J. (Serbia)
Milan, E. (Italy)
Mindt, Thomas L. (Austria)
Minguez Gabiña, P. (Spain)
Mitjavila Casanovas, M. (Spain)
Monteiro, M. (Switzerland)
Morbelli, S. (Italy)
Morigi, Joshua J. (Australia)
Morland, D. (France)
Mottaghy, F. (Germany)
Mu, L. (Switzerland)
Nanni, C. (Italy)
Nekolla, S. (Germany)
Nock, B. A. (Greece)
Noriega Alvarez, E. (Spain)
Ocak, E. M. (Türkiye)
Olianti, C. (Italy)
Oprea-Lager, D.-E. (Netherlands)
Orlhac, F. (France)
Orrù, M. T. (Italy)
Oszlanszki, A. (Hungary)
Ozgen Kiratli, P. (Türkiye)
Palmedo, H. (Germany)
Palmieri, A. (Italy)
Panagiotidis, E. (Greece)
Papathanasiou, N. (Greece)
Pappata, S. (Italy)
Pascual, T. (Austria)
Paycha, F. (France)
Payoux, P. (France)
Pereira, L. (United Kingdom)
Petranović Ovčariček, P. (Hungary)
Piciu, D. (Romania)
Pietrzak, A. K. (Poland)
Pilkington, P. (Spain)
Pirich, C. (Austria)
Poeppel, T. (Germany)
Pruim, J. (Netherlands)
Rac, S. (Croatia)
Rajkovaca, Z. (Bosnia And Herzegovina)
Rausch, I. (Austria)
Redondo, F. (Chile)
Rep, S. (Slovenia)
Resende Geão, A. C. (Portugal)
Rijpkema, M. (Netherlands)
Rischpler, C. (Germany)
Rodríguez-Fraile, M. (Spain)
Rogasch, J. (Germany)
Roivainen, A. (Finland)
Rominger, A. (Switzerland)
Rouzet, F. (France)
Salaun, P.-Y. (France)
Sandstrom, M. (Sweden)
Santos, A. I. (Portugal)
Santos, A. (Portugal)
Saraste, A. (Finland)
Sattler, B. (Germany)
Saxtoft, E. (Denmark)
Schäfers, M. (Germany)
Schibli, R. (Switzerland)
Schmidt, E. (Hungary)
Schottelius, M. (Switzerland)
Schwarzenböck, S. (Germany)
Sciagrà, R. (Italy)
Seimbille, Y. (Netherlands)
Semah, F. (France)
Sera, T. (Hungary)
Shi, K. (Switzerland)
Siclari, G. (Italy)
Signore, A. (Italy)
Slart, R. (Netherlands)
Smith, G. (United Kingdom)
Sollini, M. (Italy)
Stefanescu, C. (Romania)
Stevens, H. (Netherlands)
Stokke, C. (Norway)
Stokkel, M. (Netherlands)
Strigari, L. (Italy)
Strobel, K. (Switzerland)
Strömvall, A. L. (Sweden)
Sunderland, J. (United States Of America)
Teräs, M. (Finland)
Terry, S. (United Kingdom)
Terwinghe, C. (Belgium)
Testanera, G. (United Kingdom)
Tolboom, N. (Netherlands)
Tosi, G. (Italy)
Tran-Gia, J. (Germany)
Treglia, G. (Switzerland)
Tuncel, M. (Türkiye)
Turco, P. (Italy)
Ugrinska, A. (North Macedonia)
Van den Wyngaert, T. (Belgium)
van Velden, F. H. P. (Netherlands)
Van Weehaeghe, D. (Belgium)
Vandenberghe, S. (Belgium)
Vanhove, C. (Belgium)
Varmenot, N. (France)
Veit-Haibach, P. (Canada)
Verberne, H. J. (Netherlands)
Verburg, F. (Germany)
Versari, A. (Italy)
Violante, L. (Portugal)
Vlajkovic, M. (Serbia)
Vrachimis, A. (Cyprus)
Walz, J. (France)
Weber, W. (Germany)
Weiler-Sagie, M. (Israel)
Zambo, K. (Hungary)
Zerizer, I. (United Kingdom)
Zhang-Yin, J. (France)

EANM'22 CHAIRPERSONS

(AS PER SEP 12, 2022)

EANM thanks all Session Coordinators for their huge engagement in organizing the session details and speakers.

Adam, J. (Netherlands)
Al-Hibrahim, A. (Jordan)
Albano, D. (Italy)
Ambrosini, V. (Italy)
Anders, O. (Sweden)
Antunovic, L. (Italy)
Aparici, C. M. (United States of America)
Artigas, C. (Belgium)
Assadi, M. (Iran, Islamic Republic of)
Atay, L. Ö. (Türkiye)
Balogova, S. (Slovakia)
Barwick, T. (United Kingdom)
Bashir, H. (United Kingdom)
Béhé, M. (Switherland)
Berti, V. (Italy)
Boubaker, A. (Switzerland)
Brendel, M. (Germany)
Brouwers, A. (Netherlands)
Buckle, T. (Netherlands)
Buteau, J. P. (Australia)
Cai, W. (Madison)
Campenni', A. (Italy)
Caobelli, F. (Switzerland)
Carrilho Vaz, S. (Portugal)
Casanueva Eliceiry, S. (Spain)
Castellucci, P. (Italy)
Catalano, O. (United States of America)
Cecchin, D. (Italy)
Ceci, F. (Italy)
Cicone, F. (Italy)
Cleeren, F. (Belgium)
Cunha, L. (Portugal)
de Geus-Oei, L.-F. (Netherlands)
de Keizer, B. (Netherlands)
Deandreis, D. (Italy)
Denis-Bacelar, A. (United Kingdom)
Deroose, C. (Belgium)
Dickson, J. (United Kingdom)
Eberlein, U. (Germany)
Ekmekcioglu, Ö. (Türkiye)
Elisei, R. (Italy)
Elvas, F. (Belgium)
Emmet, L. (Australia)
Erba, P. (Italy)
Evangelista, L. (Italy)
Fani, M. (Switzerland)
Fanti, S. (Italy)
Farolfi, A. (Italy)
Federspiel, M. (Denmark)
Ferrari, C. (Italy)
Flotats Giralt, A. (Spain)
Fragoso Costa, P. (Germany)
Gambhir, A. (United States of America)
Garcia Canamaque, L. (Spain)
Garcia, O. (Mexico)
Garibotto, V. (Switzerland)
Geao, Ana C. (Portugal)
Gear, J. (United Kingdom)
Geist, B. (Austria)
Georgoulias, P. (Greece)
Gheysens, O. (Belgium)
Giannoula, E. (Greece)
Gilmore, D. (United States of America)
Glaudemans, A. (Netherlands)
Gnanasegaran, G. (United Kingdom)
Gnesin, S. (Switzerland)
Goffin, K. (Belgium)
Gotthardt, M. (Netherlands)
Gourni, E. (Switzerland)
Guedj, E. (France)
Haberkorn, U. (Germany)
Hatt, M. (France)
Hendrikse, H. (Netherlands)
Herrmann, K. (Germany)
Herth, M. (Denmark)
Hess, S. (Denmark)
Holm, S. (Denmark)
Hustinx, R. (Belgium)
Hyafil, F. (France)
Iagaru, A. (United States of America)
Iakovou, I. (Greece)
Ilhan, H. (Germany)
Imbert, L. (France)
Jamar, F. (Belgium)
Kalnina, M. (Latvia)
Kedves, A. (Hungary)
Kiratli, P. O. (Türkyie)
Kirienko, M. (Italy)
Kiss, O. (Germany)
Konijnenberg, M. (Netherlands)
Koole, M. (Belgium)
Kreissl, M. C. (Germany)
Kumar, R. (India)
Kuo, P. (United States of America)
Kurth, J. (Germany)
Lam, M. G. E. (Netherlands)
Larsson Strömvall, A. (Sweden)
Lauri, C. (Italy)
Laverman, P. (Netherlands)
Law, I. (Denmark)
Leccisotti, L. (Italy)
Lemos Pereira, E. (Portugal)
Lewington, V. (United Kingdom)
Loos, G. (Australia)
Lueckerath, K. (Germany)
Maccauro, M. (Italy)
Mackewn, J. (United Kingdom)
Massalha, S. (Israel)
Michalski, K. (Germany)
Mihailovic, J. (Serbia)
Morbelli, S. (Italy)
Morigi, J. (Australia)
Morland, D. (France)
Mottaghy, F. (Germany)
Nagarajah, J. (Netherlands)
Nanni, C. (Italy)
Nappi, C. (Italy)
Nekolla, S. (Germany)
Noriega Alvarez, E. (Spain)
Noriega-Álvarez, E. (Spain)
Øbro Fosbøl, M. (Denmark)
Olianti, C. (Italy)
Opalinska, M. (Poland)
Oprea-Lager, D. (Netherlands)
Orlova, A. (Sweden)
Oyen, W. G. (Netherlands)
Pabst, K. M. (Germany)
Patt, M. (Germany)
Petranović Ovčariček, P. (Croatia)
Piccardo, A. (Italy)
Pietrzak, A. (Poland)
Polycarpou, I. (Cyprus)

EANM'22 CHAIRPERSONS

Privé, B. (Netherlands)
Rbah-Vidal, L. (France)
Reynés Llompart, G. (Spain)
Rischpler, C. (Germany)
Rogasch, J. (Germany)
Roldao Pereira, L. (United Kingdom)
Roldão Pereira, L. (United Kingdom)
Rossi, A. (Switzerland)
Santos, A. (Portugal)
Santos, A. I. (Portugal)
Saraste, A. (Finland)
Sathekge, M. (South Africa)
Schenke, S. (Germany)
Schottelius, M. (Switzerland)
Seimbille, Y. (Netherlands)
Semah, F. (France)
Shi, K. (Switzerland)
Singh, B. (India)
Sjogreen-Gleisner, K. (Sweden)
Sjöholm, T. (Sweden)
Slart, R. (Netherlands)
Stokke, C. (Norway)
Strand Olsen, R. (Denmark)
Strigari, L. (Italy)
Stroet, M. (Belgium)
Taralli, S. (Italy)
Telo, S. (Italy)
Terwinghe, C. (Belgium)
Testanera, G. (United Kingdom)
Trägårdh, E. (Sweden)
Traub-Weidinger, T. (Austria)
Treglia, G. (Switzerland)
Troost, E. (Germany)
Tuncel, M. (Türkiye)
Turco, P. (Italy)
Uijen, M. (Netherlands)
Van Weehaeghe, D. (Belgium)
Vanhove, C. (Belgium)
Verburg, F. (Netherlands)
Vercauteren, S. (Belgium)
Verzijlbergen, F. (Netherlands)
Vidal-Sicart, S. (Spain)
Viera, S. (Belgium)
Virgolini, I. (Austria)
Visvikis, D. (France)
Vrachimis, A. (Cyprus)
Wadsak, W. (Austria)
Walz, J. (France)
Weber, W. (Germany)
Wild, D. (Switzerland)
Zucchetta, P. (Italy)

EANM 2022 Satellite Symposium

PSMA-targeted Theranostics: Towards Clinical Implementation in Advanced Prostate Cancer

Monday 17 October
13:15–14:45 CEST
Congress Centre Barcelona, Hall 211
Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain


Ken Herrmann (Chair)


Derya Tilki


Joe O'Sullivan


Valerie Lewington

Welcome and Introduction
Ken Herrmann (Chair)


Treatment Landscape and Future Horizons
Derya Tilki

Next Generation Imaging in Treatment Decisions
Ken Herrmann

Emerging PSMA-targeted Theranostics
Joe O'Sullivan

Panel Discussion: Multidisciplinary Approaches in Clinical Practice
Valerie Lewington & Ken Herrmann

Live Q&A Session



This symposium may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities
This symposium is not intended for US healthcare professionals

NOVARTIS

AAA-NP-GL-0256-22 | 09/22; P3 Number: AI2209279168

Advanced Accelerator Applications International S.A., Rue de la Tour de l'Ile 4, 1204 Geneva, Switzerland
© 2022 AAA, Geneva, Switzerland

Advanced Accelerator Applications
A Novartis Company

EANM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

SOCIETY	DELEGATE	DEPUTY
ARMENIAN SOCIETY OF NUCLEAR MEDICINE	A. V. Barsegian	M. Grigoryan
AUSTRIAN SOCIETY OF NUCLEAR MEDICINE	H.J. Gallowitsch	I. Virgolini
AZERBAIJAN SOCIETY OF NUCLEAR MEDICINE	F. Novruzov	A. Aliyev
BELGIAN SOCIETY OF NUCLEAR MEDICINE	F. Jamar	N. Withofs
BOSNIAN SOCIETY OF NUCLEAR MEDICINE	Z. Rajkovaca	D. Rozic
BRITISH NUCLEAR MEDICINE SOCIETY	R. Graham	S. Dizdarevic
BULGARIAN SOCIETY OF NUCLEAR MEDICINE	V. Hadziyska	L. Chavdarova
CROATIAN SOCIETY OF NUCLEAR MEDICINE	D. Snajder	to be nominated
CYPRUS SOCIETY OF NUCLEAR MEDICINE	D. Kyprianou	R.K. Demetriadou
CZECH SOCIETY OF NUCLEAR MEDICINE	M. Simanek	P. Koranda
DANISH SOCIETY OF CLINICAL PHYSIOLOGY AND NUCLEAR MEDICINE	L.T. Jensen	P. Hovind
DUTCH SOCIETY OF NUCLEAR MEDICINE	A. Glaudemans	R. Keijsers
ESTONIAN NUCLEAR MEDICINE SOCIETY	S. Nazarenko	K. Ulst
FINNISH SOCIETY OF NUCLEAR MEDICINE	H. Mussalo	K. Timonen
FRENCH SOCIETY OF NUCLEAR MEDICINE	F. Cachin	J.P. Vuillez
GERMAN SOCIETY OF NUCLEAR MEDICINE	B. J. Krause	K. Herrmann
GEORGE DE HEVESY HUNGARIAN SOCIETY OF NM	T. Gyorke	L. Pavics
GEORGIAN NUCLEAR MEDICINE SPECIALISTS ASSOCIATION	N. Shengelia	K. Shamatava
HELLENIC SOCIETY OF NUCLEAR MEDICINE & BIOLOGY	A. Fotopoulos	V.C. Prassopoulos
ICELANDIC SOCIETY OF NUCLEAR MEDICINE	to be nominated	to be nominated
IRISH NUCLEAR MEDICINE ASSOCIATION	M. O'Connell	R. Killeen

SOCIETY	DELEGATE	DEPUTY
ISRAELI SOCIETY OF NUCLEAR MEDICINE	Z. Bar-Sever	Z. Keidar
ITALIAN SOCIETY OF NUCLEAR MEDICINE	R. Giubbini	M. Kirienko
LATVIAN SOCIETY OF NUCLEAR MEDICINE	M. Kalnina	J. Kedrova
LITHUANIAN SOCIETY OF NUCLEAR MEDICINE	S. Sediene	D. Vajauskas
LUXEMBOURG SOCIETY OF NUCLEAR MEDICINE	C. Als	J. Zhang-Yin
MACEDONIAN SOCIETY OF NUCLEAR MEDICINE	D. Miladinova	A. Ugrinska
MALTESE ASSOCIATION OF RADIOLOGISTS AND NUCLEAR MEDICINE PHYSICIANS	M. A. Aquilina	A. Mallia
NORWEGIAN SOCIETY OF NUCLEAR MEDICINE	T.C. Adamsen	R. Sundset
POLISH SOCIETY OF NUCLEAR MEDICINE	A. Sowa-Staszczak	A. Pietrzak
PORTUGUESE SOCIETY OF NUCLEAR MEDICINE	A. P. Moreira	R. Silva
ROMANIAN SOCIETY OF NUCLEAR MEDICINE	D. Piciu	C. R. Stolniceanu
SERBIAN NUCLEAR MEDICINE SOCIETY	J. Mihailovic	V. Artiko
SLOVAK SOCIETY OF NUCLEAR MEDICINE	L. Kaliska	E. Takacsova
SLOVENIAN SOCIETY OF NUCLEAR MEDICINE	I. Zagar	K. Zaletel
SPANISH SOCIETY OF NUCLEAR MEDICINE	L. Garcia	R. Ruano Perez
SWEDISH SOCIETY OF NUCLEAR MEDICINE	E. Tragardh	A. Stromvall Larsson
SWISS SOCIETY OF NUCLEAR MEDICINE	F. Forrer	M. Wissmeyer
TURKISH SOCIETY OF NUCLEAR MEDICINE	Z. Ozcan	L. O. Atay
UKRAINIAN SOCIETY OF NUCLEAR MEDICINE	to be nominated	to be nominated

UEMS/EBNM NATIONAL SOCIETIES: DELEGATES / DEPUTIES

Nominated from full UEMS Member Countries


COUNTRY	DELEGATE	DEPUTY
AUSTRIA	A. Kurtaran	R. Lipp
BELGIUM	K. Spaepen	G. Moulin-Romsee
BULGARIA	E. Piperkova	A. D. Tzonevska
CROATIA	D. Huic	S. Kusacic Kuna
CYPRUS	R. K. Demetriadou	
CZECH REPUBLIC	O. Lang	M. Kaminek
DENMARK	S. Hess	L. T. Jensen
ESTONIA	E. Kelk	A. Poksi
FINLAND	H. Mussalo	A. Loimaala
FRANCE	E. Gremillet	J.-L. Pelletier
GERMANY	W. Brenner	M. Gotthardt
GREECE	S. Koukouraki	I. Iakovou
HUNGARY	L. Pavics	I. Szilvasi
IRELAND	S. Skehan	R. Mcdermott
ITALY	B. Palumbo	A. Ciarmiello
LATVIA	I. Vevere	A. Berzina
LITHUANIA	D. Vajauskas	N. Jurkiene
LUXEMBOURG	P. Paulus	M. Doat
MALTA	A. Samuel	M. A. Aquilina
NETHERLANDS	R. J. Bennink	L. F. de Geus-Oei
NORWAY	A.J. Midha	M.-E. Revheim
POLAND	M. Dziuk	B. Birkenfeld
PORTUGAL	L. Salgado	T. Cruz Ferreira
ROMANIA	G. Andries	R. Mititelu
SERBIA	V. Artiko	J. Mihailovic
SLOVAKIA	A. Vondrak	
SLOVENIA	M. Grmek	D. Hrastnik
SPAIN	A. Sorriano	F. Pons
SWEDEN	E. Trägårdh	P. Grybäck
SWITZERLAND	A. Boubaker	G. Goerres
UNITED KINGDOM	Y. Du	S. Dizdarevic

Nominated from UEMS Associate Member Countries

COUNTRY	DELEGATE	DEPUTY
TÜRKIYE	Y. Yurekli	Z. Ozcan

Nominated from UEMS Observer Countries

COUNTRY	DELEGATE	DEPUTY
ISRAEL	A. Steinmetz	M. Quastel



UEMS/EBNM COMMITTEES

EXECUTIVE COMMITTEE

President	S. Mirzaei (Austria)
Secretary & Treasurer	R. Hustinx (Belgium)
Member	A. Boubaker (Switzerland)

FELLOWSHIP EXAMINATION

Chair	Z. Özcan (Türkiye)
Members	A. Boubaker (Switzerland)
	J. R. García Garzón (Spain)
	I. Kulakiene (Lithuania)
	S. Vaz (Portugal)

EDUCATION & SYLLABUS

Chair	R. Hustinx (Belgium)
Members	J. Darcourt (France)
	H. B. Sayman (Türkiye)
	D. Huic (Croatia)
	T. V. Bogsrud (Norway)
	P. Castellucci (Italy)

CME ACCREDITATION

Chair	M. Farsad (Italy)
Members	E. Lopci (Italy)
	A. Haug (Austria)
	S. Sillanmäki (Finland)

ACCREDITATION OF NUCLEAR MEDICINE DEPARTMENTS & TRAINING CENTRES

Chair	J. Prior (Switzerland)
Commitee Members	A. García-Burillo (Spain)
	N. Mutlukoca (Norway)
	P. A. L. Van Boxem (Belgium)
	M. L. Hall (United Kingdom)
Corresponding Members:	F. Giesel (Germany)
	A. Jiménez Heffernan (Spain)
	I. Sippo-Tujunen (Finland)
	N. G. Hartman (United Kingdom)
	S. E. Bouzoucef (Algeria)
	A. Ciarmiello (Italy)
	R. Zakavi (Iran)
	I. Iakovou (Greece)
	L. Torres (Cuba)

GENERAL INFORMATION



AUDIO & VIDEO RECORDINGS

Audio and/or video recordings during the congress are strictly prohibited and must not be made without prior written permission of the EANM Executive Office.

BARCELONA INFORMATION DESK

The Barcelona City Information Desk with a guide at the entrance level of the CCIB (Congress Centre) will be open:

Saturday, October 15, 2022:	16:00 - 18:00
Sunday, October 16, 2022:	09:00 - 18:00
Monday, October 17, 2022:	09:00 - 18:00
Tuesday, October 18, 2022:	09:00 - 18:00
Wednesday, October 19, 2022:	09:00 - 12:00

CANCELLATION

Conference Cancellation or Postponement

The EANM accepts no liability if an event is cancelled or postponed for reasons beyond its reasonable control resulting from an act of God, governmental regulation, fire, war, terrorist activity or civil commotion. If the EANM elects to re-schedule the conference, all registrations and additional items are automatically rolled over to the new dates of the conference. If the EANM elects to cancel the event, the liability is limited to a refund of registration costs, subject to fees and conditions. The EANM will not refund any travel costs associated with the cancellation of the event. Accommodation pre-payments will be refunded subject to the terms and conditions of the hotel.

CERTIFICATE OF ATTENDANCE

The EANM'22 Certificate of Attendance will be available in your myEANM area after submission of the overall EANM Congress evaluation.

CLOSING SESSION & FAREWELL COCKTAIL

All registered delegates and accompanying persons are cordially invited to the **Closing Session & Farewell Cocktail** on Wednesday, October 19, 2022, at 11:25-12:15.

The Closing Session will be held at the Auditorium of the CCIB and the subsequent Farewell Cocktail in the Foyer of the Auditorium.

CCIB – Centre de Convencions Internacional de Barcelona
Placa de Willy Brandt, 11-14
08019 Barcelona, Spain

Please note that only delegates and accompanying
persons wearing a valid congress name badge will be granted access.

CME CREDITS & CERTIFICATES

The EANM'22 Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 25 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

To acquire CME credits, attendees are required to scan their congress badge upon first arrival at the congress venue as well as upon entrance into each CME session. For CME sessions, an evaluation form must also be completed for each session attended. CME Sessions will be streamed live and are also available on-demand after the congress until December 20, 2022 (23:59 CET).

To obtain your CME certificate(s) please visit your myEANM area, in the section EANM'22 > Certificates, the certificate(s) will be available within 24 hours after you have scanned your congress badge.

COVID-19 SAFETY PROTOCOL

UPDATE: The EANM will abide by the regulations set by the Spanish Ministry of Health, therefore no COVID vaccination or PCR/Antigen tests will be mandatory to enter the congress venue.
We suggest wearing the FFP2 mask in closed rooms and to wash your hands frequently. Masks and hand sanitizer stations will be available on site.

Please be considerate of others and do not enter the congress venue if you have symptoms or have been diagnosed with COVID.

Kindly take note that if you are arriving from countries that do NOT belong to the European Union or are not considered Schengen associated countries you will have to provide an EU Digital COVID Certificate, the EU Equivalent or the SpTH QR to enter Spain, see all details here: **https://spth.gob.es/**

Please note that each individual participant is obliged to check the regulations that are in effect on date of entry. The EANM does not guarantee completeness of information stated on its homepage regarding current COVID regulations and is not liable for any short-term changes in said regulations.

CONGRESS BAG

All registered delegates (excluding accompanying persons and exhibitors) are entitled to receive a congress bag. Please pick up your congress bag at the congress bag distribution area by presenting your name badge.

CONGRESS e-POSTER AREA

As every year, the e-Poster Area gives you the possibility to see all uploaded e-Posters of EANM'22. You can search for authors, topics and keywords. The onsite e-Poster Area is located at Level P1, Room 128.
Additionally, you can access the e-Poster system also online via the virtual congress platform. The online access will remain open until December 20, 2022.

CONGRESS LANGUAGE

The congress language is English.
No simultaneous translation will be provided.

CONGRESS OFFICE

The congress office is located at level M2, Room M211/212 (at the CCIB – Congress Centre Barcelona) & will be open during the following days will be open during the following days and times:

Saturday, October 15, 2022:	07:30 - 18:00
Sunday, October 16, 2022:	07:30 - 18:00
Monday, October 17, 2022:	07:30 - 18:00
Tuesday, October 18, 2022:	07:30 - 18:00
Wednesday, October 19, 2022	07:30 - 12:00

CONGRESS SELF CHECK-IN

Self Check-In stations in the EANM Registration Area, located in the Entrance Hall, will help you to collect your name badge without waiting queues. Please make sure to bring your QR code and a personal ID.

CONGRESS VENUE

CCIB – Centre de Convencions Internacional de Barcelona / Barcelona International Convention Centre
Plaça de Willy Brandt, 11-14
08019 Barcelona, Spain
www.ccib.es/home

The CCIB is located at the seafront, located in the heart of the technology and business district. This unique congress centre is known for the originality of its architecture and column-free meeting halls with natural day light. It is in easy reach with the subway – line L4 (yellow line) until Maresme-Forum. Alternatively you can use the tram and bus – lines 7 and H16 until Forum.

For further information about the lines connected to the CCIB, please visit:
www.ccib.es/barcelona/#transport

DATES & DEADLINES

October 5, 2022:	Advanced Registration Deadline (after October 5, on-site registration fee)
October 15, 2022	Opening Ceremony and Welcome Reception
October 19, 2022	Closing Ceremony and Farewell Cocktail
December 20, 2022	Deadline for on-demand evaluation

EANM EXECUTIVE OFFICE

Schmalzhofgasse 26
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: **office@eanm.org**
Web: **www.eanm.org**

EANM MEMBERS' ASSEMBLY

The Members' Assembly will be held on Tuesday, October 18, 2022 at 13:15 - 14:45 CEST, Lecture Hall 113, Level P1.

Please note: Only EANM members in good standing (having paid their membership dues for the year 2022) are eligible to attend the Members' Assembly.

INSURANCE & LIABILITY

Neither the organisers nor the Conference Bureau will assume any responsibility whatsoever for damage or injury to persons or property during the congress. It is recommended that participants arrange for their personal travel and health insurance.

INTERNATIONAL MEETINGS AND ANNOUNCEMENT BOARD

Visit the International Meetings and Announcement Board in the Exhibition Hall (stand W03.B) to get information on upcoming events in Nuclear Medicine and more.

INTERNET CORNER

Internet access and limited printing possibilities will be provided at stations within the EANM Social Hub in the lobby. Please limit the viewing time to max. 5 minutes per person.

LIVE STREAM

All ticket holder for the online access will get automatically access to the online content.
Onsite congress ticket holders (except Day Ticket holders, Exhibitors and Accompanying Persons) will be granted full online access as well.

The following sessions will be live streamed and will be available also on demand until December 20, 2022: Opening Ceremony incl. Highlights Lecture, all 14 CME Sessions (incl. CME credits collection), all 7 CTE Sessions, and the Closing Ceremony. Additionally, all live streamed Satellite Symposia will be included (approx. 6 symposia).
The credits for the CME sessions can be also collected on-demand (for online and onsite participants).

LOST & FOUND

A lost and found service will be provided at the EANM registration desk for the duration of the congress.

MEDIA

By attending the event, each participant acknowledges and agrees to grant EANM the right at the congress to record, film, photograph or capture the likeness of such participant and its representatives in any media now available and in the future developed, and to use, copy, modify, distribute, broadcast or otherwise disseminate at any time and on a global basis such media, without any further approval from or payment to such participant or any of its representatives.

MEDICAL FACILITIES

Medical assistance and an ambulance service will be available throughout the congress.

MOBILE PHONES

Out of respect for other participants, you are requested to refrain from making phone calls in a lecture room. Your mobile device should be put to silent mode, at all times, when you are in the Congress Centre.

NAME BADGES

Badges for the congress will be issued on-site between October 15 and October 19, 2022. The badges must be collected in person.

A confirmation email including a QR code will be issued upon successful completion of registration. With this QR, along with a valid photo ID the name badge can be printed onsite in the registration

OPENING CEREMONY & WELCOME RECEPTION

All registered delegates and accompanying persons are cordially invited to the **Opening Ceremony & Welcome Reception** on Saturday, October 15, 2022, from 18:00-21:45.

The Opening Ceremony **including the Highlights Lecture** will be held at the Auditorium of the CCIB and the subsequent Welcome Reception at Level P0 of the CCIB, in the Entrance Hall.

CCIB – Centre de Convencions Internacional de Barcelona
Plaça de Willy Brandt, 11-14
08019 Barcelona, Spain

PARKING

Private cars can be parked at additional cost in parking areas. The closest parking area to the CCIB is Parking Pl. del Fòrum (Address: Pl. d'Ernest Lluch i Martín, 08005 Barcelona). The cost for a day is 44,20 €.
For further parking spaces in Barcelona please visit the following website:
www.aparcamentsbsm.cat/en

PUBLIC TRANSPORTATION TICKET (PTT)

All congress participants who book a hotel through the online registration page of EANM which is more than a 15-minute walk away from the congress venue will receive a complimentary public transportation ticket upon check-in at the hotel.

For further information on the public transportation system please visit:
https://www.tmb.cat/en/home

Selected tickets, at a reduced price can be purchased at the **EANM'22 Accommodation & Public Transportation Tickets Desk**, that you can find at the congress venue within the registration area.

- 2 day Hola Barcelona Travel Card (48 h): = **€ 9,00** (instead of € 16,40)
- 3 day Hola Barcelona Travel Card (72 h) = **€ 13,00** (instead of € 23,80)
- 5 day Hola Barcelona Travel Card (120 h) = **€ 20,00** (instead of € 38,20)

Payments via credit card and cash will be accepted.

REGISTRATION DESK

The registration desk at the entrance level P0 of the CCIB will be open:

Saturday, October 15, 2022:	07:30 - 21:45
Sunday, October 16, 2022:	07:30 - 18:00
Monday, October 17, 2022:	07:30 - 18:00
Tuesday, October 18, 2022:	07:30 - 18:00
Wednesday, October 19, 2022:	07:30 - 12:00

REVIEW CENTRE

The Review Centre gives you the opportunity to check the PowerPoint presentations which have been already presented during EANM'22. So, in case you have missed a session, you can review the slides here afterwards. The Review Centre is located on Level P1, Room 133/134. Some slides might not be accessible for review online.

SOCIAL HUB

All EANM´22 attendees are invited to visit the Social Hub, an area designed to take a break and socialize in between the sessions.
The Social Hub includes a photo booth, interactive games, an internet corner and a catering area. Moreover, it is possible to view the 'Inside EANM´22' Vlog by Judit Adam as well as listen to the EANM Podcast in collaboration with SAM Nordic.
The Social Hub is located in the Entrance Hall.

SOCIAL MEDIA AND NEWSLETTER

For up-to-date information follow us on our Social Media Channels and subscribe to the Congress Newsletter!


Facebook	**@officialEANM**
Twitter	**@officialEANM**
LinkedIn	**@officialEANM**
YouTube	**@officialEANM**
Congress Newsletter:	**read more about our Newsletters: www.eanm.org/about/newsletter/**

WIFI

Free WIFI will be available at the EANM'22 Congress.
Network: eanm
Password: eanm2022

ESMIT
European School of Multimodality Imaging and Therapy
Course Programme 2023
4 NEW ONLINE COURSES
7 NEW ADVANCED COURSES IN VIENNA
11 NEW LIVE WEBINARS
Registrations for 2023 will open during the EANM´22 Congress.
Do not forget to visit the ESMIT Booth!
Get your Dose of Education
More information at **eanm.org/esmit** or contact us at **esmit@eanm.org**

ABOUT BARCELONA



BANKS, CREDIT CARDS & ATM`S

Banks are usually open from 09.00 – 16:00 (Monday- Friday) – closed during the weekends. There will be ATMs (Automatic Teller Machine) in the CCIB or at the nearby shopping mall and all over the city of Barcelona. At the airport and main station and along the main streets you find currency exchange offices as well. All major credit cards, including Eurocard, Diners, Visa and MasterCard are accepted in most of the establishments like restaurants, hotels and shopping centres and stores.

When paying by credit card for your shopping, you will be asked to show identification. Please have your ID card or passport with you at all times, otherwise they may refuse to accept your credit card as payment.

Travel checks can be cashed in most of the banks and exchange offices.

CHURCHES, SYNAGOGUES, MOSQUES

Although Barcelona (like the rest of Spain) is basically Catholic, all religions are allowed and practised. Please contact your hotel concierge for current times of services or nearby places of worship.

CITY TAX

The city tax fee depends on the hotel category and varies between € 1,00 and € 3,50 per person and night. This fee applies only for the first seven nights.

CLIMATE

Barcelona enjoys a Mediterranean climate, with short cool winters and hot summers. The location of the city besides the sea increases the humidity level. Generally, it rains with more intensity during the spring and autumn. In September and October, the thunderstorms are frequent. Mostly in sunny autumn days in October, the temperatures are very nice during the day, decreasing at night.

CURRENCY

The official currency in Spain is the Euro (€). You can exchange your currency without any limits for the total amount at all banks as well as many exchange offices in Barcelona. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency.

ELECTRICITY

The power supply in Spain is 220/240 V. Most electric outlets adhere to the continental standard (Schuko). Appliances from North America require a transformer and British ones an adaptor for the two-pin sockets in use in Spain.

MUSEUM

Barcelona has a huge variety of museums, which can easily suit every taste and fancy. Some museums are mainly to appeal to tourists, whereas others contain some of the biggest art collections of some style and yet others have education as their main purpose.

You can ask your hotel reception or the Barcelona Info desk in the EANM'22 registration area for detailed information and current Covid-19 safety regulations.

RESTAURANTS & NIGHTLIFE

One of the main characteristics of Barcelona is its nightlife. The good weather contributes to sit at the terraces of the coffee-shops, bars and restaurants which ate opened until very late. Downtown restaurants normally open for lunch from 11:00 to 15:00 and for dinner from 19:30 to 23:00. Cafes and breakfast bars may open already at 08:00 or even earlier.

There is a great number of "Tapas-bars" where you can enjoy a drink and small "tapa" or "pincho" to eat at any time of the day.

Fast food, kebab, take-away-pizza stalls usually serve food all day long, and some of them stay open till midnight. Bars, night clubs and discotheques usually open from 22:00 – 04:00 (some even longer).

Please make sure to check the current Covid -19 safety regulations.

SAFETY TIPS / PICK-POCKETS

Barcelona is very safe from violent crime – ranking forth in the EU accordingly to the 'Safe Cities Index 2021' by The Economist Intelligence Unit (EIU). But there are many pickpockets and bag thieves in areas with popular tourist attractions (especially on Las Ramblas street & La Sagrada Familia), in the central subway, and the Sants train station.

Therefore, please don't carry your wallet in your back pocket – but in a pocket with a zipper. Don't put phones, cameras etc. on tables at cafés and keep your belongings always on your lap. Carry your backpack or shoulder bag in a crowded area or at street shows always in front of you so you can see it. Be wary of strangers approaching or touching you and do not play any street games. Do not carry all cash money, credit card and ID documents all together in one bag/pocket.

SHOPPING

Barcelona is an ideal destination to shop for a wide variety of items catering to everybody's tastes and wishes. Opening hours of midtown shops are 09:00 to 19:30 (Monday-Saturday). Big shopping malls open until 21:00. On Sundays, small shops are generally closed. Some malls are open 7 days a week.

Please make sure to check the current Covid-19 safety regulations.

TAXES & TIPPING

VAT is always included in the price presented to the customers/guests in shops, hotels, restaurants and other service providers. Non-EU citizens can directly claim back their VAT at the shops (excluding restaurants, hotels and other food) when the total bill exceeds € 90,15. Please ask at the shops for more information. A service charge is not always automatically included in hotel and restaurant bills, it will be stated on the bill or in the menu. Tipping is not mandatory, but a small gratuity (5-10%) is expected in restaurants if good service is received.

TAXIS

Barcelona taxi colours are black and yellow.
Taxis are an affordable alternative to the public transportation. However, it is not recommended to use taxis in the inner city as a lot of the streets are pedestrian areas and the traffic is quite high. The rates will be shown on the meter next to the driver. The initial fare for a taxi is € 2,25 plus € 1,18 to € 1,77 per kilometre depending on the time.

Possible taxi numbers are:
Ràdio Taxi Barcelona : +34 933 75 55 55
Cooperativa Radio Taxi: +34 932 25 00 00
Barnataxi: +34 933 22 22 22
Radio Taxi Barcino: +34 931 18 18 18

TIME ZONE

Barcelona is located in the Central European Time Zone (CET), i.e. one hour ahead of Greenwich Mean Time (GMT+1).

VISA

All foreign visitors entering Spain must possess valid passports. For citizen from the European Union Member countries, a valid identity card is sufficient.


Please check the current visa requirements with the nearest Spanish Consulate/Embassy in your country before your departure to Spain.

All registered congress participants may issue a visa invitation letter during the online registration process.

RESEARCH4LIFE©
EANM
EUROPEAN ASSOCIATION OF NUCLEAR MEDICINE

EARL SERVING THE COMMUNITY:
^{18}F, ^{68}G, ^{89}ZR for
PET/CT and PET/MR
HARMONISATIONS





We are growing to serve the needs of our community. EARL provides unparallel support for tomorrow's research needs with today's molecular imaging data.

earl.eanm.org
+43-(0)1-890 44 27
earl@eanm.org
earl.eanm.org

AIRPORT & ARRIVAL INFORMATION

COVID-19 TRAVEL REGULATIONS

Before travelling, you must always check the current requirements, recommendations and travel warnings of the public bodies and national authorities from your country and from Spain.

The current regulations are stated on the Spanish Ministry of Health website:
https://spth.gob.es/ as well as here:
https://travelsafe.spain.info/en/before/

Kindly check what kind of certificates and regulations apply to you before making any bookings and prepare the needed documentation on time.

Please note that each individual participant is obliged to check the regulations that are in effect on date of entry. The EANM does not guarantee completeness of information stated on this page regarding current COVID regulations and is not liable for any short-term changes in said regulations.

AIRPORT

The airport "El Prat de Llobregat" is located 12 km southwest of the city. It takes approximately 20-25 minutes by car to the city centre. There is a free bus shuttle between the two terminals T1 and T2.

For further information on the airport please visit:
www.barcelona-airport.com

Alternatively, Barcelona can be reached by train or intercity bus from neighbouring countries like France or Portugal. For further information, please check with your national railway provider.

PUBLIC TRANSPORTATION

Public transportation is by far the easiest way to get around the city.

The use of a face mask (FFP2) is mandatory at the public transport, on the subway and on the bus. The mask has to be worn covering your nose and mouth and should never be taken off (neither to talk nor eat nor drink).

The Barcelona subways, buses and trams are quick, cheap and all-around excellent. One can either buy a single trip ticket for € 2,40 or a T-casual ticket (10 rides in 1 zone) for € 7,95 or a T-dia (valid 24 hours in 1 zone) for € 10,50, which can be used for any transportation within the city. Alternatively, there is the Hola Barcelona Travel Card for 2, 3, 4 or 5 days which can be used for transportation and other travel operators.

As every year, EANM provides free public transportation tickets (PTT's) to those participants who booked a room from the official EANM congress allotment, which is more than 15 minutes' walk away from the congress venue. Each participant who booked such a room via the congress page will receive their ticket upon check-in at the hotel.

Selected tickets, at a reduced price can be purchased at the **EANM'22 Accommodation & Public Transportation Tickets Desk**, that you can find at the congress venue within the registration area.

- **2 day Hola Barcelona Travel Card (48 h):**
  € 9,00 (instead of € 16,40)
- **3 day Hola Barcelona Travel Card (72 h):**
  € 13,00 (instead of € 23,80)
- **5 day Hola Barcelona Travel Card (120 h):**
  € 20,00 (instead of € 38,20)

Payments via credit card and cash will be accepted.

For further information on the public transportation system please check the internet for:
https://www.tmb.cat/en/home

Taxi service is everywhere in the city. However, on weekend nights the waiting time might be long.

AIRPORT BUS

The blue Aerobus takes you every 5-10 minutes from the airport to the city centre (e.g. Plaça d'Espanya or Plaça de Catalunya) in about 20-30 minutes. The bus stops at both terminals, line A1 at terminal T1 and line A2 at terminal T2. Both buses stop at the same stops in the city. One-way tickets cost you € 5,90, return- tickets € 10,20. You can buy a ticket on the bus itself.

For further information please visit:
aerobusbarcelona.es/?lang=en

SUBWAY

The Metro line L9 connects the airport (both terminals) with Barcelona city. It takes about 30 minutes and leaves every 7 minutes. One cannot use the standard metro ticket but instead needs an Airport Ticket for € 4,60.

For further information please visit:
www.tmb.cat/en/barcelona-transport/map/metro

TRAIN

The train R2 Nord departs every 30 min at terminal T2 (from terminal T1, first take the free shuttle bus). It stops in the city at Passeig de Gràcia, Barcelona Sants Estació and El Prat where you can change to the metro or city buses. One can use the normal public transportation tickets without any surcharge, which can be bought at the entrance of the RENFE gate at the airport.

For further information please visit:
www.renfe.com/es/en

TAXI


To take a taxi into the city, please look for the signs for the nearest taxi stand when leaving the arrival halls. An average journey by taxi from the Barcelona Airport to downtown takes about 20-40 minutes and costs around € 29,00. The minimum fare from the airport is € 20.

Possible taxi numbers are:
Radio Taxi Barcelona : +34 933 75 55 55
Cooperativa Radio Taxi: +34 932 25 00 00
Barnataxi: +34 933 22 22 22
Radio Taxi Barcino: +34 931 18 18 18

CAR

Barcelona can be reached by several main roads from France and Spain and traffic is usually relatively light outside of peak hours. Parking, on the other hand, is quite difficult and it is recommended to either park the car a few metro stops from the centre of the city or find a car park. Alternatively, the hotel might also have a private car park.

Location and prices of the public car parks can be found here: **www.parclick.com**




LEVEL P2

Lecture Hall 211	Cutting Edge Science Track
Lecture Hall 212	TROP / Featured Sessions, Joint Symposia, Special Symposia



LEVEL M2

Room M211 / M212	EANM Congress Office
Rooms M213 - 221	Meeting Rooms & Offices



LEVEL P1


Rooms 111 - 117	Lecture Halls
Room 118 / 119	Speaker Preview Room
Rooms 120 - 123	Meeting Rooms
Room 128	e-Poster Area
Rooms 129 - 132	Meeting Rooms
Room 133 / 134	Review Centre
Rooms 124 - 127	Industry Hospitality Suites

111	e-Poster Presentations
112 (Arena)	Special Track (Debates, Challenge the Experts, Trials)
113	Learn & Improve Professional Skills (LIPS) Track
114	M2M Track, Joint Symposia
115	TROP / Featured Sessions
116	Technologists' Track
117	Clinical Oncology Track



LEVEL P0
GROUND FLOOR

Entrance Hall	Registration, Cloakroom, Congress Bags, EANM Social Hub, EANM Area, ESMIT Area
Exhibition Hall	Industry Exhibition, Catering Area, Welcome Reception Area



AUDITORIUM

Auditorium	Plenary Sessions, CME Sessions, Opening Ceremony, Closing Session
Foyer	Farewell Drink

CME CERTIFICATES

1 SCAN YOUR BADGE

ATTENTION! MANDATORY EVALUATION

Scan your badge **at the beginning of each session** when entering the Auditorium in order to acquire CME credits. In case you cannot attend the session live, you can gain the CME credits also by watching the talks on-demand.

2 EVALUATE

DEADLINE: December 20, 2022

A short evaluation has to be completed for each attended CME session, as well as for the overall congress until **December 20, 2022.** Evaluation has to be done online in your myEANM area (**myeanm.eanm.org**).

3 DOWNLOAD YOUR CERTIFICATE

Once the steps above are completed, your certificate will be **available within 24 hours** in your myEANM area (**myeanm.eanm.org**).

Attention! To obtain your CME credits (for single sessions as well as the congress itself) the respective evaluations are mandatory. **Deadline: December 20, 2022.**
After this date, or without the completed evaluation(s), no points will be accredited.

PROGRAMME OVERVIEW

SATURDAY, OCTOBER 15, 2022

Location/ Time	Auditorium			Location/ Time
08:00 - 08:30				08:00 - 08:30
08:30 - 09:00				08:30 - 09:00
09:00 - 09:30		**Advisory Council Meeting** (09:00-11:00) (Room 128)		09:00 - 09:30
09:30 - 10:00				09:30 - 10:00
10:00 - 10:30				10:00 - 10:30
10:30 - 11:00				10:30 - 11:00
11:00 - 11:30				11:00 - 11:30
11:30 - 12:00		**Delegates´ Assembly** (11:15-13:15) (Hall 212)		11:30 - 12:00
12:00 - 12:30				12:00 - 12:30
12:30 - 13:00				12:30 - 13:00
13:00 - 13:30				13:00 - 13:30
13:30 - 14:00			**Committee Meetings** (11:15-17:00)	13:30 - 14:00
14:00 - 14:30				14:00 - 14:30
14:30 - 15:00				14:30 - 15:00
15:00 - 15:30				15:00 - 15:30
15:30 - 16:00				15:30 - 16:00
16:00 - 16:30				16:00 - 16:30
16:30 - 17:00				16:30 - 17:00
17:00 - 17:30				17:00 - 17:30
17:30 - 18:00				17:30 - 18:00
18:00 - 18:30	**Opening Ceremony including Awards Ceremony** (18:00-18:35)			18:00 - 18:30
19:30 - 20:30	*101* **Plenary 1 Highlights Lecture** (18:35-19:35)			19:30 - 20:30
20:30 - 21:00				20:30 - 21:00
21:00 - 21:30	**Welcome Reception** (19:45-21:45)			21:00 - 21:30
21:30 - 22:00				21:30 - 22:00

WORLD LEADING MEETING EANM'22
OCTOBER 15 - 19, 2022

PROGRAMME OVERVIEW

SUNDAY, OCTOBER 16, 2022

Location/ Time	Auditorium	Hall 112 (Arena)	Hall 113	Hall 114	Hall 211	Hall 117	Hall 115	Hall 212	Hall 111	Hall 116	Location/ Time
08:00 - 08:30	201 CME **CME 1** Oncology & Theranostics Committee **Radionuclide Therapies - Controversies and Special Considerations**	202 **Special Track** Oncology & Theranostics Committee **Debate 1: The Weight of CT in PET/CT**	203 **Learn & Improve Professional Skills (LIPS) Track** Abstract Session **Case Report Session 1 - Oncology (including PET and Therapy)**	204 **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **New Radiopharmaceuticals - Fancy Stuff**	205 **Cutting Edge Science Track TROP Session** Physics Committee **Radiomics**	206 **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Let's Start With Some Prostate**	207 **TROP Session** Paediatrics Committee **Nephro-Urology and Paediatrics**	208 **Joint Symposium 1** Cardiovascular Committee / EACVI **Anatomical & Functional Cardiac Imaging - Friend or Foe?**	209 **e-Poster Presentations Session 1** Bone & Joint + Neuroimaging Committee **Miscellaneous - Bone / Brain / Covid-19 / Lung**	210 **Technologists' Track CTE 1** Technologists Committee / SNMMI **Tech Guide Launch**	08:00 - 08:30
08:30 - 09:00											08:30 - 09:00
09:00 - 09:30											09:00 - 09:30
09:30 - 10:00	301 CME **CME 2** Thyroid + Translational Molecular Imaging & Therapy Committee **Parathyroid Imaging**	302 **Special Track** Oncology & Theranostics Committee **Challenge the Expert 1 - Expert vs Team Barcelona: PSMA Imaging**	303 **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Cardiovascular + Inflammation & Infection Committee **Tricky Cases on Nuclear Cardiology**	304 **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Therapy - Innovations and Technical Improvements**	305 **Cutting Edge Science Track TROP Session** Radiation Protection Committee **Current Issues in Radiation Protection**	306 **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Gastro and Colorectal**	307 **Featured Session** Paediatrics Committee **A Bit of Everything - Mix NM**	308 **TROP Session** Neuroimaging Committee **Neurodegeneration - Ready for Beta! Ready for Tau?**	309 **e-Poster Presentations Session 2** Physics Committee **Physics**	310 **Technologists' Track CTE 2** Technologists Committee **Technologist Involvement in Research Imaging**	09:30 - 10:00
10:00 - 10:30											10:00 - 10:30
10:30 - 11:00											10:30 - 11:00
11:00 - 11:30											11:00 - 11:30
11:30 - 12:00	401 **Plenary 2** incl. Marie Curie Lecture **PSMA - A Never Ending Successful Story**										11:30 - 12:00
12:00 - 12:30											12:00 - 12:30
12:30 - 13:00											12:30 - 13:00
13:00 - 13:30											13:00 - 13:30
13:30 - 14:00											13:30 - 14:00
14:00 - 14:30				**Satellite Symposia 1**	**Satellite Symposia 2**	**Satellite Symposia 3**	**Satellite Symposia 4**	**Satellite Symposia 5**		**Satellite Symposia 6**	14:00 - 14:30
14:30 - 15:00											14:30 - 15:00
15:00 - 15:30	501 CME **CME 3** Physics + Oncology & Theranostics + Neuroimaging Committee **Motion Management - State of the Art**	502 **Special Track** Abstract Session **TOP Trials Session 1 - Best International Trials**	503 **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Thyroid Committee **Tricky Cases in Endocrine Imaging**	504 **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **1+1=3 ... The Promise of Combination Treatments**	505 **Cutting Edge Science Track TROP Session** Dosimetry Committee **SIRT**	506 **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Radioguided Surgery**	507 **TROP Session** Cardiovascular Committee **Quantitative Myocardial Perfusion Imaging**	508 **TROP Session** Paediatrics Committee **Paediatric Oncology**	509 **e-Poster Presentations Session 3** Inflammation & Infection Committee **Best e-Posters on Infection and Inflammation**	510 **Technologists' Track CTE 3** Technologists + Radiation Protection Committee **Radiation Protection in Radionuclide Therapy**	15:00 - 15:30
15:30 - 16:00											15:30 - 16:00
16:00 - 16:30											16:00 - 16:30
16:30 - 17:00	601 CME **CME 4** Cardiovascular + Inflammation & Infection Committee **New Role of Nuclear Medicine in Monitoring Cardiovascular Diseases**	602 **Special Track** Thyroid Committee **Challenge the Expert 2 - Expert vs Team Groningen: Thyroid & Parathyroid**	603 **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Paediatrics Committee **Tricky Cases in Paediatrics**	604 **Joint Symposium 2** Oncology & Theranostics Committee / EAU **Prostate Cancer Radionuclide Therapy**	605 **Cutting Edge Science Track TROP Session** Physics Committee **Developments in PET**	606 **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Neuroendocrinology**	607 **TROP Session** Neuroimaging Committee **Breadth of Tracers and Approaches in Brain Tumours**	608 **TROP Session** Inflammation & Infection Committee **All About Infections**	609 **e-Poster Presentations Session 4** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **New Tracers - From Production to Translation**	610 **Technologists' Track Oral Presentations 1** Technologists Committee **Technologists' Training and Best Practise**	16:30 - 17:00
17:00 - 17:30											17:00 - 17:30
17:30 - 18:00											17:30 - 18:00
18:00 - 18:30											18:00 - 18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

WORLD LEADING MEETING EANM'22
OCTOBER 15 - 19, 2022

PROGRAMME OVERVIEW

MONDAY, OCTOBER 17, 2022

Location/ Time	Auditorium	Hall 112 (Arena)	Hall 113	Hall 114	Hall 211	Hall 117	Hall 115	Hall 212	Hall 111	Hall 116	Location/ Time
08:00 - 08:30	*701* CME **CME 5** Paediatrics Committee **Nuclear Medicine in the Evaluation of Paediatric Patients with Transplants**	*702* **Special Track** Inflammation & Infection Committee **Challenge the Expert 3 - Expert vs Team Bologna: Real World in Infection**	*703* **Learn & Improve Professional Skills (LIPS) Track** Translational Molecular Imaging & Therapy Committee **Challenging Situations in TMI&T**	*704* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **GRPR vs. PSMA - A Comparison**	*705* **Cutting Edge Science Track TROP Session** Physics Committee **Quantification in Brain and Heart**	*706* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Onco Miscellanea**	*707* **Featured Session** Bone & Joint Committee **Bone and Joint en Route - Tracers, Modalities and Applications**	*708* **Joint Symposium 3** Thyroid Committee / ETA **A Nuclear Medicine Update on Diagnosis and Treatment of Medullary Thyroid Carcinoma (MTC)**	*709* **e-Poster Presentations Session 5** Cardiovascular Committee **e-Posters on Cardiovascular Topics**	*710* **Technologists' Track Oral Presentations 2** Technologists Committee **Diagnosis and Therapy**	08:00 - 08:30
08:30 - 09:00											08:30 - 09:00
09:00 - 09:30											09:00 - 09:30
09:30 - 10:00	*801* CME **CME 6** Oncology & Theranostics Committee **PET/CT - The Prediction Game**	*802* **Special Track** Abstract Session **TOP Trials Session 2 - Best FAPI Trials**	*803* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Neuroimaging Committee **Black and White or Fifty Shades of Grey? Beyond Binary Reading of Brain PET Images**	*804* **M2M Track Featured Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **T-Cells, TAM's and CAF's - Again**	*805* **Cutting Edge Science Track TROP Session** Dosimetry Committee **Clinical Lu-177 Dosimetry**	*806* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Therapy**	*807* **TROP Session** Thyroid Committee **PET in Parathyroid Disease and Thyroid Cancer**	*808* **TROP Session** Cardiovascular Committee **Novel Developments in Nuclear Cardiology**	*809* **e-Poster Presentations Session 6** Physics + Radiation Protection Committee **Physics and Radiation Protection**	*810* **Technologists' Track CTE 4** Technologists + Radiopharmaceutical Sciences Committee **Research in Radiopharmacy**	09:30 - 10:00
10:00 - 10:30											10:00 - 10:30
10:30 - 11:00											10:30 - 11:00
11:00 - 11:30											11:00 - 11:30
11:30 - 12:00	*901* **Plenary 3** **Theranostics - More Than Just the Future of Nuclear Medicine**										11:30 - 12:00
12:00 - 12:30											12:00 - 12:30
12:30 - 13:00											12:30 - 13:00
13:00 - 13:30											13:00 - 13:30
13:30 - 14:00					**Satellite Symposia 7**	**Satellite Symposia 8**		**Satellite Symposia 9**		**Satellite Symposia 10**	13:30 - 14:00
14:00 - 14:30											14:00 - 14:30
14:30 - 15:00											14:30 - 15:00
15:00 - 15:30	*1001* CME **CME 7** Radiation Protection Committee **Radiation Protection in Radionuclide Therapy - Insight on New and Emerging Therapies**	*1002* **Special Track** **EANM Sanjiv Sam Gambhir Award - Battle and Win!**	*1003* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Oncology & Theranostics + TMI & T Committee / EORTC **Setting Up and Managing Imaging Trials**	*1004* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Peptides for All Tastes**	*1005* **Cutting Edge Science Track TROP Session** Dosimetry + Thyroid Committee **I-131 Dosimetry for Thyroid Disease**	*1006* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Breast**	*1007* **TROP Session** Inflammation & Infection Committee **Nuclear Medicine and COVID-19**	*1008* **TROP Session** Cardiovascular Committee **Cardiovascular Metabolism, Innervation and Perfusion**	*1009* **e-Poster Presentations Session 7** Paediatrics Committee **e-Posters on Paediatrics & Nephro-Urology**		15:00 - 15:30
15:30 - 16:00											15:30 - 16:00
16:00 - 16:30											16:00 - 16:30
16:30 - 17:00	*1101* CME **CME 8** Bone & Joint Committee **Early Bone Scan Imaging - Let's Go 3D!**	*1102* **Special Track** Oncology & Theranostics + Radiopharmaceutical Sciences Committee **Debate 2: Fluorine-18 Alternatives for Oncological Gallium-68 Tracers**	*1103* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Dosimetry Committee **Life Drawing in Nuclear Medicine - Fact or Fiction?**	*1104* **Joint Symposium 4** Oncology & Theranostics Committee / EORTC **Evaluation of Response to Therapy**	*1105* **Cutting Edge Science Track TROP Session** Physics Committee **Image Reconstruction + Image Guided Surgery**	*1106* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Lung**	*1107* **TROP Session** Inflammation & Infection Committee **Inflammation and Beyond**	*1108* **TROP Session** Thyroid Committee **Treatment of Thyroid Cancer**	*1109* **e-Poster Presentations Session 8** Neuroimaging Committee **Neuro e-Posters**	*1110* **Technologists' Track CTE 5** Technologists Committee **Nuclear Medicine in Haematological Malignancies**	16:30 - 17:00
17:00 - 17:30											17:00 - 17:30
17:30 - 18:00											17:30 - 18:00
18:00 - 18:30											18:00 - 18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

WORLD LEADING MEETING EANM'22
OCTOBER 15 - 19, 2022

PROGRAMME OVERVIEW

TUESDAY, OCTOBER 18, 2022

Location/ Time	Auditorium	Hall 112 (Arena)	Hall 113	Hall 114	Hall 211	Hall 117	Hall 115	Hall 212	Hall 111	Hall 116	Location/ Time
08:00 - 08:30	*1201* **CME 9** Dosimetry + Oncology & Theranostics Committee **SIRT - An Example of Successful Clinical Dosimetry**	*1202* **Special Track** Abstract Session **TOP Trials Session 3 - New Radiopharmaceutical Trials**	*1203* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Oncology & Theranostics Committee **Tricky Cases in NET and Digestive Tract Oncology**	*1204* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Seeing the Brain from all Angles**	*1205* **Cutting Edge Science Track TROP Session** Physics Committee **Standardisation & Quality Control**	*1206* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Gynaecology and Others**	*1207* **TROP Session** Neuroimaging Committee **Movement Disorders - Radiomics, AI, Connectivity and What Else?**	*1208* **Featured Session** Thyroid Committee **What is New in Thyroid and Parathyroid Imaging?**	*1209* **e-Poster Presentations Session 9** Oncology & Theranostics Committee **Local Therapy and More**	*1210* **Technologists' Track Oral Presentations 3** Technologists Committee **Artificial Intelligence and Technical Novelties**	08:00 - 08:30
08:30 - 09:00											08:30 - 09:00
09:00 - 09:30											09:00 - 09:30
09:30 - 10:00	*1301* **CME 10** Oncology & Theranostics + Physics Committee **Quantitative SPECT, PET and Standardisation**	*1302* **Special Track** Neuroimaging Committee **Debate 3: Imaging Brain Tumours - Is PET Required or only a Fancy Option?**	*1303* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Inflammation & Infection Committee **[18F]FDG PET/CT Treatment Response Assessment in Inflammatory Diseases**	*1304* **Joint Symposium 5** Physics + Oncology & Theranostics Committee / ESTRO **Imaging for Radiotherapy Applications**	*1305* **Cutting Edge Science Track TROP Session** Dosimetry Committee **Radiobiology**	*1306* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Lymphoma**	*1307* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostage Staging**	*1308* **TROP Session** Cardiovascular Committee **Heart Failure and Amyloidosis**	*1309* **e-Poster Presentations Session 10** Oncology & Theranostics Committee **Oncology**	*1310* **Technologists' Track Technologists' e-Poster Presentations Session** Technologists Committee **Techs' e-Posters**	09:30 - 10:00
10:00 - 10:30											10:00 - 10:30
10:30 - 11:00											10:30 - 11:00
11:00 - 11:30											11:00 - 11:30
11:30 - 12:00	*1401* **Plenary 4** **Superfluous, Controversial and Luxury Issues in Nuclear Medicine**										11:30 - 12:00
12:00 - 12:30											12:00 - 12:30
12:30 - 13:00											12:30 - 13:00
13:00 - 13:30											13:00 - 13:30
13:30 - 14:00			**Members' Assembly** (13:15-14:45)			**Satellite Symposia 11**	**Satellite Symposia 12**	**Satellite Symposia 13**		**Satellite Symposia 14**	13:30 - 14:00
14:00 - 14:30											14:00 - 14:30
14:30 - 15:00											14:30 - 15:00
15:00 - 15:30	*1501* **CME 11** Neuroimaging Committee **Molecular Imaging and Fluid Biomarkers in Alzheimer's Disease - A Nice Couple**	*1502* **Special Track** Cardiovascular Committee **Debate 4: Myocardial Perfusion Imaging with PET - Ready for Clinical Use?**	*1503* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Oncology & Theranostics Committee **Tricky Cases in Prostate Imaging**	*1504* **Joint Symposium 6** Oncology & Theranostics Committee / ESMO **Integrated Theranostics**	*1505* **Cutting Edge Science Track TROP Session** Physics Committee **Advanced Data Analysis**	*1506* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Head & Neck and Melanoma**	*1507* **Featured Session** Thyroid Committee **New Developments and Knowledge in Thyroid Cancer Therapy**	*1508* **Special Symposium 1** EANM / FOPH / AEMPS / EU Commission **Radiopharmaceuticals Regulations - Quo Vadis?**	*1509* **e-Poster Presentations Session 11** Dosimetry Committee **Dosimetry - Novel Tracers and Computer-Based Modelling**	*1510* **Technologists' Track CTE 6** Technologists Committee **Stem Cells in Nuclear Medicine**	15:00 - 15:30
15:30 - 16:00											15:30 - 16:00
16:00 - 16:30											16:00 - 16:30
16:30 - 17:00	*1601* **CME 12** Radiopharmaceutical Sciences Committee **Optimizing Radiolabeled Biomolecules for Imaging and Therapy – The Secrets Revealed**	*1602* **Special Track** Oncology & Theranostics Committee **Challenge the Expert 4 - Expert vs Team Essen: PET/CT in Real Life**	*1603* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Radiation Protection + Physics Committee **CT Optimization in Hybrid Imaging**	*1604* **M2M Track TROP Session** Radiopharmaceutical Sciences + TMI & T Committee **New Tracers - From Scratch to Automated Synthesis**	*1605* **Cutting Edge Science Track TROP Session** Physics Committee **Predictive Artificial Intelligence**	*1606* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **NET Therapy and More**	*1607* **TROP Session** Neuroimaging Committee **The Force Awakens - Neuro Miscellaneous**	*1608* **Special Symposium 2** EANM / EU Commission **Getting to the Top QuADRANT. A European Initiative to Improve Quality for Patients**	*1609* **e-Poster Presentations Session 12** Oncology & Theranostics Committee **Prostate**	*1610* **Technologists' Track CTE 7** ***Interactive Session*** Technologists Committee **EQF7 - European Qualification Framework Document for Nuclear Medicine Technologists**	16:30 - 17:00
17:00 - 17:30											17:00 - 17:30
17:30 - 18:00											17:30 - 18:00
18:00 - 18:30											18:00 - 18:30

PROGRAMME OVERVIEW | FINAL PROGRAMME

PROGRAMME OVERVIEW

WEDNESDAY, OCTOBER 19, 2022

Location/ Time	Auditorium	Hall 112 (Arena)	Hall 113	Hall 114	Hall 211	Hall 117	Hall 115	Hall 212	Hall 111	Hall 116	Location/ Time
08:00 - 08:30	*1701* **CME 13** (CME) Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences + Oncology & Theranostics Committee **First In-Human Studies**	*1702* **Special Track** Oncology & Theranostics + Physics Committee **Debate 5: PET/MR - Lights or Shadows?**	*1703* **Learn & Improve Professional Skills (LIPS) Track** Abstract Session **Case Report Session 2 - Others than Oncology**	*1704* **Joint Symposium 7** Oncology & Theranostics Committee / ESR **Multimodality Functional Imaging**	*1705* **Cutting Edge Science Track TROP Session** Physics Committee **Developments in SPECT**	*1706* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Beyond Usual**	*1707* **TROP Session** Cardiovascular Committee **Other Cardiovascular Imaging**	*1708* **Featured Session** Thyroid Committee **Treatment of Benign Thyroid Disease**	*1709* **e-Poster Presentations Session 13** Oncology & Theranostics Committee **Haematology**	*1710* **Technologists' Track Mini Courses** Technologists Committee *1710a* **Mini Course 1** *(08:00-09:00)* **CZT in Non-Cardiac Nuclear Medicine** *1710b* **Mini Course 2** *(09:05-10:05)* **Non-Fluoride Cyclotron Production - O15-Water Applications** *1710c* **Mini Course 3** *(10:15-11:15)* **Digital PET/CT**	08:00 - 08:30
08:30 - 09:00											08:30 - 09:00
09:00 - 09:30											09:00 - 09:30
09:30 - 10:00	*1801* **CME 14** (CME) Oncology & Theranostics Committee **Rare Tumours**	*1802* **Special Track** Dosimetry Committee **Debate 6: Dosimetry in Clinical Practice - Sense vs. Nonsense**	*1803* **Learn & Improve Professional Skills (LIPS) Track** ***Interactive Session*** Radiopharmaceutical Sciences + TMI & T + Physics Committee + Cardiovascular Committee **Pharmacokinetics - From Basics to Clinical Applications**	*1804* **M2M Track TROP Session** Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee **Antibodies - Reliable Workhorses**	*1805* **Cutting Edge Science Track TROP Session** Physics Committee **AI Segmentation and Denoising**	*1806* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Prostate Recurrence**	*1807* **Clinical Oncology Track TROP Session** Oncology & Theranostics Committee **Sentinel Node**		*1809* **e-Poster Presentations Session 14** Thyroid Committee **A Spotlight on Thyroid and Parathyroid Imaging**		09:30 - 10:00
10:00 - 10:30											10:00 - 10:30
10:30 - 11:00											10:30 - 11:00
11:00 - 11:30											11:00 - 11:30
11:30 - 12:00	*1901* **Closing Session** **Farewell Drink**										11:30 - 12:00
12:00 - 12:30											12:00 - 12:30

Plenary Sessions | CME Sessions | Special Track | Learn & Improve Professional Skills (LIPS) Track | Joint Symposia | M2M Track | Cutting Edge Science Track | Clinical Oncology Track | Special Symposium | Featured/TROP Session | e-Poster Presentations | Technologists' Track Session



SCIENTIFIC PROGRAMME

INVITED SPEAKER SESSIONS

PLENARY SESSIONS

1

Saturday, October 15, 2022 | 18:35 – 19:35 | Auditorium

Highlights Lecture

Presenters: Irene Burger (Switzerland), Nathalie Albert (Germany), Benjamin Guillet (France) and Philippe Garrigue (France)

2

Sunday, October 16, 2022 | 11:30 – 13:00 | Auditorium

PSMA – A Never Ending Successful Story (incl. Marie Curie Lecture)

Chairpersons: Daniela E. Oprea-Lager (Amsterdam, Netherlands), Stefano Fanti (Bologna, Italy)

- **Once Upon a Time in the West - The History of Radiolabelled PSMA Production**, Wolfgang Fendler (Essen, Germany)
- **The Good, the Bad and the Ugly - 68 Ga vs 18 F vs Other PSMA Diagnostic Tracers**, Karolien Goffin (Leuven, Belgium)
- **The Matrix Reloaded - The Importance of Structured Reporting PSMA PET**, Macarena Rodríguez Fraile (Pamplona, Spain
- **The Maze Runner - The Interaction Between Androgen Deprivation Therapy and PSMA Expression**, Louise Emmett (Sydney Australia)
- **To Infinity and Beyond - PSMA PET in Solid Cancers Other Than Prostate Cancer**, Simona Malaspina (Turku, Finland)
- **Bohemian Rhapsody - Current Landscape of PSMA Theranostics,** Declan Murphy (Melbourne, Australia)
- **Marie Curie Lecture: Green Book - The Importance of Implementing PSMA in Guidelines**, Daniela E. Oprea-Lager (Amsterdam, Netherlands)
- **Summary**, All Speakers

3

Monday, October 17, 2022 | 11:30 – 13:00 | Auditorium

Theranostics – More Than Just the Future of Nuclear Medicine

Chairpersons: Louise Emmett (Sydney, Australia), Ken Herrmann (Essen, Germany)

- **Theranostics Overview**, Wolfgang Weber (Munich, Germany)
- **Why Theranostics should be NMs Driver to Independences**, Johannes Czernin (Los Angeles, United States of America)
- **How to Successfully Set Up a Theranostics Center**, Ana Denis Bacelar (Teddington, United Kingdom)
- **How to Raise Awareness for Theranostic Concepts**, Cristina Nanni (Bologna, Italy)
- **Getting Ready for the Next Wave of Theranostic Studies**, Louise Emmett (Sydney Australia)
- **Theranostics - The Catalyst for Nuclear Medicine Growth,** Andrei Iagaru (Stanford, United States of America)
- **Summary**, All Speakers

4

Tuesday, October 18, 2022 | 11:30 – 13:00 | Auditorium

Superfluous, Controversial and Luxury Issues in Nuclear Medicine

Chairpersons: Özgül Ekmekcioglu (Istanbul, Türkiye), Fred Verzijlbergen (Nijmegen, Netherlands)

- **Really, More New Radiolabelled Tracers?**, Samantha Terry (London, United Kingdom)
- **Nuclear Neurology - Clinical Reality or Eternal Promise?**, Silvia Morbelli (Genoa, Italy)
- **Personalized Medicine - Every Man His Own PSMA!**, Helle Damgaard Zacho (Aalborg, Denmark)
- **Dosimetry - Necessary or Redundant?**, Steffie Peters (Nijmegen, Netherlands)
- **Radiomics - Way to the Future or Useless Fancy Name?**, Xavier Boulvard (Logroño, Spain)
- **Summary**, All Speakers

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

1 Sunday, October 16, 2022 | 08:00 – 09:30 | Auditorium
Oncology & Theranostics Committee
Radionuclide Therapies - Controversies and Special Considerations

2 Sunday, October 16, 2022 | 09:45 – 11:15 | Auditorium
Thyroid + Translational Molecular Imaging & Therapy Committee
Parathyroid Imaging

3 Sunday, October 16, 2022 | 15:00 – 16:30 | Auditorium
Physics + Oncology & Theranostics + Neuroimaging Committee
Motion Management – State of the Art

4 Sunday, October 16, 2022 | 16:45 – 18:15 | Auditorium
Cardiovascular + Inflammation & Infection Committee
New Role of Nuclear Medicine in Monitoring Cardiovascular Diseases

5 Monday, October 17, 2022 | 08:00 – 09:30 | Auditorium
Paediatrics Committee
Nuclear Medicine in the Evaluation of Paediatric Patients with Transplants

6 Monday, October 17, 2022 | 09:45 – 11:15 | Auditorium
Oncology & Theranostics Committee
PET/CT - The Prediction Game

7 Monday, October 17, 2022 | 15:00 – 16:30 | Auditorium
Radiation Protection Committee
Radiation Protection in Radionuclide Therapy – Insight on New and Emerging Therapies

8 Monday, October 17, 2022 | 16:45 – 18:15 | Auditorium
Bone & Joint Committee
Early Bone Scan Imaging – Let's Go 3D!

9 Tuesday, October 18, 2022 | 08:00 – 09:30 | Auditorium
Dosimetry + Oncology & Theranostics Committee
SIRT – An Example of Successful Clinical Dosimetry

CONTINUING MEDICAL EDUCATION (CME) SESSIONS

10 Tuesday, October 18, 2022 | 09:45 – 11:15 | Auditorium
Oncology & Theranostics + Physics Committee
Quantitative SPECT, PET and Standardisation

11 Tuesday, October 18, 2022 | 15:00 – 16:30 | Auditorium
Neuroimaging Committee
Molecular Imaging and Fluid Biomarkers in Alzheimer's Disease - A Nice Couple

12 Tuesday, October 18, 2022 | 16:45 – 18:15 | Auditorium
Radiopharmaceutical Sciences Committee
Optimizing Radiolabeled Biomolecules for Imaging and Therapy – The Secrets Revealed

13 Wednesday, October 19, 2022 | 08:00 – 09:30 | Auditorium
Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences + Oncology & Theranostics Committee
First In-Human Studies

14 Wednesday, October 19, 2022 | 09:45 – 11:15 | Auditorium
Oncology & Theranostics Committee
Rare Tumours

TECHNOLOGISTS' TRACK

PLENARY SESSIONS

1 Saturday, October 15, 2022 | 18:35 – 19:35 | Auditorium
Highlights Lecture

2 Sunday, October 16, 2022 | 11:30 – 13:00 | Auditorium
PSMA – A Never Ending Successful Story (**incl. Marie Curie Lecture**)

3 Monday, October 17, 2022 | 11:30 – 13:00 | Auditorium
Theranostics – More Than Just the Future of Nuclear Medicine

4 Tuesday, October 18, 2022 | 11:30 – 13:00 | Auditorium
Superfluous, Controversial and Luxury Issues in Nuclear Medicine

CONTINUING MEDICAL EDUCATION (CTE) SESSIONS

1 Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 116
Technologists Committee / SNMMI
Tech Guide Launch

2 Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 116
Technologists Committee
Technologist Involvement in Research Imaging

3 Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 116
Technologists + Radiation Protection Committee
Radiation Protection in Radionuclide Therapy

4 Monday, October 17, 2022 | 09:45 – 11:15 | Hall 116
Technologists + Radiopharmaceutical Sciences Committee
Research in Radiopharmacy

5 Monday, October 17, 2022 | 16:45 – 18:15 | Hall 116
Technologists Committee
Nuclear Medicine in Haematological Malignancies

6 Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 116
Technologists Committee
Stem Cells in Nuclear Medicine

7 Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 116
Technologists Committee
EQF7 – European Qualification Framework Document for Nuclear Medicine Technologists - ***Interactive***

IN ADDITION TO THE CTE SESSIONS THE TECHNOLOGISTS' TRACK INCLUDES 3 MINI COURSES:

1 Wednesday, October 19, 2022 | 08:00 – 09:00 | Hall 116
Technologists Committee
CZT in Non-Cardiac Nuclear Medicine

2 Wednesday, October 19, 2022 | 09:05 – 10:05 | Hall 116
Technologists Committee
Non-Fluoride Cyclotron Production - O15-Water Applications

3 Wednesday, October 19, 2022 | 10:15 – 11:15 | Hall 116
Technologists Committee
Digital PET/CT

TECHNOLOGISTS' ORAL PRESENTATIONS

1 Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 116
Technologists Committee
Technologists' Oral Presentations 1

2 Monday, October 17, 2022 | 08:00 – 09:30 | Hall 116
Technologists Committee
Technologists' Oral Presentations 2

3 Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 116
Technologists Committee
Technologists' Oral Presentations 3

TECHNOLOGISTS' e-POSTER PRESENTATIONS

1 Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 116
Technologists Committee
Technologists' e-Poster Presentations Session

SPECIAL TRACK

1
Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
Debate 1
Oncology & Theranostics Committee
The Weight of CT in PET/CT

2
Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
Challenge the Expert 1
Oncology & Theranostics Committee
Expert vs Team Barcelona: PSMA Imaging

3
Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 112 (Arena)
TOP Trials Session 1
Best International Trials

4
Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 112 (Arena)
Challenge the Expert 2
Oncology & Theranostics Committee
Expert vs Team Groningen: Thyroid & Parathyroid

5
Monday, October 17, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
Challenge the Expert 3
Inflammation & Infection Committee
Expert vs Team Bologna: Real World in Infection

6
Monday, October 17, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
TOP Trials Session 2
Inflammation & Infection Committee
Best FAPI Trials

7
Monday, October 17, 2022 | 15:00 – 16:30 | Hall 112 (Arena)
Award Session
EANM Sanjiv Sam Gambhir Award – Battle and Win!

8
Monday, October 17, 2022 | 16:45 – 18:15 | Hall 112 (Arena)
Debate 2
Oncology & Theranostics + Radiopharmaceutical Sciences Committee
Fluorine-18 Alternatives for Oncological Gallium-68 Tracers

9
Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
TOP Trials Session 3
New Radiopharmaceutical Trials

10
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
Debate 3
Neuroimaging Committee
Imaging Brain Tumours - Is PET Required or only a Fancy Option?

11
Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 112 (Arena)
Debate 4
Cardiovascular Committee
Myocardial Perfusion Imaging with PET – Ready for Clinical Use?

12
Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 112 (Arena)
Challenge the Expert 4
Oncology & Theranostics Committee
Expert vs Team Essen: PET/CT in Real Life

13
Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
Debate 5
Oncology & Theranostics + Physics Committee
PET/MR - Lights or Shadows?

14
Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
Debate 6
Dosimetry Committee
Dosimetry in Clinical Practice – Sense vs. Nonsense

JOINT SYMPOSIA

1
Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 212
Cardiovascular Committee / EACVI
Anatomical & Functional Cardiac Imaging – Friend or Foe?

2
Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 114
Oncology & Theranostics Committee / EAU
Prostate Cancer Radionuclide Therapy

3
Monday, October 17, 2022 | 08:00 – 09:30 | Hall 212
Thyroid Committee / ETA
A Nuclear Medicine Update on Diagnosis and Treatment of Medullary Thyroid Carcinoma (MTC)

4
Monday, October 17, 2022 | 16:45 – 18:15 | Hall 114
Oncology & Theranostics Committee / EORTC
Evaluation of Response to Therapy

5
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 114
Physics + Oncology & Theranostics Committee / ESTRO
Imaging for Radiotherapy Applications

6
Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 114
Oncology & Theranostics Committee / ESMO
Integrated Theranostics

7
Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 114
Oncology & Theranostics Committee / ESR
Multimodality Functional Imaging

SPECIAL SESSIONS

1
Monday, October 17, 2022 | 08:00 – 09:45 | Meeting Room 120/121, Level P1
UEMS/EBNM - Clinical Audit Session

2
Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 212
Radiopharmaceutical Sciences Committee / EU Commission
Radiopharmaceuticals Regulations - Quo Vadis?

3
Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 212
EANM / EU Commission
Getting to the Top QuADRANT. A European Initiative to Improve Quality for Patients

LEARN & IMPROVE PROFESSIONAL SKILLS (LIPS)TRACK

1
Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 113
Abstract Session
Case Report Session 1 - Oncology (including PET and Therapy)

2
Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 113
Cardiovascular + Inflammation & Infection Committee (TBC)
Tricky Cases on Nuclear Cardiology - ***Interactive***

3
Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 113
Thyroid Committee
Tricky Cases in Endocrine Imaging - ***Interactive***

4
Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 113
Paediatrics Committee
Tricky Cases in Paediatrics - ***Interactive***

5
Monday, October 17, 2022 | 08:00 – 09:30 | Hall 113
Translational Molecular Imaging & Therapy Committee
Challenging Situations in TMI&T

6
Monday, October 17, 2022 | 09:45 – 11:15 | Hall 113
Neuroimaging Committee
Black and White or Fifty Shades of Grey? Beyond Binary Reading of Brain PET Images - ***Interactive***

7
Monday, October 17, 2022 | 15:00 – 16:30 | Hall 113
Oncology & Theranostics + Translational Molecular Imaging & Therapy Committee / EORTC
Setting Up and Managing Imaging Trials - ***Interactive***

8
Monday, October 17, 2022 | 16:45 – 18:15 | Hall 113
Dosimetry Committee
Life Drawing in Nuclear Medicine - Fact or Fiction? - ***Interactive***

9
Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 113
Oncology & Theranostics Committee
Tricky Cases in NET and Digestive Tract Oncology - ***Interactive***

10
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 113
Inflammation & Infection Committee
[^{18}F]FDG PET/CT Treatment Response Assessment in Inflammatory Diseases - ***Interactive***

11
Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 113
Oncology & Theranostics Committee
Tricky Cases in Prostate Imaging - ***Interactive***

12
Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 113
Radiation Protection + Physics Committee
CT Optimization in Hybrid Imaging - ***Interactive***

13
Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 113
Abstract Session
Case Report Session 2 - Others than Oncology

14
Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 113
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy + Physics Committee + Cardiovascular Committee
Pharmacokinetics - From Basics to Clinical Applications - ***Interactive***

CLINICAL ONCOLOGY TRACK - TROP SESSIONS:

206
Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 117
Oncology & Theranostics Committee
Let's Start With Some Prostate

306
Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 117
Oncology & Theranostics Committee
Gastro and Colorectal

506
Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 117
Oncology & Theranostics Committee
Radioguided Surgery

606
Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 117
Oncology & Theranostics Committee
Neuroendocrinology

706
Monday, October 17, 2022 | 08:00 – 09:30 | Hall 117
Oncology & Theranostics Committee
Onco Miscellanea

806
Monday, October 17, 2022 | 09:45 – 11:15 | Hall 117
Oncology & Theranostics Committee
Prostate Therapy

1006
Monday, October 17, 2022 | 15:00 – 16:30 | Hall 117
Oncology & Theranostics Committee
Breast

1106
Monday, October 17, 2022 | 16:45 – 18:15 | Hall 117
Oncology & Theranostics Committee
Lung

1206
Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 117
Oncology & Theranostics Committee
Gynaecology and Others

1306
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 117
Oncology & Theranostics Committee
Lymphoma

1307
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 115
Oncology & Theranostics Committee
Prostage Staging

1506
Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 117
Oncology & Theranostics Committee
Head & Neck and Melanoma

1606
Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 117
Oncology & Theranostics Committee
NET Therapy and More

1706
Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 117
Oncology & Theranostics Committee
Prostate Beyond Usual

1806
Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 117
Oncology & Theranostics Committee
Prostate Recurrence

1807
Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 115
Oncology & Theranostics Committee
Sentinel Node

CUTTING EDGE SCIENCE TRACK - TROP SESSIONS:

205 Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 211
Physics Committee
Radiomics

305 Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 211
Radiation Protection Committee
Current Issues in Radiation Protection

505 Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 211
Dosimetry Committee
SIRT

605 Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 211
Physics Committee
Developments in PET

705 Monday, October 17, 2022 | 08:00 – 09:30 | Hall 211
Physics Committee
Quantification in Brain and Heart

805 Monday, October 17, 2022 | 09:45 – 11:15 | Hall 211
Dosimetry Committee
Clinical Lu-177 Dosimetry

1005 Monday, October 17, 2022 | 15:00 – 16:30 | Hall 211
Dosimetry + Thyroid Committee
I-131 Dosimetry for Thyroid Disease

1105 Monday, October 17, 2022 | 16:45 – 18:15 | Hall 211
Physics Committee
Image Reconstruction + Image Guided Surgery

1205 Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 211
Physics Committee
Standardisation & Quality Control

1305 Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 211
Dosimetry Committee
Radiobiology

1505 Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 211
Physics Committee
Advanced Data Analysis

1605 Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 211
Physics Committee
Predictive Artificial Intelligence

1705 Wednesday, October 18, 2022 | 08:00 – 09:30 | Hall 211
Physics Committee
Developments in SPECT

1805 Wednesday, October 18, 2022 | 09:45 – 11:15 | Hall 211
Physics Committee
AI Segmentation and Denoising

M2M TRACK – TROP & FEATURED SESSIONS:

204 Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
New Radiopharmaceuticals – Fancy Stuff

304 Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
Therapy – Innovations and Technical Improvements

504 Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
1+1=3 … The Promise of Combination Treatments

704 Monday, October 17, 2022 | 08:00 – 09:30 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
GRPR vs. PSMA – A Comparison

804 Monday, October 17, 2022 | 09:45 – 11:15 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
T-Cells, TAM's and CAF's – Again

1004 Monday, October 17, 2022 | 15:00 – 16:30 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
Peptides for All Tastes

1204 Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
Seeing the Brain from all Angles

1604 Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
New Tracers – From Scratch to Automated Synthesis

1804 Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 114
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
Antibodies – Reliable Workhorses

FURTHER ORAL PRESENTATIONS – TROP & FEATURED SESSIONS:

207
Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 115
Paediatrics Committee
Nephro-Urology and Paediatrics

307
Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 115
Paediatrics Committee- **Featured Session**
A Bit of Everything – Mix NM

308
Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 212
Neuroimaging Committee
A Neurodegeneration – Ready for Beta! Ready for Tau?

507
Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 115
Cardiovascular Committee
Quantitative Myocardial Perfusion Imaging

508
Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 212
Paediatrics Committee
Paediatric Oncology

607
Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 115
Neuroimaging Committee
Breadth of Tracers and Approaches in Brain Tumours

608
Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 212
Inflammation & Infection Committee
All About Infections

707
Monday, October 17, 2022 | 08:00 – 09:30 | Hall 115
Bone & Joint Committee- **Featured Session**
Bone and Joint en Route – Tracers, Modalities and Applications

807
Monday, October 17, 2022 | 09:45 – 11:15 | Hall 115
Thyroid Committee
PET in Parathyroid Disease and Thyroid Cancer

808
Monday, October 17, 2022 | 09:45 – 11:15 | Hall 212
Cardiovascular Committee
Novel Developments in Nuclear Cardiology

1007
Monday, October 17, 2022 | 15:00 – 16:30 | Hall 115
Inflammation & Infection Committee
Nuclear Medicine and COVID-19

1008
Monday, October 17, 2022 | 15:00 – 16:30 | Hall 212
Cardiovascular Committee
Cardiovascular Metabolism, Innervation and Perfusion

1107
Monday, October 17, 2022 | 16:45 – 18:15 | Hall 115
Inflammation & Infection Committee
Inflammation and Beyond

1108
Monday, October 17, 2022 | 16:45 – 18:15 | Hall 212
Thyroid Committee
Treatment of Thyroid Cancer

1207
Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 115
Neuroimaging Committee
Movement Disorders – Radiomics, AI, Connectivity and What Else?

1208
Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 212
Thyroid Committee- **Featured Session**
What is New in Thyroid and Parathyroid Imaging?

1308
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 212
Cardiovascular Committee
Heart Failure and Amyloidosis

1507
Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 115
Thyroid Committee- **Featured Session**
New Developments and Knowledge in Thyroid Cancer Therapy

1607
Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 115
Neuroimaging Committee
The Force Awakens – Neuro Miscellaneous

1707
Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 115
Cardiovascular Committee
Other Cardiovascular Imaging

1708
Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 212
Thyroid Committee- **Featured Session**
Treatment of Benign Thyroid Disease

e-POSTER PRESENTATION SESSIONS

1	Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 111 Bone & Joint + Neuroimaging Committee Miscellaneous – Bone / Brain / Covid-19 / Lung
2	Sunday, October 16, 2022 | 09:45 – 11:45 | Hall 111 Physics Committee Physics
3	Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 111 Inflammation & Infection Committee Best e-Posters on Infection and Inflammation
4	Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 111 Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee New Tracers – From Production to Translation
5	Monday, October 17, 2022 | 08:00 – 09:30 | Hall 111 Cardiovascular Committee e-Posters on Cardiovascular Topics
6	Monday, October 17, 2022 | 09:45 – 11:15 | Hall 111 Physics + Radiation Protection Committee Physics & Radiation Protection
7	Monday, October 17, 2022 | 15:00 – 16:30 | Hall 111 Paediatrics Committee e-Posters on Paediatrics & Nephro-Urology
8	Monday, October 17, 2022 | 16:45 – 18:15 | Hall 111 Neuroimaging Committee Neuro e-Posters
9	Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 111 Oncology & Theranostics Committee Local Therapy and More
10	Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 111 Oncology & Theranostics Committee Oncology
Technologists' Session	Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 116 Technologists Committee Techs' e-Posters
11	Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 111 Dosimetry Committee Dosimetry – Novel Tracers and Computer-Based Modelling
12	Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 111 Oncology & Theranostics Committee Prostate
13	Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 111 Oncology & Theranostics Committee Haematology
14	Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 111 Thyroid Committee A Spotlight on Thyroid and Parathyroid Imaging

AWARDS

EANM will bestow several awards during the EANM'22 Congress.

EANM MARIE CURIE AWARD

Each year the EANM is awarding the best submitted abstract with the prestigious Marie-Curie Award. The Award is bestowed during the EANM Congress Opening Ceremony by the EANM President. It is awarding the best submitted abstract of this year's congress.

EANM YOUNG AUTHORS' AWARD

(kindly supported by United Imaging Healthcare)

EANM is offering an award to three young authors of very good quality abstracts. The purpose of this award is to encourage young and talented nuclear medicine investigators to submit their results to the annual EANM congress and to have the financial aid to attend the meeting and present their work.

EANM SANJIV SAM GAMBHIR YOUNG INVESTIGATOR AWARD

(kindly supported by Telix Pharmaceuticals)

This new award will grant a 3 months visitorship at Stanford University. A jury picked six candidates which will now battle in a session for this award. Monday, October 17, 2022 – 15:00-16:30 in Hall 112 (Arena).

EANM TECHNOLOGISTS' AWARD

(kindly supported by United Imaging Healthcare)

The purpose of the Technologists' Award is to encourage Nuclear Medicine Technologists to present the abstract of their research project at the Annual EANM Congress. 4 Awards will be handed over at the congress.

EJNMMI AWARDS

This year, the EANM and Springer again bestow the EJNMMI Awards for outstanding articles published across the whole journal family during the EANM Annual Congress.
The European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) is the official journal of the EANM and the hand-over of the certificates will take place onsite as well.

Oral Sessions

OC

Saturday, October 15, 2022, 18:00 - 18:35

Auditorium

Opening Ceremony including Awards Ceremony

OP-001
Opening Ceremony including Awards Ceremony
S. Fanti;
University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

101

Saturday, October 15, 2022, 18:35 - 19:35

Auditorium

Plenary 1: Highlights Lecture

OP-002
Highlights Lecture
I. Burger;
University Hospital of Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-003
Highlights Lecture
N. Albert;
LMU University Hospital Munich, Department of Nuclear Medicine, Munich, GERMANY.

OP-004
Highlights Lecture
B. Guillet;
APHM, Radiopharmacy department, University Hospital Marseille, Médecine Nucléaire, Marseille, FRANCE.

OP-005
Highlights Lecture
P. Garrigue;
AP-HM, CERIMED, Aix-Marseille University, Marseille, FRANCE.

201

Sunday, October 16, 2022, 08:00 - 09:30

Auditorium

CME 1 - Oncology & Theranostics Committee: Radionuclide Therapies - Controversies and Special Considerations

OP-006
Thyroid Cancer - Controversies and Special Considerations in Therapy using 131I
L. Giovanella;
Imaging Institute Southern Switzerland, Nuclear Medicine and Molecular Imaging, Bellinzona, SWITZERLAND.

OP-007
Neuroendocrine Tumours - Controversies and Special Considerations in [177Lu]Lu-DOTATATE Therapy
I. Virgolini;
Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA.

OP-008
Prostate Cancer - Controversies and Special Considerations in [^{177}Lu]Lu-PSMA Therapy
A. Agrawal;
Dept of Nuclear Medicine & Molecular Imaging, Tata Memorial Centre,Mumbai, INDIA.

OP-009
HCC and Liver metastases - Controversies and Special Considerations in Selective Internal Radiation Therapy (SIRT)
M. Weber;
Uniklinik Essen, Essen, GERMANY.

202

Sunday, October 16, 2022, 08:00 - 09:30

Hall 112 (Arena)

Debate 1 - Oncology & Theranostics Committee: The Weight of CT in PET/CT

OP-010
Low Dose CT is all we need for PET
W. Vogel;
University Hospital of Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-011
To Answer Clincial Questions You Often Need Both ceCT and PET/CT - Where is the Added Value of the Combination?
I. Burger;
Antoni van Leeuwenhoek ziekenhuis (NKI-AvL), Nuclear Medicine, Amsterdam, NETHERLANDS.

203

Sunday, October 16, 2022, 08:00 - 09:30

Hall 113

LIPS Session 1: Case Report Session 1 - Oncology (including PET and Therapy)

OP-013
Plasmacytoma of the Skull Base - an atypical case
I. C. Ferreira[1], *R. T. Ferreira*[1], *A. Tomé*[2], *F. Campos*[2], *J. G. Santos*[1], *F. Vargas*[2], *A. I. Santos*[1];
[1]*Serviço de Medicina Nuclear - Hospital Garcia de Orta, E.P.E, Almada, PORTUGAL,* [2]*Serviço de Hematologia - Hospital Garcia de Orta, E.P.E, Almada, PORTUGAL.*

OP-014
Is bone scintigraphy still of merit in breast cancer? A case report
H. Boudriga, *W. Touila, A. Ezzine, A. Bettaieb, T. Dardouri, M. Ben Fredj, K. Chatti;*
Sahloul University Hospital, Sousse, TUNISIA.

OP-015
Extensive dermatomyositis revelead Cutaneous Diffuse Large B-Cell Lymphoma
A. Castello, *F. Rossi, N. Rampi, L. Florimonte, M. Castellani;*
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, ITALY.

OP-016
Cervical glomus as possible false positive finding in lymphoma
W. Touila, *M. Maaloul, B. Khrouf, F. Hamza, W. Amouri, F. Guermazi;*
Nuclear medicine department of Habib Bourguiba Hospital, Sfax, TUNISIA.

OP-017
Unusual Late Recurrence of Papillary Thyroid Carcinoma depicted as an Asymmetric Vocal Cord Uptake on F-18-FDG PET/CT
R. Correia, *M. Firsova, N. Testart, M. Nicod-Lalonde, N. Schaefer, J. Prior;*
Lausanne University Hospital, Lausanne, SWITZERLAND.

OP-018
Retropharyngeal lymph node metastasis from papillary thyroid cancer
D. Quijano Galvis[1], *N. Hernández Hidalgo*[1], *C. Avila*[1], *M. Naranjo*[2], *A. González*[2], *H. Varela*[2], *C. Granados*[2], *S. Fanti*[3], *P. Castellucci*[3];
[1]*Fundación Universitaria Sanitas, Bogotá, COLOMBIA,* [2]*Instituto Nacional de Cancerología, Bogotá, COLOMBIA,* [3]*IRCCS Azienda Ospedaliero-Universitaria, Bologna, ITALY.*

OP-019
Interventional Molecular Imaging using 18F-FDG PET/CT in Non-Hodgkin Lymphoma
J. Gambini[1], *E. Silvera, J. Rodríguez, J. Leiva, A. Damian, A. Banchero, M. García Fontes, E. Savio, O. Alonso, P. Duarte;*
Centro Uruguayo de Imagenología Molecular, Montevideo Uruguay, Montevideo, URUGUAY.

OP-020
Peptide receptor radionuclide therapy in radioiodine refractory thyroid cancer: A case report of significant response to lu177 DOTA TATE treatment
A. Aghaee[1], *S. Ataei Nakhaei*[1], *K. Aryana*[1], *S. Mostafavi*[2], *H. Mohammadzadeh Kosari*[1];
[1]*Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

OP-021
Solitary sternal metastasis as first manifestation of a papillary thyroid microcarcinoma: a case report
T. Geliashvili, *A. S. Tyulyandina, P.V. Kononets, A.K. Valiev, I.S. Romanov, T.K. Kharatishvili, A.G. Salkov, A.I. Pronin, E.H. Gadzhieva, A.V. Parnas, V.S. Ilyakov;*
N.N. Blokhin National Medical Research Center of Oncology, Moscow, RUSSIAN FEDERATION.

OP-022
Solitary Pulmonary Nodule revealing Rosai-Dorfman disease
M. Pudis[1], *P. C. Notta*[1], *A. Feu-Llaurado*[2], *R. Llatjos-Sanuy*[2], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine - PET (IDI) Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [2]*Anatomical Pathology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN.*

OP-023
The added value of [68Ga]Ga-FAPI-46 to 2-[18F]FDG in differential diagnosis of Malignant Melanoma
F. Novruzov[1], *E. Mehdi*[1], *H. Mammadzada*[2], *R. Shukurov*[1], *Z. Dadashov*[1], *M. Valiyev*[1], *M. Balashov*[1], *G. Aliyeva*[1], *K. Farkhadzade*[3], *F. Valla*[4], *J. Aliyev*[5];
[1]*Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN,* [2]*Medical Plaza Hospitals, Department of Endocrinology, Baku, AZERBAIJAN,* [3]*Azerbaijan Medical University, Department of Radiology, Baku, AZERBAIJAN,* [4]*SOFIE, Director RCM, Totowa, NJ, UNITED STATES OF AMERICA,* [5]*Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.*

OP-024
[^{123}I]I-MIBG Adrenal Scintigraphy Value In a Case of Recurrent Malignant Pheochromocytoma With Unusual Peritoneal Metastasis
D. Patrut, *A. Montellano Fenoy, J. Villena Salinas, C. Balbin Garcia, E. Espinosa Muñoz, S. Sanz Viedma;*
University Hospital Virgen de la Victoria, Málaga, SPAIN.

OP-025
Case report of Multiple Myeloma: a comparison between 18F-FDG-PET/CT and 68Ga-PSMA-PET/CT
D. Bezzi[1], *S. Fanti*[2], *C. Nanni*[2];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine Unit, IRCCS Azienda spedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-026
Lu-177-PSMA-617 Therapy in a Patient with Chronic Renal Failure
C. Mingels[1], *L. Mercolli*[1], *K. Zeimpekis*[1], *S. Xue*[1], *I. Alberts*[1], *D. Uehlinger*[2], *A. Rominger*[1], *A. Afshar-Oromieh*[1];
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND,* [2]*Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, Bern, SWITZERLAND.*

OP-028
Foreign body type giant cell reaction with extensive granulation tissue and intense inflammation after chemotherapy mimicking residual lymphoma on FDG PET
*W. Zeng[1], **S. Kazi**[1], S. Raptis[2], F. Abbaspour[1];*
[1]The Ottawa Hospital, Ottawa, ON, CANADA,
[2]Montfort Hospital, Ottawa, ON, CANADA.

OP-029
Deramatic Cessation of gross sustained treatment resistant hematuria after lu177-psma therapy, a case report
A. Aghaee[1], *H. Ghorbani[2], V. Roshanravan[1], S. Soltani[2];*
[1]Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,
[2]Kidney transplantation research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

OP-030
NAVIGATOR: An Imaging Biobank to Precisely Prevent and Predict cancer, and facilitate the Participation of oncologic patients to Diagnosis and Treatment
G. Aghakhanyan[1], *A. Barucci[2], S. Colantonio[3], V. Colcelli[2], F. Pasquinelli[4], R. Gini[5], P. Liò[6], M. Mazzei[7], P. Erba[1], V. Miele[8], E. Neri[1,9], NAVIGATOR Consortium Group;*
[1]Department of Translational Research and of New Surgical and Medical Technology, University of Pisa, Pisa, ITALY, [2]"Nello Carrara" Institute of Applied Physics - IFAC of the National Research Council - CNR, Florence, ITALY, [3]Institute of Information Science and Technologies - ISTI of the National Research Council – CNR, Pisa, ITALY, [4]Azienda USL Toscana Centro, Florence, ITALY, [5]Azienda Regionale di Sanità, Florence, ITALY, [6]Department of Computer Science and Technology of the University of Cambridge, Cambridge, UNITED KINGDOM, [7]Unit of Diagnostic Imaging, Department of Medical, Surgical and Neurosciences and of Radiological Sciences, University of Siena, Azienda Ospedaliero-Universitaria Senese, Siena, ITALY, [8]Department of Radiology, Careggi University Hospital, Florence, ITALY, [9]Italian Society of Medical and Interventional Radiology, SIRM Foundation, Milan, ITALY.

OP-031
PSMA PET/CT Detected Prostate Cancer Metastasis in a Patient with Negative mpMRI and Prostate Gland Biopsy
L. Vetrone[1], *G. Cuzzani[1], R. Mei[1], L. Zanoni[2], A. Bertaccini[3,4], L. Bianchi[3,4], P. Castellucci[2], C. Gaudiano[5], A. Cappelli[5], F. Giunchi[6], S. Fanti[1,2];*
[1]Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Nuclear Medicine, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, ITALY, [3]Division of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, ITALY, [4]DIMES, University of Bologna, Bologna, ITALY, [5]Department of Radiology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, ITALY, [6]Pathology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, ITALY.

OP-032
Multiple sequential tumor recurrence in the port site after laparoscopic prostatectomy detected by 68Ga-PSMA PET/CT
N. Hernandez[1], *D. Quijano[1], L. Calderoni[2], S. Fanti[2], R. Mei[2], N. Fraccascia[2], G. Argalia[2], L. Anzola[1], P. Castellucci[2];*
[1]Fundacion Universitaria Sanitas, Bogota, COLOMBIA, [2]IRCCS Azienda Ospedaliero-Universitaria, Bologna, ITALY.

OP-033
PET/MRI features of an intracranial non germinomatous germ cell tumor
B. Ronchi, *G. Peña, M. Henriquez;*
Department of Nuclear Medicine, FUESMEN, Mendoza, ARGENTINA.

204

Sunday, October 16, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: New Radiopharmaceuticals - Fancy Stuff

OP-034
Determining the ideal mass and clinical potential of a bimodal probe for image-guided surgery of GRPR-positive cancer
M. Verhoeven[1], *M. Handula[1], L. van den Brink[1], C. M. A. de Ridder[2], D. C. Stuurman[2], Y. Seimbille[1], S. U. Dalm[1];*
[1]Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS, [2]Department of Experimental Urology, Erasmus MC, Rotterdam, NETHERLANDS.

OP-035
Development and optimization of a dimeric peptide tracer for nerve-sparing surgery
T. Buckle, *M. van Meerbeek, F. W. B. van Leeuwen;*
LUMC, Leiden, NETHERLANDS.

OP-036
A novel ^{18}F-labeled molecular probe for positron emission tomography imaging of oxidative stress
R. Yan, *F. Mota, V. R. Pell, N. Singh, F. Baark, E. Waters, P. Sadasivam, R. Southworth;*
King's College London, London, UNITED KINGDOM.

OP-037
Targetting folate receptor-β expressing macrophages by ^{18}F-labelled folate PET radiotracer in rat model of myocardial infarction
I. Iqbal[1,2], *H. Liljenbäck[1,3], P. Andriana[1], M. Ståhle[1], J. Virta[1], E. A. Herre[1], M. W. G. Miner[1], M. Srinivasarao[4], P. S. Low[4], J. Knuuti[1,2,5], X. G. Li[1,6,5], A. Roivainen[1,2,5], A. Saraste[1,2,7];*
[1]Turku PET Centre, University of Turku, Turku, FINLAND, [2]Turku PET Centre, Turku University Hospital, Turku, FINLAND, [3]Turku Centre For Disease Modeling, University of Turku, Turku, FINLAND, [4]Department of Chemistry, Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA, [5]InFLAMES Research Flagship Center, University of Turku, Turku, FINLAND, [6]Turku PET Centre, Åbo Akademi University, Turku, FINLAND, [7]Heart Centre, Turku University Hospital and University of Turku, Turku, FINLAND.

OP-038
Evaluation of the benefits of a PET imaging-guided apelin-based therapeutic strategy of a preclinical model of stroke
T. Geara;
CERIMED/C2VN, Marseille, FRANCE.

OP-039
Acute response to bone loading in humans assessed using [18F]-NaF PET/MRI
B. Haddock[1], *R. S. Alcantara[2], A. A. Gatti[3], S. R. St. Pierre[4], E. Kuhl[4], M. Peirlinck[5,4,6], C. Suetta[7,8], G. E. Gold[4,3,3], F. Kogan[3];*
[1]Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen, DENMARK, [2]Department of Bioengineering, Stanford University, Stanford, CA, UNITED STATES OF AMERICA, [3]Department of Radiology, Stanford University, Stanford, CA, UNITED STATES OF AMERICA, [4]Department of Mechanical Engineering, Stanford, CA, UNITED STATES OF AMERICA, [5]Department of Biomechanical Engineering, Delft University of Technology, Delft, NETHERLANDS, [6]Department of Biomedical Engineering, Erasmus MC, Rotterdam, NETHERLANDS, [7]Geriatric Research Unit, Department of Geriatric and Palliative Medicine, Bispebjerg and Frederiksberg Hospital, Copenhagen University Hospital, Copenhagen, DENMARK, [8]Geriatric Research Unit, Department of Medicine Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, DENMARK.

OP-040
Monitoring Aspergillus fumigatus infection in rats using ^{68}Ga-siderophores
M. Petrik[1], *A. Palyzova[2], Z. Novy[1], J. Houst[2,3], V. Havlicek[2,3], M. Khoylou[1], M. Popper[1], K. Bendova[1], H. Haas[4], C. Decristoforo[5], M. Hajduch[1];*
[1]Institute of Molecular and Translational Medicine, Palacky University, Olomouc, CZECH REPUBLIC, [2]Institute of Microbiology of the Czech Academy of Sciences, Prague, CZECH REPUBLIC, [3]Department of Analytical Chemistry, Palacky University, Olomouc, CZECH REPUBLIC, [4]Division of Molecular Biology/Biocenter, Medical University Innsbruck, Innsbruck, AUSTRIA, [5]Clinical Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA.

OP-041
In vitro evaluation of [^{18}F]PQ-VE1-vancomycin for bacteria targeted PET imaging
G. Spoelstra[1], *Y. Fu[2], H. Helbert[1,2], N. A. Simeth[1], F. IJpma[1], M. van Oosten[1], J. M. van Dijl[1], D. van der Born[3], G. Luurtsema[1], W. Szymanski[1,2], B. L. Feringa[2], P. H. Elsinga[1];*
[1]University Medical Center Groningen, University of Groningen, Groningen, NETHERLANDS, [2]Faculty of Science and Engineering, University of Groningen, Groningen, NETHERLANDS, [3]FutureChemistry, Agro Business Park 10, 6708 PW, Wageningen, NETHERLANDS.

OP-042
Comparative analysis of cancer cell responses to peptide receptor radionuclide therapy with lutetium-177 labeled minigastrin analogue [^{177}Lu]Lu-PP-F11N and external beam radiotherapy
M. Grzmil[1], *P. Boersema[2], A. Sharma[3], A. Blanc[1], S. Imobersteg[1], M. Pruschy[3], P. Picotti[2], R. Schibli[1,4], M. Behe[1];*
[1]Paul Scherrer Institute, Villigen PSI, SWITZERLAND, [2]Institute of Molecular Systems Biology, Department of Biology, ETHZ, Zürich, SWITZERLAND, [3]Department of Radiation Oncology, University Hospital Zürich, Zürich, SWITZERLAND, [4]Department of Chemistry and Applied Biosciences, ETHZ, Zürich, SWITZERLAND.

205

Sunday, October 16, 2022, 08:00 - 09:30

Hall 211

Cutting Edge Science Track - TROP Session: Radiomics

OP-043
Reliable and Reproducible Tensor Radiomics Features in Prediction of Survival in Head and Neck Cancer
M. Salmanpour[1,2,3], *M. Hosseinzadeh[4,3], S. Rezaeijo[5], M. Maghsudi[6], A. Rahmim[1,2];*
[1]BC Cancer Research Institute, Vancouver, BC, CANADA, [2]University of British Columbia, Vancouver, BC, CANADA, [3]Technological Virtual Collaboration (TECVICO Corp), Vancouver, BC, CANADA, [4]Tarbiat Modares University, Tehran, IRAN, ISLAMIC REPUBLIC OF, [5]Department of Medical Physics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IRAN, ISLAMIC REPUBLIC OF, [6]Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-044
Development and external validation of a PET radiomic model for prognostication of head and neck cancer
W. A. Noortman[1,2], *N. Aide[3], D. Vriens[1], L. Arkes[1,4], C. H. Slump[2], R. Boellaard[5], C. M. Deroose[6], R. Lhommel[7], A. Alessi[8], E. Wolf[9], K. Goffin[6], C. Le Tourneau[10], J. Gal[11], S. Temam[12], J. P. Delord[13], F. H. P. van Velden[1], L. F. de Geus-Oei[1,2];*
[1]Leiden University Medical Center, Leiden, NETHERLANDS, [2]University of Twente, Enschede, NETHERLANDS, [3]Centre Hospitalier Universitaire de Caen, Caen, FRANCE, [4]Delft University of Technology, Delft, NETHERLANDS, [5]Amsterdam University Medical Center, Amsterdam, NETHERLANDS, [6]University Hospitals Leuven, Leuven, BELGIUM, [7]Cliniques Universitaires Saint Luc, Brussels, BELGIUM, [8]Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, [9]Jules Bordet Institute, Brussels, BELGIUM, [10]Institut Curie, Paris & Saint-Cloud, FRANCE, [11]Centre Antoine Lacassagne, Nice, FRANCE, [12]Gustave Roussy, Villejuif, FRANCE, [13]IUCT Oncopole, Toulouse, FRANCE.

OP-045
Recurrence-specific supervised graph clustering for supervised agnostic and perspective risk stratification based on imaging: a proof of concept study on[18F]FDG PET/CT-derived rules to predict Hodgkin Lymphoma outcome
M. Sollini[1], *L. Cavinato[2], N. Gozzi[3], M. Kirienko[4], C. Carlo-Stella[1], M. Biroli[1], C. Rusconi[4], P. Corradini[5], E. Seregni[4], F. Ieva[6], A. Chiti[1];*
[1]Humanitas University, Pieve Emanuele, ITALY, [2]Department of Mathematics, Politecnico di Milano, Milan, ITALY, [3]Department of Health Sciences and Technology, ETH, Zurich, SWITZERLAND, [4]Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY, [5]Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, ITALY, [6]Department of Mathematics, Politecnico di Milano and Center for Health Data Science, Human Technopole, Milan, ITALY.

OP-046
18F-FDG PET/CT scans radiomic features for prediction of overall survival in non-small cell lung cancer patients treated with radical radiotherapy
K. Albattat, *R. Smith, C. Marshall, N. Morley;*
Cardiff University, Cardiff, UNITED KINGDOM.

OP-047
^{68}Ga-PSMA PET radiomics enables accurate and non-invasive prostate cancer staging
S. Ghezzo[1,2], *C. Bezzi[1,2], G. Brembilla[1,3], T. Russo[1,3], I. Gotuzzo[4], E. Preza[2], A. M. Samanes Gajate[2], P. Mapelli[1,2], V. Cucchiara[1,5,6], S. Mongardi[1], I. Neri[2], N. Ahmed[7], M. Freschi[7], A. Briganti[1,5,6], F. De Cobelli[1,3], L. Gianolli[2], P. Scifo[2], M. Picchio[1,2];*
[1]Vita-Salute San Raffaele University, Milan, ITALY, [2]Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY, [3]Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY, [4]School of Medicine and Surgery, University of Milano Bicocca, Monza, ITALY, [5]Department of Urology,IRCCS San Raffaele Scientific Institute, Milan, ITALY, [6]Division of Experimental Oncology, URI, Urological Research Institute, Milan, ITALY, [7]Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-048
Role of radiomics analysis of ^{18}F-Choline (FCh)-PET/CT in predicting biochemical recurrence (BR) in a cohort of intermediate-high risk prostate cancer (PCa) patients (pts) at staging
P. Guglielmo[1], *F. Marturano[1], A. Bettinelli[1], G. Novara[2], M. Gregianin[1], M. Paiusco[1], A. Zorz[1], M. Sepulcri[1], L. Evangelista[2];*
[1]Veneto Institute of Oncology IOV - IRCCS, Padua, ITALY, [2]University of Padua, Padua, ITALY.

OP-049
Can Radiomic Features Derived from [18F]FET PET Images of Glioma Patients Be Pooled When Different Reconstruction Settings or Segmentation Methods Are Used?
A. Zounek, *A. Holzgreve, A. Bollenbacher, J. Brosch-Lenz, G. Böning, P. Bartenstein, N. L. Albert, S. Ziegler, L. Kaiser;*
Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY.

OP-050
Development of 3D-printed inserts for NEMA-phantom simulating necrotic tumor lesions for the evaluation of reproducibility of PET/CT radiomic features
D. Deandreis[1], *V. Liberini*[1], *O. Rampado*[2], *S. Deagostini*[2], *E. Gallio*[2], *P. Thuillier*[1], *L. Lambert*[2], *G. Pennisi*[1], *L. Li Donni*[2];
[1]*Nuclear Medicine Unit, Department of Medical Sciences, University of Turin, Turin, ITALY,* [2]*Medical Physics Unit, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin, ITALY.*

OP-051
Quality Assurance of PET-based Radiomic Features in the Prospective Randomised Multicentre PEPITA-trial
Z. Paquier, *H. Levillain, T. Guiot, B. Vanderlinden, E. Woff, A. Gulyban, N. Reynaert, A. Hendlisz, P. Flamen;*
Institut Jules Bordet – Université Libre de Bruxelles, Anderlecht, BELGIUM.

206

Sunday, October 16, 2022, 08:00 - 09:30

Hall 117

Clinical Oncology Track - TROP Session: Let's Start With Some Prostate

OP-052
Detection and Local Staging of Prostate Cancer by [68Ga]Ga-PSMA-PET/CT, Comparison with mpMRI and Histopathology
Z. Isik[1], *G. Güner*[2], *M. Caglar*[1], *M. Karcaaltincaba*[3], *B. Akdogan*[4], *D. Akinci*[3], *M. Tuncel*[1];
[1]*Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University, Department of Pathology, Ankara, TÜRKIYE,* [3]*Hacettepe University, Department of Radiology, Ankara, TÜRKIYE,* [4]*Hacettepe University, Department of Urology, Ankara, TÜRKIYE.*

OP-053
PSMA PET/CT SUVpeak vs SUVmax in the evaluation of PCa Gleason scores in an initial staging setting
L. Lemos[1], *R. Silva*[1,2], *A. Albuquerque*[1], *G. Costa*[1,3];
[1]*Nuclear Medicine Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,* [2]*ICNAS - Instituto de Ciências Nucleares Aplicadas à Saúde, Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL,* [3]*Faculdade de Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.*

OP-054
PRIMARY scores and primary evaluation-Looking back to see existing patterns
S. Kumar, *Y. Mathur, K. Shankar, V. Krishnaraju, R. Kumar, H. Singh, B. Mittal;*
PGIMER, Chandigarh, INDIA.

OP-055
Additional value of semiquantitative parameters in clinical staging of primary prostate cancer with 68Ga-PSMA PET/CT: preliminary results of prospective single-centre cohort study
J. Jandric[1,2], *M. Rodari*[2], *G. Lughezzani*[1,3], *N. Buffi*[1,3], *G. Guazzoni*[1,3], *P. Casale*[3], *M. Lazzeri*[3], *R. Hurle*[3], *A. Saita*[3], *K. Keus*[1], *V. Fasulo*[1,3], *P. Colombo*[1,4], *M. Cieri*[4], *M. Sollini*[1,2], *A. Chiti*[1,2];
[1]*Humanitas University, Pieve Emanuele - Milan, ITALY,* [2]*IRCCS Istituto Clinico Humanitas, Nuclear Medicine Department, Rozzano, ITALY,* [3]*IRCCS Istituto Clinico Humanitas, Department of Urology, Rozzano, ITALY,* [4]*IRCCS Istituto Clinico Humanitas, Department of Pathology, Rozzano, ITALY.*

OP-056
Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging in prostate cancer with extended lymph node dissection as reference method
E. Hvittfeldt[1,2,3], *J. Ingvar*[4,3], *E. Trägårdh*[1,2,3], *A. Simoulis*[5], *A. Bjartell*[4,3];
[1]*Wallenberg Centre for Molecular Medicine, Lund University, Lund, SWEDEN,* [2]*Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN,* [3]*Department of Translational Medicine, Lund University, Lund, SWEDEN,* [4]*Department of Urology, Skåne University Hospital, Malmö, SWEDEN,* [5]*Department of Clinical Pathology and Cytology, Skåne University Hospital, Malmö, SWEDEN.*

OP-057
68Ga-PSMA-11 PET for quantitative and qualitative response assessment in newly diagnosed prostate cancer patients following Androgen Deprivation Therapy
A. Mohite, *A. Agrawal, V. Murthy, P. Maitre, P. Mehta, N. Purandare, S. Shah, A. Puranik, S. Choudhury, V. Rangarajan;*
Tata Memorial Hospital, Mumbai, INDIA.

OP-058
18F-Choline PET/CT and conventional imaging vs. conventional imaging alone in patients with intermediate and high prostate cancer before curative intent therapy (IOV-PR-CH-1-2013): a prospective, open, randomized, multicenter study
L. Evangelista[1], *D. Bertin*[2], *E. Borsatti*[3], *G. Trifiro*[4], *E. Brugola*[4], *M. Farsad*[5], *E. Trenti*[6], *F. Chierichetti*[7], *D. Donner*[7], *M. Bartolomei*[8], *L. Urso*[8], *E. Cracco*[9], *M. Gallan*[9], *L. Setti*[10], *E. Bombardieri*[10], *P. Del Bianco*[11], *G. Magni*[11], *G. L. De Salvo*[11], *G. Novara*[12];
[1]*Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padua, ITALY,* [2]*Nuclear Medicine Unit, Istituto Oncologico Veneto IOV – IRCCS, Padua, ITALY,* [3]*Nuclear Medicine Unit, IRCCS CRO, Aviano, ITALY,* [4]*Nuclear Medicine Unit, ICS Maugeri SpA SB IRCCS, Pavia, ITALY,* [5]*Nuclear Medicine Unit, Central Hospital Bolzano/Bozen, Bolzano, ITALY,* [6]*Department of Urology, Hospital of Bolzano SABES-ASDAA, Bolzano, ITALY,* [7]*Nuclear Medicine Unit, S. Chiara Hospital, Trento, ITALY,* [8]*Nuclear Medicine Unit, Diagnostic Imaging and Laboratory Medicine Department, University of Ferrara, Ferrara, ITALY,* [9]*Nuclear Medicine Unit, Hospital of Angelo, Mestre, Venezia, ITALY,* [10]*Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, ITALY,* [11]*Clinical Research Unit, Istituto Oncologico Veneto IOV – IRCCS, Padua, ITALY,* [12]*Urology Unit, Department of Surgery, Gastroenterology and Oncology (DISCOG), Unversity of Padua, Padua, ITALY.*

OP-059
Clinical impact of [68Ga]Ga-PSMA-11 PET/CT in patients with persistent PSA after radical prostatectomy
J. C. Ferro, *J. Teixeira, S. Fontão de Castro, I. Próspero, D. Barbosa, G. Ferreira, L. Violante, I. Lucena Sampaio, F. Lopes, H. Duarte;*
Instituto Português de Oncologia do Porto Francisco Gentil, Oporto, PORTUGAL.

OP-060
PROMISE-criteria inspired quantitative response in PSMA PET to androgen deprivation in patients with treatment naïve castration sensitive prostate cancer
A. Anand[2], *N. Nickols*[1], *S. Duriseti*[1], *K. Sjostrand*[2], *G. Berenji*[1], *N. Kane*[3], *C. Smith*[3], *M. Rettig*[1];
[1]*VA Greater Los Angeles Healthcare System, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*EXINI Diagnostics, Lund, SWEDEN,* [3]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.*

207

Sunday, October 16, 2022, 08:00 - 09:30

Hall 115

Paediatrics Committee - TROP Session: Nephro-Urology and Paediatrics

OP-061
Can metabolic PET parameters help in differentiating various subtypes and grade of tumor in renal cell carcinoma ?
Y. Jain, *A. Agrawal, V. Rangarajan, N. Purandare, S. Shah, A. Puranik, S. Choudhury, G. Prakash, S. Menon, M. Pal;*
Tata Memorial Hospital, Mumbai, INDIA.

OP-062
Diagnostic accuracy of 18F-FDG PET/CT in the evaluation of lung nodules in patients affected by Clear Cells Renal Carcinoma
M. Cuomo[1,2], *L. S. Airò Farulla*[1,2], *L. L. Travaini*[1], *G. Buonsanti*[1], *S. Frassoni*[3], *D. Galetta*[4], *V. Bagnardi*[3], *L. Spaggiari*[4,2], *F. Ceci*[1,2];
[1]*Division of Nuclear Medicine and Theranostics, IEO European Institute of Oncology, IRCCS, Milan, ITALY,* [2]*Department of Oncology and Hemato-Oncology, University of Milan, Milan, ITALY,* [3]*Department of Statistics and Quantitative Methods, University of Milan-Bicocca, Milan, ITALY,* [4]*Department of Department of Thoracic Surgery, IEO European Institute of Oncology, IRCCS, Milan, ITALY.*

OP-063
Comparison of GFR measurement with a double plasma sample technique using [99mTc]Tc-DTPA vs Gates' method in potential kidney donors
J. Carvalho, *A. Marques, F. Abreu, S. Pintão;*
Centro Hospitalar de Lisboa Ocidental, Carnaxide, PORTUGAL.

OP-064
Renal [18F]PSMA-1007 uptake correlates to estimated glomerular filtration rate
K. Valind[1,2], *J. Jögi*[1,2], *D. Minarik*[1,3], *E. Trägårdh*[1,2];
[1]*Wallenberg Centre for Molecular Medicine, Lund University, Lund, SWEDEN,* [2]*Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Lund and Malmö, SWEDEN,* [3]*Radiation Physics, Skåne University Hospital, Lund and Malmö, SWEDEN.*

OP-065
Normal values of Normalised residual activity at 20 minutes (NORA20) and output efficiency at 20 minutes (OE20) on 99mTc-ethylenedicysteine (EC) diuretic renogram for children less than and equal to 12 years of age
A. Palo, *M. Ponnusamy, K. Sambandan, P. Mathiyazhagan;*
Jawaharlal Institute of Medical Education and Research, Pondicherry, INDIA.

OP-066
Determination of Normal Gastric Emptying Values in Pediatric Age Groups
Z. Isik, *B. Volkan-Salancı, P. Kıratlı;*
Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-067
Interest of whole-body SPECT-CT imaging in the management of patients with neuroblastoma
P. Blanc, *E. Cassol, L. Guillon, M. Skrzypczyk, P. Payoux;*
University Hospital of Toulouse Purpan, Toulouse, FRANCE.

OP-068
Can FDG PET-CT Predict Chemobrain in Pediatric Lymphoma Patients?
G. Kaya, *B. Volkan Salancı, P. Özgen Kıratlı;*
Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-069
Comparison of 99mTc-DTPA One-sample Glomerular Filtration Rate Determination (EANM Guideline) with Non-radionuclide Methods in Adolescents
P. Koranda[1], *H. Flögelová*[2], *R. Navrátil*[1], *L. Štefaničková*[3], *L. Quinn*[1], *M. Kamínek*[1];
[1]*Dept. of Nuclear Medicine, Univ. Hospital and Palacký University, Olomouc, CZECH REPUBLIC,* [2]*Dept. of Paediatrics, Univ. Hospital and Palacký University, Olomouc, CZECH REPUBLIC,* [3]*Dept. of Clinical Biochemistry, Univ. Hospital and Palacký University, Olomouc, CZECH REPUBLIC.*

208

Sunday, October 16, 2022, 08:00 - 09:30

Hall 212

Joint Symposium 1 - Cardiovascular Committee / EACVI: Anatomical & Functional Cardiac Imaging – Friend or Foe?

OP-070
What Have We Learned from Clinical Studies in the Past 10 Years?
D. Neglia;
Fondazione Toscana G. Monasterio, Cardiovascular and Imaging Departments, Pisa, ITALY.

OP-071
Anatomical Imaging First - For Which Patients?
A. Rossi;
University Hospital Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-072
Functional Imaging First - For Which Patients?
C. Nappi;
University Federico II, Department of Advanced Biomedical Sciences, Naples, ITALY.

OP-073
What is the Current Best Strategy for Imaging CAD Patients?
C. Rischpler;
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

210

Sunday, October 16, 2022, 08:00 - 09:30

Hall 116

CTE 1 - Technologists Committee / SNMMI: Tech Guide Launch

OP-074
The Role of a Nuclear Medicine Technologist in Radionuclide Therapy Management
D. Gilmore;
School of Medical Imaging and Therapeutics, Boston, UNITED STATES OF AMERICA.

OP-075
Pre- and Post-Therapy Imaging
C. Wendorf;
University of California San Diego Health, San Diego, UNITED STATES OF AMERICA.

OP-076
Hospitalisation During Radionuclide Therapy Assessment
L. Pereira;
Maidstone and Tunbridge Wells NHS Trust, Nuclear Medicine, Royal Turnbridge Wells, UNITED KINGDOM.

301

Sunday, October 16, 2022, 09:45 - 11:15

Auditorium

CME 2 - Thyroid + Translational Molecular Imaging & Therapy Committee: Parathyroid Imaging

OP-077
The EANM Practice Guideline for Parathyroid Imaging
P. Petranović Ovčariček;
Department of oncology and Nuclear medicine, University Hospital Center "Sestre milosrdnice", Zagreb, CROATIA.

OP-078
[^{18}F]Fluorocholine PET-CT Imaging of Parathyroid Adenoma
E. Quak;
Department of nuclear medicine, Centre François Baclesse, Caen, FRANCE.

OP-079
Parathyroid Ultrasonography - Tips and Tricks
M. Gotthardt;
Department of nuclear medicine, Radboud UMC, Nijmegen, NETHERLANDS.

OP-080
Minimal Invasive Parathyroid Surgery - What the Surgeon Wants to Know
T. van Ginhoven;
Department of surgery, ErasmusMC, Rotterdam, NETHERLANDS.

302

Sunday, October 16, 2022, 09:45 - 11:15

Hall 112 (Arena)

Challenge the Expert 1 - Oncology & Theranostics Committee: Expert vs Team Barcelona: Prostate Imaging

OP-081
D. Murphy*[1] *vs A. Flotats Giralt, A. Cobo, R. Valhondo-Rama, R. Bellviure, P. Stefaneli, M. Velasco;
[1]*The Peter MacCallum Cancer Centre, Department of Urological Oncology, Melbourne, AUSTRALIA.*

303

Sunday, October 16, 2022, 09:45 - 11:15

Hall 113

LIPS Session 2 - Cardiovascular + Inflammation & Infection Committee: Tricky Cases on Nuclear Cardiology
Interactive Session

OP-088
Cardiac Sarcoidosis
F. Caobelli;
Universitätsspital Basel, Klinik für Nuklearmedizin, Basel, SWITZERLAND.

OP-089
Cardiac Amyloidosis
S. Ben Haim;
Hadasah Medical Center, Department of Nuclear Medicine, Jerusalem, ISRAEL.

OP-090
CAD
S. Massalha;
Rambam Health Care Campus, Cardiology, Haifa, ISRAEL.

OP-091
Endocarditis
P. Ferro;
San Raffaele Hospital, Department of Nuclear Medicine, Milan, ITALY.

304

Sunday, October 16, 2022, 09:45 - 11:15

Hall 114

M2M Track - TROP Session: Therapy - Innovations and Technical Improvements

OP-092
Development and preclinical evaluation of a radiolabeled FAPI tetramer as a theranostic agent for molecular imaging and therapy in cance
Y. Pang, *L. Zhao, J. Chen, Q. Lin, H. Chen;*
The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

OP-093
Preclinical Evaluation of HER2-targeting DARPin G3: Impact of Albumin Binding Domain (ABD) Fusion
M. Oroujeni[1,2], *A. Vorobyeva*[1,3], *J. Garousi*[1,4], *A. Rosly*[1], *A. Orlova*[1,3], *A. Schulga*[3,5], *E. Konovalova*[5], *S. M. Deyev*[3,5], *V. Tolmachev*[1,3];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Affibody AB, Stockholm, SWEDEN,* [3]*Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION,* [4]*Royal Institute of Technology, Stockholm, SWEDEN,* [5]*Russian Academy of Sciences, Moscow, RUSSIAN FEDERATION.*

OP-094
Radiolabeling and preclinical evaluation of [^{225}Ac]Ac-DOTA-JR11 for targeted alpha therapy of neuroendocrine tumors
M. Handula[1], *E. de Blois*[1], *J. Nonnekens*[1], *A. Denkova*[2], *Y. Seimbille*[1,3];
[1]*Erasmus MC, Rotterdam, NETHERLANDS,* [2]*Delft University of Technology, Delft, NETHERLANDS,* [3]*TRIUMF, Vancouver, BC, CANADA.*

OP-095
Preparation of 188Re-Cetuximab as a potential Radiopharmaceutical for EGFR+ tumor treatment and performing quality control, stability study and preclinical evaluation
B. Alirezapour[1], *H. Yousefnia*[1], *A. Samani*[1], *B. Azizkalantari*[2];
[1]*Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Pars Isotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

OP-096
Standardization of labelling procedure and extraction yield of ^{188}Re-N-DEDC lipiodol using indigenously produced lyophilized freeze-dried kits for therapy of unresectable hepatocellular carcinoma (HCC) - A single center experience
N. Kumar[1], *P. Gupta*[1], *S. A. Shamim*[1], *V. Chirayil*[2], *S. Subramanian*[2], *M. Mallia*[2], *C. Bal*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*Bhabha Atomic Research Centre, Mumbai, INDIA.*

OP-097
Production experiments for ^{225}Ac using an electron linear accelerator and radiolabeling tests using the produced alpha emitter
M. Maeda[1], *T. Tadokoro*[1], *Y. Ueno*[1], *K. Nishida*[1], *Y. Kani*[1], *T. Sasaki*[2], *T. Watanabe*[2], *H. Kikunaga*[3], *S. Kashiwagi*[3], *K. Shirasaki*[4], *S. Sekimoto*[5], *T. Ohtsuki*[5], *M. Inagaki*[5], *S. Fukutani*[5], *Y. Shibahara*[5], *H. Fujii*[6], *M. Yoshimoto*[6], *K. Ohnuki*[6];
[1]*Hitachi, Ltd., Research & Development Group, Hitachi, JAPAN,* [2]*Hitachi, Ltd., Healthcare Business Division, Tokyo, JAPAN,* [3]*Research Center for Electron Photon Science, Tohoku University, Sendai, JAPAN,* [4]*Institute for Materials Research, Tohoku University, Sendai, JAPAN,* [5]*Institute for Integrated Radiation and Nuclear Science, Kyoto University, Kumatori-Cho, JAPAN,* [6]*National Cancer Center, Exploratory Oncology Research & Clinical Trial Center, Kashiwa, JAPAN.*

OP-098
Actinium-225 radiopharmaceutical quality control considerations for accelerator-produced actinium therapies
D. Abou[1], *P. Zerkel*[1], *J. Robben*[1], *M. McLaughlin*[2], *T. Hazlehurst*[2], *D. Morse*[3], *T. Wadas*[4], *P. Darpan*[4], *R. Oyama*[1], *G. Gaehle*[1], *M. Nickles*[1], *D. L. J. Thorek*[1];
[1]*Washington University School of Medicine, Saint Louis, MO, UNITED STATES OF AMERICA,* [2]*Modulation Therapeutics, Morgantown, WV, UNITED STATES OF AMERICA,* [3]*Moffitt Cancer Center, Tampa, FL, UNITED STATES OF AMERICA,* [4]*University of Iowa, Iowa city, IA, UNITED STATES OF AMERICA.*

OP-099
Practical Aspects of the (Clinical) Implementation of Ac-225 Labelled Radiopharmaceuticals
E. Hooijman, *C. M. Ntihabose, E. de Blois;*
Erasmus MC, Rotterdam, NETHERLANDS.

OP-100
Optimizing the yield of ^{211}At
M. Sevenois[1], *H. J. Jensen*[2], *M. D'Huyvetter*[1], *P. Covens*[1];
[1]*In vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel (VUB), Brussel, BELGIUM,* [2]*Cyclotron and PET unit KF-3982, Copenhagen University Hospital, Copenhagen, DENMARK.*

305

Sunday, October 16, 2022, 09:45 - 11:15

Hall 211

Cutting Edge Science Track - TROP Session: Current Issues in Radiation Protection

OP-101
Release Criteria and Exposure Evaluation after Discharge of Patients Undergoing Molecular Radiotherapies
D. Ciucci, *C. Polito, F. Martire, S. Donatiello, A. Napolitano, M. Pizzoferro, M. F. Villani, C. Altini, M. C. Garganese, V. Cannatà;*
IRCCS Bambino Gesù Children's Hospital, Rome, ITALY.

OP-102
Urinary excretion kinetics of ^{177}Lu-PSMA
S. M. B. Peters[1], *M. de Bakker*[1], *N. Dominicus*[1], *A. Meeuwis*[1], *M. J. R. Janssen*[1], *M. W. Konijnenberg*[2,1], *J. Nagarajah*[1];
[1]*Radboudumc, Nijmegen, NETHERLANDS,* [2]*Erasmus MC, Rotterdam, NETHERLANDS.*

OP-103
Thyroid blockade during ^{123}I-MIBG scan: Comparison of standard methods to last hours, on site iodine administration
A. Monaci[1], *S. Valente*[1], *P. Saletti*[1], *A. Tondo*[2], *V. Papadakis*[3], *C. Olianti*[1];
[1]*University Hospital Careggi, Florence, ITALY,* [2]*University Hospital Meyer, Firenze, ITALY,* [3]*Agia Sofia Children's Hospital, Athens, GREECE.*

OP-104
Radiation Exposure of ^{124}I-MIBG Imaging in Adult Patients with Neuroendocrine Tumours
A. Moraitis, *G. Reiter, D. Kersting, M. M. Weber, W. P. Fendler, K. Herrmann, P. Fragoso Costa, W. Jentzen;*
Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY.

OP-105
Radiological Protection in PET and PET/CT. ICRP Task Group 117
J. Martí-Climent[1], *C. J. Martin*[2], *S. Demeter*[3], *S. Holm*[4], *M. Hosono*[5], *K. Kang*[6], *M. Marengo*[7], *D. Newman*[8], *A. I. Santos*[9], *F. Vanhavere*[10];
[1]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*University of Glasgow, Glasgow, UNITED KINGDOM,* [3]*Faculty of Health Sciences, Winnipeg, MB, CANADA,* [4]*Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK,* [5]*Kindai University Faculty of Medicine, Osaka, JAPAN,* [6]*Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [7]*University of Bologna, Bologna, ITALY,* [8]*Sanford Health System, Fargo, ND, UNITED STATES OF AMERICA,* [9]*Hospital Garcia de Orta, Almada, PORTUGAL,* [10]*Belgian Nuclear Research Centre, Mol, BELGIUM.*

OP-106
Assessment of patients undergoing multiple^{18}F-FDG PET/CT scans
M. Abuqbeitah[1], *M. Demir*[1], *M. Rehani*[2];
[1]*Istanbul University-Cerrahpaşa, Istanbul, TÜRKIYE,* [2]*Massachusetts General Hospital (MGH), Boston, MA, UNITED STATES OF AMERICA.*

OP-107
Radiation exposure in nuclear medicine - evaluation of finger doses and influence of new isotopes
A. McCann[1], *N. Cherbuin*[2], *P. Covens*[3], *L. Cunha*[4], *J. Dabin*[5], *A. Zorz*[6], *R. Kollaard*[7];
[1]*St Vincent's University Hospital, Dublin, IRELAND,* [2]*Institut de Radiophysique, University Hospital (CHUV), Lausanne, SWITZERLAND,* [3]*In vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel (VUB), Brussels, BELGIUM,* [4]*Department of Nuclear Medicine, IsoPor-Azores, Angra do Heroismo, PORTUGAL,* [5]*Research in Dosimetric Applications, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM,* [6]*Department of Medical Physics, Veneto Institute of Oncology IOV-IRCCS, Padua, ITALY,* [7]*Department of Radiation Protection, Nuclear Research and Consultancy Group (NRG), Arnhem, NETHERLANDS.*

OP-108
Extremity dosimetry and real-time monitoring of nuclear medicine workers during management of Ga68-DOTATOC
M. Riveira Martin[1], *L. Struelens*[2], *J. Muñoz Iglesias*[3], *W. Schoonjans*[2], *O. Van Hoey*[2], *S. Martinez Bernardez*[4], *F. Salvador Gomez*[4], *A. Lopez Medina*[4];
[1]*Galicia Sur Health Research Institute, Vigo, SPAIN,* [2]*Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM,* [3]*University Hospital of Vigo (SERGAS), Vigo, SPAIN,* [4]*University Hospital of Vigo (GALARIA), Vigo, SPAIN.*

OP-109
Skin dose due to positrons in the manipulation of PET radiopharmaceuticals
M. Marengo[1], *S. Rubow*[2];
[1]*University of Bologna, Bologna, ITALY,* [2]*University of Stellenbosch, Stellenbosch, SOUTH AFRICA.*

306

Sunday, October 16, 2022, 09:45 - 11:15

Hall 117

Clinical Oncology Track - TROP Session: Gastro and Colorectal

OP-110
Prognostic Value of 68Ga-FAPI PET/CT compared with18F-FDG PET/CT in Esophageal Squamous Cell Carcinoma
L. Zhao, *Y. Pang, S. Chen, H. Chen, Q. Lin;*
The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

OP-111
Comparison of ^{68}Ga-FAPI-46 Uptake 20 and 60 Minutes Post Injection in Healthy Tissues and Pathologic Lesions in 15 Patients After Resection of Pancreatic Ductal Adenocarcinoma
L. van Genabith[1], *J. Hoppner*[1,2], *U. Heger*[3], *F. L. Giesel*[4,1], *A. van Genabith*[1], *U. Haberkorn*[1,5,6], *M. Röhrich*[1];
[1]*Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY,* [2]*Department of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, GERMANY,* [3]*Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, GERMANY,* [4]*Department of Nuclear Medicine, University Hospital Düsseldorf, Düsseldorf, GERMANY,* [5]*Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research DZL, Heidelberg, GERMANY,* [6]*Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, GERMANY.*

OP-112
The Role of [^{68}Ga]Ga-DOTA-FAPI-04 PET/CT on Altering Stage in Patients with Non-FDG-avid Lesions
G. Beydagi[1], *N. Alan Selcuk*[1], *E. Demirci*[1], *K. Akcay*[1], *B. Oven*[2], *S. Celik*[2], *F. Sen*[3], *O. Sonmez*[4], *B. Caner*[1], *T. Toklu*[1], *M. Ocak*[5], *L. Kabasakal*[6];
[1]*Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Yeditepe University, Department of Medical Oncology, Istanbul, TÜRKIYE,* [3]*Avrasya Hospital, Department of Medical Oncology, Istanbul, TÜRKIYE,* [4]*Yeditepe University, Faculty of Medicine, Istanbul, TÜRKIYE,* [5]*Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE,* [6]*Istanbul University-Cerrahpasa Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

OP-113
Comparison of Ga68-FAPI-04 PET/CT and F18-FDG PET/CT for the Evaluation of Gastric Adenocarcinoma: Preliminary Results
E. Beyhan, *Ö. Erol Fenercioğlu, R. Şahin, G. Alçın, T. Aksoy, E. Arslan, N. Ergül, T. F. Çermik;*
University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

OP-114
[68Ga]Ga-FAPI-04 and [18F]FDG PET/CT in Patients With Primary Liver Malignancies
S. Karadogan[1], *Y. Sanli*[1], *S. M. Erturk*[2], *A. C. Ibis*[3], *S. Kuyumcu*[1];
[1]*Istanbul University, Istanbul Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Istanbul Medical Faculty, Department of Radiology, Istanbul, TÜRKIYE,* [3]*Istanbul University, Istanbul Medical Faculty, Department of General Surgery, Istanbul, TÜRKIYE.*

OP-115
Role of ^{68}Ga FAPI-04 PET/CT in imaging signet ring cell carcinoma of gastro-intestinal tract (SRC-GIT)
S. Choudhury, *A. Agrawal, S. Shah, N. Purandare, A. Puranik, A. Mohite, Y. Jain, V. Rangarajan;*
Tata Memorial Hospital, Homi Bhaba National Institute, Mumbai, INDIA.

OP-116
The Relationship of Parameters Obtained From 18F-FDG PET/MR and Pelvic MR Images With Distance Metastasis in Primary Rectal Cancer
L. Atay[1], *K. Şeker*[1], *U. Aydos*[1], *M. Uçar*[2], *Ü. Ö. Akdemir*[1];
[1]*Gazi University Faculty of Medicine, Department of Nuclear Medicine, Besevler Ankara, TÜRKIYE,* [2]*Gazi University Faculty of Medicine, Department of Radiology, Besevler Ankara, TÜRKIYE.*

OP-117
The Role of 68Ga-FAPI-04 PET/CT in Staging of Rectal Cancer
Ö. Erol Fenercioglu, *E. Beyhan, R. Şahin, G. Alçın, T. Aksoy, E. Arslan, T. F. Çermik, N. Ergül;*
University of Health Sciences Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

OP-118
The value of 18F-FDG PET/MR whole body imaging in staging of hepatoblastoma in children
Y. Xu[1], *J. Wang*[2], *J. Liang*[1], *F. Wang*[1];
[1]*Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA,* [2]*Children's Hospital of Soochow University, Suzhou, CHINA.*

307

Sunday, October 16, 2022, 09:45 - 11:15

Hall 115

Paediatrics Committee - Featured Session: A Bit of Everything - Mix NM

OP-119
Miscellaneous Conventional Nuclear Medicine - What For?
M. Kalnina;
Pauls Stradins Clinical University Hospital, Radiology, Riga, LATVIA.

OP-120
SPECT VQ Parenchymal PE quantification correlation with clinical sequelae
B. Fernando[1,2], *B. Mukherjee*[2], *L. Lefteris*[1,2], *C. J. Fowler*[1,2];
[1]*King's College London, London, UNITED KINGDOM,* [2]*Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UNITED KINGDOM.*

OP-121
Biodistribution of Indium111-radiolabelled platelets: feasibility of examination on 360° CZT digital SPECT/CT16
P. Guerard, *E. Cassol, P. Blanc, M. Alonso, P. Payoux, A. Salabert;*
University Hospital of Toulouse Purpan, Toulouse, FRANCE.

OP-122
Clinical validation of ^{99m}Tc-MDP and ^{99m}Tc-MIBI labeled with cyclotron-produced sodium ^{99m}Tc pertechnetate, an advantageous alternative to generator-produced pertechnetate
E. Croteau[1,2], *A. Huot-Daneault*[2], *R. Ouellet*[1], *C. Pouliot*[1], *J. Rousseau*[1], *E. Lavallee*[1], *E. E. Turcotte*[1,2], *E. Rousseau*[1,2], *B. Guérin*[1,2];
[1]*Sherbrooke Molecular Imaging Center (CIMS), Sherbrooke University Hospital Research Center (CR-CHUS), Sherbrooke, QC, CANADA,* [2]*Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health Sciences, Sherbrooke University, Sherbrooke, QC, CANADA.*

OP-123
^{18}F-FDG Gallbladder Uptake: Observation from a Total-Body PET/CT Scanner
A. Calabro'[1], *Y. G. Abdelhafez*[2], *E. K. A. Triumbari*[3], *B. A. Spencer*[2], *M. S. Chen, Jr.*[2], *D. Albano*[1], *C. R. Cassim*[4], *F. Bertagna*[1], *F. Dondi*[1], *S. R. Cherry*[2], *R. D. Badawi*[2], *F. Sen*[2], *L. Nardo*[2];
[1]*ASST Spedali Civili of Brescia, University of Brescia, Brescia, ITALY,* [2]*University of California Davis, Davis, CA, UNITED STATES OF AMERICA,* [3]*Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY,* [4]*Sangre Grande Hospital, Eastern Regional Health Authority, Sangre Grande, TRINIDAD AND TOBAGO.*

OP-124
Utility of gastric emptying scintigraphy in the diagnosis of diabetic and non-diabetic gastroparesis: 2018 - 2022 preliminary results
J. Echeverri Diaz, *C. Espinet Coll, A. Cardozo Saavedra, D. Villasboas Rosciolesi, S. Aguadé Bruix;*
Hospital Univeritario Valle Hebron, Barcelona, SPAIN.

OP-125
Collateral Findings In Early And Late [68Ga]Ga-FAPI-PET/CT Scans Among Oncological Patients
E. Fortunati[1], *G. Cuzzani*[1], *S. Telo*[1,2], *C. Nanni*[3], *P. Castellucci*[3], *A. Farolfi*[3], *L. Zanoni*[3], *C. Malizia*[4], *F. Lodi*[4], *V. Cabitza*[4], *F. Antonacci*[5], *P. Solli*[5], *M. Ferrari*[6], *F. Natali*[6], *T. Galasso*[6], *G. Bandelli*[6], *P. Candoli*[6], *S. Grendele*[7], *S. Zanotti*[7], *M. Taffurelli*[7], *A. Perrone*[8,9], *M. Tesei*[8,9], *P. De Iaco*[8,9], *S. Fanti*[1,3];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine Department, AUSL Romagna, Romagna, ITALY,* [3]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Division of Thoracic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*Interventional Pulmunology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [7]*Breast Surgery, Department of Oncology and Hematological Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [8]*Division of Oncologic Gynecology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [9]*Department of Medical and Surgical Sciences (DIMEC)-Centro di Studio e Ricerca delle Neoplasie Ginecologiche (CSR), University of Bologna, Bologna, ITALY.*

OP-126
Analysis of liver and pancreatic enzymes and ^{68}Ga-FAPI-46 uptake of hepatic and pancreatic parenchyma after 20 and 60 minutes in patients after resection of pancreatic ductal adenocarcinoma
J. Hoppner, *L. Steinbach, L. Sperling, T. Colbatzky, U. Heger, U. Haberkorn, M. Röhrich;*
Universitätsklinikum Heidelberg, Heidelberg, GERMANY.

OP-127
Quantitative Lymphoscintigraphy of the Lower Limbs: is Unusually High Ilio-Inguinal Nodal Uptake a Sign of Underlying Venous Disease?
H. McMeekin[1,2], *A. M. Peters*[3], *M. Burniston*[1], *M. Vadrucci*[1];
[1]*Barts Health NHS Trust, London, UNITED KINGDOM,* [2]*Hermes Medical Solutions, London, UNITED KINGDOM,* [3]*King's College London, London, UNITED KINGDOM.*

308

Sunday, October 16, 2022, 09:45 - 11:15

Hall 212

Neuroimaging Committee - TROP Session: Neurodegeneration - Ready for Beta! Ready for Tau?

OP-128
Visual assessment of [^{18}F]flortaucipir PET across the Alzheimer's disease continuum and in dementia with Lewy Bodies

E. Coomans[1], *L. de Koning*[1], *R. Rikken*[1], *S. Verfaillie*[1], *D. Visser*[1], *A. den Braber*[2], *E. Lemstra*[2], *P. Scheltens*[2], *W. van der Flier*[2], *R. Ossenkoppele*[2], *B. van Berckel*[1], *E. van der Giessen*[1];
[1]*Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,*
[2]*Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS.*

OP-129
Deep learning-based classification improves clinical interpretation of [^{18}F]florzolotau PET

J. Lu[1,2], *C. Clement*[2], *Q. Zhao*[3], *X. Li*[3], *M. Wang*[4,5], *T. Yen*[6], *J. Hong*[2], *M. Brendel*[7], *L. Lopes*[2], *A. Rominger*[2], *J. Wang*[3], *F. Liu*[3], *C. Zuo*[1], *K. Shi*[2,5], *Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI);*
[1]*PET Center & National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA,*
[2]*Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND,* [3]*Department of Neurology & National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA,* [4]*Institute of Biomedical Engineering, School of Life Science, Shanghai University, Shanghai, CHINA,* [5]*Department of Informatics, Technical University of Munich, Munich, GERMANY,* [6]*APRINOIA Therapeutics Co., Ltd, Suzhou, CHINA,* [7]*Department of Nuclear Medicine, University of Munich, Munich, GERMANY.*

OP-130
Regional amyloid load contributes to stage-dependent tau spreading

M. Hoenig[1,2], *G. Bischof*[1,2], *T. van Eimeren*[2], *A. Drzezga*[1,2,3];
[1]*Research Center Juelich, Juelich, GERMANY,* [2]*University Clinic Cologne, Cologne, GERMANY,* [3]*German Center for Neurodegenerative Diseases, Cologne, GERMANY.*

OP-131
New ^{18}F-MK6240 PET quantification method (Total Tau Brain Load) outclasses CSF P-tau/AB42 ratio for predicting cognitive performances in Alzheimer-spectrum subjects

T. Gérard, *L. Quenon, V. Malotaux, L. Colmant, A. Ivanoiu, B. Hanseeuw, R. Lhommel;*
Université Catholique de Louvain, Brussels, BELGIUM.

OP-132
Feasibility of a simplified semi-quantification approach for Flortaucipir-PET

L. Iaccarino, *M. Lu, A. Arora, S. Southekal, V. Kotari, S. Shcherbinin, M. Pontecorvo;*
Eli Lilly and Company, Indianapolis, IN, UNITED STATES OF AMERICA.

OP-133
[^{18}F]PI-2620 staging tau pathology in Down Syndrome

V. Camacho[1], *J. Pegueroles*[2,3], *I. Barroeta*[2,3], *A. Fernández*[1], *D. López-Mora*[1], *M. Sizova*[1], *S. Abouzian*[1], *P. Stefanelli*[1], *M. Carmona-Iragui*[2,3], *J. Duch*[1], *M. Estorch*[1], *A. Lleó*[2,3], *J. Forteа*[2,3], *A. Flotats*[1];
[1]*Nuclear Medicine Department. Hospital Sant Pau.Universitat Autònoma de Barcelona, Barcelona, SPAIN,* [2]*Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, SPAIN,* [3]*CIBERNED, Madrid, SPAIN.*

OP-134
Prognostic Value of ATN Profiles in a Memory Clinic Cohort

D. Peretti, *F. Ribaldi, S. Tomczyk, S. Stampacchia, M. Scheffler, G. Frisoni, V. Garibotto;*
University of Geneva, Geneva, SWITZERLAND.

OP-135
The use of amyloid-PET in memory clinic patients: AMYPAD Diagnostic and Patient Management Study

D. Altomare[1], *F. Barkhof*[2], *C. Caprioglio*[1], *L. E. Collij*[2], *P. Scheltens*[3], *B. N. M. van Berckel*[2], *I. Lopes Alves*[2], *J. Berkhof*[2], *I. S. van Maurik*[2], ***V. Garibotto***[1], *C. Moro*[1], *J. Delrieu*[4], *J. Molinuevo*[5], *O. Grau-Rivera*[5], *J. Gispert*[5], *A. Drzezga*[6], *F. Jessen*[6], *A. Nordberg*[7], *Z. Walker*[8], *J. Demonet*[9], *R. Gismondi*[10], *G. Farrar*[11], *A. W. Stephens*[10], *G. B. Frisoni*[1];
[1]*University of Geneva, Geneva, SWITZERLAND,* [2]*Amsterdam UMC, Amsterdam, NETHERLANDS,* [3]*Amsterdam UM, Amsterdam, NETHERLANDS,* [4]*Toulouse University Hospital, Toulouse, FRANCE,* [5]*BarcelonaBeta Brain Research Center, Barcelona, SPAIN,* [6]*University of Cologne, Cologne, GERMANY,* [7]*Karolinska Institutet, Stockholm, SWEDEN,* [8]*University College London, London, UNITED KINGDOM,* [9]*Lausanne University Hospital, Lausanne, SWITZERLAND,* [10]*Life Molecular Imaging, Berlin, GERMANY,* [11]*GE Healthcare, Amersham, UNITED KINGDOM.*

OP-136
The Centiloid scale applied to 18f-florbetaben and 18f-flutemetamol PET renders comparable estimates of amyloid burden in memory clinic patients

J. Gispert[1], *C. J. Buckley*[2], *L. E. Collij*[3], *D. Vállez-García*[3], *H. G. Pemberton*[2], *S. Bullich*[4], *N. Roé-Vellvé*[4], *M. Shekari*[1], *D. Altomare*[5], *V. Garibotto*[6], *G. B. Frisoni*[5], *F. Barkhof*[3], *A. W. Stephens*[7], *G. Farrar*[2], *On behalf of the AMYPAD consortium;*
[1]*Barcelonabeta Brain Research Center, Barcelona, SPAIN,* [2]*GE Healthcare, Amersham, UNITED KINGDOM,* [3]*Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS,* [4]*Life Molecular Imaging GmbH, Berlin, GERMANY,* [5]*Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, SWITZERLAND,* [6]*Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,* [7]*Life Molecular Imaging, Berlin, GERMANY.*

310

Sunday, October 16, 2022, 09:45 - 11:15

Hall 116

CTE 2 - Technologists Committee: Technologist Involvement in Research Imaging

OP-137
EARL Harmonisation of PET/CT Systems - Why, How, When and Next Steps

R. Boellaard;
Amsterdam UMC, Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-138
Technicalities in Pre-Clinical SPECT-CT and PET-CT Imaging

J. Kim;
King's College London, Department of Imaging Chemistry and Biology, London, UNITED KINGDOM.

OP-139
PET-MRI in Research - Phantom Scanning and Healthy Volunteers

S. Kinsella;
King's College London & Guy's and St Thomas' PET Centre School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM.

401

Sunday, October 16, 2022, 11:30 - 13:00

Auditorium

Plenary 2 (incl. Marie Curie Lecture): PSMA - A Never Ending Successful Story

OP-140
Introduction by Chairpersons

OP-141
Once Upon a Time in the West - The History of Radiolabelled PSMA Production

W. Fendler;
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-142
The Good, the Bad and the Ugly - 68Ga vs 18F vs Other PSMA Diagnostic Tracers

K. Goffin;
University Hospital Leuven and KU Leuven, Department of Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

OP-143
The Matrix Reloaded - The Importance of Structured Reporting PSMA PET

M. Rodríguez Fraile;
Clínica Universidad de Navarra, Department of Nuclear Medicine, Pamplona, SPAIN.

OP-144
The Maze Runner - The Interaction Between Androgen Deprivation Therapy and PSMA Expression

L. Emmet;
St. Vincent's Hospital Sydney, University of New South Wales, Kensington, NSW, Department of Theranostics and Nuclear Medicine, Sydney, AUSTRALIA.

OP-145
To Infinity and Beyond - PSMA PET in Solid Cancers Other Than Prostate Cancer

S. Malaspina;
University of Turku and Turku University Hospital, Turku PET Centre, Turku, FINLAND.

OP-146
Bohemian Rhapsody - Current Landscape of PSMA Theranostics

D. Murphy;
The Peter MacCallum Cancer Centre, Department of Urological Oncology, Melbourne, AUSTRALIA.

OP-147
Marie Curie Lecture: Green Book - The Importance of Implementing PSMA in Guidelines

D. Oprea-Lager;
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-148
Session Summary by Chairpersons

501

Sunday, October 16, 2022, 15:00 - 16:30

Auditorium

CME 3 - Physics + Oncology & Theranostics + Neuroimaging Committee: Motion Management – State of the Art

OP-149
A Decade of Motion Management Developments in NM Imaging

I. Polycarpou;
European University, Nicosia, CYPRUS.

OP-150
Motion Management in NM Imaging for Oncology Applications

F. Buther;
Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY.

OP-151
Respiratory Motion Management for Cardiac PET/CT and PET/MR Imaging

R.C. Siekkinen;
Turku PET center, Turku, FINLAND.

OP-152
Motion Management in Brain Multimodality Imaging

K. Thielemans;
University College London, Institute of Nuclear Medicine, London, UNITED KINGDOM.

502

Sunday, October 16, 2022, 15:00 - 16:30

Hall 112 (Arena)

TOP Trials Session 1: Best International Trials

OP-153
Results from the PYTHON trial: A Prospective Study On [18F]DCFPyL-PET/CT Imaging In First Biochemical Recurrence - Prostate Cancer After Primary Therapy With Curative Intent

C. Rischpler[1], *E. Gontier*[2], *L. García Cañamaque*[3], *M. Gauthé*[4], *P. Olivier*[5], *M. Mitjavila Casanovas*[6], *P. Tamayo*[7], *P. Robin*[8], *A. García Vicente*[9], *A. Bouyeure*[10], *D. Oprea-Lager*[11], *B. Alban*[12], *A. Rodríguez-Fernández*[13], *S. Ben Mahmoud*[14], *J. Vallejo-Casas*[15], *P. Maksud*[16], *M. Charles*[17], *P. Blanc-Durand*[18], *C. Drouet*[19], *H. Tissot*[20], *I. Vierasu*[21], *T. Vander Borght*[22], *E. Boos*[23], *M. Hodolič*[23], *F. Chossat*[23], *C. Rousseau*[24]; [1]*Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, GERMANY,* [2]*Institut inter-régional de cancérologie, Centre Jean Bernard, Le Mans, FRANCE,* [3]*Madrid Sanchinarro University Hospital, Madrid, SPAIN,* [4]*Scintep, Grenoble, FRANCE,* [5]*Service de médecine nucléaire, CHRU de Nancy, Nancy, FRANCE,* [6]*Hospital Universitario Puerta de Hierro, Madrid, SPAIN,* [7]*Servicio de Radiodiagnóstico, Hospital Clínico Universitario de Salamanca, Salamanca, SPAIN,* [8]*Service de médecine nucléaire, CHRU de Brest, Brest, FRANCE,* [9]*Nuclear Medicine Department, University General Hospital, Ciudad Real, SPAIN,* [10]*Service de médecine nucléaire, Henri Becquerel Cancer Center, Rouen, FRANCE,* [11]*Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, NETHERLANDS,* [12]*Service de médecine nucléaire, Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, FRANCE,* [13]*Nuclear Medicine Department, Virgen de las Nieves Hospital, Granada, SPAIN,* [14]*Service de médecine nucléaire, CHR Metz-Thionville, Metz, FRANCE,* [15]*UGC Medicina Nuclear, Hospital Universitario "Reina Sofía", Córdoba, SPAIN,* [16]*Service de médecine nucléaire, Pitié-Salpêtrière Hospital, Paris, FRANCE,* [17]*Service de médecine nucléaire, Jean Perrin Oncology Institute of Clermont-Ferrand, Clermont-Ferrand, FRANCE,* [18]*Service de médecine nucléaire, Henri Mondor Hospital, Créteil, FRANCE,* [19]*Service de médecine nucléaire, Centre Georges-François-Leclerc, Dijon, FRANCE,* [20]*Service de médecine nucléaire, Institut Curie, Paris, FRANCE,* [21]*Nuclear Medicine Department and PET/Biomedical Cyclotron Unit, Erasme Hospital, Université Libre de Bruxelles, Brussels, BELGIUM,* [22]*Department of Nuclear Medicine, Université Catholique de Louvain, CHU-UCL-Namur, site Godinne, Yvoir, BELGIUM,* [23]*Curium, Paris, FRANCE,* [24]*Service de médecine nucléaire, Institut de cancérologie de l'Ouest René-Gauducheau, Saint-Herblain, FRANCE.*

OP-154
Results from OCLURANDOM: the first multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with lutetium-177 octreotate (OCLU) in patients with unresectable progressive neuroendocrine pancreatic tumors

E. Baudin[1], *T. Walter*[2], *A. Beron*[3], *D. Smith*[4], *J. Hadoux*[1], *C. Moreau-Triby*[2], ***D. Taieb***[5], *C. Ansquer*[6], *L. Dierickx*[7], *L. De Mestier*[8], *E. Deshayes*[9], *E. Quak*[10], *L. Dahan*[5], *R. Guimbaud*[11], *Y. Touchefeu*[12], *M. Haissaguerre*[13], *J. Vuillez*[14], *F. Courbon*[7], *E. Hindié*[15], *C. Do Cao*[16], *C. Lombard-Bohas*[2], *M. Attard*[1], *S. Foulon*[17], *ENDOCAN-RENATEN network and GTE;* [1]*Gustave Roussy Institut de Cancérologie, Villejuif, FRANCE,* [2]*Hospice Civils de Lyon, Lyon, FRANCE,* [3]*Huriez Hospital, Lille, FRANCE,* [4]*Saint André Bordeaux Hospital, Bordeaux, FRANCE,* [5]*Aix-Marseille University, Marseille, FRANCE,* [6]*Hôtel Dieu University Hospital Center, Nantes, FRANCE,* [7]*Claudius Regaud Institute, Toulouse, FRANCE,* [8]*Beaujon hospital, Paris, FRANCE,* [9]*CHU Montpellier, Marseille, FRANCE,* [10]*François Baclesse Center, Caen, FRANCE,* [11]*University Hospital Center Toulouse Rangueil, Toulouse, FRANCE,* [12]*CHU de Nantes, Nantes, FRANCE,* [13]*CHU Bordeaux, Bordeaux, FRANCE,* [14]*CHU Grenoble Alpes, Grenoble, FRANCE,* [15]*Bordeaux University Hospital, Bordeaux, FRANCE,* [16]*CHU Lille, Lille, FRANCE,* [17]*Gustave Roussy, Villejuif, FRANCE.*

OP-155
Impact of ^{18}F-rhPSMA-7.3 PET on Nodal and Metastatic Upstaging of Patients with Biochemical Recurrence of Prostate Cancer: Results from the Prospective, Phase 3, Multicenter, SPOTLIGHT Study

R. Hermsen, *SPOTLIGHT Study Group;*
Canisius Wilhelmina Hospital, Nijmegen, NETHERLANDS.

OP-156
An International study of inter-site variability in ^{99m}Tc MAA multi-compartment dosimetry for yttrium-90 radioembolization: analyses from the TARGET phantom study

G. Keane, *H. de Jong, R. Van Rooij, M. Lam;*
UMCU, Utrecht, NETHERLANDS.

OP-157
Radioembolization for HCC Patients with Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D): an interim analysis

S. Kappadath, *E. Henry, A. Mahvash;*
UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-158
Evaluation of Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)

L. Emmett[1], *S. Pathmanandavel*[1], *M. Stockler*[2], *M. Crumbaker*[1], *S. Sharma*[1], *M. Ayers*[1], *R. Niman*[3], *P. Wilson*[3], *A. Martin*[2], *A. Hickey*[1], *A. Joshua*[1], *A. Nguyen*[1]; [1]*St Vincent's Hospital, Sydney, AUSTRALIA,* [2]*University of Sydney, Sydney, AUSTRALIA,* [3]*MIM, Chicago, IL, UNITED STATES OF AMERICA.*

OP-159
Safety and Effectiveness of Lutetium-177-Prostate-Specific Membrane Antigen (^{177}Lu-PSMA) Therapy Used in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (^{223}Ra): The RALU Study

K. Rahbar[1], *M. Essler*[2], *M. Eiber*[3], *C. la Fougère*[4], *V. Prasad*[5], *W. P. Fendler*[6], *P. Rassek*[1], *E. Hasa*[3], *H. Dittmann*[4], *R. A. Bundschuh*[2], *K. M. Pabst*[6], *M. Kurtinecz*[7], *A. Schmall*[8], *F. Verholen*[8], *O. Sartor*[9]; [1]*Department of Nuclear Medicine, University of Münster Medical Center, Münster, GERMANY,* [2]*Department of Nuclear Medicine, University Hospital Bonn, Bonn, GERMANY,* [3]*Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY,* [4]*Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tübingen, Tübingen, GERMANY,* [5]*Department of Nuclear Medicine, University of Ulm, Ulm, GERMANY,* [6]*Department of Nuclear Medicine, German Cancer Consortium (DKTK) University Hospital Essen, Essen, GERMANY,* [7]*Bayer HealthCare Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA,* [8]*Bayer Consumer Care, Basel, SWITZERLAND,* [9]*Tulane Cancer Center, Tulane Medical School, New Orleans, LA, UNITED STATES OF AMERICA.*

OP-160
PSMA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial of [177Lu]Lu-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603)

J. Buteau[1], *A. Martin*[2], *L. Emmett*[3], *A. Iravani*[4], *S. Sandhu*[1], *A. M. Joshua*[3], *R. J. Francis*[5], *A. Y. Zhang*[2], *A. M. Scott*[6], *S. Lee*[6], *A. Azad*[1], *M. McJannett*[7], *M. R. Stockler*[8], *S. Williams*[1], *I. D. Davis*[9], *M. S. Hofman*[1]; [1]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [2]*NHMRC Clinical Trials Centre, Sydney, AUSTRALIA,* [3]*St-Vincent's Hospital, Sydney, AUSTRALIA,* [4]*Washington University, St. Louis, MO, UNITED STATES OF AMERICA,* [5]*Sir Charles Gairdner Hospital, Perth, AUSTRALIA,* [6]*Austin Health, Melbourne, AUSTRALIA,* [7]*ANZUP, Sydney, AUSTRALIA,* [8]*NHMRC CTC, Sydney, AUSTRALIA,* [9]*Monash University and Eastern Health, Melbourne, AUSTRALIA.*

OP-161
Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

K. Herrmann[1], *B. J. Krause*[2], *K. Rahbar*[3], *K. N. Chi*[4], *M. J. Morris*[5], *O. Sartor*[6], *S. T. Tagawa*[7], *A. T. Kendi*[8], *N. Vogelzang*[9], *J. Calais*[10], *J. Nagarajah*[11], *X. X. Wei*[12], *V. Koshkin*[13], *J. Beauregard*[14], *B. Chang*[15], *M. DeSilvio*[16], *R. A. Messmann*[17], *J. de Bono*[18], *K. Fizazi*[19]; [1]*Universitätsklinikum Essen, Essen, GERMANY,* [2]*Rostock University Medical Center, Rostock, GERMANY,* [3]*University Hospital Munster, Munster, GERMANY,* [4]*British Columbia Cancer Agency, Vancouver Centre, BC, CANADA,* [5]*Memorial Sloan Kettering Cancer Centre, New York, NY, UNITED STATES OF AMERICA,* [6]*Tulane Medical School, New Orleans, LA, UNITED STATES OF AMERICA,* [7]*Weill Cornell Medicine, New York, NY, UNITED STATES OF AMERICA,* [8]*Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA,* [9]*Comprehensive Cancer Centers, Las Vegas, NV, UNITED STATES OF AMERICA,* [10]*University of California, Los Angeles, CA, UNITED STATES OF AMERICA,* [11]*Radboud University Medical Center, Nijmegan, NETHERLANDS,* [12]*Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA,* [13]*University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, UNITED STATES OF AMERICA,* [14]*CHU de Québec-Université Laval, Québec, QC, CANADA,* [15]*Radiation Oncology Associates, Parkview Hospital, Fort Wayne, IN, UNITED STATES OF AMERICA,* [16]*Novartis Pharmaceuticals Corporation, East Hanover, NJ, UNITED STATES OF AMERICA,* [17]*Novartis Pharmaceuticals Corporation, Eas, NJ, UNITED STATES OF AMERICA,* [18]*The Institute of Cancer Research and Royal Marsden Hospital, London, UNITED KINGDOM,* [19]*Gustav Roussy Institute, University of Paris-Saclay, Villejuif, FRANCE.*

503

Sunday, October 16, 2022, 15:00 - 16:30

Hall 113

LIPS Session 3 - Thyroid Committee: Tricky Cases in Endocrine Imaging
Interactive Session

OP-162
Ultrasonographic Correlates of Scintigrapy in Endocrine Imaging

S. Ilgan;
Güven Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-163
Tricky Cases and Pitfalls in Parathyroid Imaging

D. Deandreis;
Nuclear Medicine Division, Department of Medical Sciences, University of Turin, AOU Città della Salute e della Scienza, Turin, ITALY.

OP-164
Pitfalls in Radioiodine Imaging

B. de Keizer;
University Medical Center Utrecht, Department of Nuclear Medicine and Radiology, Utrecht, NTERHERLANDS.

504

Sunday, October 16, 2022, 15:00 - 16:30

Hall 114

M2M Track - TROP Session: 1+1=3 … The Promise of Combination Treatments

OP-165
Pharmacological upregulation of monoamine transporters by histone deacetylase inhibitors improves ^{123}I-mIBG imaging of neuroendocrine tumors: a preclinical proof-of-concept study

R. Mansi[1], *J. Grand-Guillaume*[2], *S. Zanger*[1], *P. J. Eugster*[2], *E. Grouzmann*[2], *M. Fani*[1], *K. A. Abid*[2]; [1]*University Hospital Basel, Basel, SWITZERLAND,* [2]*Lausanne University Hospital, Lausanne, SWITZERLAND.*

OP-166
Modulating the Epigenetic Machinery for Increased SSTR2 Expression in Small-Cell Lung Cancer Cells

M. J. Klomp, *L. J. Hofland, L. van den Brink, P. M. van Koetsveld, M. de Jong, S. U. Dalm;*
Erasmus MC, Rotterdam, NETHERLANDS.

OP-167
S-phase enrichment by hydroxyurea treatment enhances [^{177}Lu]Lu-DOTA-TATE uptake in vitro

J. Cheng, *L. Livieratos, S. Terry;*
King's College London, London, UNITED KINGDOM.

OP-168
Doxorubicin pre-treatment alters radiosensitivity and GRPR radiotracer uptake of breast cancers cells

T. S.T. Damiana, *L. W. de Kreij-de Bruin, S. U. Dalm;*
Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-169
High-throughput screens identify DNA-PKcs inhibition as radiosensitization strategy for peptide receptor radionuclide therapy in vitro and in vivo

T. Reuvers, *D. Stuurman, C. De Ridder, J. Nonnekens;*
Erasmus Medical Center, Rotterdam, NETHERLANDS.

OP-170
Preclinical evaluation of targeted radionuclide therapy combined with immune checkpoint inhibition

S. Kleinendorst[1], *M. Konijnenberg*[1], *R. Merkx*[1], *K. Twumasi-Boateng*[2], *P. Chandler*[2], *M. Wheatcroft*[2], *E. Oosterwijk*[1], *S. Heskamp*[1]; [1]*RadboudUMC, Nijmegen, NETHERLANDS,* [2]*Telix Pharmaceuticals Ltd., Melbourne, AUSTRALIA.*

OP-171
Potential Combination Therapy with ^{177}Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Colorectal Cancer

T. Mohajer Shojai[1], *P. Jha*[2], *A. Boström*[3], *F. Y. Frejd*[1], *P. J. Yazaki*[4], *M. Nestor*[1]; [1]*Uppsala University, Uppsala, SWEDEN,* [2]*University of Texas Southwestern Medical Centre, Dallas, TX,*

UNITED STATES OF AMERICA, [3]Ridgeview Instruments AB, Uppsala, SWEDEN, [4]Beckman Research Institute, Durate, CA, UNITED STATES OF AMERICA.

OP-172

Disturbing the redox balance as a new radiosensitizing strategy for Peptide Receptor Radionuclide Therapy with ^{177}Lu-DOTATATE

W. Delbart, *G. Marin, B. Stamatopoulos, G. E. Ghanem, P. Flamen, Z. Wimana;*
Institut Jules Bordet, Brussels, BELGIUM.

OP-173

Potentiation of TRT using gadolinium based nanoparticles is driven by lysosomal mediated cell disruption

C. Diaz Garcia-Prada[1], *L. Carmès*[2,3], *F. Lux*[3], *O. Tillement*[3], *S. du Manoir*[1], *J. Constanzo*[1], *J. Pouget*[1];
[1]*IRCM, Inserm U1194, Montpellier, FRANCE,* [2]*NH TherAguix, Lyon, FRANCE,* [3]*Université Claude Bernard Lyon 1, Lyon, FRANCE.*

505

Sunday, October 16, 2022, 15:00 - 16:30

Hall 211

Cutting Edge Science Track - TROP Session: Dosimetry - SIRT

OP-174

Dosimetric impacts of breathing motion compensated reconstruction in radioembolization

L. Vergnaud[1], *A. Robert*[2], *T. Baudier*[1], *S. Parisse-Di Martino*[3], *P. Boissard*[3], *S. Rit*[4], *J. Badel*[3], *D. Sarrut*[1];
[1]*Centre Léon Bérard / CREATIS, Lyon, FRANCE,* [2]*Kitware / CREATIS, Villeurbanne, FRANCE,* [3]*Centre Léon Bérard, Lyon, FRANCE,* [4]*CREATIS, Lyon, FRANCE.*

OP-175

Observed TCP(EUD) in HCC radioembolization and in EBRT are similar and can be predicted using the in vitro radiosensitivity

S. Walrand, *P. D'Abadie, M. Hesse, R. Lhommel, F. Jamar;*
Université Catholique de Louvain, Brussels, BELGIUM.

OP-176

How does the Internal Bremsstrahlung contribute to the Dose Point Kernel? The case of ^{90}Y

L. Auditore[1,2], *A. Italiano*[2,3], *D. Pistone*[1,2], *E. Amato*[1,2];
[1]*BIOMORF Department, University of Messina, Messina, ITALY,* [2]*INFN Section of Catania, Catania, ITALY,* [3]*MIFT Department, University of Messina, Messina, ITALY.*

OP-177

Dosimetry and survival in unresectable primary hepatocellular carcinoma patients undergoing selective internal radiotherapy with resin 90Y: the interim analysis of a randomized clinical trial

L. Strigari[1], *G. Della Gala*[2], *M. Santoro*[2], *G. Paolani*[2], *E. Lodi Rizzini*[2], *A. Golemi*[2], *A. Cappelli*[2], *C. Mosconi*[2], *L. Calderoni*[2], *E. Tabacchi*[2], *S. Rea*[3], *S. Ungania*[3], *R. Sciuto*[3];
[1]*IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola, Bologna, ITALY,* [2]*IRRCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola, Bologna, ITALY,* [3]*IRCCS Regina Elena National Cancer Institute, Rome, ITALY.*

OP-178

Utility of Pre-procedural ^{99m}TC-MAA SPECT/CT Multicompartment Dosimetry for Treatment Planning of Y-90 Glass Microspheres in Patients with Hepatocellular Carcinoma: Dosimetry Method Comparison of The Global Retrospective TARGET Study

E. Garin[1], *R. Salem*[2], *K. Fowers*[3], *M. Lam*[4];
[1]*INSERM U 991, Rennes, FRANCE,* [2]*Northwestern Feinberg School of Medicine, Chicago, IL, UNITED STATES OF AMERICA,* [3]*Boston Scientific Corporation, Marlborough, MA, UNITED STATES OF AMERICA,* [4]*University Medical Center Utrecht, Utrecht, NETHERLANDS.*

OP-179

Observer Reproducibility in the Calculation of Yttrium-90 Absorbed Dose in Patients with Hepatocellular Carcinoma: The Round Robin Sub-Study of The Global Retrospective TARGET Study

K. Herrmann[1], *E. Garin*[2], *K. Fowers*[3], *R. Salem*[4], *M. Lam*[5];
[1]*Universitätsklinikum Essen, Essen, GERMANY,* [2]*Eugene Marquis Center, Rennes, FRANCE,* [3]*Boston Scientific Corporation, Marlborough, MA, UNITED STATES OF AMERICA,* [4]*Northwestern Feinberg School of Medicine, Chicago, IL, UNITED STATES OF AMERICA,* [5]*University Medical Center Utrecht, Utrecht, NETHERLANDS.*

OP-180

Pre-treatment dosimetry of ^{90}Y-SIRT in hepatic tumours: optimisation of reconstruction and calculation methods

T. Pham[1], *B. Presles*[1], *R. Popoff*[1,2], *J. L. Alberini*[1,2], *J. M. Vrigneaud*[1,2];
[1]*IFTIM, ImViA laboratory, EA 7535, University of Burgundy, Dijon, FRANCE,* [2]*Department of Nuclear Medecine, Centre Georges-François Leclerc, Dijon, FRANCE.*

OP-181

Longitudinal results of Yttrium-90 resin microsphere radioembolization in HCC: dosimetry related to lesion changes and serum tumour markers

E. Veenstra, *S. J. Ruiter, R. J. de Haas, R. P. Bokkers, K. de Jong, W. Noordzij;*
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-182

Dose-toxicity analysis for NET patients treated with ^{166}Ho-radioembolization following PRRT

M. Stella, R. van Rooij, ***M. G. E. Lam****, H. de Jong, A. Braat;*
University Medical Center, Utrecht, NETHERLANDS.

506

Sunday, October 16, 2022, 15:00 - 16:30

Hall 117

Clinical Oncology Track - TROP Session: Radioguided Surgery

OP-183

Breast-Cancer-Related Lymphedema (BCRL) After Axillary Reverse Mapping And Selective Dissection (ARM-SAD) Versus Axillary Lymph Node Dissection (ALND): Results Of A Single-Center Prospective Study

M. Maccauro, *A. Lorenzoni, M. Chisari, G. Aliberti, A. De Vivo, A. Caraceni, I. Maugeri, C. Sigari, L. Mariani, D. Mansi, S. Folli, E. Seregni, M. Gennaro;*
Foundation IRCCS Istituto Nazionale dei Tumori, Milan, ITALY.

OP-184

A metabolic signature to predict the location of second tumor recurrence after re-irradiation in head and neck cancer

A. Beddok[1,2], *V. Calugaru*[2], *L. Champion*[1,3], *C. Nioche*[1], *F. Orlhac*[1], *G. Crehange*[2], *I. Buvat*[1];
[1]*Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, Orsay, FRANCE,* [2]*Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Orsay, FRANCE,* [3]*Institut Curie, Nuclear Medicine Department, Saint-Cloud, FRANCE.*

OP-185

Pulmonary Roll with Da Vinci Robot. Tarragona experience

D. Carrera, *G. Rosado, P. M. Fierro, A. Guedea, P. Rodriguez-Taboada, C. A. Achury, D. L. Baquero, I. R. Jimenez, F. M. Paz, M. Mila;*
Hospital Universitario Joan XXIII de Tarragona, Tarragona, SPAIN.

OP-186

Minimally invasive radioguided surgery in primary hyperparathyroidism

A. Alomar, *I. Blanco Saiz, I. Saura, N. Rudic, J. Cruz, E. Goñi, M. Ribelles, A. Camarero Salazar, M. Martí Martinez;*
Hospital Universitario de Navarra, Pamplona, SPAIN.

OP-187

ROLL Technique in Subcentimeter Lung Nodules Through Electromagnetic Navigation Bronchoscopy and Videothoracoscopy Pulmonary Resection in a Single Time. Pilot Experience

M. Ollarves Carrero, *J. Rodríguez Gomez, C. A. Fraile Olivero, R. Couto Caro, A. Ortega Candil, P. Nespral Torres, P. Romero Fernández, P. Dauden Oñate, E. Fernández Martín, M. J. Bernabé Barrios, J. Carreras Delgado, M. N. Cabrera Martín;*
Hospital Clínico San Carlos, Madrid, SPAIN.

OP-188

Radioguided surgery with direct beta detection: a feasibility study in cervical cancer with 18F-FDG

F. Collamati[1], *A. Florit*[2], *N. Bizzarri*[3], *L. Valerio*[4], *R. Faccini*[5], *V. Rufini*[4], *R. Mirabelli*[5], *A. Collarino*[2];
[1]*INFN Rome, Rome, ITALY,* [2]*Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY,* [3]*Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli, Rome, ITALY,* [4]*Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [5]*Università Sapienza Roma, Rome, ITALY.*

OP-189

Performance guided surgery - kinematics of DROP-IN gamma probe use during robotic sentinel lymph node and PSMA-receptor targeted procedures in prostate cancer patients

S. Azargoshasb[1], *H. A de Barros*[2], *D. D.D. Rietbergen*[3], *C. Wagner*[4], *T. Maurer*[5], *P. J van Leeuwen*[2], *H. G. van der Poel*[2], *M. N. van Oosterom*[1], *F. W.B. van Leeuwen*[1];
[1]*Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Cent, Leiden, NETHERLANDS,* [2]*Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS,* [3]*Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS,* [4]*St. Antonius - Hospital Gronau, Head of Robotic Urology, Gronau, GERMANY,* [5]*Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.*

OP-190

Salvage robot-assisted PSMA-radioguided surgery inrecurrent prostate cancer using a novel DROP-INgamma probe

F. Falkenbach[1], *L. Budäus*[1], *M. Graefen*[1], *D. Köhler*[2], *F. W. B. van Leeuwen*[3], *M. N. van Oosterom*[3], *A. Berrens*[4], *H. de Barros*[4], *P. van Leeuwen*[4], *H. van der Poel*[4], *S. Knipper*[1], *T. Maurer*[1,5];
[1]*Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY,* [2]*Department of Radiology and Nuclear Medicine, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY,* [3]*Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS,* [4]*Department of Urology, Antoni van Leeuwenhoek Hospital – the Netherlands Cancer Institute, Amsterdam, NETHERLANDS,* [5]*Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, GERMANY.*

OP-191

^{99m}Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer

T. Maurer[1], *M. Sauer*[2], *S. Klutmann*[2], *I. Apostolova*[2], *W. Lehnert*[2], *L. Budäus*[1], *S. Knipper*[1], *D. Koehler*[2];
[1]*Martini-Klinik Prostate Cancer Center, Hamburg-Eppendorf, GERMANY,* [2]*Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg-Eppendorf, GERMANY.*

507

Sunday, October 16, 2022, 15:00 - 16:30

Hall 115

Cardiovascular Committee - TROP Session: Quantitative Myocardial Perfusion Imaging

OP-192

Prognostic Value of Myocardial Flow Capacity and Global Absolute Perfusion Measurements using Rubidium-82 with SiPM PET/CT

M. Dietz, *C. H. Kamani, G. Allenbach, V. Rubimbura, S. Fournier, M. Nicod Lalonde, N. Schaefer, E. Eeckhout, O. Muller, J. O. Prior;*
Centre Hospitalier Universitaire Vaudois, Lausanne, SWITZERLAND.

OP-193

Risk assessment of obstructive coronary artery disease using segmental myocardial flow reserve in addition to visual evaluation of Rb-82 PET

S. Koenders[1,2], *J. A. van Dalen*[3], *P. L. Jager*[1], *M. Mouden*[4], *C. H. Slump*[2], ***J. D. van Dijk***[1];
[1]*Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS,* [2]*Technical Medical Center, University of Twente, Enschede, NETHERLANDS,* [3]*Medical Physics, Isala Hospital, Zwolle, NETHERLANDS,* [4]*Cardiology, Isala Hospital, Zwolle, NETHERLANDS.*

OP-194

Myocardial blood flow in acute myocardial infarction patients

A. Mochula[1], *K. Zavadovsky*[1], *D. Vorobyeva*[1], *O. Mochula*[1], *A. Maltseva*[1], *A. Baev*[1], *M. Gulya*[1], *A. Gimelli*[2], *V. Ryabov*[1];
[1]*Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION,* [2]*Fondazione Toscana/CNR Gabriele Monasterio, Pisa, ITALY.*

OP-195
Regional myocardial perfusion by ^{82}Rb PET/CT in predicting lesion-related outcome in patients with ischemia and non-obstructive coronary arteries (INOCA)
E. Zampella[1], *R. Assante*[1], *V. Gaudieri*[1], *T. Mannarino*[1], *A. D'Antonio*[1], *P. Buongiorno*[1], *C. Nappi*[1], *E. Criscuolo*[1], *R. Bologna*[1], *G. Mango*[1], *R. Green*[1], *V. Cantoni*[1], *P. Arumugam*[2], *M. Petretta*[3], *A. Cuocolo*[1], *W. Acampa*[1];
[1]*University Federico II, Naples, ITALY,* [2]*Department of Nuclear Medicine, Central Manchester Foundation Trust, Manchester, UNITED KINGDOM,* [3]*IRCCS Synlab SDN, Naples, ITALY.*

OP-196
Exploring coronary disease of patients with normal perfusion on SPECT-MPI, can we go further?
B. Pereira[1], *P. Dias*[1], *P. Medeiros*[2], *P. Soeiro*[1];
[1]*Centro Hospitalar Universitário de São João, Porto, PORTUGAL,* [2]*Hospital de Braga, EPE, Braga, PORTUGAL.*

OP-197
The incremental value of coronary artery calcium score in predicting long-term prognosis and defining warranty period of normal stress-only CZT SPECT
M. Kamerman[1,2], *J. D. Van dijk*[3], *J. R. Timmer*[4], *J. Ottervanger*[4], *S. Knollema*[5], *P. L. Jager*[5], *M. Mouden*[4];
[1]*Isala, Zwolle, NETHERLANDS,* [2]*Isala Cardiology, Zwolle, NETHERLANDS,* [3]*Isala Nuclear Medicine, Zwolle, NETHERLANDS,* [4]*Isala, Zwolle Cardiology, NETHERLANDS,* [5]*Isala, Zwolle Nuclear Medicine, NETHERLANDS.*

OP-198
Impact of changes of myocardial flow reserve after coronary revascularization on cardiovascular outcome
R. Assante[1], *A. D'Antonio*[1], *E. Zampella*[1], *V. Gaudieri*[1], *T. Mannarino*[1], *P. Buongiorno*[1], *C. Nappi*[1], *E. Criscuolo*[1], *R. Bologna*[1], *M. Petretta*[2], *A. Cuocolo*[1], *W. Acampa*[1];
[1]*Universita' di Napoli Federico II, Naples, ITALY,* [2]*IRCCS Synlab SDN, Naples, ITALY.*

OP-199
Correlation of SPECT Myocardial Flow Reserve with coronary angiography results
M. Bailly[1], *F. Thibault*[1], *G. Metrard*[1], *M. Courtehoux*[2], *D. Angoulvant*[2], *M. Ribeiro*[2];
[1]*CHR Orléans, Orleans, FRANCE,* [2]*CHRU Tours, Tours, FRANCE.*

OP-200
Quantification of MBF and MPR by Low-Dose Dynamic CZT-SPECT in Patients with Diabetes Mellitus and normal MPI
A. D'Antonio, *T. Mannarino, R. Assante, E. Zampella, V. Gaudieri, R. Bologna, E. Criscuolo, P. Buongiorno, C. Nappi, A. Cuocolo, W. Acampa;*
Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY.

508

Sunday, October 16, 2022, 15:00 - 16:30

Hall 212

Paediatrics Committee - TROP Session: Paediatric Oncology

OP-201
Application Value of PET/MR Radiomics Features in Predicting the COG Risk Stratification of Neuroblastoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

OP-202
^{64}CuCl2 PET/CT in high-grade infiltrative paediatric glioma: a diagnostic and dosimetric study
F. Fiz[1], *G. Bottoni*[1], *M. Ugolini*[1], *S. Righi*[1], *A. Cirone*[1], *M. Garganese*[2], *A. Verrico*[3], *A. Rossi*[3], *A. Ramaglia*[3], *A. Mastronuzzi*[2], *C. Gandolfo*[2], *C. Giovanna Stefania*[2], *M. Garrè*[3], *A. Cacchione*[2], *C. Milanaccio*[3], *M. Abate*[4], *G. Morana*[5], *A. Piccardo*[1];
[1]*E.O. Ospedali Galliera, Genoa, ITALY,* [2]*IRCCS Bambino Gesù Children's Hospital, Rome, ITALY,* [3]*IRCCS Istituto Giannina Gaslini, Genoa, ITALY,* [4]*AORN Santobono Pausillipon, Genoa, ITALY,* [5]*University of Turin, Turin, ITALY.*

OP-203
Are Interim TLG and MTV Better Predictors of Treatment Response Than Deauville Score for Pediatric Non-Hodgkin Lymphoma Patients?
G. Kaya[1], *B. Volkan Salancı*[1], *B. Aydın*[2], *P. Özgen Kıratlı*[1];
[1]*Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Medical School, Department of Pediatric Oncology, Ankara, TÜRKIYE.*

OP-204
Can Semiquantitative 18FDG PET/CT Parameters Predict Outcome in Paediatric Patients with Ewing Sarcoma?
B. Soydas Turan[1], *B. Volkan-Salanci*[1], *G. B. Aydın*[2], *E. Emirsüleymanoğlu*[3], *P. Özgen Kıratlı*[1];
[1]*Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Faculty of Medicine, Department of Pediatric Oncology, Ankara, TÜRKIYE,* [3]*Hacettepe University Faculty of Medicine, Ankara, TÜRKIYE.*

OP-205
18F-FDG PET / MR imaging features and staging value of nephroblastoma
Y. Xu[1], *J. Wang*[2], *J. Liang*[1], *F. Li*[1];
[1]*Hangzhou Universal Imaging Diagnostic Center, Hangzhou, CHINA,* [2]*Children's Hospital of Soochow University, Suzhou, CHINA.*

OP-206
PET/CT with^{11}C-methionine for the evaluation of low-grade brain tumours in paediatric and young adult patients
O. Alonso[1,2], *A. Damián*[1,2], *E. Lischinsky*[2], *L. Gutierrez*[2], *C. Bentancourt*[1], *A. Quagliata*[1], *P. Duarte*[1], *R. Ferrando*[1,2];
[1]*Uruguayan Centre of Molecular Imaging (CUDIM), Montevideo, URUGUAY,* [2]*Nuclear Medicine and Molecular Imaging Centre, Clinical Hospital, University of Uruguay, Montevideo, URUGUAY.*

OP-207
FDG PET/CT based scoring system in neuroblastoma: Comparison with existing MIBG based scoring system and evaluation of its utility as a prognostic tool
A. Prakash[1,2], *S. Shah*[1,2], *S. Mahambre*[1,2], *N. C. Purandare*[1,2], *A. Agrawal*[1,2], *A. D. Puranik*[1,2], *V. Rangarajan*[1,2];
[1]*Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute, HBNI, Mumbai, INDIA.*

OP-208
The value of ^{18}F-FDG PET / MR whole body imaging in children with multisystem Langerhans histiocytosi
F. Wang[1], *J. Wang*[2], *Y. Xu*[1];
[1]*Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA,* [2]*Children's Hospital of Soochow University, Suzhou, CHINA.*

OP-209
Characterization of the use of 2(18F) FDG PET-CT in initial staging and final treatment of pediatric patients with Histiocytic Disorders
M. Acuña Hernandez[1], *R. Palma Rosillo*[2], *R. Mora Ramírez*[2];
[1]*Universidad Autónoma de Bucaramanga, Bucaramanga, COLOMBIA,* [2]*Instituto Nacional de Pediatría, Ciudad de México, MEXICO.*

510

Sunday, October 16, 2022, 15:00 - 16:30

Hall 116

CTE 3 - Technologists + Radiation Protection Committee: Radiation Protection in Radionuclide Therapy

OP-210
Radiation Protection for the Public Environment after Radionuclide Therapy Procedure and Social Impact for the Patient
L. Cunha;
IsoPor-Azores, Azores, PORTUGAL.

OP-211
Regular and Emergency Patient Care - Radionuclide Therapy Routine vs Accidents
F. Jamar;
Cliniques universitaires St-Luc, Nuclear Medicine Department, Brussels, BELGIUM.

OP-212
Doses on Extremities During the Manipulation of RNT Radiopharmaceuticals
P. Covens;
Vrije Universiteit Brussel, In vivo Cellular and Molecular Imaging Lab, Brussels, BELGIUM.

601

Sunday, October 16, 2022, 16:45 - 18:15

Auditorium

CME 4 - Cardiovascular + Inflammation & Infection Committee: New Role of Nuclear Medicine in Monitoring Cardiovascular Diseases

OP-213
Cardiac Sarcoidosis
L. Leccisotti;
Institute of Nuclear Medicine, Sacro Cuore Catholic University, Rome, ITALY.

OP-214
Vasculitis
O. Gheysens;
Cliniques Universitaires Saint-Luc and Institute of Clinical and Experimental Research (IREC), Department of Nuclear Medicine, Université Catholique de Louvain (UCLouvain), Brussels, BELGIUM.

OP-215
Amyloidosis
J. Sørensen;
Aarhus University Hospital, Department of Nuclear Medicine and PET Centre, Aarhus, DENMARK.

OP-216
Coronary Artery Disease
C. Nappi;
Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY.

602

Sunday, October 16, 2022, 16:45 - 18:15

Hall 112 (Arena)

Challenge the Expert 2 - Oncology & Theranostics Committee: Expert vs Team Groningen: Thyroid & Parathyroid

OP-217
P. Petranović Ovčariček[1] ***vs A. Brouwers and W. Noordzij, H.***
[1]Schouw, A. Monroy Gonzalezm, J. Visterm, W. Zandee;
Department of oncology and Nuclear medicine, University Hospital Center "Sestre milosrdnice", Zagreb, CROATIA.

603

Sunday, October 16, 2022, 16:45 - 18:15

Hall 113

LIPS Session 4 - Paediatrics Committee: Tricky Cases in Paediatrics
Interactive Session

OP-225
PET in Paediatric Oncology
R. Kluge;
Universitätsklinikum Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY.

OP-226
Discussion

OP-227
Paediatric Gastroenterology
M. Vlajkovic;
University Clinical Center Niš, Center of Nuclear Medicine, Niš, SERBIA.

OP-228
Discussion

OP-229
Paediatric Nephro-Urology
J. Rogasch;
Charité Universitätsmedizin Berlin, Department of Nuclear Medicine, Berlin, GERMANY.

OP-230
Discussion

604

Sunday, October 16, 2022, 16:45 - 18:15

Hall 114

Joint Symposium 2 - Oncology & Theranostics Committee / EAU: Prostate Cancer Radionuclide Therapy

OP-231
Systemic Treatment Landscape of Prostate Cancer
J. Walz;
Institut Paoli-Calmettes Cancer Centre, Department of Urology, Marseille, FRANCE.

OP-232
Response Assessment for Bone Disease in mCRPC by imaging - What Do We Need?
H.D. Zacho;
Aalborg University Hospital, Department of Clinical Medicine, Aalborg, DENMARK.

OP-233
LuPSMA Radionuclide Therapy - Where Do We Stand and What´s Next?
K.Michalski;
Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Würzburg, Würzburg, GERMANY.

OP-234
Alpha-Emitting PSMA-Radioligand Therapy - Ready for the Future?
J. Nagarajah;
Radboud University Medical Center, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

605

Sunday, October 16, 2022, 16:45 - 18:15

Hall 211

Cutting Edge Science Track - TROP Session: Developments in PET

OP-235
Long axial field of view PET enables ultra-low-dose PET/CT
M. Krarup[1], *S. Honoré d'Este*[1], *L. Rexhepi*[1], *F. Littrup Andersen*[1], *L. Højgaard*[1,2], *B. M. Fischer*[1,2];
[1]*Copenhagen University Hospital, Rigshospitalet, Copenhagen, DENMARK,* [2]*Copenhagen University, Department of Clinical Medicine, Copenhagen, DENMARK.*

OP-236
Clinical impact of ultra-high sensitivity mode in comparison to the currently available high sensitivity mode in long axial FOV PET scanner
C. Mingels[1], *S. Weidner*[1], *H. Sari*[1,2], *D. Buesser*[1], *K. Zeimpekis*[1], *M. Viscione*[1], *A. Afshar-Oromieh*[1], *K. Shi*[1], *I. Alberts*[1], *A. Rominger*[1];
[1]*Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND,* [2]*Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.*

OP-237
Clinical Performance Comparison of a Long versus a Short Axial Field of View PET/CT
M. Roya[1], *J. H. van Snick*[1], *R. Boellaard*[1,2], *A. Glaudemans*[1], *C. Tsoumpas*[1], *J. van Sluis*[1];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Amsterdam University Medical Center, Amsterdam, NETHERLANDS.*

OP-238
Image quality and detectability assessment of a new Digital-BGO PET/CT in comparison to TOF technology
Q. Maronnier[1], *J. S. Texier*[1], *S. Brillouet*[1], *F. Courbon*[1], *C. Mezdad*[1], *K. Lacaze*[1], *M. Levy*[2], *O. Caselles*[1];
[1]*Institut Claudius Regaud - IUCT Oncopole, Toulouse, FRANCE,* [2]*GE Healthcare, Tirat HaCarmel, ISRAEL.*

OP-239
Deep Learning Based Missing Information Recovery in Partial Ring Total Body PET Scanner
H. Rezaei[1], *P. Sheikhzadeh*[2], *P. Ghafarian*[3], *I. Shiri*[4], *M. Ay*[1];
[1]*Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*Division of Nuclear Medicine and Molecular Imaging, Geneva University Hospital, Geneva, SWITZERLAND.*

OP-240
Clinical Validation of a Dedicated Brain PET Scanner for the Assessment of Neurodegenerative Disorders
P. Nespral Torres[1], *P. Bascuñana*[1], *A. Delgado-Cano*[1], *A. Canora*[1], *G. González-Pavón*[2], *C. Morera-Ballester*[2], *J. A. Matías-Guiu*[3], *J. L. Carreras-Delgado*[1], *M. N. Cabrera-Martín*[1];
[1]*Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN,* [2]*Oncovision, General Equipment for Medical Imaging S.A., Madrid, SPAIN,* [3]*Department of Neurology. Instituto de Investigación Sanitaria San Carlos (IdISSC). Hospital Clínico San Carlos, Madrid, SPAIN.*

OP-241
Development of a PET System Capable of Imaging Organs-on-Chips
C. Clement[1], *G. Birindelli*[1], *M. Pizzichemi*[2,3], *F. Pagano*[2,3], *M. Kruithof-De Julio*[1], *S. Ziegler*[4], *A. Rominger*[1], *E. Auffray*[2], *K. Shi*[1];
[1]*Inselspital Bern, Bern, SWITZERLAND,* [2]*CERN, Geneva, SWITZERLAND,* [3]*University of Milano-Bicocca, Milan, ITALY,* [4]*LMU Munich, Munich, GERMANY.*

OP-242
Practice of domain knowledge in trustworthy deep learning for CT-free PET imaging
S. Xue[1], *R. Guo*[2], *J. Hu*[1], *H. Sari*[3], *C. Mingels*[1], *K. Zeimpekis*[1], *G. Prenosil*[1], *R. Szniman*[1], *A. Rominger*[1], *B. Li*[2], *K. Shi*[1];
[1]*University of Bern, Bern, SWITZERLAND,* [2]*Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA,* [3]*Advanced Clinical Imaging Technology Siemens Healthcare AG, Lausanne, SWITZERLAND.*

OP-243
Impact of Different Crystal Material on Performance Characteristics of Long Axial Field-Of-View PET Scanner: A Monte Carlo Simulation Study
P. Sheikhzadeh[1], *H. Rezaei*[2], *M. Ay*[1];
[1]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

606

Sunday, October 16, 2022, 16:45 - 18:15

Hall 117

Clinical Oncology Track - TROP Session: Neuroendocrinology

OP-244
Impact of interim PET staging with SSTR-analogs after two cycles of ^{177}Lu-PRRT in NET patients: a multicenter analysis
H. Ilhan[1,2], *N. Bauer*[1], *A. Todica*[2,1], *C. Pfob*[3], *L. Fenzl*[3], *L. Beyer*[1], *V. Wenter*[1], *P. Bartenstein*[1], *A. Buck*[4], *R. Werner*[4], *C. Lapa*[3], *P. Hartrampf*[4];
[1]*Department of Nuclear Medicine, LMU Munich, Munich, GERMANY,* [2]*DIE RADIOLOGIE, Center for Oncological Diagnostics and Radiation Therapy, Munich, GERMANY,* [3]*Department of Nuclear Medicine, University Augsburg, Augsburg, GERMANY,* [4]*Department of Nuclear Medicine, University Würzburg, Würzburg, GERMANY.*

OP-245
Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
M. Weber[1], *O. Pettersson*[2], *R. Seifert*[1], *B. M. Schaarschmidt*[1], *W. P. Fendler*[1], *C. Rischpler*[1], *H. Lahner*[1], *K. Herrmann*[1], *A. Sundin*[1];
[1]*Uniklinik Essen, Essen, GERMANY,* [2]*Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.*

OP-246
Novel 99mTc-labeled somatostatin receptor antagonists in the diagnostic algorithm of neuroendocrine neoplasms - study design of clinical part of a multicentre, first phase TECANT study
A. Hubalewska-Dydejczyk[1], *C. Decristoforo*[2], *R. Mikolajczak*[3], *P. Kolenc*[4], *L. Lezaic*[4], *M. Opalinska*[5], *A. Studen*[6], *P. Garnuszek*[3], *C. Rangger*[2], *M. Trofimiuk-Muldner*[1], *U. Simončič*[6], *I. Virgolini*[2], *M. Fani*[7], *M. Krošelj*[4], *K. Skorkiewicz*[8], *B. Glowa*[5], *A. Sowa-Staszczak*[1], *B. Janota*[3], *A. Sawicka*[3];
[1]*Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND,* [2]*Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA,* [3]*Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND,* [4]*Department of Nuclear Medicine, University Medical Centre Ljubljana, University of Ljubljana, Ljubljana, SLOVENIA,* [5]*Nuclear Medicine Unit, Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital, Krakow, POLAND,* [6]*Faculty of Mathematics and Physics, University of Ljubljana, Ljubljana, SLOVENIA,* [7]*Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND,* [8]*University Hospital, Krakow, POLAND.*

OP-247
PepProtect: Improved detection of cancer and metastases by peptide scanning under the protection of enzyme inhibitors
R. Valkema[1], *L. E. Schonebaum*[1], *A. C. Froberg*[1], *T. Maina*[2], *B. A. Nock*[2], *E. de Blois*[1], *M. W. Konijnenberg*[1], *S. L. W. Koolen*[1], *R. P. Peeters*[1], *W. E. Visser*[1], *Q. G. de Lussanet de la Sabloniere*[1], *F. A. Verburg*[1];
[1]*Erasmus Medical Center, Rotterdam, NETHERLANDS,* [2]*National Center for Scientific Research Demokritos, Athens, GREECE.*

OP-248
Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [^{18}F]SiTATE
G. T. Sheikh[1], *R. Eschbach*[1], *M. Hofmann*[1], *L. Späth*[1], *L. M. Unterrainer*[1], *A. Delker*[1], *S. Lindner*[1], *K. Jurkschat*[2], *C. Wängler*[3], *B. Wängler*[4], *R. Schirrmacher*[5], *R. Tiling*[1], *M. Brendel*[1], *V. Wenter*[1], *F. J. Dekorsy*[1], *M. J. Zacherl*[1], *A. Todica*[1], *H. Ilhan*[1], *F. Grawe*[6], *C. C. Cyran*[6], *M. Unterrainer*[6], *J. Rübenthaler*[6], *T. Knösel*[7], *T. Paul*[7], *S. Boeck*[8], *C. Benedikt Westphalen*[8], *C. Spitzweg*[9], *C. J. Auernhammer*[9], *P. Bartenstein*[1], *L. Beyer*[1];
[1]*Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY,* [2]*Faculty for Chemistry and Chemical Biology, TU Dortmund, Dortmund, GERMANY,* [3]*Biomedical Chemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, GERMANY,* [4]*Molecular Imaging and Radiochemistry, Clinic of Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, GERMANY,* [5]*Department of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, AB, CANADA,* [6]*Department of Radiology, University Hospital LMU Munich, Munich, GERMANY,* [7]*Institute of Pathology, University Hospital LMU Munich, Munich, GERMANY,* [8]*Department of Internal Medicine 3, University Hospital LMU Munich, Munich, GERMANY,* [9]*Department of Internal Medicine 4, University Hospital LMU Munich, Munich, GERMANY.*

OP-249
Validation of SSTR-RADS 1.0 for SSTR-PET/CT in the diagnosis and treatment planning of NET patients
F. Grawe, *M. Fabritius, L. Beyer, J. Ruebenthaler;*
LMU, Munich, GERMANY.

OP-250

A prospective head-to-head comparison of [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT for detection of insulinoma

L. Li[1,2], *G. Wang*[2], *L. Zhu*[1], *H. Kung*[3], *Z. Zhu*[2];
[1]*College of Chemistry, Beijing Normal University, Beijing, CHINA,* [2]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, CHINA,* [3]*Department of Radiology, University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.*

OP-251

Comparison of Al[18F]F-NOTA-octreotide and [68Ga]Ga-DOTATATE in Neuroendocrine Tumors

A. Haeger[1], *R. Fernández*[1], *C. Soza-Ried*[1,2], *A. Hurtado*[1], *J. Wettlin*[1], *H. Amaral*[1,2], *V. Kramer*[1];
[1]*Positronmed, Santiago, CHILE,*
[2]*Positronpharma SA, Santiago, CHILE.*

OP-252

SSR-PET/CT compared to contrast-enhanced liver MRI in detection of liver metastases in neuroendocrine tumors (NET) - a 15-year retrospective European single-center analysis

F. Grawe, *N. Rosenberger, J. Ruebenthaler, P. Bartenstein, L. Beyer, R. Eschbach, C. J. Auernhammer, M. P. Fabritius;*
LMU, München, GERMANY.

607

Sunday, October 16, 2022, 16:45 - 18:15

Hall 115

Neuroimaging Committee - TROP Session: Breadth of Tracers and Approches in Brain Tumours

OP-253

Intra-arterial Administration of [68Ga]Ga-PSMA and [68Ga]Ga-DOTA-TATE in CNS Tumors; a Novel Approach that Highly Increases the Potential Effect of Future Theranostic Strategies

I. J. Pruis, *P. J. van Doormaal, F. A. Verburg, R. K. Balvers, E. M. Bos, M. J. van den Bent, M. Smits, S. E. M. Veldhuijzen van Zanten;*
Erasmus MC, Rotterdam, NETHERLANDS.

OP-254

A Single Center 18F-DOPA PET/CT Experience In Patients With Primary Brain Tumors After Treatment: Preliminary Results

E. Califaretti[1], *S. Di Gregorio*[1], *M. Zotta*[1], *R. Passera*[1], *A. Lesca*[1], *A. Pellerino*[2], *F. Bruno*[2], *R. Soffietti*[2], *D. Garbossa*[3], *D. Deandreis*[1];
[1]*Division of Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, ITALY,* [2]*Division of Neuro-Oncology, Department of Neuroscience, University of Turin, Turin, ITALY,* [3]*Division of Neurosurgery, Department of Neuroscience, University of Turin, Turin, ITALY.*

OP-255

18F-FDOPA PET and MR perfusion weighted images complementary techniques in the diagnostic of treatment related changes versus tumor recurrence/persistance in brain tumors

M. Suárez-Piñera[1], *A. Pons-Escoda*[2], *L. Rodriguez-Bel*[1], *M. Pudis*[1], *M. Macia i Garau*[3], *A. F. Coello*[4], *N. Vilariño*[5], *J. Bruna*[6], *C. Majos*[2], *M. Cortés-Romera*[1];
[1]*Department of Nuclear Medicine. Institut de Diagnòstic Per La Imatge (IDI), Bellvitge University Hospital, Barcelona, SPAIN,* [2]*Department of Radiology. Institut de Diagnòstic Per La Imatge (IDI), Bellvitge University Hospital, Barcelona, SPAIN,* [3]*Department of Radiation Oncology. Catalan Institute of Oncology, Barcelona, SPAIN,* [4]*Department of Neurosurgery. Bellvitge University Hospital, Barcelona, SPAIN,* [5]*Department of Medical Oncology. Catalan Institute of Oncology, Barcelona, SPAIN,* [6]*Department of Neurology. Bellvitge University Hospital, Barcelona, SPAIN.*

OP-256

The association between [18F]FET PET/CT and TERTp mutational status in glioma patients

A. Castello[1], *L. Dellavedova*[2], *E. Bonatto*[1], *G. Fiore*[1], *F. Zito*[1], *L. Schisano*[1], *M. Rognoni*[1], *F. Buffoni*[1], *G. Lopez*[1], *M. Arnaboldi*[3], *E. Galli*[1], *M. Caroli*[1], *M. Castellani*[1], *L. Florimonte*[1];
[1]*Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, ITALY,* [2]*A.S.S.T Ovest Milanese, Ospedale di Legnano, Legnano, ITALY,* [3]*Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ITALY.*

OP-257

[18F]FET PET/MRI; a Novel and Improved Technique for Detection of Pituitary Microadenoma

I. J. Pruis, *F. A. Verburg, S. J. C. M. Neggers, R. K. Balvers, M. Smits, S. E. M. Veldhuijzen van Zanten;*
Erasmus MC, Rotterdam, NETHERLANDS.

OP-258

Long axial field-of-view dynamic FET PET for voxelwise kinetic modeling in CNS tumor patients using aortic image-derived arterial input curves

T. Pyka[1], *K. Krieger*[1], *P. Schucht*[2], *E. Ermis*[3], *K. Shi*[1], *P. Cumming*[1], *A. Rominger*[1];
[1]*Universitätsklinik für Nuklearmedizin, Inselspital, Bern, SWITZERLAND,* [2]*Universitätsklinik für Neurochirurgie, Inselspital, Bern, SWITZERLAND,* [3]*Universitätsklinik für Radio-Onkologie, Inselspital, Bern, SWITZERLAND.*

OP-259

[18F]FACBC PET/MRI in diagnostic assessment of gliomas

A. Karlberg[1,2], *L. Kjelsberg Pedersen*[3], *B. E. Vindstad*[2], *A. Jarstein Skjulsvik*[4,5], *H. Johansen*[1], *E. M. Berntsen*[1,2], *O. Solheim*[6,7,8], *T. V. Bogsrud*[9,10], *J. A. Totland*[11], *T. Ingebrigtsen*[3,12], *L. Eikenes*[2];
[1]*Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NORWAY,* [2]*Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, NORWAY,* [3]*Department of Neurosurgery, University Hospital of North Norway, Tromsø, NORWAY,* [4]*Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NORWAY,* [5]*Department of Clinical and Molecular Medicine, Faculty of Medical and Health Sciences, Norwegian University of Science and Technology, Trondheim, NORWAY,* [6]*Department of Neurosurgery, St. Olavs hospital, Trondheim University Hospital, Trondheim, NORWAY,* [7]*Department of Neuroscience, Norwegian University of Science and Technology, Trondheim, NORWAY,* [8]*Norwegian National Advisory Unit for Ultrasound and Image Guided Therapy, St. Olavs hospital, Trondheim University Hospital, Trondheim, NORWAY,* [9]*PET-Centre, University Hospital of North Norway, Tromsø, NORWAY,* [10]*Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, DENMARK,* [11]*Department of Radiology, University Hospital of North Norway, Tromsø, NORWAY,* [12]*Department of Clinical Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, NORWAY.*

OP-260

Head to head comparison of18F-Fluorocholine PET/CT and conventional MRI as predictors of outcome inIDH wild-type high grade gliomas

A. Garcia Vicente[1], *J. Perez-Beteta*[2], *M. Amo-Salas*[2], *J. J. Bosque*[2], *A. Padilla Bermejo*[1], *M. N. Sicilia Pozo*[1], *C. Lucas Lucas*[1], *F. J. Pena Pardo*[1], *L. Garcia Zoghby*[1], *E. Noriega Álvarez*[1], *V. M. Pérez-García*[2], *A. M. Soriano Castrejón*[1];
[1]*Hospital General Universitario. Nuclear Medicine Department., Ciudad Real, SPAIN,* [2]*Universidad de Castilla-La Mancha. Mathematics Department, Ciudad Real, SPAIN.*

OP-261

Feasibility of different meningioma delineation approaches on 18F-SiTATE PET/CT imaging

S. C. Kunte[1], *L. M. Unterrainer*[1], *A. Delker*[1], *S. Lindner*[1], *M. Brendel*[1], *A. Holzgreve*[1], *W. G. Kunz*[2], *C. C. Cyran*[2], *J. Ricke*[2], *K. Jurkschat*[3], *C. Wängler*[4], *B. Wängler*[5], *R. Schirrmacher*[6], *M. Niyazi*[7], *J. C. Tonn*[8], *L. Beyer*[1], *P. Bartenstein*[1], *N. L. Albert*[1], *M. Unterrainer*[1,2];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY,* [3]*Fakultät für Chemie und Chemische Biologie, Technische Universität Dortmund, Dortmund, GERMANY,* [4]*Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Heidelberg, GERMANY,* [5]*Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, GERMANY,* [6]*Department of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, AB, CANADA,* [7]*Department of Radiation Oncology University Hospital, LMU Munich, Munich, GERMANY,* [8]*Department of Neurosurgery, University Hospital, LMU Munich, Munich, GERMANY.*

608

Sunday, October 16, 2022, 16:45 - 18:15

Hall 212

Inflammation & Infection Committee - TROP Session: All About Infections

OP-262

The Incremental Value of 18F FDG Labelled Leukocytes PET CT Over 18F FDG PET CT Scan in the Detection of Occult Infection

D. Manda, *I. Sen, P. Thakral, D. Malik, S. S. Das, V. CB;*
Fortis Memorial Research Institute, Gurugram, INDIA.

OP-263

Can We Identify Subtle Cardiac Device Infection In Asymptomatic Patients? An Insight Through The Diagnostic And Prognostic Role Of [18F]F-FDG-PET/CT

R. Mei[1], *N. Fraccascia*[1], *L. Vetrone*[1], *D. Bezzi*[1], *C. Nanni*[2], *G. Bono*[3], *V. Marinelli*[3], *L. Calderoni*[2], *R. Bonfiglioli*[2], *N. Galiè*[3], *I. Diemberger*[3], *S. Fanti*[1];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Cardiovascular Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-264

[18F]FDG PET/CT for the diagnosis of device-related infections in patients with a left ventricular assist device

D. ten Hove[1], *A. R. Wahadat*[2], *R. H. J. Slart*[1], *M. Wouthuyzen-Bakker*[1], *G. Mecozzi*[1], *K. Damman*[1], *H. Witteveen*[1], *K. Caliskan*[3], *O. C. Manintveld*[3], *B. Sinha*[1], *R. P. J. Budde*[1], *A. W. J. M. Glaudemans*[1];
[1]*Rijksuniversiteit Groningen, Groningen, NETHERLANDS,* [2]*Erasmus University Medical Center, Rotterdam, NETHERLANDS,* [3]*Erasmus Medical Center, Rotterdam, NETHERLANDS.*

OP-265

Evolution and prognostic value of white-blood-cell SPECT imaging in patients with prosthetic valve endocarditis treated medically

J. Grambow[1], *M. Besma*[1], *K. Benali*[1], *L. Deconinck*[2], *C. Chong-Nguyen*[3], *C. Cimadevilla*[4], *X. Duval*[2], *B. Iung*[3], *F. Rouzet*[1], *F. Hyafil*[5];
[1]*Bichat University Hospital, Department of Nuclear Medicine, University of Paris, Paris, FRANCE,* [2]*Bichat University Hospital, Department of Infectious Diseases, University of Paris, Paris, FRANCE,* [3]*Bichat University Hospital, Department of Cardiology, University of Paris, Paris, FRANCE,* [4]*Bichat University Hospital, Department of Cardiac Surgery, University of Paris, Paris, FRANCE,* [5]*European Hospital Georges-Pompidou, Department of Nuclear Medicine, University of Paris, Paris, FRANCE.*

OP-266

Absence of Infective Endocarditis Relapse when End-of-treatment FDG-PET/CT is Negative

C. Régis[1,2], *M. Thy*[3,4], *B. Mahida*[1,4], *L. Deconinck*[3], *S. Tubiana*[5,4], *B. Iung*[4,6], *X. Duval*[4,5], *F. Rouzet*[1,4];
[1]*Nuclear Medicine Department, Hôpital Bichat - Claude-Bernard, AP-HP, Université de Paris, Paris, FRANCE,* [2]*Department of Medical Imaging, Institut de Cardiologie de Montréal, Université de Montréal, Montréal, QC, CANADA,* [3]*Infectious Disease Department, Hôpital Bichat - Claude-Bernard, AP-HP, Université de Paris, Paris, FRANCE,* [4]*Université Paris Cité, Paris, FRANCE,* [5]*Clinical investigation Center, Hôpital Bichat - Claude-Bernard, AP-HP, Université de Paris, Paris, FRANCE,* [6]*Cardiology Department, Hôpital Bichat - Claude-Bernard, AP-HP, Université de Paris, Paris, FRANCE.*

OP-267

An infection-specific hybris tracer for image guidance towards bacterial infection on orthopedic prosthesis

T. Buckle, *M. M. Welling, C. Khursid, D. D. D. Rietbergen, F. W. B. van Leeuwen;*
LUMC, Leiden, NETHERLANDS.

OP-268

Usefulness of18F-FDG PET-CT for the management of invasive fungal infections

K. Velasquez, *B. Rodriguez, P. Meneses, L. Santamaria, I. Obedkova, I. Gutierrez, S. Garcia, M. Mitjavila, A. Fernandez;*
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

OP-269

CT Lung changes in patients with residual metabolic activity on [18F]F-FDG-PET/CT after a standard course of anti-tuberculous therapy for pulmonary tuberculosis: a comparison between patients with and without HIV infection

A. Ismaila[1], *I. O. Lawal*[2], *G. O. Popoola*[3], *M. Mathebula*[4], *I. Moagi*[4], *K. Mokoala*[1], *N. Moeketsi*[4], *M. Nchabeleng*[4], *C. Hikuam*[5], *M. Hatherill*[5], *B. P. Fourie*[6], *M. M. Sathekge*[1,7];
[1]*Department of Nuclear Medicine, University of Pretoria, Pretoria, SOUTH AFRICA,* [2]*2.Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, UNITED STATES OF AMERICA,* [3]*Saxon Court Lincolnshire Partnership NHS foundation trust (LPFT), Lincoln, Lincolnshire, UNITED KINGDOM,* [4]*Department of Medical Microbiology and MeCRU, Sefako Makgatho University of Medical Science, Pretoria, SOUTH AFRICA,* [5]*South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and*

Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, SOUTH AFRICA, [6]Department of Medical Microbiolgy, University of Pretoria, Pretoria, SOUTH AFRICA, [7]Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA.

OP-270

Comparison of ^{18}F FDG PET/CT scans and lung perfusion scintigraphy in patients with XDR pulmonary Tuberculosis pre-surgical resection

O. A. Ayeni[1,2], *O. Kolade*[1], *N. Jacobs*[1], *S. More*[1];
[1]*Groote Schuur Hospital/University of Cape Town, Cape Town, SOUTH AFRICA,* [2]*Klerksdorp/Tshepong Hospital Complex, Klerksdorp, SOUTH AFRICA.*

610

Sunday, October 16, 2022, 16:45 - 18:15

Hall 116

Technologists' Oral Presentations 1: Technologists' Training and Best Practice

OP-271

You can do it! Optimizing working methods for preparing of SPECT radiopharmaceuticals

A. Keinänen, *S. Myöhänen, H. Gröhn;*
Kuopio University Hospital, Kuopio, FINLAND.

OP-272

Optimization and quality control of blood glucose monitoring before FDG-PET/CT scan

C. Rolsted[1,2], *T. Q. Chistensen*[3,2], *S. Hess*[1,2,4];
[1]*Department of Radiology and Nuclear Medicine. Hospital South West Jutland, Esbjerg, DENMARK,* [2]*IRIS - Imaging Research Initiative Southwest, Esbjerg, DENMARK,* [3]*Department of Clinical Engineering, Region of Southern Denmark, Odense, DENMARK,* [4]*Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, DENMARK.*

OP-273

How to practically reduce events of radiopharmaceutical extravasation in a newly established PET/CT facility

M. Anelli, *M. Leandri, L. Travascio, A. D. Di Nicola;*
Azienda ASL di Pescara, Pescara, ITALY.

OP-274

Optimization of Radiolabeling Protocol of 68Ga-DOTA-FAPI-04 and preclinical assessment of its in-vitro performance characteristics

B. Shetye, *M. Maria, A. Agrawal, V. Rangarajan;*
Tata Memorial Hospital, Mumbai, INDIA.

OP-275

Pulmonary right-to-left shunt estimation with ^{99m}Tc-labeled macroaggregated albumin (MAA): Establishing a normal range with correction for unbound ^{99m}Tc

M. Coelho, *P. Fragoso Costa, K. Herrmann, H. Hautzel;*
University Hospital Essen, Department of Nuclear Medicine, University Duisburg - Essen, Essen, GERMANY.

OP-276

The application of Data-Driven Respiratory Gating in 18FDG PET/CT: study of thoracic lesions, INT Milan experience

M. Zucca, *M. Di Cresce, M. Cantù, M. Magistretti, M. Faedi, M. Ragazzoni, D. Mansi, T. Monica;*
Istituto nazionale Tumori, Milan, ITALY.

OP-277

Optimization And Adquisition Of The 18-FCholine PET/CT Protocol In The Detection Of Parathyroid Adenomas

F. Mercado Moreno[1], *I. Sánchez Rodriguez*[2], *M. Suárez Piñera*[2], *A. Benitez Segura*[3], *E. Llinares Tello*[2], *J. Vercher Conejero*[2], *M. Cortés Romera*[2];
[1]*(Hospital Bellvitge) Institut D'imatge Per Al Diagnòstic, Barcelona, SPAIN,* [2]*Hospital Bellvitge IDI, L'hospitalet, SPAIN,* [3]*Hospital Bellvitge ICS, L'hospitalet, SPAIN.*

OP-278

(Re)thinking patient education and preparation in Nuclear Medicine and Radiology Departments: perspectives from Technologists and recent-graduates

P. Costa[1], *S. M. Rua*[2], *A. Salgado*[3];
[1]*Nuclear Medicine Department, School of Health - Polytechnic Institute of Porto (ESS|P.Porto), Porto, PORTUGAL,* [2]*Radiology Department, School of Health - Polytechnic Institute of Porto (ESS|P.Porto), Porto, PORTUGAL,* [3]*Social and Human Sciences Department, School of Health - Polytechnic Institute of Porto (ESS|P.Porto), Porto, PORTUGAL.*

OP-279

Development of a Framework for Radiographer Online Clinical Education (FORCE): the specific strand of Nuclear Medicine within this European Project

P. Costa[1], *J. Atutornu*[2], *P. Bezzina*[3], *N. Dalen*[4], *J. Huhtanen*[5], *M. Jaronen*[6], *T. Saila*[6], *B. Kraus*[7], *L. Rainford*[8], *K. Matthews*[8];
[1]*Nuclear Medicine Department, School of Health - Polytechnic Institute of Porto (ESS|P.Porto), Porto, PORTUGAL,* [2]*School of Health and Sports Sciences - University of Suffolk, Suffolk, UNITED KINGDOM,* [3]*Faculty of Health Sciences - University of Malta, Msida, MALTA,* [4]*Department of Health and Functioning - Western Norway University of Applied Sciences, Bergen, NORWAY,* [5]*Health and Well-being, Rehabilitation, Oral Health Care and Diagnostic Services - Turku University of Applied Sciences, Turku, FINLAND,* [6]*Social Services and Health Care - Tampere University of Applied Sciences, Tampere, FINLAND,* [7]*University of Applied Sciences FH Campus Wien, Wien, AUSTRIA,* [8]*School of Medicine - University College Dublin, Dublin, IRELAND.*

701

Monday, October 17, 2022, 08:00 - 09:30

Auditorium

CME 5 - Paediatrics Committee: Nuclear Medicine in the Evaluation of Paediatric Patients with Transplants

OP-280

Clinical and Surgical Challenges of Transplants in Paediatrics

J. Hogan;
University of Paris, Department of Nephrology - Transplantation - Pediatric Hemodialysis, Paris, FRANCE.

OP-281

Kidney Transplant in Paediatrics

B. Volkan-Salanci;
Hacettepe University Faculty of Medicine Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-282

Paediatric Transplant Nuclear Imaging is not just for Kidneys!

L. Borgwardt;
Rigshospitalet Copenhagen University Hospital, Department Nuclear Medicine, Copenhagen, DENMARK.

OP-283

Nuclear Medicine and PostTransplant Immunosuppression's Disorders

F.M. Montes de Jesus;
University of Groningen, Department of Nuclear Medicine, Groningen, NETHERLANDS.

702

Monday, October 17, 2022, 08:00 - 09:30

Hall 112 (Arena)

Challenge the Expert 3 - Inflammation & Infection Committee: Expert vs Team Bologna: Real World in Infection

OP-284

Real World Infection Guidelines

A. Glaudemans[1] ***vs L. Muraglia, F. Serani, R. Ussia, F. Mattana, N. Fraccascia***;
[1]*University of Groningen, University Medical Center Groningen, Medical Imaging Center, Groningen, NETHERLANDS.*

703

Monday, October 17, 2022, 08:00 - 09:30

Hall 113

LIPS Session 5 - Translational Molecular Imaging & Therapy Committee: Challenging Situations in TMI&T

OP-290

Technology vs Clinical Needs - What Drives Translational Research?

T. Buckle;
Leiden University Medical Center, Interventional Molecular Imaging laboratory, Department of Radiology, Leiden, NETHERLANDS.

OP-291

Regulatory Hurdles and Directions Along the Translational Pipeline

P. Kolenc;
University Medical Center Ljubljana, Department of Nuclear Medicine, Ljubljana, SLOVENIA.

OP-292

Ownership of Clinical Studies - What is the Role of Nuclear Medicine?

W. Fendler;
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-293

Building a Business Case

T. Wendler;
Klinikum rechts der Isar (Technische Universität München), Interdisciplinary Research Lab, Munich, GERMANY.

OP-294

Discussion

704

Monday, October 17, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: GRPR vs. PSMA - A Comparison

OP-295

Preclinical characterization of a stabilized GRPR antagonist for targeted cancer theranostics

A. Abouzayed[1], *A. Gorislav*[1], *P. Kanellopoulos*[2], *V. Tolmachev*[1], *T. Maina*[2], *B. A. Nock*[2], *A. Orlova*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Molecular Radiopharmacy, INRaSTES, NCSR "Demokritos", Athens, GREECE.*

OP-296

Evaluation of the imaging potential of the GRPR ligand ^{64}Cu-/^{68}Ga-AMTG renders this metabolically more stable peptide a promising tool for future theranostic applications

T. Günther[1], *L. Koller*[1], *B. J. Krause*[2], *H. J. Wester*[1];
[1]*Technical University of Munich, Garching, GERMANY,* [2]*Rostock University Medical Center, Rostock, GERMANY.*

OP-297

Development of ^{68}Ga-labeled [Thz^{14}]Bombesin(7-14) analogues for imaging gastrin-releasing peptide receptor expression with positron emission tomography

L. Wang[1,2], *I. Bratanovic*[1], *Z. Zhang*[1], *H. Merkens*[1], *N. Colpo*[1], *J. Zeisler*[1], *C. Zhang*[1], *R. Tan*[1], *R. Wilson*[1], *F. Bénard*[1,2], *K. Lin*[1,2];
[1]*BC Cancer Research Centre, Vancouver, BC, CANADA,* [2]*University of British Columbia, Vancouver, BC, CANADA.*

OP-298

Straightforward Synthesis and In Vivo Characterization of a Heterobivalent Radiotracer Targeting PSMA and GRPR

I. Valverde[1], *T. Bailly*[1], *V. Goncalves*[1], *C. Morgat*[2], *A. Prignon*[3], *F. Denat*[1];
[1]*Institut de Chimie Moléculaire de l'Université de Bourgogne - ICMUB UMR6302, Dijon, FRANCE,* [2]*Institut de Neurosciences Cognitives et Intégratives d'Aquitaine - INCIA UMR 5287 - Université de Bordeaux, Bordeaux, FRANCE,* [3]*Laboratoire d'Imagerie Positonique - LIMP UMS28 - Sorbonne Université, Paris, FRANCE.*

OP-299

Comparison of PSMA- and GRPR-targeting radiotracers in prostate cancer samples of different disease stages: is there a role for GRPR-targeting radiotracers?

M. Verhoeven[1], *E. A. M. Ruigrok*[1], *L. van den Brink*[1], *G. J. L. H. van Leenders*[2], *H. E. Balcioglu*[3], *W. M. van Weerden*[4], *S. U. Dalm*[1];
[1]*Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, NETHERLANDS,* [2]*Department of Pathology, Erasmus MC, Rotterdam, NETHERLANDS,* [3]*Department of Medical Oncology, Erasmus MC, Rotterdam, NETHERLANDS,* [4]*Department of Experimental Urology, Erasmus MC, Rotterdam, NETHERLANDS.*

OP-300

Synthesis and evaluation of ^{18}F-labeled bisAmBF3-conjugated PSMA-targeting tracers derived from the Lys-urea-Aad and Lys-urea-Cms pharmacophores

H. Kuo[1], *Z. Zhang*[1], *H. Merkens*[1], *C. Zhang*[1], *D. Perrin*[2], *K. Lin*[1,3], *F. Bénard*[1,3];
[1]*BC Cancer, Vancouver, BC, CANADA,* [2]*Department of Chemistry, University of British Columbia, Vancouver, BC, CANADA,* [3]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.*

OP-301
Evaluation of Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms pharmacophores to reduce kidney uptake of ^{177}Lu-labeled PSMA-targeting radiotherapeutic agents
H. Kuo[1], *Z. Zhang*[1], *H. Merkens*[1], *C. Zhang*[1], *N. Colpo*[1], *F. Bénard*[1,2], *K. Lin*[1,2];
[1]*BC Cancer, Vancouver, BC, CANADA,* [2]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.*

OP-302
High activity fractionated treatment with ^{177}Lu-PSMA-617 in a mouse model to investigate α1-microglobulin as a kidney radioprotector
A. Örbom[1], *A. Kristiansson*[1], *O. Vilhelmsson Timmermand*[2], *M. Altai*[1], *S. Strand*[3], *B. Åkerström*[4];
[1]*Oncology, Lund University, Lund, SWEDEN,* [2]*Imaging Chemistry & Biology, Kings College London, London, UNITED KINGDOM,* [3]*Medical Radiation Physics, Lund University, Lund, SWEDEN,* [4]*Infection Medicine, Lund University, Lund, SWEDEN.*

OP-303
In vivo evaluation of enhanced blood retention and tumor uptake PSMA-targeting ^{225}Ac-labeled radioconjugates
Z. Novy[1], *M. Petrik*[1], *K. Bendova*[1], *F. Reissig*[2], *K. Zarschler*[3], *K. Kopka*[2], *D. Kurfurstova*[1], *J. Bouchal*[1], *C. Mamat*[2], *M. Hajduch*[1];
[1]*Faculty of Medicine and Dentistry, Olomouc, CZECH REPUBLIC,* [2]*Technische Universität Dresden, Dresden, GERMANY,* [3]*Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY.*

705

Monday, October 17, 2022, 08:00 - 09:30

Hall 211

Cutting Edge Science Track - TROP Session: Quantification in Brain and Heart

OP-304
Parametric Mapping of Total Volume of Distribution in [^{11}C] PK11195-PET in Relapsing-Remitting Multiple Sclerosis
D. B. A. Mantovani[1], *M. S. Pitombeira*[2], *P. N. Schuck*[3], *A. S. de Araújo*[1], *C. Buchpiguel*[2], *D. de Paula Faria*[2], *A. Marques da Silva*[1];
[1]*Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, BRAZIL,* [2]*University of São Paulo, São Paulo, BRAZIL,* [3]*Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA.*

OP-305
Supervised Clustering Analysis in Neuroinflammation Assessment of Relapsing-Remitting Multiple Sclerosis with [^{11}C]PK11195
D. B. A. Mantovani[1], *M. S. Pitombeira*[2], *P. N. Schuck*[3], *A. S. de Araújo*[1], *C. Buchpiguel*[2], *D. de Paula Faria*[2], *A. Marques da Silva*[1];
[1]*Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, BRAZIL,* [2]*University of São Paulo, São Paulo, BRAZIL,* [3]*Weill Cornell Medical College, New York, NY, UNITED STATES OF AMERICA.*

OP-306
Metabolic connectivity is associated with post-TLE surgery patient outcome: a seed correlation and SICE analysis
M. Doyen[1], *M. B. Chawki*[2], *S. Heyer*[2], *E. Guedj*[3], *P. Marie*[4], *L. Tyvaert*[5], *L. Maillard*[5], *A. Verger*[1];
[1]*Université de Lorraine, Department of Nuclear Medicine - Nancyclotep Imaging Platform - IADI INSERM U1254, Nancy, FRANCE,* [2]*Université de Lorraine, Department of Nuclear Medicine - Nancyclotep Imaging Platform, Nancy, FRANCE,* [3]*Aix Marseille Univ, APHM, CNRS, Centrale Marseille, Institut Fresnel, Timone Hospital, CERIMED, Nuclear Medicine Department, Marseille, FRANCE,* [4]*Université de Lorraine, Department of Nuclear Medicine - Nancyclotep Imaging Platform - DCAC, Nancy, FRANCE,* [5]*Department of Neurology, CHRU Nancy, National Reference Center for Rare Epilepsies - CRAN UMR 7039, Nancy, FRANCE.*

OP-307
Semi-quantitation in nuclear cardiology: Automated analysis vs. expert reading - Correlations with the angiographic score
G. Angelidis[1], *V. Valotassiou*[1], *I. Tsougos*[1], *C. Tzavara*[1], *D. Psimadas*[1], *E. Theodorou*[2], *A. Ziaka*[2], *S. Giannakou*[1], *C. Ziangas*[2], *J. Skoularigis*[1], *F. Triposkiadis*[1], *P. Georgoulias*[1];
[1]*University of Thessaly, Larissa, GREECE,* [2]*University Hospital of Larissa, Larissa, GREECE.*

OP-308
Can we simplify semiquantitative analysis in 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTcDPD) scintigraphy performed in patients with transthyretin-related cardiac amyloidosis (cATTR)?
S. Mattoni[1], *G. della Gala*[2], *A. Paccagnella*[1], *M. Morrone*[2,3], *S. Prisco*[1], *L. Strigari*[2], *S. Longhi*[4], *N. Galiè*[4], *M. Sguazzotti*[4], *V. Pettinato*[5], *S. Fanti*[1,6], *R. Bonfiglioli*[6];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Specialization School in Medical Physics, University of Bologna, Bologna, ITALY,* [4]*Cardiovascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, ITALY,* [6]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-309
Machine Learning Model To Predict Diagnosis Of Mild Cognitive Impairment By Using Radiomic And Amyloid Brain PET
G. Giovacchini[1], *E. Giovannini*[1], *S. Pastorino*[1], *O. Ferrando*[1], *A. Mannironi*[1], *A. Tartaglione*[1,2], *A. Ciarmiello*[1];
[1]*S. Andrea Hospital, La Spezia, ITALY,* [2]*Memory Laboratory CNS-ONLUS, La Spezia, ITALY.*

OP-310
Effects of Implementing the Point Spread Function to Detect the IDH Mutation in Newly Diagnosed Gliomas: a Dynamic 18F-FDOPA PET Radiomics Study
S. Ahrari[1,2], *T. Zaragori*[1,2], *M. Bros*[3], *L. Imbert*[1,2,3], *A. Verger*[1,2,3];
[1]*Lorraine university, IADI, INSERM, Nancy, FRANCE,* [2]*Nancyclotep Imaging Platform, Nancy, FRANCE,* [3]*Lorraine university, Department of Nuclear Medicine, CHRU Nancy, Nancy, FRANCE.*

OP-311
[^{18}F]FDG-PET/CT Radiomics in Infective Endocarditis
R. Zanca[1], *P. Erba*[2], *M. Sollini*[1], *L. Cavinato*[3], *A. Ragni*[3], *D. Ten Hove*[4], *A. Glaudemans*[4], *S. Aguadè-Bruix*[5], *M. Pizzi*[6], *A. Roque*[7], *F. Ieva*[8], *R. Slart*[4];
[1]*Humanitas University, Pieve Emanuele, Milan, ITALY,* [2]*Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa and AOUP, Pisa, ITALY,* [3]*MOX – Modeling and Scientific Computing, Department of Mathematics, Politecnico di Milano, Milan, ITALY,* [4]*University of Groningen, University Medical Center Groningen, Medical Imaging Center, Groningen, NETHERLANDS,* [5]*Department of Nuclear Medicine, Hospital Universitari Vall d'Hebron, Barcelona, SPAIN,* [6]*Department of Cardiology, Hospital Universitari Vall d'Hebron, Barcelona, SPAIN,* [7]*Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, SPAIN,* [8]*MOX – Modeling and Scientific Computing, Department of Mathematics, Politecnico di Milano and CHDS – Center for Health Data Science, Human Technopole, Milan, ITALY.*

OP-312
Automated AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PET-CT imaging
L. Duff[1], *A. F. Scarsbrook*[1,2], *N. Ravikumar*[1], *R. Frood*[1,2], *S. L. Mackie*[1,2], *M. Bailey*[1,2], *J. M. Tarkin*[3], *J. C. Mason*[4], *A. Frangi*[1], *A. W. Morgan*[1,2], *C. Tsoumpas*[1,5];
[1]*University of Leeds, Leeds, UNITED KINGDOM,* [2]*Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM,* [3]*University of Cambridge, Cambridge, UNITED KINGDOM,* [4]*Imperial College London, London, UNITED KINGDOM,* [5]*University of Groningen, Groningen, NETHERLANDS.*

706

Monday, October 17, 2022, 08:00 - 09:30

Hall 117

Clinical Oncology Track - TROP Session: Onco Miscellanea

OP-313
Diagnostic Performance of Whole-Body ^{18}F-FDG PET/MR in M Staging: A Systematic Review and Meta-Analysis
S. Mirshahvalad[1], *R. Hinzpeter*[1], *A. Kohan*[1], *R. Anconina*[2], *R. Kulanthaivelu*[1], *C. Ortega*[1], *U. Metser*[1], *P. Veit-Haibach*[1];
[1]*Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA,* [2]*Sunnybrook Health Sciences Center, Toronto, ON, CANADA.*

OP-314
A prospective head-to-head comparison of [^{68}Ga]Ga-P16-093 and [^{18}F]F-FDG PET/CT in patients with clear cell renal cell carcinoma
G. Wang[1], *L. Li*[2], *L. Zhu*[2], *H. Kung*[3], *Z. Zhu*[1];
[1]*Peking Union Medical College Hospital, Beijing, CHINA,* [2]*Beijing Normal University, Beijing, CHINA,* [3]*University of Pennsylvania, Pennsylvania, PA, UNITED STATES OF AMERICA.*

OP-315
[68Ga]Ga-PSMA-PET/CT Performance in Neoplasms Different from Prostate Cancer: Preliminary Results from a Prospective Single-center Study
L. Vetrone[1], *G. Argalia*[1], *R. Mei*[1], *D. Bezzi*[1], *F. Serani*[1], *L. Calderoni*[1], *E. Tabacchi*[2], *C. Nanni*[2], *P. Castellucci*[2], *A. Farolfi*[2], *S. Fanti*[1,2];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-316
ITA-IMMUNO-PET: The Role Of FDG PET/CT In The Evaluation Of Response To Immunotherapy In Patients (PTS) With Lung Cancer (LG) And Malignant Melanoma (MM)
L. Evangelista[1], *M. L. De Rimini*[2], *A. Annovazzi*[3], *M. Bauckneht*[4], *V. Rossetti*[5], *C. Ferrari*[6], *S. Ialuna*[7], *L. Urso*[8], *V. Liberini*[9], *L. Cuppari*[10], *D. Arico*[11], *R. Gallicchio*[12], *L. Ruffini*[13], *G. Trifiro*[14], *F. Bertagna*[15], *A. Alessi*[16], *S. Gusella*[17], *A. Bianchi*[18];
[1]*University of Padua, Padua, ITALY,* [2]*AORN Ospedali dei Colli, Naples, ITALY,* [3]*IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [4]*University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY,* [5]*IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, ITALY,* [6]*Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, ITALY,* [7]*Az. Ospedaliera Ospedali Riuniti Villa Sofia-Cervello di Palermo, Palermo, ITALY,* [8]*Azienda Ospedaliero Universitaria di Ferrara, Ferrara, ITALY,* [9]*University of Torino, Turin, ITALY,* [10]*IOV-IRCCS, Padua, ITALY,* [11]*Humanitas Istituto Clinico Catanese, Misterbianco, Catania, ITALY,* [12]*IRCCS CROB Referral Cancer Center of Basilicata, Rionero in Vulture, Potenza, ITALY,* [13]*Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY,* [14]*ICS MAUGERI SPA SB – IRCCS, Pavia, ITALY,* [15]*University of Brescia, Brescia, ITALY,* [16]*Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY,* [17]*Central Hospital Bolzano (SABES-ASDAA), Bolzano-Bozen, Bolzano, ITALY,* [18]*ASO S.Croce e Carle, Cuneo, ITALY.*

OP-317
^{68}GA-FAPI PET/CT in the evaluation of Non-Small Cell Lung Cancer (NSCLC)
H. Lanzafame[1], *N. Hirmas*[1], *M. Schuler*[2,3], *K. Darwiche*[4,3], *W. E. E. Eberhardt*[2,3], *C. Aigner*[5,3], *M. Stuschke*[6,3], *L. Kessler*[1], *K. M. Pabst*[1], *F. Barbato*[1], *C. Rischpler*[1], *H. Hautzel*[1], *K. Herrmann*[1], *W. Fendler*[1];
[1]*Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,* [2]*Department of Medical Oncology, West German Cancer Center, Essen, GERMANY,* [3]*University Hospital Essen, Essen, GERMANY,* [4]*Department of Pneumology, Ruhrlandklinik, Essen, GERMANY,* [5]*Department of Thoracic Surgery and Thoracic Endoscopy, Ruhrlandklinik, Essen, GERMANY,* [6]*Department of Radiation Oncology, West German Cancer, Essen, GERMANY.*

OP-318
Application Value of PET/MR radiomics features and metabolic parametersin predicting lung adenocarcinoma and squamous cell carcinoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

OP-319
Correlation between Rubidium-82 and FDG uptake in thoracic lesions
L. Tamkeviciute, *B. Sathyamurthi, I. S. Armstrong, P. Arumugam;*
Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM.

OP-320
PET/MRI of hypoxia in ER+ breast cancer: Correlations with immunohistochemistry
J. Carmona-Bozo, *R. Manavaki, J. Miller, C. Brodie, C. Caraco, G. Baxter, T. Fryer, E. Provenzano, F. Gilbert;*
University of Cambridge, Cambridge, UNITED KINGDOM.

OP-321
With F-18 FDG PET/CT SUVmax Values in Gastric Cancers Evaluation of Histopathological HER-2 Relationship
N. Talay, *B. Cagdas, S. Turkolmez;*
Ankara City Hospital Nuclear Medicine Department, Ankara, TÜRKIYE.

707

Monday, October 17, 2022, 08:00 - 09:30

Hall 115

Bone & Joint Committee - Featured Session: Bone and Joint en Route - Tracers, Modalities and Applications

OP-322
Bone and Joint en Route
S. Annunziata;
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY.

OP-323
Characterization of joint associated ^{68}Gallium-FAPI Uptake in 430 osteoarthritis lesions in 163 patients
M. Roehrich, *A. van Genabith, J. Hoppner, P. Kvacskay, F. Giesel, H. Lorenz, U. Haberkorn, W. Merkt;*
Unversity hospital Heidelberg, Heidelberg, GERMANY.

OP-324
Role of 68Ga-Pentixafor PET/CT For In Vivo Imaging Of CXCR4 Receptor Expression In Bone And Soft Tissue Sarcoma
B. Singh, *S. R. Jena, V. Bachhal, H. Singh, A. Watts, S. K. Arora, B. D. Radotra;*
PGIMER, Chandigarh, INDIA.

OP-325
Dynamic ^{18}F-Sodium Fluoride (18F-NaF) PET/CT analysis: a comparison between oral and intravenous 18F-NaF administration in the assessment of breast and prostate cancer patients
N. H. Rocha, *H. Sado, C. A. Buchpiguel, P. S. Duarte, M. T. Sapienza;*
Universidade de São Paulo, São Paulo, BRAZIL.

OP-326
Prediction of bone marrow involvement in follicular lymphoma based on 18F-FDG healthy organs uptake
D. Morland[1,2,3], *E. Triumbari*[2], *E. Durot*[4], *F. Godard*[5], *S. Annunziata*[2], *D. Papathanassiou*[1,3,6];
[1]*Nuclear Medicine Department, Institut Godinot, Reims, FRANCE,* [2]*TracerGLab, Fondazione Policlinico Universitario A. Gemelli, Rome, ITALY,* [3]*CReSTIC EA 3804, Université de Reims Champagne-Ardenne, Reims, FRANCE,* [4]*Hematology Department, CHU Reims, Reims, FRANCE,* [5]*Nuclear Medicine Department, centre Georges-François Leclerc, Dijon, FRANCE,* [6]*Laboratoire de Biophysique, Université de Reims Champagne-Ardenne, Reims, FRANCE.*

OP-327
Digital pathology-guided tissue characterization with multimodality imaging for response monitoring in sarcomas
G. Kalisvaart, *A. Broersen, J. V. Bovée, R. P. van den Ende, K. van Langevelde, A. Navas, H. Gelderblom, S. A. Krol, J. A. van der Hage, M. A. van de Sande, J. Dijkstra, L. de Geus-Oei, J. L. Bloem, W. Grootjans;*
Leiden University Medical Center, Leiden, NETHERLANDS.

OP-328
Dual time point [18F]FDG PET/CT for differentiating benign from malignant musculoskeletal tumors
P. D'Abadie, *O. Gheysens, R. Lhommel, A. De Roo, T. Schubert;*
Cliniques universitaires Saint Luc, Brussels, BELGIUM.

OP-329
Dual high-speed whole-body SPECT-CT recordings of the blood pool and delayed phases of bone scintigraphy in patients with known or suspected chronic inflammatory arthritis (CIA)
A. Bahloul, *F. Rajadhas, D. Loeuille, I. Chary-Valckenaere, P. Marie, L. Imbert;*
CHU de Nancy, Vandoeuvre Les Nancy, FRANCE.

OP-330
Bone SPECT/CT for assessing persistent or recurrent pain post spondylodesis: a retrospective study and pattern analysis
J. Mertens[1,2], *B. Van Den Bossche*[1,2], *D. Berwouts*[1,2], *J. Bleyen*[3], *A. Harth*[4], *T. Matton*[5], *T. Van den Wyngaert*[6,7], *B. Lambert*[1,2,8];
[1]*Department of Nuclear Medicine, AZ Maria Middelares, Ghent, BELGIUM,* [2]*Department of Nuclear Medicine, AZ Jan Palfijn, Ghent, BELGIUM,* [3]*Department of Neurosurgery, AZ Maria Middelares, Ghent, BELGIUM,* [4]*Department of Orthopaedic Surgery and Traumatology, AZ Jan Palfijn, Ghent, BELGIUM,* [5]*Department of Radiology, AZ Maria Middelares, Ghent, BELGIUM,* [6]*Department of Nuclear Medicine, Antwerp University Hospital, Edegem, BELGIUM,* [7]*Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM,* [8]*Department of Diagnostic Sciences, Ghent University, Ghent, BELGIUM.*

708

Monday, October 17, 2022, 08:00 - 09:30

Hall 212

Joint Symposium 3 - Thyroid Committee / ETA: A Nuclear Medicine Update on Diagnosis and Treatment of Medullary Thyroid Carcinoma (MTC)

OP-331
Update on Systemic Treatment of MTC
R. Elisei;
Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ITALY.

OP-332
State of the Art Nuclear Medicine Imaging of MTC
M. Luster;
Department of Nuclear Medicine, University Hospital Marburg, Marburg, GERMANY.

OP-333
Radioligand Therapy in MTC
G. Nicolas;
Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND.

710

Monday, October 17, 2022, 08:00 - 09:30

Hall 116

Technologists' Oral Presentations 2: Diagnosis and Therapy

OP-335
Absolute quantification of thyroid uptake and volume using SPECT-CT in pre and post low dose iodine-131 therapy in patients with Grave's disease
K. Kaur, *M. Kaur, B. Mittal;*
Post graduate institute of medical education and research, Chandigarh, INDIA.

OP-336
Assessment of Pretreatment Diffusion Parameters in Low- and Intermediate-Risk Prostate Cancer Patients Treated with Stereotactic Ablative Radiotherapy
A. Kedves[1,2,3], *K. Kisiván*[1], *C. Glavak*[1], *A. Lorincz*[3,4], *A. Kovacs*[2,5,6], *F. Lakosi*[1,2,5];
[1]*"Moritz Kaposi" Teaching Hospital, Dr. József Baka Diagnostic, Radiation Oncology, Research and Teaching Center, Kaposvar, HUNGARY,* [2]*Doctoral School of Health Sciences, University of Pecs, Pecs, HUNGARY,* [3]*Institute of Information and Electrical Technology, Faculty of Engineering and Information Technology, University of Pecs, Pecs, HUNGARY,* [4]*Institute for Translational Medicine, Medical School, University of Pécs, Pecs, HUNGARY,* [5]*Department of Medical Imaging, Faculty of Health Sciences, University of Pécs, Pecs, HUNGARY,* [6]*Department of Oncoradiology, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY.*

OP-337
A Tale of Serendipity from Misadministration
M. Vyas[1,2], *A. M. Henderson, A.Rowlings, J. Fagan, R. Joseph;*
[1]*Unitec Institute of Technology, Auckland, NEW ZEALAND,* [2]*Mercy Radiology, Auckland, NEW ZEALAND.*

OP-338
Using a novel long-axial field-of-view (LAFOV) PET/CT system for dual tracer scanning with [68Ga]Ga-PSMA-11 and [18F]FDG PET/CT for PSMA-therapy assessment
R. Schepers, *K. Zeimpekis, M. Viscione, A. Rominger, A. Afshar-Oromieh, I. Alberts;*
Inselspital, Bern, SWITZERLAND.

OP-339
Delayed [^{68}Ga]Ga-PSMA-PET/CT Pelvic Acquisition With a Single CT Scan in High-Risk Prostate Cancer: Dosimetry and Acquisition Time Considerations of a Single Center Experience
M. Moscarino[1], *C. Sgro*[2], *R. Mei*[2], *A. Farolfi*[1], *S. Civollani*[3], *L. Romagnoli*[1], *A. Zappacosta*[1], *P. Castellucci*[1], *S. Fanti*[1,2];
[1]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [3]*Department of Medical Physics, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-340
Serial ^{18}F-PSMA-1007 PET/CT imaging: A comparative study with ^{68}Ga-PSMA-11
P. Sharma, *A. Watts, H. Singh;*
PGIMER Chandigarh, Chandigarh, INDIA.

OP-341
Use of Ga68-PSMA PET-CT in the Detection of Suspected Clear Cell Renal Cell Carcinoma: Initial Prospective Study
E. Chen[1,2], *T. H. Tan*[1,2], *M. T. Chew*[2], *T. Subramaniam*[1,2], *S. C. Peh*[2];
[1]*Sunway Medical Centre, Petaling Jaya, MALAYSIA,* [2]*Sunway University, Petaling Jaya, MALAYSIA.*

OP-342
Practical Aspects of Intrathecal Radio immunotherapy in Pediatric Patients
V. Setterberg[1], *M. Møller Jørgensen*[2];
[1]*Rigshospitalet, København N, DENMARK,* [2]*Rigshospitalet, København Ø, DENMARK.*

OP-343
Impact of Voxel Size and Temporal Resolution on the ^{15}O-Water-PET Method for Calculating Left Ventricular Function
J. Sigfridsson[1,2], *J. Nordström*[1,3], *H. Harms*[1], *T. Kero*[1,2], *T. Baron*[4], *F. Flachskampf*[4], *M. Lubberink*[1,5], *J. Sörensen*[1,2];
[1]*Department of Surgical Sciences, Nuclear Medicine & PET, Uppsala University, Uppsala, SWEDEN,* [2]*PET Centre and Nuclear Medicine, Uppsala University Hospital, Uppsala, SWEDEN,* [3]*Centre for Research and Development, Uppsala/Gävleborg County, Gävle, SWEDEN,* [4]*Department of Medical Sciences, Clinical Physiology and Cardiology, Uppsala University, Uppsala, SWEDEN,* [5]*Medical Physics, Uppsala University Hospital, Uppsala, SWEDEN.*

801

Monday, October 17, 2022, 09:45 - 11:15

Auditorium

CME 6 - Oncology & Theranostics Committee: PET/CT – The Prediction Game

OP-344
FDG in Haematology
B.M. Fischer;
Dept. of Clinical Physiology and Nuclear Medicine Rigshospitalet, University of Copenhagen, Copenhagen, DENMARK.

OP-345
FDG in Solid Tumours
M. Bauckneht;
Ospedale San Martino, Nuclear Medicine, Genoa, ITALY.

OP-346
Non-FDG in Oncology
S. Balogová;
Department of Nuclear Medicine of Medical faculty of Comenius University in Bratislava and St.Elisabeth Oncology Institute, Bratislava, SLOVAKIA.

802

Monday, October 17, 2022, 09:45 - 11:15

Hall 112 (Arena)

TOP Trials Session 2: Best FAPI Trials

OP-346a
Introduction into FAPI
U. Haberkorn;
University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY.

OP-347
Head-to-head comparison of new FAP binders designed to enhance tumor residence for Targeted Radionuclide Therapy
J. Millul[1], *L. Koepke*[2], *R. H. Gaonkar*[1], *K. Sparrer*[2], *R. Mansi*[1], *M. Fani*[1];
[1]*University Hospital Basel, Basel, SWITZERLAND,* [2]*Ulm University, Ulm, GERMANY.*

OP-348
First Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer
P. Backhaus[1,2,3], *M. C. Burg*[4], *I. Asmus*[1], *M. Pixberg*[1], *F. Büther*[1,2], *H. Breyholz*[1], *S. Weigel*[4], *P. Stichling*[4], *W. Heindel*[4], *S. Bobe*[5], *P. Barth*[5], *J. Tio*[6], *M. Schäfers*[1,2];
[1]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,* [2]*European Institute for Molecular Imaging, University of Münster, Münster, GERMANY,* [3]*Molecular Imaging and Therapy Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York City, NY, UNITED STATES OF AMERICA,* [4]*Clinic for Radiology, University Hospital Münster, Münster, GERMANY,* [5]*Gerhard-Domagk Institute for Pathology, University Hospital Münster, Münster, GERMANY,* [6]*Department of Gynecology & Obstetrics, University Hospital Münster, Münster, GERMANY.*

OP-349

[68Ga]Ga-FAPI-46 PET/CT In Staging Lung Cancer Patients: A Preliminary Study

S. Telo[1,2], *E. Fortunati*[1], *G. Cuzzani*[1], *C. Nanni*[3], *P. Castellucci*[3], *L. Zanoni*[3], *A. Farolfi*[3], *C. Malizia*[4], *F. Lodi*[4], *V. Cabitza*[4], *F. Antonacci*[5], *P. Solli*[5], *M. Ferrari*[6], *F. Natali*[6], *T. Galasso*[6], *G. Bandelli*[6], *P. Candoli*[6], *S. Fanti*[1,3];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine Department, AUSL Romagna, Romagna, ITALY,* [3]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Division of Thoracic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*Interventional Pulmunology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

OP-350

Assessing the performance of Ga-68-Fibroblast activating protein inhibitor-04 (FAPI) in the diagnosis the hepatobiliary malignancies (HBM)- A prospective pilot study

V. Rajaraman, *A. Jeba, D. Halanaik, B. Pottakkat;*
Jawaharlal institute of post graduate medical education and research institute, Puducherry, INDIA.

OP-351

Comparison of 68Ga-FAPI-46 PET/CT and 18-FDG PET/CT in breast carcinoma staging: Results of 100 patients

F. Novruzov[1], *E. Mehdi*[1], *N. Orucova*[1], *G. Aliyeva*[1], *F. Giesel*[2], *F. Valla*[3], *S. Rahimzade*[4], *J. Aliyev*[5];
[1]*Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN,* [2]*University Hospital Düsseldorf, Department of Nuclear Medicine, Dusseldorf, GERMANY,* [3]*SOFIE, Director RCM, Totowa, NJ, UNITED STATES OF AMERICA,* [4]*Azerbaijan National Centre Of Oncology, Department of Woman Health, Baku, AZERBAIJAN,* [5]*Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.*

OP-352

FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCRPC): a triple tracer comparison

K. M. Pabst[1,2], *W. P. Fendler*[1,2], *B. Hadaschik*[3,2], *C. Kesch*[3,2], *N. Hirmas*[1,2], *L. Kessler*[1,2], *V. Grünwald*[3,2], *R. Hamacher*[4,2], *M. Nader*[1,2], *C. Berliner*[1,2], *L. Umutlu*[5,2], *L. Püllen*[3,2], *K. Herrmann*[1,2], *K. Lückerath*[1,2], *P. Castellucci*[6], *S. Fanti*[6], *R. Mei*[6,1];
[1]*Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [2]*German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY,* [3]*Department of Urology, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [4]*Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [5]*Department of Diagnostic and Interventional Radiology and Neuroradiology, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [6]*Division of Nuclear Medicine, IRCCS University Hospital Bologna, Bologna, ITALY.*

OP-353

Comparison of diagnostic performance between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET/CT in the diagnosis of various radioiodine resistant thyroid cancers of follicular cell origin

S. Ballal[1], *M. P. Yadav*[1], *F. Roesch*[2], *C. Bal*[1], *N. Wakade*[1], *E. S. Moon*[3], *M. Tripathi*[1], *S. Agarwal*[1], *R. K. Sahoo*[1];
[1]*All India Institute of Medical Sciences, Delhi, INDIA,* [2]*SCV company, Koppenstraße. 82, 10243, Berlin, GERMANY,* [3]*Johannes Gutenberg-University Mainz, Mainz, GERMANY.*

OP-354

Target Expression and FAP-Directed Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities

N. Hirmas[1], *M. Ingenwerth*[2], *M. Sraieb*[1], *L. Kessler*[1], *K. M. Pabst*[1], *H. Lanzafame*[1], *K. Lueckerath*[1], *S. Kasper*[3], *M. Nader*[1], *H. Schildhaus*[2,4], *B. Hadaschik*[5], *V. Gruenwald*[5], *B. von Tresckow*[6], *C. Hanoun*[6], *C. Aigner*[7], *M. Glas*[8], *K. Herrmann*[1], *J. T. Siveke*[9,10], *R. Hamacher*[3], ***W. P. Fendler***[1];
[1]*Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [2]*Institute of Pathology, University Hospital Essen, Essen, GERMANY,* [3]*Department of Medical Oncology, West German Cancer Centre, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [4]*Targos Molecular Pathology Inc., Kassel, GERMANY,* [5]*Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [6]*Department of Haematology and Stem Cell Transplantation, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [7]*Department of Thoracic Surgery and Thoracic Endoscopy, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [8]*Division of Clinical Neurooncology, Department of Neurology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [9]*Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [10]*Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, Partner Site Essen) and German Cancer Research Center, DKFZ, Heidelberg, GERMANY.*

OP-355

^{177}Lu-FAP-2286 in patients with advanced or metastatic solid tumours: updated data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumour activity (LuMIERE)

T. Hope[1], *R. Aggarwal*[1], *A. H. Goenka*[2], *R. H. Moy*[3], *Y. Menda*[4], *B. Chasen*[5], *P. Bhambhvani*[6], *M. Khushman*[6], *A. Mintz*[3], *M. Doubrovin*[3], *D. Thompson*[1], *Y. Zakharia*[4], *J. J. Sunderland*[4], *O. Bowles*[7], *A. D. Simmons*[7], *K. Wride*[7], *A. Enke*[7], *J. McConathy*[6];
[1]*University of California, San Francisco, CA, UNITED STATES OF AMERICA,* [2]*Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA,* [3]*Columbia University Irving Medical Center, New York, NY, UNITED STATES OF AMERICA,* [4]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA,* [5]*The University of Texas MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA,* [6]*University of Alabama School of Medicine, Birmingham, AL, UNITED STATES OF AMERICA,* [7]*Clovis Oncology, Inc., Boulder, CO, UNITED STATES OF AMERICA.*

OP-356

Fibroblast activation protein alpha (FAPa) as theranostic target in solitary fibrous tumor (SFT)

W. Fendler[1], *L. Kessler*[1], *P. F. Cheung*[2], *C. E. Heilig*[3], *S. Liffers*[2], *S. Borchert*[4], *P. F. Costa*[1], *K. M. Pabst*[1], *M. M. Miera*[2], *M. Droste*[2], *M. Akbulut*[2], *J. Falkenhorst*[2], *K. Kostbade*[2], *I. A. Mavroeidi*[2], *L. Umutlu*[5], *M. Schuler*[2], *S. Bauer*[2], *S. Fröhling*[3], *K. Herrmann*[1], *J. T. Siveke*[2], *H. Schildhaus*[4], *R. Hamacher*[2];
[1]*Department of Nuclear Medicine, Essen, GERMANY,* [2]*Department of Oncology, Essen, GERMANY,* [3]*Department of Oncology, Heidelberg, GERMANY,* [4]*Department of Pathology, Essen, GERMANY,* [5]*Department of Radiology, Essen, GERMANY.*

803

Monday, October 17, 2022, 09:45 - 11:15

Hall 113

LIPS Session 6 - Neuroimaging Committee: Black and White or Fifty Shades of Grey? Beyond Binary Reading of Brain PET Images

Interactive Session

OP-357

The A/T/N Model Through Imaging Biomarkers in a Memory Clinic

S. Morbelli*;*
San Martino Hospital, Department of Health Sciences, University of Genoa, Genoa, ITALY.

OP-358

To Be or Not to Be? An AMY PET Challenge

N. Tolboom*;*
Imaging Division, Department of Radiology, University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-359

To Be or Not to Be? A TAU PET Challenge

A. Drzezga*;*
Department of Nuclear Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, GERMANY.

OP-360

Discussion

804

Monday, October 17, 2022, 09:45 - 11:15

Hall 114

M2M Track - Featured Session: T-Cells, TAM's and CAF's - Again

OP-361

Dissecting the TME by Molecular Imaging

W. Weber*;*
TUM, Nuclear Medicine, Munich, GERMANY.

OP-362

DTPA-Receptor: A novel PET-reporter gene system for the imaging of cell and gene therapies

V. Morath, *K. Fritschle, M. Zivanic, L. Krumwiede, M. Anneser, S. Dötsch, L. Warmuth, S. Robu, P. Bösl, T. Bozoglu, S. Kossatz, C. Kupatt, M. Schwaiger, K. Steiger, D. Busch, A. Skerra, W. Weber;*
Technische Universität München, Munich, GERMANY.

OP-363

Pharmacokinetic imaging and therapeutic efficacy of the bispecific CD3xTRP-1 antibody in syngeneic mouse tumor models

G. Sandker[1], *J. Middelburg*[2], *E. Wilbrink*[1], *J. Molkenboer-Kuenen*[1], *E. Aarntzen*[1], *T. van Hall*[2], *S. Heskamp*[1];
[1]*Department of Medical Imaging, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, NETHERLANDS,* [2]*Department of Medical Oncology, Leiden University Medical Center, Leiden, NETHERLANDS.*

OP-365

Head-to-head comparison of nuclear imaging approaches to quantify tumor CD8$^+$ T-cell infiltration

G. Sandker[1], *R. Raavé*[1], *I. Antunes*[2], *M. Boswinkel*[1], *L. Cornelissen*[3], *G. Franssen*[1], *J. Molkenboer-Kuenen*[1], *D. Boreel*[3], *P. Wierstra*[1], *I. Hagemans*[4], *J. Bussink*[3], *G. Adema*[3], *E. Aarntzen*[1], *M. Verdoes*[4], *S. Heskamp*[1];
[1]*Department of Medical Imaging, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, NETHERLANDS,* [2]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University Medical Center Groningen, Groningen, NETHERLANDS,* [3]*Department of Radiation Oncology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, NETHERLANDS,* [4]*Department of Tumor Immunology and the Institute for Chemical Immunology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, NETHERLANDS.*

OP-366

Development of anti-CD103 PET imaging tracer for noninvasive assessment of cancer immunotherapy

X. Fan, *A. Kol, M. Wazynska, N. Perujo-Holland, H. Nijman, P. Elsinga, M. d. Bruyn;*
University of Groningen, Groningen, NETHERLANDS.

OP-367

Tumor cells drive 18 kDa translocator protein (TSPO) PET tracer signals of experimental and clinical glioblastoma

L. Bartos[1], *S. Kirchleitner*[1], *J. Blobner*[1], *K. Wind*[1], *A. Holzgreve*[1], *L. Gold*[1], *L. Kunze*[1], *M. Antons*[1], *S. T. Kunte*[1], *P. Beumers*[1], *S. Quach*[1], *D. Messerer*[1], *P. Bartenstein*[1], *J. C. Tonn*[1], *L. von Baumgarten*[1], *M. J. Riemenschneider*[2], *N. L. Albert*[1], *M. Brendel*[1];
[1]*University Hospital of Munich, Munich, GERMANY,* [2]*University of Regensburg, Regensburg, GERMANY.*

OP-368

Novel Fibroblast Activation Protein Targeting Radioligands for Improved Theranostic Application

C. D. van der Heide, *M. W. H. Hoorens, Y. Seimbille, S. U. Dalm;*
Erasmus MC, Rotterdam, NETHERLANDS.

OP-369

Targeted diagnostic applications of tumor stroma using radiolabeled fibroblast activation protein (FAP) inhibitors. Preclinical evaluation of a series of FAP-based probes labeled with ^{68}Ga

S. Imlimthan[1], *E. Menéndez*[1], *A. Escudero-Castellanos*[1], *E. Moon*[2], *T. Läppchen*[1], *H. Rathke*[1], *A. Afshar-Oromieh*[1], *F. Rösch*[2], *A. Rominger*[1], ***E. Gourni***[1];
[1]*University Hospital Bern, Department of Nuclear Medicine, Bern, SWITZERLAND,* [2]*Department of Chemistry – TRIGA site, Johannes Gutenberg - University Mainz, Mainz, GERMANY.*

805

Monday, October 17, 2022, 09:45 - 11:15

Hall 211

Cutting Edge Science Track - TROP Session: Clinical Lu-177 Dosimetry

OP-370
A Population Pharmacokinetic Model Using Imaging Data to Assess Variability in Pharmacokinetics of [^{177}Lu] Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients

H. Siebinga[1,2], *B. M. Privé*[3], *S. M. B. Peters*[3], *J. Nagarajah*[3], *B. J. de Wit - van der Veen*[2], *A. D. R. Huitema*[1,4,5], *J. J. M. Hendrikx*[1,2];
[1]*Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,* [2]*Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,* [3]*Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [4]*Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, NETHERLANDS,* [5]*Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.*

OP-371
Tumour dosimetry after Lutetium-177 PSMA Therapy: a new voxel-based approach with time-integration at the volume level

R. Danieli, *C. Marin, C. Artigas, Q. Shagera, B. Vanderlinden, N. Reynaert, P. Flamen, H. Levillain;*
Institut Jules Bordet, Anderlecht, BELGIUM.

OP-372
Clinical dosimetry in [^{177}Lu]Lu-PSMA therapy: fewer imaging time points, still useful

D. de Vries-Huizing, *E. Rijkhorst, E. Owers, B. de Wit-van der Veen;*
Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-373
Bone marrow dosimetry in low volume hormone mHSPC receiving Lu-177-PSMA therapy using SPECT/CT

D. Grob[1], *B. M. Privé*[1], *J. Nagarajah*[1], *M. W. Konijnenberg*[2,1], *S. M. B. Peters*[1];
[1]*Radboud University Medical Center, Nijmegen, NETHERLANDS,*
[2]*Erasmus Medical Center, Rotterdam, NETHERLANDS.*

OP-374
Investigation of the biodistribution and dosimetry for combined Lu-177/Ac225-PSMA-I&T therapy using multi-isotope quantitative SPECT imaging

A. Delker, *M. Schleske, G. Liubchenko, I. Berg, M. J. Zacherl, M. Brendel, F. J. Gildehaus, A. Harbach, M. Rumiantcev, S. Resch, L. Kaiser, J. Brosch-Lenz, V. Wenter, L. Unterrainer, P. Bartenstein, S. Ziegler, L. Beyer, G. Böning;*
Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY.

OP-375
Absorbed dose estimation for ^{177}Lu-HA-DOTATATE therapy using a PBPK model or a mono-exponential fit

V. Vasic, *B. Schemmer, C. Orlov, V. Prasad, A. Beer, G. Glatting;*
Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY.

OP-376
Implementation of Simplified Protocol for Tumour Dosimetry in Molecular Radiotherapy with ^{177}Lu-DOTATATE

R. Danieli, *G. Marin, M. Mileva, B. Vanderlinden, I. Karfis, N. Reynaert, P. Flamen, H. Levillain;*
Institut Jules Bordet, Anderlecht, BELGIUM.

OP-377
Effects of imaging time points on uncertainty in absorbed dose to the kidneys in patients with neuroendocrine tumours receiving ^{177}Lu-DOTATATE therapy

M. Sandstrom[1,2], *E. Ilan*[1,2], *C. Widström*[1], *A. Sundin*[2], *M. Lubberink*[1,2];
[1]*Medical Physics, Uppsala, SWEDEN,* [2]*Nuclear Medicine and PET, Uppsala, SWEDEN.*

OP-378
Optimal sampling of a single-time-point dosimetry for peptide receptor radionuclide therapy using a non-linear mixed effects model and a sum of exponential functions

G. Glatting[1,2], *A. Riana*[3], *A. J. Beer*[2], *D. Hardiansyah*[3];
[1]*Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, GERMANY,* [2]*Department of Nuclear Medicine, Ulm University, Ulm, GERMANY,* [3]*Medical Physics and Biophysics, Physics Department, Faculty of Mathematics and Natural Sciences, Universitas Indonesia, Depok, INDONESIA.*

806

Monday, October 17, 2022, 09:45 - 11:15

Hall 117

Clinical Oncology Track - TROP Session: Prostate Therapy

OP-379
Multi-cycle dosimetry of [^{177}Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study

J. Kurth[1], *K. Rahbar*[2], *M. Eiber*[3], *R. Sparks*[4], *N. Baca*[4], *B. J. Krause*[1], *M. Lassmann*[5], *W. Jentzen*[6], *D. Chicco*[7], *P. Klein*[8], *L. Blumenstein*[9], *J. Basque*[10], *K. Herrmann*[6];
[1]*Rostock University Medical Center, Rostock, GERMANY,* [2]*University Hospital Münster, Münster, GERMANY,* [3]*Technical University of Munich, Munich, GERMANY,* [4]*CDE Dosimetry Services, Knoxville, TN, UNITED STATES OF AMERICA,* [5]*University Hospital Würzburg, Würzburg, GERMANY,* [6]*University Hospital Essen, Essen, GERMANY,* [7]*Advanced Accelerator Applications, a Novartis Company, Turin, ITALY,* [8]*Novartis Institutes for BioMedical Research, East Hanover, NY, UNITED STATES OF AMERICA,* [9]*Novartis Institutes for BioMedical Research, Basel, SWITZERLAND,* [10]*Novartis Pharma AG, Basel, SWITZERLAND.*

OP-380
VISION read criteria of 68Ga-PSMA-11 PET scans for patient eligibility to 177Lu-PSMA-617 therapy: a simple and reproducible methodology

P. Kuo[1], *D. C. Yoo*[2], *R. Avery*[3], *M. Seltzer*[4], *J. Calais*[5], *J. Nagarajah*[6], *W. A. Weber*[7], *W. P. Fendler*[8], *M. S. Hofman*[9], *B. J. Krause*[10], *A. Catafau*[11], *E. Kpamegan*[12], *M. Brackman*[13], *A. T. Kendi*[14];
[1]*University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA,* [2]*Warren Alpert Medical School of Brown University, Providence, RI, UNITED STATES OF AMERICA,* [3]*Northwestern University, Evanston, IL, UNITED STATES OF AMERICA,* [4]*Geisel School of Medicine at Dartmouth, Hanover, NH, UNITED STATES OF AMERICA,* [5]*Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, UNITED STATES OF AMERICA,* [6]*Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS,* [7]*TUM School of Medicine, Technical University of Munich, Munich, GERMANY,* [8]*Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [9]*Cancer Imaging, Prostate Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [10]*Rostock University Medical Center, Rostock, GERMANY,* [11]*Advanced Accelerator Applications, a Novartis Company, Geneva, SWITZERLAND,* [12]*Novartis Pharmaceuticals Corporation, East Hanover, NJ, UNITED STATES OF AMERICA,* [13]*Novartis Pharmaceuticals Corporation, Indianapolis, IN, UNITED STATES OF AMERICA,* [14]*Mayo Clinic, Rochester, MN, UNITED STATES OF AMERICA.*

OP-381
Safety and efficacy of PSMA targeted radionuclide therapy with ^{177}Lu-ITG-PSMA-1 in metastatic castration resistant prostate cancer patients: preliminary results of a Swiss wide prospective multicentre registry study

G. Nicolas[1], *A. Chirindel*[1], *A. Bauman*[1], *M. Fani*[1], *N. Schaefer*[2], *D. Wild*[1], *SSNM Therapy Working Group;*
[1]*University Hospital Basel, Basel, SWITZERLAND,* [2]*University Hospital Lausanne, CHUV, Lausanne, SWITZERLAND.*

OP-382
Effect of ^{177}Lu-PSMA-617 radioligand therapy on quality of life in patients with advanced metastatic prostate cancer

C. Scheer, *M. Jüptner, Y. Zhao, M. Zuhayra, U. Lützen;*
Department of Nuclear Medicine, Molecular Diagnostic Imaging and Therapy, University Hospital of Schleswig-Holstein (UKSH), Karl Lennert Cancer Center North, Kiel, GERMANY.

OP-383
Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)

G. Beydagi[1], *N. Alan Selcuk*[1], *E. Demirci*[1], *M. Ocak*[2], *T. Toklu*[1], *K. Akcay*[1], *B. Caner*[1], *L. Kabasakal*[3];
[1]*Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE,* [3]*Istanbul University-Cerrahpasa Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

OP-384
Tandem Therapy Versus Single Agent 177Lu-PSMA and 225Ac-PSMA Therapy of Advanced Stage Metastatic Castration Resistant Prostate Carcinoma: Clinical Trial From Azerbaijan

F. Novruzov[1], *E. Mehdi*[1], *N. Orucova*[1], *G. Aliyeva*[1], *F. Guliyev*[2], *F. Giesel*[3], *J. Aliyev*[4];
[1]*Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN,* [2]*Azerbaijan National Centre of Oncology, Department of Uro-Oncology, Baku, AZERBAIJAN,* [3]*University Hospital Düsseldorf, Department of Nuclear Medicine, Dusseldorf, GERMANY,* [4]*Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.*

OP-385
^{177}Lu-PSMA Radioligand Therapy in metastatic castration-resistant prostate cancer: preliminary results of a IRST - "Dino Amadori" prospective phase II clinical trial in 80 patients

M. Caracciolo[1], *M. Sansovini*[2], *S. Nicolini*[2], *I. Grassi*[2], *C. Cittanti*[1,3], *F. Foca*[4], *V. Di Iorio*[5], *I. Marini*[6], *M. L. Belli*[7], *L. Urso*[1], *A. Di Paolo*[2], *G. Paganelli*[2], *S. Severi*[2];
[1]*Nuclear Medicine Unit, University Hospital of Ferrara, Ferrara, ITALY,* [2]*Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), ITALY,* [3]*Department of Translational Medicine, University of Ferrara, Ferrara, ITALY,* [4]*Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), ITALY,* [5]*Oncology Pharmacy, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), ITALY,* [6]*Nuclear Medicine, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola (FC), ITALY,* [7]*Medical Physics, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola (FC), ITALY.*

OP-386
ProstACT TARGET: oligometastatic prostate cancer treated by external beam and Theranostics radioligand therapy

M. Jessel[1], *L. Ravasi*[1], *N. Lenzo*[2], *T. Lim*[2], *S. Sia*[2], *D. Meyrick*[1];
[1]*Telix Radiopharmaceuticals, Melbourne, AUSTRALIA,* [2]*Genesis Care, Alexandria, AUSTRALIA.*

OP-387
Treatment efficacy and safety of ^{177}Lu-PSMA Radioligand Therapy in Octogenarians with metastatic castration-resistant prostate cancer

T. Langbein[1], *M. Retz*[2], *C. D'Alessandria*[1], *S. Grigorascu*[1], *K. Hansen*[1], *H. Wester*[3], *J. Gschwend*[2], *W. Weber*[1], *M. Eiber*[1], *R. Tauber*[2];
[1]*Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Nuclear Medicine, Munich, GERMANY,* [2]*Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Department of Urology, Munich, GERMANY,* [3]*Technical University of Munich, Chair of Radiopharmacy, Garching, GERMANY.*

807

Monday, October 17, 2022, 09:45 - 11:15

Hall 115

Thyroid Committee - TROP Session: PET in Parathyroid Disease and Thyroid Cancer

OP-388
The Diagnostic Value of 18F-Fluorocholine PET/CT for Medullary Thyroid Cancer Detection

J. Jamsek[1], *M. Hocevar*[2], *D. Bergant*[2], *K. Zaletel*[1], *S. Rep*[1], *L. Lezaic*[1];
[1]*UMC Ljubljana, Ljubljana, SLOVENIA,* [2]*IO Ljubljana, Ljubljana, SLOVENIA.*

OP-389
Impact of pre-ablation Thyrogen stimulated FDG PET/CT on the management of high-risk thyroid cancer patients post thyroidectomy

A. Abdelrahman, *S. Gavane;*
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

OP-390
Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer

L. Piscopo[1], *C. Nappi*[1], *F. Volpe*[1], *V. Romeo*[1], *E. Nicolai*[2], *R. Gallicchio*[3], *A. Giordano*[3], *G. Storto*[3], *L. Pace*[4], *C. Cavaliere*[2], *M. Salvatore*[2], *M. Klain*[1], *A. Cuocolo*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY,* [2]*IRCCS Synlab SDN, Naples, ITALY,* [3]*IRCCS CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, ITALY,* [4]*Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, ITALY.*

OP-392
Diagnostic Value of ^{18}F-Flurocholine PET/CT in Detecting Primary Hyperparathyroidism - A First-Line Imaging Approach in a Large Population Cohort
S. Seyedinia[1], *S. Mirshahvalad*[2], *G. Schweighofer-Zwink*[1], *H. Lukas*[1], *C. Pirich*[1], *M. Beheshti*[1];
[1]*Division of Molecular imaging and Theranostics Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA,* [2]*Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, CANADA.*

OP-393
Impact of ^{18}F-Fluorocholine PET/CT in the Assessment of Patients with Normocalcemic or Normohormonal Primary Hyperparathyroidism
S. Mirshahvalad[1], *S. Seyedinia*[2], *G. Rendl*[2], *L. Hehenwarter*[2], *C. Pirich*[2], *M. Beheshti*[2];
[1]*Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA,* [2]*Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA.*

OP-394
Choline PET/CT for the diagnosis of parathyroid adenoma: is there any role for a dual time-point imaging?
J. Bastidas[1], *L. Garcia Belaustegui*[1], *A. Bronte*[1], *V. Betech*[1], *H. Casal-de Andres*[2], *J. J. Rosales*[1], *F. Minguez*[1], *M. Garcia-Goñi*[2], *P. Salvador*[3], *J. Arbizu*[1];
[1]*Clínica Universidad de Navarra. Medicina Nuclear, Pamplona, SPAIN,* [2]*Clínica Universidad de Navarra. Endocrinología., Pamplona, SPAIN,* [3]*Hospital Universitario de Navarra. Cirugía Endocrina, Pamplona, SPAIN.*

OP-395
Comparison Between Analogic and Digital PET-CT Imaging with ^{18}F-Fluorocholine in the Diagnosis of Primary Hyperparathyroidism, a Reliability Study
M. Meneses Navas, *P. Romero Fernández, A. Ortega Candil, C. Rodríguez Rey, J. C. Rodríguez Gómez, M. F. Ollarves Carrero, P. Nespral Torres, G. Cuesta Domingo, M. N. Cabrera Martín; Nuclear Medicine Department ,Health Research Institute of Hospital Clínico San Carlos., Madrid, SPAIN.*

OP-396
The Relationship between 18F-FCH uptake intensity and Cell Content in Parathyroid Lesions
M. Araz, *C. Soydal, H. Kivrak, S. D. Sak, G. Sutcu, M. K. Kir, O. N. Kucuk; Ankara University, Ankara, TÜRKIYE.*

808

Monday, October 17, 2022, 09:45 - 11:15

Hall 212

Cardiovascular Committee - TROP Session: Novel Developments in Nuclear Cardiology

OP-397
The role of a deep learning attenuation correction software in the performance of MPI using a cardio dedicated CZT camera with ICA correlation
M. Ochoa Figueroa, *A. Davidsson, V. Sanchez-Rodriguez, M. Ressner, P. Norberg, E. Good, J. Frias-Rose, C. Pagonis; Universitetssjukhuset i Linköping, Linköping, SWEDEN.*

OP-398
Quantification of absolute myocardial blood flow from ^{13}N-NH3PET images is more affected by the choice of compartment models and time-of-flight than by the use of different time frames and reconstruction algorithms
S. Akil[1,2], *A. Székely*[1], *B. Olsson*[1], *F. Hedeer*[1], *S. Saran*[1], *H. Engblom*[1], *C. Hindorf*[3,4];
[1]*Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, SWEDEN,* [2]*Division of Clinical Physiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, SWEDEN,* [3]*Department of Medical Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, SWEDEN,* [4]*Department of Medical Radiation Physics, Lund university, Lund, SWEDEN.*

OP-400
The Influence of Anthropometric Variables on Count Rate in ^{82}Rubidium myocardial perfusion imaging with PET/CT
D. Agnarsdóttir, *T. W. Gustafson, B. Zerahn, L. D. L. Duchstein, B. Kristensen; Herlev Hospital, Herlev, DENMARK.*

OP-401
xSPECT-based myocardial perfusion scintigraphy: feasibility of myocardial uptake quantitation in patients with suspected coronary artery disease - a pilot study
F. Caobelli[1], *D. Wild*[2], *C. Eigler*[2], *I. Kohlberger*[2], *A. H. Vija*[3], *M. Reymann*[3], *P. Haaf*[2], *M. J. Zellweger*[2];
[1]*Universitätsspital Inselspital Bern, Bern, SWITZERLAND,* [2]*Universitätsspital Basel, Basel, SWITZERLAND,* [3]*Siemens Healthineers AG, Erlangen, GERMANY.*

OP-402
Accuracy of Gated Rubidium PET for the Determination of Left Ventricular Ejection Fraction: Validation Using Cardiovascular Magnetic Resonance and Echocardiography
S. Townrow, *M. Burniston, L. Price, S. Tyebally, L. Menezes; Barts Health NHS Trust, London, UNITED KINGDOM.*

OP-403
Myocardial Perfusion Imaging and Coronary Flow Reserve using ^{82}RbCl on an Extended Bore Length Solid-State Digital-BGO PET/CT System
S. Massalha, *J. A. Kennedy, T. Palchan-Hazan, A. Nemirovsky, N. Mazzawi, Z. Keidar; Rambam HealthCare Campus, Haifa, ISRAEL.*

OP-404
Repeatability of myocardial flow reserve measurement using quantitative dynamic SPECT perfusion imaging
M. Bailly[1], *F. Thibault*[1], *G. Metrard*[1], *M. Courtehoux*[2], *D. Angoulvant*[2], *M. Ribeiro*[2];
[1]*CHR Orléans, Orleans, FRANCE,* [2]*CHRU Tours, Tours, FRANCE.*

810

Monday, October 17, 2022, 09:45 - 11:15

Hall 116

CTE 4 - Technologists + Radiopharmaceutical Sciences Committee: Research in Radiopharmacy

OP-406
Good Manufacturing Practice in Radiochemistry Principles - Standard Operating Procedures and Documentation
A.S. Capacho;
Fundação Champalimaud, Nuclear Medicine/Radiopharmacology Department and Pharmacy Department, Lisbon, PORTUGAL.

OP-407
GMP Elements - Quality Control & Quality Management
N. Hartman;
Faculty of Medicine (Swansea University), Head of nuclear medicine, Singleton Hospital, Swansea, UNITED KINGDOM.

OP-408
Radiopharmaceutical Metabolism Activity - How to Trace What's Left?
G. Luurtsema;
Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.

901

Monday, October 17, 2022, 11:30 - 13:00

Auditorium

Plenary 3: Theranostics - More Than Just the Future of Nuclear Medicine

OP-409
Introduction by Chairpersons

OP-410
Theranostics Overview
W. Weber;
TUM, Nuclear Medicine, Munich, GERMANY

OP-411
Why Theranostics should be NM´s Driver to Independence
J. Czernin;
University of California Los Angeles,Nuclear Medicine/Molecular and Medical Pharmacology, Los Angeles, UNITED STATES OF AMERICA.

OP-412
How to Successfully Set Up a Theranostics Center
A.D. Bacelar;
National Physical Laboratory, Teddington, UNITED KINGDOM.

OP-413
How to Raise Awareness for Theranostic Concepts
C. Nanni;
IRCCS AOU di Bologna Policlinico S.Orsola-Malpighi, Nuclear Medicine, Bologna, ITALY.

OP-414
Getting Ready for the Next Wave of Theranostic Studies
L. Emmet;
St. Vincent's Hospital Sydney, University of New South Wales, Kensington, NSW, Department of Theranostics and Nuclear Medicine, Sydney, AUSTRALIA.

OP-415
Theranostics - The Catalyst for Nuclear Medicine Growth
A. Iagaru;
Stanford University, Radiology / Nuclear Medicine and Molecular Imaging, Stanford, UNITED STATES OF AMERICA.

OP-416
Summary by Chairpersons

1001

Monday, October 17, 2022, 15:00 - 16:30

Auditorium

CME 7 - Radiation Protection Committee: Radiation Protection in Radionuclide Therapy – Insight on New and Emerging Therapies

OP-417
General Issues of Radiation Protection in NM Therapies
F. Jamar;
Cliniques universitaires St-Luc, Nuclear Medicine Department, Brussels, BELGIUM.

OP-418
Radiation Protection Issues for SIRT (90Y and 166Ho)
C. Leijen;
University Medical Centre, Department of Radiation Protection, Utrecht, NETHERLANDS.

OP-419
Radiation Protection Issues for 177Lu-Based Therapies (SMS and PSMA)
J. Kurth;
Hospital/Institute, Rostock University Medical Centre, Nuclear Medicine Department, Rostock, GERMANY.

OP-420
Radiation Protection Issues for Alpha Emitters
A. Craig;
The Royal Marsden NHSFT, Joint Department of Physics, London, UNITED KINGDOM.

OP-421
Wrap-Up by Chairpersons

1002

Monday, October 17, 2022, 15:00 - 16:30

Hall 112 (Arena)

Award Session: EANM Sanjiv Sam Gambhir Award – Battle and Win!

OP-428
EANM Sanjiv Sam Gambhir Award – Battle and Win!
Moderators: ***S. Fanti***[1]*,* ***J. Morigi***[2]*;*
[1]*University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY,* [2]*Royal Darwin Hospital, Darwin, AUSTRALIA. Award Nominees: D. Kersting*[1]*, R. Laudicella*[2]*, S. Veldhuijzen van Zanten*[3]*, B. Privé*[4]*, O. Ivashchenko*[5]*, I. Alberts*[6]*;*
[1]*Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMNAY,* [2]*Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY,* [3]*Erasmus MC, Rotterdam, NETHERLANDS,* [4]*Radboudumc, Nuclear Medicine, Nijmegen, NETHERLANDS,* [5]*University Medical Center Groningen, Nuclear Medicine and Molecular imaging, Groningen, NETHERLANDS,* [6]*Inselspital Bern, Department of Nuclear Medicine, Bern, SWITERLAND.*

1003

Monday, October 17, 2022, 15:00 - 16:30

Hall 113

LIPS Session 7 - Oncology & Theranostics + Translational Molecular Imaging & Therapy Committee / EORTC: Setting Up and Managing Imaging Trials
Interactive Session

OP-429
Challenges of Introducing Imaging Biomarkers as End-Points into Clinical Trials
S. Litière*;*
European Organisation for Research and Treatment of Cancer (EORTC), Brussels, BELGIUM.

OP-430
How do I share my Trial Data?
M. Smits*;*
Erasmus MC, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-431
What is the Shelf-Life of Imaging Data?
L. Bidaut*;*
University of Lincoln, College of Science, Lincoln, UNITED KINGDOM.

1004

Monday, October 17, 2022, 15:00 - 16:30

Hall 114

M2M Track - TROP Session: Peptides for All Tastes

OP-432
Comparison of the Biodistribution and Efficacy of a Novel Theranostic Agent [$^{203/212}$Pb]PSC-PEG2-TOC with [$^{203/212}$Pb]DOTAMTATE and [^{177}Lu]DOTATATE for Image-Guided Therapy for SSTR2 Positive Tumors in Mice
D. Liu[1]*, M. Li*[1]*, B. S. Cagle*[1]*, Z. Dai*[2]*, D. Lee*[3]*, E. Sagastume*[1]*, K. Orcutt*[1]*, N. J. Baumhover*[1]*, I. Vance*[1]*, A. Hedt*[1]*, F. L. Johnson*[1]*, M. K. Schultz*[1,2]*;*
[1]*Viewpoint Molecular Targeting Inc., Coralville, IA, UNITED STATES OF AMERICA,* [2]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA,* [3]*Korea Military Academy, Seoul, KOREA, REPUBLIC OF.*

OP-433
Optimisation of αvβ6-specific peptides for use in targeted radionuclide therapy
R. Kashani*, N. Khan, J. Foster, J. Young, J. Marshall, J. K. Sosabowski;*
Queen Mary University, Molecular Oncology, London, UNITED KINGDOM.

OP-434
^{177}Lu-FAPI-dimer shows enhanced anti-tumor efficacy in patient-derived xenografts, comparsion with ^{177}Lu-FAPI-46
J. Chen*, L. Zhao, Y. Pang, H. Chen, Q. Lin;*
The First Affiliated Hospital of Xiamen University, Xiamen, CHINA.

OP-435
[^{177}Lu]Lu-DPI-4452, a new radiopeptide targeting Carbonic Anhydrase IX, displays strong anti-tumoral activity in colorectal cancer and clear cell renal cell carcinoma mouse models
A. Attinger[1]*, N. Wiedemann*[1]*, M. Paschke*[2]*, D. Zboralski*[2]*, A. Schumann*[2]*, A. Bredenbeck*[2]*, F. Osterkamp*[2]*, A. Hoehne*[2]*;*
[1]*Debiopharm International S.A., Lausanne, SWITZERLAND,* [2]*3B Pharmaceuticals GmbH, Berlin, GERMANY.*

OP-436
Nectin-4 targeted PET imaging of urothelial carcinoma with newly synthesized ^{68}Ga labeling bicyclic peptide
D. Wu[1]*, Y. Zhao*[2]*, X. Zhong*[3]*, J. Chen*[1]*, G. Shao*[4]*, L. Zhang*[1]*;*
[1]*Department of pediatrics, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA,* [2]*Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA,* [3]*Department of pediatrics, Taizhou People's Hospital, Nanjing University of Chinese medicine, Nanjing, CHINA,* [4]*Department of nuclear medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA.*

OP-437
Development and preclinical evaluation of novel ^{177}Lu-labelled radiohybrid CCK-2R-targeted ligands based on [^{177}Lu]Lu-DOTA-PP-F11N
N. Holzleitner[1]*, T. Günther*[1]*, C. Lapa*[2]*, H. J. Wester*[1]*;*
[1]*Technical University of Munich, Munich, GERMANY,* [2]*University Hospital Augsburg, Augsburg, GERMANY.*

OP-438
Promising performance of PET/CT using [68Ga]Ga-PentixaFor (PentixaFor PET/CT) for initial staging and therapeutic evaluation of symptomatic multiple myeloma (MM) patients in first line treatment or first relapse: preliminary results of an exploratory phase 2 study
C. Bodet-Milin[1,2]*, A. Mouton*[1]*, B. Jamet*[1,2]*, C. Dubegny*[3,2]*, C. Bailly*[1,2]*, M. Frindel*[4]*, H. Bouterfa*[5]*, J. Kaufmann*[5]*, C. Touzeau*[6,2]*, P. Moreau*[6,2]*, F. Kraeber-Bodere*[1,2]*;*
[1]*Nuclear Medicine department, Nantes University Hospital, Nantes, FRANCE,* [2]*Nantes Université, Angers Université, INSERM, CNRS, CRCI2NA, Nantes, FRANCE,* [3]*Radiopharmacy unit, Nantes University Hospital, Nantes, FRANCE,* [4]*Radiopharmacy unit, ICO institut de cancérologie de l'Ouest, Saint-Herblain cedex, FRANCE,* [5]*Pentixapharm GmbH, Würzburg, GERMANY,* [6]*Hematology department, Nantes University Hospital, Nantes, FRANCE.*

OP-439
Proof-of-concept of CXCR4 targeting in vivo using radiotracers based on the endogenous antagonist EPI-X4
R. Gaonkar[1]*, Y. Schmidt*[1]*, J. Millul*[1]*, R. Mansi*[1]*, M. Harms*[2]*, J. Münch*[2]*, M. Fani*[1]*;*
[1]*University Hospital Basel, Basel, SWITZERLAND,* [2]*Ulm University, Ulm, GERMANY.*

OP-440
Tuning the kinetics of protein-based nanomedicine by metal ion coordination assisted self assembly
K. Saatchi[1]*, G. Engudar*[2]*, C. Rodriguez-Rodriguez*[1]*, N. K. Mishra*[3]*, M. Bergamo*[1]*, G. Amouroux*[1]*, K. J. Jensen*[3]*, U. O. Hafeli*[1]*;*
[1]*UBC, Vancouver, BC, CANADA,* [2]*TRIUMF, Vancouver, BC, CANADA,* [3]*UCPH, Copenhagen, DENMARK.*

1005

Monday, October 17, 2022, 15:00 - 16:30

Hall 211

Cutting Edge Science Track - Featured Session: I-131 Dosimetry for Thyroid Disease

OP-441
I-131 Dosimetry - An Introduction
F. Verburg*;*
Erasmus MC, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-442
Implementing dosimetry in a multicentric environment: Results of the MEDIRAD project
A. Vergara Gil[1]*, J. Taprogge*[2,3]*, D. Vallot*[4]*, U. Eberlein*[5]*, M. Lassmann*[5]*, T. Schurrat*[6]*, A. Ashfaq*[6]*, G. D. Flux*[2,3]*, M. Bardiès*[7]*;*
[1]*CRCT, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, FRANCE,* [2]*Royal Marsden NHSFT, Sutton, UNITED KINGDOM,* [3]*The Institute of Cancer Research, London, UNITED KINGDOM,* [4]*IUCT Oncopole, Av. Irène Joliot-Curie, Toulouse, FRANCE,* [5]*Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY,* [6]*Department of Nuclear Medicine, Philipps-University Marburg, Marburg, GERMANY,* [7]*Département de Médecine Nucléaire, Institut Régional du Cancer de Montpellier (ICM), Montpellier, FRANCE.*

OP-443
Are There Differences in DNA Damage Induction and Repair Before and After Radioiodine Therapy?
S. Schumann[1]*, H. Scherthan*[2]*, S. Schoof*[2]*, P. E. Hartrampf*[1]*, A. K. Buck*[1]*, M. Port*[2]*, M. Lassmann*[1]*, U. Eberlein*[1]*;*
[1]*Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY,* [2]*Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.*

OP-444
The application of [^{123}I]NaI as a surrogate radiopharmaceutical for the pre-therapeutic dosimetry in differentiated thyroid cancer with [^{131}I]NaI: A preclinical study using the xenograft mouse model
S. Kim[1,2]*, H. Kim*[1,2]*, I. Song*[2]*, H. Park*[2,3]*, S. Kim*[2,3,4]*;*
[1]*Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF,* [3]*Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [4]*Advanced Institutes of Convergence Technology, Suwon, KOREA, REPUBLIC OF.*

OP-445
Finger-tip Blood Sampling for Dosimetry Measurements Post I-131 Administration in Thyroid Cancer Patients
A. Al Jabri[1,2]*, J. Cooke*[3]*, S. Cournane*[4]*, M. Healy*[5]*;*
[1]*Trinity College Dublin, Dublin, IRELAND,* [2]*Sultan Qaboos University, Muscat, OMAN,* [3]*Children's Health Ireland at Crumlin, Dublin, IRELAND,* [4]*St Vincent's University Hospital, Dublin, IRELAND,* [5]*St James's Hospital, Dublin, IRELAND.*

OP-446
Value of Personalized Radiation Absorbed Dose Calculation for Radioiodine Ablation Therapy
O. Sahin[1]*, N. A. Selcuk*[2]*, N. Yeyin*[1]*, R. Akyel*[3]*, T. Toklu*[2]*, M. F. Beytur*[1]*, G. Can*[4]*, E. Demirci*[2]*, A. Boz*[5]*, F. Yapar*[6]*, L. Kabasakal*[1]*;*
[1]*Department of Nuclear Medicine, Istanbul University-Cerrahpasa, Faculty of Medicine, Istanbul, TÜRKIYE,* [2]*Department of Nuclear Medicine, Yeditepe University, Faculty of Medicine, Istanbul, TÜRKIYE,* [3]*Clinic of Nuclear Medicine, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, TÜRKIYE,* [4]*Department of Public Health, Istanbul University-Cerrahpasa, Faculty of Medicine, Istanbul, TÜRKIYE,* [5]*Department of Nuclear Medicine, Akdeniz University, Faculty of Medicine, Antalya, TÜRKIYE,* [6]*Department of Nuclear Medicine, Baskent University, Faculty of Medicine, Adana, TÜRKIYE.*

OP-447
Post-therapeutic dose estimates of salivary glands and iodine-avid lesions in ^{131}I therapy
M. Abuqbeitah*, M. Demir, S. Sager;*
Istanbul University, Istanbul, TÜRKIYE.

OP-448
Effect of furosemide on whole-body radioactivity retention in patients treated with radioiodine (RAI) for differentiated thyroid cancer (DTC)
B. Criscuoli[1]*, G. Rossi*[2]*, G. Follacchio*[1]*, C. Manni*[1]*, H. Castagnoli*[1]*, S. Fattori*[2]*, F. Capoccetti*[1]*;*
[1]*Nuclear Medicine Unit, Macerata Hospital, AV3, ASUR Marche, Macerata, ITALY,* [2]*Medical Physic Unit, Macerata Hospital, AV3, ASUR Marche, Macerata, ITALY.*

OP-449
Radioactive iodine uptake measurements using gamma camera-specific general reference standards
J. Mourik[1], *M. Derks*[2], *M. ten Broek*[2];
[1]*Franciscus Gasthuis & Vlietland, Rotterdam, NETHERLANDS,*
[2]*IJsselland ziekenhuis, Capelle aan den IJssel, NETHERLANDS.*

1006

Monday, October 17, 2022, 15:00 - 16:30

Hall 117

Clinical Oncology Track - TROP Session: Breast

OP-450
Metabolic features of 18F-FDG PET in women carriers of germline patogenic variants with locally advanced and metastatic breast cancer
O. Garcia-Perez, *L. Torres- Agredo, R. Pedrero-Piedras, E. Vega Zolano, I. Soldevilla-Gallardo, E. Igancio-Alvarez, E. Michel-Sanchez, P. Casanova, R. Alvarez Gomez, P. Cabrera Galeana;*
Instituto Nacional de Cancerologia, Mexico city, MEXICO.

OP-451
Value of semiquantitative parameters derived from 18F-FDG PET/CT to predict 3-years-disease-free survival in patients affected by grade III breast cancer with different luminal type undergoing neoadjuvant chemoterapy
N. Quartuccio[1], *L. Urso*[2,3], *P. Alongi*[1], *I. Rambaldi*[2], *N. Ortolan*[2,3], *F. Borgia*[2,3], *A. Nieri*[2], *L. Uccelli*[2,3], *A. Schirone*[4], *C. Cittanti*[2,3], *D. Cecchin*[5], *G. Arnone*[1], *M. Bartolomei*[2], *L. Evangelista*[5];
[1]*Nuclear Medicine Unit, A.R.N.A.S. Ospedali Civico, Di Cristina e Benfratelli, Palermo, ITALY,* [2]*Nuclear Medicine Unit, University Hospital of Ferrara, Ferrara, ITALY,* [3]*Translational Medicine Department, Ferrara University, Ferrara, ITALY,* [4]*Oncological Medical and Specialists Department, Oncology Unit, University Hospital of Ferrara, Ferrara, ITALY,* [5]*Nuclear Medicine Unit, Department of Medicine DIMED, University of Padua, Padua, ITALY.*

OP-452
The Functional Adipose Tissue in 18F-FDG PET/CT in Estrogen Receptor Positive Postmenopausal Breast Carcinoma
S. A. Yilmaz, *A. Akbulut, G. Koca, M. Korkmaz;*
University of Health Sciences, Ankara Training and Research Hospital, Nuclear Medicine Department, Ankara, TÜRKIYE.

OP-453
SUV-based features from baseline 2-[^{18}F]FDG-PET/CT in breast cancer patients differentiate tumor phenotypes but do not predict pathologic response to neoadjuvant chemotherapy
C. Oliveira[1,2], *F. Oliveira*[1], *C. Constantino*[1], *H. Pinto Marques*[2,3,4], *F. Cardoso*[5];
[1]*Nuclear Medicine – Radiopharmacology Department, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, PORTUGAL,* [2]*NOVA Medical School, Lisbon, PORTUGAL,* [3]*Centro Hospitalar Universitário de Lisboa Central/Hepato-Biliary-Pancreatic and Transplantation Center, Lisbon, PORTUGAL,* [4]*Hepatobiliary and Pancreatic Surgery CUF Tejo Hospital, Lisbon, PORTUGAL,* [5]*Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, PORTUGAL.*

OP-454
Preliminary results of a prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuximab PET-CT in metastatic triple negative breast cancer patients
C. Rousseau[1], *M. F. Heymann*[2], *A. Mallet*[3], *E. Picot-Dilly*[3], *M. Le Thiec*[3], *M. Taupin*[4], *A. Mouton*[3], *J. S. Frenel*[1], *E. Bourbouloux*[3], *N. Allam*[3], *L. Ravasi*[5], *L. Ferrer*[1], *F. Kraeber-Bodere*[6];
[1]*ICO René Gauducheau, F-44800 Saint-Herblain, Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000, Nantes, FRANCE,* [2]*ICO René Gauducheau, Research pathology platform, Tumor Heterogeneity and Precision Medicine, F-44800, Saint Herblain, FRANCE,* [3]*ICO René Gauducheau, F-44800, Saint Herblain, FRANCE,* [4]*ICO René Gauducheau, Research pathology platform, F-44800, Saint Herblain, FRANCE,* [5]*Telix Pharmaceuticals Limited, B-4040, Herstal, BELGIUM,* [6]*Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, F-44000, Nantes, FRANCE.*

OP-455
Value of semiquantitative parameters derived from 18F-FDG PET/CT to predict response to neoadjuvant chemotherapy in a cohort of patients with different luminal types of breast cancer
L. Urso[1,2], *P. Alongi*[3], *N. Quartuccio*[3], *L. Evangelista*[4], *I. Rambaldi*[2], *N. Ortolan*[1,2], *F. Borgia*[1,2], *A. Nieri*[2], *L. Uccelli*[1,2], *C. Cittanti*[1,2], *A. Schirone*[5], *D. Cecchin*[4], *G. Arnone*[3], *M. Bartolomei*[2];
[1]*Translational Medicine Department, Ferrara University, Ferrara, ITALY,* [2]*Nuclear Medicine Unit, University Hospital of Ferrara, Ferrara, ITALY,* [3]*Nuclear Medicine Unit, ARNAS Ospedali Civico, di Cristina e Benfratelli, Palermo, ITALY,* [4]*Nuclear Medicine Unit, Department of Medicine DIMED University of Padua, Padua, ITALY,* [5]*Oncological Medical and Specialists Department, Oncology Unit, University Hospital of Ferrara, Ferrara, ITALY.*

OP-456
Absolute ^{99m}Tc tumor activity uptake quantification with Molecular Breast Imaging
S. Kappadath, *B. P. Lopez;*
UT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA.

OP-457
Optimization of ^{89}Zr immunoPET scan protocols for a long axial field of view PET/CT scanner
P. Mohr[1], *J. van Sluis*[1], *P. van Snick*[1], *M. N. Lub-de Hooge*[1], *R. Boellaard*[1,2], *A. A. Lammertsma*[1], *A. H. Brouwers*[1], *C. Tsoumpas*[1];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Amsterdam VU University Medical Center, Amsterdam, NETHERLANDS.*

OP-458
Are baseline 18F-FDG PET/CT parameters able to predict response to neoadjuvant chemotherapy and risk of recurrence in patients with locally advanced breast cancer?
V. Tempesta[1], *S. Taralli*[2], *M. Lorusso*[2], *A. Di Leone*[3], *L. Scardina*[3], *A. Orlandi*[4], *L. Pontolillo*[4], *I. Paris*[5], *P. C. Pafundi*[6], *M. L. Calcagni*[1];
[1]*Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS - Nuclear Medicine Institute, Università Cattolica del Sacro Cuore, Rome, ITALY,* [2]*Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [3]*Breast Center Unit, Health Sciences of Women, Children and Public Health Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [4]*Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [5]*Unit of Gynecologic Oncology, Health Sciences of Women, Children and Public Health Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [6]*Facility of Epidemiology and Biostatistics - GEMELLI GENERATOR, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY.*

1007

Monday, October 17, 2022, 15:00 - 16:30

Hall 115

Inflammation & Infection Committee - TROP Session: Nuclear Medicine and COVID-19

OP-459
Metabolic characterization of structural lung changes in patients with suggestive COVID-19 pneumonia on ^{18}F-FDG PET/CT
C. Wakfie Corieh[1], *F. Ferrando-Castagnetto*[2], *M. García García-Esquinas*[1], *C. Rodríguez Rey*[1], *A. Ortega Candil*[1], *R. M. Couto Caro*[1], *J. L. Carreras Delgado*[1], *M. N. Cabrera-Martín*[1];
[1]*Hospital Clínico San Carlos, Madrid, SPAIN,* [2]*Hospital de Clínicas Dr. Manuel Quintela, Montevideo, URUGUAY.*

OP-460
Utility of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in COVID-19 infection- a single centre retrospective observational study
J. Jaleel, *A. K. Majeed, A. S. Babu, S. Kalra, S. Jha, K. B. Chandra, R. Kumar, C. S. Bal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

OP-461
Post-COVID-19 Lung disease (PCLD) patients show a strong correlation between IL-6 and SUVmax on FDG PET/CT
Y. Khandelwal, *M. K. Rai, P. Singh, B. Jain, M. Ora, D. P. Misra, M. Dixit, V. Agarwal, S. Gambhir;*
S.G.P.G.I., Lucknow, INDIA.

OP-462
New perspectives obtained during the COVID 19 pandemic: the importance of an adequate directed structured clinical interview prior to [18]FDG-PET/CT in cancer patients
M. Gutiérrez Guerrero, *M. Gómez Martínez, P. Azpeitia Hernández, A. Martínez Lorca, J. Bonilla Plaza, P. Paredes Rodríguez, O. Ajuria Illarramendi, M. Rioja Martín, T. Navarro Martínez, M. Orduña Díez;*
Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

OP-463
PET after COVID19 vaccination: influence of patient characteristics, vaccine types and radiotracers in the lymph node uptake
V. Betech Antar, *L. García-Belaustegui, F. Mínguez, Á. Bronte, J. Bastidas, E. Guillen, L. Sancho-Rodriguez, J. J. Rosales, J. Arbizu;*
Clínica Universidad de Navarra, Pamplona, SPAIN.

OP-464
The Impact of different COVID-19 vaccines in 18F-FDG PET/CT
T. Nazerani Hooshmand[1], *C. Gstettner*[1], *B. Pernthaler*[1], *G. Schwantzer*[2], *R. Aigner*[1];
[1]*Division of Nuclear Medicine, Department of Radiology, Medical University of Graz, Graz, AUSTRIA,* [2]*Medical University of Graz, Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, AUSTRIA.*

OP-465
The effect of oral paracetamol on [^{18}F]FDG PET/CT in oncology patients following COVID-19 vaccination
W. Wong;
Queen Elizabeth Hospital, Hong Kong, HONG KONG.

OP-466
[^{89}Zr]Df-crefmirlimab PET/CT imaging to assess the in vivo distribution of CD8+ T-cells in hospitalized COVID-19 patients
E. Aarntzen, *I. Kouijzer, S. Peters, D. Lobeek, M. De Groot, F. Van de Veerdonk, M. Netea, M. Prokop, H. Koenen;*
Radboud University Nijmegen Medical Centre, Nijmegen, NETHERLANDS.

OP-467
Novel application of [^{18}F]DPA714 for visualizing the lower respiratory tract of SARS-CoV-2-exposed rhesus monkeys
M. A. Stammes[1], *J. Bakker*[1], *L. Meijer*[1], *K. P. Böszörményi*[1], *J. A. M. Langermans*[1], *E. J. Verschoor*[1], *A. D. Windhorst*[2];
[1]*BPRC, Rijswijk, NETHERLANDS,* [2]*Amsterdam UMC, Amsterdam, NETHERLANDS.*

1008

Monday, October 17, 2022, 15:00 - 16:30

Hall 212

Cardiovascular Committee - TROP Session: Cardiovascular Metabolism, Innervation and Perfusion

OP-468
Combined assessment of autonomic failure in alpha-synucleinopathies, using ^{123}I-mIBG cardiac scintigraphy, cardiovascular autonomic tests and sweating dysfunction
M. Skrzypczyk[1], *L. Guillon*[1,2], *F. Hives*[3], *C. Georges*[4], *F. Ory-Magne*[4], *M. Fabbri*[4], *M. Kermorgant*[5], *A. Pavy-Le Traon*[5,4], *P. Payoux*[1,2];
[1]*Department of Nuclear Medicine, Toulouse University Hospital, Toulouse, FRANCE,* [2]*INSERM URM 1214, Toulouse NeuroImaging Center (ToNIC), Toulouse, FRANCE,* [3]*Department of Nuclear Medicine, Lille University Hospital, Lille, FRANCE,* [4]*Department of Neurology, Toulouse University Hospital, Toulouse, FRANCE,* [5]*INSERM UMR 1297, Institute of Cardiovascular and Metabolic Diseases (I2MC), Toulouse, FRANCE.*

OP-469
Role of 18F-FDOPA PET/CT in the imaging of cardiac sympathetic dysfunction in patients with heart failure: A feasibility study
C. Patel[1], *A. Sharma*[2], *T. Thanigainathan*[1], *P. Gupta*[1], *A. Pandey*[1], *S. Seth*[1], *A. Roy*[1], *R. Kumar*[1], *P. Kumar*[1], *C. Bal*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*HBCHRC (TMC), Mullanpur, Punjab, INDIA.*

OP-470
Level of circulating ketone bodies predicts myocardial glucose metabolism suppression in adults
S. Hartikainen[1], *T. Tompuri*[1], *T. M. Laitinen*[1], *T. Laitinen*[1,2];
[1]*Kuopio University Hospital, Kuopio, FINLAND,* [2]*University of Eastern Finland, Kuopio, FINLAND.*

OP-471
Intravenous insulin injection supplemented with subsequentmilkconsumptionis a safer formulation for cardiac viability^{18}F-FDG imaging
Y. Chen[1], *M. Pan*[2], *Q. Wang*[2], *Y. Wang*[2], *H. Zhuo*[2], *R. Dai*[2], *H. Wang*[3];
[1]*Shanghai Pulmonary Hospital, Shanghai, CHINA,* [2]*Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, CHINA,* [3]*Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai, CHINA.*

OP-472
Metabolic predictors of poor prognosis in acute myocardial infarction patients after percutaneous transluminal coronary intervention by combined visual and semi-quantitative evaluation of 18F-FDG PET/CT
T. Yuan[1], *Q. Zhang*[2], *X. Li*[1], *R. Wang*[1];
[1]*Peking University International Hospital, Beijing, CHINA,* [2]*the First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, CHINA.*

OP-473
Recalculations of gated ^{82}Rubidium PET/CT scans in patients with atrial fibrillation or sinus rhythm after re-binning
H. Bayram, *T. Gustafson, L. Duchstein, B. Zerahn;*
Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, DENMARK.

OP-474
Regional myocardial perfusion by CZT SPECT imaging in predicting lesion-related outcome in patients with suspected or known CAD
T. Mannarino, *A. D'Antonio, E. Criscuolo, R. Bologna, R. Assante, E. Zampella, V. Gaudieri, V. Cantoni, R. Green, C. Nappi, P. Buongiorno, A. Cuocolo, W. Acampa;*
Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, ITALY.

OP-475
Serum neurofilament light chain (sNfL) in relation to myocardial sympathetic neuronal damage based on ^{123}I-meta-iodobenzylguanidine (MIBG) scintigraphy in hereditary transthyretin (ATTRv) amyloidosis
M. Berends, *H. L. A. Nienhuis, A. Brunger, J. Bijzet, P. A. van der Zwaag, B. P. C. Hazenberg, W. Noordzij, R. H. J. Slart;*
University Medical Center Groningen, Groningen, NETHERLANDS.

OP-476
Prospective diagnostic performance of CZT myocardial perfusion reserve to detect territories with simultaneous impaired invasive CFR and IMR reflecting a very high cardiovascular risk in patient without obstructive coronary artery disease
L. Djaileb[1], *O. Phan Sy*[1], *N. De Leiris*[1], *M. Canu*[2], *J. Leenhardt*[1], *A. Broisat*[3], *A. Borel*[4], *S. Lablanche*[4], *C. Betry*[4], *G. Vanzetto*[2], *C. Ghezzi*[3], *D. Fagret*[1], *L. Riou*[3], *G. Barone-Rochette*[2];
[1]*Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, nuclear medicine department, LRB, Grenoble, FRANCE,* [2]*Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, cardiology department, LRB, Grenoble, FRANCE,* [3]*Univ. Grenoble Alpes, INSERM, LRB, Grenoble, FRANCE,* [4]*Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, endocrinology department, LRB, Grenoble, FRANCE.*

1101

Monday, October 17, 2022, 16:45 - 18:15

Auditorium

CME 8 - Bone & Joint Committee: Early Bone Scan Imaging - Let's Go 3D!

OP-481
From 3 Phases in 2D to 2 Phases in 3D
P. Jallerat;
APHP - Hôpital Saint Louis, Nuclear Medicine, Paris, FRANCE.

OP-482
Technical Aspects of Multiphase Imaging
S. Cade;
Royal United Hospitals Bath NHS Trust, Medical Physics and bioengineering, Bath, UNITED KINGDOM.

OP-483
Early Bone SPECT - New Insights on Orthopaedics and Post-Operative Skeleton
N. Icard;
Hôpital Yves le Foll, Nuclear Medicine, Saint-Brieuc, FRANCE.

OP-484
Usefulness of Early Bone SPECT in Rheumatological Pathologies and Pain of Unknown Origin
J. Zhang-Yin;
Vivalia, Nuclear Medicine, Arlon, BELGIUM.

1102

Monday, October 17, 2022, 16:45 - 18:15

Hall 112 (Arena)

Debate 2 - Oncology & Theranostics + Radiopharmaceutical Sciences Committee: Fluorine-18 Alternatives for Oncological Gallium-68 Tracers

OP-485
Gallium-68 Champion
C. Decristoforo;
Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA.

OP-486
Fluorine-18 Champion
G. Bormans;
KU Leuven, University of Leuven, Lab Radiopharmacy, Leuven, BELGIUM.

1103

Monday, October 17, 2022, 16:45 - 18:15

Hall 113

LIPS Session 8 - Dosimetry Committee: Life Drawing in Nuclear Medicine – Fact or Fiction?
Interactive Session

OP-488
Recognising Physiology and Pathology - The Challenges of Hybrid Image Segmentation for Diagnostics and Therapy Planning
A. Boubaker;
Institut de Radiologie, Clinique de La Source, Lausanne, SWITZERLAND.

OP-489
Discussion

OP-490
Image Segmentation for Dosimetry - Emission or Transmission?
J. Ruben Gustafsson;
University of Lund, Lund, SWEDEN.

OP-491
Discussion

OP-492
Making it Quicker - Automated and AI Methods for Image Segmentation
I. Buvat;
Laboratoire d'Imagerie Translationnelle en Oncologie, Inserm U1288, PSL Research University, Institut Curie, Orsay, FRANCE.

OP-493
Discussion

1104

Monday, October 17, 2022, 16:45 - 18:15

Hall 114

Joint Symposium 4 - Oncology & Theranostics Committee / EORTC: Evaluation of Response to Therapy

OP-494
RECIST, mRECIST and iRECIST at a Glance
V. Vandecaveye;
University Hospitals Leuven, KU Leuven, Department of Radiology, Leuven, BELGIUM.

OP-495
From EORTC to iPERCIST and PERCIMT Criteria
E. Lopci;
IRCCS - Humanitas Research Hospital, Nuclear Medicine Unit, Milan, ITALY.

OP-496
LUGANO Classification and LYRIC in ImmunoOncology
A.-S. Cotterau;
University of Paris, Cochin Hospital, APHP, Department of Nuclear medicine, Paris, FRANCE.

OP-497
Response Assessment with non-FDG PET Tracers
D. Oprea-Lager;
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

1105

Monday, October 17, 2022, 16:45 - 18:15

Hall 211

Cutting Edge Science Track - TROP Session: Image Reconstruction + Image Guided Surgery

OP-498
Re-projection strategies in 3D Fourier-Based analytical reconstruction of Long Axial Field of View (LAFOV) scanners data
V. Panin;
Siemens Medical Solutions USA, Knoxville, TN, UNITED STATES OF AMERICA.

OP-499
Use of AI with MLAA for CT free quantitative FDG PET studies
R. Boellaard;
Amsterdam UMC, Amsterdam, NETHERLANDS.

OP-500
Quantitative evaluation of a non-CT based attenuation correction method for a new dedicated brain PET
M. Gandia-Ferrero[1], *I. Torres-Espallardo*[2], *B. Martínez-Sanchis*[2], *C. Morera*[3], *P. Sopena*[2], *G. González-Pavón*[3], *L. Martí-Bonmatí*[2];
[1]*Health Research Institute La Fe, Valencia, SPAIN,* [2]*Hospital Universitario y Politécnico La Fe, Valencia, SPAIN,* [3]*Oncovision, Valencia, SPAIN.*

OP-501
Clinical Significance of Bayesian penalized-likelihood and Motion Correction PET Reconstruction Algorithms
G. Kaya, *H. Pala, M. Tuncel, Ö. Uğur;*
Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-502
Evaluation of a respiratory motion correction algorithm for PET images using a customized dynamic phantom
T. Cuenca[1], *E. Prieto*[1], *L. Irazola*[1], *L. Soria*[2], *V. Morán*[2], *V. Betech-Antar*[1], *F. Mínguez*[1], *M. J. García-Velloso*[1], *J. M. Martí-Climent*[1];
[1]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Clínica Universidad de Navarra, Madrid, SPAIN.*

OP-503
Improving cerebral blood flow measurements from dynamic [^{15}O]H2O PET study using complementary frame reconstruction and isotope-specific resolution modelling
A. J. Gonçalves[1], *G. Krokos*[1], *O. A. Jones*[1], *Y. Xia*[1], *I. K. Djoukhadar*[2], *A. Jackson*[1], *J. C. Matthews*[1], *J. M. Anton-Rodriguez*[1], *M. C. Asselin*[1];
[1]*The University of Manchester, Manchester, UNITED KINGDOM,* [2]*Salford Royal NHS Foundation Trust, Manchester, UNITED KINGDOM.*

OP-504
Assessing the impact of scatter correction techniques on ^{68}Ga PET/CT Quantitative Imaging Parameters - a patient and phantom study
A. McCann[1,2], *A. Stone*[2], *A. Dowling*[2], *S. Cournane*[1,2], *L. Leon Vintro*[1], *J. Lucey*[2];
[1]*School of Physics, UCD, Dublin, IRELAND,* [2]*St Vincent's University Hospital, Dublin, IRELAND.*

OP-505
Fluorescence and radioactive breast sentinel lymph node biopsy: an hybrid approach
J. Gambini[1], *E. Silvera*[1], *F. Portugal*[1], *M. Cabrera*[2], *X. Camacho*[2], *P. Cabral*[2], *M. Tassano*[2], *J. Hermida*[1], *O. Alonso*[1];
[1]*Centro de Medicina Nuclear e Imagenología Molecular, UDELAR, Montevideo, URUGUAY,* [2]*Centro de Investigaciones Nucleares, UDELAR, Montevideo, URUGUAY.*

OP-506
Prospective Validation of Tumor Folate Receptor Alpha Expression's Correlation with Pafolacianine Fluorescence During Intraoperative Molecular Imaging Guided Lung Cancer Resections
F. Azari[1], *K. Zhang*[1], *G. T. Kennedy*[1], *A. Chang*[1], *B. Nadeem*[1], *I. Marfatia*[1], *A. Din*[1], *A. Galandarova*[2], *A. Ibrahimli*[2], *J. Kucharczuk*[1], *S. Singhal*[1];
[1]*University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA,* [2]*Ankara Yildirim Faculty of Medicine, Ankara, TÜRKIYE.*

1106

Monday, October 17, 2022, 16:45 - 18:15

Hall 117

Clinical Oncology Track - TROP Session: Lung

OP-507
Metabolic patterns on ^{18}F-FDG PET/CT in inoperable stage III NSCLC undergoing chemoradiotherapy ± immune checkpoint inhibition with durvalumab
A. Holzgreve[1], *J. Taugner*[2], *L. Käsmann*[2], *P. Müller*[3], *A. Tufman*[4], *N. Reinmuth*[5], *M. Li*[2], *L. M. Unterrainer*[1], *P. Bartenstein*[1], *W. G. Kunz*[3], *J. Ricke*[3], *C. Belka*[2], *C. Eze*[2], *F. Manapov*[2], *M. Unterrainer*[3];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*Department of Radiation Oncology, University Hospital, LMU Munich, Munich, GERMANY,* [3]*Department of Radiology, University Hospital, LMU Munich, Munich, GERMANY,* [4]*Department Internal Medicine V, University Hospital, LMU Munich, Munich, GERMANY,* [5]*Asklepios Lung Clinic, MunichGauting, Munich, GERMANY.*

OP-508
EBUS-TBNA within 8 days prior to ^{18}FDG PET/CT affects ^{18}FDG uptake in mediastinal and hilar lymph nodes of patients during staging for lung cancer
P. Sandach[1], *R. Seifert*[1], *K. Darwiche*[2], *F. Funke*[2], *S. C. Maier*[3], *K. Herrmann*[1], *H. Hautzel*[1];
[1]*University Hospital Essen, Department of Nuclear Medicine, University Duisburg - Essen, Essen, GERMANY,* [2]*University Hospital Essen, Department of Pulmonary Medicine, Section of Interventional Pneumology, West German Lung Center, Ruhrlandklinik, University Duisburg - Essen, Essen, GERMANY,* [3]*University Hospital Essen, Department of Diagnostic and Interventional Radiology and Neuroradiology, University Duisburg - Essen, Essen, GERMANY.*

OP-509
Respiratory-gated FDG PET/CT versus PET/MRI with zero-echo time: Assessment of the capability to detect and differentiate lung lesions and the precision of fused images
J. Inukai[1], *M. Nogami*[2], *F. Zeng*[2], *M. Tachibana*[1], *S. Sakamoto*[3], *D. Takenaka*[3], *K. Kubo*[2], *T. Kurimoto*[4], *T. Murakami*[1];
[1]*Kobe University Graduate School of Medicine, Kobe, JAPAN,* [2]*Kobe University Hospital, Kobe, JAPAN,* [3]*Hyogo Cancer Center, Akashi, JAPAN,* [4]*GE Healthcare, Hino, JAPAN.*

OP-510
Imaging tumor-infiltrating CD8$^+$ T-cells in non-small cell lung cancer patients upon neo-adjuvant treatment with durvalumab
E. Aarntzen, *E. A. J. Van Genugten, B. Piet, G. Schreibelt, T. Van Oorschot, G. Van den Heuvel, F. Ciompi, C. Jacobs, J. De Vries, M. M. Van den Heuvel;*
Radboud University Nijmegen Medical Centre, Nijmegen, NETHERLANDS.

OP-511
Evaluation of LAT1 expression in patients with lung cancers and mediastinal tumors: [^{18}F]FBPA PET study with immuno-histopathological comparison
T. Watabe[1], *N. Ose*[1], *S. Naka*[2], *E. Fukui*[1], *T. Kanou*[1], *S. Funaki*[1], *H. Sasaki*[2], *T. Kamiya*[1], *K. Kurimoto*[1], *E. Shimosegawa*[1], *H. Kato*[1], *R. Ohgaki*[1], *Y. Kanai*[1], *Y. Shintani*[1];
[1]*Osaka University, Suita, JAPAN,* [2]*Osaka University Hospital, Suita, JAPAN.*

OP-512
Machine learning using combined [18F]FDG-PET and contrast enhanced CT radiomics for histopathological and immunological characterization of non-small cell lung cancer lesions
W. Grootjans, *D. D. D. Rietbergen, L. M. Kurucz, F. H. P. van Velden;*
Leiden University Medical Center, Leiden, NETHERLANDS.

OP-513
Improving TNM staging predictive value with PET/CT imaging features and deep learning model in non-small cell lung cancer
E. Giovannini[1], *F. Tutino*[1], *G. Giovacchini*[1], *L. Florimonte*[2], *M. Castellani*[2], *A. Ciarmiello*[1];
[1]*ASL5, La Spezia, ITALY,* [2]*Ca' Granda Ospedale Maggiore Policlinico, Milan, ITALY.*

OP-514
Heterogeneity of Glycolytic Phenotype Determined by 18F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced NSCLC
S. Pellegrino[1], *R. Fonti*[1], *C. Vallone*[1], *R. Lepre*[1], *R. Morra*[2], *E. Matano*[2], *S. De Placido*[2], *S. Del Vecchio*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY,* [2]*Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY.*

OP-515
Novel deep learning-based noise reduction for zero echo time MRI on PET/MRI: Utility of half-minute lung imaging for oncology patients
M. Nogami[1], *M. Tachibana*[2], *J. Inukai*[2], *F. Zeng*[2], *T. Kurimoto*[3], *K. Kubo*[1], *T. Murakami*[1,2];
[1]*Kobe University Hospital, Kobe, JAPAN,* [2]*Kobe University Graduate School of Medicine, Kobe, JAPAN,* [3]*GE Healthcare, Hino, Tokyo, JAPAN.*

1107

Monday, October 17, 2022, 16:45 - 18:15

Hall 115

Inflammation & Infection Committee - TROP Session: Inflammation and Beyond

OP-516
AI-Based Monitoring of Idiopathic Inflammatory Myopathy by FDG PET/CT
J. Simonsen[1,2], *S. Hvidsten*[1], *L. Edenbrandt*[3], *O. Gerke*[1,2], *L. P. Diederichsen*[4,1];
[1]*Odense University Hospital, Odense, DENMARK,* [2]*University of Southern Denmark, Odense, DENMARK,* [3]*Sahlgrenska University Hospital, Gothenburg, SWEDEN,* [4]*Rigshospitalet, Copenhagen, DENMARK.*

OP-517
The presence of extrathoracic disease emerging from 18F-FDG PET/CT increases the risk of fatigue in sarcoidosis patients.
A. Georgakopoulos[1], *E. Manali*[2], *A. Papaioannou*[2], *M. Metaxas*[3], *L. Kolilekas*[4], *H. Gialafos*[5], *S. Papiris*[2], *S. Chatziioannou*[1,3];
[1]*2nd Department of Radiology, General University Hospital "Attikon", Medical School, National and Kapodistrian University, Athens, GREECE,* [2]*2nd Pulmonary Medicine Department, General University Hospital "Attikon", Medical School, National and Kapodistrian University, Athens, GREECE,* [3]*Foundation for Biomedical Research of the Academy of Athens, Athens, GREECE,* [4]*7th Pulmonary Department, Athens Chest Hospital "Sotiria", Athens, GREECE,* [5]*Aiginitio Hospital, Medical School, National and Kapodistrian University, Athens, GREECE.*

OP-518
^{99m}Tc labelled glucosamine in the identification of active disease in patients with rheumatoid arthritis
O. Evbuomwan[1], *J. Horn-Lodewyk*[2], *B. Van Rensburg*[1], *C. Driver*[3], *G. Engelbrecht*[1], *M. Labuschagne*[1];
[1]*University Of The Free State, Bloemfontein, Free State, SOUTH AFRICA,* [2]*Central University of Technology, Bloemfontein, Free State, SOUTH AFRICA,* [3]*NECSA, Pretoria, Gauteng, SOUTH AFRICA.*

OP-519
Imaging Characteristics and Diagnostic Accuracy of FDG-PET/CT, Contrast Enhanced CT and Combined Imaging in Patients with Suspected Mycotic or Inflammatory Abdominal Aortic Aneurysms
L. Husmann[1], *M. W. Huellner*[1], *H. Gruenig*[1], *M. Messerli*[1], *Z. Rancic*[2], *B. Hasse*[3];
[1]*University Hospital Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND,* [2]*University Hospital Zurich, Department of Vascular Surgery, Zurich, SWITZERLAND,* [3]*University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology, Zurich, SWITZERLAND.*

OP-520
^{18}F FDG labelled autologous leukocyte PET/CT scan in infective and inflammatory conditions- a single-centre review
Y. Mathur, *S. Kumar, A. Bhattacharya, P. Aggarwal, R. Kumar, H. Singh, B. R. Mittal;*
PGIMER, Chandigarh, INDIA.

OP-521
[^{18}F]FDG PET/CT role in FUO: an Italian multicentric study
D. Albano[1], *F. Dondi*[2], *C. Ferrari*[3], *G. Santo*[3], *M. Bauckneht*[4], *R. Laffranchi*[4], *A. Coccarelli*[5], *S. Capitanio*[6], *A. Franchini*[6], *R. Laudicella*[7], *G. Giacoppo*[8], *R. Piva*[9], *V. Liberini*[10], *S. Peano*[10], *M. Balma*[10], *P. Ferro*[11], *I. Gotuzzo*[12], *A. Muni*[9], *C. Rossetti*[6], *S. Morbelli*[4], *G. Rubini*[3], *A. Papaleo*[10], *D. Deandreis*[5], *S. Baldari*[8], *F. Bertagna*[1];
[1]*University of Brescia and Spedali Civili of Brescia, Brescia, ITALY,* [2]*ASST Spedali Civili di Brescia, Brescia, ITALY,* [3]*Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Bari, ITALY,* [4]*University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY,* [5]*Department of Medical Sciences, AOU Città della Salute e della Scienza, University of Turin, Turin, ITALY,* [6]*ASST Grande Ospedale Metropolitano Niguarda, Milan, ITALY,* [7]*Unit of Nuclear Medicine, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY,* [8]*Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY,* [9]*Azienda Ospedaliera S.S. Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, ITALY,* [10]*Nuclear Medicine Department, S. Croce E Carle Hospital, Cuneo, ITALY,* [11]*IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [12]*School of Medicine and Surgery, University of Milano Bicocca, Monza, ITALY.*

OP-522
CXCR4 directed Plaque imaging using^{68}Ga-Pentixafor: A retrospective comparative study with^{18}F-FDG in multiple myeloma patients
A. Watts, *P. Yadav, H. Kaur, R. Vijayvergiya, B. Singh;*
Post graduate institute of medical education & Research, Chandigarh, INDIA.

OP-523
The challenge of [^{18}F]FDG PET/CT in the unexplored field of osteomyelitis
C. Ferrari, *G. Santo, A. G. Nappi, N. C. Merenda, P. Mammucci, A. Sciacqua, A. R. Pisani, G. Rubini;*
Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University Aldo Moro, Bari, ITALY.

OP-524
Usefulness of quantitative approach for salivary scintigraphy in histologically confirmed coohort of patients with Sjogren Syndrome
A. Martini[1], *L. Fedeli*[1], *E. Tardelli*[1], *I. Laghai*[1], *A. Coppola*[1], *A. Arena*[1], *G. Montelatici*[1], *M. Dona*[1], *S. Maddali Bongi*[2], *S. Sestini*[1];
[1]*Unit of Nuclear Medicine, Department of Diagnostic Imaging, N.O.P. - S. Stefano, U.S.L. Toscana Centro, Prato, ITALY,* [2]*Casa di cura Villa Donatello, Firenze, ITALY.*

1108

Monday, October 17, 2022, 16:45 - 18:15

Hall 212

Thyroid Committee - TROP Session: Treatment of Thyroid Cancer

OP-525
How Current Risk Stratification Changed Our Practice in Pediatric Thyroid Cancer Patients? An Institutional Experience
Z. Isik, *B. Volkan-Salancı, P. Kıratlı;*
Hacettepe University, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-526
Age dependence of thyroid carcinoma - do we have enough age cut-offs for staging or one too many
B. Schemmer;
Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY.

OP-527
Comparison of 8th and 7th Editions of TNM Staging in Terms of Mortality, Persistent Disease, and Response to Treatment in Patients With Differentiated Thyroid Cancer
S. Zakavi[1], *G. Gholami*[1], *A. Aghaee*[1], *S. Shafiei*[1], *B. Rasoulian*[2], *E. Askari*[1], *S. Zare Namdar*[1];
[1]*Nuclear Medicine Research Center, Mashhad University of medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*head and neck surgery, Mashhad University of medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

OP-528
Thyroglobulin Levels Independently Predict Iodine-123 Imaging Results At Early Follow-Up In Differentiated Thyroid Cancer Patients
A. Campenni'[1], *M. Siracusa*[1], *D. Romano*[1], *G. Giacoppo*[1], *L. Croce*[1], *H. Rosarno*[1], *D. Cardile*[1], *A. Alibrandi*[2], *F. Capoccetti*[3], *R. Ruggeri*[4], *S. Baldari*[1], *L. Giovanella*[5];
[1]*Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, ITALY,* [2]*Unit of Statistical and Mathematical Sciences, Department of Economics, University of Messina, Messina, ITALY,* [3]*Service Department Macerata Hospital, ASUR Marche AV3, Nuclear Medicine Unit, Macerata, ITALY,* [4]*Department of Clinical and Experimental Medicine, Unit of Endocrinology, University of Messina, Messina, ITALY,* [5]*Clinic for Nuclear Medicine and Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, ITALY.*

OP-529
Second Radioiodine Treatment In Patients With Differentiated Thyroid Carcinoma: Causes And Effects
M. N. Sicilia Pozo[1], *F. J. Pena Pardo*[1], *J. Torres Hernández*[2], *A. M. García Vicente*[1], *M. Amo Salas*[3], *A. Padilla Bermejo*[1], *L. García Zoghby*[1], *C. Lucas Lucas*[1], *E. Noriega Álvarez*[1], *Á. Soriano Castrejón*[1];
[1]*Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [2]*Clinical Biochemistry Department, University General Hospital of Albacete, Albacete, SPAIN,* [3]*Department of Mathematics, Castilla-La Mancha University, Ciudad Real, SPAIN.*

OP-530
Secondary primary malignancy and radioiodine administration in differentiated thyroid cancer patients: a second check
F. Volpe, *L. Piscopo, M. Manganelli, C. Nappi, E. Zampella, V. Gaudieri, F. Volpicelli, M. Klain, S. Maurea, A. Cuocolo;*
Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY.

OP-531
Experienced surgeons make the difference in Thyroid Cancer management
J. Koutsikos[1], *S. Giourgouli*[2], *A. Kokkini - Paschou*[1], *V. Pantzou*[2], *M. Stathopoulou*[2], *T. Petropoulos*[2];
[1]*Nuclear Medicine Department, 401 General Military Hospital; Henry Dunant Hospital Center, Athens, GREECE,* [2]*Nuclear Medicine Department, Henry Dunant Hospital Center, Athens, GREECE.*

OP-532
Incremental Prognostic value of Circulating CD4+T cell Subsets in the First 131I Treatment of Papillary Thyroid Carcinoma
D. Fan[1], *Z. Shi*[1], *S. Zhang*[2], *Y. Xue*[1], *Z. Cheng*[1], *X. Lu*[1], *J. Zhang*[1], *R. Hu*[1], *C. Li*[1], *L. Wu*[1], *K. Lu*[1], *H. Wang*[1], *Y. Cheng*[1], *X. Li*[2], *Z. Wu*[1], *H. Liu*[1], *S. Li*[1];
[1]*First Hospital of Shanxi Medical University, Taiyuan, CHINA,* [2]*Second Hospital of Shanxi Medical University, Taiyuan, CHINA.*

OP-533
Identification of risk factors for recurrence of differentiated thyroid cancer
A. Savchenko[1], *Y. Radzishevska*[2], *L. Vasylyev*[3];
[1]*V. N. Karazin Kharkiv National University, Kharkiv, UKRAINE,* [2]*Kharkiv National Medical University, Kharkiv, UKRAINE,* [3]*SO «Grigoriev Institute for Medical Radiology and Oncology of the National Academy of Medical Sciences of Ukraine», Kharkiv, UKRAINE.*

1110

Monday, October 17, 2022, 16:45 - 18:15

Hall 116

CTE 5 - Technologists Committee: Nuclear Medicine in Haematological Malignancies

OP-534
Nuclear Haematology - A Clinical Overview
A.I. Santos;
Hospital Garcia de Orta, E.P.E. , Department of Nuclear Medicine, Almada, PORTUGAL.

OP-535
Radiomics in Haematological Malignancies
K.J. Fábián;
Department of Control Engineering and Information Technology, Faculty of Electrical Engineering and Informatics, Budapest University of Technology and Economics, Budapest, HUNGARY.

OP-536
Working with New Protocols - From PET-FDG to FAPI?
J. Doraku;
Hospital 'Sacro Cuore Don Calabria', Department of Nuclear Medicine and Radioligand Therapy; Negrar di Valpolicella, Verona, ITALY.

1201

Tuesday, October 18, 2022, 08:00 - 09:30

Auditorium

CME 9 - Dosimetry + Oncology & Theranostics Committee: SIRT - An Example of Successful Clinical Dosimetry

OP-537
SIRT is a Good Candidate for Dosimetry Lead Treatment
M. Rodríguez Fraile;
Clínica Universidad de Navarra, Department of Nuclear Medicine, Pamplona, SPAIN.

OP-538
Dose Effect Relationships
H. Levillain;
Department of Nuclear Medicine, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, BELGIUM.

OP-539
The EANM Clinical Dosimetry Guidelines
E. Garin;
Centre de Lutte Contre le Cancer Eugène Marquis; University of Rennes; Inra, Inserm, Institut Nutrition, Métabolismes et Cancer, Rennes, FRANCE.

OP-540
Ho 166 - A Way to Bright the Future
R. Sciuto;
Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY.

1202

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 112 (Arena)

TOP Trials Session 3: New Radiopharmaceutical Trials

OP-541
HER2-targeted ^{227}Th/^{89}Zr theranostics for colorectal cancer
D. Abou[1], *M. Longtine*[1], *A. Hasson*[1], *A. Fears*[1], *R. Unnerstall*[1], *N. Benabdallah*[1], *D. Tatum*[2], *D. Magda*[2], *R. Wahl*[1], *D. Thorek*[1];
[1]*Washington University School of Medicine, Saint Louis, MO, UNITED STATES OF AMERICA,* [2]*Lumiphore, Berkeley, CA, UNITED STATES OF AMERICA.*

OP-542
Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial
N. LaFrance[1,2], *A. Brenner*[3], *M. Youssef*[4], *A. Bao*[5], *W. Phillips*[3], *M. Hedrick*[2];
[1]*Norman LaFrance, Newtown, PA, UNITED STATES OF AMERICA,* [2]*PLUS Therapeutics, San Antonio, TX, UNITED STATES OF AMERICA,* [3]*University of Texas, San Antonio, TX, UNITED STATES OF AMERICA,* [4]*University of Texas, Dallas, TX, UNITED STATES OF AMERICA,* [5]*Case Western Reserve University, Cleveland, OH, UNITED STATES OF AMERICA.*

OP-543
Next generation PET/CT imaging in meningioma using the novel SSTR-targeting peptide ^{18}F-SiTATE - first clinical experiences
M. Unterrainer[1], *S. C. Kunte*[1], *L. M. Unterrainer*[1], *A. Delker*[1], *S. Lindner*[1], *M. Brendel*[1], *A. Holzgreve*[1], *W. G. Kunz*[1], *C. C. Cyran*[1], *J. Ricke*[1], *K. Jurkschat*[2], *C. Waengler*[3], *B. Waengler*[3], *R. Schirrmacher*[4], *M. Niyazi*[1], *J. Tonn*[1], *L. Beyer*[1], *P. Bartenstein*[1], *N. L. Albert*[1];
[1]*University of Munich, Munich, GERMANY,* [2]*TU Dortmund, Dortmund, GERMANY,* [3]*University of Heidelberg, Heidelberg, GERMANY,* [4]*University of Alberta, Edmonton, AB, CANADA.*

OP-544
[^{18}F]AlF-NOTA-octreotide vs. [^{68}Ga]Ga-DOTA-somatostatin analogue PET in neuroendocrine tumour patients: final results of a prospective multicentre trial
E. Pauwels[1], *F. Cleeren*[2], *T. Tshibangu*[2], *M. Koole*[1], *K. Serdons*[1], *L. Boeckxstaens*[1], *J. Dekervel*[3], *T. Vandamme*[4,5], *W. Lybaert*[5], *B. Van den Broeck*[6], *P. M. Clement*[7], *K. Geboes*[8], *E. Van Cutsem*[3], *S. Stroobants*[9], *C. Verslype*[3], *G. Bormans*[2], *C. M. Deroose*[1];
[1]*Nuclear Medicine, University Hospitals Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM,* [2]*Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, BELGIUM,* [3]*Digestive Oncology, University Hospitals Leuven, Leuven, BELGIUM,* [4]*Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, BELGIUM,* [5]*Oncology, NETwerk Antwerpen-Waasland CoE, Antwerpen, BELGIUM,* [6]*Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM,* [7]*General Medical Oncology, University Hospitals Leuven, Leuven, BELGIUM,* [8]*Digestive Oncology, Department of Gastroenterology, Ghent University Hospital, Ghent, BELGIUM,* [9]*Nuclear Medicine, Antwerp University Hospital; Molecular Imaging and radiology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.*

OP-545
Exendin PET shows the importance of beta cell mass for glycaemic control in people with type 1 diabetes
M. Boss[1], *T. J. P. Jansen*[1], *M. Brom*[1], *M. Buitinga*[2], *C. J. Tack*[1], *L. A. van Meijel*[1], *B. E. de Galan*[1], *M. Gotthardt*[1];
[1]*Radboudumc, Nijmegen, NETHERLANDS,* [2]*Maastricht University, Maastricht, NETHERLANDS.*

OP-546
PET/CT and PET/MR imaging with ^{68}Ga-TVH in patients with pancreatic cancer - First clinical experience
J. Rehm[1], *J. Kotzerke*[1], *R. Winzer*[1], *J. Notni*[2];
[1]*Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Dresden, Dresden, GERMANY,* [2]*TRIMT GmbH, Radeberg, GERMANY.*

OP-547
Final results of a GRAN-T-MTC phase I clinical trial using a novel CCK2 receptor-localising radiolabelled peptide probe for personalized diagnosis and therapy of patients withmetastatic medullary thyroid cancer
L. Lezaic[1], *P. Kolenc*[1], *K. Zaletel*[1], *P. Erba*[2], *C. Decristoforo*[3], *R. Mikolajczak*[4], *P. Garnuszek*[4], *I. Virgolini*[3], *C. Rangger*[3], *G. Di Santo*[3], *H. Maecke*[5], *T. Maina*[6], *B. A. Nock*[6], *M. Trofimiuk-Müldner*[7], *E. Przybylik-Mazurek*[7], *M. de Jong*[8], *A. C. Fröberg*[8], *M. Konijnenberg*[8], *K. Skorkiewicz*[9], *B. Solnica*[10], *D. Fedak*[10], *P. Gaweda*[10], *A. Hubalewska-Dydejczyk*[7];
[1]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,* [2]*University of Pisa and Azienda Ospedaliero-Universitaria Pisana, Pisa, ITALY,* [3]*Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA,* [4]*National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND,* [5]*University Hospital Freiburg, Freiburg, GERMANY,* [6]*Molecular Radiopharmacy, INRASTES, NCSR Demokritos, Athens, GREECE,* [7]*Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND,* [8]*Erasmus MC, Rotterdam, NETHERLANDS,* [9]*University Hospital, Krakow, POLAND,* [10]*Department of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, POLAND.*

OP-548
Subtyping and Staging Progressive Supranuclear Palsy using the Second-Generation Tau PET Tracer [^{18}F] florzolotau
J. Lu[*1,2], *J. Hong*[*2], *F. Liu*[3], *M. Wang*[4,5], *C. Clement*[2], *T. Yen*[6], *X. Li*[3], *M. Brendel*[7], *A. Rominger*[2], *J. Wang*[3], *C. Zuo*[1], *K. Shi*[2,5], *Progressive Supranuclear Palsy Neuroimage Initiative (PSPNI);*
[1]*PET Center & National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA,* [2]*Department of Nuclear Medicine, Inselspital, University of Bern, Bern, SWITZERLAND,* [3]*Department of Neurology & National Center for Neurological Disorders & National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, CHINA,* [4]*Institute of Biomedical Engineering, School of*

Life Science, Shanghai University, Shanghai, CHINA, [5]Department of Informatics, Technical University of Munich, Munich, GERMANY, [6]APRINOIA Therapeutics Co., Ltd, Suzhou, CHINA, [7]Department of Nuclear Medicine, University of Munich, Munich, GERMANY. (shared first authors)*

OP-549

^{212}Pb-Targeted Alpha-Emitter Therapy of Neuroendocrine Tumor in Subjects with progression Following Prior PRRT

*E. Delpassand[1], **I. Tworowska**[1], R. Esfandiari[2], J. Torgue[3], J. Hurt[3], R. Nuñez[2]; [1]RadioMedix Inc., Houston, TX, UNITED STATES OF AMERICA, [2]Excel Diagnostics and Nuclear Oncology, Houston, TX, UNITED STATES OF AMERICA, [3]Orano Med, Plano, TX, UNITED STATES OF AMERICA.*

1203

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 113

LIPS Session 9 - Oncology & Theranostics Committee: Tricky Cases in NET and Digestive Tract Oncology

Interactive Session

OP-550

Tricky NET Cases

***V. Ambrosini**; University of Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department Nuclear Medicine, Bologna, ITALY.*

OP-551

Tricky Gastro-Esophageal Cases

***G. Polverari**; University of Torino Azienda Ospedaliero-Universitaria Città della salute e della Scienza di Torino, Department of Medical Science, Nuclear Medicine Unit, Turin, ITALY.*

OP-552

Tricky Liver and Pancreatic Carcinoma Cases

***G. Nicolas**; Clinic for Radiology and Nuclear Medicine, Theragnostics University Hospital Department, Basel, SWITZERLAND.*

OP-553

Tricky Intestinal Carcinoma Cases

***S. Carrilho Vaz**; Nuclear Medicine Specialist, Champalimaud Centre for the Unknown, Champalimaud Foundation Portugal, Lisbon, PORTUGAL*

1204

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: Seeing the Brain from All Angles

OP-554

Evaluation of brain ^{18}F-FDG-PET imaging as a translational biomarker for therapeutic monitoring in creatine transporter deficiency

***A. Soyer**[1], S. Goutal[1], N. Ziani[1], L. Breuil[1], G. Hugon[1], A. Winkeler[1], C. Disdier[2], H. Benech[2], T. Joudinaud[2], A. Mabondzo[3], N. Tournier[1]; [1]Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, FRANCE, [2]CERES BRAIN Therapeutics, ICM, Hôpital Pitié Salpêtriere, Paris, FRANCE, [3]Department of Medicines and Healthcare Technologies, Paris-Saclay University-CEA, Gif-sur-Yvette, FRANCE.*

OP-555

Advances of Novel [^{18}F]F-diarylbisthiazoles as Specific PET tracer for α-Synucleinopathies imaging

***B. Hooshyar Yousefi**[1], B. C. Uzuegbunam[2], W. Paslawski[3], J. Li[4], D. Librizzi[5], M. Luster[5], W. Weber[2], P. Svenningsson[3], H. Ågren[4], T. Arzberger[6]; [1]Philipps University of Marburg, Nuclear Medicine Department, Radiopharmacy, Marburg, GERMANY, [2]Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY, [3]Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, SWEDEN, [4]Department of Physics and Astronomy, Uppsala University, Uppsala, SWEDEN, [5]Philipps University of Marburg, Nuclear Medicine Department, Marburg, GERMANY, [6]Ludwig-Maximilians-University of Munich, Munich, GERMANY.*

OP-556

Neuroplasticity and brain connectivity in a rat model of bilateral labyrinthectomy - a longitudinal [18]UCB-H/[18F] FDG study

***M. Antons**[1], H. McGregor[2], M. Lindner[2], M. Grosch[1], R. Oos[2], G. Palumbo[2], M. Brendel[2], S. Ziegler[2], P. Bartenstein[2], M. Dieterich[3], A. Zwergal[1]; [1]German Center for Vertigo and Balance Disorders, DSGZ, Ludwig-Maximilians-University of Munich, Munich, GERMANY, [2]Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, GERMANY, [3]Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, GERMANY.*

OP-557

The Evaluation of ATP5A as a Novel Target for Imaging Mitochondrial Dysfunction in Alzheimer's disease

***C. Jie**[1], A. Delparente[1], C. Keller[1], R. Schibli[1,2], L. Mu[1]; [1]ETH Zürich, Zurich, SWITZERLAND, [2]Paul Scherrer Institute, Villigen, SWITZERLAND.*

OP-558

^{64}Cu-Azacyclopeptide targeting soluble Aβ oligomers as an early Alzheimer's disease diagnostic PET tracer

***V. Dumulon-Perreault**[1], S. Ait-Mohand[2], O. Sarrhini[2], R. Mulamreddy[3], S. Vutla[3], K. Fernandes[4,1,5], W. D. Lubell[3], S. Rahimipour[6], B. Guérin[2,1]; [1]Sherbrooke Molecular Imaging Center (CIMS)/Research Center of the CHUS (CRCHUS), Sherbrooke, QC, CANADA, [2]Department of nuclear medicine and radiobiology, Université de Sherbrooke, Sherbrooke, QC, CANADA, [3]Department of chemistry, Université de Montréal, Montréal, QC, CANADA, [4]Department of medicine, Université de Sherbrooke, Sherbrooke, QC, CANADA, [5]Research Centre on Aging, CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, CANADA, [6]Department of Chemistry, Bar-Ilan University, Ramat-Gan, ISRAEL.*

OP-559

Specific loss of NPC1 in myeloid cells drives single cell 18kDa translocator protein expression in microglia and leads to reactive astrocytosis and loss of synaptic function

***S. Hummel**[1,2], L. Dinkel[2], L. Bartos[1], K. Wind[1], L. Sebastian Monasor[2], L. Slemann[1], L. Kunze[1], J. Gnörich[1,2], S. Lindner[1], P. Bartenstein[1], N. Albert[1], M. Brendel[1,2], S. Tahirovic[2]; [1]Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, GERMANY, [2]DZNE—German Center for Neurodegenerative Diseases, Munich, GERMANY.*

OP-560

Direct comparison of the blood-brain barrier transport and vulnerability to P-glycoprotein-mediated drug-drug interaction of domperidone versus metoclopramide assessed using in vitro assay and pharmacokinetic PET imaging

***L. Breuil**[1], S. Goutal[1], A. Soyer[1], M. Goislard[1], V. Lebon[1], D. Audisio[2], A. Del Vecchio[3], F. Caille[1], N. Tournier[1]; [1]Biomaps, Orsay, FRANCE, [2]CEA, Saclay, FRANCE, [3]CEA, Orsay, FRANCE.*

OP-561

Evaluation of synaptic density using SV2A PET imaging as a readout of depression and antidepressant response in a mice model of depression

***C. Leroy**[1], S. Goutal[1], I. Mendez-David[2], W. Saba[1], M. Goislard[1], M. Bottlaender[1], F. Caillé[1], A. Gardier[2], E. Corruble[3,4], V. Lebon[1], R. Colle[3,4], N. Tournier[1], D. David[2]; [1]Inserm U1281, CNRS, Université Paris Saclay, CEA-SHFJ, Orsay, FRANCE, [2]Université Paris-Saclay, Faculté de Pharmacie, CESP-Inserm, équipe MOODS, Chatenay Malabry, FRANCE, [3]Université Paris-Saclay, Faculté de Médecine, CESP, MOODS Team, INSERM, Le Kremlin Bicêtre, FRANCE, [4]Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Le Kremlin Bicêtre, FRANCE.*

OP-562

In vivo characterization of [^{11}C](+)3-MPB binding to mAChR in the brain of living mice

***S. Kim**[1,2], H. Kim[1,2], B. Moon[3], B. Lee[2], H. Park[2,4], S. Kim[2,4,5]; [1]Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF, [2]Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF, [3]Department of Nuclear Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF, [4]Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF, [5]Advanced Institutes of Convergence Technology, Suwon, KOREA, REPUBLIC OF.*

1205

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 211

Cutting Edge Science Track - TROP Session: Standardisation & Quality Control

OP-563

Calibration Procedures for Multi-Center Dosimetry Studies with ^{177}Lu Radiopharmaceuticals: Early Experience from the Canadian Cancer Trial Group PR.21 Trial (NCT 04663997)

***C. Uribe**[1], N. Colpo[1], J. Brosch-Lenz[1], C. Dellar[2], W. Parulekar[2], F. Saad[3], K. Chi[1], K. Zukotynski[4], J. Beauregard[5], F. Benard[1]; [1]BC Cancer, Vancouver, BC, CANADA, [2]Canadian Cancer Trials Group, Kingston, ON, CANADA, [3]University of Montreal Hospital Center, Montreal, QC, CANADA, [4]Hamilton Health Sciences Centre, Hamilton, ON, CANADA, [5]Université Laval, Quebec City, QC, CANADA.*

OP-564

The EARL Quantitative^{177}Lu-SPECT-CT accreditation programme

***J. Dickson**[1], M. Cremonesi[2], A. M. Denis-Bacelar[3], I. Hristova[4], M. Koole[5], S. Peters[6], K. Sjögreen Gleisner[7], J. Tran-Gia[8], M. Lassmann[8]; [1]University College London Hospitals, London, UNITED KINGDOM, [2]Istituto Europeo di Oncologia, Milan, ITALY, [3]National Physics Laboratory, Teddington, UNITED KINGDOM, [4]EANM Forschungs GmbH, Vienna, AUSTRIA, [5]KU Leuven, Leuven, BELGIUM, [6]Radboudumc, Nijmegen, NETHERLANDS, [7]Lund University, Lund, SWEDEN, [8]University of Würzburg, Würzburg, GERMANY.*

OP-565

A multicenter study on observed discrepancies between vendor-stated and ^{90}Y PET-measured activities for both glass and resin ^{90}Y microsphere devices

***T. Carlier**[5], S. Gnesin[1], J. K. Mikell[2], M. Conti[3], J. O. Prior[4], T. V. Lima[6], Y. K. Dewaraja[7]; [1]Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [2]Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, [3]Siemens Healthineers, Molecular Imaging, Knoxville, TN, UNITED STATES OF AMERICA, [4]Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [5]Nuclear Medicine Department, University Hospital of Nantes, Nantes, FRANCE, [6]Department of Radiology and Nuclear Medicine, Luzerner Kantonsspital, Luzern, SWITZERLAND, [7]Division of Nuclear Medicine, Department of Radiology, University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA.*

OP-566

Harmonization of Brain PET Images in Multi-Center PET Studies Using Hoffman Phantom Scan

***M. Shekari**[1,2,3], E. Verwer[4], M. Yaqub[4], J. D. Gispert[1,2,5], R. Boellaard[4], on behalf of AMYPAD consortium; [1]Barcelonaβeta Brain Research Center, Barcelona, SPAIN, [2]IMIM (Hospital del Mar Medical Research Institute), Barcelona, SPAIN, [3]Universitat Pompeu Fabra, Barcelona, SPAIN, [4]Department of Radiology & Nuclear Medicine, University Medical Centers, Amsterdam, NETHERLANDS, [5]Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, SPAIN.*

OP-567

PET image quality assessment for quantitative radiotherapy-tailored PET/MR in multicenter trials: a phantom study

***R. Winter**[1], O. Engelsen[2], O. Sæther[3], K. R. Redalen[1]; [1]Department of Physics, Norwegian University of Science and Technology (NTNU), Trondheim, NORWAY, [2]PET Imaging Center, University Hospital of North Norway (UNN), Tromsø, NORWAY, [3]Department of Radiology and Nuclear Medicine, St. Olav University Hospital, Trondheim, NORWAY.*

OP-568

Image quality assessment along the one meter axial field-of-view of the total-body Biograph Vision Quadra PET/CT system for ^{18}F

***I. Rausch**[1], J. G. Mannheim[2], J. Kupferschläger[3], C. la Fougère[3], F. P. Schmidt[2]; [1]Medical University of Vienna, Vienna, AUSTRIA, [2]Eberhard-Karls University Tuebingen, Tübingen, GERMANY, [3]University hospital Tuebingen, Tübingen, GERMANY.*

OP-569

Explore general image quality measurements on PET/CT systems with long axial fields of view

*G. A. Prenosil[1], K. Zeimpekis[1], H. Wang[2], L. P. Meier[1], Y. Zan[2], T. Läppchen[1], R. Guo[2], L. Mercolli[1], A. Rominger[1], B. Li[2], **K. Shi**[1]; [1]University of Bern, Bern, SWITZERLAND, [2]Ruijin Hospital, Shanghai Jiaotong University, Shanghai, CHINA.*

OP-570
Standardization in preclinical imaging: The need and the current practice
M. Bernsen[1], *M. Aswendt*[2], *F. Gremse*[3], *M. C. Huisman*[4], *G. D. Ielacqua*[5], *W. A. McDougald*[6], *L. Mezzanotte*[1], *C. M. Moran*[6], *G. Warnock*[7,8,9], *C. Kuntner*[10], *A. A. S. Tavares*[6], *C. Vanhove*[1];
[1]*Erasmus MC, Rotterdam, NETHERLANDS,* [2]*University Hospital Cologne, Cologne, GERMANY,* [3]*Gremse IT, Aachen, GERMANY,* [4]*Amsterdam UMC/Vrije Universiteit Amsterdam, Amsterdam, NETHERLANDS,* [5]*Max Delbrück Center, Berlin, GERMANY,* [6]*University of Edinburgh, Edinburgh, UNITED KINGDOM,* [7]*University Hospital Zurich, Zurich, SWITZERLAND,* [8]*University of Zurich, Zurich, SWITZERLAND,* [9]*PMOD Technologies LLC, Zurich, SWITZERLAND,* [10]*Medical University of Vienna, Vienna, AUSTRIA.*

OP-571
Preclinical QC made easy: automated analysis of imaging data from a NEMA NU 4-based phantom
S. van Tiel[1], *A. Höfter*[2], *J. Haeck*[1], *F. Gremse*[2], *M. Bernsen*[1];
[1]*ErasmusMC, Rotterdam, NETHERLANDS,*
[2]*Gremse-IT, Aachen, GERMANY.*

1206

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 117

Clinical Oncology Track - TROP Session: Gynaecology and Others

OP-572
A combination of MRI and [18F]FDG-PET measures independently predicts the overall survival in patients with locally advanced cervical cancer (LACC) treated with chemoradiotherapy
S. Raffa[1], *F. Lanfranchi*[1], *C. Satragno*[2], *S. E. Cena*[2], *A. Coco*[2], *S. Chiola*[1], *A. Miceli*[1], *M. I. Donegani*[1], *F. D'Amico*[1], *T. Di Raimondo*[1], *F. Giannelli*[2], *M. Marcenaro*[2], *M. Bauckneht*[1], *G. Sambuceti*[1], *L. Belgioia*[2], *S. Morbelli*[1];
[1]*Nuclear Medicine Unit, Policlinico San Martino, University of Genoa, Genoa, ITALY,* [2]*Radiation Oncology, Policlinico San Martino, University of Genoa, Genoa, ITALY.*

OP-573
Diagnostic efficacy and prognostic biomarkers including radiomics of 18F-FDG PET/MR in the 2018 revised FIGO staging of patients with cervical cancer
J. Garcia, *A. Compte, J. Romero, M. Pujol, E. Valls, S. Mourelo, M. Kauak, M. Soler, M. Buxeda, E. Riera;*
CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

OP-574
Head-to-head comparison of 18F-FDG PET/CT and PET/MRI for the imaging of peritoneal recurrence of ovarian carcinoma
M. Baltacioglu, *C. Soydal, M. Araz, D. Kuru Oz, S. Taskin, N. Kucuk, G. Erden, A. Elhan;*
Ankara University Medical School, Ankara, TÜRKIYE.

OP-575
Lymphatic Mapping for Image Guided Radiotherapy Treatment Planning in Locally Advanced Uterine Cervical Cancer
J. Adam, *E. Poel, B. van Eck-Smit, C. Mom, L. Stalpers, J. Stoker, S. Bipat;*
Amsterdam UMC University of Amsterdam, Amsterdam, NETHERLANDS.

OP-576
Superiority of [^{68}Ga]Ga-FAPI-46 over [^{18}F]F-FDG PET/CT for cholangiocarcinoma imaging
K. M. Pabst[1,2], *M. Trajkovic-Arsic*[3,2,4], *P. F. Cheung*[3,2,4], *L. Kessler*[1,2], *N. Hirmas*[1,2], *M. Nader*[1,2], *T. Bartel*[1,2], *B. M. Schaarschmidt*[5,2], *S. Kasper*[6,2], *J. T. Siveke*[7,6,4], *R. Hamacher*[6,2], *H. H. J. Schmidt*[8,2,9], *M. Ingenwerth*[10,2], *K. Herrmann*[1,2], *W. P. Fendler*[1,2];
[1]*Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [2]*German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY,* [3]*Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [4]*Division of Solid Tumor Translational Oncology, German Cancer Research Center, DKFZ, Heidelberg, GERMANY,* [5]*Department of Diagnostic and Interventional Radiology, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [6]*Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [7]*Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY,* [8]*Department of Gastroenterology and Hepatology, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [9]*Medical Clinic B, Department of Gastroenterology, Hepatology, Endocrinology, Infectiology, University Hospital Muenster, Muenster, GERMANY,* [10]*Department of Pathology, West German Cancer Center, University Hospital Essen, Essen, GERMANY.*

OP-577
^{68}Ga-PSMA-11 PET Angiogenesis Imaging In Metastatic Clear Cell Renal Cancer: Can It Replace ^{18}F-FDG PET?
H. Singh, *P. Aggarwal, C. K. Das, R. Mavuduru, N. Kakkar, R. Kumar, B. Mittal;*
Post Graduate Institute of Medical Education & Research, Chandigarh, INDIA.

OP-578
Is there a place for [^{68}Ga]Ga-FAPI-46 PET/CT in locoregional lymph node staging of urothelial carcinoma in the bladder prior to cystectomy?Preliminary results
L. Unterrainer (née Mittlmeier)[1], *S. Lindner*[1], *L. Eismann*[2], *F. J. Gildehaus*[1], *J. Toms*[1], *N. Albert*[1], *A. Holzgreve*[1], *M. Brendel*[1], *C. C. Cyran*[3], *A. Karl*[4], *G. B. Schulz*[2], *S. T. Ledderose*[5], *F. Valla*[6], *C. G. Stief*[2], *P. Bartenstein*[1], *M. Unterrainer*[3], *A. Kretschmer*[2], *V. Wenter*[1];
[1]*LMU Munich, Department of Nuclear Medicine, Munich, GERMANY,* [2]*LMU Munich, Department of Urology, Munich, GERMANY,* [3]*LMU Munich, Department of Radiology, Munich, GERMANY,* [4]*Krankenhaus Barmherzige Brüder, Department of Urology, Munich, GERMANY,* [5]*LMU Munich, Institute of Pathology, Munich, GERMANY,* [6]*SOFIE, Dulles, VA, UNITED STATES OF AMERICA.*

OP-579
18F-FDG PET/CT in Pyrexia of unknown origin: Guiding light from unknown to known
D. Khan, *S. Sagar, S. Saraswat, S. Kumar, S. A. Shamim, R. Kumar;*
AIIMS Delhi, Delhi, INDIA.

OP-580
Development of ^{68}Ga-DOTA.SA.FAPI as a broad-spectrum diagnostic probe in various epithelial carcinomas: A head-to-head comparison with ^{18}F-FDG
S. Chopra[1], *J. Shukla*[1], *Y. Mathur*[1], *F. Rosch*[2], *E. Moon*[2], *H. Singh*[1], *N. Rana*[1], *R. Walia*[1], *A. Duseja*[1], *S. Irrinki*[1], *B. Mittal*[1];
[1]*Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, INDIA,* [2]*Johannes Gutenberg-University Mainz, Mainz, GERMANY.*

1207

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 115

Neuroimaging Committee - TROP Session: Movement Disorders: Radiomic, AI, Connectivity and What Else?

OP-581
Metabolic brain connectivity architecture is associated with tau accumulation in progressive supranuclear palsy
M. Wang[1], *J. Lu*[2], *F. Liu*[2], *M. Brendel*[3], *J. Hong*[4], *A. Rominger*[4], *T. Wendler*[5], *J. Wang*[2], *C. Zuo*[2], *J. Jiang*[1], *K. Shi*[4];
[1]*Shanghai University, Shanghai, CHINA,* [2]*Fudan University, Shanghai, CHINA,* [3]*Ludwig-Maximilians-Universität München, Munich, GERMANY,* [4]*Inselspital, Bern, SWITZERLAND,* [5]*Technische Universität München, Munich, GERMANY.*

OP-582
Development and Validation of a Radiomic Model For the Diagnosis of Dopaminergic Denervation on [18F]FDOPA PET/CT
V. Comte[1], *H. Schmutz*[2], *D. Chardin*[1,2], *F. Orlhac*[3], *J. Darcourt*[1,2], *O. Humbert*[1,2];
[1]*Dept. of Nuclear Medicine, Centre Antoine Lacassagne, Nice, FRANCE,* [2]*Laboratoire TIRO UMR E4320, UCA, Nice, FRANCE,* [3]*Institut Curie, Université PSL, Inserm, U1288 LITO, Université Paris Saclay, Orsay, FRANCE.*

OP-583
Prediction of Cognitive Decline in Parkinson's Disease using Deep and Handcrafted Radiomics Features
A. Fathi Jouzdani[1,2], *A. Gorji*[1,2], *M. Hosseinzadeh*[3,2], *A. Rahmim*[4,5], *M. R. Salmanpour*[2,4,5];
[1]*Neuroscience and Artificial Intelligence Research Group (NAIRG), Student Research Committee, Hamadan University of Medical Sciences, Hamadan, IRAN, ISLAMIC REPUBLIC OF,* [2]*Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, CANADA,* [3]*Tarbiat Modares University, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*University of British Columbia, Vancouver, BC, CANADA,* [5]*BC Cancer Research Institute, Vancouver, BC, CANADA.*

OP-584
Feasibility of Artificial Intelligence in Predicting Early Phenotype Conversion of REM Sleep Behavior Disorder
L. Lopes[1], *P. Wu*[2], *J. Lu*[1,2], *J. Wang*[3], *C. Bassetti*[4], *A. Rominger*[1], *C. Zuo*[2], *H. Yu*[3], *K. Shi*[1,5];
[1]*Department of Nuclear Medicine, University of Bern, Bern, SWITZERLAND,* [2]*PET Center, Huashan Hospital, Fudan University, Shanghai, CHINA,* [3]*Department of Neurology, Huashan Hospital, Fudan University, Shanghai, CHINA,* [4]*Department of Neurology, University of Bern, Bern, SWITZERLAND,* [5]*Department of Informatics, Technische Universität München, Munich, GERMANY.*

OP-585
Development of AI based Delay Images Generation Technique using Early [^{18}F]FP-CIT PET Imaging
C. Sung, *J. S. Oh, M. Oh, S. Lee, S. Oh, S. Chung, J. Kim;*
Asan Medical Center, Seoul, KOREA, REPUBLIC OF.

OP-586
Machine-Learning Assisted Diagnosis of Atypical Parkinsonisms Using FDG-PET
M. Ollarves Carrero, *J. C. Rodríguez Gómez, J. Matías-Guiu Antem, P. Bascuñana, C. Rodríguez Rey, M. Pedrera Canal, M. K. Meneses Navas, G. Cuesta Domingo, J. L. Carreras Delgado, M. N. Cabrera Martin;*
Hospital Clinico San Carlos, Madrid, SPAIN.

OP-587
Stereotactical normalization with multiple templates representative of normal and Parkinson-typical reduction of striatal uptake improves the diagnostic power of automatic semi-quantitative analysis in dopamine transporter SPECT
I. Apostolova[1], *T. Schiebler*[1], *C. Lange*[2], *F. Mathies*[1], *W. Lehnert*[1], *S. Klutmann*[1], *R. Buchert*[1];
[1]*University Hospital Hamburg Eppendorf, Hamburg, GERMANY,* [2]*Charité - Universitätsmedizin Berlin, Berlin, GERMANY.*

OP-588
Different cut-offs of z-score for Striatal Binding ratio (SBR) of DaT SPECT are needed to support of diagnosis of Parkinson's Disease (PD) and Dementia with Lewy Body (DLB)
F. Lanfranchi[1], *S. Chiola*[2], *D. Arnaldi*[3], *S. Raffa*[4], *M. I. Donegani*[1], *P. Mattioli*[3], *M. Pardini*[3], *M. Bauckneht*[1,4], *A. Miceli*[1], *F. D'Amico*[1], *G. Sambuceti*[1,4], *F. Nobili*[3], *S. Morbelli*[1,4];
[1]*Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,* [2]*Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, ITALY,* [3]*Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, ITALY,* [4]*Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY.*

OP-589
Comparison of Dopaminergic and Metabolic Imaging in Monogenic and Idiopathic Parkinson Disease
B. Soydas Turan[1], *B. Volkan-Salancı*[1], *E. Lay Ergün*[1], *Ö. Uğur*[1], *G. Yalçın-Çakmaklı*[2], *K. Karlı Oğuz*[3], *B. Elibol*[2];
[1]*Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University Faculty of Medicine, Department of Neurology, Ankara, TÜRKIYE,* [3]*Hacettepe University Faculty of Medicine, Department of Radiology, Ankara, TÜRKIYE.*

1208

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 212

Thyroid Committee - Featured Session: What is New in Thyroid and Parathyroid Imaging?

OP-590
Advances in (Para-) Thyroid Imaging
L. Giovanella;
Imaging Institute Southern Switzerland, Nuclear Medicine and Molecular Imaging, Bellinzona, SWITZERLAND.

OP-591
Interobserver Agreement of Semi-quantitative and visual Methods of MIBI Imaging for the Risk Stratification of Hypofunctioning Thyroid Nodules
J. Vogel[1], *S. A. Schenke*[2], *S. Haghghi*[3], *T. Wallbaum*[4], *C. Herkula*[1], *P. Seifert*[5], *M. Kreißl*[1];
[1]*Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University Hospital Magdeburg, Magdeburg, GERMANY,* [2]*Clinic of Nuclear Medicine Bayreuth Hospital, Bayreuth, GERMANY,* [3]*Department of Nuclear Medicine, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, GERMANY,* [4]*Radiology and Nuclear Medicine Sudenburg, Magdeburg, GERMANY,* [5]*Clinic of Nuclear Medicine, Jena University Hospital, Jena, GERMANY.*

OP-592
Diagnostic Performance of ^{99m}Tc-methoxy-isobutyl-isonitrile (MIBI) Imaging in Hypofunctioning Thyroid Nodules: A European Multicenter Study
S. Schenke[1,2], *A. Campenni*[3], *M. Tuncel*[4], *A. Piccardo*[5], *S. Sager*[6], *T. Bogovic Crncic*[7], *D. Rozic*[8], *R. Görges*[9], *P. P. Özcan*[10], *D. Gröner*[11], *H. Hautzel*[9], *R. Klett*[12], *M. C. Kreissl*[2], *L. Giovanella*[13,14];
[1]*Clinic for Nuclear Medicine, City Hospital Bayreuth, Bayreuth, GERMANY,* [2]*Division of Nuclear Medicine, University Hospital Magdeburg, Magdeburg, GERMANY,* [3]*Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, Messina, ITALY,* [4]*Department of Nuclear Medicine, Hacettepe University, Ankara, TÜRKIYE,* [5]*Department of Nuclear Medicine, Galliera Hospital, Genoa, ITALY,* [6]*Department of Nuclear Medicine, University Hospital Istanbul, Istanbul, TÜRKIYE,* [7]*Department of Nuclear Medicine, Clinical Hospital Center Rijeka, Rijeka, CROATIA,* [8]*Department of Nuclear Medicine, University Hospital Mostar, Mostar, BOSNIA AND HERZEGOVINA,* [9]*Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,* [10]*Department of Nuclear Medicine, University Hospital Mersin, Mersin, TÜRKIYE,* [11]*Department of Nuclear Medicine, University Hospital Frankfurt, Frankfurt, GERMANY,* [12]*Practice of Nuclear Medicine Hanau, Giessen, GERMANY,* [13]*Clinic for Nuclear Medicine and Competence Centerfor Thyroid Diseases, Bellinzona, SWITZERLAND,* [14]*Clinic for Nuclear Medicine and Interdisciplinary Thyroid Center, University Hospital Zürich, Zürich, SWITZERLAND.*

OP-593
The FDG pattern of autonomously functioning thyroid nodules correlates with TSH and histopathology
F. Fiz[1], *G. Bottoni*[1], *M. Massollo*[1], *M. Puntoni*[2], *U. Catrambone*[1], *L. Foppiani*[1], *F. Bertagna*[3], *D. Albano*[3], *P. Trimboli*[4], *A. Piccardo*[1];
[1]*E.O. Ospedali Galliera, Genoa, ITALY,* [2]*Clinical and epidemiological research unit, University Hospital of Parma, Parma, ITALY,* [3]*University of Brescia, Brescia, ITALY,* [4]*Lugano and Mendrisio Regional Hospital, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND.*

OP-594
The contribution of PET/MR in benign malignant nodule separation in thyroid incidentalomas detected in FDG PET/CT imaging
A. Nazari, *S. Sağer, S. Bilgiç, K. Toplutaş, F. Beytur, L. Uslu Beşli, S. Asa, C. Samancı, H. Burçak Sayman, K. Sönmezoğlu;*
Istanbul University-Cerrahpaşa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

OP-595
Utilization of ^{68}Ga-FAPI PET/CT in the Evaluation of Thyroid Nodules with 'Suspected' or 'Malignant' FNAB: Preliminary Results
U. Elboga[1], *G. Maralcan*[2], *M. Bastemir*[2], *E. Sahin*[1], *M. Okuyan*[1], *M. Sokucu*[2], *M. Mutlu*[2], *Y. B. Cayirli*[1], *Y. Z. Celen*[1];
[1]*Gaziantep University, Gaziantep, TÜRKIYE,*
[2]*SANKO University, Gaziantep, TÜRKIYE.*

OP-596
[^{18}F]FDG-PET/CT and Molecular Diagnostics in the Workup of Indeterminate Thyroid Nodules: Complementing Techniques or Waste of Valuable Resources?
E. J. de Koster[1], *L. de Geus-Oei*[2], *H. Morreau*[2], *W. J. G. Oyen*[3], *D. Vriens*[2];
[1]*Radboud University Medical Center, Nijmegen, NETHERLANDS,*
[2]*Leiden University Medical Center, Leiden, NETHERLANDS,*
[3]*Rijnstate Hospital, Arnhem, NETHERLANDS.*

OP-597
Unexpected Images during Parathyroid Scintigraphy
J. Wu, *L. Gong, H. Ying;*
Second Affiliated Hospital, Nanchang University, Nanchang, CHINA.

OP-598
Do analytical parameters influence the sensitivity and specificity of parathyroid scintigraphy in patients with nephrolithiasis?
F. Sebastián Palacid, *M. García Aragón, N. Álvarez Mena, B. Pérez López, M. Alonso Rodriguez, C. Gamazo Laherrán, R. Ruano Pérez;*
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

1210

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 116

Technologists' Oral Presentations 3: Artificial Intelligence and Technical Novelties

OP-599
Analysis Of PET Radiomic Features With Different Reconstruction Algorithms
P. Dwivedi[1], *V. Vajarkar*[1], *S. Choudhury*[2], *A. Jha*[3], *V. Rangarajan*[3];
[1]*Advanced Centre for Treatment Research and Education In Cancer, Mumbai, INDIA,* [2]*Advanced Centre for Treatment Research and Education In Cancer, Mumbai, India, Mumbai, INDIA,* [3]*Tata Memorial Centre, MUMBAI, INDIA.*

OP-600
Occupational radiation exposure of nuclear medicine personnel during administration of [^{177}Lu]Lu-HA-DOTATATE with two different administration devices
S. Woudsma, *C. Mylvaganan-Young, D. M. V. de Vries-Huizing, I. Sutherland-van den Heuvel, M. P. M. Stokkel, M. Sonneborn-Bols, E. A. Aalbersberg;*
Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-601
Estimating attenuation-corrected PET images using GAN from non-attenuation-corrected PET images
K. Nishigami;
Biomedical Science and Engineering, Hokkaido University Graduate School, Sapporo, JAPAN.

OP-602
Introduction of a new dosimetry software for selective internal radiation therapy (SIRT) using Y-90 microspheres in liver tumors and impact on clinical practice
M. Mendes De Carvalho, *M. Da Mota, J. O. Prior, P. Leite Ferreira, N. Schaefer, S. Boughdad;*
CHUV, Lausanne, SWITZERLAND.

OP-603
Validation of the Appliance of a Commercially Available AI-Powered Method for Coronary Calcium Scoring on Non-ECG-Triggered Attenuation Correction CTs Acquired for Myocardial Perfusion PET
L. Does;
Noordwest Ziekenhuisgroep, Alkmaar, NETHERLANDS.

OP-604
Evaluation Of Image Quality Of BSREM Reconstruction Algorithm And Performance Comparison With Conventional Reconstruction Method
P. Dwivedi[1], *V. Sawant*[1], *A. Jha*[2], *V. Rangarajan*[2];
[1]*Advanced Centre for Treatment Research and Education In Cancer, Tata Memorial Centre, Mumbai, INDIA,* [2]*Tata Memorial Centre, MUMBAI, INDIA.*

OP-605
The optimal acquisition time for 123-I-FP-CIT DAT-scan with AnyScan trio SPECT-CT with unique multi-pine-hole collimators
G. Thomsen, *C. Poulsen, S. Olsen, R. de Nijs, L. H. Pinborg, G. M. Knudsen;*
Neurobiology Research Unit 6002, Rigshospitalet, 2100 Copenhagen, DENMARK.

OP-606
Comparing a 360° CZT digital SPECT/CT64 to an Anger camera using a dedicated ^{123}I-Iuflupane phantom
A. Davidsson[1], *P. Norberg*[2], *M. Ressner*[2];
[1]*Department of Clinical Physiology, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, SWEDEN,* [2]*Department of Medical Radiation Physics, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, SWEDEN.*

OP-607
Experience with a New Brain-Dedicated PET Scanner
A. Delgado-Cano[1], *P. Bascuñana*[1], *P. Nespral*[1], *C. Morera-Ballester*[2], *G. Gonzalez-Pavon*[2], *J. Carreras-Delgado*[1], *M. Cabrera-Martín*[1];
[1]*Nuclear Medicine Department, health research institute of Hospital Clinico San Carlos, Madrid, SPAIN,* [2]*General equipment for medical imaging, S.A., Valencia, SPAIN.*

1301

Tuesday, October 18, 2022, 09:45 - 11:15

Auditorium

CME 10 - Oncology & Theranostics + Physics Committee: Quantitative SPECT, PET and Standardisation

OP-608
Quantitative SPECT
J. Dickson;
University College London Hospital, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-609
Quantitative PET
A. Larsson Strömvall;
Norrlands universitetssjukhus Umeå universitet, Department of Radiation Sciences, Umeå, SWEDEN.

OP-610
Clinical Use Cases
L.-F. de Geus-Oei;
Leiden University Medical Center and Professor in Molecular Imaging, Leiden, NETHERLANDS.

1302

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 112 (Arena)

Debate 3 - Neuroimaging Committee: Imaging Brain Tumours - Is PET Required or only a Fancy Option?

OP-611
MRI is Sufficient in the Management of Patients with Brain Tumours
M. Smits + *I. Pruis, S. Derks;*
Erasmus MC, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

OP-612
PET Imaging Adds Value to MRI in Patients with Brain Tumours
N. Galldiks + *P. Lohmann, J. M. Werner;*
Research Center Jülich, Institute of Neuroscience and Medicine, Juelich, GERMANY.

1303

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 113

LIPS Session 10 - Inflammation & Infection Committee: [^{18}F]FDG PET/CT Treatment Response Assessment in Inflammatory Diseases
Interactive Session

OP-614
The Role of PET in Treatment Monitoring of Large Vessel Vasculitis and Retroperitoneal Fibrosis
L.C. Gormsen;
Aarhus University Hospital, Department of Nuclear Medicine and PET-Centre, Aarhus, DENMARK.

OP-615
Treatment Response Assessment in Inflammatory Bowel Disease using PET
P. Lovinfosse;
University Hospital of Liège, Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, Liège, BELGIUM.

OP-616
Treatment Response Assessment by PET in Interstitial Lung Diseases
L. Leccisotti;
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Nuclear Medicine Unit, Rome, ITALY.

1304

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 114

Joint Symposium 5 - Physics + Oncology & Theranostics / ESTRO Committee: Imaging for Radiotherapy Applications

OP-617
Advances of PET Combined with Anatomical Imaging in Radiation Oncology
E. Troost;
Chair of Department of Radiotherapy and Radiation Oncology, University Hospital Carl Gustav Carus, Dresden, GERMANY.

OP-618
Practical Implementation of Nuclear Medicine Imaging in Radiotherapy
F.L. Andersen;
Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen, DENMARK.

OP-619
Challenges of Combining Molecular Radiotherapy and External Beam Radiation Therapy
J. Costanzo;
National Institute of Health and Medical Research (INSERM), Montpellier Cancer Research Institute, Montpellier, FRANCE.

1305

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 211

Cutting Edge Science Track - TROP Session: Radiobiology

OP-620
Immunological effects drive efficacy differences of alpha vs. beta radiopharmaceutical agents in prostate cancer
R. Hernandez, *C. A. Ferreira, H. Potluri, C. Massey, Z. Rosenkrans, J. J. Grudzinski, C. Choi, E. Aluicio-Sarduy, J. Engle, J. Weichert, D. McNeel;*
University of Wisconsin-Madison, Madison, WI, UNITED STATES OF AMERICA.

OP-621
DNA damage repair in PBMCs after simultaneous internal ex vivo irradiation with [^{223}Ra]RaCl2and [^{177}Lu]LuCl3
I. Strobel[1], *H. Scherthan[2], J. Müller[2], S. Schumann[1], A. K. Buck[1], M. Port[2], M. Lassmann[1], U. Eberlein[1];*
[1]Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY, [2]Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Munich, GERMANY.

OP-622
Cellular Dosimetry from the ^{225}Ac Decay Chain: Impact of Progeny Internalization and Migration
H. Koniar[1,2], *C. Miller[2,3], A. Rahmim[2,3,4], P. Schaffer[1,4,5], C. Uribe[4,6];*
[1]Life Sciences Division, TRIUMF, Vancouver, BC, CANADA, [2]Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, [3]Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, [4]Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, [5]Department of Chemistry, Simon Fraser University, Vancouver, BC, CANADA, [6]Functional Imaging, BC Cancer, Vancouver, BC, CANADA.

OP-623
A multi-region model of a mouse kidney for preclinical internal dosimetry of beta- and alpha-particle emitting radionuclides
C. Saldarriaga Vargas[1,2], *L. Struelens[1], M. D'Huyvetter[2], V. Caveliers[2], P. Covens[2];*
[1]Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, [2]Vrije Universiteit Brussel, Brussels, BELGIUM.

OP-624
Biological response of cancer-associated fibroblasts (CAF) to Targeted Radionuclide Therapy of pancreatic cancer microenvironment
L. Ordas[1], *M. D'Huyvetter[2], T. Lahoutte[2], S. Poty[1], J. Pouget[1];*
[1]Institut de Recherche en Cancérologie, Montpellier, FRANCE, [2]Precirix, Brussels, BELGIUM.

OP-625
Absorbed dose microdistribution of ^{177}Lu and ^{225}Ac in a model of cancer associated fibroblasts
J. Tranel[1], *S. Palm[2], S. A. Graves[3], F. Y. Feng[1], T. A. Hope[1];*
[1]University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA, [2]University of Gothenburg, Gothenburg, SWEDEN, [3]University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA.

OP-626
Preclinical characterization of ^{177}Lu-DOTATATE binding and internalization
S. Lundsten[1,2], *H. Berglund[1], J. Buijs[1,2], M. Nestor[1], S. Bondza[1,2];*
[1]Uppsala University, Uppsala, SWEDEN, [2]Ridgeview Instruments, Uppsala, SWEDEN.

OP-627
Effect of Tumor Receptor Density on Time Integrated Activity of Radiopharmaceutical Therapy in Tumors via Physiologically based Pharmacokinetic Modeling
N. Shakourifar[1], *M. Soltani[1,2,3], F. Moradi Kashkooli[1], B. Saboury[4], A. Rahmim[4,5];*
[1]K. N. Toosi University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, [2]Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, CANADA, [3]Centre for Biotechnology and Bioengineering (CBB), University of Waterloo, Waterloo, ON, CANADA, [4]Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, [5]Departments of Radiology and Physics, University of British Columbia, Vancouver, BC, CANADA.

OP-628
In-vitro dosimetry of Phosphorus-32 patches for radionuclide therapy of superficial skin diseases
P. Gupta[1], *S. P. Lochab[2], G. P. Bandopadhyaya[1], R. Kumar[1], C. S. Bal[1];*
[1]AIIMS, New Delhi, INDIA, [2]Inter Univercity Accelerator Centre, New Delhi, INDIA.

1306

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 117

Clinical Oncology Track - TROP Session: Lymphoma

OP-629
Total Metabolic Tumor Volume And Tumor Dissemination Calculated From PET/CT Scan Before First Line Therapy Are Predictors Of Outcome In Patients With Follicular Lymphoma
R. Durmo[1,2], *L. Guerra[3], S. Chauvie[4], S. Peano[5], A. Franceschetto[6], F. Bergesio[4], F. Fallanca[7], A. Pinto[8], C. Ghiggi[9], A. Pulsoni[10], M. Merli[11], L. Farina[11], M. Tani[12], C. Boccomini[13], G. Musuraca[14], B. Falini[15], F. Ballerini[16], P. M. Stefani[17], S. A. M. Bolis[18], G. Pietrantuono[8], M. Manni[19], L. Marcheselli[20], M. Federico[21], S. Luminari[1], A. Versari[1];*
[1]AUSL-IRCCS of Reggio Emilia, Reggio Emilia, ITALY, [2]PhD program in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, ITALY, [3]ASST Monza Ospedale S. Gerardo, Monza, ITALY, [4]Department of Medical Physisc, Santa Croce e Carle Hospital, Cuneo, ITALY, [5]Department of Nuclear Medicine, Santa Croce e Carle Hospital, Cuneo, ITALY, [6]Department of Oncology and Hematology, Modena Cancer Center, Unit of Nuclear Medicine, University of Modena and Reggio Emilia, Modena, ITALY, [7]Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY, [8]Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, ITALY, [9]Hematology and Transplant Center Division, IRCCS San Martino Hospital, Genoa, ITALY, [10]Dipartimento di Biotecnologie Cellulari ed Ematologia, Sapienza Università di Roma, Rome, ITALY, [11]University Hospital Ospedale di Circolo e Fondazione Macchi, ASST Settelaghi, Varese, ITALY, [12]Ospedale Civile S Maria delle Croci, Azienda Unità Sanitaria Locale Ravenna, Ravenna, ITALY, [13]A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia, Turin, ITALY, [14]Department of Hematology, IRCCS -Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, ITALY, [15]Institute of Hematology and CREO (Center for Hemato-Oncological Research), Ospedale S. Maria della Misericordia, Perugia, ITALY, [16]University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'Oncologia, Genoa, ITALY, [17]Hematology, General Hospital Ca' Foncello, Treviso, ITALY, [18]SC di Ematologia - ASST MONZA, Monza, ITALY, [19]Hematology Unit, Azienda Unità Sanitaria Locale IRCCS, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, ITALY, [20]Fondazione Italiana Linfomi Onlus, Modena, ITALY, [21]CHIMOMO Department, University of Modena and Reggio Emilia, Modena, ITALY.

OP-630
Metabolic Tumor Volume for Outcome Prediction in Patients with Large B-Cell Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Treatment
C. Voltin[1], *P. Gödel[1], L. Beckmann[1], J. Heger[1], C. Kobe[1], N. Kutsch[1], P. Borchmann[1], M. Dietlein[1], K. Herrmann[2], M. Stelljes[3], K. Rahbar[3], G. Lenz[3], H. C. Reinhardt[2], M. Teichert[2], R. Noppeney[2], J. C. Albring[3], R. Seifert[2], B. von Tresckow[2], S. Floßdorf[2], C. Hanoun[2];*
[1]University Hospital Cologne, Cologne, GERMANY, [2]University Hospital Essen, Essen, GERMANY, [3]University Hospital Münster, Münster, GERMANY.

OP-631
CAR-T therapy response assessment with ^{18}F-FDG PET/CT in Non-Hodgkin Lymphoma (NHL): Simplified LYRIC criteria (sLYRIC) proposal
S. Casanueva Eliceiry[1], *A. Rivas[2], S. Rodriguez[3], N. Martinez[2], V. Ortiz[2], J. Delgado[2], A. Fritsch[1], M. Tormo[1], E. Giné[2,4,5], A. López-Guillermo[2,4,5], X. Setoain[1,6,7];*
[1]Department of Nuclear Medicine, Hospital Clínic Barcelona, Barcelona, SPAIN, [2]Department of Hematology, Hospital Clínic Barcelona, Barcelona, SPAIN, [3]Department of Radiology, Hospital Clínic Barcelona, Barcelona, SPAIN, [4]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN, [5]Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, SPAIN, [6]University of Barcelona, Barcelona, SPAIN, [7]de Investigación Biomédica en Red de Cáncer (CIBERBBN), Madrid, SPAIN.

OP-632
May baseline ^{18}F-FDG PET/CT parameters predict the time to first treatment in follicular lymphoma patients in a watch-and-wait approach?
S. Casanueva Eliceiry*[1], *P. Mozas*[2], S. Rodriguez[3], N. Sánchez[1], M. Tormo[1], A. Ninerola[1], A. Rivero[2], A. Rivas-Delgado[2], J. Gonzalo Correa[2], A. Bataller[2], E. Giné[2,4,5], L. Magnano[2,4,5], M. Simó[6], A. López-Guillermo[2,4,5], X. Setoain[1,7,8];*
[1]Department of Nuclear Medicine, Hospital Clínic Barcelona, Barcelona, SPAIN, [2]Department of Hematology, Hospital Clínic Barcelona, Barcelona, SPAIN, [3]Department of Radiology, Hospital Clínic Barcelona, Barcelona, SPAIN, [4]Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, SPAIN, [5]Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, SPAIN, [6]Nuclear Medicine Department, Hospital Universitari Vall d'Hebron, Barcelona, SPAIN, [7]University of Barcelona, Barcelona, SPAIN, [8]Centro de Investigación Biomédica en Red de Cáncer (CIBERBBN), Madrid, SPAIN.
(shared first authors)*

OP-633
The prognostic value of quantitative parameters of ^{18}F-FDG PET/CT imaging for extranodal NK/T cell lymphoma
T. Yuan[1,2], *Y. Zhang[3], M. Wei[1], X. Chen[1], X. Lin[1], X. Wang[1];*
[1]Peking University Cancer Hospital & Institute, Beijing, CHINA, [2]Peking University International Hospital, Beijing, CHINA, [3]Beijing Hospital, Beijing, CHINA.

OP-634
Baseline ^{18}F-FDG PET/CT radiomics in classical Hodgkin's Lymphoma: the predictive role of the largest and the hottest lesions
E. Triumbari[1,2], *R. Gatta[3,4,5], E. Maiolo[6], A. Cuccaro[7], M. De Summa[8], A. Collarino[9], L. Boldrini[5], M. E. Mayerhoefer[10,11], S. Hohaus[6,12], D. Morland[13], L. Nardo[2], S. Annunziata[9];*
[1]Section of Nuclear Medicine, Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY, [2]Department of Radiology, UC Davis, Sacramento, CA, UNITED STATES OF AMERICA, [3]Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ITALY, [4]Department of Oncology, Lausanne University Hospital, Lausanne, SWITZERLAND, [5]Radiotherapy Unit, Radiomics, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY, [6]Hematology Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY, [7]Hematology Unit, Center for Translational Medicine, Azienda USL Toscana NordOvest, Livorno, ITALY, [8]Medipass S.p.a. Integrative Service PET/CT–Radiofarmacy TracerGLab, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY, [9]Nuclear Medicine Unit, TracerGLab, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico

Universitario A.Gemelli IRCCS, Rome, ITALY, [10]Division of General and Pediatric Radiology, Department of Biomedical Imaging and ImageGuided Therapy, Medical University of Vienna, Vienna, AUSTRIA, [11]Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA, [12]Hematology Section, Department of Radiological Sciences and Hematology, Università Cattolica del Sacro Cuore, Rome, ITALY, [13]Nuclear Medicine Department, Institut Godinot, Reims, FRANCE.

OP-635

Added prognostic value of 18FFDG PET/CT Imaging Texture Analysis in the characterisation of refractoriness of Bulky Mediastinal Hodgkin Lymphoma

E. Abenavoli[1], *F. Linguanti*[1], *F. Mungai*[2], *L. Nassi*[3], *M. Palazzo*[3], *I. Romano*[3], *B. Puccini*[3], *A. Vannucchi*[3], *R. Sciagrà*[4], *V. Berti*[4]; [1]*Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria Careggi, Firenze, ITALY,* [2]*Department of Radiology, Azienda Ospedaliero-Universitaria Careggi, L, Firenze, ITALY,* [3]*Hematology Department, Azienda Ospedaliero-Universitaria Careggi, Firenze, ITALY,* [4]*Nuclear Medicine Unit, Experimental and Clinical Biomedical Sciences Department "Mario Serio", AOU Careggi, Firenze, ITALY.*

OP-636

Baseline 18F-FDG cerebellum/liver index as a prognostic factor in diffuse large B-cell lymphoma: validation on RT3 multicentric cohort

D. Morland[1,2,3], *F. Godard*[4], *E. Triumbari*[2], *C. Portugues*[5], *L. Chartier*[5], *R. Ricci*[6], *P. Blanc-Durand*[7], *E. Itti*[7], *T. Lamy de la Chapelle*[8], *C. Copie-Bergman*[9], *A. Traverse-Glehen*[10], *A. Delmer*[11], *D. Papathanassiou*[1,12,3], *C. Haioun*[13], *F. Jardin*[14], *E. Durot*[11]; [1]*Médecine Nucléaire, Institut Godinot, Reims, FRANCE,* [2]*TracerGLab, Fondazione Policlinico Universitario A. Gemelli, Rome, ITALY,* [3]*CReSTIC EA 3804, Université de Reims Champagne-Ardenne, Reims, FRANCE,* [4]*Médecine Nucléaire, Centre Georges-François Leclerc, Dijon, FRANCE,* [5]*Biostatistiques, LYSARC, Centre Hospitalier Lyon-Sud, Pierre Bénite, FRANCE,* [6]*Département d'imagerie, LYSARC, LYSA-IM, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, FRANCE,* [7]*Médecine Nucléaire, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, FRANCE,* [8]*Hématologie Clinique, CHU de Rennes, Rennes, FRANCE,* [9]*Département de Pathologie, Hôpitaux Universitaires Henri Mondor, INSERM U955, AP-HP, Créteil, FRANCE,* [10]*Département de Pathologie, Hospices civils de Lyon/Université Lyon 1, Centre Hospitalier Lyon Sud, Pierre Bénite, FRANCE,* [11]*Hématologie Clinique, CHU de Reims, Reims, FRANCE,* [12]*Laboratoire de Biophysique, Université de Reims Champagne-Ardenne, Reims, FRANCE,* [13]*Unité Hémopathies Lymphoïdes, Hôpitaux Universitaires Henri Mondor, AP-HP, Créteil, FRANCE,* [14]*Hématologie, Centre Henri Becquerel, Rouen, FRANCE.*

OP-637

Metabolic Tumor Volume Improves Outcome Prediction in Untreated Mantle Cell Lymphoma

V. K. J. Vergote[1], *G. Verhoef*[1], *A. Janssens*[1], *F. Woei-a-jin*[1], *A. Laenen*[2], *T. Tousseyn*[1], *D. Dierickx*[1], *C. M. Deroose*[1]; [1]*University Hospitals Leuven, Leuven, BELGIUM,* [2]*Biostatistics and Statistical Bioinformatics Center, Leuven, BELGIUM.*

1307

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 115

Clinical Oncology Track - TROP Session: Prostate Staging

OP-638

Complimentary role of ^{68}Ga-GRPR PET/CT and ^{68}Ga-PSMA PET/CT in initial diagnosis of prostate cancer

Y. Tang, *M. Zhou, J. Li, B. Chen, W. Rao, S. Hu; Xiangya Hospital Central South University, Changsha, CHINA.*

OP-639

Predictive value of extra prostatic disease detection by PSMA PET for BCR free survival in patient by radical prostatectomy: follow up analysis of a multicenter prospective phase 3 imaging trial

L. Djaileb[1,2], *W. Armstrong*[1], *D. Thompson*[3], *K. Nguyen*[1], *A. Gafita*[1], *A. Farolfi*[1], *M. Hotta*[1], *A. Rajagopal*[3], *R. Juarez*[3], *M. Cooperberg*[3], *P. Carroll*[3], *S. Washington*[3], *J. Czernin*[1], *R. Reiter*[1], *T. Hope*[3], *J. Calais*[1]; [1]*Ahmanson Translational Theranostics Division, University of California, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Univ. Grenoble Alpes, INSERM, CHU Grenoble Alpes, nuclear medicine department, Grenoble, FRANCE,* [3]*University of California, San Francisco, CA, UNITED STATES OF AMERICA.*

OP-640

Multiparametric MRI and [^{18}F]PSMA-1007 PET to detect local prostate cancer: a prospective comparative study with correlation to histopathology

B. Privé, *B. Israël, M. J. Janssen, M. M. Van der Leest, M. De Rooij, M. G. Schilham, S. M. Peters, P. Zamecnik, J. G. Bomers, W. A. Van Gemert, M. Gotthardt, M. Sedelaar, J. O. Barentsz, I. M. Van Oort, J. Nagarajah; Radboudumc, Nijmegen, NETHERLANDS.*

OP-641

A prospective head-to-head comparison of [^{68}Ga]Ga-P16-093 and [^{68}Ga]Ga-PSMA-617 PET/CT in patients with primary prostate cancer

G. Wang[1], *L. Li*[2], *W. Yan*[1], *L. Zhu*[2], *H. Kung*[3], *Z. Zhu*[1]; [1]*Peking Union Medical College Hospital, Beijing, CHINA,* [2]*Beijing Normal University, Beijing, CHINA,* [3]*University of Pennsylvania, Philadelphia, PA, UNITED STATES OF AMERICA.*

OP-642

Association Between ^{68}Ga-PSMA PET/MRI and Circulating Biomarkers in High-Risk Prostate Cancer: an Explorative Study

S. Ghezzo[1,2], *B. Mattorre*[3], *L. Cogrossi*[1,3], *A. Samanes Gajate*[2], *E. Preza*[2], *V. Cucchiara*[1,4,5], *P. Mapelli*[2], *C. Bezzi*[1,2], *S. Mongardi*[1], *A. Elia*[6], *A. Alimonti*[6], *A. Briganti*[1,4,5], *F. De Cobelli*[1,7], *P. Scifo*[2], *M. Bellone*[1,3], *L. Gianolli*[2], *M. Picchio*[1,2]; [1]*Vita-Salute San Raffaele University, Milan, ITALY,* [2]*Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [3]*Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan, ITALY,* [4]*Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [5]*Division of Experimental Oncology, URI, Urological Research Institute, Milan, ITALY,* [6]*Cancer Immunotherapy, Institute of Oncology Research, Bellinzona, SWITZERLAND,* [7]*Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY.*

OP-643

^{99m}Tc-PSMA-SPECT/CT is a valuable alternative to ^{68}Ga-PSMA-PET/CT in prostate cancer patients

K. Liepe[1], *M. Baehr*[1], *T. Hoang*[2]; [1]*Klinikum Frankfurt, Frankfurt (Oder), GERMANY,* [2]*Independent statistician, Duesseldorf, GERMANY.*

OP-644

Phase I evaluation of [^{99m}Tc]Tc-maSSS-PEG2-RM26 for imaging of GRPR expression

A. Orlova[1], *A. Rybina*[2], *N. Lushnikova*[2], *A. Doroshenko*[2], *E. Usynin*[2], *J. Sörensen*[1], *A. Abouzayed*[1], *S. S. Rinne*[1], *V. Tolmachev*[1], *V. Chernov*[2]; [1]*Uppsala University, Uppsala, SWEDEN,* [2]*TNIMC, Tomsk, RUSSIAN FEDERATION.*

OP-645

PSMA-density predicts pathological and oncological outcomes in patients submitted to 18F-PSMA-1007 PET/CT for the primary staging of unfavorable intermediate and high-risk prostate cancer

M. Donegani[1], *F. Ambrosini*[2], *G. Mantica*[2], *N. Piol*[3], *A. Miceli*[1], *F. D'Amico*[1], *M. Riondato*[1], *T. Di Raimondo*[1], *F. Lanfranchi*[1], *S. Raffa*[1], *S. Chiola*[1], *B. Spina*[3], *N. Suardi*[4], *S. Morbelli*[1], *M. Borghesi*[2], *P. Nozza*[3], *R. Fiocca*[3], *G. Sambuceti*[1], *C. Terrone*[2], *M. Bauckneht*[1]; [1]*Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,* [2]*Department of Urology, Policlinico San Martino Hospital, University of Genoa, Genoa, ITALY,* [3]*Department of Pathology, Policlinico San Martino Hospital, University of Genoa, Genoa, ITALY,* [4]*Department of Urology, Spedali Civili of Brescia, Brescia, ITALY.*

OP-646

Effects of furosemide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study

M. Donswijk[1], *M. Wondergem*[1], *L. de Wit - van der Veen*[1], *N. Bruin*[1], *P. van Leeuwen*[1], *H. van der Poel*[1,2], *M. Stokkel*[1], *W. Vogel*[1]; [1]*Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS,* [2]*Amsterdam University Medical Center, Amsterdam, NETHERLANDS.*

1308

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 212

Cardiovascular Committee - TROP Session: Heart Failure and Amyloidosis

OP-647

Assessment of Incidental Cardiac Uptake in Bone Scintigraphy across Spain. ECCINGO Study

L. Mohamed Salem[1], *F. De Haro del Moral*[2], *S. Aguadé Bruix*[3], *M. Tabuenca Mateo*[4], *M. Tamayo Alonso*[5], *D. Primiano*[6], *P. Tarilonte*[6]; [1]*Universitary Clinical Hospital Virgen de la Arrixaca, El Palmar, Murcia, SPAIN,* [2]*Hospital Puerta de Hierro, Majadahonda, Madrid, SPAIN,* [3]*Universitary Hospital Vall d'Hebron, Barcelona, SPAIN,* [4]*Universitary Hospital 12 de Octubre, Madrid, SPAIN,* [5]*Universitary Hospital of Salamanca, Salamanca, SPAIN,* [6]*Pfizer SLU, Madrid, SPAIN.*

OP-648

Predictors of super response to cardiac resynchronization therapy in patients with nonischemic heart failure

T. Atabekov, *A. Mishkina, R. Batalov, S. Sazonova, S. Krivolapov, V. Saushkin, K. Zavadovsky, S. Popov; Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.*

OP-649

[^{99m}Tc]Tc-DPD Scintigraphy Associating Semi-Quantitative Methods for the Diagnosis of Cardiac Amyloidosis: Experience in an Endemic Area

J. Amaya[1], *N. Orta*[1,2], *S. Rubi*[1,2], *T. Ripoll*[3,2], *F. Cepa*[1], *E. Fortuny*[1,2], *J. Pons*[1,2], *T. Bosch*[1,2], *C. Medina*[1], *A. Cherino*[1], *S. Chamizo*[1], *M. Valiente*[1], *B. Luna*[1], *L. Nieto*[1], *C. Sampol*[1,2], *C. Peña*[1,2]; [1]*Hospital Universitario Son Espases, Palma de Mallorca, SPAIN,* [2]*Instituto de Investigación Sanitaria Illes Balears (IdISBa)., Palma de Mallorca, SPAIN,* [3]*Hospital Universitario Son Llatzer, Palma de Mallorca, SPAIN.*

OP-650

Regression of Cardiac Bone-Tracer Uptake in Patients with Hereditary Transthyretin Amyloidosis after One Year Treatment with Patisiran. An early Marker of Treatment Response?

H. Tingen[1], *A. Tubben*[1], *J. Bijzet*[1], *P. van der Meer*[1], *M. P. van den Berg*[1], *E. J. Houwerzijl*[1], *P. A. van der Zwaag*[1], *B. P. C. Hazenberg*[1], *R. H. J. Slart*[1,2], *H. L. A. Nienhuis*[1]; [1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*University of Twente, Enschede, NETHERLANDS.*

OP-651

Quantitative assessment of myocardial perfusion by dynamic SPECT in patients with acute coronary syndrome

O. Mochula, *A. Mochula, A. Maltseva, A. Sulejmanova, K. Zavadovsky; Cardiology Research Institute, TNIMC, Tomsk, RUSSIAN FEDERATION.*

OP-652

Heart-to-femoral diaphysis ratio: an alternative method to differentiate cardiac transthyretin amyloidosis from light chain amyloidosis

A. Roteta Unceta Barrenechea[1,2], *M. Parra Rina*[1], *Y. Saker Diffalah*[1], *L. Tardin Cardoso*[1], *D. Nogueira Souto*[1], *P. Razola Alba*[1], *M. Delgado Castro*[1], *T. Escalera Temprado*[1], *M. Aibar Arregui*[3,2], *J. Melero Polo*[3,2], *P. Revilla Marti*[3,2], *A. Gracia Gutierrez*[4,2], *E. Bueno Juana*[3,2], *I. Moreno Gazquez*[3,2], *S. Menao Guillen*[3,2], *R. Perez Palacios*[5,2], *L. Abengochea Quílez*[2], *S. Atienza Ayala*[3,2], *C. Lahuerta Pueyo*[3,2], *A. Andres Gracia*[1,2]; [1]*UCMHMNA - Clinic Hospital "Lozano Blesa", Zaragoza, SPAIN,* [2]*Instituto de Investigacion Sanitaria de Aragon, Zaragoza, SPAIN,* [3]*Clinic Hospital "Lozano Blesa", Zaragoza, SPAIN,* [4]*Hospital de la Defensa de Zaragoza, Zaragoza, SPAIN,* [5]*Universidad de Zaragoza, Zaragoza, SPAIN.*

OP-653

Noninvasive Screening Of Transthyretin Cardiac Amyloidosis In Patients With Spinal Stenosis

A. Padilla Bermejo[1], *M. Negreira Caamaño*[2], *A. M. García Vicente*[1], *M. A. Ramírez Huaranga*[3], *D. Castro Corredor*[4], *Á. Plasencia Ezaine*[3], *P. Otero Fernández*[5], *J. Piqueras Flores*[2], *Á. Soriano Castrejón*[1]; [1]*Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [2]*Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [3]*Pain Unit, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [4]*Rheumatology Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [5]*Neurosurgery Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN.*

OP-654
Quantification of right ventricular amyloid with ^{99m}Tc-DPD in patients with transthyretin amyloidosis: Comparison with Cardiac MR and biomarkers
M. Zhao[1,2], *R. Calabretta*[2], *X. Li*[2], *M. Hacker*[2];
[1]*Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA,* [2]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.*

OP-655
The Value of Left Ventricle Regional Dyssynchrony as Cardiac Resynchronization Therapy Response Predictors in Patients with Heart Failure
K. Zavadovsky, *A. Mishkina, T. Atabekov, V. Saushkin, S. Sazonova, S. Popov;*
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

1401

Tuesday, October 18, 2022, 11:30 - 13:00

Auditorium

Plenary 4: Superfluous, Controversial and Luxury Issues in Nuclear Medicine

OP-656
Introduction by Chairpersons

OP-657
Really, More New Radiolabelled Tracers?
S. Terry*;*
King's College London, School of Biomedical Engineering & Imaging Sciences, London, UNITED KINGDOM.

OP-658
Nuclear Neurology - Clinical Reality or Eternal Promise?
S. Morbelli*;*
San Martino Hospital, Department of Health Sciences, University of Genoa, Genoa, ITALY.

OP-659
Theranostics - Treat or Trick?
J.J. Cerci*;*
Quanta – Diagnostic and Therapy, PET/CT Department, Curitiba, BRAZIL.

OP-660
Personalized Medicine - Every Man His Own PSMA!
H.D. Zacho*;*
Aalborg University Hospital, Department of Clinical Medicine, Aalborg, DENMARK.

OP-661
Dosimetry - Necessary or Redundant?
S. Peters*;*
Radboudumc, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

OP-662
Radiomics - Way to the Future or Useless Fancy Name?
X. Boulvard-Chollet*;*
Centro Investigación Biomédica de La Rioja (CIBIR), Department of Nuclear Medicine, Logroño (La Rioja), SPAIN.

OP-663
Summary by Chairpersons

1501

Tuesday, October 18, 2022, 15:00 - 16:30

Auditorium

CME 11 - Neuroimaging Committee: Molecular Imaging and Fluid Biomarkers in Alzheimer's Disease - A Nice Couple

OP-664
Fluid markers in AD - Is it a Revolution?
M. Otto*;*
Universitätsklinikum Martin Luther Universität Halle-Wittenberg Klinik und Poliklinik für Neurologie, Halle, GERMANY.

OP-665
PET and Fluid Markers Compared
A. Pichet Binette*;*
Lund University, Lund, SWEDEN.

OP-666
From a Comparison to an Integrated Algorithm
N. Franzmeier*;*
Institute for Stroke and Dementia Research, LMU University Hospital, Alzheimer's Disease Neuroimaging Group, Munich, GERMANY.

1502

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 112 (Arena)

Debate 4 - Cardiovascular Committee: Myocardial Perfusion Imaging with PET – Ready for Clinical Use?

OP-667
Yes - Ready for Clinical Use
J. Knuuti*;*
Turku University Hospital, Turku PET Centre, Turku, FINLAND.

OP-668
No - Not Ready for Clinical Use
F. Bengel*;*
Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover, GERMANY.

OP-669
L. Imbert*;*
CHU Nancy Hopital Brabois, Nuclear Medicine Department, Vandoeuvre Les Nancy, FRANCE.

1503

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 113

LIPS Session 11 - Oncology & Theranostics Committee: Tricky Cases in Prostate Imaging
Interactive Session

OP-670
PSMA Characteristics and Immunohistochemistry Expression
M. Castillo-Martin*;*
Champalimaud Foundation, Pathology, Lisbon, PORTUGAL.

OP-671
PSMA Radiopharmaceuticals, Physiological Distribution and Pathologic Uptake
P. Pilkington Woll*;*
Department of Nuclear Medicine, Hospital Universitario 12 de Octubre, Madrid, SPAIN.

OP-672
PSMA Uptake in Non-Prostate Tumours
F. Kleiburg*;*
Leiden University, Radiology Department, Leiden, NETHERLANDS.

OP-673
PSMA Uptake in Non-Oncologic Entities
L. Vercellino*;*
Hôpital Saint-Louis, Nuclear Medicine, Paris, FRANCE.

OP-674
Discussion

1504

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 114

Joint Symposium 6 - Oncology & Theranostics Committee / ESMO: Integrated Theranostics

OP-675
Hot-Hot Theranostics (e.g. Iodine, Dotatoc, PSMA, FAPI)
A.K. Buck*;*
Universitätsklinikum Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-676
Hot „Cold" Theranostics (e.g. Trastuzumab, Bevacizumab, Pembrolizumab, Atezolizumab, TGFβ-antibody)
A. Brouwers*;*
Universitair Medisch Centrum Groningen, Department of Nuclear Medicine, Groningen, NETHERLANDS.

OP-677
Therapy Response Monitoring of Immunotherapy
C. Caramella*;*
Hopital Marie Lannelongue, Imagerie medicale, Paris, FRANCE.

OP-678
Summary by Chairpersons

1505

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 211

Cutting Edge Science Track - TROP Session: Advanced Data Analysis

OP-679
Metabolic fingerprinting: Towards multiorgan PET-driven systemic analysis for early-stratification of lung cancer patients with and without cachexia
L. Shiyam Sundar[1], *E. M. Abenavoli*[2], *T. Beyer*[1], *D. Ferrara*[1], *S. Gruenert*[1], *M. Hacker*[1], *S. Hesse*[3], *L. Hofmann*[3], *S. H. Holm*[4], *P. Sandoe*[4], *R. Sciagra*[2], *H. Wirtz*[3], *J. Yu*[1], *A. Frille*[3], *O. Sabri*[3];
[1]*Medical university of Vienna, Vienna, AUSTRIA,* [2]*AOU Careggi, Florence, ITALY,* [3]*University Hospital Leipzig, Leipzig, GERMANY,* [4]*University of Copenhagen, Copenhagen, DENMARK.*

OP-680
ENHANCE-PET: Exploring the human functional connectome using total-body [18F]FDG-PET imaging
D. Ferrara[1], *R. D. Badawi*[2], *B. Spencer*[3], *S. R. Cherry*[3], *M. Hacker*[4], *T. Beyer*[1], *L. K. Shiyam Sundar*[1];
[1]*Quantitative Imaging and Medical Physics (QIMP) Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Radiology, UC Davis, Davis, CA, UNITED STATES OF AMERICA,* [3]*Department of Biomedical Engineering, UC Davis, Davis, CA, UNITED STATES OF AMERICA,* [4]*Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.*

OP-681
Towards holistic assessment of human physiology: Fully-automated construction of tracer independent total-body PET/CT normative database using diffeomorphisms
S. Gutschmayer[1], *O. Muzik*[2], *M. Hacker*[3], *D. Ferrara*[1], *S. Zuehlsdorff*[4], *H. Newiger*[5], *T. Beyer*[1], *L. Shiyam Sundar*[1];
[1]*QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Wayne State University, Department of Pediatrics, Detroit, MI, UNITED STATES OF AMERICA,* [3]*Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,* [4]*Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA,* [5]*Siemens Healthcare GmbH, Erlangen, GERMANY.*

OP-682
Fast algorithms for motion correction (FALCON) for fully-automated motion correction of dynamic total-body 18F-FDG PET/CT studies
L. Shiyam Sundar[1], *S. Gutschmayer*[1], *A. Calabro*[2], *A. Selfridge*[2], *J. Yu*[1], *L. Nardo*[2], *Y. Abdelhafez*[2], *S. R. Cherry*[2], *B. A. Spencer*[2], *R. D. Badawi*[2], *T. Beyer*[1], *O. Muzik*[3];
[1]*Medical university of Vienna, Vienna, AUSTRIA,* [2]*University of California-Davis, Davis, CA, UNITED STATES OF AMERICA,* [3]*Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA.*

OP-683
Data-driven gating-based Auto Attenuation Mismatch Correction for Whole-body PET
K. Su[1], *R. Johnsen*[1], *J. Bouhnik*[2], *T. Pan*[3];
[1]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA,* [2]*GE Healthcare, Haifa, ISRAEL,* [3]*Department of Imaging Physics, M. D. Anderson Cancer Center, University of Texas, Houston, TX, UNITED STATES OF AMERICA.*

OP-684
Clinical validation of a population-based input function for 20-min dynamic whole-body ^{18}FDG multiparametric PET imaging
A. H. Dias[1], *D. Pigg*[2], *A. M. Smith*[2], *V. Shah*[2], *L. C. Gormsen*[1,3], *O. L. Munk*[1,3];
[1]*Aarhus University Hospital, Aarhus, DENMARK,* [2]*Siemens Medical Solutions USA, Inc, Knoxville, TN, UNITED STATES OF AMERICA,* [3]*Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK.*

OP-685
Comparison of static and dynamic whole-body PET/CT acquisitions with ultra-low-dose and standard-dose [18F] FDG injections in healthy volunteers and lung cancer patients
D. Ferrara[1], *T. Beyer*[1], *L. K. Shiyam Sundar*[1], *M. Hacker*[2], *W. Langsteger*[2], *R. Bartosch*[2], *I. Leitinger*[2], *H. Ibeschitz*[2], *B. K. Geist*[2], *K. Kluge*[2], *J. Yu*[2], *I. Rausch*[1];
[1]*Quantitative Imaging and Medical Physics (QIMP) Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA.*

OP-686
Repeatability of Pixelwise and Regional Analysis of Glucose Uptake Rates Measured by Dynamic Whole-body ^{18}F-FDG-PET/MR in T2DM Subjects
I. Laitinen[1], *S. Ekström*[2], *H. Haraldsson*[1], *A. Korenyushkin*[2], *S. Pierrou*[1], *H. Litorp*[3], *F. Sjöberg*[3], *S. Southekal*[4], *M. Lu*[4], *T. Coskun*[5], *Z. Milicevic*[5], *J. Kullberg*[2], *L. Johansson*[1];
[1]*Antaros Medical, Mölndal, SWEDEN,* [2]*Antaros Medical, Uppsala, SWEDEN,* [3]*Clinical Trial Consultants AB, Uppsala, SWEDEN,* [4]*Avid Radiopharmaceuticals Inc, Philadelphia, PA, UNITED STATES OF AMERICA,* [5]*Eli Lilly, Indianapolis, IN, UNITED STATES OF AMERICA.*

OP-687
Quantitative Brain Perfusion Estimation by Model-Free Deconvolution in Long Axial Field of View PET
H. Larsson, *T. L. Andersen, F. L. Andersen, B. M. Fischer, L. Højgaard, I. Law, U. Lindberg;*
Department of Clinical Physiology and Nuclear Medicine, Rigshospitalet, Copenhagen, DENMARK.

1506

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 117

Clinical Oncology Track - TROP Session: Head & Neck and Melanoma

OP-688
PSMA-directed imaging and therapy of salivary gland tumors: a single-center retrospective study
C. Civan[1,2], *S. Kasper*[2,3], *C. Berliner*[1,2], *P. Fragoso-Costa*[1,2], *V. Grünwald*[2,3], *M. Pogorzelski*[2,3], *B. M. Schaarschmidt*[2,4], *S. Lang*[2,5], *D. Kersting*[1,2], *M. Nader*[1], *K. Lückerath*[1,2], *K. Herrmann*[1,2], *W. P. Fendler*[1,2], *M. Weber*[1,2];
[1]*Department of Nuclear Medicine, University Hospital Essen, Essen, GERMANY,* [2]*German Cancer Consortium (DKTK), partner site Essen, Essen, GERMANY,* [3]*Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, GERMANY,* [4]*Institute of Diagnostic and Interventional Radiology and Neuroradiology, University of Duisburg-Essen, Essen, GERMANY,* [5]*Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Essen, University Duisburg-Essen, Essen, GERMANY.*

OP-689
Head and neck squamous cell carcinomas display distinct inter-organ connectivity depending on the original tumour location
J. Yu[1], *T. Beyer*[1], *D. Ferrara*[1], *S. Gutschmayer*[1], *M. Hacker*[2], *L. Shiyam Sundar*[1];
[1]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.*

OP-690
PET/MR Radiomics Analysisand Metabolic Parameters in Predicting the Ascending and Descending Nasopharyngeal Carcinoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

OP-691
Diagnostic performance of [^{18}F]FDG PET/CT for lymph node involvement in head and neck squamous cell carcinoma: visual versus semi-quantitative analysis
P. D'Abadie, *N. Michoux, T. Duprez, S. Schmitz, M. Magremanne, P. Van Eeckhout, O. Gheysens;*
Cliniques universitaires Saint Luc, Brussels, BELGIUM.

OP-692
Accuracy of FDG-PET/CT in diagnosis of immune-related adverse events in patients with high-risk malignant melanoma treated with adjuvant immune checkpoint inhibitors
B. Gideonse[1,2], *M. Birkeland*[1,2], *M. H. Vilstrup*[1,2], *P. Grupe*[1,2], *C. H. Ruhlmann*[1,3], *M. Naghavi-Behzad*[1,2,4], *O. Gerke*[1,2], *M. G. Hildebrandt*[2,4,5];
[1]*Department of Clinical Research, University of Southern Denmark, Odense, DENMARK,* [2]*Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK,* [3]*Department of Oncology, Odense University Hospital, Odense, DENMARK,* [4]*Centre for Personalized Response Monitoring in Oncology, Odense University Hospital, Odense, DENMARK,* [5]*Centre for Innovative Medical Technology, Odense University Hospital, Odense, DENMARK.*

OP-693
Baseline TMTV and Dmax prognostic value in patients with advanced melanoma treated with first-line immune checkpoint inhibitors
L. Vercellino, *P. Jallerat, J. Delyon, A. Martineau, B. Baroudjian, W. Poudroux, C. Lebbé, P. Merlet;*
Hôpital Saint Louis, Paris, FRANCE.

OP-694
Application of the long axial field-of-view PET/CT in metastatic melanoma patients studied with ^{18}F-FDG
C. Sachpekidis[1], *L. Pan*[1], *J. C. Hassel*[2], *A. Dimitrakopoulou-Strauss*[1];
[1]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,* [2]*Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany, Heidelberg, GERMANY.*

OP-695
Significance of Preoperative PET/CT for Treatment Planning in Patients with High Risk Melanoma
S. Divosevic;
Medikol Polyclinic, Zagreb, CROATIA.

OP-696
PET-Based Prognostic Stratification In Patients With Advanced Melanoma Treated With Immunotherapy: A Criteria Comparison
N. Bonazzi[1], *G. Battisti*[1], *V. Dragonetti*[1], *F. Comito*[2], *R. Pagani*[3], *M. Aprile*[3], *C. Malizia*[4], *B. Melotti*[2,3], *A. Ardizzoni*[3,2], *S. Fanti*[1,5], *C. Nanni*[5];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Medical Oncology, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [4]*PET Radiopharmacy, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

1507

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 115

Thyroid Committee - Featured Session: New Developments and Knowledge in Thyroid Cancer Therapy

OP-697
Radionuclide Therapy of Thyroid Cancer
M. Luster;
University Hospital Marburg, Department of Nuclear Medicine, Marburg, GERMANY.

OP-698
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: The Single-Center Prospective Two-Arm ERRITI Trial
D. Kersting[1], *M. Weber*[1], *B. Riemann*[2], *T. Brandenburg*[3], *D. Führer-Sakel*[3], *F. Grünwald*[4], *M. C. Kreissl*[5], *H. Dralle*[6], *F. Weber*[6], *K. W. Schmid*[7], *I. Binse*[1], *K. Herrmann*[1], *W. Jentzen*[1], *H. Grafe*[1], *C. Rischpler*[1], *S. Theurer*[7], *A. Bockisch*[1], *J. Nagarajah*[8], *W. P. Fendler*[1];
[1]*Department of Nuclear Medicine and German Cancer Consortium (DKTK), West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [2]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,* [3]*Department of Endocrinology and Metabolism, Division of Laboratory Research, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [4]*Department of Nuclear Medicine, University Hospital Frankfurt, Frankfurt, GERMANY,* [5]*Division of Nuclear Medicine, Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, Magdeburg, GERMANY,* [6]*Department of General, Visceral and Transplantation Surgery, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [7]*Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [8]*Department of Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS.*

OP-699
[^{177}Lu]Lu-DOTAGA.(SA.FAPi)2 therapy in advanced stage radioiodine-resistant thyroid cancers of follicular and parafollicular cell origins
S. Ballal[1], *M. P. Yadav*[1], *C. Bal*[1], *F. Roesch*[2], *S. Rajput*[1], *E. S. Moon*[3], *N. Wakade*[1], *M. Tripathi*[1], *S. Agarwal*[1], *R. K. Sahoo*[1];
[1]*All India Institute of Medical Sciences, Delhi, INDIA,* [2]*SVC company, Koppenstraße. 82, 10243, Berlin, GERMANY,* [3]*Johannes Gutenberg-University Mainz, Mainz, GERMANY.*

OP-700
Higher in-vivo stability and tumor doses of [^{177}Lu]Lu-PP-F11N in patients with medullary thyroid carcinoma after pretreatment with the neutral endopeptidase-1 inhibitor Sacuitril
C. Rottenburger[1], *L. McDougall*[1], *M. Hentschel*[1], *M. Fürstner*[2], *R. Mansi*[3], *L. Del Pozzo*[3], *M. Fani*[3], *D. Kottoros*[1], *F. Kaul*[1], *E. Christ*[4], *R. Schibli*[5], *S. Geistlich*[6], *M. Behe*[6], *D. Wild*[1];
[1]*Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND,* [2]*Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Bern, SWITZERLAND,* [3]*Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, SWITZERLAND,* [4]*Division of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, SWITZERLAND,* [5]*Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH, Zürich, SWITZERLAND,* [6]*Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, SWITZERLAND.*

OP-701
Initial results of a multi centre multi national study of radioiodine ablation for patients with differentiated thyroid cancer
L. Vija[1], *J. Taprogge*[2], *F. Leek*[2], *C. Abreu*[2], *L. Vavrova*[2], *L. Carnegie-Peake*[2], *D. Rushforth*[2], *P. Gape*[2], *J. Gear*[2], *I. Murray*[2], *K. H. Wong*[2], *K. Newbold*[2], *S. Yusuf*[2], *F. Courbon*[1], *D. Vallot*[1], *S. Zerdoud*[1], *M. Luster*[3], *A. Pfestroff*[3], *K. R. Pfestroff*[3], *T. Schurrat*[3], *A. Ashfaq*[3], *M. Bardies*[4], *A. Vergara-Gil*[5], *G. Flux*[2];
[1]*Institut Claudius Regaud-Oncopole, Toulouse Cedex 9, FRANCE,* [2]*Royal Marsden NHSFT, Sutton, UNITED KINGDOM,* [3]*Philipps-University Marburg, Marburg, GERMANY,* [4]*Institut de Recherche en Cancérologie de Montpellier (U1194), Montpellier, FRANCE,* [5]*Oncology Cancer Institute Toulouse, Toulouse Cedex 9, FRANCE.*

OP-702
BRAF Mutation And AXL (Hyper)Expression As Markers Of High Risk For Persistent/Recurrent Papillary Thyroid Cancer (PTC)
A. Campenni'[1], *L. Giovanella*[2], *R. Ruggeri*[3], *M. Siracusa*[1], *H. Rosarno*[1], *C. Pizzimenti*[4], *S. Baldari*[1], *G. Fadda*[4], *M. Martini*[4];
[1]*Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, ITALY,* [2]*Clinic for Nuclear Medicine and Competence Centre for Thyroid Diseases, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, SWAZILAND,* [3]*Department of Clinical and Experimental Medicine, Unit of Endocrinology, Messina, ITALY,* [4]*Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', Unit of Pathological Anatomy, University of Messina, Messina, ITALY.*

OP-703
Radioiodine Treatment After Thyroid Hormone Withdrawal Or rhTSH Stimulation - A Single Centre Retrospective Study In Disseminated Thyroid Cancer In Pediatric Patients
D. Handkiewicz-Junak, *A. Kropinska, A. Ledwon, E. Paliczka-Cieslik, J. Roskosz, A. Blewaska, D. Kuta, Z. Puch, B. Jarzab;*
MSC National Research Institute of Oncology, Gliwice, POLAND.

OP-704
Comparison of differentiated thyroid cancer in Children(≤14) and 'Adolescents and Young Adults'(15-39)
A. K Majeed, *C. Bal, S. S Ballal, J. Jaleel, R. Kumar, D. Khan, s. sagar;*
Department of Nuclear Medicine, New Delhi, INDIA.

OP-705
Long-term prognostic value of response to therapy assessed 12 months after radioiodine treatment in pediatric patients with differentiated thyroid cancer
L. Piscopo[1], *M. Manganelli*[1], *F. Volpe*[1], *E. Zampella*[1], *V. Gaudieri*[1], *C. Nappi*[1], *L. Pace*[2], *M. Klain*[1], *A. Cuocolo*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY,* [2]*Department of Medicine, Surgery and Dentistry, University of Salerno, Salerno, ITALY.*

1508

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 212

Special Symposium 1 - Radiopharmaceutical Sciences Committee / EU Commission: Radiopharmaceuticals Regulations - Quo Vadis?

OP-706
TBA
TBA
TBA

OP-707
TBA
TBA
TBA

OP-708
In-house Preparation and Manufacturing of Radiopharmaceuticals With and Without Market Authorization - Swiss Regulation as Example
***R. Hesselmann**;*
Federal Office of Public Health (FOPH), Bern, SWITZERLAND.

OP-709
Quality Requirements for Radiopharmaceuticals in Marketing Authorization and Clinical Trial Applications
***E. Moya Sánchez**;*
Spanish Agency of Medicines and Medical Devices (AEMPS), Chemical and Pharmaceutical Division, Medicines for Human Use Department, Madrid, SPAIN.

OP-710
In-house Prepared Radiopharmaceuticals - Essential but not Sufficiently Available
***C. Decristoforo**;*
Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA.

1510

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 116

CTE 6 - Technologists Committee: Stem Cells in Nuclear Medicine

OP-714
Introduction by Chairpersons

OP-715
Stem Cell - What Is It All About?
***W. Suchorska**;*
Greater Poland Cancer Centre, Radiobiology Lab, Poznan, POLAND.

OP-716
Stem Cells and Nuclear Medicine - How and Why Does These Two Correlate?
***L. Lezaic**;*
University Medical Centre, Department of Nuclear Medicine, Ljubljana, SLOVENIA.

OP-717
Preparation of the Stem Cells
***A. Sočan**;*
University medical centre Ljubljana, Dept. for Nuclear Medicine, Ljubljana, SLOVENIA.

OP-718
Summary by Chairpersons

1601

Tuesday, October 18, 2022, 16:45 - 18:15

Auditorium

CME 12 - Radiopharmaceutical Sciences Committee: Optimizing Radiolabeled Biomolecules for Imaging and Therapy - The Secrets Revealed

OP-719
Albumin Binders and Their Role in Radiopharmaceutical Development
***C. Müller**;*
Paul Scherrer Institute, Villigen, SWITZERLAND.

OP-720
The Role of Chelators in Design and in Vivo Behaviour of Radiopharmaceuticals
***M. Ma**;*
King's College London, Department of Imaging Chemistry and Biology, London, UNITED KINGDOM.

OP-721
Strategies to Reduce Kidney Uptake of Radiolabelled Biomolecules
***R. Wodtke**;*
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY.

OP-722
Pretargeting Strategies to Optimize Pharmacokinetics
***M. Stroet**;*
Vrije Universiteit Brussel, Dept of Medical Imaging, In vivo cellular and molecular imaging lab, Brussels, BELGIUM.

1602

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 112 (Arena)

Challenge the Expert 4 - Oncology & Theranostics Committee: Expert vs Team Essen: PET/CT in Real Life

OP-723
***K. Goffin[1] vs M. Sraieb, H. Lanzafame, K. Pabst, D. Kersting, P. Sandach, F. Barbato**;*
[1]University Hospital Leuven and KU Leuven, Department of Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

1603

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 113

LIPS Session 12 - Radiation Protection + Physics Committee: CT Optimization in Hybrid Imaging
Interactive Session

OP-731
Clinical Application of Auxiliary CT in Hybrid Imaging - More than Attenuation Correction and Co-Registration
***T. van den Wyngaert**;*
Senior consultant UZA, Edegem, BELGIUM.

OP-732
CTDI, DLP, SSDE & Co - How to Estimate and Optimize Patient Dose in Computed Tomography
***K. Bacher**;*
University Gent, Department of Human Structure and Repair, Ghent, BELGIUM.

OP-733
Protocol Optimization of Auxiliary CT in Hybrid Imaging
***M. Burniston**;*
Barts Health NHS Trust, Department of Nuclear Medicine Physics, London, UNITED KINGDOM.

OP-734
Practical Aspects of Radiation Protection When Using Hybrid Modalities
***E. Prieto**;*
Universidad Navarra, Clínica Universidad de Navarra, Medical Physics Department, Navarra, SPAIN.

1604

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 114

M2M Track - TROP Session: New Tracers - From Scratch to Automated Synthesis

OP-735
Small Molecule-Based Radiotracers for PET Imaging of PD-L1 With Copper-64
***F. Krutzek**, C. K. Donat, M. Ullrich, K. Kopka, S. Stadlbauer;*
Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY.

OP-736
Development of a novel ^{11}CO labelled PET radioligand ^{11}C-BIO-1819578 for the detection of O-GlcNAcase (OGA) enzyme in the living brain
***S. Nag**[1], R. Arakawa[1], P. Datta[1], A. Forsberg[1], M. Moein[1], M. Bolin[1], T. Lin[2], N. Genung[2], H. Heiring[2], K. Guckian[2], L. Martarello[2], M. Kaliszczak[2], C. Halldin[1];*
[1]Karolinska Institutet, Stockholm, SWEDEN, [2]BIOGEN MA Inc, Cambridge, MA, UNITED STATES OF AMERICA.

OP-737
Evaluation of two novel pharmacophores for the design of FAP-targeting PET tracers
***S. Bendre**;*
BC Cancer Research Center, Vancouver, BC, CANADA.

OP-738
New synthesis pathway and automatization in different systems of [^{18}F]-4-amino-fluorobenzoic acid for infection imaging
***J. Simon**[1,2], K. R. Pulagam[3], M. Rúa[4], M. Collantes[1,5], R. Ramos-Membrive[1,2], G. Quincoces[1,2], F. Pareja[1,2], M. Otabashi[6], C. Vriamont[6], J. Llop[3], I. Peñuelas[1,2,5];*
[1]Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN, [2]Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, [3]Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, Basque Research and Technology Aliance (BRTA), San Sebastian, SPAIN, [4]Clinical Microbiology Department, Clínica Universidad de Navarra, Pamplona, SPAIN, [5]Translational Molecular Imaging Unit, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, SPAIN, [6]Trasis Radiopharmacy Instruments, Ans, BELGIUM.

OP-739
Development Of A New Synthesis And Quality Control System Of A CCR2-Targeted Molecular Imaging Probe: [68Ga]Ga-DOTA-ECL1i
***S. Migliari**[1], E. Masselli[2], M. Scarlattei[1], G. Baldari[1], M. Vitale[2], L. Ruffini[1];*
[1]Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY, [2]Anatomy Unit, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY.

OP-740
Rapid high-yield enzymatic synthesis of n.c.a. 6-[^{18}F] fluorodopamine (6-[^{18}F]FDA) for in vivo application
***K. Bamminger**[1,2], C. Plank[1,3], J. Raitanen[1,4,5], G. Karanikas[1], S. Rasul[1], L. Nics[1], M. Mitterhauser[1,4], W. Wadsak[1,2], M. Hacker[1], V. Pichler[3], C. Vraka[1];*
[1]Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, [2]CBmed GmbH - Centre for Biomarker Research in Medicine, Graz, AUSTRIA, [3]Department of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, University of Vienna, Vienna, AUSTRIA, [4]Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, [5]University of Vienna, Vienna Doctoral School in Chemistry (DoSChem), Währinger Str. 42, 1090 Vienna, AUSTRIA.

OP-741
An automated [^{89}Zr]ZrCl4-based platform for radiolabelling of [^{89}Zr]Zr-DFOsq agents on the iPhase MultiSyn module
***C. Fitzgerald**[1], A. Noor[2], P. Roselt[3], E. R. McGowan[2], S. E. Rudd[2], S. Poniger[4], M. P. Wheatcroft[1], G. Santamaria[5], P. S. Donnelly[2];*
[1]Telix Pharmaceuticals Pty Ltd, Melbourne, AUSTRALIA, [2]University of Melbourne, Melbourne, AUSTRALIA, [3]Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, [4]Deparment of Molecular Imaging and Therapy, Austin Health, Melbourne, AUSTRALIA, [5]Cyclotek Pty Ltd, Melbourne, AUSTRALIA.

OP-742
Simplified [18F]fluorodestannylation Approach For The One-pot Production Of 6-L-[18F]FDopa With the Synthera Module
*I. Antunes[1], **C. Kwizera**[1], S. Blok[1], R. Zijlma[1], G. Alachouzos[2], W. Szymanski[1], B. Feringa[2], H. Boersma[1], P. Elsinga[1], E. de Vries[1], G. Luurtsema[1];*
[1]UMCG, Groningen, NETHERLANDS, [2]RUG, Groningen, NETHERLANDS.

OP-743

A Specific HPLC Method To Determine Residual HEPES In [^{68}Ga]Ga-Radiopharmaceuticals: Development And Validation

S. Migliari[1], *M. Scarlattei*[1], *G. Baldari*[1], *C. Silva*[2], *L. Ruffini*[1];
[1]*Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY,* [2]*Food and Drug Sciences Department, Parma, ITALY.*

1605

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 211

Cutting Edge Science Track - TROP Session: Predictive Artificial Intelligence

OP-744

A Comparison of Transfer learning with BERT and ClinicalBERT for Classification of Radiology Reports

S. Mithun[1,2,3], *A. K. Jha*[1,4,3], *U. B. Sherkhane*[1,4], *V. Jaiswar*[1,4], *N. C. Purandare*[2,3], *V. Rangarajan*[4,3], *A. Dekker*[1], *L. Wee*[1];
[1]*Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, 6229 ET, Maastricht, NETHERLANDS,* [2]*Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA,* [3]*Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA,* [4]*Department of Nuclear Medicine & Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA.*

OP-745

Machine learning model using ^{18}F-FDG PET/CT-based biomarkers to support clinical decision making in advanced chemorefractory metastatic colorectal cancer

J. Dhont, *H. Levillain, T. Guiot, B. Vanderlinden, K. Brou Boni, P. Flamen, A. Hendlisz, N. Reynaert, E. Woff;*
Institut Jules Bordet, Brussels, BELGIUM.

OP-746

Machine learning to diagnose obstructive coronary artery disease using calcium scoring, PET imaging and clinical data

S. Koenders[1,2], ***J. A. van Dalen***[3], *R. J. Metselaar*[1], *B. Vendel*[1], *D. J. Slotman*[4], *M. Mouden*[5], *C. H. Slump*[2], *J. D. van Dijk*[1];
[1]*Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS,* [2]*Technical Medical Centre, University of Twente, Enschede, NETHERLANDS,* [3]*Medical Physics, Isala Hospital, Zwolle, NETHERLANDS,* [4]*Radiology, Isala Hospital, Zwolle, NETHERLANDS,* [5]*Cardiology, Isala Hospital, Zwolle, NETHERLANDS.*

OP-747

Assessment of the potential of convolutional neuronal networks in the differential diagnosis of Parkinson's disease based on brain imaging [^{123}I]FP-CIT SPECT

N. Valador[1,2], *F. P. M. Oliveira*[1], *P. M. S. Ferreira*[1], *L. Vieira*[3,4], *D. C. Costa*[1];
[1]*Champalimaud Foundation, Lisbon, PORTUGAL,* [2]*Instituto Superior de Engenharia de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL,* [3]*Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL,* [4]*Health and Technology Research Center, Escola Superior de Tecnologia da Saúde de Lisboa, Instituto Politécnico de Lisboa, Lisbon, PORTUGAL.*

OP-748

Machine Learning-based classification using ^{18}F-FDG PET-derived quantitative parameters in predicting Endometrial Cancer aggressiveness

C. Bezzi[1,2], *P. Mapelli*[1,2], *G. Mathoux*[3], *L. Monaco*[3], *S. Ghezzo*[1,2], *A. Bergamini*[1,4], *F. Fallanca*[2], *A. M. Samanes Gajate*[2], *F. Vasta*[1,4], *G. Candotti*[1,4], *G. L. Taccagni*[5], *G. Mangili*[4], *L. Gianolli*[2], *M. Picchio*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,* [2]*Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [3]*University of Milano-Bicocca, Milan, ITALY,* [4]*Unit of Obstetrics and Gynaecology, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [5]*Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY.*

OP-749

Kinetic filtering and deep learning for the automatic detection and quantification of primary brain tumors using dynamic ^{18}F-FET PET imaging

M. Rahimpour[1], *R. Boellaard*[2], *W. Deckers*[3], *K. Goffin*[3], *M. Koole*[1];
[1]*KU Leuven, Leuven, BELGIUM,* [2]*Amsterdam UMC, Amsterdam, NETHERLANDS,* [3]*UZ Leuven, Leuven, BELGIUM.*

OP-750

Deep learning derived input-function in dynamic ^{18}F-FDG PET imaging of mice

S. Kuttner[1,2], *L. T. Luppino*[2], *K. K. Wickstrøm*[2], *N. T. D. Midtbø*[2], *E. Dorraji*[3], *A. Oteiza*[1,2], *M. Martin-Armas*[1,2], *K. Fenton*[2], *L. Convert*[4], *O. Sarrhini*[4], *R. Lecomte*[4], *M. C. Kampffmeyer*[2], *R. Jenssen*[2], *J. Axelsson*[5], *R. Sundset*[1,2];
[1]*University Hospital of North Norway, Tromsø, NORWAY,* [2]*UiT The Arctic University of Norway, Tromsø, NORWAY,* [3]*Oslo University Hospital, Oslo, NORWAY,* [4]*Université de Sherbrooke, Sherbrooke, QC, CANADA,* [5]*Umeå University, Umeå, SWEDEN.*

OP-751

^{18}FDG PET/CT and Machine Learning for the prediction of lung cancer response to immunotherapy

H. Schmutz[1], *P. Mattei*[2], *S. Contu*[3], *D. Chardin*[4], *O. Humbert*[4];
[1]*Universite Cote d'Azur, Tiro-Matos, Inria, Laboratoire J.A. Dieudonne, Nice, FRANCE,* [2]*Universite Cote d'Azur, Inria, Laboratoire J.A. Dieudonne, Nice, FRANCE,* [3]*Department of Biostatistics, Centre Antoine Lacassagne, Nice, FRANCE,* [4]*Department of Nuclear Medicine, Centre Antoine Lacassagne, Nice, FRANCE.*

OP-752

Deep versus handcrafted tensor radiomics features: application to survival prediction in head and neck cancer

M. Salmanpour[1,2,3], *M. Hosseinzadeh*[4,5], *S. Rezaeijo*[6], *M. Ramezani*[5], *S. Marandi*[5], *M. Einy*[5], *A. Rahmim*[7,2];
[1]*University of British Columbia, Burnaby, BC, CANADA,* [2]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [3]*Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, CANADA,* [4]*Tarbiat Modares University, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [5]*Technological Virtual Collaboration (TECVICO Corp), Vancouver, BC, CANADA,* [6]*Department of Medical Physics, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IRAN, ISLAMIC REPUBLIC OF,* [7]*University of British Columbia, Vancouver, BC, CANADA.*

1606

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 117

Clinical Oncology Track - TROP Session: NET Therapy and More

OP-753

Preliminary results of [^{177}Lu]Lu-DOTAGA.(SA.FAPi)2 therapy in low SSTR expressing neuroendocrine tumours

C. Bal[1], *M. P. Yadav*[1], *S. Ballal*[1], *F. Roesch*[2], *S. Rajput*[1], *E. S. Moon*[3], *R. K. Sahoo*[1], *S. Rastogi*[1], *S. Agarwal*[1], *N. Wakade*[1], *M. Tripathi*[1];

[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*SVC company, Koppenstraße. 82, 10243, Berlin, GERMANY,* [3]*Johannes Gutenberg-University Mainz, Mainz, GERMANY.*

OP-754

Peptide Receptor Alpha-particle-emitting Radionuclide Therapy of Progressive Metastatic Neuroendocrine Neoplasms Prolongs Progression-free Survival in an Upfront as well as Salvage Treatment Setting

H. Kulkarni[1], *J. Zhang*[1,2], *A. Singh*[1], *F. Robiller*[1], *C. Schuchardt*[1], *R. P. Baum*[1,3];
[1]*Zentralklinik Bad Berka, Bad Berka, GERMANY,* [2]*National University of Singapore, Singapore, SINGAPORE,* [3]*Curanosticum, Wiesbaden, GERMANY.*

OP-755

^{177}Lu-DOTATATE therapy in advanced pancreatic neuroendocrine tumors: data from 187 patients of the national registry SEPTRALU

M. Mitjavila-Casanovas[1], *P. Belló*[2], *V. Pubul*[3], *A. Garcia-Burillo*[4], *J. Hernando*[5], *J. Alonso-Farto*[6], *J. Arbizu*[7], *E. Rodeño*[8], *M. Estorch*[9], *P. Gajate*[10], *D. Marin*[11], *L. García-Cañamaque*[12], *B. Llana*[13], *B. Miguel*[14], *M. Castellón*[15], *E. Caballero*[16], *M. Coronado*[17], *J. Cano*[18], *A. Repetto*[19], *J. Vercher*[20], *A. Muros*[21], *P. García-Alonso*[22], *M. del Olmo*[23], *A. Carmona-Bayonas*[24], *P. Jimenez-Fonseca*[13];
[1]*Hospital Universitario Puerta de Hierro Majadahonda, Madrid, SPAIN,* [2]*Hospital Universitario La Fé, Valencia, SPAIN,* [3]*Hospital Universitario Santiago de Compostela, Santiago de Compostela, SPAIN,* [4]*Hospital Universitario Vall d'Hebron, Barcelona, SPAIN,* [5]*Hospital Universitario Vall d'Hebron, Barcelona, SPAIN,* [6]*Hospital Universitario Gregorio Marañón, Madrid, SPAIN,* [7]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [8]*Hospital Universitario de Cruces, Bilbao, SPAIN,* [9]*Hospital de la Santa Creu i San Pau, Barcelona, SPAIN,* [10]*Hospital Universitario Ramón y Cajal, Madrid, SPAIN,* [11]*Hospital Universitario 12 de Octubre, Madrid, SPAIN,* [12]*Hospital HM Sanchinarro, Madrid, SPAIN,* [13]*Hospital Universitario Central de Asturias, Oviedo, SPAIN,* [14]*Hospital Universitario de Burgos, Burgos, SPAIN,* [15]*Hospital Universitario Virgen de la Arrixaca, Murcia, SPAIN,* [16]*Hospital Universitario Doctor Peset, Valencia, SPAIN,* [17]*Hospital Universitario La Paz, Madrid, SPAIN,* [18]*Hospital General Universitario de Ciudad Real, Ciudad Real, SPAIN,* [19]*Hospital Universitario Son Espases, Mallorca, SPAIN,* [20]*ICO - H Universitario Bellvitge, Barcelona, SPAIN,* [21]*Hospital Universitario Virgen de las Nieves, Granada, SPAIN,* [22]*Hospital Universitario de Getafe, Madrid, SPAIN,* [23]*Hospital Universitario La Fe, Valencia, SPAIN,* [24]*Hospital Universitario Morales Meseguer, Murcia, SPAIN.*

OP-756

Re-challenge Peptide Receptor Radionuclide Therapy using the SSTR Antagonist Lu-177 DOTA-JR11: Pilot Results assessing Dosimetry, Safety and Response

H. Kulkarni, *C. Schuchardt, F. Robiller;*
Zentralklinik Bad Berka, Bad Berka, GERMANY.

OP-757

Inflammation based index and tumor heterogeneity on pretherapeutic ^{68}Ga DOTATOC PET/CT predict outcome in midgut neuroendocrine tumor patients treated with ^{177}Lu-oxodotreotide

L. Vija[1], *L. Dierickx*[1], *S. Kanoun*[1], *J. Texier*[1], *M. Terroir*[1], *T. Cassou Mounat*[1], *S. Zerdoud*[1], *E. Gabiache*[1], *S. Brillouet*[1], *C. Lamesa*[1], *R. Guimbaud*[1], *I. Berry*[1], *F. Savagner*[2], *F. Courbon*[1];
[1]*Institut Claudius Regaud-Oncopole, Toulouse Cedex 9, FRANCE,* [2]*Institut Fédératif de Biologie, Toulouse Cedex 9, FRANCE.*

OP-758

Pharmaco-kinetic and -dynamic analysis of 177Lu-DOTATATE in patients with gastroenteropancreatic metastatic neuroendocrine tumors and correlation with treatment outcome

L. Dierickx[1,2], *M. Lambert*[3], *S. Brillouet*[1,2], *R. Guimbaud*[4,2], *F. Mokrane*[4,2], *C. Zadro*[4,2], *E. Partouche*[4,2], *E. Chatelut*[3];
[1]*Institut Claudius Regaud, Institut Universitaire de Cancer Toulouse-Oncopole, Toulouse, FRANCE,* [2]*Universitary Center of Excellence for Neuroendocrine Tumors Toulouse, Toulouse, FRANCE,* [3]*Institut Claudius Regaud, Cancer Research Center of Toulouse, Inserm U1037, Université Paul-Sabatier, Toulouse, FRANCE,* [4]*Centre Hospitalier Universitaire Toulouse, Toulouse, FRANCE.*

OP-759

Safety and Feasibility of Rhenium-186 Nanoliposome (^{186}RNL) in Leptomeningeal Metastases [LM] Phase 1 dose escalation Trial

N. LaFrance[1,2], *A. Brenner*[1,3], *M. Youssef*[1], *A. Bao*[1], *W. Phillips*[1], *M. Hedrick*[1];
[1]*Norman LaFrance, Newtown, PA, UNITED STATES OF AMERICA,* [2]*PLUS Therapeutics, San Antonio, TX, UNITED STATES OF AMERICA,* [3]*University of Texas, San Antonio, TX, UNITED STATES OF AMERICA.*

OP-760

^{177}Lu-PSMA radioligand therapy for recurrent/metastatic salivary gland cancer patients, a phase II pilot study PrimaryAuthor.AuthorBlock:

M. J. M. Uijen[1], *M. Gotthardt*[2], *J. Nagarajah*[2], *C. M. L. van Herpen*[1];
[1]*Radboud University Medical Center, Department of Oncology, Nijmegen, NETHERLANDS,* [2]*Radboud University Medical Center, Department of Medical Imaging, Nijmegen, NETHERLANDS.*

OP-761

Efficacy, Early toxicity and Cosmetics in Patients with Non-Melanoma Skin Cancers Treated with Rhenium [188RE]-Resin

L. Vetrone[1], *C. Baraldi*[2], *F. Savoia*[3], *A. Farina*[1], *S. Vichi*[4], *F. Zagni*[5], *C. Malizia*[6], *B. Piraccini*[2], *L. Strigari*[5], *S. Fanti*[1,7], *P. Castellucci*[7];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Dermatology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Skin Cancer Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [4]*Clinical Engineering Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Medical Physics Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [7]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

1607

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 115

Neuroimaging Committee - TROP Session: The Force Awakens - Neuro Miscellaneous

OP-762

Assessing synaptic density in amyotrophic lateral sclerosis with ^{18}F-SynVesT-1 positron emission tomography imaging

Y. Tang, *M. Zhou, J. Li, B. Chen, W. Rao, L. Xiao, S. Hu;*
Xiangya Hospital Central South University, Changsha, CHINA.

OP-763

Beyond steady-state amyloid PET to detect demyelination in multiple sclerosis (MS)

M. Donegani[1], *M. Pardini*[2], *A. Chincarini*[3], *L. Roccatagliata*[4], *A. Donniaquio*[2], *R. Gianeri*[3], *F. Sensi*[3], *F. D'Amico*[1], *G. Novi*[5], *A. Laroni*[2], *A. Murialdo*[5], *G. Ribizzi*[5], *G. Sambuceti*[1], *A. Uccelli*[2], *M. Inglese*[2], *F. Nobili*[2], *S. Morbelli*[1];
[1]*Department of Health Sciences (DISSAL), University of Genoa,*

Genoa, ITALY, [2]Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, ITALY, [3]National Institute of Nuclear Physics (INFN), Genoa section, Genoa, ITALY, [4]Neuroradiology Unit, University of Genoa, Genoa, ITALY, [5]Division of Neurology, IRCCS Policlinico San Martino, Genoa, ITALY.

OP-764
The Expression of Fructose-1,6-Bisphosphatase 1 is Associated with [18F]-FDG Uptake and Prognosis in Patients with Temporal Lobe Epilepsy
W. Rao[1], *Y. Tang*[1], *B. Chen*[1], *L. Xiao*[1], *H. Zhu*[2], *S. Hu*[1];
[1]*Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha City, CHINA,* [2]*Department of Neurology, Xiangya Hospital, Central South University, Changsha City, CHINA.*

OP-765
A review of tools for estimation of brain connectivity from positron emission tomography data
A. Lizarraga[2], *A. Sala*[1], *S. P. Caminiti*[3], *V. Calhoun*[4], *S. Eickhoff*[5], *C. Habeck*[6], *S. Jamadar*[7], *D. Perani*[3], *J. Pereira*[8], *M. Veronese*[9], *I. Yakushev*[2];
[1]*University of Liège, Liege, BELGIUM,* [2]*Technical University of Munich, Munich, GERMANY,* [3]*Vita-Salute San Raffaele University, Milan, ITALY,* [4]*Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, GA, UNITED STATES OF AMERICA,* [5]*Heinrich-Heine-University, Düsseldorf, GERMANY,* [6]*Columbia University, New York, NY, UNITED STATES OF AMERICA,* [7]*Monash University, Melbourne, AUSTRALIA,* [8]*Karolinska Institutet, Stockholm, SWEDEN,* [9]*King's College, London, UNITED KINGDOM.*

OP-766
The effects of bariatric surgery on the brain glucose metabolism and its biological mediators: an insight from dynamic [18F]FDG PET/CT study
G. Aghakhanyan[1], *G. Daniele*[2], *A. Dardano*[2], *F. Betti*[1], *L. Antonacci*[1], *L. Giusti*[3], *A. Ciccarone*[2], *F. Guidoccio*[1], *F. Santini*[4], *R. Bellini*[5], *G. Ceccarini*[4], *S. Del Prato*[2], *D. Volterrani*[1];
[1]*Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, ITALY,* [2]*Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Diseases, University of Pisa, Pisa, ITALY,* [3]*Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Diseases, University of Pisa, Pisa,, Pisa, ITALY,* [4]*Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Pisa, ITALY,* [5]*Section Bariatric Surgery Unit, Nuovo Ospedale Santa Chiara, Pisa, ITALY.*

OP-767
Analysis of brain metabolism using FDG-PET/CT in patients with acute Covid-19
S. De Souza[1], *N. Colet*[1], *A. Fernandes*[1], *N. Tobar*[1], *S. Dertkigil*[2], *M. Takahashi*[3], *B. Amorim*[1], *C. Yasuda*[4], *J. Rodrigues*[1], *D. Zantut-Wittmann*[5], *C. Ramos*[1];
[1]*Nuclear Medicine Division, Department of Radiology, Faculty of Medical Sciences, University of Campinas, Campinas, BRAZIL,* [2]*Department of Radiology, Faculty of Medical Sciences, University of Campinas, Campinas, BRAZIL,* [3]*Gleb Wataghin Physics Institute, University of Campinas, Campinas, BRAZIL,* [4]*Department of Neurology, Faculty of Medical Sciences, University of Campinas, Campinas, BRAZIL,* [5]*Endocrinology Division, Department of Internal Medicine, Faculty of Medical Sciences, University of Campinas, Campinas, BRAZIL.*

OP-768
How reproducible are PET- and MRI-derived measures of brain connectivity?
A. Lizarraga[1], *I. Ripp*[1], *A. Sala*[2], *K. Koch*[1], *I. Yakushev*[1];
[1]*Technical University of Munich, Munich, GERMANY,* [2]*University of Liege, Liege, BELGIUM.*

OP-769
Tracking of radiolabelled mesenchymal stem cells after intrathecal transplantation in patients with traumatic spinal cord injury
L. Lezaic[1], *A. Socan*[1], *F. Bajrovic*[1], *U. Svajger*[2], *M. Sever*[1], *M. Jug*[1];
[1]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,* [2]*Blood Transfusion Centre of Slovenia, Ljubljana, SLOVENIA.*

OP-770
Correlation between brain metabolism and headache in early breast cancer patients candidate for neoadjuvant chemotherapy
L. Antunovic[1], *A. Artesani*[1,2], *R. De Sanctis*[1,2], *C. Pini*[2], *C. Benvenuti*[1,2], *F. Jacobs*[1,2], *M. Gaudio*[1,2], *A. Viganò*[3], *A. Santoro*[1,2], *A. Chiti*[1,2], *S. Morbelli*[4,5];
[1]*IRCCS Humanitas Research Hospital, Rozzano, ITALY,* [2]*Humanitas University, Pieve Emanuele, ITALY,* [3]*Fondazione Don Gnocchi, Milan, ITALY,* [4]*Department of Health Sciences, Genoa, ITALY,* [5]*IRCCS Ospedale Policlinico San Martino, Genoa, ITALY.*

1608

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 212

Special Symposium 2 - EANM / EU Commission: Getting to the Top QuADRANT. A European Initiative to Improve Quality for Patients

OP-771
Introduction and Definitions

OP-772
Why Do We Need Clinical Audits?
TBA;
TBA.

OP-773
What Nuclear Medicine Can Learn from Radiology in Clinical Audits
A. Brady;
Mercy University Hospital, Radiology, Cork, IRELAND.

OP-774
Why Patients Need to be Fully Included
E. Briers;
European Prostate Cancer Coalition (Europa Uomo), Limburg, BELGIUM.

OP-775a
What Regulators/Authorities Want from Us
M. Vandecapelle;
FANC - Federal Agency for Nuclear Control, Brussels, BELGIUM.

OP-775b
What Regulators/Authorities Want from Us
R. Hesselmann;
Federal Office of Public Health (FOPH), Bern, SWITZERLAND.

OP-776
Round Table Discussion
W. Wadsak;
Medical University Vienna, Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine), Vienna, AUSTRIA.

1610

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 116

CTE 7 - Technologists Committee: EQF7 - European Qualification Framework Document for Nuclear Medicine Technologists

OP-785
History in the Making - From Basic Competencies to Higher Education
G. Testanera;
King's College London and GSTT Hospital, PET Centre, London, UNITED KINGDOM.

OP-786
NMTs Higher Education in Europe
L. Roldão Pereira;
Maidstone and Tunbridge Wells NHS Trust, Maidstone, UNITED KINGDOM.

OP-787
EQF7 for NMTs Document - An Overview
A. Santos;
Hospital Cuf Descobertas, Nuclear Medicine Department, Lisbon, PORTUGAL.

OP-788
Interactive Survey
A. Pietrzak;
Poznan University of Medical Sciences, Electroradiology Dep., Greater Poland Cancer Centre, Nuclear Medicine Dep., Poznan, POLAND.

1701

Wednesday, October 19, 2022, 08:00 - 09:30

Auditorium

CME 13 - Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences + Oncology & Theranostics Committee: First In-Human Studies

OP-789
First In-Human Dosimetry
C. Stokke;
Nuclear Medicine & PET physics Division of Radiology and Nuclear Medicine Oslo University Hospital, Oslo, NORWAY.

OP-790
Potential Pitfalls in Neurotracer Development from Bench to Bedside
H. Barthel;
University Hospital Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY.

OP-791
Important Aspects to be Taken into Account in Bringing a New Radiopharmaceutical to the Bedside
L. García Varela;
Molecular Imaging Group, Health Research Institute of Santiago de Compostela (IDIS).,Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, SPAIN.

OP-792
First-In-Human Approaches of Nuclear Medicine (Probes) in Inflammation / Infection
E. Aarntzen;
Department of Medical Imaging, Radboud University Nijmegen Medical Center, Nijmegen, NETHERLANDS.

1702

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 112 (Arena)

Debate 5 - Oncology & Theranostics + Physics Committee: PET/MR – Lights or Shadows?

OP-793
Lights
M. Picchio + *C. Bezzi, S. Ghezzo;*
Vita Salute San raffaele University, Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-794
Shadows
B. Fueger + *P. D. Stelzer;*
Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Division of General Radiology and Pediatric Radiology, Vienna, AUSTRIA.

1703

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 113

LIPS Session 13: Case Report Session 2 - Others than Oncology

OP-796
Rasmussen encephalitis and brain 18F-FDG PET-CT: a clear answer for a tricky clinical case
M. Mattoli[1,2], *F. Dono*[1], *L. Travascio*[2], *A. Cinquino*[2], *C. Villano*[2], *A. Di Nicola*[2], *S. Sensi*[1];
[1]*Department of Neurosciences, Imaging and Clinical Sciences, "G. d'Annunzio" Chieti-Pescara University, Chieti, ITALY,* [2]*Nuclear Medicine Unit, Santo Spirito Hospital, Pescara, ITALY.*

OP-797
Utility of F-18 FDG PET/CT in a Rare Case of Tolosa-Hunt Syndrome secondary to COVID 19 nasopharyngeal swab trauma, when MRI is inconclusive
A. Dixit;
MPCT Hospital, Navi Mumbai, INDIA.

OP-798
Primary Hyperparathyroidism with severe bone involvement in an adolescent with an Ectopic Mediastinal Parathyroid Adenoma: A case report
M. Ben Nasr[1], *W. EL Ajmi*[1], *M. Hadj Dahmane*[2], *M. Abdennadher*[2], *A. Sellem*[1], *F. Ben Amar*[1], *H. Hammami*[1];
[1]*Nuclear medicine department, The Principal Military Hospital of Instruction of Tunis, Tunisie, TUNISIA,* [2]*Thoracic surgery department, Hospital Abderahmen*

Mami of Pneumophistiologie, Tunisie, TUNISIA.

OP-799
The curious case of99mTc-DPD
***A. Farina**, G. Argalia, L. Vetrone, M. Maccagnani, S. Fanti;*
Nuclear Medicine Department, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, ITALY.

OP-800
Time course of functional recovery of hibernating myocardium after revascularization analyzed by myocardial perfusion imaging and gated cardiac 18F-FDG PET :A case report
***Y. Lu**, X. Zhang;*
Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA.

OP-801
Case series of extra cardiac findings with increased perfusion during clinical ^{15}O-H2O PET myocardial perfusion imaging
***M. Jochumsen**[1,2], D. L. Overgaard[1], M. H. Vendelbo[1,3], M. A. Madsen[1], L. C. Gormsen[1,2], T. Ø. Barkholt[1];*
[1]Dept of Nuclear Medicine and PET-Centre, Aarhus University Hospital, Aarhus, DENMARK, [2]Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK, [3]Department of Biomedicine, Aarhus University, Aarhus, DENMARK.

OP-802
[^{99m}Tc]Tc-anti-NCA-95 (Besilesomab) scintigraphy in spondylodiscitis - a case report
***A. Teixeira**, H. Martins, M. Silva, L. Costa;*
Centro Hospitalar Universitário do Porto, Porto, PORTUGAL.

OP-803
Bone scan in asymptomatic patients with TTR gene mutation at risk for amyloid cardiomyopathy:carpe diem, tempus fugit!
***R. Bonfiglioli**[1], A. Paccagnella[2], F. Mattana[3], M. Sguazzotti[4,5], G. Caponetti[4,5], S. Longhi[5], N. Galiè[4], S. Fanti[4];*
[1]Nuclear Medicine,IRCCS,Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [2]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [3]Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, ITALY, [4]Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, ITALY, [5]Cardiology Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

OP-804
Role of 24-Hour ^{18}F-FDG PET/CT and Normalized Semiquantitative Analysis in Planning and Evaluation of Local Microwave Ablative Therapy in Lung Lesion
***N. Kelemen**[1], Z. Bánsághi[2], S. Czibor[1], B. Futácsi[2], F. Kiss[1], I. Takács[2], Z. Varga[1], M. Barra[1], O. Albert[1], A. Bohács[3], P. Nagy[4], G. Forika[4], T. Györke[1];*
[1]Semmelweis University, Medical Imaging Centre, Department of Nuclear Medicine, Budapest, HUNGARY, [2]Semmelweis University, Medical Imaging Centre, Department of Radiology, Budapest, Budapest, HUNGARY, [3]Semmelweis University, Department of Pulmonology, Budapest, HUNGARY, [4]Semmelweis University, Department of Pathology and Experimental Cancer Research, Budapest, HUNGARY.

OP-807
Unusually seen pattern of T99m-DPD soft tissue uptake in a patient with AL amyloidosis
***I. Armenis**[1], A. Doumas[2], V. Chatzoglou[1], S. Kitziri[1], M. Koutelou[1];*
[1]Onassis Cardiac Surgery Center, Athens, GREECE, [2]Aristotle University of Thessaloniki, Thessaloniki, GREECE.

OP-808
Using 18-F FDG PET-CT to Detect Diffuse Eosinophilic Myositis- Pediatric Case Report
***K. M. Zuna Vasquez**, P. G. Limeira Nobre de Lacerda, S. A. Lopes de Souza, J. L. de Medeiros Amarante Júnior, P. H. Rosado de Castro, J. Calvino de Albuquerque Marinho, M. Pinto Pellini, B. Arruda Matheos de Lima, P. Gomes da Cruz Netto, B. Nóbrega de Oliveira, L. M. Muniz Assis dos Santos, R. de Souza Leão Lima, M. Bonifácio das Neves, M. C. Pinheiro Pessoa Landesmann, J. Cunha de Azevedo;*
Hospital Universitário Clementino Fraga Filho / Universidade Federal do Rio de Janeiro, Rio de Janeiro, BRAZIL.

OP-809
Renal scintigraphy as confirmatory test for the diagnosis of urinothorax, regardlessthe pleural fluid/serum creatinine ratio
***J. Koutsikos**[1], A. Kokkini - Paschou[1], S. Bakalis[2], S. Vasileiou[2], T. Riba[3], K. Psathakis[3];*
[1]Nuclear Medicine Department. 401 General Military Hospital; Henry Dunant Hospital Center, Athens, GREECE, [2]401 General Military Hospital; Nuclear Medicine Department., Athens, GREECE, [3]401 General Military Hospital; Department of Pneumonology, Athens, GREECE.

OP-810
Lymphoscintigraphy in newborns with chylous ascites: a simple tool for an early diagnosis of congenital lymphatic dysplasia
***H. Noamen**[1], M. Somai[1,2], R. Layouni[1], I. Meddeb[1,2], I. Yeddes[1,2], A. Mhiri[1];*
[1]Nuclear Medecine Department ,Institut Salah Azaiez, Tunis, TUNISIA, [2]faculté de médecine de Tunis, Tunis, TUNISIA.

OP-811
Incidental Diagnosis of Gastrointestinal Amyloidosis Through 99mTc-DPD Scintigraphy: Case Report
***N. Martínez-Amador**, F. Gómez-de la Fuente, I. Martínez-Rodríguez, J. Jiménez-Bonilla, M. de Arcocha-Torres, V. Mendi-Barcina, A. Sánchez-Salmón, J. Andrés-Pacheco, A. Gutiérrez-González, M. Pombo-López, A. Bota-Bota, M. Rodil-Gallego, A. García-Ruiz, R. Quirce;*
Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

OP-812
SPECT/CT Lymphoscintigraphy in Verifying Lymphorrhea: an Example Case of Posttreatment Extra-Abdominal Desmoid Fibroma
***T. Makurova**, P. Simeshchenko;*
Mariinskaya Hospital, Saint Petersburg, RUSSIAN FEDERATION.

OP-813
The Utility Of The Role Of Two-Phase Whole-Body Bone ^{99m}Tc-Hydroxyphosphonate Scintigraphy For The Diagnosis Of Multifocal Osteonecrosis In Patients With Chronic HIV Infection And Retroviral Treatment
***M. Feriche Aragon**, C. Balbin García, J. Villena Salinas, M. Cañada Rodriguez, D. Patrut, S. Sanz Viedma;*
Hospital Universitario Virgen de la Victoria, Málaga, SPAIN.

OP-814
Unusual skeletal scintigraphic pattern in a case of polyostotic fibrous dysplasia: The "eye-mask sign"?
***S. Jain**, D. Singh, S. Jain;*
All India Institute of Medical Sciences, Bhopal, INDIA.

OP-815
Diagnosis of devitalized femoral shaft segment in delayed union by dynamic 18F-NaF-PET/CT - a case report
***M. Grunert**[1,2], B. Klemenz[1];*
[1]Department of Nuclear Medicine, German Armed Forces Hospital of Ulm, Ulm, GERMANY, [2]Department of Nuclear Medicine, University Hospital of Ulm, Ulm, GERMANY.

OP-816
[^{68}Ga]Ga-DOTA-UBI(29-41) PET/CT: First test in Brazil
***S. Nogueira**, V. Iacone, K. A. K. Sato, F. A. B. Da Luz, R. S. Da Silva, M. F. Barboza, A. Osawa, L. Y. I. Yamaga;*
Hospital Israelita Albert Einstein, São Paulo, BRAZIL.

1704

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 114

Joint Symposium 7 - Oncology & Theranostics Committee / ESR: Multimodality Functional Imaging

OP-817
MI - State of the Art and Future Perspectives
***C. C. Cyran**;*
Klinik und Poliklinik für Radiologie, LMU Klinikum, Munich, GERMANY.

OP-818
MI - PET/MR - When and Why?
P. Mapelli;
Vita Salute San Raffaele University, Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY.

OP-819
MI in Organ-Confined Prostate Cancer
***F. de Galiza Borbosa**;*
Universitätsspital Zürich, Zurich, SWITZERLAND.

OP-820
MI in Radioguided Surgery
***D.D.D. Rietbergen**;*
LUMC, Leiden, NETHERLANDS.

1705

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 211

Cutting Edge Science Track - TROP Session: Developments in SPECT

OP-821
Head-to-head Comparison of a Conventional or CZT-based SPECT/CT with a Next Generation Multidetector CZT-based SPECT/CT System
***H. Duan**, V. Ferri, P. Castaneda, T. Visser, K. Luong, G. A. Davidzon, C. Mari Aparici, A. Iagaru;*
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-822
Performance study of a 360° CZT camera for dosimetry planning step in SIRT treatment of liver cancer and liver metastases
***A. Krzyzaniak**[1], S. Parisse Di-Martino[1], L. Vergnaud[2], T. Mognetti[1], D. Sarrut[2], J. N. Badel[1];*
[1]Centre Léon Bérard, Lyon, FRANCE, [2]CREATIS; CNRS UMR5220; Inserm U1044; INSA-Lyon; Université Lyon 1, Lyon, FRANCE.

OP-823
Feasibility of 177Lu quantification with a 360° CZT gamma camera
***J. Badel**[1], L. Vergnaud[2], T. Baudier[2], P. Boissard[1], H. Rida[3], A. Dieudonne[3], D. Sarrut[2];*
[1]Centre Leon-Berard, Université de Lyon, Lyon, FRANCE, [2]CREATIS, CNRS UMR5220, Université de Lyon, Lyon, FRANCE, [3]Centre Henri Becquerel, Rouen, FRANCE.

OP-824
Towards accurate ^{177}Lu SPECT activity quantification and standardization of the gamma camera calibration protocol
***S. Raskin**[1], A. Chicheportiche[2], D. Gamliel[3], D. Abookasis[3], S. Ben-Haim[2];*
[1]University of Ariel, Jerusalem, ISRAEL, [2]Department of Nuclear Medicine & Biophysics, Hadassah Medical Center, Jerusalem, ISRAEL, [3]University of Ariel, Ariel, ISRAEL.

OP-825
Effect of Kilovoltage and Quality Reference mAs on CT-Based Attenuation Correction in ^{177}Lu SPECT/CT Imaging: a Phantom Study
***M. Salas Ramirez**, M. Lassmann, J. Tran-Gia;*
University of Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY.

OP-826
Exploring the Quantitative Impact of Non-Uniformities in SPECT-Imaging With ^{161}Tb
***F. Westerbergh**[1], T. Rydén[2], M. van Essen[3], N. P. van der Meulen[4,5], C. Müller[5], P. Bernhardt[1,2];*
[1]Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, [2]Department of Medical Physics and Biomedical Engineering (MFT), Sahlgrenska University Hospital, Gothenburg, SWEDEN, [3]Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, SWEDEN, [4]Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, SWITZERLAND, [5]Center for Radiopharmaceutical Sciences, Paul Scherrer Institute, Villigen, SWITZERLAND.

OP-827
An experimental and computational evaluation of a novel Timepix3 detector for Compton imaging in Nuclear Medicine
***B. Kamtchou**[1], S. Cournane[1,2], L. Vintro[1];*
[1]Centre for Physics in Health and Medicine (CPHM), School of Physics, University College Dublin, Dublin, IRELAND, [2]St. Vincent's University Hospital, Dublin, IRELAND.

OP-828
Effect of High-Uptake Regions with Inconsistent Motion on Data Driven Respiratory Gating in SPECT Myocardial Perfusion Imaging using Digital Phantoms
***M. Reymann**[1], F. Massanes[2], T. Kuwert[3], A. H. Vija[2], A. K. Maier[4];*
[1]Siemens Healthcare GmbH, Forchheim, GERMANY, [2]Siemens Medical Solutions Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA, [3]Department of Nuclear Medicine, Universitätsklinikum Erlangen, Erlangen, GERMANY, [4]Pattern Recognition Lab, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, GERMANY.

OP-829
Initial Assessment of a Novel Multi-pinhole Collimator on Triple-head SPECT for Cardiovascular Imaging
Á. Krizsán[1], *K. Kukuts*[1], *W. Al-Muhanna*[1,2], *Z. Szoboszlai*[1], *L. Balazs*[2], *J. Kiss*[3], *S. Nekolla*[4], *S. Barna*[1], *I. Garai*[1], *T. Bukki*[2], *A. Forgacs*[1,2];
[1]*ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY,* [2]*Mediso Ltd., Budapest, HUNGARY,* [3]*Division of Radiology and Imaging Science, Department of Medical Imaging, University of Debrecen, Debrecen, HUNGARY,* [4]*Technische Universität München, Munich, GERMANY.*

1706

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 117

Clinical Oncology Track - TROP Session: Prostate Beyond Usual

OP-830
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
W. Fendler[3], *A. Gafita*[1], *I. Rauscher*[2], *V. Murthy*[1], *W. Hui*[2], *W. Armstrong*[1], *K. Herrmann*[3], *W. Weber*[2], *J. Calais*[1], *M. Eiber*[2], *M. Weber*[3], *M. Benz*[1];
[1]*University of California, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Technical University Munich, Munich, GERMANY,* [3]*University of Duisburg-Essen, Essen, GERMANY.*

OP-831
Combined [18F]FDG and [68Ga]Ga-PSMA-11 PET/CT for [177Lu]-PSMA-Radioligand therapy assessment with long-axial field of view (LAFOV) PET/CT
I. Alberts, *R. Schepers, K. Zeimpekis, M. Viscione, A. Rominger, A. Afshar-Oromieh;*
Institut für Nuklearmedizin, Bern, SWITZERLAND.

OP-832
When to Repeat Imaging after a Negative PSMA PET Scan in Patients with Recurrent Prostate Cancer under Active Surveillance: A Single-Center Retrospective Study
P. Thin[1,2], *M. Hotta*[1], *A. Gafita*[1], *J. Calais*[1], *I. Sonni*[1];
[1]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Western University of Health Sciences, Pomona, CA, UNITED STATES OF AMERICA.*

OP-833
Head-to-head comparison between the diagnostic accuracy of 68Ga-PSMA PET/CT and pelvic mp-3Tesla MRI in patients with biochemical / clinical suspicion of clinically-significant prostate cancer: a per-patient and per-lobe analysis
M. Celli[1], *R. Gunelli*[2], *F. Ferroni*[3], *A. Vici*[2], *P. Caroli*[1], *O. Saleh*[2], *L. Fantini*[1], *V. Rossetti*[1], *U. De Giorgi*[4], *D. Barone*[3], *V. Di Iorio*[5], *G. Paganelli*[1], *F. Matteucci*[1];
[1]*Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [2]*Urology Unit, Ospedale "G.B.Morgagni - L.Pierantoni", Azienda USL della Romagna, Forlì, ITALY,* [3]*Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [4]*Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [5]*Unit of Oncological Pharmacy, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.*

OP-834
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0):an international multicenter study
W. Fendler[3], *A. Gafita*[1], *I. Rauscher*[2], *M. Weber*[3], *B. Hadaschik*[3], *H. Wang*[2], *W. Armstrong*[1], *R. Tauber*[2], *T. Grogan*[1], *J. Czernin*[1], *M. Rettig*[1], *K. Herrmann*[3], *J. Calais*[1], *W. Weber*[2], *M. Benz*[1], *M. Eiber*[2];
[1]*University of California, Los Angeles, CA, UNITED STATES OF AMERICA,* [2]*Technical University Munich, Munich, GERMANY,* [3]*University of Duisburg-Essen, Essen, GERMANY.*

OP-835
Contribution of PSMA PET/CT to Evaluation of Response to Systemic Therapies: Preliminary Results
G. Beydagi[1], *E. Demirci*[1], *N. Alan Selcuk*[1], *K. Akcay*[1], *M. Ocak*[2], *T. Toklu*[1], *B. Caner*[1], *L. Kabasakal*[3];
[1]*Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE,* [3]*Istanbul University-Cerrahpasa Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

OP-836
Artificial intelligence for the detection of primary tumour, recurrence and metastases in PSMA PET-CT in prostate cancer
E. Tragardh[1,2], *O. Enqvist*[3,4], *J. Ulén*[3], *J. Jögi*[1], *L. Edenbrandt*[5];
[1]*Skåne University Hospital, Malmo, SWEDEN,* [2]*Lund University, Malmö, SWEDEN,* [3]*Eigenvision AB, Malmo, SWEDEN,* [4]*Chalmers University of Technology, Gothenburg, SWEDEN,* [5]*Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN.*

OP-837
PSMA-PET/CT-guided External Beam Radiotherapy of Osseous Metastases in an Oligometastatic Prostate Cancer Setting
G. T. Sheikh[1], *P. Rogowski*[2], *M. J. Zacherl*[1], *L. M. Unterrainer*[1], *V. Wenter*[1], *F. J. Dekorsy*[1], *R. Tiling*[1], *T. Pfluger*[1], *M. Unterrainer*[3], *J. Rübenthaler*[3], *C. C. Cyran*[3], *P. Bartenstein*[1], *M. Li*[2], *L. Beyer*[1];
[1]*Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY,* [2]*Department of Radiotherapy and Radiation Oncology, University Hospital LMU Munich, Munich, GERMANY,* [3]*Department of Radiology, University Hospital LMU Munich, Munich, GERMANY.*

OP-838
Evaluation of biochemical response with different metabolic response assessment methods on ^{68}GaPSMA-PET/CT imaging in metastatic castration-resistant prostate cancer patients treated with ^{177}Lu-Prostate Specific Membrane Antigen Radioligand Therapy
E. Sahin, *U. Elboga, Y. B. Çayırlı, U. Çimen, V. Mumcu, M. Okuyan, E. Ekinci, Y. Z. Çelen;*
Gaziantep University Faculty of Medicine, Gaziantep, TÜRKIYE.

1707

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 115

Cardiovascular Committee - TROP Session: Other Cardiovascular Imaging

OP-839
Repeated measurements of lower leg skeletal muscle perfusion using ^{15}O-water PET/CT
N. Christensen[1,2], *C. S. Buhl*[2], *J. Sørensen*[1], *K. Bouchelouche*[1], *M. A. Madsen*[1], *L. P. Tolbod*[1];
[1]*Department of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus N, DENMARK,* [2]*Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, DENMARK.*

OP-840
[^{18}F]GP1 PET/CT in Patients with Prosthetic Valve Thrombosis - Diagnosis - Therapy - Follow up
V. Hugenberg[1], *R. Zabel*[1], *R. Preuss*[1], *K. Friedrichs*[2], *T. Rudolph*[2], *N. Koglin*[3], *W. Burchert*[1], *M. Deutsch*[4];
[1]*Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY,* [2]*Department of General und Interventional Cardiology/ Angiology, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY,* [3]*Life Molecular Imaging GmbH, Berlin, GERMANY,* [4]*Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY.*

OP-841
Comparison between ^{99m}Tc-WBC SPECT/CT and ^{18}F-FDG PET/CT in suspected VGEI
C. Lauri, *G. Campagna, R. Ottaviani, M. Taurino, A. Signore;*
Sapienza University, Rome, ITALY.

OP-842
The Value of Multimodal Studies in the Diagnosis and Prognosis of Patients with Pulmonary Hypertension
P. Hsu[1,2,3], ***H. Hsu***[4], *Y. Lin*[5], *M. Cheng*[6], *J. Chen*[4], *Y. Wu*[7,8,9];
[1]*Division of Nuclear Medicine, Fu Jen Catholic University Hospital, Fu Jen Catholic University, New Taipei City, TAIWAN,* [2]*Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, TAIWAN,* [3]*School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, TAIWAN,* [4]*Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN,* [5]*Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN,* [6]*Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN,* [7]*Cardiology Division of Cardiovascular Medical Center and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, TAIWAN,* [8]*National Yang-Ming University School of Medicine, Taipei, TAIWAN,* [9]*Departments of Nuclear Medicine and Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN.*

OP-843
Increased 18F-Fluorodeoxyglucose Uptake in the Cardiac Atria: An Evidence for Increased Atrial Inflammation in Patients with Atrial Fibrillation?
O. Nakamura[1], *T. Arentz*[2], *P. T. Meyer*[1], *A. S. Jadidi*[2], *C. Goetz*[1];
[1]*University Medical Center Freiburg, Freiburg im Breisgau, GERMANY,* [2]*University Heart Center Freiburg • Bad Krozingen, Freiburg im Breisgau, GERMANY.*

OP-844
Bariatric surgery is associated with brown adipose tissue recruitment and reduced arterial inflammation in individuals with morbid obesity
O. Kulterer[1], *C. T. Herz*[2], *A. Gruber*[1], *G. Prager*[3], *M. Hacker*[1], *F. W. Kiefer*[4], *A. R. Haug*[1];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, AUSTRIA,* [3]*Division of General Surgery, Department of Surgery, Medical University of Vienna, Vienna, AUSTRIA,* [4]*Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, AUSTRIA.*

OP-845
Association of a new arterial inflammation PET biomarker with coronary stenosis in patients with cardiovascular risk factors
A. Bronte, *F. Guillen, L. García, L. Sancho, J. Rosales, J. Bastidas, V. Betech, F. Minguez, S. Browne, M. Marcos, A. Fernandez-Montero, D. Martinez-Urbistondo, M. Colina, J. Pastrana, M. García-Velloso;*
University Clinic of Navarra, Pamplona, SPAIN.

OP-846
Assessing The Metabolic Activity of the Arterial Wall on PET/CT Using a Semi-Automated Method
L. Lezaic[1], *J. Jamsek*[1], *M. Kastelic*[2], *Z. Macek Lezaic*[3];
[1]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,* [2]*Celje General Hospital, Celje, SLOVENIA,* [3]*Rozna Dolina, c. VI/8, 1000 Ljubljana, Ljubljana, SLOVENIA.*

OP-847
Increased central blood volume during adenosine-induced hyperemia in standard Rubidium-82 cardiac perfusion imaging
M. Lassen, *C. Byrne, J. Hartmann, A. Kjaer, R. M. G. Berg, P. Hasbak;*
Rigshospitalet, Copenhagen, DENMARK.

1708

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 212

Thyroid Committee - Featured Session: Treatment of Benign Thyroid Disease

OP-848
Current Standard and Outcomes in Treatmnet of Benign Thyroide Disease
A. Campenni';
Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, ITALY.

OP-849
Salvage 131-I therapy in course of life-threating amiodarone-induced hyperthyroidism
M. Opalinska[1], *J. Pantofliński*[2], *G. Sokołowski*[3], *D. Pach*[3], *M. Kostecka-Matyja*[3], *B. Partyński*[2], *K. Żabicka*[2], *M. Kieć-Klimczak*[3], *A. Hubalewska-Dydejczyk*[3];
[1]*Nuclear Medicine Unit, Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital, Krakow, POLAND,* [2]*Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital, Krakow, POLAND,* [3]*Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.*

OP-850
Early Outcome of Radioiodine Treatment in Graves' Disease Patients
T. Zaletel[1], *Ž. Rot*[2], *S. Gaberšček*[2,3], *K. Zaletel*[2,3];
[1]*School of Clinical Medicine, University of Cambridge, Cambridge, UNITED KINGDOM,* [2]*Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA,* [3]*Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.*

OP-851
Radioiodine and Thyroid Eye Disease (TED): lessons learned from and internal audit of 101 patients
A. Maenhout[1], *N. Quah Qin Xian*[1], *A. M. Wren*[1], *J. S. Cleland*[1], *E. Kalogianni*[2], *M. M. Sobti*[1];
[1]*Chelsea and Westminster Hospital, London, UNITED KINGDOM,* [2]*King's College London, London, UNITED KINGDOM.*

OP-852
Definitive treatment of hyperthyroidism with radioactive iodine (RAI) in children and adolescents
J. Jandric[1,2], *G. Tosi*[3], *M. Vigone*[4], *M. Abbate*[4], *G. Vincenzi*[4], *G. Pepe*[5], *A. Chiti*[1,2];
[1]*Humanitas University, Pieve Emanuele - Milan, ITALY,* [2]*IRCCS Istitito Clinico Humanitas, Nuclear Medicine Department, Rozzano, ITALY,* [3]*IRCCS Istitito Clinico Humanitas, Health Physics Department, Rozzano, ITALY,* [4]*IRCCS Ospedale San Raffaele, Pediatric and Neonatology Unit, Milan, ITALY,* [5]*IRCCS Policlinico San Matteo, Nuclear Medicine Department, Pavia, ITALY.*

OP-853
The efficacy of radioiodine therapy in patients with non-toxic multinodular goiter with large cold nodule
S. Abdelrazek, *P. Szumowski, J. Mysliwiec;*
Medical University of Bialystok, Bialystok, POLAND.

OP-854
Radioiodine therapy and the induction of hyperthyroidism in patients with non-toxic goitre
S. Abdelrazek, *P. Szumowski, J. Mysliwiec, W. Madra;*
Medical University of Bialystok, Bialystok, POLAND.

OP-855
The radioiodine therapy out come in patient with subclinical hyperthyroidism
S. Abdelrazek, *P. Szumowski, L. Zukowski, J. Mysliwiec, W. Madra;*
Medical University of Bialystok, Bialystok, POLAND.

OP-856
The effects assessment of ^{131}I radioiodine therapy in patients with autonomously functioning thyroid nodules
Z. Adamczewski[1], *J. Kuśmierek*[1], *J. Makarewicz*[2], *P. Jarek*[2];
[1]*Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND,* [2]*Department of Nuclear Medicine and Oncological Endocrinology, Maria Skłodowska-Curie Memorial District Hospital, Zgierz, POLAND.*

1710a

Wednesday, October 19, 2022, 08:00 - 09:00

Hall 116

Mini Course 1 - Technologists Committee: CZT in Non-Cardiac Nuclear Medicine

OP-857
Why we Choose a CTZ Scanner
R. Strand Olsen;
Bispebjerg Hospital, clinical physiology and nuclear medicine department, Copenhagen, DENMARK.

OP-858
The CZT Scanner
L. Raes;
Universitair Ziekenhuis Brussel, Nuclear Medicine, Brussels, BELGIUM.

OP-859
Optimization of the Acquisition and Reconstruction
R. Danieli;
Jules Bordet Institute, Department of Medical Physics, Brussels, BELGIUM.

OP-860
Session Summary

1710b

Wednesday, October 19, 2022, 09:05 - 10:05

Hall 116

Mini Course 2 - Technologists Committee: Non-Fluoride Cyclotron Production - O15-Water Applications

OP-861
General Design and Challenges of Non-Fluorine-18 Labeled Radiopharmaceuticals
F. Cleeren;
Laboratory for Radiopharmaceutical Research Department of Pharmaceutical and Pharmacological Sciences Faculty of Pharmaceutical sciences – KU Leuven, Leuven, BELGIUM.

OP-862
Cyclotron Production for 15O-Water
P. Rafn Hansen;
Bispebjerg and Frederiksberg Hospital: Department of Clinical Physiology and Nuclear Medicine, Copenhagen, DENMARK.

OP-863
Scanning with 15O-Water - From Patient Preparation to Image Reconstruction
K.J. Erenskjold;
Bispebjerg and Frederiksberg Hospital: Department of Clinical Physiology and Nuclear Medicine, Copenhagen, DENMARK.

1801

Wednesday, October 19, 2022, 09:45 - 11:15

Auditorium

CME 14 - Oncology & Theranostics Committee: Rare Tumours

OP-864
Salivary Gland Cancer
M.J.M. Uijen;
Radboud university medical centre, Medical Oncology, Nijmegen, NETHERLANDS.

OP-865
Medullary Thyroid Cancer
C. Rottenburger;
University Hospital Basel, Division of Nuclear Medicine, Basel, SWITZERLAND.

OP-866
Merkel Cell Carcinoma
S. Taralli;
Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

OP-867
Insulinoma
M. Gotthardt;
Radboud university medical centre, Department of Medical Imaging, Nijmegen, NETHERLANDS.

1802

Wednesday, October 19, 2022, 09:45 - 11:15

Hall 112 (Arena)

Debate 6 - Dosimetry Committee: Dosimetry in Clinical Practice – Sense vs. Nonsense

OP-868
A. Eccles;
Guys and St Thomas NHS Foundation Trust, Nuclear Medicine Department, London, UNITED KINGDOM.

OP-869
S. Peters;
Radboudumc, Department of Radiology and Nuclear Medicine, Nijmegen, NETHERLANDS.

1803

Wednesday, October 19, 2022, 09:45 - 11:15

Hall 113

LIPS Session 14 - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy + Physics Committee: Pharmacokinetics - From Basics to Clinical Applications
Interactive Session

OP-871
Pharmacokinetics - Back to Basics
L. Rbah-Vidal;
CRCI2NA, INSERM, CNRS, University of Nantes, Nantes, FRANCE.

OP-872
PK Modelling in Cardiology
M. Lubberink;
Uppsala University, Department of Surgical Sciences, Radiology, Uppsala, SWEDEN.

OP-873
PK Modelling and Parametric Imaging in Clinical Oncology
A. Dimitrakopoulou-Strauss;
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY.

1804

Wednesday, October 19, 2022, 09:45 - 11:15

Hall 114

M2M Track - TROP Session: Antibodies - Reliable Workhorses

OP-874
PET-CT imaging of CD69 in rheumatoid arthritis model
E. Puuvuori[1,2], *Y. Shen*[3], *B. Zhang*[1,2], *G. Hulsart Billström*[4,2], *J. Persson*[4,2,5], *S. Ståhl*[5], *O. Korsgren*[6], *J. Löfblom*[5], *F. Wermeling*[3], *O. Eriksson*[1,2];
[1]*Department of Medicinal Chemistry, Uppsala, SWEDEN,* [2]*Science for Life Laboratory, Uppsala, SWEDEN,* [3]*Department of Medicine, Karolinska Institute, Stockholm, SWEDEN,* [4]*Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN,* [5]*Department of Protein Science, Division of Protein Engineering, KTH Royal Institute of Technology, Stockholm, SWEDEN,* [6]*Department of IGP, Uppsala University, Uppsala, SWEDEN.*

OP-875
Evaluation of Affibody-Based Binder for Targeting of Immune Check-Point Molecule B7-H3
M. Oroujeni[1,2], *E. Bezverkhniaia*[3], *T. Xu*[1], *Y. Liu*[1], *E. Plotnikov*[3], *I. Karlberg*[2], *A. Orlova*[1,3], *V. Tolmachev*[1,3], *F. Y. Frejd*[1,2];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*Affibody AB, Stockholm, SWEDEN,* [3]*Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.*

OP-876
Non-invasive in vivo assessment of CD4$^+$ T cells using Positron Emission Tomography
N. Perujo-Holland, *X. Fan, M. Requesens, H. W. Nijman, P. H. Elsinga, M. de Bruyn;*
University Medical Centre Groningen, Groningen, NETHERLANDS.

OP-877
Nanobody targeting CD70 for immunoPET imaging in preclinical tumor models
F. Elvas[1], *J. Dewulf*[1], *T. Flieswasser*[1], *T. Delahaye*[2], *C. Vanghestel*[1], *A. Miranda*[1], *J. Jacobs*[2], *E. Smits*[1], *T. Van den Wyngaert*[1];
[1]*University of Antwerp, Antwerp, BELGIUM,*
[2]*Argenx BVBA, Ghent, BELGIUM.*

OP-878
Optimizing the therapeutic index of sdAb-based radiopharmaceuticals using a pretargeting strategy
S. Poty[1], *L. Ordas*[1], *Y. Dekempeneer*[2], *A. A. Parach*[1], *L. Navarro*[2], *F. Santens*[2], *M. Bardiès*[1], *M. D'huyvetter*[2], *T. Lahoutte*[2], *J. Pouget*[1];
[1]*Institut de Recherche en Cancérologie de Montpellier - INSERM, Montpellier, FRANCE,* [2]*PRECIRIX, Brussels, BELGIUM.*

OP-879
In vivo imaging of HER2 receptor status with a novel ^{52}Mn-labelled antibody
A. Vágner[1], *M. T. Ngo*[2], *G. Nagy*[1], *T. Nagy*[2], *G. Z. Sajtos*[3], *B. Váradi*[3,4,5], *D. Szikra*[2], *G. Tircsó*[3], *I. Garai*[1];
[1]*Scanomed Ltd., Debrecen, HUNGARY,* [2]*University of Debrecen, Faculty of Medicine, Department of Medical Imaging, Division of Nuclear Medicine and Translational Imaging, Debrecen, HUNGARY,* [3]*University of Debrecen, Faculty of Science and Technology, Department of Physical Chemistry, Debrecen, HUNGARY,* [4]*University of Debrecen, Faculty of Science and Technology, Doctoral School of Chemistry, Debrecen, HUNGARY,* [5]*ELKH Institute for Nuclear Research, ATOMKI, Debrecen, HUNGARY.*

OP-880
Evaluation of influence of cytotoxic payload on biodistribution of HER2-targeting affibody-drug conjugates using a radioactive label
A. Vorobyeva[1], *T. Xu*[1], *Y. Liu*[1], *M. Oroujeni*[1], *W. Yin*[2], *H. Ding*[2], *V. Bodenko*[3], *M. S. Tretyakova*[3], *M. V. Belousov*[4], *T. Gräslund*[2], *A. Orlova*[1], *V. Tolmachev*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*KTH Royal Institute of Technology, Stockholm, SWEDEN,* [3]*Research Centrum for Oncotheranostics, Tomsk, RUSSIAN FEDERATION,* [4]*Siberian State Medical University, Tomsk, RUSSIAN FEDERATION.*

OP-881
Labelling anti-HER2-affibodies with ^{52}Mn via pyclen based bifunctional ligands: from ligand design to in vivo PET/MR experiments
B. Váradi[1,2,3], *Z. Garda*[1], *E. Madarasi*[1,2], *K. Brezovcsik*[3], *A. Vágner*[4], *T. Nagy*[4], *I. Garai*[4,5], *T. M. Ngô*[4], *A. G. Puiu*[6], *A. M. Vasilescu*[6], *Z. Szűcs*[3], *S. E. Szedlacsek*[6], *G. Nagy*[4], *G. Tircsó*[1];
[1]*Department of Physical Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen, HUNGARY,* [2]*Doctoral School of Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen, HUNGARY,* [3]*ELKH Institute for Nuclear Research, ATOMKI, Debrecen, HUNGARY,* [4]*Scanomed Ltd., Debrecen, HUNGARY,* [5]*Division of Nuclear Medicine, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY,* [6]*Department of Enzymology, Institute of Biochemistry of the Romanian Academy, Bucharest, ROMANIA.*

OP-882
[^{89}Zr]Zr-ImmunoPET to evaluate the efficacy of cleavable linkers in antibody drug conjugates
M. Dominguez Garcia, *S. J. Raheem, J. C. Sharpe, B. M. Toosi, C. P. Phenix, E. W. Price;*
University of Saskatchewan, Saskatoon, SK, CANADA.

1805

Wednesday, October 19, 2022, 09:45 - 11:15

Hall 211

Cutting Edge Science Track - TROP Session: AI Segmentation and Denoising

OP-883
Computational Models for Patient Stratification in Molecular Radiotherapy (COMPASS): a first dataset analysis in hyperthyroid patients
D. Deandreis[1], *L. Vija*[2], *G. Rovera*[1], *L. Spagnoli*[3], *F. Courbon*[4], *G. Flux*[5], *J. Taprogge*[5], *F. Buettner*[6,7,8], *L. Strigari*[3];
[1]*Università degli Studi di Torino, Turin, ITALY,* [2]*Oncopole and Paul Sabatier University, Touluse, FRANCE,* [3]*IRCCS Azienda Ospedaliero-Universitaria, Bologna, ITALY,* [4]*Oncopole and Paul Sabatier University, Toulouse, FRANCE,* [5]*Royal Marsden Hospital, London, UNITED KINGDOM,* [6]*German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Frankfurt, GERMANY,* [7]*Goethe University, Frankfurt, GERMANY,* [8]*Frankfurt Cancer Institute, Frankfurt, GERMANY.*

OP-884
Deep representation learning enables automated high-grade cardiac amyloidosis detection on ^{99m}Tc-DPD scans
D. Haberl[1], *C. P. Spielvogel*[1], *M. Hacker*[1], *G. Goliasch*[2], *C. Nitsche*[2];
[1]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Division of Cardiology, Department of Medicine II, Medical University of Vienna, Vienna, AUSTRIA.*

OP-885
Automatic multilabel aorta segmentation in PET/CT using a modified 3D U-Net
G. van Praagh[1], *P. H. Nienhuis*[1], *M. Reijrink*[1], *M. E. J. Davidse*[2], *B. S. Spottiswoode*[3], *F. Gao*[3], *N. H. J. Prakken*[1], *J. M. Wolterink*[2], *K. Mouridsen*[1], *B. Sinha*[1], *R. J. H. Borra*[1], *R. H. J. Slart*[1];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*University of Twente, Enschede, NETHERLANDS,* [3]*Siemens Medical Solutions USA Inc., Knoxville, TN, UNITED STATES OF AMERICA.*

OP-886
PET-based pre-segmentation improves deep learning-based automated renal segmentation based on only CT
J. Leube, *M. Horn, P. Hartrampf, M. Lassmann, J. Tran-Gia;*
Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY.

OP-887
Performance Evaluation of CNN Model for Automatic Segmentation of Intraprostatic Cancer Lesions
S. Ghezzo[2,1], *S. Mongardi*[1], *C. Bezzi*[1,2], *I. Neri*[2], *P. Mapelli*[2], *A. M. Samanes Gajate*[2], *E. Preza*[2], *V. Bettinardi*[2], *T. Russo*[1], *G. Brembilla*[1,3], *F. De Cobelli*[1,3], *L. Gianolli*[2], *P. Scifo*[2], *M. Picchio*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,* [2]*Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [3]*Department of Radiology, IRCCS San Raffaele Scientific Institute, Milan, ITALY.*

OP-888
Automated total metabolic tumour volume on 2-[^{18}F]FDG PET/CT for patients with diffuse large B-cell lymphoma utilising deep learning auto-segmentation of organs for automatic physiologic uptake removal
P. Wilson[1], *R. Niman*[1], *T. Susman*[1], *J. Buteau*[2], *E. Turcotte*[3], *A. S. Nelson*[1];
[1]*MIM Software Inc., Beachwood, OH, UNITED STATES OF AMERICA,* [2]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [3]*CHUS Fleurimont, Sherbrooke, QC, CANADA.*

OP-889
Multi-organ objective segmentation (MOOSE): A data-centric AI solution solution for the semantic segmentation of 18F-FDG PET/CT total-body datasets
L. Shiyam Sundar[1], *J. Yu*[1], *O. Muzik*[2], *O. C. Kulterer*[1], *B. Fueger*[1], *D. Kifjak*[1], *T. Nakuz*[1], *H. Shin*[1], *A. K. Sima*[1], *D. Kitzmantl*[1], *R. D. Badawi*[3], *S. R. Cherry*[3], *B. A. Spencer*[3], *L. Nardo*[3], *M. Hacker*[1], *T. Beyer*[1];
[1]*Medical university of Vienna, Vienna, AUSTRIA,* [2]*Wayne State University School of Medicine, Detroit, MI, UNITED STATES OF AMERICA,* [3]*University of California-Davis, Davis, CA, UNITED STATES OF AMERICA.*

OP-890
Artificial Intelligence Based PET Denoising for Optimizing ^{68}Ge/^{68}Ga Generator Use throughout its Lifetime
C. Lasnon, *K. Weyts, A. Prigent, G. Foucras, C. Jaudet, E. Quak;*
François Baclesse Cancer Centre, Caen, FRANCE.

OP-891
The feasibility study of low dose PET / MR brain imaging based on deep learning in children with epilepsy
Y. Xu[1], *J. Wang*[2];
[1]*Hangzhou Universal Imaging Diagnostic Center, Hangzhou, CHINA,* [2]*Children's Hospital of Soochow University, Suzhou, CHINA.*

1806

Wednesday, October 19, 2022, 09:45 - 11:15

Hall 117

Clinical Oncology Track - TROP Session: Prostate Recurrence

OP-892
Modified PROMISE Criteria for Standardized Interpretation of GRPR-targeted PET
H. Duan, *G. A. Davidzon, F. Moradi, T. Liang, A. Iagaru;*
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

OP-893
Comparison of hormone-sensitive oligometastatic prostate cancer patients based on routine use Choline and/or PSMA PET/CT to guide metastasis-directed therapy
R. Metz[1], *B. Maucherat*[1], *F. Drouet*[2], *M. Le Thiec*[1], *D. Rusu*[1], *A. Morel-Thierry*[1], *E. Picot-Dilly*[1], *V. Fleury*[1], *L. Campion*[3], *C. Rousseau*[3];
[1]*ICO René Gauducheau, F-44800 Saint-Herblain, FRANCE,* [2]*Clinique Mutualiste de l'Estuaire, F-44600 Saint-Nazaire, FRANCE,* [3]*ICO René Gauducheau, F-44800 Saint-Herblain, Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000 Nantes, FRANCE.*

OP-894
[18F]F-DCFPyL-PSMA PET-CT performing dynamic early pelvic acquisition in patients(p) with biochemical recurrence (BR) of Prostate Cancer (PCa): Clinical impact
S. Menendez-Sanchez, *F. Dellepiane-Clarke, I. Navales-Mateu, A. Cardozo-Saavedra, S. Aguadé, M. Simo;*
Hospital Universitario Vall d'Hebron, Barcelona, SPAIN.

OP-895
Interobserver Variability in Assessment of ^{18}F-PSMA-1007 PET Positive Bone Lesions in Prostate Cancer Patients
J. Janssen[1], *W. Noordzij*[2], *T. Velleman*[2], *I. J. de Jong*[3], *J. A. Langendijk*[1], *J. F. Verzijlbergen*[4], *G. N. Stormezand*[2], *S. Aluwini*[1];
[1]*Department of Radiation Oncology, University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Department of Radiology and Nuclear medicine, University Medical Center Groningen, Groningen, NETHERLANDS,* [3]*Department of Urology, University Medical Center Groningen, Groningen, NETHERLANDS,* [4]*Department of Radiology and Nuclear medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS.*

OP-896
Predictors of ^{68}Ga-PSMA PET Positivity in PCa Patients After Radical Prostatectomy: a Machine Learning Approach
S. Ghezzo[1,2], *P. Mapelli*[2], *A. Samanes Gajate*[2], *E. Preza*[2], *A. Spataro*[3,4], *I. Gotuzzo*[5], *C. Bezzi*[1,2], *S. Mongardi*[1], *V. Cucchiara*[1,6,7], *A. Briganti*[1,6,7], *L. Gianolli*[2], *M. Picchio*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,* [2]*Department of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [3]*Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Messina, ITALY,* [4]*University of Messina, Messina, ITALY,* [5]*School of Medicine and Surgery, University of Milano Bicocca, Monza, ITALY,* [6]*Department of Urology, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [7]*Division of Experimental Oncology, URI, Urological Research Institute, Milan, ITALY.*

OP-897
PSMA PET/CT Patterns of Recurrence After Mono-Brachytherapy in Men with Low and Intermediate Prostate Cancer and Subsequent Management
G. Loos[1,2], *J. P. Buteau*[1], *J. Oh*[3], *K. Koo*[1], *S. Van Dyk*[1], *N. Lawrentschuk*[1], *D. G. Murphy*[1], *M. S. Hofman*[1], *S. Williams*[1], *S. Chander*[1];
[1]*Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA,* [2]*Centre Jean Perrin, Clermont-Ferrand, FRANCE,* [3]*BC Cancer Agency, Vancouver, BC, CANADA.*

OP-898
Can we predict skeletal lesion on bone scans based on quantitative PSMA PET/CT features?
R. Laudicella[1,2,3], *M. Bauckneht*[4,5], *A. Maurer*[2], *J. Heimer*[6], *A. G. Gennari*[2], *T. Di Raimondo*[4], *G. Paone*[7], *M. Cuzzocrea*[7], *M. Messerli*[2], *D. Eberli*[8], *I. A. Burger*[1,2];
[1]*Department of Nuclear Medicine, Cantonal Hospital Baden, Baden, SWITZERLAND,* [2]*Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND,* [3]*Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY,* [4]*Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genova, ITALY,* [5]*Department of Health Sciences (DISSAL), University of Genova, Genova, ITALY,* [6]*Department of Mathematics, Seminar for Statistics, ETH Zurich, Zurich, SWITZERLAND,* [7]*Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND,* [8]*Department of Urology, University Hospital of Zürich, Zurich, SWITZERLAND.*

OP-899
Diagnostic Value of ^{99m}Tc-I&S PSMA SPECT/CT for the Restaging of Prostate Cancer
I. Farkas, *G. Sipka, A. Bakos, Z. Mikó, T. Czékus, S. Urbán, L. Pávics, Z. Besenyi;*
University of Szeged, Szeged, HUNGARY.

OP-900
Diagnostic accuracy and therapeutic impact of [^{18}F] DCFPyL (PSMA) PET/CT in biochemical recurrence of prostate cancer
J. Fernández Fernández, *E. Triviño Ibáñez, T. Rudolphi Solero, D. Rivas Navas, A. Rodríguez Fernández;*
Virgen de las Nieves University Hospital, Granada, SPAIN.

1807

Wednesday, October 19, 2022, 09:45 - 11:15

Hall 115

Clinical Oncology Track - TROP Session: Sentinel Node

OP-901
A multicentre clinical trial evaluating the safety and performance of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer
C. Solà Marquès[1], *J. Abascal Junquera*[1], *J. Walz*[2], *W. Everaerts*[3], *K. Goffins*[3], *M. Grootendorst*[4], *F. Oldfield*[4], *A. Mestre Fusco*[5], *S. Vidal-Sicart*[1], *L. Fumado*[1];
[1]*Hospital Del Mar, Barcelona, SPAIN,* [2]*Institut Paoli-Calmettes Cancer Centre, Marseille, FRANCE,* [3]*University Hospitals Leuven and KU Leuven, Leuven, BELGIUM,* [4]*Lightpoint Medical Ltd, Chesham, UNITED KINGDOM,* [5]*Hospital University Dr Josep Trueta, Girona, SPAIN.*

OP-902
Effectiveness of sentinel-node biopsy in detecting nodal metastatic involvement in non-small cell lung carcinoma: a prospective study
C. Pini[1], *F. Fiz*[2], *E. Bottoni*[3], *U. Cariboni*[3], *V. Giudici*[1], *M. Rodari*[3], *A. Chiti*[1], *L. Antunovic*[3];
[1]*Humanitas University, Pieve Emanuele, ITALY,* [2]*E.O. Ospedali Galliera, Genoa, ITALY,* [3]*IRCCS Humanitas Research Hospital, Rozzano, ITALY.*

OP-903
Sentinel lymph node detection in thyroid carcinoma using ^{68}Ga-tilmanocept PET/CT: a proof of concept study
L. H. de Vries, *L. Lodewijk, F. F. T. Ververs, A. J. Poot, I. H. M. Borel Rinkes, M. R. Vriens, B. de Keizer;*
University Medical Center Utrecht, Utrecht, NETHERLANDS.

OP-904
Performance evaluation of the FIS-00 high-definition fluorescence camera prototype during 599 hybrid sentinel node procedures
T. Buckle[1], *D. D. D. Rietbergen*[1], *S. Vidal-Sicart*[2], *A. Perissinotti*[2], *B. Karakullukcu*[3], *M. Klop*[3], *O. Brouwer*[3], *F. W. B. van Leeuwen*[1];
[1]*LUMC, Leiden, NETHERLANDS,* [2]*Hospital Clinic Barcelona, Barcelona, SPAIN,* [3]*Netherlands cancer Insitute- Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS.*

OP-905
Evaluation of a drop-in gamma probe during sentinel lymph node dissection in gynaecological malignancies - comparing use with ridged and steerable laparoscopic instruments
S. Vidal-Sicart[1], *B. Diaz-Feijoo*[2], *A. Glickman*[2], *M. Rius*[2], *N. Carreras*[2], *M. Marina*[2], *A. Perissinotti*[1], *N. Sánchez-Izquierdo*[1], *P. Paredes*[1], *A. Torné*[2], *M. van Oosterom*[3], *F. van Leeuwen*[3];
[1]*Nuclear Medicine Dpt. Hospital Clínic Barcelona, Barcelona, SPAIN,* [2]*Gynaecology Dpt. Hospital Clinic Barcelona, Barcelona, SPAIN,* [3]*Interventional molecular imaging laboratory. Leiden University Medical Centre., Leiden, NETHERLANDS.*

OP-906
Initial experience in the technique of targeted axillary dissection (TAD) in patients with breast cancer and positive axilla, treated with neoadjuvant chemotherapy. Three-year experience.
P. Zaragoza Ballester[1], *D. Vega Pérez*[1], *S. Angiolillo Grau*[1], *S. Ruiz Solís*[1], *S. Aragón Sánchez*[2], *E. Ciruelos Gil*[3], *L. López Marín*[2], *M. Marín Ferrer*[1], *Á. Galiana Morón*[1], *P. Sarandeses Fernández*[1], *V. Godigna Guilloteau*[1], *A. Gómez Grande*[1], *A. Saviatto Nardi*[1], *E. Martínez Alvero*[1], *S. Pérez Quirós*[1], *M. Tabuenca Mateo*[1];
[1]*Nuclear Medicine Department, Hospital Universitario 12 De Octubre, Madrid, SPAIN,* [2]*Gynecology and Obstetrics Department, Hospital Universitario 12 De Octubre, Madrid, SPAIN,* [3]*Medical Oncology Department, Hospital Universitario 12 De Octubre, Madrid, SPAIN.*

OP-907
What is the best tracer for sentinel node detection in early-stage epithelial ovarian cancer?
P. Paredes Barranco, *A. Fritsch Medina, N. Agustí, B. Díaz-Feijoo, F. Campos, J. Cases, J. Ribera, I. Romero, A. Glickman, A. Torné, N. Sánchez-Izquierdo, M. Santos Virosta, S. Vidal-Sicart;*
Hospital Clínic, Barcelona, SPAIN.

OP-908
Preliminary results of the application of sentinel lymph node biopsy (SLNB) in endometrial cancer
S. Asadurova, *S. Fuertes, D. Villasboas, I. Navales, A. Cardozo, S. Cabrera, S. Menéndez, R. Bellviure, F. Velazquez, J. Echeverri, S. Aguadé;*
University Hospital Vall d'Hebron, Barcelona, SPAIN.

OP-909
Sentinel node mapping in conjunctival and eyelid malignancies: a pilot study
G. Pisano[1], *R. Giancipoli*[2], *T. Scotognella*[2], *M. Sammarco*[3], *G. Barbera*[4], *T. Musarra*[5], *D. Di Giuda*[1,2], *L. Zagaria*[2];
[1]*Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY,* [2]*Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [3]*Department of Ophtalmology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [4]*Maxillofacial Surgery Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [5]*Head and neck, lung and endocrine pathology unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY.*

1710c

Wednesday, October 19, 2022, 10:15 - 11:15

Hall 116

Mini Course 3 - Technologists Committee: Digital PET/CT

OP-916
Innovations in PET/CT: Changing from Analogue to Digital Systems
I. Rausch;
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA.

OP-917
Large FOV Digital PET/CT Protocols
B.M. Fischer;
Dept. Clinical Physiology & Nuclear Medicine, Rigshospitalet, Copenhagen, DENMARK.

OP-918
Large FOV Digital PET/CT Protocols
E. Sànchez Saxtoft;
Dept. Clinical Physiology & Nuclear Medicine, Rigshospitalet, Copenhagen, DENMARK.

1901

Wednesday, October 19, 2022, 11:25 - 11:45

Auditorium

Closing Session

OP-919
S. Fanti;
University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

e-Poster Presentation Sessions

209

Sunday, October 16, 2022, 08:00 - 09:30

Hall 111

e-Poster Presentation Session 1 - Bone & Joint + Neuroimaging Committee: Miscellaneous - Bone / Brain / Covid-19 / Lung

EPS-001
Lung Perfusion SPECT/CT in Suspected Chronic Thromboembolic Pulmonary Hypertension: Impact on Classification of Pulmonary Hypertension and Therapeutic Decision
N. Alvarez Mena, *F. Sebastián Palacid, M. García Aragón, B. Pérez López, C. Gamazo Laherrán, M. Alonso Rodríguez, M. González Soto, A. Sainz Esteban, R. Ruano Pérez;*
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

EPS-002
Reproducibility of semi-automated hepatic perfusion measurements using ^{15}O-water PET
M. Lubberink, *P. Runesson, E. Lindström, S. Roslin, J. Vessby, G. Antoni, F. Rorsman;*
Uppsala University, Uppsala, SWEDEN.

EPS-003
Lymphoscintigraphy of lower limbs: A mapping technique for surgery needing lymph node transfer in DIEP reconstruction after breast cancer
E. Isenborghs, *J. Prior, P. di Summa, N. Schaefer, M. Nicod-Lalonde, N. Testart;*
CHUV, Lausanne, SWITZERLAND.

EPS-004
Impact of COVID infection on brain metabolism: the revealing role of 18F-FDG PET/CT
C. Ferrari, *T. Masi, A. G. Nappi, V. Lavelli, P. Mammucci, R. Ruta, A. R. Pisani, G. Rubini;*
Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University Aldo Moro, Bari, ITALY.

EPS-005
Assessment of neuroinflammation using [^{18}F]DPA714 PET in post-COVID-19 patients with and without persisting complaints
D. Visser[1], *S. S. V. Golla*[1], *S. C. J. Verfaillie*[2], *E. M. Coomans*[1], *R. M. Rikken*[1], *E. M. van de Giessen*[1], *S. Boesveldt*[3], *D. M. A. Kamalski*[4], *M. E. den Hollander*[1], *A. Verveen*[2], *M. Yaqub*[1], *F. Barkhof*[1,5], *L. A. Schwarte*[6], *D. W. Koch*[2], *R. C. Schuit*[1], *A. D. Windhorst*[1], *R. Boellaard*[1], *M. van Vugt*[7], *H. Knoop*[2], *B. N. M. van Berckel*[1], *N. Tolboom*[8];
[1]*Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [2]*Department of Medical Psychology, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [3]*Division of Human Nutrition & Health, Wageningen University, Wageningen, NETHERLANDS,* [4]*Department of ENT, University Medical Centre Utrecht, Utrecht, NETHERLANDS,* [5]*Institute of Neurology and Healthcare Engineering, University College London, London, UNITED KINGDOM,* [6]*Department of Anaesthesiology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [7]*Department of Internal Medicine, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS,* [8]*Department of Radiology & Nuclear Medicine, University Medical Centre Utrecht, Utrecht, NETHERLANDS.*

EPS-006
Increased cerebral blood flow and neuroinflammation post COVID-19
M. Jonasson[1,2], *K. Hedman*[2], *A. Tolf*[1,2], *E. Kumlien*[1,2], *G. Antoni*[1,2], *M. Hultström*[1,2], *R. Frithiof*[1,2], *J. Burman*[1,2], *M. Lubberink*[1,2], *M. Lipcsey*[1,2];
[1]*Uppsala University Hospital, Uppsala, SWEDEN,*
[2]*Uppsala University, Uppsala, SWEDEN.*

EPS-007
Effect of Donepezil on cerebral metabolism with ^{18}F-FDG PET: Pharmacog study
L. Guillon[1,2], *N. Khadidja*[2], *M. Beaurain*[1,2], *P. Peran*[2], *P. Payoux*[1,2];
[1]*Nuclear Medicine Department CHU Toulouse, Toulouse, FRANCE,* [2]*ToNIC: ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, Inserm, UPS, Toulouse, FRANCE.*

EPS-008
Illuminating the nature of work-related stress and the underlying functions of cognitive performance and mood regulation in the human brain by nuclear medicine
S. Madsen[1,2,3], *T. Andersen*[4], *S. Hvidsten*[2], *P. Fisher*[5], *J. Pihl-Thingvad*[6,1], *O. Gerke*[2,1], *P. Videbech*[3];
[1]*Department of Clinical Research, University of Southern Denmark, Odense, DENMARK,* [2]*Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK,* [3]*Center for Neuropsychiatric Depression (CNDR), Mental health center Glostrup, Copenhagen, DENMARK,* [4]*Department of Clinical Physiology, Nuclear Medicine and PET, University Hospital Rigshospitalet, Copenhagen, DENMARK,* [5]*Neurobiology Research Unit, Copenhagen University Hospital Rigshospitalet, Copenhagen, DENMARK,* [6]*Department of Occupational and Environmental Medicine, Odense University Hospital, Odense, DENMARK.*

EPS-009
Vectorial analysis of dual-tracer PET imaging in Parkinson's disease: a pixel-by-pixel-based approach
A. Avendaño-Estrada, *M. Ávila-Rodríguez;*
UNAM, Mexico City, MEXICO.

EPS-011
^{99m}Tc-HMPAO Brain perfusion SPECT: An useful tool in presurgical and postsurgical evaluation of moyamoya disease
S. Menendez-Sanchez, *R. Bellviure-Meiro, S. Asadurova, F. Velazquez, S. Aguadé, C. Lorenzo;*
Hospital Universitario Vall d'Hebron, Barcelona, SPAIN.

EPS-012
Longitudinal assessment of remyelination and demyelination in the brain and spinal cord in Multiple Sclerosis using [^{11}C]MeDAS PET: A pilot study
C. Van Der Weijden[1], *J. F. Meilof*[1], *A. van der Hoorn*[1], *J. Zhu*[2], *C. Wu*[2], *Y. Wang*[2], *A. T. M. Willemsen*[1], *R. A. J. Dierckx*[1], *A. A. Lammertsma*[1], *E. F. J. de Vries*[1];
[1]*UMCG, Groningen, NETHERLANDS,* [2]*Case Western Reserve University, Cleveland, OH, UNITED STATES OF AMERICA.*

EPS-013
A Mesh-based Model of Brain Vasculature: Improved Internal Dosimetry to Brain Parenchyma for Radiopharmaceuticals
C. M. Correa Alfonso[1], *J. Withrow*[1], *S. Domal*[1], *L. McCullum*[2,3], *C. Beekman*[2,3], *C. Grassberger*[2,3], *H. Paganetti*[2,3], *W. E. Bolch*[1];
[1]*University of Florida, Gainesville, FL, UNITED STATES OF AMERICA,* [2]*Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,* [3]*Massachusetts General Hospital, Boston, MA, UNITED STATES OF AMERICA.*

EPS-014
Predictive value of ^{18}F-FDG PET/MR in the pathological prognosis of intermediate and high-risk neuroblastoma
J. Liang;
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

EPS-015
Quantitative measurement of Paget's disease activity on bone scintigraphy: association with analytical and clinical parameters and response to treatment
B. Pereira, *F. Mendonça, M. Faria, J. Neves, A. Fernandes;*
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EPS-016
Assessment of Cancer Treatment- Induced Bone Loss in Breast Cancer Patients
M. Punda, *T. Jukić, A. Fröbe;*
UHC Sestre Milosrdnice, Zagreb, CROATIA.

EPS-017
The added value of trabecular bone score to DXA for fracture prediction in liver transplant patients
J. Bastidas[1], *A. Cabrera*[2], *A. Bronte*[2], *J. J. Rosales*[2], *C. Beorlegui*[1], *V. Betech*[2], *F. Minguez*[2], *J. Escalada*[3], *I. Herrero*[4], *J. Arbizu*[2], *M. Rodriguez-Fraile*[2];
[1]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Clínica Universidad de Navarra, Medicina Nuclear, Pamplona, SPAIN,* [3]*Clínica Universidad de Navarra, Endocrinología, Pamplona, SPAIN,* [4]*Clínica Universidad de Navarra. Hepatología, Pamplona, SPAIN.*

EPS-018
^{18}F-FDG PET/CT metabolic parameters in predicting response to therapy and overall survival for paediatric rhabdomyosarcoma
K. Hlongwa, *K. M. G. Mokoala, L. C. Maserumule, M. M. Sathekge;*
University of Pretoria, Pretoria, SOUTH AFRICA.

EPS-019
Ga-68 Pentixafor PET/CT in initial evaluation and response assessment to chemotherapeutic regimes in patients with multiple myeloma: First results and comparison with F-18 FDG PET/CT
H. Kaur, *P. Malhotra, R. Basher, A. Watts, H. Singh, P. Aggarwal, B. Singh;*
Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EPS-020
Clinical Contribution of ^{18}F-FDG PET/CT in Pediatric Patients with Bone and Soft Tissue Sarcoma
M. Engin[1], *G. Bural*[2], *E. Guler*[3], *A. Boz*[2];
[1]*Necip Fazil City Hospital, Department of Nuclear Medicine, Kahramanmaras, TÜRKIYE,* [2]*Akdeniz University Medical Faculty, Department of Nuclear Medicine, Antalya, TÜRKIYE,* [3]*Akdeniz University Medical Faculty, Department of Pediatric Oncology, Antalya, TÜRKIYE.*

309

Sunday, October 16, 2022, 09:45 - 11:15

Hall 111

e-Poster Presentation Session 2 - Physics
Committee: Physics

EPS-021
Feasibility of very fast whole-body [^{18}F]FDG PET/CT acquisitions using a digital scanner without image enhancement technology
C. S. Constantino, *M. Silva, F. P. M. Oliveira, D. C. Costa;*
Champalimaud Foundation, Lisbon, PORTUGAL.

EPS-022
A New Method to Conventional Dynamic Kidney Scintigraphy: Dynamic ^{99m}TC-MAG-3 SPECT/CT- Preliminary Results
B. Onal[1], *F. Beytur*[2], *E. A. Kırlı*[1], *K. C. Şahin*[1], *E. Kazanasmaz*[3], *H. B. Sayman*[2];
[1]*Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine Department of Urology, Istanbul, TÜRKIYE,* [2]*Istanbul University-Cerrahpasa Cerrahpasa Faculty of Medicine Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [3]*Siemens-Healthineers Türkiye, Istanbul, TÜRKIYE.*

EPS-023
Comparison of Q.Clear and OSEM reconstruction algorithm on PET/CT images in patients with metastatic breast cancer
M. Naghavi-Behzad[1,2,3], *M. Vogsen*[4,2,3], *O. Gerke*[1,2], *S. E. Dahlsgaard-Wallenius*[1,2], *H. J. Nissen*[1,2], *N. M. Jakobsen*[1,2], *P. Braad*[1,2], *M. H. Vilstrup*[1,2], *P. Deak*[5], *M. G. Hildebrandt*[1,3,6], *T. L. Andersen*[7,2];
[1]*Department of Nuclear Medicine, Odense University Hospital, Odense, DENMARK,* [2]*Department of Clinical Research, University of Southern Denmark, Odense, DENMARK,* [3]*Centre for Personalized Response Monitoring in Oncology, Odense University Hospital, Odense, DENMARK,* [4]*Department of Oncology, Odense University Hospital, Odense, DENMARK,* [5]*Healthcare Science Technology, GE Healthcare, Chicago, IL, UNITED STATES OF AMERICA,* [6]*Centre for Innovative Medical Technology, Odense University Hospital, Odense, DENMARK,* [7]*Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, DENMARK.*

EPS-024
A reference database for ^{123}I-FP-CIT SPECT using Fan Beam collimators: Comparison with healthy subjects data obtained with HR collimators
M. Pepponi[3], *M. De Cristofaro*[1], *S. Ramat*[2], *E. M. Abenavoli*[1], *V. Alfarano*[4], *V. Berti*[3];
[1]*Nuclear Medicine Unit - Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY,* [2]*Parkinson Unit, Department of NeuroMuscular- Skeletal and Sensorial Organs, Azienda Ospedaliero-Universitaria Careggi, Florence, ITALY,* [3]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, ITALY,* [4]*Radiodiagnostics - CMT Centro Medico Toscano, Florence, ITALY.*

EPS-025
Assessment of semi-quantitative analysis of human [^{18}F] MC225 PET data
G. Salvi de Souza[1,2,3], *P. Mossel*[3], *C. Tsoumpas*[3], *A. A. Lammertsma*[3], *A. M. Marques da Silva*[1,2], *G. Luurtsema*[3];
[1]*School of Medicine, PUCRS, Porto Alegre, BRAZIL,* [2]*Medical Image Computing Laboratory, School of Technology, PUCRS, Porto Alegre, BRAZIL,* [3]*Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.*

EPS-026
Investigation of an Image Derived Input Function to measure P-glycoprotein function at the human blood-brain barrier using [^{18}F]MC225 and PET
P. Mossel[1], *C. W. J. van der Weijden*[1,2], *A. T. M. Willemsen*[1], *P. H. Elsinga*[1], *P. de Deyn*[3,4], *R. A. J. Dierckx*[1], *A. A. Lammertsma*[1], *A. L. Bartels*[5], *G. Luurtsema*[1];
[1]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Department of Radiology, University Medical Center Groningen, Groningen, NETHERLANDS,* [3]*Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BELGIUM,* [4]*Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Born-Bunge (IBB), University of Antwerp, Antwerp, BELGIUM,* [5]*Department of Neurology, Ommelander Ziekenhuis Groep, Scheemda, NETHERLANDS.*

EPS-027
The effect of background placement on Specific Binding Ratio in Ioflupane Imaging
C. Lim, *A. Notghi, J. Burmiston, J. O'Brien, A. Perry;*
Birmingham City Hospital, Birmingham, UNITED KINGDOM.

EPS-028
CT-free patient specific attenuation correction method for dedicated cardiac pinhole CZT system
M. Hesse, *V. Roelants;*
Cliniques Universitaires Saint-Luc, Brussels, BELGIUM.

EPS-029
Determination of PET arterial input function in mice using an extracorporeal shunt: validation of a new dispersion model
J. Cufe[1], *F. Gierse*[2], *K. Schäfers*[3], *S. Hermann*[3], *M. Schäfers*[1], *P. Backhaus*[1], *F. Büther*[1];
[1]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,* [2]*European Institute for Molecular Imaging(EIMI), University of Münster, Münster, GERMANY,* [3]*European Institute for Molecular Imaging (EIMI), University of Münster, Münster, GERMANY.*

EPS-030
Automated analysis of aortic Na[^{18}F]F-uptake in macrocalcifications and noncalcified plaques in PET/CT scans
G. van Praagh[1], *M. E. J. Davidse*[2], *J. M. Wolterink*[2], *R. H. J. Slart*[1];
[1]*University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*University of Twente, Enschede, NETHERLANDS.*

EPS-032
Multi-Centre Image Analysis of Tumor-Bearing Mouse FDG-PET/(CT) Data
C. Kuntner-Hannes[1,2], *C. Alcaide*[3], *J. P. Bankstahl*[4], *H. Boutin*[5], *D. Brasse*[6], *F. Elvas*[7], *D. Forster*[5], *L. Ivancic*[1], *A. Tavares*[3], *T. Wanek*[1], *J. G. Mannheim*[8,9];
[1]*Medical University of Vienna, Vienna, AUSTRIA,* [2]*Medical Imaging Cluster (MIC), Vienna, AUSTRIA,* [3]*University of Edinburgh, Edinburgh, UNITED KINGDOM,* [4]*Hannover Medical School, Hannover, GERMANY,* [5]*University of Manchester, Manchester, UNITED KINGDOM,* [6]*Université de Strasbourg, Strasbourg, FRANCE,* [7]*University of Antwerpen, Antwerpen, BELGIUM,* [8]*Eberhard-Karls University Tuebingen, Tuebingen, GERMANY,* [9]*Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies, Tuebingen, GERMANY.*

EPS-033
Heterogeneity and Activity Quantification of ^{90}Yttrium PET/CT for a Range of Acquisition Times
J. Blakkisrud[1], *L. Gridset*[1], *A. Sherwani*[1], *C. Stokke*[1,2];
[1]*Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,* [2]*Department of Physics, University of Oslo, Oslo, NORWAY.*

EPS-034
^{18}F-FDG PET radiomics and machine learning models as a novel preoperative predictive tool for Endometrial Cancer's aggressiveness
C. Bezzi[1,2], *P. Mapelli*[1,2], *G. Mathoux*[3], *L. Monaco*[3], *S. Ghezzo*[1,2], *A. Bergamini*[1,4], *F. Fallanca*[2], *A. M. Samanes Gajate*[2], *G. Sabetta*[1,4], *F. Galli*[1,4], *G. Candotti*[1,4], *G. L. Taccagni*[5], *G. Mangili*[4], *L. Gianolli*[2], *M. Picchio*[1,2];
[1]*Vita-Salute San Raffaele University, Milan, ITALY,* [2]*Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [3]*University of Milano-Bicocca, Milan, ITALY,* [4]*Unit of Obstetrics and Gynaecology, IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [5]*Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY.*

EPS-035
A exhaustive innovative approach to profile and test the predictive role of intra-tumor [18F]FMCH PET/CT heterogeneity in recurrent prostate cancer patients with multiple lesions
M. Sollini[1], *L. Cavinato*[2], *F. Bartoli*[3], *A. Ragni*[2], *R. Zanca*[1], *C. Bachi*[3], *F. Ieva*[4], *P. A. Erba*[3];
[1]*Humanitas University, Pieve Emanuele, ITALY,* [2]*Department of Mathematics - MOX, Politecnico di Milano, Milan, ITALY,* [3]*Department of Translational Research and of New Surgical and Medical Technologies; University of Pisa, Pisa, ITALY,* [4]*Department of Mathematics, Politecnico di Milano and Center for Health Data Science, Human Technopole, Milan, ITALY.*

EPS-036
Radiomics in locally advanced cervical cancer using ^{18}F-FDG-PET/CT images
A. Florit[1], *V. Feudo*[1], *T. Pasciuto*[2], *G. Ferrandina*[2,3], *E. Pfaehler*[4], *R. Boellaard*[5], *V. Rufini*[1,6], *F. H. P. van Velden*[7], *A. Collarino*[6];
[1]*Section of Nuclear Medicine, University Department of Radiological Sciences and Haematology, Università Cattolica del Sacro Cuore, Rome, ITALY,* [2]*Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [3]*Department of Life Science and Public Health, Section of Obstetrics and Gynaecology, Università Cattolica del Sacro Cuore, Rome, ITALY,* [4]*Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, GERMANY,* [5]*Department of Radiology and Nuclear Medicine, Amsterdam UMC - Location VU University Medical Center, Amsterdam, NETHERLANDS,* [6]*Nuclear Medicine Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [7]*Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, Leiden, NETHERLANDS.*

EPS-037
3D printing of Germanium-68 solid-state phantoms with varying background and without cold interfaces for high-resolution PET/CT systems
G. Prenosil, *L. P. Meier, T. Läppchen, A. Rominger;*
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EPS-038
Introduction of a 3D printed anthropomorphic left ventricle myocardial phantom for nuclear cardiology applications
J. Kiss[1], *L. Balkay*[2], *K. Kukuts*[3], *M. Miko*[2], *A. Forgacs*[3,4], *G. Trencsenyi*[2], *A. Krizsan*[3];
[1]*Division of Radiology and Imaging Science, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY,* [2]*Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, HUNGARY,* [3]*ScanoMed Nuclear Medicine Centers, Debrecen, HUNGARY,* [4]*Mediso Ltd., Budapest, HUNGARY.*

EPS-039
Optimizing Dose Regimen for Ga-PSMA PET/CT Imaging While Preserving Image Quality required for Lesion Detection
P. Sheikhzadeh[1], *A. Monsef*[1], *A. Ghafari*[1], *E. Ahmadi*[2];
[1]*Tehran University Of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Mashhad University Of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EPS-040
A highly reproducible ejection fraction estimation through PACS data-driven deep learning for automatic segmentation of diastole and systole regions of interest in ERNA scans
S. Seo[1,2], *J. Oh*[1], *B. Park*[1,2], *D. Lee*[1], *S. Han*[1], *D. Moon*[1];
[1]*Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Biomedical Engineering, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.*

509

Sunday, October 16, 2022, 15:00 - 16:30

Hall 111

e-Poster Presentation Session 3 - Inflammation & Infection Committee: Best e-Posters on Infection and Inflammation

EPS-041
18F-FDG PET/CT In Infective Endocarditis: Impact As A Major Diagnostic Duke Criterion And In The Evaluation Of Extracardiac Infectious Manifestations
A. Padilla Bermejo[1], *A. M. García Vicente*[1], *M. Amo Salas*[2], *M. N. Sicilia Pozo*[1], *C. Lucas Lucas*[1], *M. Negreira Caamaño*[3], *L. García Zoghby*[1], *F. J. Pena Pardo*[1], *E. Noriega Álvarez*[1], *M. Á. Pérez Martínez*[3], *Á. Soriano Castrejón*[1];
[1]*Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [2]*Department of Mathematics, Castilla-La Mancha University, Ciudad Real, SPAIN,* [3]*Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN.*

EPS-042
Viewing tuberculosis through the antitubercular lens - Ethambutol scintigraphy with SPECT/CT in extrapulmonary tuberculosis
N. Damle, *D. Khan, S. Sagar, A. Tyagi, G. Arora, P. Ranjan, C. Bal, M. Tripathi, B. Bhattacharya, A. Ray, G. Tej, S. Sikdar, P. Naranje, A. Goyal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EPS-044
Exploring the clinical ambit of ^{99m}Tc Ubiquicidin scintigraphy
D. Khan, *S. Sagar, N. A. Damle, V. Tiwari, A. Tyagi, G. Arora, C. Bal, R. Kumar, H. Verma, R. Meel;*
AIIMS Delhi, Delhi, INDIA.

EPS-046
Lung Ventilation and Perfusion SPECT in long-COVID-19
I. Lopo[1], *A. P. Moreira*[1,2], *P. Lapa*[1,3], *G. Costa*[1,3];
[1]*Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,* [2]*Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL,* [3]*Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.*

EPS-047
Lung perfusion assessment in Long-COVID children: a pilot study
D. Pizzuto[1], *D. Buonsenso*[2,3,4], *A. Fragano*[1], *F. Baldi*[5], *D. Di Giuda*[1,6];
[1]*Nuclear Medicine Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY,* [2]*Dipartimento di Scienze di Laboratorio e Infettivologiche, Policlinico Fondazione Universitario A Gemelli IRCCS, Rome, ITALY,* [3]*Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, ITALY,* [4]*Global Health Research Institute, Istituto di Igiene, Università Cattolica del Sacro Cuore, Rome, ITALY,* [5]*Division of Respiratory Medicine, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, ITALY,* [6]*Section of Nuclear Medicine, University Department of Radiological Sciences and Hematology, Uniiversità Cattolica del Sacro Cuore, Rome, ITALY.*

EPS-048
Antibody-negative silent thyroiditis after vaccination with SARS-CoV-2 mRNA-vaccine: a novel entitity (not) to be confused
B. Schemmer;
Department of Nuclear Medicine, Ulm University Medical Centre, Ulm, GERMANY.

EPS-049
Expiratory filter sets substantially reduce exhaled small bioaerosol particles and potential COVID-19 virus load
H. Hautzel[1], *T. Bartel*[1], *K. Darwiche*[2], *C. Aigner*[3], *C. Taube*[4], *K. Herrmann*[1];
[1]*University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY,* [2]*University Hospital Essen, Department of Pulmonary Medicine, Section of Interventional Pneumology, West German Lung Center, Ruhrlandklinik, Essen, GERMANY,* [3]*University Hospital Essen, Department of Thoracic Surgery and Endoscopy, West German Lung Center, Ruhrlandklinik, Essen, GERMANY,* [4]*University Hospital Essen, Department of Pulmonary Medicine, West German Lung Center, Ruhrlandklinik, Essen, GERMANY.*

EPS-050
Scintigraphic Patterns In Planar Pulmonary Perfusion-Only Studies In Patients With Dyspnea And Clinical Suspicion Of COVID-19 Infection
C. Balbín García, *T. Amrani Raissouni, M. Feriche Aragón, M. Cañada Rodríguez, J. Villena Salinas, D. Patrut, S. Sanz Viedma;*
Hospital Universitario Virgen de la Victoria, Malaga, SPAIN.

EPS-051
Post COVID Thyroiditis as Documented on Tc-99m Pertechnetate Thyroid Scan
B. Jain, *Y. Khandelwal, P. Singh, M. Ora, A. H. Nazar, P. K. Pradhan, A. Arya, S. Barai, S. Gambhir;*
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EPS-052
Lung scintigraphy with SPECT/CT in the assessment of post COVID-19 respiratory complications
R. Ferrando[1], *K. Bayardo*[1], *N. Maciel*[2], *J. Naula*[1], *J. Rios*[1], *R. Hitateguy*[3], *O. Alonso*[1], *S. Traverso*[2];
[1]*University of the Republic, Montevideo, URUGUAY,* [2]*Hospital General de Agudos Dr. Cosme Argerich, Buenos Aires, ARGENTINA,* [3]*Consultorio de Medicina Nuclear Ferrari Ferrando Páez, Montevideo, URUGUAY.*

EPS-053
Pulmonary embolism on ventilation/perfusion scintigraphy during the COVID-19 pandemic
B. Pernthaler[1], *F. Weitzer*[1], *C. Gstettner*[1], *G. Pregartner*[2], *R. M. Aigner*[1];
[1]*Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA,* [2]*Medical University of Graz, Institute of Medical Informatics, Statistics and Documentation, Graz, AUSTRIA.*

EPS-054
Did the COVID-19 pandemic influence the early diagnosis of bone metastatic disease? Experience in our health area
F. Sebastián Palacid, *M. García Aragón, N. Álvarez Mena, M. Alonso Rodríguez, B. Pérez López, C. Gamazo Laherrán, M. Ruiz Gómez, R. Ruano Pérez;*
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EPS-055
Sentinel Lymph Node Biopsy in Melanoma Patients a Year after Introduction of COVID-19 Epidemic Restrictions: A Comparison with Pre-COVID Period in the National Referral Melanoma Centre
M. Punda[1], *I. Jakšić*[1], *M. Romić*[1], *I. Milas*[1], *F. Grladinović*[1], *Z. Puljiz*[1], *H. Nikles*[1], *S. Divošević*[2], *T. Jukić*[1], *A. Fröbe*[1], *M. Šitum*[1];
[1]*UHC Sestre Milosrdnice, Zagreb, CROATIA,*
[2]*2Department of Radiology and Nuclear Medicine, PET/CT Center, Polyclinic Medikol, Zagreb, CROATIA.*

EPS-056
Incidential Covid-19-Associated Findings During Routine Oncological 18F-FDG-fdPET/CT Staging and Restaging
L. Chavdarova, *E. Piperkova;*
University Specialized Hospital for Active Treatment in Oncology, Sofia, BULGARIA.

EPS-057
Educational and Psychological Impact of COVID-19 Pandemic on Nuclear Medicine Residents - A Survey Study in Romania
I. Almasan[1], *G. Rusu*[2], *I. Pirsan*[3], *H. Haba*[1], *G. Kermoison*[1], *D. Piciu*[1];
[1]*Institute of Oncology „Prof Dr. Ion Chiricuta", Cluj-Napoca, ROMANIA,* [2]*MedLife Polisano Hospital, Sibiu, ROMANIA,* [3]*Institute of Oncology „Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA.*

609

Sunday, October 16, 2022, 16:45 - 18:15

Hall 111

e-Poster Presentation Session 4 - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: New Tracers – From Production to Translation

EPS-058
Immediate and delayed impact of transient blood-brain barrier disruption induced by focused ultrasound on the brain kinetics of ^{11}C-metoclopramide, a PET probe for P-glycoprotein
N. Tournier[1], *S. Goutal*[1], *A. Novell*[1], *L. Breuil*[1], *E. Selingue*[2], *S. Leterrier*[1], *M. Gerstenmayer*[2], *S. Marie*[1], *F. Caillé*[1], *V. Lebon*[1], *C. Truillet*[1], *B. Larrat*[1];
[1]*Université Paris-Saclay, Orsay, FRANCE,*
[2]*CEA/JOLIOT, Saclay, FRANCE.*

EPS-059
Predicting [^{177}Lu]Lu-DOTATATE Organ and Tumor Distribution Based on [^{68}Ga]Ga-DOTATATE Diagnostic Imaging Using Semi-Physiological Population Pharmacokinetic Modeling
H. Siebinga[1,2], *B. J. de Wit - van der Veen*[2], *D. M. V. de Vries - Huizing*[2], *T. P. C. Dorlo*[1], *A. D. R. Huitema*[1,3,4], *J. J. M. Hendrikx*[1,2];
[1]*Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,* [2]*Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,* [3]*Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, NETHERLANDS,* [4]*Department of Pharmacology, Princess Máxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.*

EPS-060
Effect of isoflurane anaesthesia depth on renal function measured with ^{99m}Tc-Mercaptoacetyltriglycine SPECT in mice
F. Schmitz-Peiffer[1,2], *M. Lukas*[1], *W. Brenner*[1,2], *N. Beindorff*[2];
[1]*Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, GERMANY,* [2]*Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, GERMANY.*

EPS-062
Investigation of crucial influence of the meta-substituted analogs of a potential game changer - ^{18}F-AF78, a novel PET radiotracer trageting NET
S. Mühlig[1,2], *X. Chen*[1,2], *A. Tutov*[3], *R. Werner*[1], *M. Decker*[3], *T. Higuchi*[1,2,4];
[1]*University Hospital, Departement of Nuclear medicine, Würzburg, GERMANY,* [2]*University Hospital, Comprehensive Heart Failure Center, Würzburg, GERMANY,* [3]*University, Institute of Pharmacy and Food Chemistry, Würzburg, GERMANY,* [4]*Graduate School of Medicine Okayama University, Denistry and Pharmaceutical sciences, Okayama, JAPAN.*

EPS-063
Preparation, characterization and in vitro assessment of 68Ga labeled fragmented antibody for HER2 expressing Breast Cancer
S. Mithun[1,2,3], *A. K. Jha*[1,2,3], *M. Maria*[1,2], *N. Nisar*[1,2], *P. Bhardwaj*[1,2], *K. Chitnis*[1,2], *M. Babu*[1,2], *J. A. Maniar*[4], *S. Shah*[1,2], *M. Kameswaran*[1], *S. Gupta*[4,2], *V. Rangarajan*[1,2];
[1]*Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA,* [3]*Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, 6229 ET, Maastricht, NETHERLANDS,* [4]*Advanced Centre for Treatment Research & Education in Cancer, Tata Memorial Centre, Mumbai, INDIA.*

EPS-066
A multitracer approach using ^{11}C-buprenorphine and ^{18}F-FDG PET imaging to explore the neuropharmacology of buprenorphine in rats
A. Soyer, *S. Leterrier, L. Breuil, F. Caillé, M. Goislard, C. Leroy, W. Saba, M. Bottlaender, S. Goutal, N. Tournier;*
Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Université Paris-Saclay, Orsay, FRANCE.

EPS-067
Neuroinflammation process in a murine model of Down syndrome a throughout lifespan evaluation
L. Estessi de Souza[1], *C. Cristiano Real*[2], *C. A. Buchpiguel*[1], *D. de Paula Faria*[1];
[1]*Universidade de São Paulo, São Paulo, BRAZIL,* [2]*Aarhus University Hospital, Aarhus, DENMARK.*

EPS-068
Preclinical comparison of NeoB and RM2: Which GRPR-targeting radiotracer is most optimal for targeted radionuclide therapy?
T. S. T. Damiana, *A. L. van den Berg, S. U. Dalm;*
Department of Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, NETHERLANDS.

EPS-070
Targeting fibrosis via the fibroblast activation protein (FAP): preclinical experiences with [^{68}Ga]DATA^{5m}.SA.FAPi
C. Philippe[1], *V. Weissenböck*[1], *M. Schlederer*[1], *F. Rösch*[2], *L. Kenner*[1], *M. Hacker*[1];
[1]*Medizinische Universität Wien, Vienna, AUSTRIA,* [2]*University of Mainz, Mainz, GERMANY.*

EPS-071
Preclinical Evaluation of CXCR4-Targeted Radionuclide Therapy Against Glioblastoma
A. Waked[1,2,3], *K. Vermeulen*[2], *S. Baatout*[1], *B. Rogister*[3], *R. Benotmane*[1];
[1]*Radiobiology Group, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM,* [2]*NURA-TRA Group, Belgian Nuclear Research Centre, (SCK CEN), Mol, BELGIUM,* [3]*Laboratory of Nervous System Disorders and Therapy, GIGA Neurosciences, Université de Liège, Liège, BELGIUM.*

EPS-072
Copper-64 radiopharmaceuticals as theranostic agents for hypoxia tumours: in vitro studies of cell survival, internalisation, and kinase activity
T. Liu[1,2], *M. H. Lystad*[1], *M. Karlsen*[2], *K. R. Redalen*[1];
[1]*Department of Physics, Norwegian University of Science and Technology, Trondheim, NORWAY,* [2]*Department of Radiology and Nuclear Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, NORWAY.*

EPS-073
Investigating the effect of replacing tranexamic acid in ^{68}Ga-HTK03149 with various phenyl derivatives on the uptake in PSMA-expressing tumor xenografts
H. Kuo[1], *Z. Zhang*[1], *H. Merkens*[1], *C. Zhang*[1], *N. Colpo*[1], *K. Lin*[1,2], *F. Bénard*[1,2];
[1]*BC Cancer, Vancouver, BC, CANADA,* [2]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.*

EPS-074
Effects of PI3kα inhibitor BYL719 on overcoming everolimus resistance and inducing re-expression of somatostatin receptors in an everolimus-resistant orthotopic pancreatic NET xenograft mouse model
A. Mohan[1,2], *S. Prasad*[1,2], *F. Schmitz-Peiffer*[1,2], *C. Lange*[1], *M. Lukas*[1], *E. J. Koziolek*[1,3], *K. Pacak*[4], *M. Ilmer*[3,5,6], *A. Grossman*[7,8,9], *K. Wang*[10], *A. Reul*[11], *J. Maurer*[10], *L. Schober*[10], *J. Friemel*[11], *M. Reincke*[10], *C. J. Auernhammer*[10], *F. Beuschlein*[10,11], *W. Brenner*[1,2,3], *S. Nölting*[*10,11], *N. Beindorff*[*2];
[1]*Department of Nuclear Medicine, Charité – Universitätsmedizin Berlin, Berlin, GERMANY,* [2]*Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, GERMANY,* [3]*German Cancer Consortium (DKTK), partner site, Berlin, GERMANY,* [4]*Department of Medical Neuroendocrinology, Developmental Endocrinology, Metabolism, Genetics and Endocrine Oncology Affinity Group, National Institute of Health (NIH) /NICHD, Bethesda, NY, UNITED STATES OF AMERICA,* [5]*Department of General, Visceral, and Transplantation Surgery, Klinikum der Universität München (KUM), Ludwig-Maximilians-Universität, Munich, GERMANY,* [6]*German Cancer Research Center (DKFZ), Heidelberg, GERMANY,* [7]*Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, London, UNITED KINGDOM,* [8]*Department of Endocrinology, Green Templeton College, University of Oxford, London, UNITED KINGDOM,* [9]*Department of Neuroendocrinology, Barts and the London School of Medicine, London, UNITED KINGDOM,* [10]*Department of Internal Medicine IV, University Hospital, LMU Klinikum, Ludwig Maximilian University of Munich, Munich, GERMANY,* [11]*Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital, University of Zurich, Zurich, SWITZERLAND.*
(shared last authors)*

EPS-075
In vitro investigation of a potential complementary expression of the imaging biomarkers AR and PSMA during prostate cancer progression
T. Balber[1,2], *J. Raitanen*[1,2,3], *K. Benčurová*[1,2], *T. Franssen*[1], *P. Schwarzl*[4], *J. Kalla*[5], *Z. Culig*[6], *M. Hacker*[2], *G. Egger*[1,7], *M. Mitterhauser*[1,2,8];
[1]*Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA,* [2]*Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA,* [3]*University of Vienna, Vienna Doctoral School in Chemistry (DoSChem), Vienna, AUSTRIA,* [4]*Biomedical Science, University of Applied Science, Wiener Neustadt, AUSTRIA,* [5]*Department of Pathology, Medical University of Vienna, Vienna, AUSTRIA,* [6]*Department of Urology, Experimental Urology, Medical University of Innsbruck, Innsbruck, AUSTRIA,* [7]*Department of Pathology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, AUSTRIA,* [8]*University of Vienna, Faculty of Chemistry, Department of Inorganic Chemistry, Vienna, AUSTRIA.*

EPS-076
Effective Folate-Targeted Delivery of the Anti-Arthritic Macromolecular Methotrexate Prodrug to Inflamed Rheumatoid Arthritis Joints
U. Hafeli, *Z. Nosrati, Y. A. Chen, M. Bergamo, C. Rodriguez-Rodriguez, K. Saatchi;*
University of British Columbia, Vancouver, BC, CANADA.

EPS-077
Can nutritional regimens affect radiotracers uptake ? Ketogenic diet: the possible key to enhance [^{18}F]FDG performances
M. Asti, *S. Rubagotti, P. C. Capponi, F. Lacaria, M. Iori, C. Coruzzi, M. Paci, A. Filice, A. Versari;*
AUSL-IRCCS, Reggio Emilia, ITALY.

EPS-078
Initial evaluation of the effectiveness of ^{67}Cu-EB-TATE theranostic as an alternative to ^{177}Lu-DOTATATE in pancreatic neuroendocrine tumur models
F. Njotu[1], *A. Nambisan*[1], *J. Ketchemen*[1], *F. Tikum*[1], *H. Babeker*[1], *K. Pak*[2], *M. Uppalapati*[1], *H. Fonge*[1];
[1]*University of Saskatchewan, Saskatoon, SK, CANADA,* [2]*Molecular Targeting Technologies, Inc, West Chester, PA, UNITED STATES OF AMERICA.*

709

Monday, October 17, 2022, 08:00 - 09:30

Hall 111

e-Poster Presentation Session 5 - Cardiovascular Committee: e-Posters on Cardiovascular Topics

EPS-079
ECG-gated myocardial perfusionSPECT in the assessment of risk for hospitalization due to heart failure in patients with coronary artery disease
T. Laitinen[1,2], *H. Hämäläinen*[1], *A. Hokkanen*[1], *M. Hedman*[1,2], *T. M. Laitinen*[1];
[1]*Kuopio University Hospital, Kuopio, FINLAND,* [2]*University of Eastern Finland, Kuopio, FINLAND.*

EPS-080
Decreased liver to spleen ratio in low dose CT as a biomarker of fatty liver disease reflects risk for myocardial ischemia
A. Hokkanen[1], *H. Hämäläinen*[1], *T. M. Laitinen*[1], *T. Laitinen*[1,2];
[1]*Kuopio University Hospital, Kuopio, FINLAND,* [2]*University of Eastern Finland, Kuopio, FINLAND.*

EPS-081
Is Discovery NM530c CZT SPECT Gamma Camera a Viable Alternative to PET for assessment of Myocardial Flow Reserve?
P. Cichocki[1], *M. Błaszczyk*[2], *J. Kuśmierek*[1], *Z. Adamczewski*[1], *A. Płachcińska*[2];
[1]*Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND,* [2]*Department of Quality Control and Radiation Protection, Medical University of Lodz, Lodz, POLAND.*

EPS-082
Multichannel 3D deep learning model predicts functional improvements in myocardial perfusion imaging after coronary revascularization
C. Ko[1,2], *C. Huang*[2], *S. Lin*[2], *C. Chang*[2], *C. Chen*[2], *Y. Wu*[3,4];
[1]*Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, TAIWAN,* [2]*Department of Biomedical Engineering, National Taiwan University, Taipei, TAIWAN,* [3]*Division of Cardiology, Cardiovascular Medical Center, and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, TAIWAN,* [4]*School of Medicine, National Yang Ming Chiao Tung University, Taipei, TAIWAN.*

EPS-083
Accuracy verification of myocardial flow reserve calculated through the net retention method using dynamic cadmium-zinc-telluride camera
T. Niimi[1], *K. Unno*[1], *S. Yoshida*[2];
[1]*Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, JAPAN,* [2]*Graduate School of Medicine, Nagoya University, Nagoya, JAPAN.*

EPS-084
The prognostic value of right ventricular strain derived from ammonia PET for major adverse cardiac events
A. Yamamoto[1], *M. Nagao*[1], *M. Kawakubo*[2], *K. Ando*[1], *R. Nakao*[1], *Y. Matsuo*[1], *A. Sakai*[1], *M. Momose*[1], *K. Kaneko*[1], *K. Fukushima*[3], *S. Sakai*[1];
[1]*Tokyo Women's Medical University Hospital, Shinjuku, JAPAN,* [2]*Kyushu University, Fukuoka, JAPAN,* [3]*Fukushima Medical University, Fukushima, JAPAN.*

EPS-085
Do global values of myocardial blood flow and perfusion objectively reflect the extent and severity ofatherosclerotic lesionsin patients with stable coronary artery disease
A. Shakhova, *I. Aslanidis, I. Shurupova, I. Ekaeva, M. Rumyantseva, V. Losev;*
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EPS-086
Evaluation of Left Ventricular Healing with SPECT Perfusion parameters and Dobutamine Stress Echo after Primary PTCA or Stenting in patients with AMI
A. Özdal[1], *G. Amioğlu*[2];
[1]*University of Health Sciences Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE,* [2]*Sivas Numune Hospital, Sivas, TÜRKIYE.*

EPS-087
The feasibility of dynamic SPECT CZT measurement of myocardial blood flow and reserve in patients with dyslipidemia and non-obstructive coronary artery disease
K. Zavadovsky, *A. Maltseva, K. Kopeva, A. Mochula, O. Dymbrylova, E. Grakova;*
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EPS-088
Prognostic value of coronary flow reserve estimated using dynamic SPECT with CZT camera
M. Havel[1], *M. Kaminek*[1,2], *P. Koranda*[1], *L. Quinn*[1], *I. Metelkova*[1], *L. Henzlova*[1], *V. Kincl*[2];
[1]*Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, CZECH REPUBLIC,* [2]*International Clinical Research Center, Center of Molecular Imaging, Brno, CZECH REPUBLIC.*

EPS-089
Coronary flow reserve and extracellular matrix remodeling in heart failure with preserved left ventricle ejection fraction and non-obstructive coronary artery disease
E. Grakova, *K. Kopeva, A. Maltseva, A. Mochula, K. Zavadovsky;*
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EPS-090
Impaired myocardial perfusion and blood flow in patients with multivessel CAD: diagnostic solution capabilities
A. Shakhova, *I. Aslanidis, I. Shurupova, I. Ekaeva, M. Rumyantseva, N. Surkova;*
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian Federation, Moscow, RUSSIAN FEDERATION.

EPS-091
Linking cardiac and extra-cardiac sarcoidosis and their clinical course: serial FDG-PET/CT analysis
K. Kaneko, *M. Nagao, A. Yamamoto, A. Sakai, S. Sakai;*
Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, JAPAN.

EPS-092
Imaging characteristics and prediction of therapeutic efficacy in patients with dilated cardiomyopathy treated with angiotensin II receptor blocker using F-18 FDG PET and I-123 MIBG scan: a preliminary study
Y. Jeong, *K. Park, D. Kang, D. Jung;*
Dong-A University Hospital, Busan, KOREA, REPUBLIC OF.

EPS-093
The value of cardiac sympathetic innervation imaging and epicardial adipose tissue characteristics in predicting of atrial fibrillation catheter ablation outcomes
Y. Varlamova[1], *S. Sazonova*[1], *E. Popov*[1], *S. Minin*[2], *A. Romanov*[2], *R. Batalov*[1], *S. Popov*[1];
[1]*Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION,* [2]*E. Meshalkin National Medical Research Center» of the Ministry of Health of the Russian Federation, Novosibirsk, RUSSIAN FEDERATION.*

EPS-094
The role of microvascular dysfunction in heart failure with preserved left ventricle ejection fraction
K. Kopeva, *A. Mochula, A. Maltseva, E. Grakova, V. Shipulin, K. Zavadovsky;*
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EPS-095
Assessment of microinflammation severity with the use of Na[18F]F PET/CT in the evaluation of aortic valve degeneration after TAVI: preliminary results
M. Opalinska[1], *D. Sorysz*[2], *A. Sowa-Staszczak*[3], *A. Grochowska*[4], *A. Dziewierz*[2], *N. Maruszak*[2], *M. Bagieński*[5], *A. Surdacki*[2], *S. Bartuś*[2], *D. Dudek*[2];
[1]*Nuclear Medicine Unit, Department of Endocrinology, University Hospital, Krakow, POLAND,* [2]*Department of Cardiology, Jagiellonian University Medical College, Krakow, POLAND,* [3]*Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND,* [4]*Department of Radiology, University Hospital, Krakow, POLAND,* [5]*Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, POLAND.*

EPS-096
Prognostic value of cardiac scintigraphy in the prediction of responders to cardiac resynchronization therapy in patients with chronic heart failure
T. Atabekov, *A. Mishkina, R. Batalov, S. Sazonova, S. Krivolapov, V. Saushkin, M. Khlynin, Y. Varlamova, K. Zavadovsky, S. Popov;*
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EPS-099
Relationship between diphosphonate uptake distribution and myocardial contractility in ATTR
L. Santamaría-Chico, *K. E. Velásquez-Díaz, P. M. Meneses-Soares, I. Obedkova, V. B. Moñivas-Palomero, A. Sánchez-Gómez, F. de Haro-del Moral;*
Hospital Universitario Puerta de Hierro, Madrid, SPAIN.

809

Monday, October 17, 2022, 09:45 - 11:15

Hall 111

e-Poster Presentation Session 6 - Physics + Radiation Protection Committee: Physics & Radiation Protection

EPS-100
Phantom Validation of SPECT-CT Quantification with Varying ^{99m}Tc Uptake
C. Turner[1,2];
[1]*Swansea Bay University Health Board, Swansea, UNITED KINGDOM,* [2]*Swansea University, Swansea, UNITED KINGDOM.*

EPS-101
Novel CZT-based multi detector SPECT/CT system: daily QCs and performance evaluation at one year after installation
V. Ferri, *K. Luong, P. Castaneda, A. Iagaru;*
Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA.

EPS-102
XBONE versus SPECT/TC and bone scintigraphy in the detection of metastatic bone disease in patients with prostate cancer
J. Vallejo Casas, *P. Luque Camacho, E. Zurera Pareja, S. Castejón Echevarne, A. López Cano, M. Guiote Moreno;*
Hospital Universitario Reina Sofía. IMIBIC., Córdoba, SPAIN.

EPS-103
Investigation of a portable gamma camera with pinhole collimator for Lu-177 imaging using Monte Carlo simulations
P. Papadimitroulas, *G. Savvidis, E. Fysikopoulos, M. Georgiou, E. Lamprou, K. Chatzipapas, G. Loudos;*
BIOEMTECH, Athens, GREECE.

EPS-105
Zero-TE MR-based Attenuation Correction with a Deep Learning Approach: Impact of bone components on Attenuation Correction for Chest FDG PET/MRI
M. Tachibana[1], *M. Nogami*[2], *H. Matsuo*[1], *M. Nishio*[1], *J. Inukai*[1], *F. Zeng*[1], *T. Kurimoto*[3], *K. Kubo*[2], *T. Murakami*[1,2];
[1]*Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN,* [2]*Department of Radiology, Kobe University Hospital, Kobe, JAPAN,* [3]*GE Healthcare, Hino, JAPAN.*

EPS-106
Experimental studies with a Compton camera for phantom and patient imaging
G. Llosá[1], *L. Barrientos*[1], *J. Calatayud*[2], *J. Casaña*[1], *P. Bello*[2], *S. Prado*[2], *J. Roser*[1], *C. Senra*[1], *I. Torres-Espallardo*[2];
[1]*IFIC (CSIC-U.Valencia), Valencia, SPAIN,*
[2]*HUiP La Fe, Valencia, SPAIN.*

EPS-107
The use of synthetic lesions insertion to objectively asses the performance of PET systems: The IQ vs MI prospective clinical trial results
F. Courbon, *N. Robaine, Q. Maronnier, E. Gabiache, J. Texier, L. Vija, M. Terroir, T. Casso-Mounat, S. Zerdoud, L. Dierickx, L. Chloé, S. Brillouet, D. Vallot, T. Filleron, O. Caselles;*
IUCT-Oncopole Toulouse, Toulouse, FRANCE.

EPS-108
Partial volume effect and voxel noise along the one meter axial field-of-view of a total-body PET/CT system for multiple isotopes
J. G. Mannheim[1,2], *F. P. Schmidt*[1,3], *I. Rausch*[4], *J. Kupferschläger*[3], *C. la Fougère*[2,3], *B. J. Pichler*[1,2];
[1]*Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls University Tuebingen, Tübingen, GERMANY,* [2]*Cluster of Excellence iFIT (EXC 2180) "Image Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, Tübingen, GERMANY,* [3]*Department of Nuclear Medicine and Clinical Molecular Imaging, University hospital Tuebingen, Tübingen, GERMANY,* [4]*QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA.*

EPS-109
Comparison of a brain-dedicated PET to a whole body scanner for the diagnose of neurodegenerative disorders
P. Bascuñana[1], *P. Nespral*[1], *A. Delgado-Cano*[1], *A. Canora*[1], *C. Morera-Ballester*[2], *G. González-Pavón*[2], *J. Matias-Guiu*[3], *J. Carreras-Delgado*[1], *M. Cabrera-Martín*[1];
[1]*Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN,* [2]*General Equipment for Medical Imaging S.A., Valencia, SPAIN,* [3]*Department of Neurology, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN.*

EPS-110
Dose reduction of [^{68}Ga]Ga-DOTA-TATE PET/MR in comparison with PET/CT
C. P. Cox, *T. Brabander, F. A. Verburg, M. Segbers;*
Erasmus MC, Rotterdam, NETHERLANDS.

EPS-111
Preliminary Experience and Performance Characteristics of an Extended Bore Length Solid-State Digital-BGO PET/CT System
J. Kennedy[1,2], *T. Palchan Hazan*[1], *Q. Maronnier*[3], *O. Caselles*[3], *F. Courbon*[3], *M. Levy*[4], *Z. Keidar*[1,2];
[1]*Rambam - Health Care Campus, Haifa, ISRAEL,* [2]*B. and R. Rappaport School of Medicine, Technion – Israel Institute of Technology, Haifa, ISRAEL,* [3]*Institut Claudius Regaud, Toulouse, FRANCE,* [4]*GE Healthcare, Tirat HaCarmel, ISRAEL.*

EPS-112
Development and validation of a Monte Carlo model for a SiPM-based PET scanner
A. Merlet[1], *B. Presles*[1], *K. H. Su*[2], *A. Cochet*[1,3], *J. M. Vrigneaud*[1,3];
[1]*ImViA EA 7535, Dijon, FRANCE,* [2]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA,* [3]*Department of Nuclear Medicine, Georges-François Leclerc Cancer Center, Dijon, FRANCE.*

EPS-113
Optimization of a phase gating parameter for AMF-PET/CT images based on body types and acquisition time
N. Miyaji[1], *K. Motegi*[1], *K. Yamashita*[1], *K. Miwa*[2], *T. Takiguchi*[1], *T. Terauchi*[1];
[1]*Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN,* [2]*Department of Radiological Sciences, School of Health Sciences, Fukushima Medical University, Fukushima, JAPAN.*

EPS-114
The Impact of Overlap Size on Image Quality of ^{18}F-FDG PET/CT: Phantom and Clinical Study
S. Gholami Zahedi[1,2], *P. Ghafarian*[3,4], *S. Aghamiri*[5];
[1]*Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC*

REPUBLIC OF, [2]Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, [3]Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, [4]PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF, [5]Department of Medical Physics, Shahid Beheshti University, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EPS-115

The SIREN Project: Development of a Real Time Reporting System in Abnormal Events in Nuclear Medicine Therapy

C. Canzi[1], *G. Stendardo*[2], *S. Grande*[2], *C. Nuccetelli*[2], *A. Palma*[2], *C. Zicari*[3], *C. Andenna*[3], *G. Frau*[4], *I. Bonanno*[4], *V. Landoni*[5], *F. Murtas*[5], *R. Sciuto*[5], *V. Bruzzaniti*[5], *B. Cassano*[5], *G. Iaccarino*[5], *F. Zito*[1], *P. Fattibene*[2];
[1]*Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, ITALY,* [2]*Istituto Superiore di Sanità, Rome, ITALY,* [3]*INAIL DIT, Rome, ITALY,* [4]*Deep Blue srl, Rome, ITALY,* [5]*IRCCS Regina Elena-IFO, Rome, ITALY.*

EPS-116

Radiation protection safety and hospitalization involvment for patients treated with 177-Lu-Dotatate

O. Ferrando[1], *E. Giovannini*[2], *G. Giovacchini*[2], *S. Pastorino*[2], *F. Tutino*[2], *F. Foppiano*[1], *A. Ciarmiello*[2];
[1]*Physics Department - St Andrea Hospital - ASL5 Spezzino, La Spezia, ITALY,* [2]*Nuclear Medicine Department - St Andrea Hospital - ASL5 Spezzino, La Spezia, ITALY.*

EPS-117

Diagnostic quality of [18F]FDG-PET data of whole-body oncology imaging using different injected radioactivity levels

H. Kertesz[1], *D. Amereller*[2], *W. R. Armstrong*[3], *J. Czernin*[3], *M. Dahlbom*[4], *B. J. Fueger*[2], *M. Hotta*[3], *C. Meyer*[4], *I. Rausch*[1], *T. Beyer*[1];
[1]*QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Biomedical Imaging and Image-guided Therapy, Division of General and Pediatric Radiology, Medical University of Vienna, Vienna, AUSTRIA,* [3]*Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,* [4]*Physics and Biology in Medicine Interdepartmental Graduate Program, David Geffen School of Medicine, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.*

EPS-118

Dose Savings Associated with Personalised CT Scan Range in F-18 Sodium-Fluoride PET-CT

N. Bebbington[1,2], *H. D. Zacho*[2,3], *P. C. Holdgaard*[4];
[1]*Siemens Healthcare A/S, Aarhus, DENMARK,* [2]*Dept. of Clinical Medicine, Aalborg University, Aalborg, DENMARK,* [3]*Dept. of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK,* [4]*Dept. of Nuclear Medicine, University Hospital Lillebælt, Vejle, DENMARK.*

EPS-119

Clinical audit on administered activities to patients undergoing Bone Scintigraphy and estimation of effective dose

V. de Sousa, *G. Cardoso, A. I. Santos;
Hospital Garcia de Orta, E.P.E., Almada, PORTUGAL.*

1009

Monday, October 17, 2022, 15:00 - 16:30

Hall 111

e-Poster Presentation Session 7 - Paediatrics
Committee: e-Posters on Paediatrics & Nephro-Urology

EPS-120

The Optimal Use And Effectiveness Of ^{131}I-meta Iodobenzylguanidine (^{131}I-mIBG) Molecular Radiotherapy For High-Risk And Relapsed/Refractory Neuroblastoma

I. Plaza de las Heras, *M. Osuna Marco, L. Martín López, M. Villa Alcazar, C. Field Galan, L. García Cañamaque, B. Lopez Ibor;
HM Hospitales, Madrid, SPAIN.*

EPS-121

Does age influence bone scan detection of osteoarticular findings in clinically unsuspicious locations in acute pediatric scenarios? A retrospective decade-long analysis

M. Monteiro[1], *A. P. Moreira*[1,2], *A. Albuquerque*[1], *G. Costa*[1,3];
[1]*Serviço de Medicina Nuclear do Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,* [2]*Instituto de Ciências Nucleares Aplicadas à Saúde, Coimbra, PORTUGAL,* [3]*Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.*

EPS-122

Management of non-refluxing megaureter in children. The role of diuretic renography with ^{99m}Tc-mercapto-acetyl-triglycil (MAG3-F0).

M. Pudis[1], *M. D. Marin-Ferrer*[2], *V. M. Godigna-Guilloteau*[2], *L. F. Delgado-Niño*[3], *S. Pérez-Quirós*[2], *D. Vega-Pérez*[2], *E. Martínez Albero*[2], *S. Angiolillo-Grau*[2], *P. Zaragoza-Ballester*[2], *A. Gómez-Fraile*[4], *M. J. Tabuenca Mateo*[2];
[1]*Nuclear Medicine - PET (IDI) Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, SPAIN,* [2]*Nuclear Medicine Department, 12 de Octubre University Hospital, Madrid, SPAIN,* [3]*Nuclear Medicine Department, HM Sanchinarro Hospital, Madrid, SPAIN,* [4]*Pediatric Surgery Department, 12 de Octubre University Hospital, Madrid, SPAIN.*

EPS-123

Dose Reduction in DMSA Renal SPECT in infants: Beyond the Guidelines

F. Fahey[1], *H. Pretorius*[2], *S. Treves*[3], *N. Kwatra*[1], *R. Vali*[4], *M. Dugan*[1], *X. Cao*[1], *W. Fu*[5], *J. Liu*[5], *Y. Yang*[5], *M. King*[2];
[1]*Boston Children's Hospital, Boston, MA, UNITED STATES OF AMERICA,* [2]*University of Massachusetts Medical Center, Worcester, MA, UNITED STATES OF AMERICA,* [3]*Brigham and Women's Hospital, Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,* [4]*Toronto Hospital for Sick Children, Toronto, ON, CANADA,* [5]*Illinois Institute of Technology, Chicago, IL, UNITED STATES OF AMERICA.*

EPS-124

Comparison Between 75-Selenium Homocholic Acid Taurine (SeHCAT) Scintigraphy And Clinical Response To Cholestyramine In Patients Affected By Chronic Diarrhoea: A Pilot Study

I. Bossert[1], *A. Schiepatti*[2,3], *M. Cincotta*[4], *D. D'Ambrosio*[5], *A. Marchetto*[1], *F. Biagi*[2,3], *G. Trifirò*[1];
[1]*Nuclear Medicine Service, Istituti Clinici Scientifci Maugeri SpA SB IRCCS, Pavia, ITALY,* [2]*Gastroenterology Unit, Istituti Clinici Scientifci Maugeri SpA SB IRCCS, Pavia, ITALY,* [3]*Gastroenterology Unit, University of Pavia, Pavia, ITALY,* [4]*University of Pavia, Pavia, ITALY,* [5]*Medical Physics Unit, Istituti Clinici Scientifci Maugeri SpA SB IRCCS, Pavia, ITALY.*

EPS-125

Radioisotope Nephrography - Tie the Knot between Chronic Kidney Disease and Cardiovascular Disease

I. Grierosu[1,2], *M. Starcea*[1,3], *R. Tibu*[2], *W. Jalloul*[1], *T. Ionescu*[1], *C. Stolniceanu*[1], *A. Statescu*[2], *C. Stefanescu*[1,2];
[1]*UMF "Grigore T. Popa", Iasi, ROMANIA,* [2]*County Emergency Hospital „Sf. Spiridon", Iasi, ROMANIA,* [3]*Children's Hospital "Sf. Maria", Iasi, ROMANIA.*

EPS-127

The usefulness of superficial and deep lymphoscintigraphic study in patients with suspected primary lymphedema of lower limbs: a sei-quantitative and qualitative approach

D. Donner[1], *M. Povolato*[2], *M. Rensi*[2], *G. Grassetto*[3], *S. Ave*[4], *V. Vultaggio*[1], *F. Magnani*[1], *S. Agostini*[1], *L. Leveghi*[5], *C. Strazzabosco*[6], *A. Onorato*[7], *F. Chierichetti*[1];
[1]*UO Nuclear Medicine S. Chiara Hospital APSS, Trento, ITALY,* [2]*UO Nuclear Medicine Azienda Ospedaliero Universitaria, Udine, ITALY,* [3]*UO Nuclear Medicine S.M. della Misericordia Hospital Aulss 5 Polesana, Rovigo, ITALY,* [4]*UO Nuclear Medicine S. Bortolo Hospital AULSS 8 Berica, Vicenza, ITALY,* [5]*UO Malattie Rare S. Chiara Hospital APSS, Trento, ITALY,* [6]*UO Medicina Fisica e Riabilitazione S. Chiara Hospital APSS, Trento, ITALY,* [7]*Linfamed, Udine, ITALY.*

EPS-128

Utility Of Peritoneal Scintigraphy In The Evaluation Of Hydrothorax In Patients On Peritoneal Dialysis

J. Carvalho, *A. Marques, F. Abreu, S. Pintão;
Centro Hospitalar de Lisboa Ocidental, Carnaxide, PORTUGAL.*

EPS-129

Value of visual estimation of cortical transit time on renal [^{99m}Tc]Tc-DTPA scintigraphy in surgical management of antenatally diagnosed ureteropelvic junction obstruction in infants

M. A. Hubaut[1], *A. Jaillard-Dubois*[1], *G. Petyt*[2], *R. Priso*[3], *A. Lauriot dit Prevost*[3], *D. Sharma*[3], *H. Lahousse*[1], *F. Hives*[1], *G. Delaby*[1], *C. Faes*[1], *K. Sadoune*[1], *J. F. Legrand*[1], *B. Dekyndt*[1], *E. Cailliau*[4], *J. Labreuche*[4], *D. Huglo*[1], *F. Semah*[1], *R. Besson*[3];
[1]*CHU Lille, Department of Nuclear Medicine, Lille, FRANCE,* [2]*Centre Oscar Lambret, Department of Nuclear Medicine, Lille, FRANCE,* [3]*CHU Lille, Department of Pediatric Urology, Lille, FRANCE,* [4]*CHU Lille, Department of Biostatistics, Lille, FRANCE.*

EPS-130

Ga-68 Psma For The Kidney Function Evaluation: Preliminary Results: Comparison Of Ga-68 Psma Findings With Mag-3 Findings

B. Özdemir, *U. Korkmaz, S. Soyluoglu, G. Durmus-Altun;
Trakya University, Edirne, TÜRKIYE.*

EPS-131

99mTc-Sestamibi SPECT/CT for the diagnosis of indeterminate renal tumours: a pilot diagnostic accuracy study

H. Warren[1,2], *T. Wagner*[2], *D. Pencharz*[2], *A. Reza*[2], *A. Boydell*[2], *J. Neves*[1,2], *M. G. B. Tran*[1,2];
[1]*University College London, London, UNITED KINGDOM,* [2]*Royal Free Hospital, London, UNITED KINGDOM.*

EPS-132

SPECT/CT in the Evaluation of Occult Osteochondral Lesions After Surgical Fixation Ankle Fractures

M. Lara Martínez, *L. López Urquía, S. Romero Acevedo, J. Vela León, F. Medina Romero, M. Canelas Subieta, M. González Díaz, M. Gómez Rodríguez-Bethencourt;
Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN.*

EPS-133

Gastrointestinal bleeding scintigraphy- is there still value in the 21st century?

B. Pernthaler, *E. Steiner, E. Plhak, R. M. Aigner;
Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA.*

EPS-134

Lymphoscintigraphic Evaluation of Lymphatic Insufficiency After Total Knee Arthroplasty

H. Gencer, *K. Gençer, S. Karaçavuş, F. Ozan;
University of Health Sciences, Kayseri City Hospital, Kayseri, TÜRKIYE.*

EPS-135

Comparison of lung perfusion scan and blood perfusion volume (PBV-CT) in emphysematous patients

L. Burroni[1], *A. Borgheresi*[2], *A. Palucci*[1], *F. M. Fringuelli*[1], *G. Biscontini*[1], *C. Romagnolo*[1], *C. Cottignoli*[1], *M. Carotti*[2], *S. Balducci*[2], *E. Cesari*[2], *A. Giovagnoni*[2];
[1]*Nuclear Medicine Unit, Ospedali Riuniti di Torrette, Ancona, ITALY,* [2]*Dept. of Clinical Radiology, University Politecnica delle Marche, Ancona, ITALY.*

EPS-136

Intestinal 99mTc hydroxymethylene diphosphonate uptake in bone scans : improper radiopharmaceutical administration as a cause?

M. Bettaieb, *H. Trabelsi, A. Ezzine, M. Ouachem, W. Touila, M. Nouira, K. Chatti;
Nuclear Medicine, Sahloul University hospital, Sousse, TUNISIA.*

EPS-137

Clinical utility of SPECT/CT imaging in bone infarction

K. Bayardo[1], *D. Gutierrez*[1], *A. Damian*[1], *J. Vilar*[2], *O. Alonso*[1], *R. Ferrando*[1];
[1]*University of the Republic, Montevideo, URUGUAY,* [2]*Consulotrio de Medicina Nuclear Ferrari Ferrando Páez, Montevideo, URUGUAY.*

EPS-138

Body Mass Index Assessment In PET/CT Imaging Patients

G. Mutevelizade, *Y. Parlak, C. Sezgin, E. Sayıt, G. Gumuser;
Department of Nuclear Medicine, School of Medicine, Celal Bayar University, Manisa, TÜRKIYE.*

EPS-139

Incremental Value of SPECT/CT Over Planar Images in Pre-operative Quantification of Lobar Lung Perfusion

N. Alvarez Mena, *F. Sebastián Palacid, M. García Aragón, A. Hurtado Romero, B. Pérez López, C. Gamazo Laherrán, M. Alonso Rodríguez, M. González Soto, A. Sainz Esteban, R. Ruano Pérez;
Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.*

1109

Monday, October 17, 2022, 16:45 - 18:15

Hall 111

e-Poster Presentation Session 8 - Neuroimaging Committee: Neuro e-Posters

EPS-142
Biodistribution and pharmacokinetic evaluation of different mAb formats, targeting endothelin A receptor-positive glioblastoma stem cells using in vivo immunoPET imaging
M. Hautiere[1,2], *D. Vivier*[3], *D. Pineau*[4], *A. Herbet*[1], *N. Costa*[1], *C. Denis*[2], *D. Kereselidze*[2], *A. Guyot*[1], *A. Mabondzo*[1], *J. Hugnot*[4], *F. Denat*[3], *D. Boquet*[*1], *C. Truillet*[*2];
[1]*CEA/DMTS/SPI/LENIT, Saclay, FRANCE,* [2]*CEA-CNRS-Inserm-BioMaps, Orsay, FRANCE,* [3]*ICMUB UMR CNRS 6302, Dijon, FRANCE,* [4]*INSERM U1191-CNRS UMR 5203, Montpellier, FRANCE.*

EPS-143
Imaging analysis of gliomas: comparison of T1-Gd-MRI and PET/CT with 18F-FET and 68Ga-NODAGA-RGDyK
N. Testart Dardel[1], *F. Cicone*[1,2], *P. Mitsakis*[1], *A. Hottinger*[1], *M. Nicod Lalonde*[1], *N. Schaefer*[1], *S. Gnesin*[1], *M. Meyer*[1], *J. Prior*[1];
[1]*CHUV, Lausanne, SWITZERLAND,* [2]*Magna Graecia University of Catanzaro, Catanzaro, ITALY.*

EPS-144
Diagnostic performance of ^{11}C-Methionine PET-CT for differential diagnosis between tumour recurrence and radiation-induced changes in patients with brain metastases
M. Calcagni[3,4], *M. Mattoli*[1,2], *V. Scolozzi*[3], *V. Tempesta*[3,4], *S. Taralli*[3], *F. Cocciolillo*[3], *G. Trevisi*[1], *M. Balducci*[5], *A. Giordano*[3,4];
[1]*Department of Neurosciences, Imaging and Clinical Sciences, "G. d'Annunzio" Chieti-Pescara University, Chieti, ITALY,* [2]*Nuclear Medicine Unit, Santo Spirito Hospital, Pescara, Pescara, ITALY,* [3]*Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY,* [4]*Nuclear Medicine Institute, Università Cattolica del Sacro Cuore, Rome, ITALY,* [5]*Radiation Oncology Unit, Diagnostic Imaging, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY.*

EPS-145
Multimodal imaging of vascular and molecular biomarkers in glioblastoma
E. Lysvik[1,2], *E. Fuster-Garcia*[1,3], *M. Revheim*[1,2], *S. F. Svensson*[1,2], *G. Ager-Wick*[1], *R. Bugge*[1], *O. M. Geier*[1], *K. Skogen*[1], *H. Blakstad*[1], *P. Brandal*[1], *K. E. Emblem*[1], *T. Hjørnevik*[1];
[1]*Oslo University Hospital, Oslo, NORWAY,* [2]*University of Oslo, Oslo, NORWAY,* [3]*Universitat Politècnica de València, Valencia, SPAIN.*

EPS-146
PET-imaging and Protein Expression of Prostate Specific Membrane Antigen in Glioblastoma
S. van Lith[1], *I. J. Pruis*[2], *N. Tolboom*[3], *D. Henssen*[1], *T. J. Snijders*[3], *M. ter Laan*[1], *P. C. de Witt Hamer*[4], *P. Wesseling*[4,5], *R. K. Balvers*[2], *C. M. F. Dirven*[2], *M. Smits*[2], *M. J. van den Bent*[2], *E. van de Giessen*[4], *S. E. M. Veldhuijzen van Zanten*[2];
[1]*Radboud University Medical Center, Nijmegen, NETHERLANDS,* [2]*Erasmus MC, Rotterdam, NETHERLANDS,* [3]*UMC Utrecht, Utrecht, NETHERLANDS,* [4]*Amsterdam UMC, Amsterdam, NETHERLANDS,* [5]*Princess Maxima Center for Pediatric Oncology, Utrecht, NETHERLANDS.*

EPS-148
To explore the value of ^{18}F-FDG PET / MR imaging combined with magnetic resonance functional imaging in the diagnosis and grading of glioma
F. Wang;
Hangzhou Universal medical imaging diagnostic center, Hangzhou, CHINA.

EPS-149
Regional brain glucose metabolism is differently affected by ketogenic diet: A human semi-quantitative positron emission tomography study
T. Horowitz, *E. Doche, M. Philip, S. Cammilleri, L. Suissa, E. Guedj; APHM, Marseille, FRANCE.*

EPS-150
Myelin imaging of the spinal cord in patients with multiple sclerosis using [^{11}C]MeDAS PET
C. Van Der Weijden[1], *A. K. M. Ahmed*[2], *A. van der Hoorn*[1], *J. Zhu*[3], *Y. Wang*[3], *C. Wu*[3], *G. N. Stormezand*[1], *R. A. J. Dierckx*[1], *A. T. M. Willemsen*[1], *J. F. Meilof*[1], *E. F. J. de Vries*[1];
[1]*UMCG, Groningen, NETHERLANDS,* [2]*Osaka University, Osaka, JAPAN,* [3]*Case Western Reserve University, Cleveland, OH, UNITED STATES OF AMERICA.*

EPS-153
Correlation of Brain Glucose Metabolism and Glymphatic System Activity in Alzheimer's Disease Continuum Using Hybrid PET/MR Imaging
E. Balci[1], *U. O. Akdemir*[1], *M. A. Topcuoglu*[2], *E. Saka*[2], *L. O. Atay*[1];
[1]*Gazi University Medical Faculty Department of Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Hacettepe University , Faculty of Medicine , Department of Neurology, Ankara, TÜRKIYE.*

EPS-154
Assessment of cerebral glucidic metabolism in preclinical dementia using 18F-FDG PET/CT: implications for future studies on funcional hyperactivation in preclinical AD
B. Garcia-Garcia[1,2], *E. N. Molloy*[1,2], *D. Kupitz*[1], *P. Genseke*[1], *M. C. Kreissl*[1];
[1]*Otto von Guericke University Magdeburg, Magdeburg, GERMANY,* [2]*German Center for Neurodegenerative Diseases, Magdeburg, GERMANY.*

EPS-155
Spectrum of [18F]FDG brain metabolism changes in patients with Down syndrome
P. Stefaneli Mormandi[1], *R. Nuñez-Muñoz*[2], *A. Fernández-León*[1], *A. Flotats-Giralt*[1], *V. Camacho*[1];
[1]*Nuclear Medicine Department. Hospital de la Santa Creu i Sant Pau, Barcelona, SPAIN,* [2]*Nuclear Medicine Department. Hospital de Cruces, Barakaldo, SPAIN.*

EPS-156
Prevalence of amyloidopathy in frailty elderly subjects: the CogFrail study
L. Saint-Aubert[1,2], *G. Soriano*[3], *A. Hitzel*[2], *S. Sourdet*[3], *P. Payoux*[2];
[1]*INSERM laboratory ToNIC, Toulouse, FRANCE,* [2]*Service of nuclear medicine, Toulouse university hospital, Toulouse, FRANCE,* [3]*Frailty daycare unit, Gerontopole, Toulouse university hopsital, Toulouse, FRANCE.*

EPS-157
Reproducibility of SUV-ratio (SUVr) dependent and independent methods for semiquantification of Amyloid PET included in DOlab Platform
F. D'Amico[1], *C. Mantarro*[2], *A. Chincarini*[3], *F. Lanfranchi*[1], *R. Gianeri*[3], *E. Peira*[3], *F. Sensi*[3], *M. Donegani*[1], *M. Bauckneht*[1], *M. Pardini*[4], *F. Massa*[4], *D. Arnaldi*[4], *F. Minutoli*[2], *G. Sambuceti*[1], *F. Nobili*[4], *S. Baldari*[2], *S. Morbelli*[1];
[1]*Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,* [2]*Nuclear Medicine Unit, University of Messina, Messina, ITALY,* [3]*National Institute of Nuclear Physics (INFN), Genoa section, Genoa, ITALY,* [4]*Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genoa, ITALY.*

EPS-158
Metabolic pattern and prognostic predicators on [^{18}F]-FDG PET in patients with autoimmune encephalitis
Z. Zhu, *Y. Dai, X. Liu, L. Long, S. Hu;*
Central South University, Changsha, CHINA.

EPS-159
Neuromelanin MRI as Biomarker for Treatment Resistance in First Episode Schizophrenia Patients
E. Van de Giessen[1], *M. van der Pluijm*[1], *G. Horga*[2], *K. Wengler*[2], *C. Cassidy*[3], *L. de Haan*[1], *J. Booij*[1];
[1]*Academic University Medical Centers, Amsterdam, NETHERLANDS,* [2]*Columbia University Medical Centers, New York, NY, UNITED STATES OF AMERICA,* [3]*Royal Ottowa Mental Healthy Care Center, Ottowa, ON, CANADA.*

EPS-160
Selective agonist PET radioligand [^{18}F]F13640 for functional 5-HT1A receptor imaging in humans
P. Courault[1,2], *S. Lancelot*[1,2], *N. Costes*[1,3], *D. Le Bars*[2], *J. Redoute*[3], *F. Gobert*[1,2], *F. Dailler*[2], *S. Isal*[2], *A. Newman-Tancredi*[4], *I. Merida*[3], *L. Zimmer*[1,2,3];
[1]*Lyon Neuroscience Research Center, Lyon, FRANCE,* [2]*Hospices Civils de Lyon, Lyon, FRANCE,* [3]*CERMEP, Lyon, FRANCE,* [4]*Neurolixis, Castres, FRANCE.*

1209

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 111

e-Poster Presentation Session 9 - Oncology & Theranostics Committee: Local Therapy and More

EPS-161
Lung Mean Dose Prediction in SIRT: Feasibility of ^{166}Ho-scout Compared to ^{99m}Tc-MAA
M. Wagemans, *A. J. A. Braat, R. van Rooij, M. L. J. Smits, M. G. E. Lam;*
UMC Utrecht, Utrecht, NETHERLANDS.

EPS-162
Distribution of Transarterial Radioembolization Holmium Microspheres in Ex Situ Perfused Human Livers
A. van den Brekel[1], *T. J. Snoeijink*[1], *J. Roosen*[1], *S. J. S. Ruiter*[2], *K. P. de Jong*[2], *V. E. de Meijer*[2], *J. F. W. Nijsen*[1];
[1]*Radboud University Medical Center, Radboud Institute for Health Sciences, Department of Medical Imaging, Nijmegen, NETHERLANDS,* [2]*Department of HPB Surgery and Liver Transplantation, University of Groningen, University Medical Center Groningen, Groningen, NETHERLANDS.*

EPS-163
Response assessment and clinical efficacy of ^{188}Re-N-DEDC/Lipiodol trans-arterial Radionuclide therapy (TART) in patients with Hepatocellular carcinoma: A prospective single center study
S. Shamim, *N. Kumar, P. Gupta, S. Gamanagatti,.. Shalimar, C. Bal; AIIMS New Delhi, Delhi, INDIA.*

EPS-164
Towards Microscopic Level Dosimetry for Colorectal Hepatic Metastases Treated with Trans-arterial ^{90}Y Radioembolization using Micro-CT and Autoradiography of ^{90}Y PET/CT-guided Biopsy Specimens
A. Kirov[1], *N. Naydenov*[1], *X. Nie*[2], *O. Talarico*[1], *A. Teplov*[1], *M. Zirakchian Zadeh*[1], *S. Ruan*[1], *M. Iraca*[3], *H. Kunin*[1], *B. W. Miller*[4], *D. Lafontaine*[1], *J. Schwartz*[1], *A. Kesner*[1], *S. Alam*[1], *B. Beattie*[1], *V. Sotirchos*[1], *M. Silk*[1], *L. Furenlid*[4], *J. L. Humm*[1], *Y. Yagi*[1], *P. Zanzonico*[1], *C. T. Sofocleous*[1];
[1]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [2]*University of Kentucky, Lexington, KY, UNITED STATES OF AMERICA,* [3]*Lock Haven University of Pennsylvania, Lock Haven, PA, UNITED STATES OF AMERICA,* [4]*University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA.*

EPS-165
First clinical experiences on fractionated intracavitary radioimmunotherapy with Lu-177 labeled 6A10 Fab fragments in patients with glioblastoma
W. Roll[1], *M. Müther*[2], *G. Böning*[3], *A. Delker*[3], *N. Warneke*[2], *F. J. Gildehaus*[3], *M. Schäfers*[1], *W. Stummer*[2], *R. Zeidler*[4], *H. J. Reulen*[5], *L. Stegger*[1];
[1]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,* [2]*Department of Neurosurgery, University Hospital Münster, Münster, GERMANY,* [3]*Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY,* [4]*Helmholtz Centre Munich, German Research Center for Environmental Health, Munich, GERMANY,* [5]*Department of Neurosurgery, University Hospital LMU Munich, Munich, GERMANY.*

EPS-166
PET/MRI obtained tumor-to-normal tissue (T/N) dosimetry ratio used in predicting Y-90 microspheres liver therapy
K. Knesaurek, *A. Abdelrahman, M. Ghesani;*
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

EPS-167
Voxel S-value based personalized dosimetry for predicting response to trans-arterial radioembolization therapy for hepatocellular carcinoma
M. Suh, *K. Kim, J. Paeng, H. Kim, J. Lee;*
Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EPS-168
Impact of Personalized Dosimetry using ^{90}Y glass microsphere Radioembolization on response and survival rate of patients with liver metastases
A. Nappi[1], *V. Lavelli*[1], *C. Ferrari*[1], *C. D'Alò*[1], *A. Sciacqua*[1], *G. Santo*[1], *V. Didonna*[2], *G. Rubini*[1];
[1]*Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University Aldo Moro, Bari, ITALY,* [2]*Department Unit of Medical Physics, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, ITALY.*

EPS-169
Efficacy assessment of Radio-embolization for Hepatocellular carcinoma mainly posts an in-complete response to Chemo-embolization
S. Binzaqr, *F. Debordeaux, J. Blanc, E. Hindie, B. Lapuyade, J. Pinaquy;*
University of Bordeaux, Bordeaux, FRANCE.

EPS-170
Hepatic transarterial radioembolization with ^{90}Yttrium spheres of colorectal hepatic metastases: safety and survival outcomes
T. Rudolphi-Solero[1], *E. M. Triviño Ibáñez*[1,2], *M. Rueda-Cáceres*[3], *J. Ciampi-Dopazo*[4], *P. Pardo-Moreno*[4], *E. González-Flores*[3], *A. Rodríguez-Fernández*[1,2];
[1]*Unidad de Gestión Clínica de Medicina Nuclear. Hospital Universitario Virgen de las Nieves, Granada, SPAIN,* [2]*Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, SPAIN,* [3]*Unidad de Gestión Clínica de Oncología Médica. Hospital Universitario Virgen de las Nieves, Granada, SPAIN,* [4]*Unidad de Gestión Clínica de Radiodiagnóstico. Hospital Universitario Virgen de las Nieves, Granada, SPAIN.*

EPS-171
The value of ALBI grade for prognostic stratification in patients with hepatocarcinoma undergoing Transarterial Radioembolization
F. Gelardi[1,2], *M. Rodari*[2], *C. Pini*[1,2], *R. Zanca*[1,2], *A. Artesani*[1,1], *G. Tosi*[2], *M. Sollini*[1,2], *A. Chiti*[1,2];
[1]*Humanitas University, Pieve Emanuele, ITALY,* [2]*IRCCS Humanitas Research Hospital, Rozzano, ITALY.*

EPS-172
Efficacy of the personalized, dosimetry-based PRRT treatment of patients with neuroendocrine tumors using [177Lu]Lu-DOTA-TATE or [177Lu]/[90Y]Lu/Y-DOTA-TATE mixture - the DUONEN multicenter study
M. Opalinska[1], *R. Mikołajczak*[2], *G. Kamiński*[3], *M. Dedecjus*[4], *A. Kowalska*[5], *M. Kołodziej*[3], *M. Saracyn*[3], *P. Garnuszek*[2], *I. Cieszykowska*[2], *A. Sowa-Staszczak*[6], *A. Hubalewska-Dydejczyk*[7];
[1]*Nuclear Medicine Unit, Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital in Krakow, Krakow, POLAND,* [2]*Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, POLAND,* [3]*Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, POLAND,* [4]*Department of Endocrine Oncology and Nuclear Medicine, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, POLAND,* [5]*Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, POLAND,* [6]*Jagiellonian University Medical Collage, Krakow, POLAND,* [7]*Chair and Department of Endocrinology, Jagiellonian University Medical College, Krakow, POLAND.*

EPS-173
Evaluation of the efficacy of second 177Lu-DOTATATE PRRT course in patients with progressive GEP-NET using dual-tracer imaging with 18FDG and 68Ga-DOTA-TOC/TATE PET/CT. Preliminary results of a multicenter study
M. Rodrigues[1], *D. Paez*[2], *L. Kabasakal*[3], *K. Kairemo*[4], *C. Grana*[5], *R. Baum*[6], *I. Virgolini*[1];
[1]*Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, AUSTRIA,* [2]*Nuclear Medicine and Diagnostic Imaging Section, Division of Human Health, International Atomic Energy Agency, Vienna, AUSTRIA,* [3]*Department of Nuclear Medicine, Faculty of Medicine, Yeditepe University School of Medicine, İstanbul, TÜRKIYE,* [4]*Nuclear Medicine & Theragnostics, Docrates Cancer Center, Helsinki, FINLAND,* [5]*Radiometabolic Therapy Unit, IRCCS IEO European Institute of Oncology, Milan, ITALY,* [6]*Theranostics Centre for Molecular Radiotherapy and Precision Oncology, Zentralklinik, Bad Berka, GERMANY.*

EPS-174
GEPNET and Early Progression after LRT. Application of a Modified TGR to Increase the Accuracy of Prediction Model
F. Scalorbi, *G. Calareso, E. M. Garanzini, S. Mazzaglia, G. Argiroffi, V. Fuoco, E. Seregni, M. Maccauro;*
Istituto Nazionale Tumori Milano, Milan, ITALY.

EPS-175
Rhenium-188 as irradiation therapy for non-melanoma skin cancer- Study update
S. Schwarzenböck, *M. Krönert, J. Kurth, M. Heuschkel, G. Ojak, J. Roewer, P. Troitzsch, A. Riedmiller-Schraven, M. Doerschner, B. J. Krause, S. Emmert, J. K. Tietze;*
Rostock University Medical Center, Rostock, GERMANY.

EPS-176
Locoregional treatment of glioblastoma with targeted alpha therapy: [^{213}Bi]Bi-DOTA-substance P vs [^{225}Ac]Ac-DOTA-substance P - analysis of influence parameters
L. Krolicki[1], *J. Kunikowska*[1], *F. Bruchertseifer*[2], *R. Kuliński*[1], *D. Pawlak*[3], *H. Koziara*[4], *R. Rola*[5], *A. Morgenstern*[2], *A. Merlo*[6];
[1]*Medical University of Warsaw, Warszawa, POLAND,* [2]*European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe, GERMANY,* [3]*Radioisotope Centre POLATOM, National Centre for Nuclear Research, Owock, POLAND,* [4]*Department of Neurosurgery, The Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology, Warszawa, POLAND,* [5]*Department of Neurology, Military Institute of Aviation Medicine, Warszawa, POLAND,* [6]*Department of Neurosurgery, Bern and University of Basel, Basel, SWITZERLAND.*

EPS-177
Semi-automated segmentation method of ^{68}Ga-DOTATOC PET for dosimetry prediction in refractory meningiomas treated by ^{177}Lu-DOTATATE
C. Boursier[1,2,3], *T. Zaragori*[2,3], *M. Bros*[1], *E. Mairal*[1], *L. Imbert*[1,2,3], *A. Verger*[1,2,3];
[1]*Department of Nuclear Medicine, CHRU Nancy, Vandoeuvre-les Nancy, FRANCE,* [2]*Nancyclotep Imaging Platform, Vandoeuvre-les-Nancy, FRANCE,* [3]*Université de Lorraine, IADI, INSERM U1254, Vandoeuvre-les-Nancy, FRANCE.*

EPS-178
Safety and efficacy of ^{90}Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and cancer entities
W. Fendler[1], *K. M. Pabst*[1], *L. Kessler*[1], *P. F. Costa*[1], *J. Ferdinandus*[1], *M. Weber*[1], *M. Lippert*[1], *K. Lueckerath*[1], *N. Hirmas*[1], *K. Kostbade*[2], *I. A. Mavroeidi*[2], *M. Schuler*[2], *M. Ahrens*[3], *C. Rischpler*[1], *S. Bauer*[2], *K. Herrmann*[1], *J. T. Siveke*[2], *R. Hamacher*[2];
[1]*Department of Nuclear Medicine, Essen, GERMANY,* [2]*Department of Oncology, Essen, GERMANY,* [3]*Department of Oncology, Frankfurt, GERMANY.*

EPS-179
Peptide receptor radionuclide therapy (PRRT) in Vipoma-NETs followed in second line by the surgical excision of the liver metastases, aiming to a longer term survival and quality of life
G. Limouris[1,2], *G. Fragulidis*[3], *V. Krylov*[4], *M. B. Dolgushin*[5], *A. G. Zafeirakis*[2];
[1]*Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GREECE,* [2]*Nucl Med Dept, Army Share Fund Hospital of Athens, Athens, GREECE,* [3]*Second Surgical Clinic, National and Kapodistrian University of Athens, Athens, GREECE,* [4]*Nuclear Medicine Department "Anatoly Tsyb" Research Center, Obninsk, RUSSIAN FEDERATION,* [5]*Radiology Dept, FTsMN Federal State Institute, Federal Med Biol Agency, Moscow, RUSSIAN FEDERATION.*

EPS-180
Y-90 glass microspheres residue after selective internal radiation therapy (SIRT) and impact on tumor absorbed dose by comparison to planned dosimetry with Tc99m MAA scintigraphy
S. Boughdad, *R. Duran, J. O. Prior, M. Da Mota, M. Mendes-De-Carvalho, J. Costes, N. Cherbuin, S. Gnesin, N. Schaefer;*
CHUV, Lausanne, SWITZERLAND.

EPS-181
Multimodality treatment of Advanced Hepatocellular Carcinoma: An audit of a novel strategy for treating HCC with porto-venous tumour thrombus with a combination of SIRT, SBRT and targeted chemotherapy
D. Malik, *I. Sen, A. Abhishek, M. Patekar, P. Thakral, A. Singhal, D. Manda;*
Fortis Memorial research institute (FMRI), Gurugram, INDIA.

1309

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 111

e-Poster Presentation Session 10 - Oncology & Theranostics Committee: Oncology

EPS-183
Sentinel lymph node biopsy in pediatric Wilms tumor
R. Sadeghi, *R. Shojaeian, M. Horadfar, A. Mohammadipour, A. Azadmand, M. Parvizi Mashhadi;*
Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EPS-184
The application of 18F-FDG PET/MR in postoperative metastasis and restaging of liver cancer
S. Yun, *Y. Xu;*
Hangzhou Universal Medical Imaging Diagnostic Center, Hang Zhou, CHINA.

EPS-185
Prevalence and clinical response to treatment of patients with diarrhoea and borderline 75SeHCAT results
S. Bondía-Bescos[1], *P. Notta*[1], *M. Pudis*[1], *B. Hervás-Sanz*[1], *A. Palomar-Muñoz*[1], *E. Llinares-Tello*[1], *A. Rodriguez-Gasén*[1], *J. Suils-Ramón*[1], *I. Gil-Viciano*[2], *M. Buaki-Sogo*[2], *A. Ruiz-Cerulla*[3], *J. Guardiola-Capón*[3], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, L'Hospitalet de Llobregat (Barcelona), SPAIN,* [2]*Radiopharmaceutical Department, Bellvitge University Hospital, L'Hospitalet de Llobregat (Barcelona), SPAIN,* [3]*Digestive System Department, Bellvitge University Hospital, L'Hospitalet de Llobregat (Barcelona), SPAIN.*

EPS-186
Comparison of ^{18}F-FDG and ^{68}Ga-PSMA PET-CT for evaluation of hepatocellular carcinoma
S. Shamim[1], *N. Kumar*[2], *G. Arora*[1], *S. Gamanagatti*[1], *Shalimar*[1], *C. Bal*[1];
[1]*AIIMS New Delhi, Delhi, INDIA,* [2]*AIIMS, New Delhi, Delhi, INDIA.*

EPS-187
[^{68}Ga]Ga-DOTANOC PET/CT in NEN in a Prospective Five-Years Electronic Archive: an Interim Analysis
N. Bonazzi[1], *E. Fortunati*[1], *G. Argalia*[1], *L. Zanoni*[2], *D. Campana*[3,4], *R. Casadei*[5,4], *C. Ricci*[5,4], *C. Mosconi*[6], *S. Fanti*[1,2], *V. Ambrosini*[1,2];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*Pancreatic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*Radiology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EPS-188
Comparison of 68 Ga-FAPI and 18 F-FDG in Patients With Different Types of Cancer
M. Assadi[1], *G. Norouzi*[2], *G. Divband*[3], *H. Amini*[3], *B. Nikkholgh*[3], *N. Norouzbeigi*[4], *H. Dadgar*[4], *E. Jafari*[1];
[1]*Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF,* [2]*Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Khatam PET/CT center, Khatam-al-anbia Hospital, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*The Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EPS-189
Role of PET / CT with ^{68}Ga-DOTA-TATE in the evaluation of patients with gynecologic tract neuroendocrine tumors
J. Gambini[1], *E. Silvera, G. dos Santos, E. Savio, O. Alonso, P. Duartei;*
Centro Uruguayo de Imagenología Molecular, Montevideo Uruguay, Montevideo, URUGUAY.

EPS-190
Method for direct correlation of high-resolution ^{18}F-FDG-PET/CT images with histopathology in resected breast cancer specimens
L. Maris[1,2], *J. Debacker*[3,4,5], *K. De Man*[6], *M. Göker*[7], *V. Keereman*[1,2], *B. Van den Broeck*[6], *K. Van de Vijver*[8,9], *R. Vanholen*[1,2], *C. Vanhove*[1,10];
[1]*Department of Electronics and Information Systems, Ghent University, Ghent, BELGIUM,* [2]*XEOS Medical, Ghent, BELGIUM,* [3]*Department of Head and Skin, Ghent University, Ghent, BELGIUM,* [4]*Department of Head and Neck Surgery, Ghent University Hospital, Ghent, BELGIUM,* [5]*Department of Nuclear Medicine, University Hospital Brussels, Brussels, BELGIUM,* [6]*Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM,* [7]*Department of Gynaecology, Ghent University Hospital, Ghent, BELGIUM,* [8]*Department of Pathology, Ghent University Hospital, Ghent, BELGIUM,* [9]*Department of Diagnostic Sciences, Ghent University, Ghent, BELGIUM,* [10]*INFINITY Lab, Ghent University, Ghent, BELGIUM.*

EPS-191
Preliminary resultats of correlatation between triple-negative breast cancer cluster, SUV parameters, TLG and textural features assessed with 18F-FDG PET/CT in a prospective study
V. Fleury[1], *L. Ferrer*[2], *O. Kerdraon*[1], *B. Maucherat*[1], *M. Le Thiec*[1], *D. Rusu*[1], *A. Morel-Thierry*[1], *E. Picot-Dilly*[1], *M. Lacombe*[3], *C. Rousseau*[2], *F. Kraeber-Bodéré*[4];
[1]*ICO René Gauducheau, Saint-Herblain, FRANCE,* [2]*ICO René Gauducheau, Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, Saint-Herblain, FRANCE,* [3]*ICO René Gauducheau, Angers, FRANCE,* [4]*Nantes Université, Univ Angers, CHU Nantes, INSERM, CNRS, CRCI2NA, Nantes, FRANCE.*

EPS-192
Can 68Ga-FAPI PET/CT Replace 18F-FDG PET/CT in Breast Cancer Staging?
G. Alçin, *E. Arslan, T. Aksoy, Ö. Erol Fenercioğlu, E. Beyhan, N. Ergül, T. F. Çermik;*
University of Health Sciences Türkiye, Istanbul Training and Research Hospital Nuclear Medicine Clinic, Istanbul, TÜRKIYE.

EPS-193
Advantages Of Minimally Invasive Parathyroidectomy Using Radioguided Gamma Probe Versus Conventional Technique
L. Delgado Niño, *I. Plaza de las Heras, H. Durán Gimenez-Rico, C. Field Galán, U. Vera Schmülling, P. Alonso de Caso Vaquero, L. García Cañamaque;*
Hospital HM Sanchinarro, Madrid, SPAIN.

EPS-194
The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression
B. Hu, *H. Jin, X. Li, X. Wu, J. Xu, Y. Gao;*
Department of Nuclear Medicine of Henan Provincial People's Hospital, Zhengzhou, CHINA.

EPS-195
Radiomic analysis of pre-surgery FDG-PET images in early stage Non Small Lung Cancer patients can improve overall survival prediction
P. Artioli[1,2], *L. L. Travaini*[1], *L. S. Airò Farulla*[1,3], *F. Bellerba*[4], *M. d'Arcangelo*[5], *L. Rinaldi*[6,7], *S. Raimondi*[4], *F. Botta*[8], *M. Ferrari*[8], *F. Ceci*[1,3];
[1]*Nuclear Medicine Division, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [2]*Nuclear Medicine Unit, Department of Medicine, University Hospital, Padua, ITALY,* [3]*Department of Oncology anf Hemato-Oncology, University of Milan, Milan, ITALY,* [4]*Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [5]*Department of Physics, University of Milan, Milan, ITALY,* [6]*Department of Physics, University of Pavia and INFN, Pavia, ITALY,* [7]*Radiation Research Uni, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [8]*Medical Physics Unit, IEO European Institute of Oncology IRCCS, Milan, ITALY.*

EPS-197
Sentinel lymph node biopsy in patients with early oral squamous cell carcinoma using the Receptor-Targeted Radiotracer ^{99m}Tc-Tilmanocept
F. Linguanti[1], *L. G. Locatello*[2], *E. M. Abenavoli*[1], *M. Matteini*[1], *E. Costanzo*[1], *V. Briganti*[1], *R. Recenti*[1], *M. Cilona*[2], *G. Fantini*[1], *G. Maggiore*[2], *O. Gallo*[2], *L. Vaggelli*[1], *R. Sciagrà*[3];
[1]*Medicina Nucleare, Firenze, ITALY,* [2]*Otorhinolaryngology Unit, Firenze, ITALY,* [3]*Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence., Firenze, ITALY.*

EPS-198
Sentinel node in endometrial cancer. Our six years experience.
P. Zaragoza Ballester[1], *S. Angiolillo Grau*[1], *D. Vega Perez*[1], *P. Sarandeses Fernández*[1], *S. Ruiz Solís*[1], *R. Oliver Pérez*[2], *Á. Tejerizo García*[2], *Á. Galiana Morón*[1], *A. Saviatto Nardi*[1], *E. Martínez Alvero*[1], *S. Pérez Quirós*[1], *M. Marín Ferrer*[1], *V. Godigna Guilloteau*[1], *A. Gómez Grande*[1], *M. Tabuenca Mateo*[1];
[1]*Nuclear Medicine Department, Hospital Universitario 12 De Octubre, Madrid, SPAIN,* [2]*Department of Gynecology and Obstetrics, Hospital Universitario 12 De Octubre, Madrid, SPAIN.*

EPS-199
Prognostic role of baseline ^{18}F-FDG PET/CT in stage I and II non small cell lung cancer
F. Dondi[1], *D. Albano*[2], *M. Bertoli*[1], *P. Bellini*[2], *A. Calabrò*[2], *M. Gregorelli*[2], *A. Talin*[2], *G. Ferrarini*[2], *G. Franzoni*[2], *F. Bertagna*[2];
[1]*ASST Spedali Civili di Brescia, Brescia, ITALY,* [2]*Università degli Studi di Brescia and ASST Spedali Civili di Brescia, Brescia, ITALY.*

EPS-200
Baseline and interim ^{18}FDG-PET/MRI to assess treatment response and survival in patients with esophageal squamous cell carcinoma treated by curative-intent therapy
S. Chan[1,2], *S. Ng*[3], *Y. Chao*[3];
[1]*Hualien Tzu Chi Hospital, Hualien, TAIWAN,* [2]*School of Medicine, Tzu Chi University, Hualien, TAIWAN,* [3]*Linkou Chang Gung Memorial Hospital, Taoyuan, TAIWAN.*

EPS-201
Prognostic Value of Morphofunctional Imaging Methods in Pre-therapy Inoperable Intrahepatic Cholangiocarcinoma
V. Dragonetti[1], *N. Fraccascia*[1], *C. Mosconi*[2], *M. Barakat*[3], *A. Palloni*[4,5], *A. Paccapelo*[2], *R. Golfieri*[3,2], *G. Brandi*[4,5], *S. Fanti*[1,6], *C. Nanni*[6];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Abdominal-pelvic Diagnostic and Interventional Radiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Abdominal-pelvic Diagnostic and Interventional Radiology Unit, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [4]*Medical Oncology, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [5]*Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

1310

Tuesday, October 18, 2022, 09:45 - 11:15

Hall 116

Technologists' e-Poster Presentations Session: Techs' e-Posters

TEPS-01
An italian survey on the use and purpose of ct protocols and related technical parameters in pet ct
G. Rompianesi[1], *A. Palmieri*[2], *&. GI-TMN group*[3], *E. Vaccari*[1], *S. Panareo*[1];
[1]*University Hospital of Modena, Modena, ITALY,* [2]*Santa Maria Nuova Hospital AUSL, Reggio Emilia, ITALY,* [3]*GI-TMN group, ITALY.*

TEPS-02
Large axial field-of-view PET/CT and the claustrophobic patient
R. Schepers, *I. Alberts, M. Viscione, A. Afshar-Oromieh, A. Rominger;*
Inselspital, Bern, SWITZERLAND.

TEPS-03
Evaluation of the use of breath hold acquisitions in routine practice
C. Pozza, *J. O. Prior, M. Nicod Lalonde, N. Schaefer, C. Soares Sobral, S. Boughdad;*
CHUV, Lausanne, SWITZERLAND.

TEPS-04
A practical tool to evaluate the quality of myocardial perfusion images
V. Ostermann, *B. Hoyer Mathiasen;*
Department of Nuclear Medicine, Vejle, DENMARK.

TEPS-05
Clinical Audits in Nuclear Medicine: a Modified Model Adapted to the Portuguese Reality
A. Martins[1,2], *P. Almeida*[1,3,4], *I. Rodrigues*[1,2], *M. J. Vieira*[1], *S. Carmona*[1], *C. Pio*[1], *A. Alvernaz*[1], *L. Oliveira*[1];
[1]*Joaquim Chaves Saúde, Lisbon, PORTUGAL,* [2]*Medical Imaging and Radiotherapy Department, Portuguese Red Cross Health School, Lisbon, PORTUGAL,* [3]*Instituto de Biofísica e Engenharia Biomédica - Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL,* [4]*Departamento de Física- - Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL.*

TEPS-06
Interest of the "Medrad Intego" combined automatic dispenser and injector system during 18F-FDG PET imaging
A. Ben Amor[1], *A. Ezzine*[1,2], *H. Boudriga*[1,2], *S. Mensi*[1], *M. Nouira*[1,2], *M. Ben Fredj*[1,2], *K. Chatti*[1];
[1]*Nuclear medicine department, Sousse, TUNISIA,* [2]*Université de Sousse, faculté de médecine de Sousse, "LR12Es02", Sousse, TUNISIA.*

TEPS-07
Dose Received to Hands (Fingers) While Dispensing and Administration of Radioactive Injections (F-18) to Patients
M. Khaskhali, *C. Crouch;*
Oxford University Hospitals NHS Foundation Trust, Oxford, UNITED KINGDOM.

TEPS-08
Radiation Dose To The Patients From F18-FDG WB PETCT Study And Optimization Analysis
P. Dwivedi[1], *A. Jha*[2], *V. Rangarajan*[2];
[1]*Advanced Centre for Treatment Research and Education In Cancer, Tata Memorial Centre, Mumbai, INDIA,* [2]*Tata Memorial Centre, Mumbai, INDIA.*

TEPS-09
Radiation safety assessment of ^{177}Lu-DOTATATE Intra-Arterial peptide receptor therapy (PRRT)
M. Chauhan[1,2], *A. K. Jha*[3,2], *S. Mithun*[3,4], *R. Parab*[3,2], *A. Nautiyal*[1,4], *V. Rangarajan*[3,2];
[1]*Advanced Centre for Treatment Research & Education in Cancer, New Mumbai, INDIA,* [2]*Homi Bhabha National Institute, Mumbai, INDIA,* [3]*Tata Memorial Hospital, Mumbai, INDIA,* [4]*Homi Bhabha National Institute, Mumbai, INDIA.*

TEPS-10
Diagnostic Reference Levels in Nuclear Medicine: Development of a Simple Tool to Help Assessing the Portuguese Reality
A. Martins[1,2], *P. Almeida*[1,3,4], *I. Rodrigues*[1,2], *S. Carmona*[1], *M. J. Vieira*[1], *C. Pio*[1], *T. Martins*[1], *A. Alvernaz*[1], *L. Oliveira*[1,2];
[1]*Joaquim Chaves Saúde, Lisbon, PORTUGAL,* [2]*Medical Imaging and Radiotherapy Department, Portuguese Red Cross Health School, Lisbon, PORTUGAL,* [3]*Instituto de Biofísica e Engenharia Biomédica - Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL,* [4]*Departamento de Física- - Faculty of Sciences of the University of Lisbon, Lisbon, PORTUGAL.*

TEPS-11
Reduction of the finger dose of technologists by the use of an automatic injection unit in mycardial perfusion PETCT studies with ^{13}N-ammonia
V. Schober, *P. von Schulthess, R. R. Büchel, J. Trinckauf, T. Berthold, P. Kaufmann, M. Hofbauer;*
University Hospital Zurich, Zurich, SWITZERLAND.

TEPS-12
Head & Neck Sentinel Node procedure - lessons from practical experience
L. Pereira[1,2], *J. Elliott*[3,2], *K. Brooks*[1,2], *P. Norris*[4,2], *A. Corrigan*[1,2], *B. Bisase*[4], *T. Barnden*[1,2];
[1]*NHS, Maidstone, UNITED KINGDOM,* [2]*Maidstone and Tunbridge Wells NHS Trust, Maidstone, UNITED KINGDOM,* [3]*Canterbury Christ Church University, Canterbury, UNITED KINGDOM,* [4]*Queen Victoria Hospital (QVH), East Grinstead, Sussex, UNITED KINGDOM.*

TEPS-13
Value of continuous blood pressure monitoring in the evaluation of maximal hyperemia during myocardial perfusion imaging with Rubidium-82 PET/CT
A. Tegelaar - Kuiper[1], *S. S. Koenders*[1,2], *J. A. van Dalen*[3], *P. L. Jager*[1], *J. D. van Dijk*[1];
[1]*Department of Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS,* [2]*Technical Medical Centre, University of Twente, Enschede, NETHERLANDS,* [3]*Department of Medical Physics, Isala Hospital, Zwolle, NETHERLANDS.*

TEPS-14
Providing Water before Myocardial Perfusion Imaging with Digital Gamma Camera, Investigating Mechanics and Logistics of Inferior-Lateral Artefact Reduction with Profile Analysis
V. Ostermann, *M. R. Pedersen;*
Department of Nuclear medicine, Vejle, DENMARK.

TEPS-16
Around the Clock
V. Ostermann, *B. Hoyer Mathiasen, J. Terzic;*
Department of Nuclear Medicine, Vejle, DENMARK.

TEPS-17
Improvement In Morphological Image Quality in Spect/Ct Lung Studies In Patients With Differentiated Thyroid Carcinoma Theated With ^{131}I
F. Mercado Moreno[1], *P. Borredá Ayala*[2], *L. Felix Macias*[2], *A. Badenes Romo*[3], *S. Loste Martinez*[2], *M. Kargbo Kargbo*[2], *G. Albertos Roncal*[3], *J. Vercher Conejero*[2], *S. Rustarazo Lozada*[2], *I. Liarte Trias*[2], *M. Albadalejo Castaño*[2], *N. Xavier Eloi*[2], *S. Rodriguez Lara*[2], *M. Rodriguez Lora*[2], *J. Suils Ramón*[2], *A. Palomar Muñoz*[2], *A. Rodriguez Gasén*[3], *V. Ruiz Fernández*[2], *M. Cortés Romera*[4];
[1]*(Hospital Bellvitge) Institut D'imatge Per Al Diagnòstic, L'hospitalet (Barcelona), SPAIN,* [2]*Hospital Bellvitge IDI, L'hospitalet, SPAIN,* [3]*Hospital Bellvitge ICS, L'hospitalet, SPAIN,* [4]*Hospital Bellvitge, L'hospitalet - Barcelona, SPAIN.*

TEPS-18
A cost effectiveness comparison using two different pharmaceuticals as oral contrast media for PET/CT scans
C. Hansen;
Rigshospitalet, København, DENMARK.

1509

Tuesday, October 18, 2022, 15:00 - 16:30

Hall 111

e-Poster Presentation Session 11 - Dosimetry Committee: Dosimetry – Novel Tracers and Computer-Based Modelling

EPS-202
Safety, biodistribution and internal radiation dosimetry of the cell death tracer [Tc99m]-Duramycin in healthy volunteers

T. Cappenberg[1], *S. De Schepper*[1], *F. Elvas*[2], *C. Vangestel*[3], *S. De Lombaerde*[4], *L. Wyffels*[2], *T. Van den Wyngaert*[3], *J. Mattis*[5], *B. Gray*[5], *K. Pak*[5], *S. Stroobants*[6];
[1]*Nuclear Medicine, university hospital Antwerp, Antwerp, BELGIUM,* [2]*Molecular imaging and radiology, Antwerp university, Antwerp, BELGIUM,* [3]*Molecular imaging and radiology, Antwerp university and Nuclear medicine, university hospital Antwerp, Antwerp, BELGIUM,* [4]*Nuclear medicine, university hospital Antwerp, Antwerp, BELGIUM,* [5]*Molecular Targeting Technologies, Inc, West Chester, PA, UNITED STATES OF AMERICA,* [6]*Molecular imaging and radiology, Antwerp university and nuclear Medicine, university hospital Antwerp, Antwerp, BELGIUM.*

EPS-203
Biodistribution and normal tissue dosimetry of radium-224 labelled calcium carbonate microparticles administered intraperitoneally in a phase 1 clinical trial involving patients with peritoneal carcinomatosis from colorectal cancer

S. Grønningsæter[1], *J. Blakkisrud*[1], *M. E. Revheim*[1,2], *L. T. Mikalsen*[1,3], *S. Selboe*[1], *Ø. S. Bruland*[4,5], *T. B. Bønsdorff*[6], *S. G. Larsen*[7], *C. Stokke*[1,8];
[1]*Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,* [2]*Faculty of Medicine, University of Oslo, Oslo, NORWAY,* [3]*Department of Life Science and Health, Oslo Metropolitan University, Oslo, NORWAY,* [4]*Department of Oncology, Oslo University Hospital, Oslo, NORWAY,* [5]*Institute of Clinical Medicine, University of Oslo, Oslo, NORWAY,* [6]*Oncoinvent AS, Oslo, NORWAY,* [7]*Department of Gastrointestinal and Pediatric Surgery, Oslo University Hospital, Oslo, NORWAY,* [8]*Department of Physics, University of Oslo, Oslo, NORWAY.*

EPS-204
First-in-man ^{90}Y-FAPI-46 PET/CT Based Tumour Dosimetry in Radioligand Therapy of Advanced Stage Solid Tumours

P. Fragoso Costa[1,2], *W. Jentzen*[1,2], *K. M. Pabst*[1,2], *L. Kessler*[1,2], *J. Ferdinandus*[1,2], *M. Weber*[1,2], *I. A. Mavroeidi*[3,2], *R. Hamacher*[3,2], *S. Bauer*[3,2], *K. Herrmann*[1,2], *W. P. Fendler*[1,2], *D. Kersting*[1,2];
[1]*Clinic for Nuclear Medicine, Essen, GERMANY,* [2]*German Cancer Consortium (DKTK), Partner Site University Hospital Essen, and German Cancer Research Center (DKFZ), Essen, GERMANY,* [3]*Department of Medical Oncology, Essen, GERMANY.*

EPS-205
Patient-Specific Biodistribution and Tumor Dosimetry of [^{131}I]IMAZA in Patients with Adrenal Tumors

S. Beykan[1], *H. Hänscheid*[1], *S. Hahner*[2], *A. K. Buck*[1], *M. Lassmann*[1], *A. Schirbel*[1];
[1]*Department of Nuclear Medicine, University of Würzburg, Würzburg, GERMANY,* [2]*Division of Endocrinology and Diabetes, Department of Medicine I, University Hospital of Würzburg, University of Würzburg, Würzburg, GERMANY.*

EPS-206
Comparison of two new bone marrow dosimetry techniques for Y-90 anti-CD66 radioimmunotherapy

N. Sizer[1], *F. Wickham*[1], *R. Chiesa*[2], *R. Hough*[3], *H. McMeekin*[1,4], *K. Orchard*[5], *E. Trahair*[1], *M. Burniston*[1];
[1]*Barts Health NHS Trust, London, UNITED KINGDOM,* [2]*Great Ormond Street Hospital for Children NHS Foundation Trust, London, UNITED KINGDOM,* [3]*University College London Hospitals NHS Foundation Trust, London, UNITED KINGDOM,* [4]*Hermes Medical Solutions, London, UNITED KINGDOM,* [5]*University Hospital Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM.*

EPS-207
Investigation of influencing factors on the yield of double-strand-breaks and the relative biological effectiveness of Ac-225-PSMA and Lu-177-PSMA therapy using TOPAS-nBio particle track structure simulations

M. Rumiantcev[1], *W. B. Li*[2], *S. Lindner*[1], *G. Liubchenko*[1], *S. Resch*[1], *P. Bartenstein*[1], *L. Beyer*[1], *S. Ziegler*[1], *G. Böning*[1], *A. Delker*[1];
[1]*Department of Nuclear Medicine, LMU Hospital, München, GERMANY,* [2]*Helmholtz Zentrum München Institut für Strahlenmedizin (IRM), Neuherberg, GERMANY.*

EPS-208
Impact of Metronomic Radiopharmaceutical Therapy on Tumor and Organ-at-risk Absorbed Doses: A PBPK Modeling Approach

A. Golzaryan[1], *M. Soltani*[1,2,3], *F. Moradi Kashkooli*[1], *B. Saboury*[4,5], *A. Rahmim*[4,6];
[1]*Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, CANADA,* [3]*Centre for Biotechnology and Bioengineering (CBB), University of Waterloo, Waterloo, ON, CANADA,* [4]*Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA,* [5]*National Institutes of Health (NIH), Clinical Center (CC) Bethesda, Bethesda, MD, UNITED STATES OF AMERICA,* [6]*Departments of Radiology and Physics, University of British Columbia, Vancouver, BC, CANADA.*

EPS-209
Regression models for single time point dosimetry optimized across range of timepoints with application in 177 Lu-DOTATATE therapy

C. Wang[1], *A. B. Peterson*[2], *K. Wong*[1], *M. J. Schipper*[1], *Y. K. Dewaraja*[1];
[1]*University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,* [2]*Wayne State University, Detroit, MI, UNITED STATES OF AMERICA.*

EPS-211
Impact of Dosimetry Method on Healthy Organ and Tumor Absorbed Dose Estimates for Lutetium-177-DOTATATE Therapy of Neuroendocrine Tumors

J. Brosch-Lenz[1], *A. Rahmim*[1], *J. Sunderland*[2], *E. Frey*[3], *Y. K. Dewaraja*[4], *C. Uribe*[5];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA,* [3]*Rapid, LLC, Baltimore, MD, UNITED STATES OF AMERICA,* [4]*University of Michigan, Michigan, MI, UNITED STATES OF AMERICA,* [5]*BC Cancer, Vancouver, BC, CANADA.*

EPS-212
Accuracy assessment of absorbed dose rate calculation: evaluation of two treatment planning systems for molecular radiotherapy

J. Fragoso Negrin[1,2,3], *A. Vergara Gil*[4], *L. Santoro*[2,3], *S. Vauclin*[1], *J. Pouget*[2,3], *P. Kotzki*[2,3], *E. Deshayes*[2,3], *M. Bardiès*[2,3];
[1]*DOSIsoft SA, Cachan, FRANCE,* [2]*IRCM, UMR 1194 INSERM, Université de Montpellier and Institut Régional du Cancer de Montpellier (ICM), Montpellier, FRANCE,* [3]*Département de Médecine Nucléaire, Institut Régional du Cancer de Montpellier (ICM), Montpellier, FRANCE,* [4]*CRCT, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, FRANCE.*

EPS-213
Assessing the Impact of Dosimetry Method on Healthy organ and Lesion Absorbed Dose Estimates for 177Lu-PSMA-617 Therapy of Prostate Cancer: Early Experience from the Canadian Cancer Trials Group PR21 trial (NCT 04663997)

J. Brosch-Lenz[1], *X. Hou*[1], *I. Bloise*[1], *N. Colpo*[2], *W. R. Parulekar*[3], *C. Dellar*[3], *F. Saad*[4], *K. Chi*[2], *D. Wilson*[2], *F. Bénard*[2], *A. Rahmim*[1], *C. Uribe*[2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*BC Cancer, Vancouver, BC, CANADA,* [3]*Canadian Cancer Trials Group, Queen's University Kingston, Kingston, ON, CANADA,* [4]*Prostate cancer research, Montreal Cancer Institute / CRCHUM, Montréal, QC, CANADA.*

EPS-215
Revision of the reference biokinetic models for dosimetry in diagnostic nuclear medicine

A. Kamp[1], *M. Andersson*[2], *A. Giussani*[1], *M. Hosono*[3], *K. W. Kang*[4], *S. Leide-Svegborn*[5,6], *S. Mattsson*[5,6], *D. Nosske*[7], *J. C. Ocampo Ramos*[8], *N. Petoussi-Henss*[9], *L. Söderberg*[5,6];
[1]*Federal Office for Radiation Protection, Oberschleissheim, GERMANY,* [2]*Gothenburg University, Gothenburg, SWEDEN,* [3]*Kindai University, Osaka-Sayama, JAPAN,* [4]*Seoul National University, Seoul, KOREA, REPUBLIC OF,* [5]*Skane University Hospital, Malmö, SWEDEN,* [6]*Lund University, Lund, SWEDEN,* [7]*Federal Office for Radiation Protection (retired), Oberschleissheim, GERMANY,* [8]*Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA,* [9]*Helmholtz Zentrum München, Oberschleissheim, GERMANY.*

EPS-216
A new option for fast and accurate voxel-level dosimetry in radiopharmaceutical therapy with a grid-based linear Boltzmann dose transport solver

B. Van[1], *J. K. Mikell*[1], *G. Andl*[2], *Y. K. Dewaraja*[1];
[1]*University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA,* [2]*Varian Medical Systems, Atlanta, GA, UNITED STATES OF AMERICA.*

EPS-217
The Use of Machine Learning to Choose the Best Fit Model and Evaluate Biokinetic Parameters in Molecular Radiotherapy

D. Ciucci[1], *B. Cassano*[2], *C. Polito*[1], *A. Napolitano*[1], *S. Donatiello*[1], *E. Solfaroli Camillocci*[1], *M. Pizzoferro*[1], *M. F. Villani*[1], *C. Altini*[1], *M. C. Garganese*[1], *V. Cannatà*[1];
[1]*IRCCS Bambino Gesù Children's Hospital, Rome, ITALY,* [2]*IRCCS Regina Elena National Cancer Institute, Rome, ITALY.*

EPS-218
Deep learning vs. deformable registration for image segmentation: which is better for dosimetry after multiple cycles of molecular radiotherapy?

N. Cole, *D. M. Mirando, R. D. Deshpande, A. S. Nelson;
MIM Software, Cleveland, OH, UNITED STATES OF AMERICA.*

EPS-219
Improvement of ^{177}Lu SPECT Images Reconstructed with Deep Learning Generated Synthetic Projections from Sparsely Acquired Projections

E. Wikberg[1], *M. van Essen*[2], *T. Rydén*[1], *J. Svensson*[1], *P. Gjertsson*[2], *P. Bernhardt*[1];
[1]*Institute of Clinical Sciences, Gothenburg, SWEDEN,* [2]*Institute of Medicine, Gothenburg, SWEDEN.*

EPS-220
Voxel-based Internal Dosimetry Using Deep Residual Learning

K. Kim[1,2,3], *M. Lee*[4], *M. Suh*[5,6], *G. Cheon*[5,6], *J. Lee*[1,2,3];
[1]*Interdisciplinary Program in Bioengineering, Seoul National University Graduate School, Seoul, KOREA, REPUBLIC OF,* [2]*Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, KOREA, REPUBLIC OF,* [3]*Artificial Intelligence Institute, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [4]*Korea Atomic Energy Research Institute, Daejeon, KOREA, REPUBLIC OF,* [5]*Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [6]*Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, KOREA, REPUBLIC OF.*

EPS-221
Open-Source, Modular, High-Computational-Throughput Physiologically Based Pharmacokinetics (PBPK) Modeling Fine-Tuned for Optimization of Radiopharmaceutical Therapy

A. Fele Paranj[1], *C. Uribe*[1], *B. Saboury*[2], *A. Rahmim*[1];
[1]*University of British Columbia, Vancouver, BC, CANADA,* [2]*National Institutes of Health, Bethesda, MD, UNITED STATES OF AMERICA.*

1609

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 111

e-Poster Presentation Session 12 - Oncology & Theranostics Committee: Prostate

EPS-222
Tracer kinetics in the dual time-point ^{177}Lu-PSMA post-therapy SPECT/CT scan predicts outcome in metastatic castration-resistant prostate cancer patients

F. Fiz[1], *M. Straub*[2], *J. Küpferschläger*[2], *L. Serna Higuita*[2], *C. la Fougère*[2];
[1]*E.O. Ospedali Galliera, Genoa, ITALY,* [2]*University of Tübingen, Tübingen, GERMANY.*

EPS-223
The Therapeutic Efficacy and Safety of ^{177}Lu-Prostate-Specific Membrane Antigen Radionuclide Therapy for Elderly Patients with Metastatic Castration Resistant Prostate Cancer

E. Sahin, *U. Elboga, Y. B. Çayırlı, U. Çimen, V. Mumcu, M. Okuyan, E. Ekinci, Y. Z. Çelen;
Gaziantep University Faculty of Medicine, Gaziantep, TÜRKIYE.*

EPS-225
Seven Years of Clinical Experience Outcome Review on Radium223 Therapy In Bone Metastatic Castrate-resistant Prostate Cancer (mCRPC)

M. Cantinho-Lopes[1], *H. Pena*[1], *P. Filipe*[2], *A. Mansinho*[2], *I. Fernandes*[2], *L. Costa*[2];
[1]*Instituto de Medicina Nuclear. Faculdade de Medicina de Lisboa, Lisbon, PORTUGAL,* [2]*S. Oncologia CHULN, Lisbon, PORTUGAL.*

EPS-226
Outcome and prognostic predictors of Lu177-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (Asian population study)
*W. Chua[1], W. Lam[1,2], A. Tong[1,2], R. Sultana[3], S. Kua[1], R. Kanesvaran[4,3], A. Wong[5], K. Tay[6,3], **T. Cheng**[7], D. Ng[1,2], S. Thang[1,2];*
[1]Division of Radiological Sciences, Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, SINGAPORE, [2]Radiological Sciences Academic Clinical Program, SingHealth Duke-NUS Academic Medical Centre, Singapore, SINGAPORE, [3]Duke-NUS Graduate Medical School, Singapore, SINGAPORE, [4]Department of Medical Oncology, National Cancer Centre, Singapore, SINGAPORE, [5]Department of Hematology-Oncology, National University Cancer Institute, Singapore, SINGAPORE, [6]Department of Urology, Singapore General Hospital, Singapore, SINGAPORE, [7]Department of Diagnostic Imaging, National University Hospital, Singapore, SINGAPORE.

EPS-227
Response assessment using volumetric parameters in mCRPC patients treated with 177 Lu PSMA therapy: A Prognostic yardstick
***P. Singh**, A. H. Nazar, M. Ora, A. Mishra, Y. Khandelwal, B. Jain, V. Mishra, P. K. Pradhan, S. Gambhir;*
S.G.P.G.I., Lucknow, INDIA.

EPS-228
A prospective trial of ^{177}Lu-EB-PSMA-617 Radioligand Therapy in patients with metastatic castration-resistantprostatecancer
***G. Wang**[1], J. Zang[2], X. Fan[1], X. Chen[3], Z. Zhu[1];*
[1]Peking Union Medical College Hospital, Beijing, CHINA, [2]The First Affiliated Hospital of Fujian Medical University, Fuzhou, CHINA, [3]National University of Singapore, Singapore, SINGAPORE.

EPS-229
PSMA-targeted prostate biopsy: a single-center retrospective analysis
***A. Farolfi**[1], L. Djaileb[1], M. Hotta[1], A. Gafita[1], M. Benz[1], J. Czernin[1], D. Kuppermann[2], L. S. Marks[2], J. Calais[1];*
[1]Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA, [2]Department of Urology, David Geffen School of Medicine, UCLA, Los Angeles, CA, UNITED STATES OF AMERICA.

EPS-230
Detection of oligometastatic disease by ^{68}Ga-PSMA PET/CT in intermediate to high-risk Prostate Cancer: preliminary data from a multi-centric, retrospective study
***F. Mattana**[1], L. Grappeja[1], G. Zuccotti[1], A. Barone[1], P. Artioli[1], L. Muraglia[1], R. Mei[2], A. Farolfi[2], P. Rajwa[3], M. Miszczyk[4], V. Kasivisvanathan[5], F. Zattoni[6], G. Gandaglia[7], A. Briganti[8], S. Shariat[3], D. Robesti[7], A. D'Amico[4], A. Sartorello[9], P. Castellucci[2], S. Fanti[2], F. Ceci[1];*
[1]Department of Nuclear Medicine, European Institute of Oncology, Milan, ITALY, [2]Department of Nuclear Medicine, Sant'Orsola Hospital, Bologna, ITALY, [3]Department of Urology, University of Vienna, Vienna, AUSTRIA, [4]Department of Nuclear Medicine, Narodowy Instytute Onkologii, Gliwice, POLAND, [5]Department of Urology, Imperial College of London, London, UNITED KINGDOM, [6]Department of Urology, University of Padova, Padua, ITALY, [7]Department of Urology, San Raffaele Hospital, Milan, ITALY, [8]Department of Urology, San Raffaele Hospitl, Milan, ITALY, [9]Nuclear Medicine Department, Istituto oncologico Veneto, Padova, ITALY.

EPS-231
Use of ^{18}F-NaF-PET in the Staging of Skeletal Metastases of Newly Diagnosed, High-Risk Prostate Cancer Patients - a Nationwide Cohort Study
*A. Mogensen[1], L. J. Petersen[1], C. Torp-Pedersen[2], M. Nørgaard[3], M. T. Pank[4], **H. D. Zacho**[1];*
[1]Department of Nuclear Medicine, Aalborg, DENMARK, [2]Department of Clinical Investigations and Department of Cardiology, Hillerød, DENMARK, [3]Department of Clinical Epidemiology, Aarhus, DENMARK, [4]Department of Urology, Aalborg, DENMARK.

EPS-233
Immunohistochemical PSMA Expression and Histology Predictors in Primary Staging High-risk Prostate Cancer Patients Studied with PSMA PET/CT: a PSMA Expression Investigation
***L. Vetrone**[1], R. Mei[1], A. Farolfi[2], L. Bianchi[3], F. Giunchi[4], A. De Giovanni[4], L. Calderoni[1], F. Serani[1], F. Costa[3], A. Pissavini[3], R. Schiavina[3], E. Brunocilla[3], P. Castellucci[2], S. Fanti[1,2];*
[1]Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Nuclear Medicine, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, ITALY, [3]Division of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, ITALY, [4]Pathology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, ITALY.

EPS-235
Predictors of bone metastases at ^{68}Ga-PSMA-11 PET/CT in early-recurrent hormone-sensitive prostate cancer (HSPC) patients
***G. Rovera**[1], S. Grimaldi[1], S. Dall'Armellina[1], R. Passera[1], M. Oderda[2], G. C. Iorio[3], A. Guarneri[3], P. Gontero[2], U. Ricardi[3], D. Deandreis[1];*
[1]Nuclear Medicine, Department of Medical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, ITALY, [2]Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, University of Turin, Turin, ITALY, [3]Department of Oncology, University of Torino, Turin, ITALY.

EPS-236
Delaying diuretics injection and adding a late acquisition improves diagnostic accuracy and reader's confidence of [^{68}Ga]Ga-PSMA-11PET/CT in biochemically recurrent prostate cancer
***A. Miceli**[1,2], A. Signori[1], D. Albano[3], S. Capitanio[4], R. Piva[5], R. Laudicella[6,7,8], A. Franchini[4], F. D'Amico[1,2], M. Riondato[2], C. Marini[2,9], G. Fornarini[10], A. Scarale[4], A. Muni[5], F. Bertagna[3], I. A. Burger[6,7], S. Morbelli[1,2], G. Sambuceti[1,2], M. Bauckneht[1,2];*
[1]DISSAL, Genoa, ITALY, [2]Nuclear Medicine, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY, [3]Nuclear Medicine, University of Brescia and ASST Spedali Civili, Brescia, ITALY, [4]Nuclear Medicine ASST, Grande Ospedale Metropolitano Niguarda, Milan, ITALY, [5]Nuclear Medicine Unit, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, ITALY, [6]Nuclear Medicine, Cantonal Hospital Baden, Baden, SWITZERLAND, [7]Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND, [8]Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY, [9]CNR Institute of Molecular Bioimaging and Physiology, Milan, ITALY, [10]Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY.

EPS-237
Recurrence Rate after Radical Prostatectomy of Patients Primary Staged with ^{68}Ga-PSMA PET/CT
***S. Klingenberg**, J. Fredsøe, K. D. Sørensen, B. P. Ulhøi, M. Borre, M. R. Jochumsen, K. Bouchelouche;*
Aarhus University Hospital, Aarhus N, DENMARK.

EPS-238
Value of PET/CT with ^{68}Ga-PSMA in the first biochemical recurrence of prostate cancer after local treatment with curative intent
***M. Cruz**[1], J. Rosales[2], J. Bastidas[2], Á. Bronte[2], V. Betech-Antar[2], F. Mínguez[2], L. Sancho[2], F. Pareja[2], J. Arbizu[2], M. Rodríguez-Fraile[2];*
[1]Hospital Puerta del Mar, Cádiz, SPAIN, [2]Clínica Universitaria de Navarra, Pamplona, SPAIN.

EPS-239
Initial Experience With The ^{18}F-JK-PSMA-07 PET/CT Scan In Biochemical Recurrence Of Prostate Adenocarcinoma
***D. Nádasdy-Horváth**[1], S. Czibor[1,2], C. B. Jánosa[1], E. Kiss[1], O. Albert[1], M. Barra[1], Z. Varga[1], G. Tóth[2], S. Szakáll[2], J. Szalontai[3], M. Szűcs[3], P. Nyirády[3], T. Györke[1];*
[1]Department of Nuclear Medicine, Medical Imaging Centre,Semmelweis Univerisity, Budapest, HUNGARY, [2]Pozitron-Diagnostics Health Centre, Budapest, HUNGARY, [3]Department of Urology, Semmelweis Univerisity, Budapest, HUNGARY.

EPS-240
Biochemical recurrence of prostate cancer on F18-PSMA-1007 PET CT in a Sub-Saharan population: Detection rate, patterns and therapeutic implications
***S. Gitau**, K. Makhdomi, M. Mwania;*
Aga Khan University Hospital, Naitobi, KENYA.

EPS-241
PSMA PET in patients with biochemical / clinical suspicion of clinically-significant prostate cancer. Features associated with a positive outcome
***M. Celli**[1], R. Gunelli[2], F. Ferroni[3], M. Pulvirenti[2], P. Caroli[1], O. Saleh[2], L. Fantini[1], V. Rossetti[1], E. Fragalà[2], U. De Giorgi[4], D. Barone[3], V. Di Iorio[5], G. Paganelli[1], F. Matteucci[1];*
[1]Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY, [2]Urology Unit, Ospedale "G.B.Morgagni - L.Pierantoni", Azienda USL della Romagna, Forlì, ITALY, [3]Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY, [4]Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY, [5]Unit of Oncological Pharmacy, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.

EPS-242
Prostate-specific membrane antigen expression on positron emission tomography/computed tomography in patients with metastatic castration-resistant prostate cancer
***L. Calderoni**[1], E. Maietti[2], A. Farolfi[1], R. Mei[1], K. Louie[3], M. Groaning[4], S. Fanti[1];*
[1]Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, [2]Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, ITALY, [3]Amgen Ltd., Uxbridge, UNITED KINGDOM, [4]Amgen Inc., Thousand Oaks, CA, UNITED STATES OF AMERICA.

1709

Wednesday, October 19, 2022, 08:00 - 09:30

Hall 111

e-Poster Presentation Session 13 - Oncology & Theranostics Committee: Haematology

EPS-243
Prognostic value of interim PET response in first-line immunochemotherapy for Follicular lymphoma: a subset analysis of a randomised, phase 3 trial (FOLL12)
***R. Durmo**[1,2], A. Versari[1], S. Chauvie[3], F. Bergesio[3], S. Peano[4], A. Franceschetto[5], F. Fallanca[6], V. Tarantino[2], A. Pinto[7], C. Ghiggi[8], M. Merli[9], L. Farina[9], M. Tani[10], C. Boccomini[11], G. Musuraca[12], P. M. Stefani[13], B. Falini[14], G. Pietrantuono[7], S. A. M. Bolis[15], F. Ballerini[16], L. Marcheselli[17], M. Federico[18], S. Luminari[18], L. Guerra[19];*
[1]AUSL-IRCCS of Reggio Emilia, Reggio Emilia, ITALY, [2]PhD program in Clinical and Experimental Medicine (CEM), University of Modena and Reggio Emilia, Modena, ITALY, [3]Department of Medical Physisc, Santa Croce e Carle Hospital, Cuneo, ITALY, [4]Deaprtment of Nuclear Medicine, Santa Croce e Carle Hospital, Cuneo, ITALY, [5]Department of Oncology and Hematology, Modena Cancer Center, Unit of Nuclear Medicine, University of Modena and Reggio Emilia, Modena, ITALY, [6]Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Milan, ITALY, [7]Hematology and Stem Cell Transplantation Unit, IRCCS Centro di Riferimento Oncologico della Basilicata, Rionero in Vulture, ITALY, [8]Hematology and Transplant Center Division, IRCCS San Martino Hospital, Genoa, ITALY, [9]University Hospital Ospedale di Circolo e Fondazione Macchi, ASST Settelaghi, Varese, ITALY, [10]Ospedale Civile S Maria delle Croci, Azienda Unità Sanitaria Locale Ravenna, Ravenna, ITALY, [11]A.O.U. Città della Salute e della Scienza di Torino - SC Ematologia, Turin, ITALY, [12]Department of Hematology, IRCCS -Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, ITALY, [13]Hematology, General Hospital Ca' Foncello, Treviso, ITALY, [14]Institute of Hematology and CREO (Center for Hemato-Oncological Research), Ospedale S. Maria della Misericordia, Perugia, ITALY, [15]SC di Ematologia - ASST Monza, Monza, ITALY, [16]University of Genoa, Ospedale Policlinico San Martino, IRCCS per l'Oncologia, Genoa, ITALY, [17]Fondazione Italiana Linfomi Onlus, Modena, ITALY, [18]CHIMOMO Department, University of Modena and Reggio Emilia, Modena, ITALY, [19]ASST Monza Ospedale S. Gerardo, Monza, ITALY.

EPS-244
Prognostic role of end-of-therapy PET in FOLL12 Trial for Follicular Lymphoma
***F. Bergesio**[1], L. Guerra[2], A. Versari[3], R. Durmo[3], L. Marcheselli[4], S. Luminari[5], S. Chauvie[1];*
[1]Medical Physics Division, AO. S.Croce e Carle, Cuneo, ITALY, [2]Nuclear Medicine Division, San Gerardo Hospital - University of Milan Bicocca, Monza, ITALY, [3]Nuclear Medicine Division, S. Maria Nuova Hospital, Reggio Emilia, ITALY, [4]Fondazione Italiana Linfomi Onlus, Modena, ITALY, [5]Hematology Unit, Azienda Unità Sanitaria Locale-IRCCS,Department CHIMOMO, University of Modena and Reggio Emilia, Reggio Emilia, ITALY.

EPS-245
The utility of F-18 FDG PET-derived metabolic metrics to predict lymphoma treatment outcome among adults with and without HIV infection
***H. Ndlovu**[1], I. O. Lawal[1], P. Gbenga[2], K. G. M. Mokoala[1], N. P. Mokgoro[1], L. C. Maserumule[1], K. N. Hlongwa[1], J. D. Reed[1], A. Ismaila[1], M. M. Sathekge[1];*
[1]Department of Nuclear Medicine ,University of Pretoria, Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA, [2]Saxon Court Lincolnshire Partnership NHS foundation trust (LPFT), Lincoln., Lincolnshire, UNITED KINGDOM.

EPS-246
^{18}F-FDG PET/CT at baseline in DLBCL patients enrolled in the GAINED protocol: A machine learning study to assess the usefulness of combining clinical, conventional and radiomics features to predict the 2-years PFS and survival
T. Carlier[1], *G. Frécon*[2], *D. Mateus*[3], *M. Rizkallah*[3], *F. Kraeber-Bodéré*[1], *S. Kanoun*[4], *P. Blanc-Durand*[5], *E. Itti*[5], *S. Le Gouill*[6], *R. Casasnovas*[7], *C. Bodet-Milin*[1], *C. Bailly*[1];
[1]*University Hospital of Nantes, Nantes, FRANCE,* [2]*INSERM, Nantes, FRANCE,* [3]*LS2N - Team SIMS, Nantes, FRANCE,* [4]*IUCT Oncopole, Toulouse, FRANCE,* [5]*University Hospital Henri Mondor, Créteil, FRANCE,* [6]*Insitut Curie, Paris, FRANCE,* [7]*University Hospital of Dijon, Dijon, FRANCE.*

EPS-247
The FORPAN Study: A future international, prospective, multicenter Phase III Study to evaluate the diagnostic performance and safety of a new PET Tracer [^{68}Ga]Ga-PentixaFor for detection and localization of chemokine receptor 4 (CXCR4) positive tumors and their metastases in a PAN Cancer approach
A. Zehnder[1], *S. Pickel*[1], *H. Bouterfa*[1], *N. Berroterán-Infante*[1], *J. Castillo*[1], *H. Reis*[1], *J. Kaufmann*[1], *A. Janz*[1], *A. Buck*[2];
[1]*PentixaPharm GmbH, Wuerzburg, GERMANY,* [2]*University Hospital Wuerzburg, Wuerzburg, GERMANY.*

EPS-248
^{18}F-FDG uptake in the bone marrow following ^{177}Lu-lilotomab satetraxetan treatment in patients with indolent Non-Hodgkin lymphoma
E. Husby[1], *J. Blakkisrud*[1], *A. Muftuler Løndalen*[1,2], *C. Stokke*[1,2];
[1]*Oslo University Hospital, Oslo, NORWAY,*
[2]*University of Oslo, Oslo, NORWAY.*

EPS-249
Quantification of patient's tumor burden for the differentiation of lymphomas with [^{18}F]FDG PET images
C. S. Constantino[1], *S. Leocádio*[2], *F. P. M. Oliveira*[1], *M. Silva*[1], *C. Oliveira*[1], *J. C. Castanheira*[1], *Â. Silva*[1], *S. Vaz*[1], *R. Teixeira*[1], *M. Neves*[2], *P. Lúcio*[2], *C. João*[2], *D. C. Costa*[1];
[1]*Nuclear Medicine – Radiopharmacology Department, Champalimaud Foundation, Lisbon, PORTUGAL,* [2]*Hematology Department, Champalimaud Foundation, Lisbon, PORTUGAL.*

EPS-250
FDG PET/MR for therapy response evaluation of CAR T-cell therapy in large B-cell lymphoma
T. Sjöholm[1], *A. Korenyushkin*[2], *J. Kullberg*[1,2], *G. Enblad*[3], *H. Ahlström*[1,2];
[1]*Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN,* [2]*Antaros Medical AB, Mölndal, SWEDEN,* [3]*Department of Immunology, Pathology and Genetics, Uppsala University, Uppsala, SWEDEN.*

EPS-251
IMPeTUs Parameters for Staging PET/CT in Multiple Myeloma; and the Importance of the First Follow-up PET/CT Scan in Prediction of Disease Course
S. Demirtas Senlik[1], *S. Gulbahar Ates*[1], *H. Efeturk*[2], *B. Demirel*[1], *G. Ucmak*[1];
[1]*Ankara Oncology Training and Research Hospital, Ankara, TÜRKIYE,* [2]*Near East University Hospital, Nicosia, CYPRUS.*

EPS-252
Assessing somatostatin receptor expression in multiple myeloma by ^{68}Ga-DOTATATE PET/CT - preliminary results of the SCARLET trial
W. Delbart[1], *M. Vercruyssen*[2], *I. Karfis*[1], *G. Critchi*[1], *Z. Wimana*[1], *N. Meuleman*[2], *P. Flamen*[1], ***E. Woff***[1];
[1]*Institut Jules Bordet, Nuclear medicine department, Brussels, BELGIUM,* [2]*Institut Jules Bordet, Hematology department, Brussels, BELGIUM.*

EPS-253
The value of ^{18}F-FDG PET/CT in systemic evaluation of patients with Rosai-Dorfman disease: a retrospective study
X. Lu[1,2], *R. Wang*[1,2], *Z. Zhu*[1,2];
[1]*Department of Nuclear Medicine, Peking Union Medical College Hospital, Bejing, CHINA,* [2]*Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Bejing, CHINA.*

EPS-254
Prognostic impact of 18F-FDG PET-CT before CAR-T cell therapy in patients with Multiple Myeloma
V. Betech Antar[1], *M. Cruz Montijano*[2], *A. Bronte Viedma*[1], *J. Bastidas*[1], *P. Rodriguez Otero*[1], *F. Minguez*[1], *T. Cuenca*[1], *A. Alfonso*[1], *M. Panizo*[1], *M. García-Velloso*[1];
[1]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Hospital puerta del Mar, Cadiz, SPAIN.*

EPS-255
FDG-PET/CT versus genomic analysis in symptomatic Multiple Myeloma: is there a correlation?
D. Bezzi[1], *M. Martello*[2], *C. Terragna*[2], *E. Zamagni*[2], *C. Malizia*[3], *S. Fanti*[3], *C. Nanni*[3];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Seràgnoli Institute of Hematology, Bologna University, Bologna, ITALY,* [3]*Nuclear Medicine,IRCCS, AOU di Bologna, Bologna, ITALY.*

EPS-256
Testicular metabolism assessed by 18F-FDG uptake is conversely correlated with testosterone levels in men diagnosed with Erdheim Chester Disease, who present hypogonadism

EPS-257
[^{18}F]FDGPET/CT Parameters to Correlate with 5-Points Deauville Scoring in Multiple Myeloma Patients
N. C. M. Gülaldi, *M. O. Kartal, A. S. Erdoğan;*
Turkish Ministry of Health, Ankara City Hospital, Department of Nuclear Medicine, Ankara, TÜRKIYE.

EPS-258
Assessment of volumetric parameters calculated with 2-[^{18}F]FDG PET/CT and its correlation with biochemical analysis in patients with diffuse large B-cell lymphoma, unspecified
S. Guzmán Ortiz[1], *J. Mucientes Rasilla*[2], *J. Vargas Núñez*[3], *A. Royuela*[4], *M. Matilla Nacarro*[5], *M. Mitjavila Casanovas*[2];
[1]*Nuclear Medicine, Puerta de Hierro University Hospital, Autónoma University of Madrid, Madrid, SPAIN,* [2]*Nuclear Medicine, Puerta de Hierro University Hospital, Madrid, SPAIN,* [3]*Medicine Department, Autónoma University of Madrid, Madrid, SPAIN,* [4]*Biostatistics Unit, Biomedical Research Institute, Puerta de Hierro-Segovia de Arana, CIBERESP, Madrid, SPAIN,* [5]*Hematology Service, Puerta de Hierro University Hospital, Madrid, SPAIN.*

EPS-259
A planned, prospective, international, multi-center, open-label, single-arm phase II study investigating the predictive value of [^{68}Ga]GaPentixaFor PET imaging in primary and isolated secondary CNS lymphoma patients
A. Zehnder[1], *J. Castillo*[1], *H. Bouterfa*[1], *H. Reis*[1], *J. Kaufmann*[1], *U. Keller*[2], *M. Gotthardt*[3], *W. Weber*[4], *A. Ferreri*[5], *F. Kraeber-Bodéré*[6], *J. Madsen*[7], *K. Herrmann*[8];
[1]*PentixaPharm GmbH, Wuerzburg, GERMANY,* [2]*Medical University Berlin, Charitè, Berlin, GERMANY,* [3]*Radboud University Medical Centre, Nijmegen, NETHERLANDS,* [4]*Technical University of Munich, Munich, GERMANY,* [5]*IRCCS San Raffaele Scientific Institute, Milan, ITALY,* [6]*University Hospital of Nantes (CHU), Nantes, FRANCE,* [7]*University Hospital Aalborg, Aalborg, DENMARK,* [8]*University Hospital Essen, Essen, GERMANY.*

EPS-261
Post solid organ and bone marrow transplantation - FDG PET/ CT as a problem solving tool
V. Gunasekaran, *V. S. Krishnaraju, R. Kumar, H. Singh, B. R. Mittal; PGIMER, Chandigarh, INDIA.*

EPS-262
Comparison of Whole Body FDG PET and DWI In The Detection of Diffuse Bone Marrow Involvement In Simultaneous PET/MRI
F. Beytur, *S. Asa, S. Sağer, K. Sönmezoğlu; Cerrahpasa Faculty of Medicine, Nuclear Medicine Department, Istanbul, TÜRKIYE.*

EPS-263
Feasibility of fully automated deep learning-based segmentation of lymphoma lesions in whole-body [^{18}F] FDG PET/CT images
A. Ribeiro[1], *P. Leite*[1], *C. S. Constantino*[2], *S. Leocádio*[2], *F. Oliveira*[2], *M. Silva*[2], *C. Oliveira*[2], *J. C. Castanheira*[2], *Â. Silva*[2], *S. Vaz*[2], *R. Teixeira*[2], *M. Neves*[2], *P. Lúcio*[2], *C. João*[2], *M. J. Ferreira*[1], *D. C. Costa*[2];
[1]*NEADVANCE - Machine Vision, S.A., Braga, PORTUGAL,* [2]*Champalimaud Foundation, Lisbon, PORTUGAL.*

1809

Wednesday, October 19, 2022, 09:45 - 11:15

Hall 111

e-Poster Presentation Session 14 - Thyroid Committee: A Spotlight on Thyroid and Parathyroid Imaging

EPS-264
Diagnostic Performance of ^{18}F-Choline PET/CT In Presurgical Localization Of Hyperfunctioning Parathyroid Glands In Primary Hyperparathyroidism
T. Plaza Aguado, *A. Orozco Rodríguez, A. Crespo-Jara, J. M. Clavel, J. Verdú;*
Hospital Universitari Sant Joan D'Alacant, Sant Joan D'Alacant, SPAIN.

EPS-265
PET/CT with 18F-Choline in the preoperative localization of hyperparathyroidism: correlation with intraoperative findings and other imaging techniques
J. Badell, *P. Garcia-Talavera San Miguel, A. C. Peñaherrera, S. Lopez Puche, E. Campaña Diaz, M. E. Martin, J. G. Villanueva Curto, J. C. Cañadas Salazar, P. Tamayo Alonso;*
Hospital Clinico Universitario de Salamanca, Salamanca, SPAIN.

EPS-266
[^{18}F]F-Fluorocholine PET/CT in localization of hyperfunctioning parathyroid tissue in primary hyperparathiroidism with negative conventional imaging: diagnostic value and correlation with biochemical parameters
D. Rivas-Navas, *E. Triviño-Ibáñez, J. Fernández-Fernández, T. Aroui-Luquin, M. Muros de Fuentes;*
Hospital Universitario Virgen de las Nieves, Granada, SPAIN.

EPS-267
The utility of 18F-Fluorocholine PET/CT in renal hyperparathyroidism
K. Shankar, *S. Kumar, V. Krishnaraju, R. Kumar, H. Singh, B. Mittal; Postgraduate Institute of Medical Education and Research, Chandigarh, INDIA.*

EPS-268
Preoperative ^{18}F-fluorocholine PET/CT allows for minimally invasive surgery for patients with primary hyperparathyroidism and negative first-lines exams
M. Masse[1], *N. Kooshki*[2], *D. Chardin*[1], *A. Bozec*[1], *N. Guevara*[3], *N. Sapin*[1], *J. Darcourt*[1], *D. Benisvy*[1];
[1]*Centre Antoine Lacassagne, Nice, FRANCE,* [2]*Hopital Cochin, Paris, FRANCE,* [3]*IUFC, Nice, FRANCE.*

EPS-269
F-18-fluorocholine PET/CT Imaging in Primary Hyperparathyroidism after Negative or Inconclusive Neck Ultrasound and MIBI Scintigraphy
E. Pasini Nemir, *S. Fares, A. T. Golubic, D. Huic;*
Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA.

EPS-270
Diagnostic performances of ^{18}F-Fluorocholine PET/CT as a first-line method for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism
E. Bouilloux[1], *N. Santucci*[2], *A. Bertaut*[3], *P. Goudet*[2], *A. Cochet*[1], *C. Drouet*[1];
[1]*Nuclear Medicine Department, Centre Georges François Leclerc, Dijon, FRANCE,* [2]*Endocrine Surgery Department, University Hospital François Mitterand, Dijon, FRANCE,* [3]*Biostatistics and Methodology Department, Centre Georges François Leclerc, Dijon, FRANCE.*

EPS-271
^{18}F-Fluorocholine PET/CT in persistent/recurrent primary hyperparathyroidism
M. Naik, *S. R. Khan, N. H. Patel, L. Perry, A. Alsafi, C. Harvey, L. Alves, F. Palazzo, T. D. Barwick;*
Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EPS-272
Impact of PET/CT-F18Choline on the diagnosis of primary hyperparathyroidism, when the scintigraphy with ^{99m}Tc-MIBI-SPECT/CT is negative or inconclusive
J. Montalvá Pastor, *J. Ardila Manjarrés, J. Atance García de la Santa, D. Zamudio Rodríguez, M. Baquero Oliveros, M. Casallas Cepeda, I. Gómez Fernández, L. Reguera Berenguer, J. Ardila Mantilla, J. Alonso Farto;*
Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EPS-273
Combined interpretation of ^{99m}TcO4 thyroid SPECT-CT and ^{99m}Tc-MIBI double phase parathyroid scintigraphy with early SPECT-CT in the presurgical localization of hyperparatiroidism in patients with associated nodular thyroid pathology
E. Campaña Diaz, *P. García-Talavera San Miguel, F. Gómez-Caminero López, E. Martín Gómez, J. Badell Martínez, A. Peñaherrera Cepeda, S. López Puche, C. Riola Parada, M. Tamayo Alonso;*
Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EPS-274
Are the false negative results in parathyroid scintigraphy explained by their histology?
B. Pereira, *P. Dias, P. Soeiro;*
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EPS-275
Parathyroid scintigraphy: Factors affecting scan results
R. T. Ferreira[1], *I. C. Ferreira*[1], *C. R. Santos*[1], *J. C. Ferro*[2], *A. F. Gomes*[1], *R. R. Marques*[1], *S. Carmona*[1], *I. Nascimento*[1], *P. P. Costa*[1], *A. I. Santos*[1];
[1]*Hospital Garcia de Orta, Almada, PORTUGAL,* [2]*Instituto Português de Oncologia do Porto Francisco Gentil, Porto, PORTUGAL.*

EPS-276
Parathyroid Scan: Forging the Link between BAT Activation and Certain Endocrine Pathologies Evolution
W. Jalloul[1], *I. Roata*[2], *R. Tibu*[2], *I. Grierosu*[1,2], *T. Ionescu*[1], *C. Stolniceanu*[1], *R. Iacob*[1], *M. Gutu*[1], *V. Ghizdovat*[1,2], *C. Archip*[2], *C. Uritu*[1], *M. Moscalu*[1], *V. Mocanu*[1], *C. Stefanescu*[1,2];
[1]*University of Medicine and Pharmacy U.M.F „Grigore T. Popa", Iasi, ROMANIA,* [2]*Nuclear Medicine Laboratory, County Emergency Hospital „Sf. Spiridon", Iasi, ROMANIA.*

EPS-277
Imaging of Brown Tumor in Hyperparathyroidism - How Much Can We Actually See on ^{99m}Tc-MIBI Parathyroid Scan
I. Wenzel-Duszynska, *A. Kołodziejczyk, P. Piwkowski, A. Macioszek, R. Muczyński, J. Żebrowski;*
Nuclear Medicine Department, 4th Military Clinical Hospital, Wroclaw, POLAND.

EPS-278
FDG uptake reflects immune-enriched subtype of thyroid cancer: Clinical implications of imaging-based molecular characterization
H. Suh, *H. Choi, S. Cho, J. Paeng, G. Cheon, Y. Park, K. Kang;*
Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.

EPS-279
Serum Thyroglobulin Doubling Time as a Predictor of 2-[^{18}F]FDG PET/CT Findings in Differentiated Thyroid Carcinoma
J. Rebelo, *B. Araújo, G. Costa, R. Silva;*
Centro Hospitalar Universitário de Coimbra, Coimbra, PORTUGAL.

EPS-280
Preclinical Evaluation of [^{64}Cu]NOTA-HFn as a PET Imaging Agent for Radioiodine Refractory Differentiated Thyroid Cancer
R. Zhou[1], *Y. Shen*[1], *H. Jin*[2], *Y. Wang*[1];
[1]*Department of Nuclear Medicine, Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, CHINA,* [2]*Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province, CHINA.*

e-Posters

EP-01

During Congress Opening Hours

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A11 In Vitro Studies

EP-001
Is it possible to replace the measurement of GFR with creatinine clearance based eGFR in children with posterior urethral valve?
L. Kalimuthu, *M. Ora, A. H. Nazar, S. Barai, A. Arya, P. K. Pradhan, S. Gambhir;*
Sanjay Gandhi Post Graduate Institute of Medical sciences, Lucknow, INDIA.

EP-002
Dosimetric uncertainties associated with dose-response relationship in pre-clinical molecular radionuclide therapy
A. Parach[1,2], *M. Bio Idrissou*[1,2], *J. Pouget*[1,2], *M. Bardiès*[1,2];
[1]*INSERM, Montpellier, FRANCE,* [2]*Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, FRANCE.*

EP-004
Ga-68-Labelling of Tetrahydroquinoline-Based Compound as PET Tracers for C-X-C Chemokine Receptor Type 4 Imaging
P. Suwattananuruk[1], *S. Yaset*[2], *C. Chotipanich*[2], *M. Kranz*[3], *P. Rojsitthisak*[1], *O. Vajragupta*[4];
[1]*Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, THAILAND,* [2]*National Cyclotronand PET Centre, Chulabhorn Hospital, Bangkok, THAILAND,* [3]*University Hospital of North Norway, Tromso, NORWAY,* [4]*Molecular Probes for Imaging Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, THAILAND.*

EP-005
Radiochemical and preliminary biological comparison of a 3p-C-NETA-PSMA and a DOTA-GA-PSMA derivative
E. Murce[1], *S. Ahenkorah*[2,3], *S. Beekman*[1], *L. van den Brink*[1], *S. Dalm*[1], *F. Cleeren*[2], *Y. Seimbille*[1,4];
[1]*Erasmus MC, Rotterdam, NETHERLANDS,* [2]*Katholieke Universiteit Leuven, Leuven, BELGIUM,* [3]*Belgium Nuclear Research Centre (SCK CEN), Mol, BELGIUM,* [4]*TRIUMF, Vancouver, BC, CANADA.*

EP-006
Investigation of in vitro models to unravel salivary gland toxicity mechanisms after [^{177}Lu]Lu-PSMA-617 therapy
N. Heynickx[1,2], *C. Segers*[3], *S. Baatout*[1,2], *K. Vermeulen*[3];
[1]*Radiobiology Unit; Interdisciplinary Biosciences; Institute for Environment, Health and Safety; Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM,* [2]*Department of Molecular Biotechnology; Ghent University, Ghent, BELGIUM,* [3]*NURA, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM.*

EP-007
Development of Reconstruction Algorithm for High Resolution microPET Scanner Using Siddon-based System Matrix
S. Hariri Tabrizi, *B. Teimourian, M. Farahani, M. Ay;*
Research Center for Molecular and Cellular Imaging, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-008
Synthesis and in vitro evaluation of ^{227}Th-bombesin complexes
K. Lunyova[1,2], *O. Klementyeva*[1], *A. Bruskin*[1], *A. Lunev*[1];
[1]*SRC – FMBC, Moscow, RUSSIAN FEDERATION,* [2]*Moscow SAVMB, Moscow, RUSSIAN FEDERATION.*

EP-02

During Congress Opening Hours

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A12 Preclinical Cardiology and Neurology

EP-009
Comparing Folate Receptor β Targeting Tracers in Experimental Myocarditis Model
E. Atencio Herre[1], *X. Li*[1,2,3], *H. Liljenbäck*[1,4], *P. Andriana*[1], *A. Jahandideh*[1], *I. Iqbal*[1], *P. Dillemuth*[1], *S. Kärnä*[1], *J. Virta*[1], *H. Mansour*[5], *N. A. Cleveland*[5], *P. S. Low*[5], *J. Knuuti*[1,3], *A. Saraste*[1,6,7], *A. Roivainen*[1,4,3];
[1]*Turku PET Centre, Turku, FINLAND,* [2]*University of Turku, Turku, FINLAND,* [3]*InFLAMES Research Flagship Center, University of Turku, Turku, FINLAND,* [4]*Turku Centre for Disease Modeling, University of Turku, Turku, FINLAND,* [5]*Purdue University, West Lafayette, IN, UNITED STATES OF AMERICA,* [6]*Turku PET Centre, Turku University Hospital, Turku, FINLAND,* [7]*Heart Centre, Turku University Hospital, Turku, FINLAND.*

EP-010
Quantitative determination of blood-brain barrier permeability assessed using [^{18}F]2-fluoro-2-deoxy-sorbitol as a feature of neuroinflammation in a mouse model of endotoxemia
S. Leterrier, *S. Goutal, W. Saba, G. Hugon, M. Goislard, S. Specklin, V. Lebon, A. Winkeler, N. Tournier;*
CEA,CNRS, Inserm, BioMaps, Université Paris-Saclay, Orsay, FRANCE.

EP-011
Cannabidiol Treament Prevents the Expression of Cocaine Sensitization in the Hippocampus: a Dinamyc [18F]FDG PET Preclinical Study
L. Spelta[1], *D. de Paula Faria*[1], *C. C. Real*[2], *C. A. Buchpiguel*[1], *T. Marcourakis*[1];
[1]*University of São Paulo, São Paulo, BRAZIL,* [2]*Aarhus University, Aarhus, DENMARK.*

EP-012
Alcohol and tobacco: PET imaging using 2-[18F] fluoro-A-85380 unveils change in nicotinic receptor availability induced by ethanol exposure during adolescence
W. Saba, *M. Goislard, L. Breuil, F. Caillé, N. Tournier;*
1Inserm U1281, CNRS, Université Paris Saclay, CEA-SHFJ, Orsay, FRANCE.

EP-013
Albumin based molecular imaging to evaluate the age-related deterioration of subarachnoid space macromolecule clearance via lymphatics
A. Sarker, *M. Suh, Y. Choi, J. Park, Y. Lee, D. Lee;*
Seoul National University, Seoul, KOREA, REPUBLIC OF.

EP-014
Longitudinal Assessment of Cerebral Oxygen Metabolism in a Rat Model of Neonatal Hypoxic-Ischemic Encephalopathy using PET with Spontaneous Inhalation of ^{15}O-Labeled Oxygen Gases
S. Shimochi[1,2,3], *J. Ihalainen*[1,4], *V. Parikka*[1,2], *E. Kokkomäki*[1], *S. Forsback*[1], *T. Tolvanen*[1,4], *E. Yatkin*[5], *T. J. Grönroos*[1,2], *H. Iida*[1,3];
[1]*Turku PET Centre, University of Turku, Turku, FINLAND,* [2]*Medicity Research Laboratory, University of Turku, Turku, FINLAND,* [3]*Nara Instutute of Science and Technology, Ikoma City, JAPAN,* [4]*Department of Medical Physics, Turku University Hospital, Turku, FINLAND,* [5]*Central Animal Laboratory, University of Turku, Turku, FINLAND.*

EP-015
Evaluation of pet imaging as a tool for detecting neonatal hypoxic-ischemic encephalopathy in a preclinical animal model
T. Grönroos[1,2], *E. Saha*[1,2], *T. Keller*[1], *O. Eskola*[1], *F. Lopez-Picon*[1,2], *J. Rajander*[3], *S. Forsback*[1], *O. Solin*[1], *V. Parikka*[1,2];
[1]*Turku PET Centre, University of Turku, Turku, FINLAND,* [2]*Medicity Research Laboratories, University of Turku, Turku, FINLAND,* [3]*Turku PET Centre, Åbo Akademi University, Turku, FINLAND.*

EP-016
A novel PET radiotracer for imaging reparative microglia
L. Vivash[1], *R. Mudududdla*[1], *A. Wong*[1], *M. Binder*[2], *B. Jupp*[1], *U. Ackermann*[3], *T. Kilpatrick*[2], *J. Baell*[1];
[1]*Monash University, Melbourne, AUSTRALIA,* [2]*Florey Institute of Mental Health, Melbourne, AUSTRALIA,* [3]*Austin Hospital, Melbourne, AUSTRALIA.*

EP-03

During Congress Opening Hours

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A13 Preclinical Oncology

EP-017
Preclinical Models and PET/CT Imaging to Study Malignant Pleural Mesothelioma
O. Bejuy[1], *I. Senoner*[1], *S. Germain*[1], *F. Triponez*[2], *V. Serre-Beinier*[2], *D. J. Colin*[3];
[1]*CIBM Centre for BioMedical Imaging, Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,* [2]*Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, Geneva, SWITZERLAND,* [3]*Small Animal Imaging Facility, Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND.*

EP-018
Reactive astrogliosis imaging with [11]C-acetate PET in patients and mouse models with glioblastoma
H. Ko[1], *J. Chung*[1], *D. Kim*[1], *Y. Park*[2], *S. Kim*[1], *J. Kim*[1], *M. Lee*[3], *M. Nam*[4], *J. Chang*[1], *C. Lee*[2], *M. Yun*[1];
[1]*Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [2]*Institute for Basic Science, Daejeon, KOREA, REPUBLIC OF,* [3]*Incheon National University, Incheon, KOREA, REPUBLIC OF,* [4]*Korea Institute of Science and Technology, Seoul, KOREA, REPUBLIC OF.*

EP-019
PET/SPECT/MRI/Optical Imaging of the CAM Model as a Theragnostic Platform for Cancer
O. Bejuy[1], *J. Bussinger*[2,1,3], *S. Germain*[1], *A. Martinez*[1,3], *F. Bois*[2], *J. Delage*[4], *D. Viertl*[4,5], *J. Prior*[4], *V. Garibotto*[2,1], *D. J. Colin*[3];
[1]*CIBM Centre for BioMedical Imaging, Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND,* [2]*Division*

of Nuclear Medicine and Molecular Imaging, University Hospitals of Geneva, Geneva, SWITZERLAND, [3]Small Animal Imaging Facility, Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND, [4]Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND, [5]In Vivo Imaging Facility, Department of Research and Training, University of Lausanne, Lausanne, SWITZERLAND.

EP-020

Use of the fibroblast activation protein inhibitor 64Cu-DOTHA2-FAPI for PET imaging of murine orthotopic head and neck cancer

I. Ben-Salem[1], *E. Croteau*[1], *V. Dumulon-Perreault*[2], *S. Ait-Mohand*[1], *O. Bélissant*[1], *E. Turcotte*[1], *A. Oweida*[1], *B. Guérin*[1], *E. Rousseau*[1];
[1]*Département de médecine nucléaire et radiobiologie, Université de Sherbrooke, Sherbrooke, QC, CANADA,* [2]*Centre d'Imagerie Moléculaire de Sherbrooke (CIMS), Centre de Recherche du CHUS (CRCHUS), Sherbrooke, QC, CANADA.*

EP-021

Development of an easily bioconjugatable water-soluble SPECT/Optical bimodal imaging probe to target the cancer biomarkers PD-L1 and HER-2

C. Goze[1], *M. Privat*[1,2], *P. Bellaye*[3], *R. Lescure*[1], *A. Massot*[2], *D. Vivier*[1], *P. Adumeau*[1], *C. Bernhard*[1], *M. Cordonnier*[4], *F. Hermetet*[4], *A. Bettaieb*[2], *M. Moreau*[1], *C. Racoeur*[2], *B. Collin*[3], *E. Bodio*[1], *F. Denat*[1], *C. Paul*[2];
[1]*Institut de Chimie, Dijon, FRANCE,* [2]*Laboratoire d'Immunologie et Immunothérapie des Cancers, Dijon, FRANCE,* [3]*Centre Georges François Leclerc, Dijon, FRANCE,* [4]*INSERM UMR1231 « Lipides Nutrition Cancer, Dijon, FRANCE.*

EP-022

Pre-clinical Evaluation of ^{68}Ga-labeled PSMA/GRPR-targeting Heterodimeric Radiotracer for PET Imaging of Prostate Cancer

F. Lundmark[1], *A. Abouzayed*[1], *S. Rinne*[1], *V. Tolmachev*[2], *A. Orlova*[1], *U. Rosenström*[1];
[1]*Department of Medicinal Chemistry at Uppsala University, Uppsala, SWEDEN,* [2]*Department of Immunology, Genetics and Pathology at Uppsala University, Uppsala, SWEDEN.*

EP-023

A designed radiolabelled Poly (Lactic-co-Glycolic Acid) nanoparticle for theragnostic applications

M. Varani, *V. Bentivoglio, M. Serafinelli, C. Lauri, A. Signore;
La Sapienza University, Rome, ITALY.*

EP-023a

Preclinical imaging of CD8 T-Cells as a tool to predict response to immunotherapy

C. Paul[1], *D. Vivier*[2], *A. Massot*[1], *L. DaCosta*[2], *P. Baurand*[3], *M. Desbuisson*[1], *M. Privat*[1], *M. Moreau*[2], *C. Bernhard*[2], *V. Goncalves*[2], *C. Racoeur*[1], *A. Bettaieb*[1], *A. Helbling*[4], *P. Bellaye*[4], *C. Berthet*[5], *B. Collin*[4], *F. Denat*[2], *L. Ringenbach*[3];
[1]*LIIC EPHE-PSL-UB, Dijon, FRANCE,* [2]*ICMUB CNRS-UBFC, Dijon, FRANCE,* [3]*Diaclone, Besançon, FRANCE,* [4]*CGFL, Dijon, FRANCE,* [5]*Oncodesign, Dijon, FRANCE.*

EP-024

A new enzymatic conjugation for the development of bioconjugated compounds targeting HER2/Neu Antigen for Diagnostic Purposes

C. Berthet[1], *M. El Alaoui*[2], *C. Mothes*[1], *C. Bernhard*[3], *L. Mebarki*[2], *M. Moreau*[3], *M. Claron*[3], *F. Boschetti*[4], *F. Denat*[3], *S. El Alaoui*[2];
[1]*Oncodesign, Dijon, FRANCE,* [2]*Covalab, Bron, FRANCE,* [3]*Institut de Chimie Moléculaire de l'Université de Bourgogne UMR CNRS 6302, Dijon, FRANCE,* [4]*Chematech, Dijon, FRANCE.*

EP-025

A template mediated site-selective labeling method for preclinical imaging of therapeutic antibodies

L. Marx[1], *V. Postupalenko*[1], *D. Viertl*[2], *N. Gasilova*[3], *M. Pantin*[1], *N. Gsponer*[4], *A. Johannsen*[4], *T. Denoel*[2], *G. Hagens*[4], *J. Segura*[4], *F. Levy*[5], *P. Garrouste*[1], *J. Prior*[2], *M. Schottelius*[2], *N. Schaefer*[2], *O. Nyanguile*[4];
[1]*Debiopharm Research and Manufacturing SA, Martigny, SWITZERLAND,* [2]*Lausanne University Hospital, Nuclear Medicine and Moelcular Imaging, Lausanne, SWITZERLAND,* [3]*EPFL Valais-Wallis, Sion, SWITZERLAND,* [4]*HES-SO Valais-Wallis, Institute of Life Technologies, Sion, SWITZERLAND,* [5]*Debiopharm International, Lausanne, SWITZERLAND.*

EP-026

Immuno-PET Imaging for CD20 Expression in Non-Hodgkin's Lymphoma

E. T. Sarcan Bozkir[1], *S. Paisey*[2], *M. Ruthardt*[3], *A. Y. Ozer*[1], *C. Marshall*[2], *N. Hartman*[4];
[1]*Hacettepe University, Faculty of Pharmacy, Department of Radiopharmacy, Ankara, TÜRKIYE,* [2]*Cardiff University, Wales Research and Diagnostic PET Imaging Centre, Cardiff, UNITED KINGDOM,* [3]*Cardiff University, Haematology, Division of Cancer and Genetics, Cardiff, UNITED KINGDOM,* [4]*Singleton Hospital, Nuclear Medicine, Swansea, UNITED KINGDOM.*

EP-027

Development and Preclinical Evaluation of Two Bispecific PSMA/FAP-targeting Radiotracers

A. Verena[1], *Z. Zhang*[1], *H. Merkens*[1], *J. Pan*[1], *N. Colpo*[1], *R. Wilson*[1], *F. Bénard*[1,2], *K. Lin*[1,2];
[1]*British Columbia Cancer Research Institute, Vancouver, BC, CANADA,* [2]*Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.*

EP-028

Synthesis, Radiosynthesis, and In Vitro Evaluation of an Iodine-123 agent for Targeted Radionuclide Therapy of PARP-expressing Tumours

G. Destro, *Z. Chen, C. Chan, G. Dias, C. Fraser, M. Mosley, E. O'Neill, V. Gouverneur, F. Guibbal, B. Cornelissen;
University of Oxford, Oxford, UNITED KINGDOM.*

EP-029

Targeting mutant p53: Evaluation of novel anti-p53^{R175H} monoclonal antibodies as agents for molecular imaging

D. Spiegelberg[1,2], *L. Hwang*[3], *X. Y. Koh*[3], *K. Sabapathy*[3], *X. H. Koh*[3], *D. P. Lane*[3,4], *M. Nestor*[1];
[1]*Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, SWEDEN,* [2]*Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN,* [3]*p53 lab, Agency for Science, Technology and Research (A*STAR), Singapore, SINGAPORE,* [4]*Department of Microbiology, Tumour and Cell Biology, Science for Life Laboratory, Karolinska Institutet, Stockholm, SWEDEN.*

EP-030

The pharmacologic effect of PSMA-617 on Prostate cancer cell growth

Y. Zhao, *N. Nithack, A. Helm, A. Alfteimi, M. Marx, U. Lützen, M. Zuhayra;
Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of S, Kiel, GERMANY.*

EP-031

[^{68}Ga]Ga-DOTA-Ahx-(DLys6)-LHRH peptide as potential prostate cancer imaging agent

X. Camacho[1], *L. Alfaya*[1], *C. Perroni*[1], *M. Tassano*[1], *M. Cabrera*[1], *L. Reyes*[2], *A. Paolino*[2], *M. Fernández*[1], *E. Savio*[2], *P. Duarte*[2], *P. Cabral*[1], *J. Gambini*[1,2];
[1]*Universidad de la República, Montevideo, URUGUAY,* [2]*Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY.*

EP-033

The easyPET technology in bone metastasis induction of human colon and breast cancer: an experimental animal study

G. Figueiredo[1,2], *F. M. Ribeiro*[1], *A. C. A. Santos*[2], *R. Santos*[2], *M. Marques*[2], *P. M. C. C. Encarnação*[1], *P. M. M. Correia*[1], *A. L. M. Silva*[1], *I. F. C. Castro*[3], *J. F. C. A. Veloso*[1];
[1]*Institute for Nanostructures, Nanomodelling and Nanofabrication (i3N), Department of Physics, University of Aveiro, Aveiro, PORTUGAL,* [2]*Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine of the University of Coimbra (FMUC), Area of Environment Genetics and Oncobiology (CIMAGO), Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, PORTUGAL,* [3]*Radiation Imaging Technologies Lda (RI-TE), Ilhavo, PORTUGAL.*

EP-04

During Congress Opening Hours

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A14 Preclinical Therapy

EP-034

Multimeric PSMA-targeting small molecule thorium-227 conjugates for the treatment of prostate cancer

A. Papple[1], *B. Indrevoll*[1], *S. Hammer*[2], *A. Kristian*[1], *D. Mumberg*[2], *A. Cuthbertson*[1], *S. Zitzmann-Kolbe*[2], *N. Boehnke*[2];
[1]*Bayer AS, Oslo, NORWAY,* [2]*Bayer AG, Berlin, GERMANY.*

EP-035

Targeting glioblastoma cancer cells and stroma with Thorium-227 radioimmunotherapy

D. Abou[1], *M. Longtine*[1], *A. Hasson*[1], *A. Fears*[1], *R. Unnerstall*[1], *C. Storey*[2], *M. Altai*[3], *N. Peekhaus*[4], *D. Tatum*[5], *D. Magda*[5], *R. Wahl*[1], *D. Ulmert*[6], *D. Thorek*[1];
[1]*Washington University School of Medicine, Saint Louis, MO, UNITED STATES OF AMERICA,* [2]*UCLA, LA, CA, UNITED STATES OF AMERICA,* [3]*Lund University Cancer center, Lund, SWEDEN,* [4]*Pharma 15, LA, CA, UNITED STATES OF AMERICA,* [5]*Lumiphore, Berkeley, CA, UNITED STATES OF AMERICA,* [6]*Molecular and Medical Pharmacology UCLA, LA, CA, UNITED STATES OF AMERICA.*

EP-036

Locoregional Astatine-211 Radioimmunotherapy Targeting Syndecan-1 in a Syngeneic Glioblastoma Mouse Model

L. Roncali[1,2], *C. Roy*[1,3], *S. Marionneau-Lambot*[2,4,5], *S. Gouard*[1,6], *R. Eychenne*[2,6], *S. Avril*[1], *F. Guérard*[2], *F. Hindré*[1,3], *M. Chérel*[2,4,6], *E. Garcion*[1,3,7];
[1]*Université d'Angers, Inserm U1307, CNRS U6075, Nantes Université, CRCI2NA, Angers, FRANCE,* [2]*Nantes Université, Inserm U1307, CNRS U6075, Université d'Angers, CRCI2NA, Nantes, FRANCE,* [3]*PRIMEX (Plateforme de Radiobiologie et d'Imageries Expérimentales), SFR 4208, Université d'Angers, Angers, FRANCE,* [4]*Department of Nuclear Medicine, CHU Nantes, Nantes, FRANCE,* [5]*CIMA (Centre d'Imagerie Multi-modalités et Applications), Inserm U1307, CNRS U6075, Nantes Université, CRCI2NA, Nantes, FRANCE,* [6]*Groupement d'Intérêt Public ARRONAX, Saint-Herblain, FRANCE,* [7]*PACEM (Plateforme d'Analyse Cellulaire et Moléculaire), SFR 4208, Université d'Angers, Angers, FRANCE.*

EP-037

Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (^{225}Ac-pelgifatamab) a targeted alpha therapy for prostate cancer

C. Schatz[1], *S. Zitzmann-Kolbe*[1], *I. Moen*[2], *V. Stickel*[1], *G. Petros*[2], *T. Lindberg*[2], *B. Indrevoll*[2], *Y. Feng*[2], *V. Cruciani*[2], *A. Mobergslien*[2], *V. Le*[1], *M. Klotz*[1], *S. Stargard*[1], *J. Karlsson*[2], *O. Ryan*[2], *A. Scholz*[1], *R. Bjerke*[2], *A. Papple*[2], *U. B. Hagemann*[1], *H. Hennekes*[1], *A. Cuthbertson*[2], *A. Larsen*[2];
[1]*Bayer AG, Berlin, GERMANY,* [2]*Bayer AS, Oslo, NORWAY.*

EP-038

Metabolic Index using Glucose-Thymidine Ratio from ^{18}F-FDG and ^{18}F-FLT PET as a Potential Imaging Biomarker for Evaluating Response to Immune Checkpoint Inhibitor Therapy

S. Oh, *H. Youn, J. Paeng, Y. Kim, C. Lee, H. Choi, K. Kang, J. Chung, G. Cheon;
Seoul National University, Seoul, KOREA, REPUBLIC OF.*

EP-039

Development and characterization of a next-generation ^{225}Ac-PSMA radioligand

A. Vito[1], *M. Dornan*[1], *T. Beale*[1], *A. Felten*[1], *M. Ernste*[1], *Q. Nguyen*[2], *S. Ahn*[3,4], *A. P. Belanger*[3,4], *S. Pan*[5], *W. Wu*[5], *Y. Liu*[5], *J. H. Lai*[5], *W. W. Bachovchin*[5], *V. Hergott*[1], *J. McCann*[1], *R. Hallett*[1];
[1]*POINT Biopharma, Toronto, ON, CANADA,* [2]*Lurie Family Imaging Center, Center for Biomedical Imaging in Oncology, Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA,* [3]*Molecular Cancer Imaging Facility, Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, UNITED STATES OF AMERICA,* [4]*Harvard Medical School, Boston, MA, UNITED STATES OF AMERICA,* [5]*Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, MA, UNITED STATES OF AMERICA.*

EP-040

Preclinical evaluation of a promising novel, antibody-based ^{177}Lu-labeled radiopharmaceutical for potential use in advanced thyroid cancer

A. Mortensen[1,2], *H. Berglund*[2], *C. Juhlin*[1], *A. Stenman*[1], *P. Jha*[2], *F. Frejd*[2], *J. Zedenius*[1], *M. Nestor*[2];
[1]*Karolinska Institutet, Stockholm, SWEDEN,* [2]*Uppsala University, Uppsala, SWEDEN.*

EP-041

Citrate dependence in hepatocellular carcinoma prevents hypoxic tumor progression via HIF1adegradation

S. Kim[1], *J. Kim*[1], *H. Ko*[1], *M. Lee*[2], *M. Yun*[1];
[1]*Yonsei university college of Medicine, Seoul, KOREA, REPUBLIC OF,* [2]*Incheon national university, Incheon, KOREA, REPUBLIC OF.*

EP-042

[^{123}I]CC1: A Potent Auger Electron Emitting PARP-Targeting Theragnostic Agent

B. Cornelissen[1,2], *C. Chan*[1], *Z. Chen*[1], *G. Destro*[1], *M. Veal*[1], *D. Lau*[1], *E. O'Neill*[1], *G. Dias*[1], *M. Mosley*[1], *T. Wilson*[1], *V. Gouverneur*[1];
[1]*University of Oxford, Oxford, UNITED KINGDOM,* [2]*University Medical Center Groningen, Groningen, NETHERLANDS.*

EP-043

Theranostic Nanoparticles Activated by Cathepsin B Enzyme for Glioblastoma Therapy and Magnetic Resonance Imaging

C. Huang, *E. Chang, L. Zheng, J. G. J. Raj, L. Pisani, H. Daldrup-Link;
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.*

EP-044
Chelator-free Radiolabelling of Graphene Oxide Nanoparticles for in vivo Imaging
H. Grover[1], *B. Ananthoju*[2], *A. Gravagnuolo*[3], *B. Ellis*[1], *K. Kostarelos*[3], *D. Jasim*[3];
[1]*Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM,* [2]*School of Chemistry & National Graphene Institute, University of Manchester, Manchester, UNITED KINGDOM,* [3]*Nanomedicine Lab, National Graphene Institute and Faculty of Biology, Medicine & Health, The University of Manchester, Manchester, UNITED KINGDOM.*

EP-045
Therapeutic Response Monitoring with ^{89}Zr-DFO-Petuzumab ImmunoPET for anti-HER2 immunotherpy and HSP90 inhibitor treatment in JIMT-1 Xenograft Model
T. Lee[1], *M. Kang*[1], *J. Shin*[1], *S. Han*[1], *J. Kim*[1], *J. Park*[2], *K. Kim*[1], *J. Kang*[1];
[1]*Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF,* [2]*KAERI, Jeongup, KOREA, REPUBLIC OF.*

EP-046
Comparative study of rheumatoid arthritis treatment by ^{90}Y-hydroxyapatite and ^{188}Re- sulfide in rat knee joints
S. Mazidi, *M. Shirsalimian, R. Nami;*
Parsisotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-05

During Congress Opening Hours

e-Poster Area

A: Preclinical Studies -> A1 Medical Preclinical -> A15 Other Medical Preclinical

EP-047
Inhibition studies to evaluate receptor-specific radioligand binding in the CAM model
J. Loeffler[1,2], *C. Hamps*[2], *C. Solbach*[2], *M. Wirth*[1], *G. Glatting*[3], *V. Rasche*[1,4], *A. Beer*[2], *G. Winter*[2];
[1]*Center for Translational Imaging, Internal Medicine II, Ulm University Medical Center, Ulm, GERMANY,* [2]*Department of Nuclear Medicine, Ulm University Medical Center, Ulm, GERMANY,* [3]*Medical Radiation Physics, Department of Nuclear Medicine, Ulm University Medical Center, Ulm, GERMANY,* [4]*Department of Internal Medicine II, Ulm University Medical Center, Ulm, GERMANY.*

EP-048
Image-based evaluation of adjuvant efficacy in a vaccine candidate against Norovirus infection
I. Kim[1,2,3], *Y. Shim*[1,3], *H. Kim*[1,3], *S. Hong*[1,3,4], *H. Youn*[1,3,5];
[1]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [2]*Radiation Medicine Research Institute, Medical Research Center, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [3]*Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [4]*Center for Medical Innovation, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [5]*Cancer Imaging Center, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.*

EP-049
Multimodal MRI/PET/CT imaging to monitor disease progression in a reproducible lung injury rat model
I. Mahmutovic Persson[1,2], *M. Boswinkel*[3], *R. Raave*[3], *A. Veltien*[3], *R. In 't Zandt*[1], *L. E. Olsson*[2], *K. von Wachenfeldt*[4], *S. Heskamp*[3];
[1]*Lund University BioImaging Center, Lund, SWEDEN,* [2]*Department of Translational Medicine, Medical Radiation Physics, Malmö, SWEDEN,* [3]*Department of Medical Imaging – Nuclear Medicine, Radboud university medical center, Nijmegen, NETHERLANDS,* [4]*Truly Labs, Medicon Village, Lund, SWEDEN.*

EP-050
Comparative studies of ^{89}Zr-labeled human serum albumin in the mouse and CAM model
C. Hilbrig[1], *J. Loeffler*[1], *H. Herrmann*[1], *C. Solbach*[1], *M. Huber-Lang*[2], *V. Rasche*[3], *A. Beer*[1], *G. Winter*[1];
[1]*Klinik für Nuklearmedizin, Ulm, GERMANY,* [2]*Klinische und Experimentelle Trauma-Immunologie, Ulm, GERMANY,* [3]*Experimental Cardiovascular MRI, Ulm, GERMANY.*

EP-051
Biodistribution of a technetium-99m radiolabeled chimeric endolysin in a mouse model of acute infection
M. Collantes[1,2], *J. Simón*[1,3], *H. Shahrour*[4], *M. Morales*[5], *M. Ecay*[1,2], *F. Pareja*[1,3], *R. Ramos-Membrive*[1,3], *G. Quincoces*[1,3], *R. Díez-Martínez*[5], *G. Martínez de Tejada*[4], *I. Peñuelas*[1,2,3];
[1]*Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Translational Molecular Imaging Unit, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, SPAIN,* [3]*Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN,* [4]*Department of Microbiology and Parasitology, University of Navarra, Pamplona, SPAIN,* [5]*Telum Therapeutics, Noáin, SPAIN.*

EP-052
Preclinical evaluation of ^{18}F-fluorocholine PET for evaluating skeletal muscle atrophy in starvation induced rat model
B. Moon, *S. Park, B. Kim, K. Lee;*
Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-053
Diagnostic performance of PET radiotracers for infection: in vitro and in vivo studies in an acute infection animal model in mice
M. Collantes[1,2], *M. Rúa*[3], *J. A. Simón*[1,4], *M. Ecay*[1,2], *R. Ramos-Membrive*[1,4], *G. Quincoces*[1,4], *F. Pareja*[1,4], *J. J. Rosales*[1], *F. Carmona*[5], *J. Leiva*[3], *I. Peñuelas*[1,2,4];
[1]*Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Translational Molecular Imaging Unit, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, SPAIN,* [3]*Clinical Microbiologý Department, Clínica Universidad de Navarra, Pamplona, SPAIN,* [4]*Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN,* [5]*Infectious Diseases Service, Clínica Universidad de Navarra, Pamplona, SPAIN.*

EP-054
Development of intranasal microimplants with ^{125}I-radiolabelled risperidone for in vivo and in vitro release studies
I. Penuelas[1,2], *J. A. Simón*[1], *A. Otero*[2], *E. Utomo*[3], *M. Ecay*[2], *F. Pareja*[1], *G. Quincoces*[1], *E. Larrañeta*[3], *M. Collantes*[1,2], *J. Arbizu*[1];
[1]*Department of Nuclear Medicine. Clinica Universidad de Navarra, Pamplona, SPAIN,* [2]*Translational Molecular Imaging Unit. University of Navarra. Navarra Institute for Health Research (IdisNA), Pamplona, SPAIN,* [3]*School of Pharmacy, Queen's University Belfast, Belfast, UNITED KINGDOM.*

EP-055
Uptake of ^{18}F-FDG in a mouse model of rheumatoid arthritis
L. Badier[1,2], *E. Lacoste*[3], *C. Pestourie*[4], *P. Payoux*[1,2], *I. Quelven*[1,2];
[1]*INSERM ToNIC, Toulouse, FRANCE,* [2]*Toulouse Hospital University, Toulouse, FRANCE,* [3]*IMAVITA, Toulouse, FRANCE,* [4]*INSERM CREFRE, Toulouse, FRANCE.*

EP-056
Cerenkov luminescence imaging (CLI) of interscapular brown adipose tissue (iBAT) using TSPO-targeting [^{18}F]fm-PBR28-d2 in UCP1 Thermomouse
S. Lee[1,2,3], *H. Oh*[1,2,3], *Y. Kim*[1,3], *S. Bae*[1,3], *Y. Lee*[4], *Y. Lee*[1,4,5], *B. Lee*[6,7], *G. Cheon*[1,3], *K. Kang*[1,2,3], *H. Youn*[1,3,4];
[1]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [3]*Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [4]*Cancer Imaging Center, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [5]*Radiation Medicine Research Institute, Medical Research Center, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [6]*Department of Nuclear Medicine, Seoul National University Bundang Hospital, Bundang, KOREA, REPUBLIC OF,* [7]*Center for Nanomolecular Imaging and Innovative Drug Development, Advanced Institutes of Convergence Technology, Seoul National University, Suwon, KOREA, REPUBLIC OF.*

EP-057
PET to assess the pulmonary disposition of inhalation drugs
S. Mairinger[1,2], *I. Hernández-Lozano*[1], *T. Filip*[3], *M. Löbsch*[3], *J. Stanek*[2], *T. Wanek*[2], *O. Langer*[1,2];
[1]*Department of Clinical Pharmacology, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA,* [3]*Core Facility Laboratory Animal Breeding and Husbandry, Medical University of Vienna, Vienna, AUSTRIA.*

EP-058
Use of 18F-fluorodeoxysorbitol (^{18}F-FDS), and 18F-fluoroparaaminobenzoic acid (^{18}F-PABA) as gram positive and negative specific PET radiotracers for diagnosis of infection in a chronic model of foreign body osteomyelitis in rats
M. Collantes[1,2], *M. Rúa*[3], *J. A. Simón*[1,4], *M. Ecay*[1,2], *R. Ramos-Membrive*[1,4], *G. Quincoces*[1,4], *F. Pareja*[1,4], *J. Payo*[5], *A. Valenti*[5], *I. Peñuelas*[1,2,4];
[1]*Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Translational Molecular Imaging Unit, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, SPAIN,* [3]*Clinical Microbiologý Department, Clínica Universidad de Navarra, Pamplona, SPAIN,* [4]*Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN,* [5]*Orthopedic Surgery and Traumatology Department, Clínica Universidad de Navarra, Pamplona, SPAIN.*

EP-059
Nanosized graphite encapsulating technetium-99m metal complexes for lung ventilation studies in rats
F. Pareja del Rio[1,2], *V. Salinas*[3], *R. Passannante*[3], *M. Ecay*[2,4], *M. Collantes*[2,4], *G. Quincoces*[1,2], *A. Bronte*[2], *J. Rosales*[2], *J. Simon*[1,2], *J. Llop*[3], *I. Peñuelas*[1,2,4];
[1]*Radiopharmacy Unit. Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Nuclear Medicine Department. Clínica Universidad de Navarra, Pamplona, SPAIN,* [3]*Radiochemistry and Nuclear Imaging Group, CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, SPAIN,* [4]*Translational Molecular Imaging Unit, University of Navarra, Navarra Institute for Health Research (IdisNA)., Pamplona, SPAIN.*

EP-060
The Scintigraphic Evaluation of The Effect of Extremely Low Frequency Magnetic Fields Exposure on Nasal Mucociliary Clerance
N. Dizdar[1], *A. Akbulut*[2], *G. Koca*[2], *N. Yumusak*[3], *A. Canseven Kurşun*[4], *M. Korkmaz*[2];
[1]*Department of Nuclear Medicine University of Health Sciences, Gulhane Training and Research Hospital, Ankara, TÜRKIYE,* [2]*Department of Nuclear Medicine, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TÜRKIYE,* [3]*Department of Pathology, University of Harran, Faculty of Veterinary Medicine, Sanlıurfa, TÜRKIYE,* [4]*Department of Biophysics, Faculty of Medicine, Gazi University, Ankara, TÜRKIYE.*

EP-061
High Resolution PET Detector Design Using SiPM Array
A. Radnia[1], *M. Farahani*[1], *M. Ay*[2];
[1]*Research Center for Molecular and Cellular Imaging, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*2Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-062
Prognostic value of 18F-FDG brain PET in suicidal hanging: A preclinical study using a rat model of hanging-induced hypoxic brain injury
D. Kim[1], *H. Yoon*[2];
[1]*Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, KOREA, REPUBLIC OF,* [2]*Ewha Womans University, Seoul, KOREA, REPUBLIC OF.*

EP-063
Angiogenesis probe,68Ga-NODAGA-RGD: Study of pharmacokinetic behavior and quality control parameters
H. Pise[1,2], *B. Shetye*[1,2], *M. Maria*[1,2], *V. Rangarajan*[1,2];
[1]*Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute, Mumbai, INDIA.*

EP-064
The Process of Radiation Exposure Lymphocyte Damage Assessed by γH2AX Expression Level using Flow Cytometry
Z. Chen[1], *H. Wakabayashi*[1], *R. Kuroda*[2], *Y. Kitamura*[3], *T. Kozaka*[3], *S. Saito*[1], *A. Inaki*[1], *D. Kayano*[1], *S. Kinuya*[1];
[1]*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN,* [2]*Department of Pediatrics, Kanazawa University Hospital, Kanazawa, JAPAN,* [3]*Division of Probe Chemistry for Disease Analysis, Research Center for Experimental Modeling of Human Disease, Kanazawa, JAPAN.*

EP-065
GFR determination in pigs based on late samples only
L. Jødal[1], *J. I. Brignone*[2], *P. C. Ladefoged*[1], *L. Lund*[3,2], *T. B. Andersen*[1];
[1]*Dept. of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK,* [2]*Dept. of Urology, Aalborg University Hospital, Aalborg, DENMARK,* [3]*Dept. of Urology, Odense University Hospital, Odense, DENMARK.*

EP-06

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B11 Central Nervous System

EP-070
^{18}F-FET PET/CT performance in characterization of radiotherapy effects in Non-small-cell lung carcinoma brain metastases
A. Doma[1,2];
[1]*Onkološki inštitut Ljubljana, Ljubljana, SLOVENIA,* [2]*Medicinska fakulteta, Univerza v Ljubljani, Ljubljana, SLOVENIA.*

EP-071
Dynamic ^{18}F-FET PET aids in treatment planning of patients with brain tumor: a prospective study in Taiwan
S. Chan[1,2], *T. Chiu*[1], *S. Tsai*[1];
[1]*Hualien Tzu Chi Hospital, Hualien, TAIWAN,* [2]*School of Medicine, Tzu Chi University, Hualien, TAIWAN.*

EP-072
18F-FDOPA PET fused to MRI improves differentiation between tumor viability and treatment related changes in brain tumors
M. Suárez-Piñera[1], *L. Rodriguez-Bel*[1], *A. Pons-Escoda*[2], *C. Martinez-Ramos*[1], *M. Pudis*[1], *P. Plaza-López*[3], *M. Cortes-Romera*[1];
[1]*Department of Nuclear Medicine. Institut de Diagnòstic Per La Imatge (IDI), Bellvitge University Hospital, Barcelona, SPAIN,* [2]*Department of Radiology. Institut de Diagnòstic Per La Imatge (IDI), Bellvitge University Hospital, Barcelona, SPAIN,* [3]*Department of Nuclear Medicine. Hospital Quirónsalud, Barcelona, SPAIN.*

EP-073
^{18}F-FET PET/CT imaging: preliminary experience in a group of patients with recurrent glioma- a single-center experience
S. Mazzarri[1], *M. Della Porta*[1], *R. Pratali*[1], *C. Gambacciani*[2], *F. Pieri*[2], *E. Borsò*[1], *D. Bacciardi*[1], *O. Santonocito*[2], *N. Mazzuca*[1];
[1]*Dept. Nucl. Med., Azienda ASL Toscana Nord Ovest,LI, Livorno, ITALY,* [2]*Dept. Neurosurgery, Azienda ASL Toscana Nord Ovest, LI, Livorno, ITALY.*

EP-074
Clinical impact of 11C-Methionine PET/CT findings in the management of patients with brain lesions
Á. Gutiérrez-González, *I. Martínez-Rodríguez, J. Andrés-Pacheco, M. De Arcocha-Torres, A. Sánchez-Salmón, J. Jiménez-Bonilla, V. Mendi-Barcina, N. Martínez-Amador, F. Gómez-De la Fuente, A. Bota-Bota, M. Pombo-López, A. García-Ruiz, M. Rodil-Gallego, R. Quirce;*
Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

EP-075
To evaluate the diagnostic efficacy of [99mTc] methionine: A head-to-head comparison with [11C] methionine in glioma patients
P. Kumar[1], *A. Kumar*[1], *C. Nagaraj*[1], *J. Saini*[1], *S. Mangalore*[1], *N. Sadashiva*[1], *M. Beniwal*[1], *P. Panwar*[2], *A. K. Mishra*[3];
[1]*National Institute of Mental Health & Neuro Sciences (NIMHANS), Bengaluru, INDIA,* [2]*2Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA,* [3]*Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA.*

EP-076
Our Experiences with 18F-DOPA PET/CT in Detecting Tumor Recurrance in Patients with Glioma
Z. Mikó, *G. Sipka, S. Urban, A. Bakos, I. Farkas, T. Czekus, S. Nagy, L. Pavics, Z. Besenyi;*
University of Szeged Institution of Nuclear Medicine, Szeged, HUNGARY.

EP-077
Diagnostic value of [^{18}F]FACBC PET in brain metastases
K. Johannessen[1], *S. Øen*[1,2], *L. Pedersen*[3], *E. M. Berntsen*[1,2], *J. Totland*[4], *H. Johansen*[2], *T. Bogsrud*[5,6], *T. S. Solheim*[7,8], *A. Karlberg*[1,2], *L. Eikenes*[1];
[1]*Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, NORWAY,* [2]*Department of Radiology and Nuclear Medicine, St. Olavs hospital, Trondheim University Hospital, Trondheim, NORWAY,* [3]*Department of Neurosurgery, University Hospital of North Norway, Tromsø, NORWAY,* [4]*Department of Radiology, University Hospital of North Norway, Tromsø, NORWAY,* [5]*Aarhus University Hospital, Aarhus, DENMARK,* [6]*PET-Centre, University Hospital of North Norway, Tromsø, NORWAY,* [7]*Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, NORWAY,* [8]*Cancer Clinic, St. Olavs Hospital, Trondheim University Hospital, Trondheim, NORWAY.*

EP-078
Value of amino acid PET vs. MRI RANO criteria in assessment of response to bevacizumab therapy in recurrent high grade glioma: a meta-analysis
A. Chaban[1], *B. Waschulzik*[2], *W. Weber*[1], *I. Yakushev*[1];
[1]*Dept. of Nuclear Medicine, Technical University of Munich, Munich, GERMANY,* [2]*Institute of AI and Informatics in Medicine, Technical University of Munich, Munich, GERMANY.*

EP-07

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B12 Head and Neck

EP-079
Estimation of machine learning prediction model accuracy improvement with metastatic gene and image features in head and neck cancer
B. Kim[1], *K. Kim*[1], *H. Ju*[2], *I. Lim*[1], *S. Woo*[1];
[1]*Korea institutes of radiological and medical sciences, Seoul, KOREA, REPUBLIC OF,* [2]*Radiological & Medico-Oncological Sciences, University of science & technology, Daejeon, KOREA, REPUBLIC OF.*

EP-080
Prognostic value of ^{18}F-FDG PET/CT radiomics in patients undergoing salvage total laryngectomy for a recurrent or second primary squamous cell carcinoma of the larynx and hypopharynx
K. Goffin[1,2], *J. Debacker*[3,4,5], *Y. D'Asseler*[6,7], *V. Schelfhout*[6,7], *V. Vander Poorten*[8,9], *J. Meulemans*[8,9], *W. Huvenne*[3,4];
[1]*Department of Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM,* [2]*Division of Nuclear Medicine & Molecular Imaging, KU Leuven, Leuven, BELGIUM,* [3]*Department of Head and Skin, Ghent University, Ghent, BELGIUM,* [4]*Department of Head and Neck Surgery, Ghent University Hospital, Ghent, BELGIUM,* [5]*Department of Nuclear Medicine, University Hospital Brussels, Brussels, BELGIUM,* [6]*Department of Diagnostic Sciences, Ghent University, Ghent, BELGIUM,* [7]*Department of Medical Imaging, Nuclear Medicine, Ghent University Hospital, Ghent, BELGIUM,* [8]*Department of Otorhinolaryngology-head and neck surgery, University Hospitals Leuven, Leuven, BELGIUM,* [9]*Department of Oncology, Section Head and Neck Oncology, KU Leuven, Leuven, BELGIUM.*

EP-081
Prediction of the evolution of patients with laryngeal cancer, based on SUVMAXas a metabolic index
F. Sebastián Palacid[1], *J. Á. Badell Martínez*[2], *A. C. Peñaherrera Cepeda*[2], *J. C. Cañadas Salazar*[2], *J. G. Villanueva Curto*[2], *C. Riola Parada*[2], *L. G. Diaz González*[2], *P. García-Talavera San Miguel*[2], *F. Gómez-Caminero López*[1];
[1]*Hospital Clínico Universitario Valladolid, Valladolid, SPAIN,* [2]*Complejo Asistencial Universitario Salamanca, Salamanca, SPAIN.*

EP-082
Utilility of sentinel lymph node biopsy as a diagnostic method to detect occult cervical metastases in Early Squamous Cell Carcinoma of the Oral Cavity
T. Moreno-Monsalve, *J. Navarro Fernández, M. Castellón Sánchez, T. Rodriguez Locarno, A. Leiva Montejo, A. De Agrela Serrao, L. Frutos Esteban, L. Mohamed Salem, A. Hernández Martínez, F. Hernandez Almagro, R. Mears Baño, J. Contreras Gutiérrez;*
Hospital Universitario Virgen De La Arrixaca, Murcia, SPAIN.

EP-083
Improved Value of [18F]-FDG PET/CT for Lymph Node Metastasis in Head and Neck Cancer
V. Betech-Antar[1], *F. Minguez*[1], *A. Bronte*[1], *J. F. Bastidas*[1], *J. J. Rosales*[1], *Z. Serrano*[2], *F. Pareja*[1], *M. J. García-Velloso*[1];
[1]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Hospital Universitario de Navarra, Pamplona, SPAIN.*

EP-084
Predictive Value of Tumor SUVmax in 18FDG-PET/CT Before and After Radiotherapy Treatment of Squamous Cell Head and Neck Carcinoma
F. Demir[1], *G. G. Avcı*[2];
[1]*Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE,* [2]*Tokat GOP University, Tokat, TÜRKIYE.*

EP-08

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B13 Breast

EP-085
[68Ga]Ga-FAPI-46 PET/CT: A Preliminary Study in Breast Cancer Patients at Presentation
G. Cuzzani[1], *S. Telo*[1,2], *E. Fortunati*[1], *A. Farolfi*[3], *C. Nanni*[3], *P. Castellucci*[3], *C. Malizia*[4], *F. Lodi*[4], *V. Cabitza*[4], *S. Grendele*[5], *S. Zanotti*[5], *M. Taffurelli*[5], *S. Fanti*[1,3];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine Department, AUSL Romagna, Romagna, ITALY,* [3]*Nuclear Medicine IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*PET Radiopharmacy Unit, St. Orsola Hospital, University of Bologna, Bologna, ITALY,* [5]*Breast Surgery, Department of Oncology and Hematological Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-086
The added value of quantitative SPECT-CT data in differentiating metastatic and degenerative lesions in breast cancer patients
M. Mutuleanu, *A. Lazar, I. Irimescu, M. Gherghe;*
National Institute of Oncology "Prof. Dr. Alexandru Trestioreanu", Bucharest, ROMANIA.

EP-087
Morphological and metabolic criteria of COVID-19 vaccine associated axillary nodes on ^{18}FDG PET/CT in patients with breast cancer
M. Zaman[1], *N. Fatima*[1], *S. Zaman*[2], *A. Zaman*[3], *U. Zaman*[3], *A. Zaman*[4];
[1]*AKUH, Karachi, PAKISTAN,* [2]*Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, PAKISTAN,* [3]*Sunny Downstate Medical Center, New York, NY, UNITED STATES OF AMERICA,* [4]*Liaqat College of Medicine and Dentistry, Karachi, PAKISTAN.*

EP-088
Axillary sentinel nodes with a fatty hilum in breast cancer with SPECT/CT
W. Zeng, ***S. Liu****, R. A. Aghdam, N. Su;*
The Ottawa Hospital, Ottawa, ON, CANADA.

EP-089
Prognostic role of ^{18}F-FDG PET/CT in different molecular subtypes of breast cancer
R. Kumar, *S. K. Velliangiri, A. Mahalik, D. Khan, S. Arora, A. Passah, C. Bal;*
AIIMS, New Delhi, INDIA.

EP-090
Evaluating the power of FDG PET/CT in breast cancer
E. Gokdemir, *Ü. Korkmaz, B. Ö. Günay;*
Trakya University, Edirne Merkez, TÜRKIYE.

EP-091
Effects of out-of-field radioactivity on dedicated breast PET images
Y. Satoh[1,2], *M. Imai*[1], *C. Ikegawa*[1], *K. Hirata*[3], *N. Abo*[4], *M. Kusuzaki*[5], *N. Oyama-Manabe*[6], *H. Onishi*[2];
[1]*Yamanashi PET Imaging Clinic, Chuo, JAPAN,* [2]*Department of Radiology, University of Yamanashi, Chuo, JAPAN,* [3]*Department of Diagnostic Imaging, Hokkaido University Graduate School of Medicine, Sapporo, JAPAN,* [4]*Central Institute of Isotope Science, Hokkaido University, Sapporo, JAPAN,* [5]*Research Institute for Electronic Science, Hokkaido University, Sapporo, JAPAN,* [6]*Department of Radiology, Jichi Medical University Saitama Medical Center, Saitama, JAPAN.*

EP-092
The Contribution of ^{18}F-FES PET/CT in Therapy Management of Estrogen Receptor Positive Breast Cancer
M. Oflas[1], *D. Has Simsek*[1], *E. Isik*[1], *N. Cabioglu*[2], *K. Ibis*[3], *A. Aydiner*[4], *A. Mudun*[1], *Y. Sanli*[1];
[1]*Istanbul University,Istanbul Faculty of Medicine,Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University,Istanbul Faculty of Medicine,Department of General Surgery, Istanbul, TÜRKIYE,* [3]*Istanbul University,Instutition of Oncology, Department of Radiation Oncology, Istanbul, TÜRKIYE,* [4]*Istanbul University,Instutition of Oncology, Department of Medical Oncology, Istanbul, TÜRKIYE.*

EP-093
Assessment of Cardiac Toxicity of HER2-Targeted Therapies: Results After 6 Month Follow-up
A. Lazar[1], *M. Mutuleanu*[1,2], *C. Sterea*[1], *I. Irimescu*[1], *C. Petroiu*[1], *M. Gherghe*[1,2];
[1]*Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA,* [2]*University of Medicine and Pharmacy "Carol Davila", Bucharest, ROMANIA.*

EP-094
Visceral fat metabolic activity evaluated by preoperative [18F]-FDG PET/CT in patients with recently diagnosed breast cancer
A. González-Jiménez[1], *R. Sánchez-Sánchez*[2], *L. Jurado Fasoli*[3,4], *I. Pérez-Herrezuelo*[5], *J. M. Llamas-Elvira*[2];
[1]*University Hospital of Jaén, Nuclear Medicine Department, Jaén, SPAIN,* [2]*University Hospital Virgen de las Nieves, Nuclear Medicine Department, Granada, SPAIN,* [3]*PROmoting FITness and Health through Physical Activity Research Group (PROFITH), Sport and Health University Research Institute (iMUDS), Department of Physical Education and Sports, Faculty of Sport Sciences, University of Granada, Granada, SPAIN,* [4]*Department of Physiology, Faculty of Medicine, University of Granada, Granada, SPAIN,* [5]*University Hospital Virgen de las Nieves, Gynecology and Obstetrics Departments, Granada, SPAIN.*

EP-095
Sentinel lymph node mapping in breast cancer patients following neoadjuvant chemotherapy: systematic review and meta-analysis about head to head comparison of clinically N zero and cN positive patients
A. Aghaee[1], *R. Sadeghi*[1], *L. Zarif Mahmoudi*[2];
[1]*Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EP-096
Prognostic correlation between 18F-FDG PET/CT and molecular markers in breast cancer patients
V. Baghel, *J. K. Rai, S. B. Kumar, S. K. Abua, B. Bhushan, V. Meshram; Balco Cancer Centre, Raipur, INDIA.*

EP-097
Incidence of nodal and distant metastasis and their correlation with primary breast tumor size on pre-therapy FDG PET/CT imaging
N. Fatima[1,2], *S. Zaman*[3], *A. Zaman*[4], *U. Zaman*[4], *M. Zaman*[1,2];
[1]*Aga Khan University, Karachi, PAKISTAN,* [2]*Dept of Nuclear Cardiology, KIHD, Karachi, PAKISTAN,* [3]*Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, Pakistan, Karachi, PAKISTAN,* [4]*SUNNY Downstate Hospital, New York, NY, UNITED STATES OF AMERICA.*

EP-098
Clinical relevance of breast lesions incidentally detected on [18F]fluorocholine PET/CT
L. Lezaic[1], *M. Hocevar*[2], *S. Rep*[1], *K. Zaletel*[1], *A. Androjna*[1];
[1]*University Medical Centre Ljubljana, Ljubljana, SLOVENIA,* [2]*Institute of Oncology Ljubljana, Ljubljana, SLOVENIA.*

EP-099
Diagnostic Accuracy of Lumbar Spine Bone Mineral Density (BMD) Measurements via Quantitative Computed Tomography (QCT) in the Assessment of Osteoporosis in Filipino Women Diagnosed with Breast Cancer using Dual-Energy X-ray Absorptiometry (DXA) as Gold Standard
I. Bandong, *R. R. Cabatu, A. V. Pedroso;*
St. Luke's Medical Center-Quezon City, Quezon City, PHILIPPINES.

EP-100
Spinal Cord Metastasis of Breast Cancer Demonstrated on FDG PET/CT
S. Kesim, *S. Ozguven, C. O. Engur, N. Filizoglu, K. Niftaliyeva, T. N. Kissa, Z. C. Balaban Genc, K. Oksuzoglu, F. Sen, T. Ones, H. T. Turoglu, T. Y. Erdil;*
Marmara University Istanbul Pendik Training and Research Hospital, Istanbul, TÜRKIYE.

EP-101
Utility of [18F]-FDG PET/CT for initial staging in patients with recently diagnosed breast cancer
A. González-Jiménez[1], *R. Sánchez-Sánchez*[2], *D. Rivas*[2], *I. Pérez-Herrezuelo*[3], *J. M. Llamas-Elvira*[2];
[1]*University Hospital of Jaén, Nuclear Medicine Department, Jaén, SPAIN,* [2]*University Hospital Virgen de las Nieves, Nuclear Medicine Department, Granada, SPAIN,* [3]*University Hospital Virgen de las Nieves, Gynecology and Obstetrics Departments, Granada, SPAIN.*

EP-09

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B14 Lung (including Mesothelioma)

EP-102
Value of 18F-FDG PET/MR in the Detection of Pulmonary Malignancies: A Systematic Review and Meta-Analysis on the Diagnostic Performance
S. Mirshahvalad[1], *R. Hinzpeter*[1], *A. Kohan*[1], *R. Anconina*[2], *R. Kulanthaivelu*[1], *C. Ortega*[1], *U. Metser*[1], *P. Veit-Haibach*[1];
[1]*Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA,* [2]*Sunnybrook Health Sciences Center, Toronto, ON, CANADA.*

EP-103
Clinical translation of the dead cancer cell-targeting antibody chimeric DAB4 (chDAB4) as a theranostic tool for diagnosing cancer treatment responses
A. H. Staudacher[1], *V. Liapis*[1], *N. L. Wittwer*[1], *M. P. Wheatcroft*[2], *M. P. Brown*[1];
[1]*Central Adelaide Local Health Network, Adelaide, AUSTRALIA,* [2]*Telix Pharmaceuticals Limited, Melbourne, AUSTRALIA.*

EP-104
Impact of respiratory motion correction in F-18-FDG PET/CT on staging in lung cancer patients
W. Roll[1], *B. Noto*[2], *R. Rischen*[2], *L. Kerschke*[3], *G. Evers*[4], *W. Heindel*[2], *M. Schäfers*[1], *F. Büther*[1];
[1]*Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY,* [2]*Clinic for Radiology, University Hospital Münster, Münster, GERMANY,* [3]*Institute of Biostatistics and Clinical Research, University of Münster, Münster, GERMANY,* [4]*Department of Internal Medicine A, University Hospital Münster, Münster, GERMANY.*

EP-105
A Meta-Analysis Review of [18F]FLT-PET in Diagnosis, Staging and Treatment of Non-Small Cell Lung Cancer
J. McCormick[1], *S. J. Colosimo*[1], *I. N. Fleming*[2], *F. I. McKiddie*[1], *R. T. Staff*[1];
[1]*NHS Grampian, Aberdeen, UNITED KINGDOM,* [2]*The University of Aberdeen, Aberdeen, UNITED KINGDOM.*

EP-106
A systemic approach to understanding disease progression in NSCLC patients using [18F]FDG-PET
J. Yu[1], *T. Beyer*[1], *D. Ferrara*[1], *S. Gutschmayer*[1], *M. Hacker*[2], *L. Shiyam Sundar*[1];
[1]*QIMP Team, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.*

EP-107
Comparison of Molecular Oncological Features and FDG Uptake in Lung Cancer
F. Kiss, *S. Czibor, M. Barra, Z. Varga, T. Györke;*
Semmelweis University, Budapest, HUNGARY.

EP-108
Prediction of EGFR mutation status through radiomic features from 18F FDG PET/CT in NSCLC cohort of patients
L. Monaco[1], *E. De Bernardi*[1,2], *F. Bertola*[3], *F. Bono*[4], *G. Casati*[4], *D. Cortinovis*[5], *C. Crivellaro*[6], *F. Elisei*[6], *V. L'Imperio*[4], *C. Landoni*[1,6], *F. Pagni*[4], *E. Turolla*[1,7], *C. Messa*[1], *L. Guerra*[1,6];
[1]*School of Medicine and Surgery, University of Milan-Bicocca, Monza, ITALY,* [2]*Centro di ricerca interdipartimentale Bicocca Bioinformatics Biostatistics and Bioimaging Centre – B4, Università degli studi di Milano-Bicocca, Monza, ITALY,* [3]*Medical Genetics, San Gerardo Hospital, ASST Monza, Monza, ITALY,* [4]*Department of Medicine and Surgery, Pathology, ASST Monza, San Gerardo Hospital, University of Milan-Bicocca, Monza, ITALY,* [5]*Medical Oncology, ASST Monza, San Gerardo Hospital, Monza, ITALY,* [6]*Nuclear Medicine Department, ASST Monza, San Gerardo Hospital, Monza, ITALY,* [7]*Tecnomed Foundation, University of Milan-Bicocca, Monza, ITALY.*

EP-109
Characterization of untreated non-small cell lung cancer by voxel-by-voxel texture analysis in F18-FDG-PET/MR
W. Thaiss[1,2], *K. Kneer*[1], *P. Korf*[3], *C. Kropf-Sanchen*[4], *G. Schmidtke-Schrezenmeier*[4], *A. Liewald*[5], *B. Mühling*[5], *M. Beer*[6], *A. Beer*[1];
[1]*Nuclear Medicine, University Hospital Ulm, Ulm, GERMANY,* [2]*University Hospital Ulm, Diagnostic and Interventional Radiology, Ulm, GERMANY,* [3]*Siemens Healthcare GmbH, Erlangen, GERMANY,* [4]*Internal Medicine II, University Hospital Ulm, Ulm, GERMANY,* [5]*Department of Cardiothoracic and Vascular Surgery, University Hospital Ulm, Ulm, GERMANY,* [6]*Diagnostic and Interventional Radiology, University Hospital Ulm, Ulm, GERMANY.*

EP-110
A multicenter 18F-FDG-PET/CT study in solitary pulmonary nodule: Qualitative and Semiquantitative parameters to predict the risk of malignancy
V. Frantellizzi[1], *F. Corica*[1], *M. Rondini*[2], *M. S. De Feo*[1], *M. L. Stazza*[2], *M. Conte*[1], *A. Marongiu*[2], *S. Nuvoli*[2], *A. Farcomeni*[3], *G. De Vincentis*[1], *A. Spanu*[2];
[1]*Sapienza University of Rome, Rome, ITALY,* [2]*University of Sassari, Sassari, ITALY,* [3]*University of Rome Tor Vergata, Rome, ITALY.*

EP-111
Differentiating Primary from Secondary Lung Cancer with FDG PET/CT and Extra-Pulmonary Tumor Grade
W. Zeng, ***J. Ghossein***, *S. Gingras;*
The Ottawa Hospital, Ottawa, ON, CANADA.

EP-112
Influence of long versus short axial field-of-view PET/CT on stage migration in non-small cell lung cancer (NSCLC): interim analysis of a quasi-experimental study using real-world data
I. Alberts[1], *S. Seibel*[1], *M. Viscione*[1], *C. Mingels*[2], *A. Asfhar-Oromieh*[1], *A. Rominger*[1];
[1]*Institut für Nuklearmedizin, Bern, SWITZERLAND,* [2]*Inselspital, Bern, SWITZERLAND.*

EP-113
Accuracy of [18F]FDG-PET/CT in differential diagnosis of solitary pulmonary nodules (SPN)
C. Medina[1], *L. Nieto*[1], *M. Giménez*[1], *B. Luna*[1], *S. Chamizo*[1], *J. Amaya*[1], *A. Cherino*[1], *N. Orta*[1,2], *C. Peña*[1,2];
[1]*Hospital Universitario Son Espases, Palma de Mallorca, SPAIN,* [2]*Institut d'Investigació Sanitària Illes Balears (IdiSBa), Palma de Mallorca, SPAIN.*

EP-10

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B15 Gastro-Intestinal (including Liver and Non-Endocrine Pancreas)

EP-114
Significance of incidental uptake in the upper gastrointestinal tract on FDG-PET/CT
D. Fraga, *L. Gomes, R. Sousa, I. Vitorino, D. Rombo, E. Sousa, I. Carvalho, T. Ferreira, I. Claro, L. Salgado;*
Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, PORTUGAL.

EP-115
Whole body 18F Choline PET/CT: a potential role for surveillance post liver transplant in patients with hepatocellular carcinoma
M. Abouzied, *A. Fathala, A. Almuhaideb, M. Alqahtani;*
King Faisal Specialist Hospital and Research Center, Riyadh, SAUDI ARABIA.

EP-116
Combining preoperative 99mTc-mebrofenin Hepatobiliary Scintygraphy (HBS) with Indocyanine Green Elimination rate(ICG-K) remnant: Too many assumptions?
M. Velasco Nuño, *L. Guernica, C. Espinet, R. Bellviure, E. Hidalgo;*
Vall d'Hebron Hospital Campus, Barcelona, SPAIN.

EP-117
Prognostic Value of Morphofunctional Imaging Methods In Post-Therapy Inoperable Intrahepatic Cholangiocarcinoma
V. Dragonetti[1], *N. Fraccascia*[1], *C. Mosconi*[2], *M. Barakat*[3], *A. Palloni*[4,5], *A. Paccapelo*[2], *R. Golfieri*[3,2], *G. Brandi*[4,5], *S. Fanti*[1,6], *C. Nanni*[6];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Abdominal-pelvic Diagnostic and Interventional Radiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Abdominal-pelvic Diagnostic and Interventional Radiology Unit, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [4]*Medical Oncology, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [5]*Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*Nuclear Medicine, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-118
The Relationship Of Histone Deacetlase (HDAC) Overexpression With 18F-FDG PET/CT Parameters And The Prognostic Importance In Gastric Cancers
Ö. Ulas Babacan, *Z. Hasbek, M. Yilmaz, H. Ozer, H. Ataseven;*
Cumhuriyet University, Sivas, TÜRKIYE.

EP-119
The role of 99mTc-Mebrofenin SPECT/CT in preoperative determination of liver functional volume
A. Bakos[1], *L. Pávics*[1], *G. Sipka*[1], *I. Farkas*[1], *Z. Mikó*[1], *T. Czékus*[1], *S. Nagy*[1], *R. Német*[1], *S. Urban*[1], *L. Libor*[2], *T. Géczi*[2], *J. Hőhn*[2], *Z. Besenyi*[1];
[1]*Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY,* [2]*Department of Surgery University of Szeged, Szeged, HUNGARY.*

EP-120
Prognostic and predictive value of ^{18}F-FDG PET/CT in assessment of treatment response and PFS in gastric cancer patient underwent neoadjuvant chemotherapy using FLOT regimen
S. Seyedinia[1], *F. Huemer*[2], *S. Mirshahvalad*[3], *O. Koch*[4], *L. Weiss*[2], *K. Emmanuel*[4], *C. Pirich*[1], *R. Greil*[2], *M. Beheshti*[1];
[1]*Division of Molecular Imaging & Theranostics, Department of Nuclear Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA,* [2]*Department of Hematology, Deprtment of Medical Oncology and Hematology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA,* [3]*Joint Department of Medical Imaging, University Health Network, University of Toronto, Toronto, ON, CANADA,* [4]*Department of Surgery, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA.*

EP-121
Prognostic value of sarcopenia and metabolic parameters of^{18}F-FDG-PET/CT in patients with advanced gastroesophageal cancer
R. Hinzpeter, *S. Mirshahvalad, R. Kulanthaivelu, C. Ortega, U. Metser, Z. Liu, P. Veit-Haibach;*
University of Toronto, Toronto, ON, CANADA.

EP-11

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B16 Neuroendocrine (Pancreatic and Others)

EP-123
Coefficient of Variation Assessed by ^{68}Ga-DOTATOC-PET/CT in the Evaluation of the Heterogeneity of SSTR2 Expression in Patients with Neuroendocrine Tumors
R. Fonti[1], *S. Pellegrino*[1], *M. Panico*[2], *R. Bologna*[1], *R. Morra*[3], *M. Giuliano*[3], *G. Palmieri*[4], *S. De Placido*[3], *S. Del Vecchio*[1];
[1]*Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY,* [2]*Institute of Biostructures and Bioimaging, National Research Council, Naples, ITALY,* [3]*Department of Clinical Medicine and Surgery, University Federico II, Naples, ITALY,* [4]*CRCTR Coordinating Rare Tumors Reference Center of Campania Region, AOU Federico II, Naples, ITALY.*

EP-124
The establishment of tumor size threshold of SSTR PET: appropriate application criteria for suspected gastrointestinal neuroendocrine neoplasm in endoscopy
Y. Wang, *Z. Quan, M. Zhang, J. Ye, J. Wang, F. Kang;*
Xijing Hospital, Xi'an, CHINA.

EP-125
Baseline [68Ga]Ga-DOTANOC-PET/CT Derived Volumetric Parameters (RTV, TLA) Of The Primary Lesion Are Not A Waste Of Time In Pancreatic NET Before First Line Surgery
G. Argalia[1], *E. Fortunati*[1], *N. Bonazzi*[1], *L. Zanoni*[2], *C. Malizia*[3], *C. Ricci*[4,5], *R. Casadei*[4,5], *D. Campana*[6,5], *S. Fanti*[1,2], *V. Ambrosini*[1,2];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*Pancreatic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-126
Asphericity of tumor ^{123}I-MIBG uptake in defining the "ultra-high-risk" neuroblastoma
M. Yadgarov[1], *N. Matveev*[2], *C. Kailash*[1], *T. Shamanskaya*[1], *D. Kachanov*[1], *Y. Likar*[1];
[1]*Dmitry Rogachev National Medical Research Center, Moscow, RUSSIAN FEDERATION,* [2]*Russian National Research Medical University, Moscow, RUSSIAN FEDERATION.*

EP-127
Dynamic Hepatobiliary Scintigraphy for hepatic function evaluation in GEP-NET patients treated with PRRT
G. Argiroffi, *S. Mazzaglia, V. Fuoco, K. Margarita, L. Alice, S. Federica, G. Aliberti, C. Chiesa, N. Prinzi, S. Pusceddu, J. Coppa, E. Seregni, M. Maccauro;*
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY.

EP-128
Response Assessment in Neuroblastoma Using 131I-MIBG Scintigraphy by Semi-quantitative (Curie and SIOPEN) Scoring
A. Hemrom, *A. Tupalli, A. Kumar, R. Seth, S. Agarwala, R. Kumar;*
All India Institute Of Medical Sciences, New Delhi, INDIA.

EP-129
Association between SUVs parameters and immunohistochemical features in neuroendocrine patients undergoing ^{68}Ga-DOTATATE PET/CT on new generation digital PET/CT scanners
M. Firsova, *A. Schaefer, N. Schaefer, M. Nicod-Lalonde, J. Prior, S. Boughdad;*
Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, SWITZERLAND.

EP-130
Do Pre-PRRT [68Ga]Ga-DOTANOC PET/CT Functional Parameters Correlate With Overall Survival In Patients With GEP-NET?
E. Fortunati[1], *G. Argalia*[1], *N. Bonazzi*[1], *L. Zanoni*[2], *G. Paolani*[3], *G. Della Gala*[3], *M. Santoro*[3], *L. Strigari*[3], *C. Malizia*[4], *D. Campana*[5,6], *S. Fanti*[1,2], *V. Ambrosini*[1,2];
[1]*Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [5]*DIMEC, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [6]*Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-131
The impact of [18F]FDG PET/CT on clinical management in gastro-entero-pancreatic neuroendocrine tumors G1
G. Gentiloni Silveri[1], *L. Chiurchioni*[1], *L. Magi*[2], *V. Ambrosini*[3], *P. Pizzichini*[4], *V. Russo*[1], *M. Rinzivillo*[2], *F. Panzuto*[2], *A. Signore*[1], *D. Prosperi*[4];
[1]*Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, Rome, ITALY,* [2]*Gastroenterology Unit, Sant'Andrea University Hospital, Rome, ITALY,* [3]*Department of Experimental Diagnostic and Specialized Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, ITALY,* [4]*Nuclear Medicine Unit Sant'Andrea University Hospital, Rome, ITALY.*

EP-132
Incidentally detected, small (≤2 cm), non-functioning pancreatic neuroendocrine tumors: 68Ga-DOTATATE PET-CT findings for the initial evaluation and follow-up
L. Yamaga, *M. F. Barboza, S. A. Nogueira, J. Wagner;*
Hospital Israelita Albert Einstein, São Paulo, BRAZIL.

EP-133
Comparison of PET and MRI sequences separately in the detection of bone metastases in patients with neuroendocrine tumor who underwent 3T Ga-68 DOTA TATE PET/MR
A. Kibar[1], *S. Asa*[1], *L. Uslu-Besli*[1], *A. Eryurekli*[2], *C. Samanci*[2], *S. Sager*[1], *H. B. Sayman*[1], *K. Sonmezoglu*[1];
[1]*Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Radiology, Istanbul, TÜRKIYE.*

EP-134
Overal and disease-free survival in patients with neuroendocrine tumors based on dual imaging (somatostatin receptor scintigraphy and 18F-FDG PET/TC)
J. Vallejo Casas, *M. Mansilla Coleto, E. Zurera Pareja, S. Castejón Echevarne, Á. López Cano, M. Guiote Moreno;*
Hospital Universitario Reina Sofía. IMIBIC., Córdoba, SPAIN.

EP-135
Comparison of somatostatin receptor expression in metastatic neuroendocrine neoplasms in ^{99m}Tc-EDDA/HYNIC-TOC SPECT/CT examinations
G. Sipka, *L. Pavics, R. Nemet, Z. Miko, I. Farkas, S. Urban, T. Czekus, S. Nagy, A. Bakos, Z. Besenyi;*
University of Szeged, Department of Nuclear Medicine, Szeged, HUNGARY.

EP-136
What is the fate of small neuroendocrine tumours of the pancreas?
I. Lopo[1], *A. P. Moreira*[1,2], *P. Lapa*[1,3], *G. Costa*[1,3];
[1]*Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL,* [2]*Instituto de Ciências Nucleares Aplicadas à Saúde (ICNAS), Coimbra, PORTUGAL,* [3]*Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.*

EP-12

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B17 Colorectal

EP-137
Evaluation Of Preoperative PET/CT Parameters With Histopathological And Radiological Findings In Colon Cancer
B. Özdemir, *B. Gunay, S. Soyluoglu, U. Korkmaz, C. Aydin;*
Trakya University, Edirne, TÜRKIYE.

EP-138
Can FDG PET/CECT Accurately Restage Colon Carcinoma?
J. Paudel;
Chitwan Medical College, Bharatpur, NEPAL.

EP-139
Diagnostic Performance of ^{18}F-FDG PET/MR in Evaluating Colorectal Cancer: A Systematic Review and Meta-Analysis
S. Mirshahvalad[1], *R. Hinzpeter*[1], *A. Kohan*[1], *R. Anconina*[2], *R. Kulanthaivelu*[1], *C. Ortega*[1], *U. Metser*[1], *P. Veit-Haibach*[1];
[1]*Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA,* [2]*Sunnybrook Health Sciences Center, Toronto, ON, CANADA.*

EP-140
Prediction of treatment response in unresectable adenocarcinoma rectum treated with chemoradiotherapy using standardized uptake value ratios on baseline 18F-FDG PET/CT - A retrospective single-center experience
J. Jaleel, *S. Jha, K. B. Chandra, R. Kumar, S. A. Shamim, M. Tripathi, C. S. Bal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-141
Diagnostic performance of fibroblast activation protein (FAP) inhibitors in Colorectal Cancer at primary staging. Initial results on feasibility and diagnostic accuracy
B. Johannes[1], *C. Kratochwil*[1], *M. Röhrich*[1], *F. Giesel*[2], *M. Lang*[3], *W. Mier*[4], *U. Haberkorn*[1,5], *H. Rathke*[6,7];
[1]*Department of Nuclear Medcine, University Hospital Heidelberg, Heidelberg, GERMANY,* [2]*Department of Nuclear Medcine, University Hospital Düsseldorf, Düsseldorf, GERMANY,* [3]*Department of Surgery, University Hospital Heidelberg, Heidelberg, GERMANY,* [4]*Department of Nuclear Medcine, University Hospital Heidelberg, Division Radiopharmacy, Heidelberg, GERMANY,* [5]*Clinical Cooperation Unit Nuclear Medicine (dkfz), Heidelberg, GERMANY,* [6]*Department of Nuclear Medcine, the Inselspital, Bern, SWITZERLAND,* [7]*Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY.*

EP-13

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18a Prostate Staging

EP-144
Accuracy of Simultaneous F^{18} PSMA-1007 PET/multiparametric Prostate MRI in Tumor Staging of Prostate Cancer
A. Hussien, *M. Kula, W. H. Ibrahim, S. A. Abd El-Gaid;*
King Hamad University Hospital, Muharraq, BAHRAIN.

EP-145
Staging with [^{68}Ga]Ga-PSMA-11 PET/CT in patients with intermediate and high-risk prostate cancer prior surgery: correlation with histopathology
J. J. Rosales, *J. F. Bastidas, Á. Bronte, V. Betech-Antar, F. Mínguez, F. Pareja, E. F. Guillén, F. Diez-Caballero, B. Miñana, J. Arbizu, M. Rodríguez-Fraile;*
Clínica Universidad de Navarra, Pamplona, SPAIN.

EP-146
Correlation of Preoperative Ga-68 PSMA PET/CT imaging with Radical Prostatectomy and Pelvic Lymph Node Dissection Findings
M. Atalay[1], *Z. Hakkoymaz*[2], *B. Gumuskaya Ocal*[2], *B. Okudan Tekin*[1];
[1]*Ankara City Hospital, Nuclear Medicine, Ankara, TÜRKIYE,* [2]*Ankara City Hospital, Medical Pathology, Ankara, TÜRKIYE.*

EP-147
A Pilot Study of ^{68}Ga-PSMA11 and ^{68}Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
H. Duan, *P. Ghanouni, B. Daniel, J. Rosenberg, A. Thong, G. A. Sonn, C. Kunder, G. A. Davidzon, C. Mari Aparici, F. Moradi, A. Iagaru;*
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-148
Assessment of urinary bladder activity and detection of local prostate cancer lesions in [18F]PSMA-1007 PET/CT
K. Krieger, *A. Afshar-Oromieh, A. O. Rominger, I. L. Alberts;*
Universitätsklinik für Nuklearmedizin, Bern, SWITZERLAND.

EP-149
PSMA/PET-CT in the initial staging of prostate cancer: association between imaging findings and high-risk disease criteria
I. Próspero, *D. Barbosa, J. Castro Ferro, S. Fontão de Castro, J. Teixeira, H. Duarte, G. Ferreira;*
Instituto Português de Oncologia do Porto, Porto, PORTUGAL.

EP-150
Diagnostic accuracy of [^{18}F]PSMA-1007 PET/CT in intermediate and high risk prostate cancer primary staging: a single center retrospective analysis of semi-quantitative PET/CT parameters, bio-distribution and clinical significance of potential equivocal non-specific findings (NS-F)
G. Paone[1], *M. Cuzzocrea*[2], *G. Treglia*[2], *T. Ruberto-Macchi*[1], *M. Raditckova-Sarnelli*[1], *L. Ceriani*[1], *L. Giovanella*[2];
[1]*Imaging Institute of Southern Switzerland, EOC, Lugano, SWITZERLAND,* [2]*Imaging Institute of Southern Switzerland, EOC, Bellinzona, SWITZERLAND.*

EP-151
^{68}Ga PSMA PET/CT for staging intermediate to high-risk prostate cancer patients suitable for radical treatments: diagnostic performance, metastatic site distribution and clinical impact
F. Mattana[1], *A. Barone*[1], *L. Muraglia*[1], *L. Grappeja*[1], *G. Zuccotti*[1], *P. Artioli*[1], *A. Farolfi*[2], *R. Mei*[2], *L. Bianchi*[3], *E. Balestrazzi*[3], *G. Musi*[4], *B. A. Jereczek*[5], *P. Castellucci*[2], *S. Fanti*[2], *F. Ceci*[1];
[1]*Department of Nuclear Medicine, European Institute of Oncology, Milan, ITALY,* [2]*Department of Nuclear Medicine, Sant'Orsola University Hospital, Bologna, ITALY,* [3]*Department of Urology, Sant'Orsola University Hospital, Bologna, ITALY,* [4]*Department of Urology, European Institute of Oncology, Milan, ITALY,* [5]*Department of Radiotherapy, European Institute of Oncology, Milan, ITALY.*

EP-152
Diagnostic Performance of Hybrid Ga-68 PSMA PET/MR Compared to PET Alone and Prostate MR Imaging in Primary Prostate Cancer Patients
L. Uslu-Besli[1], *B. Bakir*[2], *N. Urganci*[3], *I. Gürses*[3], *E. Güner*[4], *Ç. Demirdag;*[5], *H. B. Sayman*[1];
[1]*Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Istanbul Medical Faculty, Department of Radiology, Istanbul, TÜRKIYE,* [3]*Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Medical Pathology, Istanbul, TÜRKIYE,* [4]*University of Health Sciences Bakırkoy Sadi Konuk Training and Research Hospital, Department of Urology, Istanbul, TÜRKIYE,* [5]*Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Urology, Istanbul, TÜRKIYE.*

EP-153
Optimization of prostate cancer patient lymph node staging via the integration of neutrophil lymphocyte ratios, platelet lymphocyte ratios and ^{68}Ga-PSMA-PET-derived SUVmax values
Y. Tang, *M. Zhou, J. Li, B. Chen, W. Rao, S. Hu;*
Xiangya Hospital Central South University, Changsha, CHINA.

EP-154
Usefulness of semi-quantitative analysis in the differentiation of spine lesions in initial staging of prostate cancer SPECT/CT multiFOV
A. Castro López, *M. Gallego Márquez, J. Venero Chaparro, D. Becerra García;*
Hospital Universitario Clínico San Cecilio, Granada, SPAIN.

EP-155
Relationship between SUVmax and ADC values of metastatic lymph nodes also ADC values of metastatic and reactive lymph nodes detected by Ga-68 PSMA PET/MR in prostate cancer patients
F. Aghazada, *A. Kibar, L. Uslu-Besli, S. Sager, H. B. Sayman, K. Sonmezoglu;*
Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-156
18F-Fluoroethilcholine PET/CT radiomic analysis for newly diagnosed prostate cancer patients: a first monocentric experience
D. Pizzuto[1], *E. K. A. Triumbari*[2], *R. Bientinesi*[3], *L. Boldrini*[4], *R. Gatta*[4,5,6], *M. De Summa*[7], *M. De Risi*[1], *C. Caldarella*[1], *S. Annunziata*[2];
[1]*Nuclear Medicine Unit, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY,* [2]*Nuclear Medicine Unit, TracerGLab, Department of Radiology, Radiotherapy nd Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY,* [3]*Clinical urology Department of Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY,* [4]*Radiotherapy Unit, Radiomics, Department of Radiology, Radiotherapy and Hematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, ITALY,* [5]*Department of Clinical and Experimental Sciences, University of Brescia, Brescia, ITALY,* [6]*Department of Oncology, Lausanne University Hospital, Lausanne, SWITZERLAND,* [7]*Medipass S.p.a. Servizio Integrativo PET-TC-Radiofarmacia Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, ITALY.*

EP-157
Role of volumetric parameters on [^{18}F]PSMA-1007 PET/CT in primary staging of prostate cancer
A. Castello, *L. Airò Farulla, V. Longari, E. Orunesu, M. Schiavini, F. Bardo, M. Arnaboldi, E. Galli, L. Florimonte, M. Castellani;*
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, ITALY.

EP-158
Evaluation of PROMISE criteria inspired intraprostatic PSMA-score against PIRAD-Index in patients undergoing radical prostatectomy
W. Wang[1], *K. Qin*[1], *A. Anand*[2], *P. Borrelli*[3], *A. Bjartell*[2], *M. Foo*[1], *D. Damien Bolton*[1], *M. Perera*[1];
[1]*Austin Health, Melbourne, AUSTRALIA,* [2]*Lund University, Lund, SWEDEN,* [3]*Gothenburg University, Gothenburg, SWEDEN.*

EP-159
Intra-individual intermodal comparison of [F-18] siPSMA-14 PET imaging and mpMRI in primary staging of prostate cancer using biopsy results as reference
J. Miksch[1], *C. Solbach*[1], *M. Beer*[2], *T. Wiegel*[3], *H. J. Wester*[4], *F. Zengerling*[5], *C. Bolenz*[5], *A. J. Beer*[1], *W. Thaiss*[1];
[1]*Department of Nuclear Medicine University Hospital Ulm, Ulm, GERMANY,* [2]*Department of Radiology, University Hospital Ulm, Ulm, GERMANY,* [3]*Department of Radiation Oncology and Therapy, University Hospital Ulm, Ulm, GERMANY,* [4]*Pharmaceutical Radiochemistry, Technical University Munich, Munich, GERMANY,* [5]*Department of Urology and Pediatric Urology, University Hospital Ulm, Ulm, GERMANY.*

EP-160
Biochemical Recurrence of Prostate Cancer Detection: ^{68}Ga-PSMA and ^{18}F-fluciclovine in Real-life Practice
D. Zogala[1], *V. Ptacnik*[1], *D. Chroustova*[1], *I. Marikova*[1], *J. Trnka*[1], *A. Pudlac*[2];
[1]*Institute of Nuclear Medicine, First Faculty of Medicine Charles University and General University Hospital, Prague, CZECH REPUBLIC,* [2]*Department of Radiology, First Faculty of Medicine Charles University and General University Hospital, Prague, CZECH REPUBLIC.*

EP-161
^{68}Ga PSMA PET-CT and PSMA Score Affecting Therapeutic Decision-Making in Treatment Naïve High-risk Prostatic Carcinoma
T. Yasmin, *M. N. Younis, S. Adnan, A. Shahid;*
Institute of nuclear medicine and oncology Lahore, Lahore, PAKISTAN.

EP-162
Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Choline in initial staging of intermediate/high risk prostate cancer
C. Lucas Lucas[1], *L. Garcia Zoghby*[1], *M. Amo salas*[2], *M. Contreras Ameduri*[1], *A. Padilla Bermejo*[1], *M. Sicilia Pozo*[1], *A. Garcia Vicente*[1], *I. Jimenez Garcia*[3], *F. Pena Pardo*[1], *E. Noriega Alvarez*[1], *A. Soriano Castrejon*[1];
[1]*Nuclear Medicine Department. General University Hospital of Ciudad Real, Ciudad Real, SPAIN,* [2]*Department of Mathematics. University of Castilla-La Mancha, Ciudad Real, SPAIN,* [3]*Radiation Oncology Department. General University Hospital of Albacete, Albacete, SPAIN.*

EP-163
Semi-quantification of bone metastases using ^{18}F-PSMA-1007 PET-CT in patients with prostate cancer
E. Zoetelief[1,2], *B. N. Vendel*[2], *J. M. Wolterink*[1], *J. van Dalen*[2], *J. D. van Dijk*[2];
[1]*University of Twente, Enschede, NETHERLANDS,* [2]*Isala, Zwolle, NETHERLANDS.*

EP-164
To evaluate the diagnostic efficacy of 99mTc-PSMA scintigraphy for disease mapping in prostate cancer patients: A comparative study with68Ga-PSMA PET
M. Hooda, *S. Prashar, H. Singh, R. Mohan, N. Kakkar, S. K. Singh, B. Singh;*
PGIMER, sector-12, Chandigarh, INDIA.

EP-164a
Reciprocal metabolism of ^{18}F-PSMA-1007 and ^{18}F-FDG PET/CT in patients with prostate cancer at staging
J. Kim[1], *S. Lee*[2], *D. Kim*[1], *H. Kim*[3], *S. Kim*[4], *H. Ko*[1], *S. Kim*[1], *W. Kim*[5], *Y. Choi*[2], *F. Giesel*[6], *M. Lee*[7], *N. Cho*[8], *M. Yun*[1];
[1]*Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [3]*Department of Nuclear Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, KOREA, REPUBLIC OF,* [4]*Department of Nuclear Medicine, National Health Insurance Service Ilsan Hospital, Goyang, KOREA, REPUBLIC OF,* [5]*Incheon National University College of Life Science and Bioengineering, Seoul, KOREA, REPUBLIC OF,* [6]*Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, GERMANY,* [7]*Institute for New Drug Development, Incheon National University College of Life Science and Bioengineering, Incheon, KOREA, REPUBLIC OF,* [8]*Department of Pathology in Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.*

EP-14

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18b Prostate BC Recurrence

EP-165
Impact Of 18F-DCFPyL With Respect To 18F-Fluorocholine PET/CT In TNM Assessment In Prostate Cancer Biochemical Recurrence
L. García Zoghby[1], *A. García Vicente*[1], *C. Lucas Lucas*[1], *M. Amo Salas*[2], *A. Padilla Bermejo*[1], *M. Sicilia Pozo*[1], *M. Contreras Ameduri*[1], *E. Noriega Álvarez*[1], *F. Pena Pardo*[1], *L. Calahorra Fernández*[1], *P. Ríos*[1], *M. De Cabo Ripoll*[3], *A. Salinas Sánchez*[4], *F. Leal Hernández*[5], *M. Villas Sánchez*[4], *Á. Soriano Castrejón*[1];
[1]*University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [2]*Castilla-La Mancha University, Ciudad Real, SPAIN,* [3]*Virgen de la Luz Hospital, Cuenca, SPAIN,* [4]*University General Hospital of Albacete, Albacete, SPAIN,* [5]*University Hospital of Guadalajara, Guadalajara, SPAIN.*

EP-166
Role of 18F-DCFPyL (PSMA) PET/CT in treatment changes decision in suspected biochemical recurrence of prostate cancer patients in our centre
S. Nieves Maldonado[1], *F. Zelaya Reinquet*[1], *S. Seijas Marcos*[1], *S. Rodriguez Martinez de Llano*[1], *I. Fouce Calvo*[2], *P. Pais Silva*[1];
[1]*Centro Oncologico de Galicia, A Coruña, SPAIN,* [2]*Hospital Arquitecto Marcide, Ferrol, SPAIN.*

EP-167
The most important clinical factors connected with the positive ^{68}Ga-PSMA PET-CT scan in patients with biochemical recurrence of prostate cancer
I. Rogic, *A. Golubic, M. Dobrenic, M. Zuvic, T. Smitran, N. Jukic, D. Huic;*
Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-168
^{18}F-DCFPYL PET/CT detection rate by prostate-specific antigen serum values in patients with biochemical recurrence prostate cancer treated with radical prostatectomy: Experience of the University Hospital of Salamanca
A. Peñaherrera Cepeda, *C. Riola Parada, L. Diaz Gonzaga, P. García-Talavera San Miguel, J. Badell Martínez, J. Villanueva Curto, J. Cañadas Salazar, S. López Puche, E. Campaña Diaz, F. Gómez-Caminero López, P. Tamayo Alonso;*
Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EP-169
Detection rate of PET-CT ^{18}F-DCFPyL in biochemical recurrence of prostate cancer and its relationship with PSA levels
P. Romero Fernandez, *M. Meneses Navas, P. Nespral Torres, P. Dauden Oñate, M. Ollarves Carrero, M. Pedrera Canal, R. Couto Caro, J. L. Carreras Delgado, M. N. Cabrera Martin;*
Hospital Clinico San Carlos, Madrid, SPAIN.

EP-170
[18F]F-DCFPyL-PSMA PET study positive rate in patients (p) with Prostate Cancer (PCa) and Biochemical Recurrence (BR) due to PSA increase (≤1ng/ml)
S. Menendez-Sanchez, *F. Dellepiane-Clarke, I. Navales-Mateu, A. Cardozo-Saavedra, M. Simo, S. Aguadé;*
Hospital Universitario Vall d'Hebron, Barcelona, SPAIN.

EP-15

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18c Prostate Other

EP-170a
Head-to-Head comparison of ^{68}Ga-PSMA-11 with ^{68}Ga-P137 in patients with suspected prostate cancer: a prospective study
Z. Quan, *M. Wang, M. Zhang, X. Meng, J. Ye, T. Han, X. Zhao, J. Wang, F. Kang;*
Xijing Hospital, Xi An, CHINA.

EP-170b
Comparative study of 68Ga-PSMA PET/CT and multiparametric MRI in detection of clinically significant prostate cancer
X. Meng, *F. Kang, Z. Quan, M. Wang, T. Han, J. Wang;*
Xijing Hospital of Airforce Military Medical University, Xi'an, CHINA.

EP-170c
Comparison of 68Ga-PSMA PET/CT and MRI in evaluating the lateralization of prostate cancer
M. Wang, *Z. Quan, X. Zhao, T. Han, X. Meng, F. Kang, J. Wang;*
Xijing Hospital, Xi An, CHINA.

EP-172
Preliminary results of a clinical feasibility study with intravesically instilled ^{89}Zr-labeled Girentuximab in patients with non-muscle-invasive bladder cancer for future alpha-immunotherapy
C. Rousseau[1], *M. Geffroy*[2], *T. Rousseau*[3], *M. F. Heymann*[4], *M. Taupin*[5], *J. Lacoste*[6], *J. F. Chatal*[7], *L. Ferrer*[1], *P. Baumgartner*[2], *N. Varmenot*[1];
[1]*ICO René Gauducheau, F-44800 Saint-Herblain, Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000, Nantes, FRANCE,* [2]*ICO René Gauducheau, F-44800, St Herblain, FRANCE,* [3]*Urological Clinic Nantes-Atlantis, F-44800, Saint Herblain, FRANCE,* [4]*ICO René Gauducheau, Research pathology platform, Tumor Heterogeneity and Precision Medicine, F-44800, Saint Herblain, FRANCE,* [5]*ICO René Gauducheau, Research pathology platform, F-44800, Saint Herblain, FRANCE,* [6]*Urological Clinic Nantes-Atlantis, F-44800, St Herblain, FRANCE,* [7]*ATONCO SAS, F-44800, St Herblain, FRANCE.*

EP-173
Head-to-head comparison between the diagnostic accuracy of 68Ga-PSMA PET/CT and pelvic mp-3Tesla MRI in patients on active surveillance: a per-patient analysis and assessment of factors influencing PSMA PET positive outcome
M. Celli[1], *R. Gunelli*[2], *F. Ferroni*[3], *C. Salaris*[2], *G. Gaziev*[2], *P. Caroli*[1], *U. Salomone*[2], *L. Fantini*[1], *V. Rossetti*[1], *U. De Giorgi*[4], *D. Barone*[3], *V. Di Iorio*[5], *G. Paganelli*[1], *F. Matteucci*[1];
[1]*Nuclear Medicine Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [2]*Urology Unit, Ospedale "G.B.Morgagni - L.Pierantoni", Azienda USL della Romagna, Forlì, ITALY,* [3]*Radiology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [4]*Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY,* [5]*Unit of Oncological Pharmacy, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, ITALY.*

EP-174
Treatment response evaluation with PSMA-PET/CT in patients with metastatic prostate cancer, a subgroup analysis
F. Kleiburg[1,2], *L. F. de Geus-Oei*[1,2], *S. A. C. Luelmo*[2], *F. A. J. Toonen*[3], *F. Smit*[3], *T. van der Hulle*[2], *L. Heijmen*[2];
[1]*University of Twente, Enschede, NETHERLANDS,* [2]*Leiden University Medical Centre, Leiden, NETHERLANDS,* [3]*Alrijne Hospital, Leiderdorp, NETHERLANDS.*

EP-175
Ga-68 PSMA PET/MRI Imaging In Detecting Local Residue Or Recurrence In Patients With Prostate Cancer
B. Ince[1], *L. Uslu Besli*[1], *B. Bakir*[2], *S. Durmaz*[2], *S. Sager*[1], *C. Demirdag*[3], *E. Guner*[4], *K. Sonmezoglu*[1], *H. B. Sayman*[1];
[1]*Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Department of Radiology, Istanbul, TÜRKIYE,* [3]*Istanbul University-Cerrahpasa, Department of Urology, Istanbul, TÜRKIYE,* [4]*University of Health Sciences, Bakirkoy Dr. Sadi Konuk Training & Research Hospital, Department of Urology, Istanbul, TÜRKIYE.*

EP-176
A Pilot Study of ^{68}Ga-PSMA11 and ^{68}Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy
H. Duan, *P. Ghanouni, B. Daniel, J. Rosenberg, G. A. Davidzon, C. Mari Aparici, A. Thong, G. A. Sonn, C. Kunder, A. Iagaru;*
Stanford University, Stanford, CA, UNITED STATES OF AMERICA.

EP-177
^{18}F-PSMA-1007 Uptake Time: 90 vs 120 mins
T. Sanderson[1], *O. Stakhiv*[2], *J. Birchall*[3], *S. O'Dowd*[1], *A. O'Connor*[1];
[1]*Nottingham University Hospitals NHS Trust, Nottingham, UNITED KINGDOM,* [2]*InHealth Nottingham PET/CT Centre, Nottingham, UNITED KINGDOM,* [3]*University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UNITED KINGDOM.*

EP-178
[11C]C-Choline, [68Ga]Ga-PSMA, [18F]F-FACBC PET/CT in Castration Resistant Prostate Cancer Patients: Which Is the Most Suitable To Assess the Therapy Response?
N. Fraccascia[1], *G. Argalia*[1], *E. Tabacchi*[2], *S. Vichi*[3], *C. Malizia*[2], *F. Massari*[4], *V. Mollica*[4], *M. Rosellini*[4], *A. Marchetti*[4], *C. Nanni*[2], *S. Fanti*[1,2];
[1]*Nuclear Medicine, Alma Mater Studiorium University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Clinical Engineering Department, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [4]*Medical Oncology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-180
Ga-68 PSMA-11 VS F-18 PSMA-1007 PET/CT Imaging In Patients With Prostate Cancer: A Head To Head Comparison
M. Vangu, *O. Mbakaza, K. Purbhoo, J. Momodu;*
University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-181
Follow-up of presumably unspecific bone uptakes in F18-PSMA-1007-PET/CT
L. Knappe, *A. Rominger, A. Afshar-Oromieh, I. Alberts;*
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, SWITZERLAND.

EP-182
^{68}Ga-PSMA-11 PET/CT for response assessment in mCRPC patients receiving abiraterone or enzalutamide
Q. Shagera[1], *C. Artigas*[1], *T. Gil*[2], *P. Flamen*[1];
[1]*Department of Nuclear Medicine, Institut Jules Bordet, Brussels, BELGIUM,* [2]*Department of Oncology, Institut Jules Bordet, Brussels, BELGIUM.*

EP-183
Comparison of Diagnostic Performance of ^{18}F-rhPSMA-7 PET and Multiparametric Prostate MRI in Detecting Clinically Significant Prostate Cancer
T. Hekimsoy[1], *M. Heck*[2], *K. Schwamborn*[3], *M. Eiber*[1], *W. Weber*[1];
[1]*Department of Nuclear Medicine, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY,* [2]*Department of Urology, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY,* [3]*Department of Pathology, Technical University of Munich, Klinikum rechts der Isar, Munich, GERMANY.*

EP-184
Comparison of ^{99m}Tc-HYNIC-PSMA-11 and Bone Scan in Detection of Metastatic Lesions in Castration-Resistant Prostate Cancer Patients before Radioligand Therapy
S. Barashki, *K. Aryana, A. Aghaee;*
Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-185
Serum PSA and SUVmax correlation in 68Ga PSMA PET/CT in localised and metastatic prostatic cancer patients
A. Mahalik, *S. Sagar, D. Khan, S. K. Velliangiri, A. S. Babu, J. Pathak, S. A. Shamim, R. Kumar;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-186
Diagnostic Quantification of Superscan Pattern with Ga-68 PSMA PET/CT in Patients with Prostate Cancer
E. Sahin Kutuk, *R. Yükseltürk, S. Türkölmez;*
Ankara City Hospital, Çankaya, TÜRKIYE.

EP-187
Diagnostic performance of Tc-99m PSMA-11 SPECT-CT in prostate carcinoma
K. Agrawal[1], *D. Satpati*[2], *P. Nayak*[1], *M. Sable*[1], *B. M. Padhy*[1], *N. Kumar*[1], *G. K. Parida*[1];
[1]*All India Institute of Medical Sciences, Bhubaneswar, INDIA,* [2]*Bhabha Atomic Research Center, Mumbai, INDIA.*

EP-188
Systemic Therapy Response Evaluation in Prostate Carcinoma with [^{68}Ga]Ga-PSMA-11 PET/CT
K. Kucuker[1,2], *Z. Yapar*[1], *I. Guney*[1], *S. Paydas*[1];
[1]*Cukurova University, Adana, TÜRKIYE,* [2]*Katip Celebi University Ataturk Training and Research Hospital, Izmir, TÜRKIYE.*

EP-189
Preliminary characterization of the biomarker related to PSMA expression in prostate cancer using radiogenomics
J. Ning[1], *C. Spielvogel*[1], *K. Trachtova*[1], *S. Stoiber*[1], *V. Bystry*[2], *L. Papp*[3], *D. Iommi*[3], *J. Yu*[3], *E. Gurnhofer*[4], *M. Hacker*[3], *A. Haug*[1], *L. Kenner*[1];
[1]*Christian Doppler Lab for Applied Metabolomics, Vienna, AUSTRIA,* [2]*Central European Institute of Technology, Masaryk, Brno, AUSTRIA,* [3]*Division of Nuclear Medicine, Department of Biomedical Imaging and Image-Guided Therapy, Vienna, AUSTRIA,* [4]*Division of Experimental and Translational Pathology,Department of Pathology, Vienna, AUSTRIA.*

EP-190
Clinical application of quantitative ^{99m}Tc-HYNIC-PSMA SPECT/CT in prostate cancer
Y. Gao, *J. Shi;*
Department of Nuclear Medicine, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital; Henan Key Laboratory of Novel Molecular Probes and Clinical Translation in Nuclear Medicine, Zhengzhou, CHINA.

EP-191
Role of robot guided, PSMA targeted percutaneous trans-gluteal prostate gland biopsy
A. Nazar, *M. Ora, S. Surekha, P. Singh, L. M K, V. Saini, Y. Khandelwal, S. Barai, P. Pradhan, S. Gambhir;*
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-192
Utility of 18F-FDG AND 68Ga-PSMA PET/CT prior to 177Lu-PSMA radioligand therapy in metastatic castration resistant prostate cancer: A prospective study
A. S Babu, *J. Jaleel, D. Khan, M. P. Yadav, S. Ballal, M. Tripathi, S. Sagar, R. V, R. K. Sahoo, C. S. Bal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-193
An International Survey On The Status Of Prostate Cancer Theranostics: Radiotracer Utilisation, Growth Predictions And Key Challenges
T. Beyer[1], *L. Freudenberg*[2], *J. Czernin*[3], *F. Giesel*[4], *M. Hacker*[1], *M. Hofman*[5], *B. Krause*[6], *R. Hicks*[7];
[1]*Med Uni Vienna, Vienna, AUSTRIA,* [2]*ZRN, Grevenbroich, GERMANY,* [3]*UCLA, Los Angeles, CA, UNITED STATES OF AMERICA,* [4]*Uni Düsseldorf, Düsseldorf, GERMANY,* [5]*PeterMac, Melbourne, AUSTRALIA,* [6]*Uni Rostock, Rostock, GERMANY,* [7]*St Vincents Hospital, Melbourne, AUSTRALIA.*

EP-194
Optimisation of Ga-68 PSMA imaging on a Siemens Biograph VISION PET/CT Scanner
C. Keele[1], *H. Tam*[1], *K. Wallitt*[1], *A. Eccles*[1], *T. Barwick*[1,2], *C. Bowen*[1];
[1]*Imperial College Healthcare NHS Trust, London, UNITED KINGDOM,* [2]*Department of Surgery and Cancer, Imperial College, London, UNITED KINGDOM.*

EP-195
Simplified Semi-Quantification of [^{18}F]PSMA-1007 Uptake in Treatment-Naïve Primary Prostate Cancer
N. Ahmadi Bidakhvidi[1,2], *M. Koole*[2], *W. Everaerts*[3], *S. Joniau*[3], *C. M. Deroose*[1,2], *K. Goffin*[1,2];
[1]*Nuclear Medicine, University Hospitals Leuven, Leuven, BELGIUM,* [2]*Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, BELGIUM,* [3]*Urology, University Hospitals Leuven; Urogenital, Abdominal and Plastic Surgery, Department of Development and Regeneration, KU Leuven, Leuven, BELGIUM.*

EP-196
The Pre-Therapeutic introduction of n.c.a. ^{177}Lu-PSMA I&T ("LuteScan") as a SPECT compatible radioligand for Imaging of Metastatic Prostate Cancer Patients
G. Limouris[1,2], *M. B. Dolgushin*[3], *V. Krylov*[4], *M. I. Paphiti*[5], *A. Manetou*[6], *V. R. McCready*[7], *A. G. Zafeirakis*[2];
[1]*Nuclear Medicine, Medical School, National and Kapodistrian University of Athens, Athens, GREECE,* [2]*Nucl Med Dept, Army Share Fund Hospital of Athens, Athens, GREECE,* [3]*Radiology Dept, FTsMN Federal State Institute, Federal Med Biol Agency, Moscow, RUSSIAN FEDERATION,* [4]*Nuclear Medicine Department "Anatoly Tsyb" Research Center, Obninsk, RUSSIAN FEDERATION,* [5]*Nucl Med Dept, National Health System, Athens, GREECE,* [6]*Nuclear Medicine Dept, Army Share Fund Hospital of Athens, Athens, GREECE,* [7]*Institute Cancer Research, Sutton Surrey and Royal Sussex County Hospital, Brighton, UNITED KINGDOM.*

EP-197
Diagnostic Performance of 18F-PSMA-1007 PET/CT in the Diagnosis and Follow-up of Patients with Prostate Cancer: Experience in CUDIM-Uruguay
G. dos Santos[1,2], *D. Gutierrez*[1], *O. Alonso*[1,2], *P. Duarte*[2], *J. Gambini*[2,1];
[1]*Hospital de Clinicas, Montevideo, URUGUAY,*
[2]*CUDIM, Montevideo, URUGUAY.*

EP-198
^{68}Ga-PSMA PET/CT scan in patients with high-risk prostate cancer (PC) with ISUP grade 5
M. Dyankova[1,2], *Z. Dancheva*[1], *T. Stoeva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *B. Chaushev*[1], *A. Klisarova*[1];
[1]*St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA,* [2]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Varna, BULGARIA.*

EP-199
Prognostic significance of semi-quantitative ^{18}F-PSMA-1007 PET/CT parameters in mCRPC patients before ^{177}Lu-PSMA-617 therapy
M. Cuzzocrea[1], *G. Paone*[1], *G. Treglia*[1,2,3], *T. Ruberto*[1], *M. Raditchkova*[1], *L. Ceriani*[1,2], *L. Giovanella*[1,4];
[1]*Clinic for Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND,* [2]*Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, SWITZERLAND,* [3]*Academic Education, Research and Innovation Area, General Directorate, Ente Ospedaliero Cantonale, Bellinzona, SWITZERLAND,* [4]*Thyroid Centre–Clinic for Nuclear Medicine, University Hospital and University of Zürich, Zürich, SWITZERLAND.*

EP-200
Comparison of biodistribution of ^{18}F-PSMA-1007 and ^{68}Ga-PSMA-11 in prostate carcinoma patients
N. Rana, *K. Tanwar, H. Singh, B. R. Mittal;*
Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA.

EP-16

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B19 Thyroid

EP-201
Head to Head Comparison of [^{68}Ga]Ga-FAPI-04 and [^{68}Ga]Ga-DOTATATE PET/CT in Patients With Recurrence Medullary Thyroid Carcinoma
E. Isik, *C. Civan, D. Has Simsek, Z. G. Özkan, N. Gül, S. M. Ertürk, Y. Sanli, S. Kuyumcu;*
Istanbul University Istanbul Faculty of Medicine Nuclear Medicine Department, Istanbul, TÜRKIYE.

EP-202
Prostate-Specific Membrane Antigen (PSMA)-Expression in Poorly Differntiated and Anaplastic Thyroid Cancer - a new theranostic option?
F. Eilsberger[1], *P. Di Fazio*[2], *E. Maurer*[2], *J. Manoharan*[2], *C. Keber*[3], *A. Pfestroff*[1], *D. Librizzi*[1], *D. K. Bartsch*[2], *M. Luster*[1], *S. Wächter*[2];
[1]*Philipps University, Department of Nuclear Medicine, University Hospital Marburg, Marburg, GERMANY,* [2]*Philipps University, Department of Visceral, Thoracic and Vascular Surgery, University Hospital Marburg, Marburg, GERMANY,* [3]*Philipps University, Department of Pathology, University Hospital Marburg, Marburg, GERMANY.*

EP-203
^{131}I-SPECT/CT usefulness in patients with Hashimoto's thyroiditis (HT) coexistence with papillary thyroid carcinoma (PC) without risk factors at surgery followed in a long-term follow-up after thyroidectomy and radioiodine ablation
A. Marongiu, *S. Nuvoli, P. Solinas, M. Rondini, A. Papaleo, A. Spanu, G. Madeddu;*
Unit of Nuclear Medicine, University of Sassari, Sassari, ITALY.

EP-203a
Establishment of PET/MRI "Dual threshold" quantitative diagnostic criteria for identifying lymph node metastasis in patients with papillary thyroid carcinoma
T. Han[1], *Z. Quan*[1], *H. Wei*[2], *X. Zhao*[1], *M. Wang*[1], *X. Meng*[1], *J. Wang*[1], *G. Li*[1], *J. Wang*[1], *F. Kang*[1];
[1]*Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road, Xi'an, CHINA,* [2]*Department of Thyroid and Breast Surgery, Xijing Hospital, Fourth Military Medical University, No.127 West Changle Road, Xi'an, CHINA.*

EP-204
The Effect of Sodium Iodine Symporter Protein on Ablation Success in Patients With Differentiated Thyroid Cancer
G. Mutevelizade[1], *N. E. Kocer*[2], *M. Reyhan*[3];
[1]*Department of Nuclear Medicine, School of Medicine, Celal Bayar University, Manisa, TÜRKIYE,* [2]*Department of Pathology, Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University, Adana, TÜRKIYE,* [3]*Department of Nuclear Medicine, Faculty of Medicine, Adana Dr. Turgut Noyan Research and Treatment Center, Baskent University, Adana, TÜRKIYE.*

EP-205
Diagnostic Performance of FDG-PET/CT in Anaplastic Thyroid Carcinoma Staging
I. Vitorino, *I. Patrocínio-Carvalho, T. Nunes da Silva, T. Cruz Ferreira, R. Sousa, D. Fraga, D. Rombo, E. Sousa, V. Leite, L. Salgado;*
Instituto Português de Oncologia Lisboa Francisco Gentil, Lisbon, PORTUGAL.

EP-206
Quantification of thyroid remnant in thyroid cancer with ^{131}I-NaI SPECT/CT
W. Zeng, *O. Bhanushali, N. Su, R. A. Aghdam;*
The Ottawa Hospital, Ottawa, ON, CANADA.

EP-207
I-131 accumulation in the digestive system: Results on the Differentiated Thyroid Cancer Population treated in our hospital the last 9 years
T. Karianos, *K. Kouvelis, C. Altani, E. Taktikou, M. Bella, S. Giannakopoulos, V. Kouridou, S. Saranti;*
"Saints Anargyroi" Cancer Hospital, Athens, GREECE.

EP-208
Thyroid cancer recurrence risk in Grave´s disease and other causes of hyperthiroidism
A. Leiva Montejo, *I. Ros Madrid, A. S. De Agrela Serrao, R. Cáceres Silva, C. Ruiz Corbalan, T. Moreno Monsalve, M. I. Castellón Sánchez, A. C. Hernández Martinez, J. Contreras Gutierrez, L. Frutos Esteban, J. L. Navarro Fernandez, L. Mohammed Salem, T. Rodriguez Lorcano;*
Hospital Virgen de la Arrixaca, Murcia, SPAIN.

EP-209
Significance of 99mTc-sestamibi SPECT parameters in thyroid nodules
D. Dezso[1], *K. Zámbó*[1], *Z. Ritter*[1], *Z. Bán*[1], *Z. Szabó*[1], *A. Szommer*[1], *E. Mezősi*[2], *L. Bajnok*[2], *E. Schmidt*[1];
[1]*University of Pécs, Medical School, Department of Medical Imaging Diagnostic, Division of Nuclear Medicine, Pécs, HUNGARY,* [2]*University of Pécs, Medical School, 1st Department of Medicine, Pécs, HUNGARY.*

EP-210
Follow-up strategy in differentiated thyroid carcinoma with incomplete biochemical response
J. Vallejo Casas, *C. Paz Lovera, M. Guiote Moreno, S. Castejón Echevarne, Á. López Cano, E. Zurera Pareja;*
Hospital Universitario Reina Sofía. IMIBIC., Córdoba, SPAIN.

EP-211
Association of Neck Ultrasound and I-131 and Whole body Scintigraphy among Adult Patients with Well-differentiated Thyroid Carcinoma and Loco-regional Lymph Node Metastasis after Total Thyroidectomy and Radioactive Iodine Ablation
I. Bandong, *N. F. Guevara, J. C. Muya;*
St. Luke's Medical Center-Quezon City, Quezon City, PHILIPPINES.

EP-212
Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine 131 in patients with intermediate risk differentiated thyroid cancer
A. Aghaee, *S. Zakavi, N. Ayati, S. Shafiei;*
Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-213
Early FDG PET-CT in staging of thyroid carcinoma of follicular origin in Balearic Islands
A. Repetto[1], *B. Luna*[1], *C. Medina*[1], *N. Orta*[1,2], *L. Nieto*[1], *C. Sampol*[1,3], *S. Rubi*[1,2], *M. Gimenez*[1], *C. Peña*[1,2];
[1]*Nuclear Medicine Department, Hospital Universitario Son Espases, Palma De Mallorca, SPAIN,* [2]*IdISBa, Palma de Mallorca, SPAIN,* [3]*IdISBa, Palma de MAllorca, SPAIN.*

EP-17

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B20 Gynaecological

EP-214
[18F]-FDG PET-CT before and after treatment can predict survival in cervical cancer
M. Markus[1], *H. Sartor*[2], *M. Bjurberg*[3], *E. Trägårdh*[1];
[1]*Department of Clinical Physiology and Nuclear Medicine, Lund University and Skåne University Hosptial, Wallenberg Centre for Molecular Medicine, Lund University, Lund, Malmö, SWEDEN,* [2]*Diagnostic Radiology, Department of Translational Medicine, Lund University, Malmö, SWEDEN,* [3]*Department of Oncology, Lund University and Skåne University Hospital, Lund, SWEDEN.*

EP-215
[18F] FDG PET/CT Derived Metabolic and Volumetric Biomarkers Can Predict Response to Treatment in Locally Advanced Cervical Cancer Patients
R. Gill[1], *R. Abdah-Bortnyak*[1,2], *A. Amit*[1,2], *U. Bar-Peled*[2], *Z. Keidar*[1,2];
[1]*Rambam health Care Campus, Haifa, ISRAEL,* [2]*Technion - Israel Institute of Technology, Haifa, ISRAEL.*

EP-216
Survival Prediction Using ^{18}F-FDG PET-CT Based Parameters in Recurrent Ovarian Cancer
B. Jain, *M. Ora, P. Singh, Y. Khandelwal, N. Rastogi, P. Lal, S. Gambhir;*
Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, INDIA.

EP-217
Cooccurrence of Perihepatic Lesions along with Peritoneal Carcinomatosis and Hematogenous Metastases in Ovarian Cancer Patients on FDG PET/CT Studies
K. Unal[1], *A. Guner*[2], *E. Vardareli*[3];
[1]*Acibadem Atakent Hospital, Istanbul, TÜRKIYE,* [2]*Acibadem Maslak Hospital, Istanbul, TÜRKIYE,* [3]*Acibadem Altunizade Hospital, Istanbul, TÜRKIYE.*

EP-218
Diagnostic Role Of ^{18}FDG PET/CT In Recurrent Cervical Cancer After Radiotherapy: Comparison With MRI
M. Stojiljkovic[1,2], *S. Odalovic*[1,2], *J. Petrovic*[1,2], *M. Popovic*[3], *D. Sobic Saranovic*[1,2], *V. Artiko*[1,2];
[1]*Centre for Nuclear Medicine with PET, University Clinical Centre of Serbia, Belgrade, SERBIA,* [2]*Faculty of Medicine, University of Belgrade, Belgrade, SERBIA,* [3]*Institute for Oncology and Radiology of Serbia, Belgrade, SERBIA.*

EP-219
Impact of metabolic parameters on [F-18] FDG PET/CT for patients with epithelial ovarian cancer undergoing neoadjuvant chemotherapy
A. Palomar-Muñoz[1], *B. Pardo-Burdalo*[2], *M. D. Marti-Cardona*[3], *G. Reynes-Llompart*[4], *J. Suils-Ramón*[1], *C. V. Martínez-Ramos*[1], *S. Bondía-Bescos*[5], *J. J. Robles-Barba*[1], *P. C. Notta*[1], *L. M. Gràcia-Sánchez*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine-PET (IDI) Department, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN,* [2]*Medical Oncology Department, Institut Catala Oncologia - Hospital Duran i Reynals, L'Hospitalet de Llobregat (Barcelona), SPAIN,* [3]*Gynecology and Obstetrics Department, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat (Barcelona), SPAIN,* [4]*Medical Physics Department, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN,* [5]*Nuclear Medicine-PET (IDI) Department, Hospital Universitario de Bellvitge, L'Hospitalet de Llobregat (Barcelona), SPAIN.*

EP-220
Prognostic significance of 18F-FDG PET-CT in Gynecological Cancer
P. Spiridon, *A. Gherman, C. Mazilu, D. Cuzino, C. Calin, F. Ionita Radu, M. Jinga, R. Mititelu;*
Central Universitary Emergency Military Hospital, Bucharest, ROMANIA.

EP-221
Clinical impact of PET/CT in paraaortic staging in patients with locally advanced cervical cancer
Y. Abadi Sedraoui, *M. Coronado Poggio, C. Lancha Hernández, J. Cordero García, C. Escabias Del Pozo, S. Rodado Marina, S. Rizkallal Monzón, D. Travaglio Morales, E. López Llobet, L. Giraldo González, L. Domínguez Gadea;*
Hospital Universitario La Paz, Madrid, SPAIN.

EP-222
Quantitative metabolic parameters of ^{18}F-FDG PET/CT as predictors of complete cytoreduction in patients with epithelial ovarian cancer
L. Sancho Rodriguez, *F. Boria Alegre, L. Sanchez Lorenzo, V. Betech-Antar, L. Garcia Belaustegui, E. F. Guillen Valderrama, A. Bronte Viedma, A. Gonzalez Martin, A. Alcazar Peral, G. Gallardo Madueño, L. Chiva De Agustin, M. J. Garcia-Velloso;*
Clinica Universidad de Navarra, Madrid, SPAIN.

EP-224
The prognostic role of baseline ^{18}F-FDG PET/CT in peripheral T-cell lymphoma
T. Czékus[1], *Z. Besenyi*[1], *L. Pávics*[1], *R. Német*[1], *I. Farkas*[1], *G. Sipka*[1], *Z. Mikó*[1], *S. Nagy*[1], *K. Piukovics*[2], *A. Bakos*[1];
[1]*Department of Nuclear Medicine, University of Szeged, Szeged, HUNGARY,* [2]*Department of Internal Medicine University of Szeged, Szeged, HUNGARY.*

EP-225
The role of 18F-FDG PET/CT biomarkers in the prognosis of patients with diffuse large B-cell lymphoma treated with Chimeric Antigen Receptor T Cell Therapy , our experience
J. Cañadas Salazar, *A. Martin Lopez, L. Diaz Gonzalez, A. Martin Garcia-Sancho, A. Peñaherrera Cepeda, J. G. Villanueva Curto, F. Gomez Caminero Lopez, P. Tamayo Alonso;*
Sacyl, Salamanca, SPAIN.

EP-226
Artificial intelligence increases agreement among physicians quantifying metabolic tumour burden in Hodgkin´s lymphoma patients staged with [^{18}F]FDG PET/CT
M. Sadik[1], *S. Barrington*[2], *J. Ulén*[3], *O. Enqvist*[4,3], *E. Trägårdh*[5], *B. Saboury*[6], *A. Lerberg Nielsen*[7], *A. Loft Jakobsen*[8], *J. Loaiza Gongora*[9], *J. López-Urdaneta*[1], *R. Kumar*[10], *L. Edenbrandt*[1];
[1]*Medicine, Gothenburg, SWEDEN,* [2]*Clinical PET Centre, London, UNITED KINGDOM,* [3]*Eigenvision AB, Malmö, SWEDEN,* [4]*Electrical Engineering, Göteborg, SWEDEN,* [5]*Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN,* [6]*Radiology and Imaging Sciences, Bethesda, WA, UNITED STATES OF AMERICA,* [7]*Nuclear Medicine, Odense, DENMARK,* [8]*Clinical Physiology, Copenhagen, DENMARK,* [9]*Diagnostic Imaging, Oslo, NORWAY,* [10]*Nuclear Medicine, Chandigarh, INDIA.*

EP-227
Bone marrow assessment in Hodgking and Non-Hodgkin lymphomas with^{18}F-FDG PET/CT imaging, how confident can we be?
A. Laverde Mächler, *C. Vigil Diaz, J. Maraña González, L. Rodríguez Díaz, S. Naranjo Sancho, M. Dominguez Grande, N. Martín Fernández, J. Suárez Fernández, M. Fernández Llana, A. Álvarez Blanco, M. García Lucero, N. Zeidán Ramón, M. López Carballo, A. Álvarez Alonso, F. González García;*
HUCA, Oviedo, SPAIN.

EP-18

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B21 Lymphoma

EP-223
Diffuse splenic 18F-FDG uptake and peripheral blood lymphocyte monocyte ratio for prognosis prediction in patients with diffuse large B-cell lymphoma
K. Kim[1], *S. Kim*[1], *S. Kim*[2];
[1]*Pusan National university, Busan, KOREA, REPUBLIC OF,* [2]*Kyungpook National University, Busan, KOREA, REPUBLIC OF.*

EP-19

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B23 Bone and Soft Tissues

EP-228
Diagnostic performance and therapeutic impact of 18F-FDG PET/MRI in monoclonal gammopathy of uncertain significance (MGUS)
J. Garcia, *A. Compte, J. Romero, E. Valls, S. Mourelo, M. Kauak, M. Soler, T. Blanch, E. Riera;*
CETIR ASCIRES Grupo biomédico, Barcelona, SPAIN.

EP-229
Metabolic Tumour Volume Improves the Prognostic Value of Pre-existing Scoring Models in Sarcoma
M. Pedersen[1,2,3], *T. Baad-Hansen*[4], *L. Gormsen*[1], *B. Sandfeld-Paulsen*[5], *N. Aggerholm Pedersen*[6], *M. Holm Vendelbo*[1,2,3];
[1]*Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK,* [2]*Institute of Biomedicine, Aarhus University, Aarhus, DENMARK,* [3]*Steno Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, DENMARK,* [4]*Department of Orthopedics, Aarhus University Hospital, Aarhus, DENMARK,* [5]*Department of Clinical Biochemistry, Viborg Regional Hospital, Viborg, DENMARK,* [6]*Department of Oncology, Aarhus University Hospital, Aarhus, DENMARK.*

EP-230
Accuracy verification of Z-score calculation software for bone metastasis diagnosis in bone SPECT/CT
Y. Yakushiji[1], *K. Miwa*[2], *S. Fukuda*[1], *K. Kurosu*[3], *T. Yamao*[2], *N. Miyaji*[4], *K. Wagatsuma*[1,5], *N. Nishikawa*[6], *T. Hasegawa*[1];
[1]*Kitasato University Graduate School of Medical Sciences, Kanagawa, JAPAN,* [2]*Fukushima Medical University, Fukushima, JAPAN,* [3]*Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, JAPAN,* [4]*Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN,* [5]*Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN,* [6]*International of University of Health and Welfare, Tochigi, JAPAN.*

EP-231
Scintigraphic diagnosis of myelolipomas
M. Navas de la Cruz, *P. Abreu, T. Mut, Á. Esteban, Á. Badenes, C. Siscar, E. Caballero, I. Latorre;*
Hospital Universitario Dr. Peset, Valencia, SPAIN.

EP-232
^{99m}Tc-MDP SPECT/CT for the characterization of enostosis
R. Ferrando[1,2], *A. Damian*[1,2], *D. Gutierrez*[1], *J. Naula*[1], *L. Gutierrez*[1], *E. Lischinsky*[1], *F. Carrera*[1], *M. Villavicencio*[1], *K. Bayardo*[1], *O. Alonso*[1,2];
[1]*University of the Republic, Montevideo, URUGUAY,* [2]*Centro Uruguayo de Imagenología Molecular - CUDIM, Montevideo, URUGUAY.*

EP-233
Feasibility and toxicity study of intra-articular Re-188 Colloid injection in patients with rheumatoid arthritis with three phase positive bone scan and refractory knee joint pain
A. Aghaee[1], *Z. Mirfeizi*[2], *N. Noroozbeigi*[1], *S. Zakavi*[1];
[1]*Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EP-234
Evaluation of vertebral destruction with SPECT/CT ^{99m}Tc-MIBI
D. Arguelles[1,2], *F. Lemus Ramírez*[1,2], *J. Dominguez*[3], *K. Vite Pineda*[4];
[1]*Instituto Nacional de Rehablitación, Mexico, MEXICO,* [2]*Instituto Nacional de Cancerología, Ciudad de México, MEXICO,* [3]*Dr. Otto Rodriguez Polyclinic II, San Pedro, BELIZE,* [4]*HGZ 35 Instituto Mexicano del Seguro Social, Ciudad Juárez, MEXICO.*

EP-235
PET/CT versus SPECT/CT and Planar Bone Scintigraphy in Characterization of Suspicious Osseous Lesions in cancer patients
N. Bashank, *A. W. Hussein, M. Mekkawy, H. Askar;*
Assuit University Hospitals, Assuit, EGYPT.

EP-236
Pitfalls in dual tracer uptake of ^{68}Ga-FAPI-46 and ^{18}F-FDG PET/CT in Ewing sarcoma
H. Dadgar;
Research Center, Imam Reza University, Razavi Nuclear Medicine and Molecular imaging, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-237
Evaluation of distribution of skeletal metastasis in lung cancer
N. Manevska[1], *D. Todorova Stefanovski*[2], *A. Tatabitovska*[3], *A. Jankulovska*[1], *T. Makazlieva*[1], *S. Stojanoski*[1];
[1]*Medical Faculty, Skopje, NORTH MACEDONIA,* [2]*University Institute for Positron Emission Tomography, Skopje, NORTH MACEDONIA,* [3]*University Clinic of Pulmonology and Allergy, Skopje, NORTH MACEDONIA.*

EP-20

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B24 Melanoma

EP-238
Response assessment in metastatic melanoma patients under immunotherapy: Comparison between metabolic and radiological response criteria
N. Testart Dardel, *B. Gautron Moura, E. Isenborghs, M. Nicod Lalonde, S. Latifyan, K. Homicsko, N. Schaefer, C. Dromain, O. Michielin, J. Prior;*
CHUV, Lausanne, SWITZERLAND.

EP-239
Whole-body FDG PET uptake decision support system for the identification of metastatic melanoma metastases
L. Pan[1], *T. Vagenas*[2], *C. Sachpekidis*[1], *T. Economopoulos*[2], *A. Dimitrakopoulou-Strauss*[1], *A. Provata*[3], *G. Matsopoulos*[2];
[1]*German Cancer Research Center, Heidelberg, GERMANY,* [2]*National Technical University of Athens, Athens, GREECE,* [3]*National Center for Scientific Research "Demokritos", Athens, GREECE.*

EP-21

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B25 Any Other Malignant (including Primary of Unknown Origin)

EP-240
Correlation of 18F-FDG PET/CT and increase of serum tumour markers in the diagnosis of relapse or metastatic progression disease in tumour histotypes outside the current recommendations Correlation of 18F-FDG PET/CT and increase of serum tumour markers in the diagnosis of relapse or metastatic progression disease in tumour histotypes outside the current recommendations
*H. Castagnoli, **G. Follacchio**, F. Chiumiento, F. Capoccetti;*
Ospedale di Macerata, ASUR Marche AV3, Macerata, ITALY.

EP-241
Potential role of 18F-FDG PET/CT in Erdheim Chester Disease
***S. Sagar**, D. Khan, A. P. S L, J. Pathak, A. S. Babu, S. A. Shamim, R. Kumar;*
AIIMS, Delhi, INDIA.

EP-242
The role of ^{18}F-FDG PET/CT on Characterization of Thymic Epithelial Tumors at Initial Stage
***C. Civan**[1], Z. Ozkan[1], B. Ozkan[2], E. Isik[1], E. Erdogdu[2], D. Has Simsek[1], S. Duman[2], Y. Sanli[1], M. Kara[2], S. Kuyumcu[1], A. Toker[2];*
[1]Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE, [2]Istanbul Faculty of Medicine, Department of Thoracic Surgery, Istanbul, TÜRKIYE.

EP-243
The Source Of Cancer Of Unknown Primary Is More Likely To Be Detected By FDG PET/ CT When Presented With Cervical LN Metastasis
***G. Al-Obthani**;*
Hadhramout University, Mukalla, YEMEN.

EP-244
Non-malignant FAPI-avid PET/CT Findings: A Review
***M. Bentestuen**, N. Al-Oybadi, H. D. Zacho;*
Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK.

EP-245
PET/CT in Patients with Cancer of Unknown Primary-Preliminary Results: Characterization of FDG PET/CT Findings in Occult Lung Cancer and Relation of Results with Pathological Diagnosis and Survival
***A. Aslan**, U. Korkmaz, S. Soyluoglu, G. Durmus Altun;*
Trakya University, Edirne, TÜRKIYE.

EP-246
The role of 18F-FDG PET/CT in primary staging and follow-up of Squamous Cell Carcinoma in patients with Dystrophic Epidermolysis Bullosa
***E. López Llobet**, S. Rodado Marina, D. Travaglio Morales, Y. Abadi Sedraoui, L. Giraldo González, S. Rizkallal Monzón, J. Cordero García, C. Lancha Hérnandez, C. Escabias del Pozo, M. Coronado Poggio, R. De Lucas Laguna, L. Domínguez Gadea;*
Hospital Universitario La Paz, Madrid, SPAIN.

EP-247
IGG4 related diseases: Utility of 18-F-FDG PET/CT
***S. Sagar**, D. Khan, A. Mahalik, A. K. Majeed, S. K. Velliangiri, J. Pathak, S. A. Shamim, R. Kumar;*
AIIMS, Delhi, INDIA.

EP-248
Role of ^{18}F-FDG PET/CT in the diagnosis of benign vs. malignant tumor thrombus: a retrospective study
***S. Sarswat**, S. Sagar, D. Khan, S. A. Shamim, N. A. Damle, M. Tripathi, C. Bal, A. Sharma, N. Wig, R. Kumar;*
All India Institute of Medical Sciences Delhi, Delhi, INDIA.

EP-22

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B31 Radioguided Surgery and Radiation Therapy Planning

EP-249
Evaluation of the Targeted Axillary Dissection(TAD) technique in Axillary Node-Positive Breast Cancer Patients Treated with Neoadyuvant Chemotherapy(NAC)
***M. Camacho Falcon**, P. De La Riva Pérez, T. Cambil Molina, I. Marín Melero, J. Velez Medina, I. Bolívar Roldán, M. Calvo Morón;*
Hospital Universitario Virgen Macarena, Sevilla, SPAIN.

EP-250
PSMA Radio-Guided Lymph Node Dissection with β-Probe, in high-risk Prostate Cancer patients
***L. Muraglia**, P. Artioli, F. Mattana, G. Renne, S. Luzzago, G. Musi, F. Ceci;*
IEO Istituto Europeo di Oncologia, Milan, ITALY.

EP-251
Radioguided surgery of pulmonary nodules with ROLL technique. Our experience.
***F. Manchon Adsuar**, V. Lopez Prior, R. Diaz Exposito;*
Fundacion Instituto Valenciano De Oncologia, Valencia, SPAIN.

EP-23

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B3 Other Oncological Clinical Study -> B32 Sentinel Node

EP-252
Evaluation of the reproducibility of the sentinel lymph node study in breast cancer, melanoma and cervical cancer
***K. Bayardo**, A. Zamora, J. Naula, F. Carrera, F. Portugal, O. Alonso, R. Ferrando;*
University of the Republic, Montevideo, URUGUAY.

EP-253
Sentinel Lymph Node Biopsy in patients with prior ipsilateral breast cancer surgery
***R. Staff**[1], M. F. Macnab[1], G. Slater[2], L. Lovell[1], M. Fuller[1,2], B. Elsberger[1,2], Y. Masannat[1,2];*
[1]Aberdeen Royal Infirmary, Aberdeen, UNITED KINGDOM, [2]The School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UNITED KINGDOM.

EP-254
Sentinel lymph node biopsy and axillary marking in breast cancer patients undergoing neoadjuvant treatment: our experience
***P. Guardia Jimena**, A. Santos Bueno, A. Rebollo Aguirre, A. Moreno Ballesteros, J. Bayo Calero, A. Jimenez Heffernan;*
Hospital Universitario Juan Ramón Jiménez, Huelva, SPAIN.

EP-255
Follow-up after radical prostatectomy with sentinel node biopsy and pelvic lymph node dissection: oncological outcome and results of advanced imaging in patients with biochemical recurrence
***A. Berrens**[1], R. van Vliet[1,2], E. Wit[1], P. J. van Leeuwen[1], O. Brouwer[1], M. L. Donswijk[1], F. W. B. van Leeuwen[3], H. G. van der Poel[1,4];*
[1]Antoni van Leeuwenhoek Hospital, Amsterdam, NETHERLANDS, [2]University of Utrecht, Utrecht, NETHERLANDS, [3]Leiden University Medical Center, Leiden, NETHERLANDS, [4]Amsterdam University Medical Center (VUmc), Amsterdam, NETHERLANDS.

EP-256
Follow-up of patients with cN0 tongue cancer and negative selective sentinel lymph node biopsy
***S. Bondia Bescós**[1], J. Suils-Ramón[1], M. Bajén-Lázaro[1], A. Benítez-Segura[1], A. Rodriguez-Gasén[1], J. Reyes-Junca[1], I. Sanchez-Rodriguez[1], E. Llinares-Tello[1], C. Soldevila-Lozano[1], M. Pudis[1], B. Hervás-Sanz[1], I. Gil-Viciano[2], M. Buaki-Sogo[2], M. Cortés-Romera[1];*
[1]Nuclear Medicine-PET (IDI) Department, Bellvitge University Hospital, L'Hospitalet de Llobregat (Barcelona), SPAIN, [2]Radiopharmaceutical Department, Bellvitge University Hospital, L'Hospitalet de Llobregat (Barcelona), SPAIN.

EP-257
Using 99mTc-Tilmanocept for sentinel node detection in patients with cutaneous melanoma allows identification of sentinel lymph node despite prior non-visualisation with SPECT-CT using 99mTc-Nanocolloid
***J. Pedersen**, B. Zerahn;*
Herlev Hospital, Department of Nuclear medicine, Herlev, DENMARK.

EP-258
Results of Sentinel Lymph Node Biopsy in Endometrial Cancer. Experience in Our Centre
***S. Naranjo Sancho**, J. P. Suárez Fernández, M. L. Domínguez Grande, A. Laverde Mächler, J. E. Maraña González, L. Rodríguez Díaz, C. Vigil Díaz, S. Fidalgo García, N. Martín Fernández, F. M. González García;*
Hospital Universitario Central de Asturias, Oviedo, SPAIN.

EP-259
Can we rationalise where we use SPECT/CT for melanoma sentinel node localisation?
***K. Pinto**, M. Naik, C. Ferguson, P. Khagram, W. Svensson, N. Soneji;*
Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EP-260
Unicentric results in sentinel lymph node biopsy (SLNB) in patients with locally advanced breast cancer (LABC)
***J. Espejo Niño**, M. Astudillo Sarmiento, R. Valverde Jorge, A. Peña Fuentes, E. Rodeño Ortiz de Zarate;*
Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-261
Sentinel Node Mapping in Vulvar Melanoma: a multicentre study
***A. Florit**[1], V. Fuoco[2], S. M. Fragomeni[3], T. Pasciuto[3], F. Martinelli[2], F. Raspagliesi[2], V. Rufini[1,3], G. Garganese[1,4], M. Maccauro[2], A. Collarino[3];*
[1]Università Cattolica del Sacro Cuore, Rome, ITALY, [2]Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, ITALY, [3]Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY, [4]Mater Olbia Hospital, Olbia, ITALY.

EP-262
Analysis of factors affecting sentinel lymph node metastatic involvement in endometrial carcinoma
***A. Jankulovska**[1], S. Stojanoski[1], I. Aluloski[2], S. Stojcevski[2], M. Tanturovski[2], A. Daneva Markova[2], N. Manevska[1], T. Makazlieva[1], M. Jovanovski-Srceva[3], D. Miladinova[1];*
[1]Institute of pathophysiology and nuclear medicine "Acad. Isak Tadzer", Faculty of Medicine, Skopje, NORTH MACEDONIA, [2]University Clinic of Gynecology and Obstetrics, Faculty of Medicine, Skopje, NORTH MACEDONIA, [3]University Clinic for Anesthesia, Reanimation and Intensive Care, Faculty of Medicine, Skopje, NORTH MACEDONIA.

EP-263
Sentinel lymph node biopsy in patients with recurrent breast cancer and previous negative sentiel lymph node biopsy: our experience
***J. Reyes**[1], M. Bajén Lázaro[2], A. Benítez-Segura[2], B. Hervás Sanz[2], C. Soldevila Lozano[2], M. Pudis[2], S. Bondia[1], J. Suils Ramon[2], J. Mora Salvado[2], A. Valdivieso Ortiz[3], L. Perez Tapia[3], M. Vicente[3], M. Pla Farnos[4], A. García Tejedor[4], M. Campos Delgado[4], M. Fernandez Montoli[4], A. Petit[5], S. Pernas[6], F. Catalina[6], E. Martínez Pérez[7], H. Pérez Montero[7], A. López Ojeda[8], D. Pérez Sidelnikova[8], S. De la Torre González[8], M. Cortés Romera[2];*
[1]Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, [2]Nuclear Medicine_Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, [3]Radiologist_ Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, [4]Gynecologist_Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, [5]Patologyst_Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, [6]Medical Oncologist_Institut Català Oncologia_Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, [7]Radiation Oncologist_Institut Català Oncologia_Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN, [8]Plastic Surgery_Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, SPAIN.

EP-264
Selective sentinel lymph node biopsy as a prognostic method in cutaneous malignant melanoma. Our experience.
***E. Noriega-Álvarez**, A. M. García Vicente, F. J. Pena Pardo, L. García Zoghby, C. Lucas Lucas, A. Padilla Bermejo, N. M. Sicilia Pozo, Á. M. Soriano Castrejón;*
University General Hospital of Ciudad Real, Ciudad Real, SPAIN.

EP-24

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B41 Perfusion

EP-265
Improvement of the detectability of perfusable tissue fraction and myocardial flow reserve after revascularization by ^{15}O-water ECG-gated PET
A. Maruo;
Hokkaido University, Sapporo, JAPAN.

EP-265a
Evaluation of the Left Ventricular Segmentation Algorithm Using B-Spline Explicit Active Surface Model in Myocardial Perfusion SPECT Images in the Presence of Perfusion Defect
M. Ariaei[1], *N. Shahamiri*[2], *M. Yazdi*[1], *M. Haghighatafshar*[3], *T. Ghaedian*[4], *M. Entezarmahdi*[5];
[1]*School of Electrical and Computer Engineering, Shiraz University, Shiraz, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Computer Science and Engineering and IT, Shiraz University, Shiraz, IRAN, ISLAMIC REPUBLIC OF,* [3]*Associate professor of nuclear medicine, Nuclear Medicine and Molecular Imaging Research Center, Shiraz University of medical Science, Shiraz, IRAN, ISLAMIC REPUBLIC OF,* [4]*Department of nuclear medicine and molecular imaging, shiraz university of medical sciences, Shiraz, IRAN, ISLAMIC REPUBLIC OF,* [5]*Nuclear Engineering Department, Shiraz University/ Division of Nuclear Medicine, Namazi Hospital, Shiraz University of Medical Science, Shiraz, IRAN, ISLAMIC REPUBLIC OF.*

EP-266
The Prediction of Cardiac Events in Patients with Diabetes Mellitus Type 2 Using ^{99m}Tc-sestamibi Myocardial Perfusion Imaging: a Single Centre Study
S. Stankovic[1,2], *V. Soldat-Stankovic*[1,2], *Z. Rajkovaca*[1,2];
[1]*University Clinical Centre Banja Luka, Banja Luka, BOSNIA AND HERZEGOVINA,* [2]*University of Banja Luka, Faculty of Medicine, Banja Luka, BOSNIA AND HERZEGOVINA.*

EP-267
Gender discrepancies in myocardial perfusion scintigraphy: CVD risk factors' assessment study
V. Laskov, *O. Lang;*
Third Faculty of Medicine, Charles University, Prague, CZECH REPUBLIC.

EP-268
Risk factors for silent coronary heart disease: value of myocardial perfusion scintigraphy
F. Ben Amar[1], *W. El Ajmi*[2], *M. Ben Nasr*[2], *A. Sellem*[2], *H. Hammami*[2];
[1]*Hôpital militaire principal d'instruction de Tunis, Tunis, TUNISIA,* [2]*Nuclear Medicine Department Of The Main Military Instruction Hospital In Tunis, Tunis, TUNISIA.*

EP-269
Regadenoson vs Adenosine : Evaluation of Heart Rate Response with During Myocardial Perfusion Test with Pharmacologic Stress
G. Sabatel Hernández, *I. Bolivar Roldán, M. Camacho Falcón, P. De La Riva Pérez, C. Calvo Morón;*
Hospital Universitario Virgen Macarena, Sevilla, SPAIN.

EP-270
Workload ≥7 METS during dynamic exercise testing in patients with normal gated myocardial perfusion imaging is a good prognostic indicator
N. Fatima[1,2], *S. Zaman*[3], *A. Zaman*[4], *U. Zaman*[4], *M. Zaman*[1,2];
[1]*Aga Khan University, Karachi, PAKISTAN,* [2]*Dept of Nuclear Cardiology, KIHD, Karachi, PAKISTAN,* [3]*Dow Medical College, Dow University of Health Sciences (DUHS), Karachi, Pakistan, Karachi, PAKISTAN,* [4]*SUNNY Downstate Hospital, New York, NY, UNITED STATES OF AMERICA.*

EP-271
The Influence Of Low- Dose CT Attenuation Correction On Artefacts Of Myocardial SPECT Images For Nuclear Medicine Studies
L. Nolan[1], *E. Seane*[2], *M. Du Toit*[1], *C. Lackay*[2], *M. Morkel*[3], *N. Korowlay*[1];
[1]*Tygerberg Hospital, Cape Town, SOUTH AFRICA,* [2]*Cape Peninsula University of Technology, Cape Town, SOUTH AFRICA,* [3]*Dr HR Morkel Inc. Panorama Medical Centre, Cape Town, SOUTH AFRICA.*

EP-272
Infarct size assessed by quantitative and qualitative analyses of myocardial perfusion associate with decreased left ventricular ejection fraction measured by SPECT and 3D echocardiography
A. Lopez-Mendez, *N. Espinola-Zavaleta, E. Aelxanderson-Rosas;*
Instituto Nacional de Cardiología, CDMX, MEXICO.

EP-273
Background of cardiac complaints after COVID-19 disease and COVID vaccination in the context of stress/rest myocardial scintigraphy
R. Jòba, *M. Moravszki, K. Buga;*
Military Hospital Medical Centre, Hungarian Defense Forces, Department of Nuclear Medicine, Budapest, HUNGARY.

EP-25

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B43 Heart Failure (including Sarcoidosis and Amyloidosis)

EP-274
Multidisciplinary approach for the early detection of amyloid in patients who undergo carpal tunnel syndrome or lumbar stenosis surgery. Preliminary results of an ongoing study
N. Orta[1], *T. Ripoll*[2], *S. Rubí*[1], *J. Pons*[1], *E. Fortuny*[1], *A. Massó*[3], *M. T. Bosch*[1], *I. Torralba*[3], *G. Salvà*[3], *N. Mora*[3], *S. Lirola*[3], *M. Méndez*[4], *J. Femenias*[3], *M. Llabrés*[3], *G. Ripoll*[3], *G. Wertheimer*[3], *B. Barceló*[1], *V. C. Daza*[1], *A. Pérez*[1], *D. Heine*[1], *V. E. Cano*[1], *A. Piñar*[3], *F. Vega*[3], *J. C. Berdeal*[3], *C. Peña*[1];
[1]*Hospital Universitari Son Espases/IdISBa, Palma, SPAIN,* [2]*Hospital Universitari Son Llàtzer/IdISBa, Palma, SPAIN,* [3]*Hospital Universitari Son Espases, Palma, SPAIN,* [4]*Hospital Sant Joan de Déu, Palma-Inca, SPAIN.*

EP-275
The Diagnostic And Prognostic Value Of Semiquantitative Evaluation In ^{99m}Tc-DPD And ^{99m}Tc-HMPD Bone Scintigraphy With SPECT/CT For TTR-Related Cardiac Amyloidosis
E. Califaretti, *R. Casoni, R. Passera, M. Finessi, A. Lesca, M. Bellò, D. Deandreis;*
Division of Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, ITALY.

EP-276
Amyloid Lumbar Assessment In Patients With Spinal Stenosis Due To Flavum Ligament Hypertrophy: A Pilot Study
A. Padilla Bermejo[1], *M. Negreira Caamaño*[2], *A. M. García Vicente*[1], *M. A. Ramírez Huaranga*[3], *D. Castro Corredor*[4], *Á. Plasencia Ezaine*[3], *P. Otero Fernández*[5], *J. Piqueras Flores*[2], *Á. Soriano Castrejón*[1];
[1]*Nuclear Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [2]*Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [3]*Pain Unit, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [4]*Rheumatology Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN,* [5]*Neurosurgery Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN.*

EP-277
^{99m}Tc-Pyrophosphate Scintigraphy for Cardiac Amyloidosis: Concordance of Planar and SPECT/CT Imaging
N. Coskun[1], *O. Kartal*[1], *S. Erdogan*[1], *E. Ozdemir*[1,2];
[1]*Ankara City Hospital, Ankara, TÜRKIYE,* [2]*Ankara Yildirim Beyazit University, Ankara, TÜRKIYE.*

EP-278
Evaluation of cardiac amyloidosis: genetic testing and work-up between nuclear medicine physicians and cardiologists
D. Grigolato, *S. Rossetto, M. Gabbani, N. Luca, G. Napoli, U. Tebano, G. Rinaldi, M. Muraro, D. Tonel, M. Coeli, G. Mon, A. De Lucchi, P. Guarise, F. Fiorica;*
Azienda Scaligera Verona, Legnago, ITALY.

EP-279
To investigate the use of Radiomic Texture Analysis Features in differentiating between Positive and Negative Cardiac Sarcoid 18-FDG PET/CT
M. Colombié[1], ***N. Forde***[1,2], *S. Cournane*[1,2], *S. Crilly*[1], *A. McCann*[1,2], *D. Murphy*[1,2];
[1]*St Vincent's University Hospital, Dublin, IRELAND,* [2]*University College Dublin, Dublin, IRELAND.*

EP-280
Transthyretin cardiac amyloidosis (ATTR-CA) by Cardiac Scintigraphy with 99mTc-diphosphonates (CS) and Cardiovascular Magnetic Resonance Imaging (CMRI)
M. Pudis[1], *S. Bondia-Bescos*[1], *B. Hervás-Sanz*[1], *P. C. Notta*[1], *I. E. Sánchez Rodríguez*[1], *A. Palomar-Muñoz*[1], *S. Yun*[2], *C. Díez-López*[3], *E. Claver-Garrido*[4], *M. Buaki-Sogo*[1], *L. M. Gràcia-Sánchez*[1], *M. Cortés-Romera*[1];
[1]*Nuclear Medicine - PET (IDI) Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [2]*Internal Medicine Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [3]*Cardiology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN,* [4]*Radiology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, Barcelona, SPAIN.*

EP-281
What is an additional value of SPECT technique in scintigraphic diagnostics of TTR cardiac amyloidosis?
A. Teresinska, *K. Jozwik-Plebanek, M. Cacko, J. Wnuk, M. Gawor, J. Grzybowski;*
National Institute of Cardiology, Warsaw, POLAND.

EP-282
Usefulness of 18F-FDG-PET/CT in the detection of cardiac involvement in patients with suspected Sarcoidosis
I. Obedkova, *B. Rodriguez Alfonso, L. T. Santamaria Chico, K. E. Velásquez Díaz, P. M. Meneses Soares, M. Mitjavila Casanovas;*
University Hospital Puerta de Hierro, Madrid, SPAIN.

EP-283
Radiological and biochemical correlation of metabolic findings on bone scintigraphy with ^{99}mTc-DPD in the evaluation of patients with transtyretin amyloidosis (TTR)
E. Campaña Diaz, *J. Cañadas Salazar, F. Gómez-Caminero López, P. García-Talavera San Miguel, J. Badell Martínez, A. Peñaherrera Cepeda, S. López Puche, L. Diaz González, J. Villanueva Curto, M. Tamayo Alonso;*
Complejo Asistencial Universitario de Salamanca, Salamanca, SPAIN.

EP-284
Semiquantitative evaluation of ^{68}Ga-DOTANOC uptake in the normal myocardium
P. Kaushik, *C. Patel, K. Chandra, S. Kumar, P. Gupta, C. Bal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-285
Towards the optimization of ^{99m}Tc-PYP scintigraphy contribution in transthyretin-induced cardiac amyloidosis
P. Valsamaki[1], *E. Kastritis*[2], *K. Liapis*[3], *M. Dimopoulos*[2], *A. Zissimopoulos*[1];
[1]*Nuclear Medicine Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE,* [2]*Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, GREECE,* [3]*Department of Haematology, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE.*

EP-286
Incidental Finding Of Avid 99mTc-DPD Cardiac Uptake On Routine Bone Scintigraphy In Cancer Patients
I. Iakovou[1], *E. Giannoula*[1], *D. Boundas*[2], *P. Exadaktylou*[1], *G. Gerasimou*[1], *G. Koutsouki*[1], *F. Spyroglou*[1], *E. Papanastasiou*[1], *A. Doumas*[1];
[1]*Nuclear Medicine dpt, AHEPA hsp., Aristotle University, Thessaloniki, GREECE,* [2]*IPPOKRATIS, Nuclear Medicine dpt, Thessaloniki, GREECE.*

EP-26

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B44 Other Cardiovascular Imaging (including Plaque)

EP-287
Myocardial Perfusion Scintigraphy - Comparison between SPECT LEHR and IQ SPECT

M. Rodrigues Correia, *A. Duarte, A. Figueiredo, S. Matos, D. Calado, B. Martins, C. Loewenthal;*
Hospital da Luz, Lisbon, PORTUGAL.

EP-288
^{18}FDG-PET/CT in Evaluation of Aortic Wall in Patients with Atherosclerosis

I. Znamenskiy[1,2,3], *M. Beregov*[2], *A. Kondakov*[3], *D. Kharina*[1], *D. Mosin*[1], *A. Nikitin*[1];
[1]*Petrovsky National Research Center of Surgery, Moscow, RUSSIAN FEDERATION,* [2]*Federal Center of Brain Research and Neurotechnologies, Federal Medical Biological Agency of Russia, Moscow, RUSSIAN FEDERATION,* [3]*Pirogov Russian National Research Medical University of the Ministry of Health of Russia, Moscow, RUSSIAN FEDERATION.*

EP-289
Detection of Chemotherapy-related Cardiotoxicity in BreastCancer Patients with Fast and Ultra-low-dose Equilibrium Radionuclide Angiographies

C. Decorads[1], *J. Salleron*[2], *R. Véronique*[1], *L. Imbert*[1], *Z. Lamiral*[1], *M. Perrin*[1], *M. Claudin*[1], *M. Chawki*[1], *A. Lambert*[3], *C. Henneton*[4], *P. Marie*[1,5];
[1]*Department of Nuclear Medicine, CHRU Nancy, Lorraine University, Nancy, FRANCE,* [2]*Department of Biostatistics, ICL, Institut de Cancérologie de Lorraine, Nancy, FRANCE,* [3]*Institut de cancérologie de Lorraine, Department of Medical Oncology, Vandœuvre-lès-Nancy, FRANCE,* [4]*Department of Cardiologie, ICL, Institut de Cancérologie de Lorraine, Nancy, FRANCE,* [5]*INSERM, UMR 1116, Lorraine University, Nancy, FRANCE.*

EP-290
SPECT-CT Imaging Aortic Wall Inflammation Using 99mTc-PyrophosphateUsing 99mTc-Pyrophosphate

J. Ilyushenkova, *D. Panfilov, V. Saushkin, E. Sonduev, B. Kozlov, S. Sazonova;*
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION.

EP-291
Declined activation within the hematopoietic tissues in patients with recurrent myocardial infarction

Y. Lu[1], *X. Li*[2], *X. Zhang*[1];
[1]*Department of Nuclear Medicine, Beijing Anzhen Hospital, Capital Medical University, Beijing, CHINA,* [2]*Center for Biomedical Research, Medical University of Vienna, The Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, AUSTRIA.*

EP-292
Myocardial Uptake As A Casual Finding In ^{99}mTc-HDP Bone Scintigraphy And Its Correlation With Cardiological History, The Presence Of Cardiac Amyloidosis And Imaging Test

S. Lopez Puche, *M. Hernandez Hidalgo, R. Eiros Bachiller, M. Gallego Delgado, F. Gomez-Caminero Lopez, A. Peñaherrera Cepeda, J. Badell Martínez, E. Campaña Diaz, L. Diaz Gonzalez, P. Garcia-Talavera San Miguel, J. Villanueva Curto, M. Tamayo Alonso;*
Hospital University of Salamanca, Salamanca, SPAIN.

EP-293
Nuclear Imaging Applied to the Cardiovascular System in the Elderly Patients

S. Ferreira;
School of Health Dr. Lopes Dias, Polytechnic Institute of Castelo Branco; AGE.COMM - Interdisciplinary Research Unit - Functional Ageing Communities, Castelo Branco, PORTUGAL.

EP-294
Radionuclide Ventriculography (RNV).What Drugs are involved "in vivo" labeling or red blood cells with ^{99m}Tc?

S. Perez Quiros, *M. D. Marín Ferrer, S. Angiolillo Grau, A. Saviatto Nardi, D. Vega Pérez, V. Godigna Guilloteau, A. Galiana Morón, E. Martínez Albero, P. Sarandeses Fernández, P. Zaragoza Ballester, M. J. Tabuenca Mateo;*
Hospital Universitario 12 de Octubre, Madrid, SPAIN.

EP-295
Estimation of Left Ventricular Axis of the Heart using SPECT Images

M. Assadi[1], *F. Salahshoori Nejad*[2], *A. Keshavarz*[2], *E. Jafari*[1];
[1]*Bushehr University of Medical Sciences (BUMS), Bushehr, IRAN, ISLAMIC REPUBLIC OF,* [2]*Artificial Intelligence and Medical Imaging Research Group, ICT Research Institute, Faculty of Intelligent Systems Engineering and Data Science, Persian Gulf university, Bushehr, IRAN, ISLAMIC REPUBLIC OF.*

EP-27

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B51 Neurodegeneration

EP-296
Clinical implications of prompt ^{123}I-ioflupane verification of pharmacogenous parkinsonism

P. Valsamaki[1], *A. Terzoudi*[2], *A. Arvaniti*[3], *E. Mavraki*[2], *V. Balomenos*[4], *A. Zissimopoulos*[1];
[1]*Nuclear Medicine Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE,* [2]*Neurology Clinic, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE,* [3]*Psychiatry Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE,* [4]*Diagnostic and Interventional Radiology Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE.*

EP-297
Impact of error propagation in the development of the centiloid conversion equation

N. Roé-Vellvé[1], *G. Farrar*[2], *L. Collij*[3], *M. Shekari*[4,5,6], *F. Heeman*[3], *D. Vállez García*[3], *F. Barkhof*[3,7], *J. Gispert*[4,5,8], *C. Buckley*[2], *S. Bullich*[1], *On behalf of the AMYPAD consortium, an IMI/EU-EFPIA funded Project (grant agreement No 115952).;*
[1]*Life Molecular Imaging GmbH, Berlin, GERMANY,* [2]*GE Healthcare, Amersham, UNITED KINGDOM,* [3]*Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS,* [4]*Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, SPAIN,* [5]*IMIM (Hospital del Mar Medical Research Institute), Barcelona, SPAIN,* [6]*Universitat Pompeu Fabra, Barcelona, SPAIN,* [7]*Institute of Neurology and Centre for Medical Image Computing, University College London, London, UNITED KINGDOM,* [8]*Centro de Investigación Biomédica en Red Bioingeniería, Biomateriales y Nanomedicina, (CIBER-BBN), Barcelona, SPAIN.*

EP-298
Cortical metabolic ^{18}F-FDG PET assessment and striatal dopamine transporter SPECT imaging in suspected early neurodegenerative disorders with uncertain movement and cognitive symptoms

S. Nuvoli[1], *A. Lazzarato*[1], *S. Carlo*[1], *P. Galleri*[1], *A. Marongiu*[1], *L. Filippi*[2], *B. Palumbo*[3], *A. Spanu*[1], *G. Madeddu*[1];
[1]*Nuclear Medicine Unit; University of Sassari, Sassari, ITALY,* [2]*Nuclear Medicine Unit, Hospital of Latina, Latina, ITALY,* [3]*Nuclear Medicine Section, University of Perugia, Perugia, ITALY.*

EP-299
Whole-brain gray matter differences according to brain amyloid status: Preliminary findings from the AGUEDA trial

P. Solis-Urra[1,2], *D. Rivas-Navas*[2], *E. Triviño-Ibáñez*[2,3], *M. Olvera-Rojas*[1], *A. Coca-Pulido*[1], *D. Bellon*[1], *A. Toval-Sanchez*[1], *K. Erickson*[4], *M. Gomez-Rio*[2], *I. Esteban-Cornejo*[1];
[1]*PROFITH "PROmoting FITness and Health Through Physical Activity" Research Group, Sport and Health University Research Institute (iMUDS), Department of Physical and Sports Education, Faculty of Sport Sciences, University of Granada, 18071, Granada, SPAIN,* [2]*Nuclear Medicine Services, "Virgen de Las Nieves" University Hospital, 18014, Granada, SPAIN,* [3]*Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, SPAIN,* [4]*Department of Psychology, University of Pittsburgh, Pittsburgh, PA, UNITED STATES OF AMERICA.*

EP-300
[^{18}F]F-florbetaben-PET/CT study of a sample of cognitive normal older adults: Description and characteristics of AGUEDA project participants

D. Rivas-Navas[1], *P. Solis-Urra*[2,1,3], *E. Triviño-Ibáñez*[1,3], *E. García-Rivero*[1,3], *B. Fernandez-Gamez*[2], *A. Sclafani*[2], *I. Martin-Fuentes*[2], *J. Mora-Gonzalez*[2], *F. Ortega*[2], *M. Gomez-Rio*[1,3], *I. Esteban-Cornejo*[2];
[1]*Hospital Universitario Virgen de las Nieves, Granada, SPAIN,* [2]*PROFITH "PROmoting FITness and Health Through Physical Activity" Research Group, Sport and Health University Research Institute (iMUDS), Granada, SPAIN,* [3]*Instituto de Investigación Biosanitaria ibs, Granada, SPAIN.*

EP-301
Whole-body PET examination with [^{18}F]SMBT-1 to observe physiological distribution of monoamine oxidase B (MAO-B) in humans

M. Tashiro[1], *Y. Ishioka*[1], *B. T. Mesfin*[1], *A. Inamura*[1], *S. Watanuki*[1], *M. Miyake*[1], *K. Hiraoka*[1], *R. Harada*[2], *S. Furumoto*[1], *K. Yanai*[1,2], *N. Okamura*[3], *H. Watabe*[1];
[1]*Cyclotron and Radioisotope Center, Tohoku University, Sendai, JAPAN,* [2]*Department of Pharmacology, Graduate School of Medicine, Tohoku University, Sendai, JAPAN,* [3]*Division of Pharmacology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, JAPAN.*

EP-302
Head-to-Head Comparison of PET and ASL-MRI BBB Permeability measurements for Dementia Imaging: Study Protocol

P. Moyaert[1,2,3], *O. Oyeniran*[1], *P. Dassanayake*[1], *L. Liu*[1], *J. Petr*[4], *E. Achten*[2], *H. Mutsaerts*[5], *J. Hicks*[1], *M. Guenther*[6], *U. Anazodo*[1,7];
[1]*Western University, London, ON, CANADA,* [2]*Ghent University, Ghent, BELGIUM,* [3]*University of Brussels, Brussels, BELGIUM,* [4]*Helmholtz-Zentrum Dresden-Rossendorf, Dresden, GERMANY,* [5]*Amsterdam UMC, Amsterdam, NETHERLANDS,* [6]*Fraunhofer Institute for Digital Medicine, Bremen, GERMANY,* [7]*McGill University, Montreal, QC, CANADA.*

EP-303
Relationship between cardiac (123)-I-metaiodobenzylguanidine (123I-MIBG) and non-motor symptoms in de-novo Parkinson disease (PD) patients

F. Lanfranchi[1], *D. Arnaldi*[2], *F. D'Amico*[1], *T. Di Raimondo*[1], *M. I. Donegani*[1], *A. Miceli*[1], *L. Sofia*[1], *P. Mattioli*[2], *S. Chiola*[3], *S. Raffa*[3], *M. Pardini*[2], *F. Massa*[2], *M. Bauckneht*[1,3], *G. Sambuceti*[1], *F. Nobili*[2], *S. Morbelli*[1,3];
[1]*Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,* [2]*Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, ITALY,* [3]*Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY.*

EP-304
Biodistribution of 99mTc-TRODAT-1 in clinically diagnosed Parkinson's disease & Parkinson plus syndrome

M. L Narayan, *T. Singhal, P. Palanivel, P. Singh, M. Negi, N. Kumar;*
Department of Nuclear Medicine, A.I.I.M.S., Rishikesh, INDIA.

EP-305
Combining imaging and inflammation improves evaluation of Alzheimer's Disease

S. Michopoulou[1], *J. Teeling*[2], *A. Prosser*[2], *J. Dickson*[3], *M. Guy*[1], *C. Kipps*[1];
[1]*University Hospital Southampton NHS Foundation Trust, Southampton, UNITED KINGDOM,* [2]*University of Southampton, Southampton, UNITED KINGDOM,* [3]*University College London Hospitals NHS Foundation Trust, London, UNITED KINGDOM.*

EP-28

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B52 Cognitive Impairment

EP-306
The influence of aging on FDG brain metabolism assessed by FDG PET/CT: study in a large cohort of healthy subjects

J. Jiménez-Bonilla[1], *M. De Arcocha-Torres*[1], *S. López-García*[2], *N. Martínez-Amador*[1], *A. Sánchez-Salmón*[1], *F. Gómez-De la Fuente*[1], *F. Martínez-Dubarbie*[2], *I. Martínez-Rodriguez*[1], *J. Andrés-Pacheco*[1], *A. Gutiérrez-González*[1], *A. Bota-Bota*[1], *M. Pombo-López*[1], *V. Mendi-Barcina*[1], *E. Rodríguez-Rodríguez*[2], *R. Quirce*[1];
[1]*Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN,* [2]*Neurology Service. Marqués de Valdecilla University Hospital. University of Cantabria, Santander, SPAIN.*

EP-307

Association Of Severe Peridontitis With The Accumulation Of Cerebral b-Amyloid In Elderly With Mild Cognitive Impairment

E. Triviño-Ibáñez[1,2], *T. Rudolphi-Solero*[1], *M. Geréz-Muñoz*[3], *P. Solís-Urra*[4,5], *M. Gómez-Río*[1,2];
[1]*Department of Nuclear Medicine, University Hospital Virgen de las Nieves, Granada, SPAIN,* [2]*Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, SPAIN,* [3]*Departamento de Estomatología, Universidad de Granada, Granada, SPAIN,* [4]*PROFITH "PROmoting FITness and Health Through Physical Activity" Research Group, Sport and Health University Research Institute (iMUDS), Department of Physical and Sports Education, Faculty of Sport Sciences, University of Granada, Granada, SPAIN,* [5]*Faculty of Education and Social Sciences, Universidad Andres Bello, Viña del Mar, CHILE.*

EP-308

The Role of Brain Perfusion 99mTc-SPECT-HMPAO with Automated Brodmann Areas Analysis in the Evaluation of Neuropsychiatric Symptoms in Dementia

V. Valotassiou[1,2], *N. Sifakis*[3], *C. Tzavara*[2], *E. Lykou*[4], *N. Tsinia*[5], *V. Kamtsadeli*[4], *D. Sali*[6], *G. Angelidis*[2], *D. Psimadas*[2], *E. Theodorou*[2], *C. Tzioumerka*[2], *C. Ziangas*[2], *I. Tsougos*[7], *S. G. Papageorgiou*[8], *P. Georgoulias*[1,2], *J. Papatriantafyllou*[4,9];
[1]*Dpt of Nuclear Medicine, Medical School, University of Thessaly, Larissa, GREECE,* [2]*Dpt of Nuclear Medicine, University Hospital of Larissa, Larissa, GREECE,* [3]*Dpt of Nuclear Medicine, "Alexandra" General Hospital, Athens, GREECE,* [4]*3rd Age Day Care Center, IASIS, Athens, GREECE,* [5]*1st University Psychiatric Department, Aeginition Hospital, Athens, GREECE,* [6]*Neurology Department, Evrokliniki, Athens, GREECE,* [7]*Medical Physics Department, Medical School, University of Thessaly, Larissa, GREECE,* [8]*2nd University Department of Neurology, Attikon Hospital, Athens, GREECE,* [9]*Memory Disorders Clinic, Medical Center, Athens, GREECE.*

EP-309

Evaluation of Agitation Perfusion Correlates in Alzheimer's Disease with Brain Perfusion 99mTc-SPECT-HMPAO and Automated Brodmann Areas Mapping

V. Valotassiou[1,2], *N. Sifakis*[3], *C. Tzavara*[2], *E. Lykou*[4], *N. Tsinia*[5], *V. Kamtsadeli*[4], *D. Sali*[6], *G. Angelidis*[2], *D. Psimadas*[2], *E. Theodorou*[2], *C. Tzioumerka*[2], *C. Ziangas*[2], *I. Tsougos*[7], *S. G. Papageorgiou*[8], *P. Georgoulias*[1,2], *J. Papatriantafyllou*[4,9];
[1]*Dpt of Nuclear Medicine, Medical School, University of Thessaly, Larissa, GREECE,* [2]*Dpt of Nuclear Medicine, University Hospital of Larissa, Larissa, GREECE,* [3]*Dpt of Nuclear Medicine, "Alexandra" General Hospital, Athens, GREECE,* [4]*3rd Age Day Care Center, IASIS, Athens, GREECE,* [5]*1st University Psychiatric Department, Aeginition Hospital, Athens, GREECE,* [6]*Neurology Department, Evrokliniki, Athens, GREECE,* [7]*Medical Physics Department, Medical School, University of Thessaly, Larissa, GREECE,* [8]*2nd University Department of Neurology, Attikon Hospital, Athens, GREECE,* [9]*Memory Disorders Clinic, Medical Center, Athens, GREECE.*

EP-310

SPECT analysis and language profile in Greek speaking patients with subtypes of frontotemporal dementia

I. Iakovou[1], *D. Mamouli*[2], *A. Doumas*[1], *S. Stavrakaki*[3], *E. Giannoula*[1], *P. Exadaktylou*[1], *G. Gerasimou*[1], *D. Parisis*[3], *D. Karacostas*[3], *E. Papanastasiou*[1], *P. Ioannidis*[3];
[1]*Nuclear Medicine dpt, AHEPA hsp., Aristotle University, Thessaloniki, GREECE,* [2]*424 General Military Training Hospital, Thessaloniki, GREECE,* [3]*Aristotle University, Thessaloniki, GREECE.*

EP-311

Differential Diagnosis between Alzheimer's Disease-Related Depression and Pseudo-Dementia in Depression - A New Indication for Amyloid-b Imaging?

J. Leonhardi[1], *H. Barthel*[2], *S. Speerforck*[3], *J. Dietzel*[3], *M. Schroeter*[4], *D. Saur*[5], *S. Tiepolt*[2], *M. Rullmann*[2], *M. Pratt*[2], *J. Claßen*[5], *G. Schomerus*[3], *O. Sabri*[2];
[1]*University of Leipzig Medical Center, Department of Radiology, Leipzig, GERMANY,* [2]*University of Leipzig Medical Center, Department of Nuclear Medicine, Leipzig, GERMANY,* [3]*University of Leipzig Medical Center, Department of Psychiatry and Psychotherapy, Leipzig, GERMANY,* [4]*University of Leipzig Medical Center, Clinic for Cognitive Neurology, Leipzig, GERMANY,* [5]*University of Leipzig Medical Center, Department of Neurology, Leipzig, GERMANY.*

EP-29

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B53 Movement Disorders

EP-312

Semiquantitative Analysis of ^{123}I-ioflupane SPECT Performance in Asymptomatic LRRK2-G2019S Mutation Carriers

I. Martínez-Rodríguez[1], *J. Andrés-Pacheco*[1], *Á. Gutiérrez-González*[1], *J. Infante Ceberio*[2], *M. De Arcocha-Torres*[1], *A. Sánchez-Salmón*[1], *A. Sánchez-Rodríguez*[3], *J. Jiménez-Bonilla*[1], *N. Martínez-Amador*[1], *M. Sierra Peña*[2], *I. González-Aramburu*[2], *F. J. Gómez-de la Fuente*[1], *A. Bota-Bota*[1], *M. Pombo-López*[1], *M. Rodil-Gallego*[1], *A. García-Ruiz*[1], *V. Mendi-Barcina*[1], *R. Quirce*[1];
[1]*Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN,* [2]*Neurology Service. Marqués de Valdecilla University Hospital. IDIVAL. Centro de Investigación Biomédica en Red de Enfermedades Degenerativas (CIBERNED). University of Cantabria, Santander, SPAIN,* [3]*Neurology Service. Cabueñes University Hospital. Centro de Investigación Biomédica en Red de Enfermedades Degenerativas (CIBERNED), Gijón, SPAIN.*

EP-313

Dual-imaging FP-CIT-SPECT and cardiac MIBG scintigraphy in the diagnosis of clinically uncertain parkinsonian syndromes (UPS)

L. Canales Rodriguez[1], *M. Mitjavila Casanovas*[2];
[1]*Hospital Central de la Defensa, Madrid, SPAIN,* [2]*Hospital Puerta de Hierro Majadahonda, Madrid, SPAIN.*

EP-314

FDG-PET/CT in the evaluation of suspected parkinsonism: our experience in daily practice

F. Pena Pardo, *V. M. Poblete García, A. M. García Vicente, E. Noriega Álvarez, L. García Zoghby, M. Sicilia Pozo, C. Lucas Lucas, A. Padilla Bermejo, Á. Soriano Castrejón;*
Nuclear Medicine Department, University General Hospital, Ciudad Real, SPAIN.

EP-315

Diagnostic role of quantified ^{123}I-FP-CIT (DaTscan) brain SPECT in suspected early-onset Parkinsonism

F. Sebastián Palacid, *N. Álvarez Mena, M. García Aragón, B. Pérez López, C. Gamazo Laherrán, M. Alonso Rodriguez, A. Sáinz Esteban, M. J. González Soto, R. Ruano Pérez;*
Hospital Clínico Universitario Valladolid, Valladolid, SPAIN.

EP-30

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B54 Neurotransmission and Receptors

EP-316

Striatal dopamine release induced by one-day high frequency repetitive transcranial magnetic stimulation: a DaTSCAN SPECT study in healthy beagles

Y. Xu[1], *A. Dobbelair*[2], *J. H. Saunders*[2], *K. Peremans*[2], *C. Baeken*[1];
[1]*Department of Head and Skin, Ghent Experimental Psychiatry (Ghep) Lab, Ghent University, Ghent, BELGIUM,* [2]*Department of Morphology, Imaging, Orthopedics, Rehabilitation and Nutrition; Faculty of Veterinary Medicine, Ghent University, Merelbeke, BELGIUM.*

EP-317

Utility of Longitudinal Semiquantitative SPECT Analysis of Dopamine Transporters with [123I]Ioflupane in the Follow-up and Diagnosis of Patients with Uncertain Parkinson Syndrome (clinical or visual doubts)

L. Lopez Urquia, *J. Vela León, S. Romero Acevedo, M. Lara Martínez, M. Canelas Subieta, F. Medina Romero, M. González Díaz, M. Gómez Rodríguez-Bethencourt;*
Hospital Universitario de Canarias, San Cristobal de la Laguna, SPAIN.

EP-318

Test-retest variability of measuring P-glycoprotein function at the blood-brain barrier using [^{18}F]MC225 and PET

P. Mossel[1], *G. Salvi de Souza*[1], *A. T. M. Willemsen*[1], *P. H. Elsinga*[1], *P. de Deyn*[2,3], *R. A. J. Dierckx*[1], *A. A. Lammertsma*[1], *A. L. Bartels*[4], *G. Luurtsema*[1];
[1]*Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, NETHERLANDS,* [2]*Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BELGIUM,* [3]*Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Born-Bunge (IBB), University of Antwerp, Antwerp, BELGIUM,* [4]*Department of Neurology, Ommelander Ziekenhuis Groep, Scheemda, NETHERLANDS.*

EP-31

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B55 Other Neurological Imaging

EP-319

Comparison of [18F]DPA-714 PET imaging with [18F]FDG PET for pre-surgical localization of the seizure onset-zone in drug-resistant focal epilepsy

M. Cheval[1], *C. Leroy*[1], *M. Bottlaender*[1], *F. Caillé*[1], *N. Tournier*[1], *A. Petrescu*[2], *D. Taussig*[2], *S. Rodrigo*[1], *V. Bouilleret*[1,2];
[1]*Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay, FRANCE,* [2]*Neurophysiology and Epileptology Department, Hôpital Bicêtre, Assistance Publique des Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Paris-Sud, Le Kremlin Bicètre, FRANCE.*

EP-320

^{11}C-PIB Brain Imaging on the Biograph Vision PET/CT Quadra - A Compromise Between Observed Patient Compliance and Image Quality?

C. Schulze, *L. Rexhepi, A. Lysemose, F. L. Andersen, K. Madsen;*
Dept. of Clinical Physiology & Nuclear Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DENMARK.

EP-322

Decision Making in Patients in Vegetative State: Role of Brain ^{18}F-FDG PET/CT

L. Rodríguez, *A. Laverde, J. E. Maraña, S. Naranjo, C. Vigil, M. B. Fernández, M. L. Domínguez, J. P. Suárez, N. Martín, F. M. González;*
Central University Hospital of Asturias, Oviedo, SPAIN.

EP-323

A review of positron emission tomography studies on brain connectivity

A. Sala[1], *A. Lizarraga*[2], *S. P. Caminiti*[3], *V. Calhoun*[4], *S. Eickhoff*[5], *C. Habeck*[6], *S. D. Jamadar*[7], *D. Perani*[3], *J. Pereira*[8], *M. Veronese*[9], *I. Yakushev*[2];
[1]*University of Liège, Liege, BELGIUM,* [2]*Technical University of Munich, Munich, GERMANY,* [3]*Vita-Salute San Raffaele University, Milan, ITALY,* [4]*Georgia State University, Georgia Institute of Technology, Emory University, Atlanta, GA, UNITED STATES OF AMERICA,* [5]*Heinrich-Heine-University, Düsseldorf, GERMANY,* [6]*Columbia University, New York, NY, UNITED STATES OF AMERICA,* [7]*Monash University, Melbourne, AUSTRALIA,* [8]*Karolinska Institutet, Stockholm, SWEDEN,* [9]*King's College, London, UNITED KINGDOM.*

EP-324

Mapping of regional brain activation during sign language translation with ^{18}F-FDG PET Imaging

M. Vangu, *B. Kagodora, N. Parkins-Maliko;*
University of the Witwatersrand, Johannesburg, SOUTH AFRICA.

EP-325
The Role of ^{18}F-FDG-PET/TC in the Diagnosis of Autoimmune Encephalitis in patients with Paraneoplastic Syndrome
M. Baquero, *J. Ardila Mantilla, J. Atance García de la Santa, J. Montalvá Pastor, M. Casallas Cepeda, I. Gómez Fernández, A. Marí Hualde, J. Orcajo Rincón, J. Alonso Farto;*
Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-326
Evaluation of calculated attenuation correction method in brain PET imaging
A. Da Costa[1], *E. Cassol*[2], *G. Arribarat*[1], *P. Peran*[1], *P. Blanc*[2], *A. Hitzel*[2], *P. Payoux*[1,2];
[1]*ToNIC, Toulouse Neuroimaging Center, Toulouse University, Inserm, Toulouse, FRANCE,* [2]*Department of Nuclear Medicine, University Hospital of Toulouse Purpan, Toulouse, FRANCE.*

EP-327
FDG-PET In Autoimmune Encephalitis: Diagnostic Confidence Of The Metabolic Signature
L. Jonghi-Lavarini, *F. E. Pozzi, V. Cerina, S. Beretta, S. Morzenti, A. Giglio, F. Elisei, M. Musarra, E. De Bernardi, C. Crivellaro, G. Basso, C. Ferrarese, L. Guerra, C. Landoni;*
University Milano-Bicocca, Milan, ITALY,

EP-328
Increased consistency reporting of FDG PETCT in pre surgical assessment of medically refractory temporal lobe epilepsy
A. Hassan, *S. J Hughes;*
Aston Medical School, Birmingham, UNITED KINGDOM.

EP-32

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B6 Endocrinological Imaging Clinical Study -> B61 Endocrinology (including Thyroid Benign)

EP-329
Usefulness of^{18}F-fluorocholine PET/CT in Patients with Primary Hyperparathyroidism and Negative Presurgical Localization Imaging Studies
L. Rodríguez Díaz, *J. P. Suárez Fernández, M. L. Domínguez Grande, A. Laverde Mächler, J. E. Maraña González, S. Naranjo Sancho, M. E. García Lucero, N. Martín Fernández, F. M. González García;*
HUCA, Oviedo, SPAIN.

EP-330
Increased glucose activity in visceral versus subcutaneous adipose tissue (VAT vs SAT) determined by [18F]-FDG PET/CT
A. González-Jiménez[1], *R. Sánchez-Sánchez*[2], *T. Rudolphi-Solero*[2], *I. Pérez-Herrezuelo*[3], *J. M. Llamas-Elvira*[2];
[1]*University Hospital of Jaén, Nuclear Medicine Department, Jaén, SPAIN,* [2]*University Hospital Virgen de las Nieves, Nuclear Medicine Department, Granada, SPAIN,* [3]*University Hospital Virgen de las Nieves, Gynecology and Obstetrics Departments, Granada, SPAIN.*

EP-331
Can we reduce post-injection waiting time in thyroid scintigraphy without compromising image quality?
P. L. Hansen[1], *M. M. Braas*[1], *K. Falch*[2], *M. H. Hansen*[2], *S. E. Wallenius*[2], *H. J. Nissen*[2], *K. Thilsing-Hansen*[2], *N. U. M. Jakobsen*[2];
[1]*UCL University College, Odense, DENMARK,* [2]*Odense University Hospital, Odense, DENMARK.*

EP-332
Focal parathyroid lesions evaluated using SUV in preoperative SPECT/CT diagnosis
M. Listewnik, *S. Kurkowska, K. Zurawska, H. Piwowarska-Bilska, J. Iwanowski, B. Birkenfeld;*
Department of Nuclear Medicine, Pomeranian Medical University in Szczecin, Szczecin, POLAND.

EP-333
Evaluation of pre- and post-transplantation parathyroid scintigraphy and ultrasonography findings in patients with persistent hyperparathyroidism after renal transplantation
A. Aktas, *N. Uslu, A. Gencoglu, T. Colak;*
Baskent University, Ankara, TÜRKIYE.

EP-334
Comparison of parathyroid scintigraphy findings in pediatric and adult patients with secondary hyperparathyroidism
A. Aktas, *E. Baskın, A. Gencoglu, T. Colak;*
Baskent University, Ankara, TÜRKIYE.

EP-335
The right timing for discharging DTC patients undergoing thyroid remnant ablation with 3.7 GBq I131 fixed activity
L. Travascio[1], *M. G. Grossi*[1], *P. Turano*[2], *S. De Novellis*[2], *A. D. Di Nicola*[1];
[1]*Nuclear Medicine Unit P.O. Pescara, Pescara, ITALY,* [2]*UOSD Medical Physics, P.O. Pescara, Pescara, ITALY.*

EP-336
^{99m}Tc MIBI thyroid scan in amiodarone induced thyrotoxicosis: how far can we get with visual interpretation
L. Fischer[1,2], *N. Girotto*[1,2], *M. Ilić Tomaš*[1,2], *S. Grbac-Ivanković*[1,2], *T. Bogović Crnčić*[1,2];
[1]*Department of Nuclear Medicine, Faculty of Medicine, University of Rijeka, Rijeka, CROATIA,* [2]*Clinical Department of Nuclear Medicine, Clinical Hospital Centre Rijeka, RIjeka, CROATIA.*

EP-337
Adrenal Gland - Revisiting Scintigraphic Patterns
P. Soeiro, *B. Pereira, M. I. Rodrigues;*
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-338
Is there a role of Choline PET-CT in localisation of parathyroid adenoma? Review of initial experience in a teaching hospital
P. Chuah, *V. Pant, F. Naeem, R. Fernando, S. Vinjamuri, N. Seshadri;*
Nuclear Medicine Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UNITED KINGDOM.

EP-339
Congenital Hypothyroidism: Role of Thyroid Scintigraphy with pertechnetate (99mTcO4)
M. Ben Nasr, *W. EL Ajmi, A. Sellem, H. Hammami;*
The Principal Military Hospital of Instruction of Tunis, Tunisie, TUNISIA.

EP-340
Usefulness of the lugol protocol in parathyroid scintigraphy
J. Villena-Salinas, *A. Montellano-Fenoy, B. Patrut, C. Balbín-García, T. Amrani-Raissouni, S. Sanz-Viedma;*
Hospital Universitario Virgen de la Victoria, Málaga, SPAIN.

EP-341
T lymphocyte subpopulation in peripheral blood and follicular fluid of patients treated with medically assisted fertilization with and without thyroid autoimmunity
S. Petretic Majnaric;
Clinical Hospital Centre Rijeka, Clinical Department of Nuclear medicine, Rijeka, CROATIA.

EP-33

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B71 Bone Infection and Inflammation

EP-342
Quantitative bone SPECT/CT for diagnosing osteomyelitis of the jaw
W. Choi[1], *S. Boo*[2], *H. Yoon*[1], *E. Han*[3];
[1]*St.Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF,* [2]*Seoul St.Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF,* [3]*Yeouido St.Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.*

EP-343
Diagnostic accuracy of SPECT/CT ^{99m}Tc UBI 29-41 in musculoskeletal infections and its correlation with microorganisms
F. Lemus Ramirez[1], *A. López Méndez*[2], *D. Arguelles Pérez*[1], *K. Vite Pineda*[3], *J. Dominguez*[4], *D. Hernández Oliver*[5];
[1]*Insitituto Nacional De Rehabilitación Luis Guillermo Ibarra Ibarra, México, MEXICO,* [2]*Insitituto Nacional De Cardiología, México, MEXICO,* [3]*HGZ 35 Instituto Mexicano del Seguro Social, Ciudad Juárez Chihuahua, MEXICO,* [4]*Dr. Otto Rodriguez Polyclinic II, San Pedro, BELIZE,* [5]*Hospital Angeles Universidad, México, MEXICO.*

EP-34

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B72 Vasculitis and Endocarditis

EP-344
Correlation between clinical and imaging parameters to assess disease activity in Large Vessel Vasculitis: ^{18}F-FDG PET/CT semi-quantitative and cut-off based scores
L. Burroni[1], *P. Pettinari*[2], *C. Romagnolo*[1], *G. Ghirelli*[2], *A. Palucci*[1], *G. Biscontini*[1], *F. M. Fringuelli*[1], *C. Cottignoli*[1], *P. Fraticelli*[2];
[1]*Dept. of Nuclear Medicine, "Ospedali Riuniti di Torrette", Ancona, ITALY,* [2]*Dept. of Medical Clinic, Università Politecnica delle Marche, Ancona, ITALY.*

EP-345
Visual Assessment of ^{18}F-FDG PET/CT in Patients Referred to Our Department Due to Clinical Suspicion of Large Vessel Vasculitis
M. Lara Martínez[1], *O. Vilahomat*[2], *E. Martínez*[2], *J. Uña*[2], *A. J. Allende Riera*[2];
[1]*Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN,* [2]*Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, SPAIN.*

EP-35

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B73 Other Infections and Inflammatory Diseases

EP-346
Visual and Semiquantitative Analysis Of 18F-FDG PET/CT Results In Patients With Vascular Graft Infection
D. Pursanova, *I. P. Aslanidis, O. V. Mukhortova, I. V. Shurupova, I. V. Ekaeva, T. A. Trifonova, M. V. Metelkina;*
A.N. Bakulev Scientific Center for Cardiovascular Surgery of the Ministry of Health of the Russian F, Moscow, RUSSIAN FEDERATION.

EP-347
The Role Of FDG-PET/CT In Tuberculosis
E. Llinares-Tello[1], *I. Sánchez-Rodríguez*[1], *M. Santín-Cerezales*[2], *J. Suils-Ramón*[1], *L. Rodríguez-Bel*[1], *P. Notta*[1], *M. Pudis*[1], *C. Martínez-Ramos*[1], *S. Bondia-Bescós*[1], *B. Hervás-Sanz*[1], *J. Robles-Barba*[1], *J. Vercher-Conejero*[1], *A. Palomar-Muñoz*[1], *M. Cortés-Romera*[1];
[1]*PET/CT Unit. Department of Nuclear medicine. IDI. Bellvitge Universitary Hospital, Hospitalet de Llobregat (Barcelona), SPAIN,* [2]*Department of Infectology/Internal Medicine. Bellvitge Universitary Hospital, Hospitalet de Llobregat (Barcelona), SPAIN.*

EP-348
Role of [^{18}F]FDG PET/CT in assessing patients with IgG4-related disease
M. Pudis[1], *M. Cortés-Romera*[1], *S. Bondia-Bescós*[1], *X. Solanich-Moreno*[2], *B. Hervás-Sanz*[1], *A. Palomar-Muñoz*[1], *M. E. De Lama Salvador*[3], *C. Martínez-Ramos*[1], *E. Llinares-Tello*[1], *J. Robles-Barba*[1], *R. Llatjos-Sanuy*[4], *M. Buaki-Sogo*[1], *L. Rodríguez-Bel*[1];
[1]*Nuclear Medicine - PET (IDI) Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [2]*Internal Medicine Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [3]*Radiology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN,* [4]*Anatomical Pathology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat, SPAIN.*

EP-349
Evaluation of the role of ^{18}F-FDG PET-CT in the assessment of response to treatment in patients with Malignant External Otitis
A. Cherino Talens[1], *C. Sampol Bas*[1,2], *B. Luna Molero*[1], *C. Medina Soldado*[1], *J. Amaya Saumet*[1], *L. Nieto Morcillo*[1], *N. Orta Tomás*[1,2], *M. Valiente Alarcón*[3], *C. Peña Viloria*[1,2];
[1]*Nuclear Medicine Department. Hospital Universitari Son Espases, Palma de Mallorca, SPAIN,* [2]*IdISBa, Palma de Mallorca, SPAIN,* [3]*Radiopharmaceutical Department. Hospital Universitari Son Espases, Palma de Mallorca, SPAIN.*

EP-350
Association of Bone Mineral Densitometry with Radiologic Grading of the Hip among Patients with Hip Osteoarthritis
I. Bandong, *S. F. Estanislao, C. J. Santos;*
St. Luke's Medical Center-Quezon City, Quezon City, PHILIPPINES.

EP-36

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B8 Nephro-Urological Imaging Study -> B81 Nephro-Urology

EP-351
Dynamic renal scintigraphy and SPECT/CT in patients with suspected chronic obstructive pathology
S. Bonfante, *A. Tavellin, D. Carazzato, S. Rossetto, D. Grigolato;*
Ospedale Mater Salutis, Legnago, ITALY.

EP-352
Diagnosis of pleuroperitoneal communication in peritoneal dialysis patients by means of Tc99m-MAA peritoneal scintigraphy
L. Burroni, *F. M. Fringuelli, G. Biscontini, A. Palucci, C. Romagnolo, C. Cottignoli;*
"Ospedali Riuniti" Hospital, Department of Nuclear Medicine, Ancona, ITALY.

EP-353
Diagnostic role of geometric mean calculation of renal split function applicable in patients with kidney disease using dynamic renoscintigraphy
P. Korol[1], *O. Shcherbina*[1], *M. Kostylev*[2];
[1]*Shupik National University of Health of Ukraine, Kiev, UKRAINE,* [2]*Shalimov National Institute of Surgery of Transplantation, Kiev, UKRAINE.*

EP-354
Drainage patterns and differential functions in patients with unilateral duplicated kidney using 99m Technitium-L,L ethylenedicysteine (LLEC) renal scintigraphy- A retrospective observational study from a tertiary care centre in India
J. Jaleel, *A. S. L, S. Jha, S. Sagar, K. Subudhi, R. Kumar, M. Bajpai, S. Agarwala, M. Tripathi, K. B. Chandra, C. S. Bal;*
AIIMS, New Delhi, INDIA.

EP-37

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B9 Paediatric Imaging Study -> B91 Paediatric Study

EP-355
Additional late imaging in diuretic renography
J. Pilz[1], *L. Steinkellner*[1], *G. Rendl*[2], *G. Schweighofer-Zwink*[2], *C. Pirich*[2], *J. Dierneder*[3];
[1]*Department of Urology, Ordensklinikum Linz, Linz, AUSTRIA,* [2]*Department of Nuclear Medicine and Endocrinology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, AUSTRIA,* [3]*Department of Nuclear Medicine and Endocrinology, Ordensklinikum Linz, Linz, AUSTRIA.*

EP-38

During Congress Opening Hours

e-Poster Area

B: Imaging Clinical Studies -> B10 Other Imaging Clinical Studies -> B101 Other Clinical Studies

EP-066
Why Technegas is Fast Replacing 99mTc-Based Aerosols in Lung Scintigraphy
H. Hughes;
BCIT, Burnaby, BC, CANADA.

EP-067
Diagnostic validity of salivary scintigraphy in patients with Sjogren's Syndrome: A restrospective and descriptive cohort study
C. Ruiz Corbalán, *A. S. De Agrela Serrao, A. M. Leiva Montejo, D. R. Cáceres Silva, T. Moreno Monsalve, J. F. Contreras Gutierrez, A. C. Hernandez Martinez, M. I. Castellón Sanchez, J. L. Navarro Fernandez, L. Frutos Esteban, T. Rodriguez Lorcano, L. Mohamed Salem;*
Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, SPAIN.

EP-068
Diagnostic value of red cell mass measurement in patients diagnosed with polyglobulia using isotope dilution techniques
L. Baz[1], *M. H. García-Ruiz*[1], *R. Maestre-Cutillas*[1], *M. Piris-Villaespesa*[2], *L. Bolea-Jarreta*[2], *G. Moreno-Jiménez*[2], *J. A. Pérez-Iruela*[1];
[1]*Radiopharmacy Unit. Ramón y Cajal University Hospital, Madrid, SPAIN,* [2]*Haematology Department. Ramón y Cajal University Hospital, Madrid, SPAIN.*

EP-069
Impact of day 1 imaging time and energy windows on SeHCAT results
I. Rutland-Turner[1], *N. Sandiford*[2], *M. J. Memmott*[3], *I. S. Armstrong*[3];
[1]*Christie Hosptial NHS Foundation Trust, Manchester, UNITED KINGDOM,* [2]*Manchester University NHS Foundation, Manchester, UNITED KINGDOM,* [3]*Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM.*

EP-39

During Congress Opening Hours

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C11 Neuroendocrine Therapy

EP-356
Tumour Absorbed Dose for Prediction of Anatomical Response to Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Pancreatic Neuroendocrine Tumours (PanNETs)
M. Mileva[1], *R. Danieli*[2], *H. Levillain*[2], *G. Marin*[2], *C. Marin*[2], *P. Flamen*[1], *I. Karfis*[1];
[1]*Nuclear Medicine Department, Institut Jules Bordet, Bruxelles, BELGIUM,* [2]*Medical Physics Department, Institut Jules Bordet, Bruxelles, BELGIUM.*

EP-357
Peptide-Receptor Radionuclide Therapy (PRRT) with 225Ac-DOTA-TATE: Initial Results and Contribution to Progression-Free Survival
G. Beydagi[1], *E. Demirci*[1], *N. Alan Selcuk*[1], *M. Ocak*[2], *T. Toklu*[1], *K. Akcay*[1], *B. Caner*[1], *L. Kabasakal*[3];
[1]*Yeditepe University, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TÜRKIYE,* [3]*Istanbul University-Cerrahpasa Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

EP-358
Receptor Saturation at Low Specific Activity of [^{177}Lu]Lu-HA-DOTATATE Due to Unlabeled HA-DOTATATE Peptide
H. Siebinga[1,2], *C. H. A. Veerman*[2], *B. J. de Wit - van der Veen*[2], *J. J. M. Hendrikx*[1,2], *M. P. M. Stokkel*[2], *E. A. Aalbersberg*[2];
[1]*Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS,* [2]*Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, NETHERLANDS.*

EP-359
Correlation study between ^{68}Ga-DOTATOC PET metrics and ^{177}Lu-DOTATATE dosimetry for metastatic midgut neuroendocrine tumors
J. Texier, *M. Jocmek, L. Dierickx, S. Brillouet, D. Vallot, O. Caselles, M. Terroir, T. Cassou-Mounat, C. Lamesa, Q. Maronnier, L. Vija, F. Courbon;*
Department of nuclear medicine, Cancer University Institute of Toulouse, Toulouse, FRANCE.

EP-360
Estimation of bone marrow absorbed doses during ^{177}Lu-DOTATATE treatments
L. Hagmarker[1], *J. Svensson*[2], *T. Ryden*[1], *M. Van Essen*[3], *A. Sundlöv*[4], *K. Sjögreen Gleisner*[5], *M. Ljungberg*[5], *P. Gjertsson*[2], *P. Bernhardt*[1];
[1]*Department of Radiation physics, Gothenburg, SWEDEN,* [2]*Department of Oncology, Gothenburg, SWEDEN,* [3]*Department of clinical physiology, Gothenburg, SWEDEN,* [4]*Department of Oncology and Pathology, Lund, SWEDEN,* [5]*Department of Radiation physics, Lund, SWEDEN.*

EP-361
Evolution of Krenning Score in scintigraphy after ^{177}Lu-DOTATATE: predictive value of therapeutic response in neuroendocrine neoplasms of pancreatic origin?
D. Barbosa, *I. Lucena Sampaio, S. Fontão de Castro, J. Castro Ferro, I. Próspero, G. Ferreira, L. Violante, J. Teixeira, F. Lopes, H. Duarte;*
Instituto Português de Oncologia do Porto Francisco Gentil E.P.E., Oporto, PORTUGAL.

EP-362
Tumour characteristics associated with the response to treatment with 177Lu-DOTATATE at 12 months
A. Roteta Unceta Barrenechea[1,2], *Y. Saker Diffalah*[1], *M. Parra Rina*[1], *L. Tardin Cardoso*[1], *M. Delgado Castro*[1], *T. Escalera Temprado*[1], *P. Razola Alba*[1], *D. Nogueira Souto*[1], *A. Andres Gracia*[1,2];
[1]*UCMHMNA - Clinic Hospital "Lozano Blesa", Zaragoza, SPAIN,* [2]*Instituto de Investigacion Sanitaria de Aragon, Zaragoza, SPAIN.*

EP-363
Comparison of the Safety and Tolerability of Para-aminohippurate (PAH) and Amino Acid (AA) Co-Infusion in Patients with Neuroendocrine Tumours Receiving Peptide Receptor Radionuclide Therapy (PRRT): A Case Series of Eight Patients
M. Sraieb[1,2], *M. Coelho*[1,2], *S. Himmen*[1,2], *K. M. Pabst*[1,2], *S. Kazek*[1,2], *C. Rischpler*[1,2], *W. P. Fendler*[1,2], *K. Herrmann*[1,2], *P. Costa*[1,2], *W. Jentzen*[1,2];
[1]*Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, GERMANY,* [2]*German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, GERMANY.*

EP-364
Does Previous 177Lu DOTATATE Treatment Effect 90Y Microsphere Treatment in Neuroendocrine Tumor Patients with Liver Metastasis
F. Aghazada[1], *A. Kibar*[1], *B. İnce*[1], *L. Uslu-Besli*[1], *C. Samanci*[2], *A. Bas*[2], *S. Sager*[1], *K. Sonmezoglu*[1];
[1]*Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Department of Interventional Radiology, Istanbul, TÜRKIYE.*

EP-365
High-Dose I-131 MIBG Treatment in Patients with Refractory Neuroblastoma and Metastatic Pheochromocytoma: A Single-Center Experience
R. Sahin[1], *M. C. Baloğlu*[1], *Ö. Erol Fenercioğlu*[1], *E. Beyhan*[1], *Ü. M. Yıldırım*[2], *G. Tatar*[3], *E. Arslan*[1], *N. Ergül*[1], *T. F. Çermik*[1];
[1]*University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE,* [2]*University of Health Sciences, Umraniye Training and Research Hospital, Clinic of Pediatric Hematology and Oncology, Istanbul, TÜRKIYE,* [3]*University of Health Sciences, Bağcılar Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

EP-40

During Congress Opening Hours

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C13 Local Radionuclide Therapy (including Spheres)

EP-366
Comparison of Predictive MAA SPECT/CT dosimetry and ^{90}Y PET/CT dosimetry in patients with liver tumors treated with Selective internal radiation therapy (SIRT)
M. Da Mota, *M. Mendes De Carvalho, J. O. Prior, P. Leite Ferreira, N. Schaefer, S. Boughdad;*
Centre Hospitalier Universitaire Vaudois, Lausanne, SWITZERLAND.

EP-367
Radioembolization with ^{90}Y-loaded glass and resin microspheres for the treatment of liver tumors: own experience
L. Casas Fernández[1], *A. M. Sánchez Tornero*[1], *M. Soria Merino*[2], *R. Maestre Cutillas*[3], *A. Simón García*[4], *M. Toscano Sánchez*[1], *M. Romero Otero*[1];
[1]Unidad de Radiofarmacia. Hospital Clínico Universitario de Valencia, Valencia, SPAIN, [2]Unidad de Radiofarmacia. Servicio de Medicina Nuclear. Hospital Universitario Parc Taulí, Sabadell, SPAIN, [3]Unidad de Radiofarmacia. Hospital Universitario Ramón y Cajal, Madrid, SPAIN, [4]Facultad de Química. Universidad de Valencia, Valencia, SPAIN.

EP-368
Unresectable intrahepatic cholangiocarcinoma - radioembolization and overall survival
S. Fontão de Castro, *J. Castro Ferro, I. Próspero, D. Barbosa, L. Violante, G. Ferreira, I. Lucena Sampaio, J. Teixeira, H. Duarte;*
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., Porto, PORTUGAL.

EP-369
Planning Of Radiation Segmentectomy In Hepatocellular Carcinoma With ^{90}Y Glass Microspheres: Activity Calculation By Single Compartment Dosimetry Versus Multi-Compartment Voxel-Based Dosimetry
J. Atance García de la Santa[1], *J. Orcajo Rincón*[1], *T. Pedraz González Tablas*[2], *M. Baquero Oliveros*[1], *J. Montalvá Pastor*[1], *M. Casallas Cepeda*[1], *L. Reguera Berenguer*[1], *J. Ardila Mantilla*[1], *I. Gómez Fernández*[1], *J. Alonso Farto*[1];
[1]Hospital Universitario Gregorio Marañón, Madrid, SPAIN, [2]Hospital Universitario La Paz, Madrid, SPAIN.

EP-370
Selective Internal Radiotherapy with 166Ho-microspheres in Liver Tumors: Experience in Our Hospital
J. Deportos, *M. Salcedo-Pujantell, S. Lafuente-Carrasco, M. Sánchez-Aguilar, J. Sampere-Moragues, G. Tovar-Felice, A. García-Gámez, V. Benito-Santamaría, J. Cordero-Ramajo, S. Ruiz-Llama, J. Riba, M. Solà, V. Vallejos, G. Moragas;*
Hospital Germans Trias i Pujol, Badalona, SPAIN.

EP-371
Holmium-166 Radioembolization, a Valuable Option in The Treatment of Liver Tumors
D. Maccora[1], *S. Rea*[1], *A. Annovazzi*[1], *G. E. Vallati*[2], *F. Cappelli*[2], *G. Iaccarino*[3], *B. Cassano*[3], *S. Ungania*[3], *F. Murtas*[3], *R. Sciuto*[1];
[1]Nuclear Medicine Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, [2]Interventional Radiology Unit, IRCCS Regina Elena National Cancer Institute, Rome, ITALY, [3]Laboratory of Medical Physics, IRCCS Regina Elena National Cancer Institute, Rome, ITALY.

EP-372
Imaging response evaluation after Ytrium-90 radioembolization treatment: our experience
P. Azpeitia Hernández, *A. Martínez Lorca, J. Bonilla Plaza, O. Ajuria Illarramendi, M. Gutierrez Guerrero, E. Pérez de los Ríos, T. Navarro Martínez, P. Paredes Rodríguez, M. Orduña Díez;*
Hospital Universitario Ramón y Cajal, Madrid, SPAIN.

EP-373
Radioembolization - efficacy in the local treatment of unresectable hepatocellular carcinoma
S. Fontão de Castro, *J. Castro Ferro, I. Próspero, D. Barbosa, L. Violante, G. Ferreira, I. Lucena Sampaio, J. Teixeira, H. Duarte;*
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E., Porto, PORTUGAL.

EP-41

During Congress Opening Hours

e-Poster Area

C: Therapy Clinical Study -> C1 Oncological Therapy Clinical Study -> C14 Thyroid Therapy

EP-374
Assessment of the Contribution of "DtcApp" in Thyroid Cancer Patients' Quality of Life
E. Giannoula[1], *P. Exadaktylou*[1], *N. Papadopoulos*[2], *G. Koutsouki*[3], *V. Chatzipavlidou*[4], *C. Mellidis*[5], *G. Sykiotis*[6], *A. Hatzitolios*[7], *A. Doumas*[1], *I. Iakovou*[1];
[1]Nuclear Medicine dpt., AHEPA hsp., Aristotle University, Thessaloniki, GREECE, [2]Aristotle University, Thessaloniki, GREECE, [3]Internal Medicine dpt., Lamia General hsp., Lamia, GREECE, [4]Nuclear Medicine dpt., Theagenio Cancer hsp., Thessaloniki, GREECE, [5]Radiation Therapy dpt., CAP Santé hsp., Bastia, FRANCE, [6]Service of Endocrinology, Diabetes and Metabolism, CHUV University hsp., Lausanne, SWITZERLAND, [7]Propedeutic dpt of Internal Medicine, AHEPA hsp, Aristotle University, Thessaloniki, GREECE.

EP-375
Influence of pathological factors in patients with differentiated thyroid cancer on predict persistent disease after radioactive iodine therapy
F. Hatipoglu;
Izmir Katip Celebi University Ataturk Education and Research Hospital, Department of Nuclear Medicine, Izmir, TÜRKIYE.

EP-376
The Effect Of High-Dose Radioiodine Therapy On Lacrimal Gland Function In Patients With Differentiated Thyroid Cancer
A. Namazova[1], *K. Sahin*[1], *C. Guneren*[1], *B. Ince*[1], *F. Aghazada*[1], *S. Sager*[1], *L. Uslu Besli*[1], *S. Asa*[1], *O. E. Sahin*[1], *T. Ozan*[2], *C. Arici*[3], *B. Mergen*[4], *K. Sonmezoglu*[1];
[1]Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE, [2]University of Health Sciences, Istanbul Beyoglu Eye Training and Research Hospital, Department of Ophthalmology, Istanbul, TÜRKIYE, [3]Istanbul University-Cerrahpasa, Department of Ophthalmology, Istanbul, TÜRKIYE, [4]University of Health Sciences, Basaksehir Cam and Sakura City Hospital, Department of Ophthalmology, Istanbul, TÜRKIYE.

EP-377
Radioiodine treatment of Differentiated Thyroid Cancer in patients with End-Stage Renal Disease on dialysis: a single-centre experience
G. Follacchio[1,2], *H. Castagnoli*[1], *B. Criscuoli*[1], *C. Manni*[1], *M. Camarda*[3], *S. Fattori*[3], *F. Sopranzi*[4], *F. Capoccetti*[1];
[1]Nuclear Medicine Unit, Macerata Hospital, Macerata, ITALY, [2]Molecular Medicine PhD program, "Sapienza" University of Rome, Rome, ITALY, [3]Medical Physics Unit, Macerata Hospital, Macerata, ITALY, [4]Nephrology Unit, Macerata Hospital, Macerata, ITALY.

EP-378
Parameters affecting Quality of Life in patients with Differentiated Thyroid Carcinoma
E. Giannoula[1], *P. Exadaktylou*[1], *N. Papadopoulos*[2], *G. Koutsouki*[3], *V. Chatzipavlidou*[4], *C. Mellidis*[5], *Z. Mughal*[6], *G. Sykiotis*[7], *A. Doumas*[1], *I. Iakovou*[1];
[1]Nuclear Medicine dpt., AHEPA hsp., Aristotle University, Thessaloniki, GREECE, [2]Aristotle University, Thessaloniki, GREECE, [3]Internal Medicine dpt., General hsp. of Lamia, Lamia, GREECE, [4]Nuclear Medicine dpt., Theagenio Cancer hsp, Thessaloniki, GREECE, [5]Radiation Therapy dpt., CAP Santé hsp., Bastia, FRANCE, [6]Medical Student, Aristotle University, Thessaloniki, GREECE, [7]Service of Endocrinology, Diabetes and Metabolism, CHUV University hsp., Lausanne, SWITZERLAND.

EP-379
Stimulated thyroglobulin (TG) prior to [131I] therapy (RAIT) in patients with differentiated thyroid cancer (DTC) as a predictive factor of recurrence
R. Nuñez-Muñoz, *Y. Carreres Ortega, M. A. Astudillo Sarmiento, R. Valverde Jorge, A. Peña Fuentes, J. Genollá Subirats, J. Santamaría Sandi, M. Badiola Molinuevo, E. Rodeño Ortiz de Zarate;*
Cruces University Hospital, Baracaldo, SPAIN.

EP-380
Dosimetric Assesment In The Treatment Of Differentiated Thyroid Cancer
C. Sandoval Moreno, *M. Tagliatori Nogueira, V. López Marcos, M. de la Rubia Marcos, B. Manzarbeitia Arroba, M. Álvarez Moreno, M. Santamaria Sánchez, M. Balsa Bretón, M. Herráez Hernández;*
Hospital Universitario de Getafe, Getafe, SPAIN.

EP-381
Effect of 131I treatment on parathyroid function in patients with differentiated thyroid carcinoma
L. Xiao;
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-382
Prognostic factors influencing the success of RAI therapy in patients with Graves disease
L. Xiao;
West China Hospital, Sichuan University, Chengdu, CHINA.

EP-383
Role of hepatic thigh ratio as a prognostic marker for response assessment after radio iodine therapy in differentiated thyroid carcinoma
P. Singh, *P. K. Pradhan, M. Ora, A. H. Nazar, V. Mishra, Y. Khandelwal, B. Jain, A. Arya;*
S.G.P.G.I., Lucknow, INDIA.

EP-384
Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Outcomes of Patients Treated with Different Doses in a Single Center
S. Orun, *S. Soyluoglu, U. Korkmaz, F. Ustun;*
Trakya University, Edirne, TÜRKIYE.

EP-385
[18F]PSMA-1007 PET-CT Imaging in Advanced Thyroid Carcinoma Patients Refractory tolodine-131 Treatment: Pilot Study from Azerbaijan
F. Novruzov[1], *A. Aliyev*[2], *E. Mehdi*[1], *S. Novruzova*[1], *N. Orucova*[1], *G. Abdurahimova*[1], *F. Giammarile*[3], *J. Aliyev*[4];
[1]Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, AZERBAIJAN, [2]Azerbaijan National Centre of Oncology, Department of Head and Neck Surgery, Baku, AZERBAIJAN, [3]International Atomic Energy Agency, Vienna, AUSTRIA, [4]Azerbaijan National Centre Of Oncology, Department of General Surgery, Baku, AZERBAIJAN.

EP-42

During Congress Opening Hours

e-Poster Area

C: Therapy Clinical Study -> C2 Non-Oncological Treatments -> C21 Non-Oncological Treatments (including Thyroid Benign)

EP-386
Non-invasive treatment of recalcitrant keloids with contact brachytherapy using Phosphorus 32 skin patch and its effectiveness: a pilot study
H. Nellaiappan, *N. Pandit, R. Kumari, S. V Chakkalakkoombil, S. Sundarraj;*
Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, INDIA.

EP-387
Metabolic Therapy with [^{131}I]INa in well differentiated thyroid cancer and hyperthyroidism in patients on hemodyalisis. Comparative study and protocol establishment
A. Cherino Talens[1], *A. Repetto*[1], *S. Chamizo*[2], *M. Romeu*[3], *P. Livianos*[4], *M. García*[3], *M. Hidalgo*[1], *C. Peña*[1,5];
[1]Nuclear Medicine Department. Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, [2]Radiopharmacy Department. Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, [3]Radiophysics Department. Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, [4]Nephrology Department. Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, [5]IdISBa, Palma de Mallorca, SPAIN.

EP-388
Establishing and Monitoring an Effective Management of Benign Nontoxic Multinodular Goiter in Kuwait - Utilizing Two Different Dose Levels of Recombinant Human TSH in Combination with Radioactive Iodine
M. Masoomi[1], *I. Al-Shammeri*[2], *N. Al-Shammeri*[3], *A. Al-Shagouli*[4];
[1]NM, Department of Medical Imaging, Al-Adan Hospital, Kuwait, KUWAIT, [2]NM, Department of Medical Imaging, Al-Adan Hospital, Kuwait, KUWAIT, [3]Department of Surgery, Al-Adan Hospital, Kuwait, KUWAIT, [4]Department of Endocrinology, Al-Adan Hospital, Kuwait, KUWAIT.

EP-389
Utility of the Health Assessment Questionnaire Score in assessing response in patients who undergo radiosynoviorthesis for refractory synovitis
S. More, *N. Jacobs, O. Kolade, B. Hodkinson;*
University of Cape Town, Cape Town, SOUTH AFRICA.

EP-390
Role of ^{99m}Tc-pertechnetate thyroid uptake scan in predicting response to RAI therapy in Graves' disease
K. Bishnoi, *R. Emerson P, A. Kumar, P. S. Patro, G. K. Parida, K. K. Behera, K. Agrawal;*
All India Institute of Medical Sciences, Bhubaneswar, INDIA.

EP-43

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D11 SPECT and SPECT/CT

EP-391
The added value of mar reconstruction to bone spet-ct in the evaluation of patients with arthroplasty
L. Pavanello, *F. Sciume, R. Egoue Mangoue, L. Locantore, M. Cucca, I. Ravelli, M. Zuffante;*
AOUI di Verona, Verona, ITALY.

EP-44

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D12 PET/CT

EP-392
Digital PET/CT Images Reconstructed Using Deep Learning Techniques Have Improved Noise and Contrast Characteristics
Y. Shirakawa, *K. Fukaya, S. Fujita, M. Kawada, H. Ichikawa, J. Suyama, A. Nakanishi;*
Kyorin University Hospital, Tokyo, JAPAN.

EP-393
Motion Correction software program can be used to correction head movement at a PETCT brain scan
V. Jensen, *S. Svalling;*
Rigshospitalet, Clinic for Clinical Physiology, Nuclear Medicine and PET., Copenhagen, DENMARK.

EP-394
Development andvalidation of 2.5-dimensional super-resolution convolutional neural network for whole-body PET images
H. Endo, *K. Hirata, C. Katoh, K. Magota, K. Kudo;*
Hokkaido University, Sapporo,Hokkaido, JAPAN.

EP-395
Implication on the use of contrast enhanced CT for2-[^{18F}] FDGPET/CTattenuation correction in state of art PET devices
N. Lampe, *A. Zander, M. Peréz Lago, H. Grünig, K. Strobel, T. Lima;*
Luzerner Kantonsspital, Luzern, SWITZERLAND.

EP-396
Efficacy of a 'Contrast Correction' Algorithm in Contrast-Enhanced Computed Tomography based Attenuation Correction of Positron Emission Tomography Imaging in the context of Lymphoma Investigations- a phantom study
V. Kilhams, *K. Thomson;*
University Hospitals Plymouth NHS Trust, Plymouth, UNITED KINGDOM.

EP-397
Last generation digital PET: FOV overlap optimization
M. Bernardini;
Hôpital Européen Georges Pompidou (HEGP), Paris, FRANCE.

EP-398
Production of parametric Ki images from dual time point (two 3 min clinical routine static scans)
N. Reshtebar[1], *S. Hosseini*[1], *M. Zhuang*[2], *P. Sheikhzadeh*[3];
[1]*Department of Energy Engineering, Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Nuclear Medicine, Meizhou People's Hospital, Meizhou, CHINA,* [3]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-399
Effect of time of flight and ultra HD reconstruction algorithms on standard uptake value of tumours with different sizes: a comparative study
A. Nautiyal, *I. Pitkin;*
Cromwell Hospital, London, UNITED KINGDOM.

EP-400
Study of the Off-Axis Sensitivity in PET Scanners
T. Cuenca[1], *E. Prieto*[1], *L. Irazola*[1], *V. Morán*[2], *L. Soria*[2], *J. M. Martí-Climent*[1];
[1]*Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Clínica Universidad de Navarra, Madrid, SPAIN.*

EP-401
The impact of Different Reconstruction Parameters along with TOF and PSF in PET/CT Imaging: Patient with Normal and High BMI
S. Rezvani[1,2], *P. Ghafarian*[3,4], *M. Ay*[1,2];
[1]*Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-45

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D1 Instrumentation -> D15 Quality Control, Performance and Standardization

EP-402
Reconstruction Parameter Optimization for EARL Criteria on an Extended Bore Length Solid-State Digital-BGO PET/CT System
J. Kennedy[1,2], *T. Palchan Hazan*[1], *Z. Keidar*[1,2];
[1]*Rambam - Health Care Campus, Haifa, ISRAEL,* [2]*B. and R. Rappaport School of Medicine, Technion – Israel Institute of Technology, Haifa, ISRAEL.*

EP-403
Optimization of Time Coincidence Window and Energy Window for Dedicated Brain PET: A Simulation Study
T. Zare[1,2], *P. Sheikhzadeh*[1,3], *A. Rahmim*[4], *B. Teimourian Fard*[2], *P. Ghafarian*[5,6], *M. Ay*[1,2];
[1]*Department of Medical Physics and Biomedical Engineering,Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [2]*Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Nuclear Medicine Department, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*Departments of Radiology and Physics, University of British Columbia, Vancouver, DC, CANADA,* [5]*Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [6]*PET/CT and Cyclotron Center, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-404
Reproducibility of FDG PET-CT liver SUV uptake metrics as reference or normalisation factor
G. Zwezerijnen[1,2], *J. J. Eertink*[3,2], *M. C. Ferrandez-Ferrandez*[1,2], *S. E. Wiegers*[1,2], *C. N. Burggraaff*[3], *P. J. Lugtenburg*[4], *H. C. W. de Vet*[5,6], *J. M. Zijlstra*[3,2], *R. Boellaard*[1,2];
[1]*Amsterdam UMC location Vrije Universiteit Amsterdam, Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS,* [2]*Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, NETHERLANDS,* [3]*Amsterdam UMC location Vrije Universiteit Amsterdam, Hematology, Amsterdam, NETHERLANDS,* [4]*Erasmus MC Cancer Institute, University Medical Center, Hematology, Rotterdam, NETHERLANDS,* [5]*Amsterdam UMC location Vrije Universiteit Amsterdam, Epidemiology and Data Science, Amsterdam, NETHERLANDS,* [6]*Amsterdam Public Health research institute, Methodology, Amsterdam, NETHERLANDS.*

EP-405
A Novel Adaptive Approach to Automatic Segmentation of PSMA-positive Lesions in Positron Emission Tomography (PET) of Prostate Cancer
J. Brynolfsson[1], *H. Sahlstedt*[1], *J. Richter*[1], *K. Sjöstrand*[2], *A. Anand*[1];
[1]*Exini Diagnostics AB, Lund, SWEDEN,* [2]*Lantheus Medical Imaging, Billerca, MA, UNITED STATES OF AMERICA.*

EP-406
3D Printing Anthropomorphic Phantoms with Grid-Based Internal Structures as a Method to Evaluate Quantitative SPECT for Non-uniform Activity Distributions
L. Jessen[1], *M. Ljungberg*[1], *J. Gustafsson*[1], *S. Curkic*[1], *M. Imsirovic*[2], *K. Sjögreen Gleisner*[1];
[1]*Medical Radiation Physics, Lund University, Lund, SWEDEN,* [2]*Skane University Hospital, Lund, SWEDEN.*

EP-407
Comparison of methods for post-SIRT residual activity assessment
N. Cherbuin, *S. Boughdad, N. Schaefer, J. Prior, R. Moeckli, S. Gnesin;*
Lausanne University Hospital, Lausanne, SWITZERLAND.

EP-408
Fanc Pet Transverse Uniformity Protocol: adapatable to Spect ?
A. Seret[1], *T. Carlier*[2];
[1]*University of Liege, Liege, BELGIUM,* [2]*CHU Nantes, Nantes, FRANCE.*

EP-409
Assessment of PET scanner SNR, and CNR factors: validation of Gate Monte Carlo code and STIR reconstruction with experimental study
M. Karimipourfard, *S. Sina, M. Sadeghi, M. Shobeiry, R. Safari, M. Alavi;*
Department of Ray-Medical Engineering, Shiraz, IRAN, ISLAMIC REPUBLIC OF.

EP-410
Quantification with 3D-printed Source Holder Shows Geometrical Difference Between Dose Calibrators with Yttrium-90
S. Pekkarinen[1], *A. Rintala*[1], *T. Miettinen*[1], *L. Koivula*[1], *E. Hippeläinen*[2], *V. Reijonen*[1];
[1]*Department of Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND,* [2]*Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND.*

EP-411
Optimizing the Performance evaluation tests of Gemini TF64 PET/CT scanner using ^{68}Ga isotope adhering NEMA-NU-2 2007 standards
B. Rawat[1,2], *V. Sawant*[3,2], *A. K. Jha*[1,2], *S. Mithun*[1,2], *V. Rangarajan*[1,2];
[1]*Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute, Mumbai, INDIA,* [3]*ACTREC, Navi Mumbai, INDIA.*

EP-412
64-Copper PET/CT Imaging using Bayesian Penalized Likelihood Reconstruction Algorithm
P. Sheikhzadeh, *A. Monsef, A. Ghafari;*
Tehran University Of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-46

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D21 Data Analysis in Neuro and Cardio

EP-413
A Problem and the Solution of the Algorithm for Calculating Washout Rate Using MyocardialSPECT Analysis Software
H. Miyauchi[1], *T. Iimori*[2], *R. Ono*[1], *K. Hoshi*[3], *K. Sawada*[2], *Y. Kobayashi*[1];
[1]*Chiba University Graduate School of Medicine, Chiba, JAPAN,* [2]*Chiba University Hospital, Chiba, JAPAN,* [3]*The University of Tokyo Hospital, Tokyo, JAPAN.*

EP-414
Nobel metabolic quantification approach of dopaminergic activity by ^{18}F-DOPA (PET-CT)
J. M. Gandía[1,2], *A. Crespo-Jara*[1], *C. M. de-Santiago*[3], *A. Orozco*[1], *T. Plaza*[1], *J. Verdú*[1];
[1]*Hospital Universitario de San Juan de Alicante, San Juan de Alicante, SPAIN,* [2]*Universidad Miguel Hernández, Elche, SPAIN,* [3]*Instituto Azorín, Petrer, SPAIN.*

EP-415
Sex Differences in Resting-state Functional and Structural Connectivity of C57BL/6 Normal Mice using MRI and 18F-FDG PET
S. Kim[1], *Y. Lee*[2], *H. Jang*[2], *Y. Choi*[3], *E. Byeon*[1], *Y. Kim*[4], *H. Lee*[2];
[1]*Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF,* [2]*Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [3]*Hanyang Univ., Seoul, KOREA, REPUBLIC OF,* [4]*Department of Nuclear Medicine, SMG-SNU Boramae Medical Center, Seoul, KOREA, REPUBLIC OF.*

EP-416
Nuclear medicine image processing software for seizure onset zone localization in refractory epilepsy
L. Latorre Moreno[1], *A. Perissinotti*[2,3], *R. Tudela*[3], *A. Fritsch*[2], *X. Setoain*[2,3], *A. Niñerola-Baizán*[2,3];
[1]*Biophysics and Bioengineering Unit, Medicine Faculty, Universitat de Barcelona, Barcelona, SPAIN,* [2]*Nuclear Medicine Department, Hospital Clínic, Barcelona, SPAIN,* [3]*Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Barcelona, SPAIN.*

EP-417
A fully-automatic, fast, tracer-independent motion correction methodology for dynamic PET brain studies
S. Gutschmayer[1], *O. Muzik*[2], *Z. Chalampalakis*[3], *I. Rausch*[1], *S. Zuehlsdorff*[4], *H. Newiger*[5], *T. Beyer*[1], *L. Shiyam Sundar*[1];
[1]*QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Wayne State University, Department of Pediatrics, Detroit, MI, UNITED STATES OF AMERICA,* [3]*Laboratoire d'Imagerie Biomédicale Multimodale (BioMaps), Université Paris-Saclay, CEA, CNRS, Inserm, Service Hospitalier Frédéric Joliot, Orsay, FRANCE,* [4]*Siemens Medical Solutions USA, Inc., Hoffman Estates, IL, UNITED STATES OF AMERICA,* [5]*Siemens Healthcare GmbH, Erlangen, GERMANY.*

EP-418
Comparison of known tracers using new detectors: Tetrosfomin vs Sestamibi
V. Ostermann, *B. Hoyer;*
Department of Nuclear Medicine, Vejle, DENMARK.

EP-47

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D22 Other Data Analysis

EP-419
Evaluation of SUL measurements in 68Ga-DOTATATE PET/CT Imaging
Y. Parlak, *G. Mutevelizade, D. Goksoy, G. Gumuser, E. Sayit;*
Celal Bayar University, Yunusemre, TÜRKIYE.

EP-420
Assessment of the Functional Distribution of Perfusion and Ventilation in the Lung Lobes Using SPECT/CT
S. Al-Atabi;
Rigshospitalet, København, DENMARK.

EP-421
Towards a better-managed "off-label" use of radiopharmaceuticals: an analysis of the European regulatory framework
A. Iudicello[1,2], *L. Urso*[3], *M. Santimaria*[4], *S. Panareo*[1];
[1]*Nuclear Medicine Unit, Oncology and Hematology Department, University Hospital of Modena, Modena, ITALY,* [2]*Pharmaceutical Department, Azienda USL of Modena, Modena, ITALY,* [3]*Translational Medicine Department, Ferrara University, Ferrara, ITALY,* [4]*Nuclear Medicine Unit, S. Bortolo Hospital, Azienda ULSS 8 Berica, Vicenza, ITALY.*

EP-422
Automatic bone scan index is feasible on pseudo planar whole body images obtained from whole body SPECT
D. Minarik, *E. Tragardh;*
Skane University Hospital, Malmö, SWEDEN.

EP-423
Characterization of Salivary Gland Uptake and Volume in PSMA PET Imaging: Novel Phantom Study Approach
R. Fedrigo[1,2], *G. Chaussé*[1], *R. Coope*[3], *F. Bénard*[1,2,4], *A. Rahmim*[1,4,2], *C. Uribe*[4,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*University of British Columbia, Vancouver, BC, CANADA,* [3]*Canada's Michael Smith Genome Science Centre at BC Cancer, Vancouver, BC, CANADA,* [4]*BC Cancer, Vancouver, BC, CANADA.*

EP-424
Optimization of parameters for PET CT image compression using singular value decomposition
J. Chaudhary[1], *A. K. Pandey*[1], *P. D. Sharma*[2], *C. Patel*[1], *R. Kumar*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*SGTB khalsa College, New Delhi, INDIA.*

EP-425
Comparative study of respiratory gating techniques in last generation PET-CT
B. Serrano[1], *K. Tebbouche*[1], *R. Amblard*[1], *F. Hugonnet*[2], *N. Garnier*[1], *R. Villeneuve*[1], *V. Nataf*[2], *F. Mocquot*[2], *B. Paulmier*[2], *M. Faraggi*[2];
[1]*Medical Physics Department, Centre Hospitalier Princesse Grace, Monaco, MONACO,* [2]*Nuclear Medicine Department, Centre Hospitalier Princesse Grace, Monaco, MONACO.*

EP-426
Joint evaluation of impact of various Collimators and iterative reconstruction protocols on ^{67}Ga SPECT/CT quantification
S. Rezaei[1,2], *E. Gharepapagh*[1,2], *P. Sheikhzadeh*[3,4];
[1]*Department of Radiology, Medical School, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF,* [2]*Medical Radiation Sciences Research Team, Tabriz University of Medical Sciences, Tabriz, IRAN, ISLAMIC REPUBLIC OF,* [3]*Department of Medical Physics and Biomedical Engineering, School of Medicine, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-427
Optimal Acquisition and Uptake Time for [^{68}Ga] Ga-cxcr4 pet/ct in Patients with Anaplastic High-grade Glioma
H. Roustaei[1], *H. Vosoughi*[2,3], *K. Aryana*[1], *N. Norouzbeigi*[3], *K. Anvari*[4];
[1]*Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [2]*Department of Medical Physics, Mashhad University of Medical Science, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [3]*Nuclear Medicine Department, Razavi Hospital, Imam Reza International University, Mashhad, IRAN, ISLAMIC REPUBLIC OF,* [4]*Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.*

EP-428
Qualification of Coronary Artery Atherosclerotic Burden and Muscle Mass: Comparison of Two Freely Available Software Programs
F. Volpicelli[1], *C. Nappi*[1], *R. Megna*[2], *F. Volpe*[1], *A. Ponsiglione*[1], *E. Caiazzo*[1], *L. Piscopo*[1], *C. G. Mainolfi*[1], *E. Vergara*[1], *M. Imbriaco*[1], *M. Klain*[1], *M. Petretta*[3], *A. Cuocolo*[1];
[1]*Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, ITALY,* [2]*Institute of Biostructure and Bioimaging, National Council of Research, Naples, ITALY,* [3]*Department of Diagnostic Imaging, IRCCS Synlab SDN, Naples, ITALY.*

EP-429
^{99m}Tc MDPBone Scan Image Restoration Using Blind Deconvolution Analysis
G. Kaur[1], *J. Chaudhary*[1], *A. K. Pandey*[1], *P. D. Sharma*[2], *C. Patel*[1], *R. Kumar*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*SGTB khalsa College, New Delhi, INDIA.*

EP-48

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D23 Image Reconstruction

EP-430
Development of Poisson noise reduction method using wavelet based BayesShrink technique in brain SPECT
K. Matsumoto[1], *Y. Wada*[2], *K. Murase*[3], *K. Endo*[1];
[1]*Kyoto College Of Medical Science, Kyoto, JAPAN,* [2]*Center for Biosystems Dynamics Research, RIKEN, Kobe, JAPAN,* [3]*Graduate School of Medicine, Osaka University, Osaka, JAPAN.*

EP-431
Optimization of Bayesian penalized likelihood reconstruction algorithm for [^{18}F]flutemetamol amyloid PET images
S. Fukuda[1], *K. Miwa*[2], *K. Wagatsuma*[1,3], *Y. Yakushiji*[1], *T. Yamao*[2], *Y. Kamitaka*[3], *N. Nishikawa*[4], *T. Hasegawa*[1];
[1]*Kitasato University Graduate School of Medical Sciences, Kanagawa, JAPAN,* [2]*Fukushima Medical University, Fukushima, JAPAN,* [3]*Tokyo Metropolitan Institute of Gerontology, Tokyo, JAPAN,* [4]*International University of Health and Welfare, Tochigi, JAPAN.*

EP-432
Optimization of ^{18}F-FDOPA Whole Body PET
B. Olsson[1], *F. Hedeer*[1], *D. Minarik*[2], *A. Akbari*[1], *E. Mellhammar*[2];
[1]*Clinical Physiology and Nuclear Medicine, Malmö/Lund, SWEDEN,* [2]*Radiation Physics, Malmö/Lund, SWEDEN.*

EP-433
Determining an Optimum Number of Reconstruction Iterations for SUV Quantification in Spinal Imaging using a Novel 360° CZT SPECT/CT System
S. Cade, *R. Leigh, M. Evans;*
Royal United Hospitals Bath NHS Foundation Trust, Bath, UNITED KINGDOM.

EP-434
Impact of Regularized Reconstruction on Image Quality of Metastases in PSMA PET Images
R. Fedrigo[1,2], *D. J. Kadrmas*[3], *R. Coope*[4], *F. Bénard*[1,2,5], *A. Rahmim*[1,2,5], *C. Uribe*[5,2];
[1]*BC Cancer Research Institute, Vancouver, BC, CANADA,* [2]*University of British Columbia, Vancouver, BC, CANADA,* [3]*University of Utah, Salt Lake City, UT, UNITED STATES OF AMERICA,* [4]*Canada's Michael Smith Genome Science Centre at BC Cancer, Vancouver, BC, CANADA,* [5]*BC Cancer, Vancouver, BC, CANADA.*

EP-435
Long axial field-of-view positron emission tomography post-radiomebolization yttrium-90 clinical protocol optimization
K. Zeimpekis[1], *L. Mercolli*[1], *G. Prenosil*[1], *M. Conti*[2], *H. Sari*[3], *K. Shi*[1], *A. Rominger*[1];
[1]*Nuclear Medicine, Inselspital, Bern University Hospital, Bern, SWITZERLAND,* [2]*Molecular Imaging, Siemens Healthineers, Knoxville, TN, UNITED STATES OF AMERICA,* [3]*Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.*

EP-436
Development and Validation of a Scatter Correction Framework for Total-Body Positron Emission Tomography using the uEXPLORER
R. Bayerlein[1], *E. K. Leung*[2], *Z. Xie*[3], *B. A. Spencer*[1], *Q. Wang*[3], *N. Omidvari*[3], *L. Nardo*[1], *S. R. Cherry*[3,1], *R. D. Badawi*[1,3];
[1]*Department of Radiology, UC Davis, CA, UNITED STATES OF AMERICA,* [2]*UIH America, Inc., Houston, TX, UNITED STATES OF AMERICA,* [3]*Department of Biomedical Engineering, UC Davis, CA, UNITED STATES OF AMERICA.*

EP-437
SPECT acquisition and reconstruction optimisation for the pre-therapeutic step of the Selective Internal Radiation Therapy (SIRT)
E. Verger[1,2], *J. Reichart*[1], *L. Vervueren*[1], *P. Fosse*[1], *O. Morel*[2], *F. Bouchet*[1], *F. Lacoeuille*[1,3];
[1]*Centre Hospitalier Universitaire (CHU) d'Angers, Service de Médecine Nucléaire, Angers, FRANCE,* [2]*Institut de Cancérologie de l'Ouest (ICO) Paul Papin, Service de Médecine Nucléaire, Angers, FRANCE,* [3]*Université d'Angers, Inserm UMR 1307, CNRS UMR 6075, Nantes Université, CRCI2NA, Angers, FRANCE.*

EP-438

Positron range correction in combination with resolution recovery image reconstruction of [124I]-PET data

H. Kertesz[1], *M. Conti*[2], *V. Panin*[2], *J. Cabello*[2], *D. Bharkhada*[2], *L. Papp*[3], *T. Beyer*[1], *W. Jentzen*[4], *J. Cal-Gonzalez*[5], *J. L. Herraiz*[6], *A. Lopez-Montes*[6], *I. Rausch*[1];
[1]*QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,* [3]*Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA,* [4]*Clinic for Nuclear Medicine, University Hospital Essen, Essen, GERMANY,* [5]*Ion Beam Applications, Protontherapy Center Quironsalud, Madrid, SPAIN,* [6]*Nuclear Physics Department and IPARCOS, Faculty of Physical Sciences, University Complutense of Madrid, Madrid, SPAIN.*

EP-439

Count dependent regularized image reconstruction of dynamic brain PET

E. Lindström[1], *J. Sousa*[2], *M. Lubberink*[2];
[1]*Uppsala University Hospital, Uppsala, SWEDEN,* [2]*Uppsala University, Uppsala, SWEDEN.*

EP-440

Optimization of the Acquisition Time and the Injected Dose of ^{18}F-FDG in High Sensitive PET-CT scanner

M. Al-Fatlawi[1,2], *F. Pak*[2], *S. Frazanefar*[3], *A. Monsef*[4], *P. Sheikhzadeh*[3,4];
[1]*Babel Health Directorate - Shaheed Al-Muhrab center of cath & cardiac surgery's, Babel, IRAQ,* [2]*Department of Radiology Technology and Radiotherapy, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [3]*Department of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF,* [4]*Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-49

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D24 Radiomics

EP-441

Radiomic analysis of NPC for treatment and prognosis correlation and prediction

C. Lee[1], *J. Hou*[2], *Y. Lin*[2], *J. Kung*[2], *S. Tsai*[2], *J. Chen*[1];
[1]*Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, TAIWAN,* [2]*Department of Nuclear Medicine, Taichung Veterans General Hospital, Taichung City, TAIWAN.*

EP-442

Development and validation of Radiomic Signature for Non-small-cell Lung Cancer: A Proof-of-Concept Study

A. Jha[1,2,3], *S. Mithun*[1,2,3], *U. B. Sherkhane*[1,2], *V. Jaiswar*[2], *B. Nath*[2], *G. M. S. Mehta*[2,3], *S. Panchal*[2,3], *N. Purandare*[2,3], *K. Prabhash*[4,3], *V. Rangarajan*[2,3], *A. Dekker*[1], *L. Wee*[1];
[1]*Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical, Maastricht, NETHERLANDS,* [2]*Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, INDIA,* [3]*Homi Bhabha National Institute, Mumbai, INDIA,* [4]*Department of Medical Oncology, Tata Memorial Hospital, Mumbai, INDIA.*

EP-443

Prognostic role of ^{18}F-FDG PET radiomics for Diffuse Large B-Cell Lymphoma patients: comparison of model performance with different segmentation methods and target lesions

L. Travaini[1], *F. Botta*[2], *M. Ferrari*[2], *S. Raimondi*[3], *G. Lo Presti*[3], *F. Corso*[3], *L. Airò Farulla*[1,4], *S. Mazzara*[5], *T. Radice*[5], *A. Vanazzi*[5], *M. Cremonesi*[6], *E. Derenzini*[5,7], *F. Ceci*[8,4];
[1]*Nuclear Medicine Division, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [2]*Medical Physics Unit, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [3]*Department of Experimental Oncology, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [4]*Department of Oncology and Hemato-oncology, University of Milan, ITALY,* [5]*Onco-Hematology Division, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [6]*Radiation Research Unit, IEO European Institute of Oncology IRCCS, Milan, ITALY,* [7]*Department of Health Sciences, University of Milan, Milan, ITALY,* [8]*Nuclear Medicine Division, European Institute of Oncology, Milan, ITALY.*

EP-445

Predicting prognosis of patients with recurrent Graves' Disease: the value of adding radiomic features of planar ^{123}I-scintigraphy

M. Dotinga[1], *F. H. P. van Velden*[1], *W. Grootjans*[1], *E. Kapiteijn*[1], *M. Snel*[1], *L. F. de Geus-Oei*[1,2], *D. Vriens*[1];
[1]*Leiden University Medical Center, Leiden, NETHERLANDS,* [2]*University of Twente, Enschede, NETHERLANDS.*

EP-446

Prognostic value of pretreatment ^{18}F-FDG PET texture features in advanced high grade serous ovarian cancer

D. Travaglio Morales, *C. Huerga Cabrerizo, E. López Llobet, Y. Abadi Sedraoui, L. Giraldo Gonzalez, S. Rodado Marina, C. Escabias del Pozo, C. Lancha Hernandez, S. Rizkallal Monzón, J. Cordero García, M. Coronado Poggio, L. Domínguez Gadea;
Hospital Universitario La Paz, Madrid, SPAIN.*

EP-447

Resectability prediction of Non-Small Cell Lung Carcinoma based on Computed Tomography Radiomic Features using Machine Learning algorithms

V. Jaiswar[1], *A. K. Jha*[2,1,3], *S. Mithun*[2,1,3], *U. K. B. Sherkhane*[2,1], *G. M. S. Mehta*[1,3], *S. Panchal*[1,3], *B. Nath*[1], *N. Purandare*[1,3], *V. Rangarajan*[1,3], *A. Dekker*[2], *L. Wee*[2];
[1]*Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA,* [2]*Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, 6229 ET, Maastricht, NETHERLANDS,* [3]*Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.*

EP-448

Can we rely on PET Segmentation for radiomic extraction for malignancy of hollow organs like the rectum?

B. Nath[1], *A. K. Jha*[1,2,3], *S. Mithun*[1,2,3], *G. M. S. Mehta*[1,3], *S. Panchal*[1,3], *A. Nautiyal*[4,3], *U. K. B. Sherkhane*[1,2], *V. Jaiswar*[1], *N. Purandare*[1,3], *V. Rangarajan*[1,3], *A. Dekker*[2], *L. Wee*[2];
[1]*Tata Memorial Hospital Mumbai, Mumbai, INDIA,* [2]*Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical Centre+, Maastricht, NETHERLANDS,* [3]*Homi Bhabha National Institute, BARC Training School Complex, Mumbai, INDIA,* [4]*Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, INDIA.*

EP-448a

Machine Learning-Based Radiomics for Multiple Primary Prostate Cancer Biological Characteristics Prediction with ^{18}F-PSMA-1007 PET: Different Thresholding Segmentation Comparison

F. Yao, *S. Bian, D. Zhu, Y. Yang;
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, CHINA.*

EP-50

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D2 Data Analysis -> D25 Artificial Intelligence

EP-449

Predicting axillary lymph node metastasis in early-stage breast cancer using primary tumor image features on [^{18}F] FDG PET: a comparative study of engineered radiomics, deep learning, and conventional methods

T. Escobar[1,2], *C. Provost*[1,3], *R. Seban*[1,3], *S. Vauclin*[2], *P. Pineau*[2], *L. Champion*[1,3], *I. Buvat*[1];
[1]*Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), Institut Curie, Inserm, Université Paris-Saclay, Orsay, FRANCE,* [2]*DOSIsoft SA, Cachan, FRANCE,* [3]*Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, Saint-Cloud, FRANCE.*

EP-450

Explainable prediction of coronary artery disease in nuclear medical imaging using deep learning

N. Papandrianos[1], *S. Moustakidis*[2], *A. Feleki*[1], *E. Papageorgiou*[1];
[1]*Department of Energy Systems, University of Thessaly, Gaiopolis, Larisa, GREECE,* [2]*AIDEAS OÜ, Narva mnt 5, Tallin, ESTONIA.*

EP-451

Deep learning-based classification of disease activity of thyroid-associated ophthalmopathy using ^{99m}Tc-DTPA SPECT/CT

M. Zhao[1], *L. Li*[2], *G. Wang*[2], *Z. Zhu*[2], *W. Zhou*[3], *F. Zhu*[2];
[1]*Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA,* [2]*School of Computer and Communication Engineering, Zhengzhou University of Light Industry, Zhengzhou, CHINA,* [3]*Department of Applied Computing, Michigan Technological University, Houghton, MI, UNITED STATES OF AMERICA.*

EP-452

Deep learning for automatic diagnosis of coronary artery disease using SPECT MPI images

N. Papandrianos[1], *A. Feleki*[1], *K. Kokkinos*[1], *D. Apostolopoulos*[2], *E. Papageorgiou*[3];
[1]*University of Thessaly, Larisa, GREECE,* [2]*University of Patras, Department of Medicine, Rion, Patras, GREECE,* [3]*University of Thessaly, Department of Energy Systems, Larisa, GREECE.*

EP-453

Investigation of 123I-FP-CIT SPECT Imaging Time Reduction Using Artificial Intelligence

Y. Ishiwata, *H. Iizuka, K. Horie, A. Onoma, T. Yamashiro, M. Ogawa, D. Utsunomiya;
Yokohama City University Hospital, Yokohama, JAPAN.*

EP-454

TOF image enhancement of non-TOF PET scans using deep learning: a generalizability study

A. Mehranian[1], *S. D. Wollenweber*[2], *K. M. Bradley*[3], *M. D. Walker*[4], *M. Huellner*[5], *L. Guerra*[6], *C. Landoni*[6], *A. Iagaru*[7], *M. Mehdi Khalighi*[7], *F. Kotasidis*[8], *K. Su*[2], *R. Johnsen*[2], *D. R. McGowan*[9];
[1]*GE Healthcare, Oxford, UNITED KINGDOM,* [2]*GE Healthcare, Waukesha, WI, UNITED STATES OF AMERICA,* [3]*Wales Research and Diagnostic PET Imaging Centre, University Hospital of Wales, Cardiff, UNITED KINGDOM,* [4]*Oxford University Hospitals NHS FT, Oxford, UNITED KINGDOM,* [5]*Zurich University Hospital, Zurich, SWITZERLAND,* [6]*Department of Nuclear Medicine, ASST Monza-University of Milano, Bicocca, ITALY,* [7]*Stanford University, Stanford, CA, UNITED STATES OF AMERICA,* [8]*GE Healthcare, Zurich, SWITZERLAND,* [9]*Department of Oncology, University of Oxford, Oxford, UNITED KINGDOM.*

EP-455

Machine learning-based approach reveals essential features for simplified TSPO PET quantification in ischemic stroke patients

A. Zatcepin[1,2], *A. Kopczak*[3], *A. Holzgreve*[1], *A. Schindler*[4], *M. Düring*[3,5], *L. Kaiser*[1], *M. Schidlowski*[6,7], *T. Stoecker*[7], *P. Bartenstein*[1,8], *M. Dichgans*[2,3], *N. Albert*[1], *M. Brendel*[1,2,8], *S. Ziegler*[1];
[1]*Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, GERMANY,* [2]*German Center for Neurodegenerative Diseases (DZNE) Munich, Munich, GERMANY,* [3]*Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, GERMANY,* [4]*Department of Neuroradiology, University Hospital, LMU Munich, Munich, GERMANY,* [5]*Medical Image Analysis Center (MIAC) & Department of Biomedical Engineering, University of Basel, Basel, SWITZERLAND,* [6]*Department of Epileptology, University of Bonn Medical Center, Bonn, GERMANY,* [7]*German Center for Neurodegenerative Diseases (DZNE) Bonn, Bonn, GERMANY,* [8]*Munich Cluster for Systems Neurology (SyNergy), Munich, GERMANY.*

EP-456

Single Tracer Recovery using Neural Ordinary Differential Equation: a step forward for dual-tracer studies

J. Hong[1], *M. Brendel*[2], *K. Erlandsson*[3], *H. Sari*[4], *J. Lu*[5], *H. Choi*[6], *A. Rominger*[1], *K. Shi*[1];
[1]*University of Bern/Inselspital, Bern, SWITZERLAND,* [2]*Department of Nuclear Medicine, Ludwig-Maximillians-University of Munich, Munich, GERMANY,* [3]*Institute of Nuclear Medicine, University College London, London, UNITED KINGDOM,* [4]*Siemens Healthineers A.G., Lausanne, SWITZERLAND,* [5]*Huashan Hospital, Fudan University, Shanghai, CHINA,* [6]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.*

EP-457

Initial clinical experience with a deep learning attenuation correction software for the performance of MPI using a cardio dedicated CZT gamma camera. A pilot study

V. Sanchez, *E. Good, A. Davidsson, M. Ressner, P. Norberg, A. Iakovidou, M. Ochoa-Figueroa;
Linköping University Hospital, Linköping, SWEDEN.*

EP-458

Generating a simulated PSMA PET map with deep learning based on anatomical MRI alone

R. Laudicella[1,2,3], *A. Comelli*[3], *M. Schwyzer*[4], *E. Konukoglu*[5], *M. Messerli*[1], *A. Stefano*[6], *D. Eberli*[7], *S. Baldari*[2], *I. A. Burger*[1,8];
[1]*Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, SWITZERLAND,* [2]*Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY,* [3]*Ri.MED Foundation, Palermo, ITALY,* [4]*Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, SWITZERLAND,* [5]*Computer Vision Lab, ETH Zurich, Zurich, SWITZERLAND,* [6]*Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalù, ITALY,* [7]*Department of Urology, University Hospital of Zürich, Zurich, SWITZERLAND,* [8]*Department of Nuclear Medicine, Cantonal Hospital Baden, Baden, SWITZERLAND.*

EP-459

AI-based detection and characterization of lung tumors in 18F-FDG-PET/CT including measurements of tumor dimension in CT

P. Borrelli[1], *M. Larsson*[2,3], *R. Rossi Norrlund*[1,4], *O. Enqvist*[3,2], *R. Kaboteh*[1], *E. Trägårdh*[5,6], *L. Edenbrandt*[1,7];
[1]*Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, SWEDEN,*

[2]Department of Electrical Engineering, Chalmers University of Technology, Gothenburg, SWEDEN, [3]Eigenvision AB, Malmö, SWEDEN, [4]Department of Radiology, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN, [5]Department of Translational Medicine and Wallenberg Center for Molecular Medicine, Lund University, Malmö, SWEDEN, [6]Department of Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEDEN, [7]Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN.

EP-460

Can deep learning predict the receptors' status of breast cancer's metastases on 18F-FDG PET/CT images ?

N. Moreau[1,2], *C. Rousseau*[3,4], *C. Fourcade*[1,2], *L. Ferrer*[3,5], *M. Lacombe*[6], *C. Guillerminet*[6], *M. Colombié*[3], *P. Jézéquel*[3,4], *M. Campone*[3,5], *M. Rubeaux*[1], *N. Normand*[2];
[1]*Keosys Medical Imaging, St Herblain, FRANCE,* [2]*Nantes Université, Ecole Centrale Nantes, CNRS, LS2N, UMR 6004, F-44000 Nantes, FRANCE,* [3]*ICO cancer center, Nantes, FRANCE,* [4]*Nantes Université, CRCINA, Nantes, FRANCE,* [5]*Université d'Angers, CRCINA, Angers, FRANCE,* [6]*ICO cancer center, Angers, FRANCE.*

EP-461

Image Augmentation for Image-to-image Translation in ^{18}F-FDG PET imaging: Does it make a difference?

A. Ghafari, *A. Monsef, P. Sheikhzadeh;
Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-462

Using Visual Recognition Based Machine Learning For The Prediction Of Survival In Patients With Colorectal Cancer With Liver Metastasis

S. Asa, *A. Kibar, B. Ince, A. Nazari, F. Aghazada, F. Beytur, S. Sager, K. Sonmezoglu;
Istanbul University Cerrahpasa Department of Nuclear Medicine, Istanbul, TÜRKIYE.*

EP-463

Detection of mediastinal lymph node non-small cell lung cancer metastasis based on an Artificial Intelligence reading system of 18f-fdg pet-ct

M. Milà López[1,1], *P. Fierro Alanis*[1], *D. Baquero Velandia*[2], *P. Borrelli*[3], *P. Rodriguez Taboada*[2], *C. Achury*[1], *G. Rosado Rodriguez*[2], *D. Carrera*[1], *M. García-Gil.*[4], *L. Quintero*[1], *I. Jiménez Romero*[1], *M. Larsson*[5], *L. Edenbrandt*[6];
[1]*Servicio Medicina Nuclear Hospital Universitari Joan XXIII de Tarragona, Tarragona, SPAIN,* [2]*Servicio Cirugía Torácica Hospital Universitari Joan XXIII de Tarragona, Tarragona, SPAIN,* [3]*Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, SWEDEN,* [4]*Coordinadora de Gestió de la Recerca i Innovació. Institut de Diagnòstic per la Imatge (IDI), Barcelona, SPAIN,* [5]*Department of Electrical Engineering, Chalmers University of Technology, Gothenburg, Sweden Eigenvision AB, Gothenburg, SWEDEN,* [6]*Department of Clinical Physiology, Region Västra Götaland, Sahlgrenska University Hospital; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, SWEDEN.*

EP-464

Estimation of CT images from PET images without non-attenuation-corrected PET images using GAN

M. Saito;
Biomedical Science and Engineering, Hokkaido University Graduate School, Sapporo, JAPAN.

EP-465

Accessing the predictability of Epidermal growth factor receptor status from Computed Tomography radiomics using machine learning

U. Sherkhane[1,2], *V. Jaiswar*[1], *S. Mithun*[1,2,3], *A. K. Jha*[1,2,3], *V. Rangarajan*[1,3], *L. Wee*[2], *A. Dekker*[2];
[1]*Tata Memorial Hospital, Mumbai, INDIA,* [2]*School for Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, NETHERLANDS,* [3]*Homi Bhabha National Institute, Mumbai, INDIA.*

EP-466

Evaluation of a convolution neural network for baseline total tumor metabolic volume on 18F-FDG PET in a diffuse large cell B lymphoma cohort

M. Karimdjee[1], *G. Delaby*[1], *D. Huglo*[1], *C. Baillet*[1], *A. Willaume*[2], *S. Dujardin*[1], *A. Bailliez*[2];
[1]*CHU Lille, Lille, FRANCE,* [2]*Groupement des Hôpitaux de l'Institut Catholique de Lille, Lille, FRANCE.*

EP-467

Physics Informed Deep Learning for PSMA-directed Pharmacokinetic Analysis

Z. Rzayeva[1], *M. Chu*[2], *K. Shi*[1,3], *G. Birindelli*[3], *J. Hong*[3], *A. Afshar-Oromieh*[4], *A. Rominger*[4];
[1]*TUM, Munich, GERMANY,* [2]*Max-Planck-Institut für Informatik, Saarbrücken, GERMANY,* [3]*University of Bern, Bern, SWITZERLAND,* [4]*Universitätsklinik für Nuklearmedizin, Bern, SWITZERLAND.*

EP-468

^{131}Iodine scan image denoising using deep neural network

A. Pandey[1], *J. Chaudhary*[1], *A. Hemrom*[1], *P. D. Sharma*[2], *C. Patel*[1], *C. S. Bal*[1], *R. Kumar*[1];
[1]*All India Institute of Medical Sciences, New Delhi, INDIA,* [2]*SGTB Khalsa College, University of Delhi, New Delhi, INDIA.*

EP-469

Towards unsupervised segmentation of hyperfunctioning parathyroid tissue in [^{18}F]Fluorocholine PET/CT by deep PET approximation

L. Jarabek[1], *J. Jamšek*[2], *A. Cuderman*[2], *F. Cvetko*[3], *S. Rep*[2,4], *M. Hočevar*[5,3], *T. Kocjan*[3,6], *M. Jensterle*[3,6], *Ž. Špiclin*[7], *Ž. Maček Ležaić*[8], *L. Ležaić*[2,3];
[1]*General hospital Novo mesto, Novo mesto, SLOVENIA,* [2]*Department of Nuclear Medicine, UMC Ljubljana, Ljubljana, SLOVENIA,* [3]*Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA,* [4]*Faculty of Health Sciences, University of Ljubljana, Ljubljana, SLOVENIA,* [5]*Department of Surgical Oncology, Institute of Oncology, Ljubljana, SLOVENIA,* [6]*Department for Endocrinology, Diabetes and Metabolic Diseases, UMC Ljubljana, Ljubljana, SLOVENIA,* [7]*Faculty of Electrical Engineering, University of Ljubljana, Ljubljana, SLOVENIA,* [8]*Rozna dolina, c.VI/8, Ljubljana, SLOVENIA.*

EP-470

Implementation of Information Technology Infrastructure for Federated Machine Learning in Tertiary Cancer Care in India

A. Jha[1,2,3], *V. Rangarajan*[2,3], *S. Mithun*[1,2,3], *U. B. Sherkhane*[1,2], *V. Jaiswar*[2], *N. Purandare*[2,3], *L. Wee*[1], *A. Dekker*[1];
[1]*Department of Radiation Oncology (Maastro), GROW School for Oncology, Maastricht University Medical, Maastricht, NETHERLANDS,* [2]*Tata Memorial Hospital, Mumbai, INDIA,* [3]*Homi Bhabha National Institute, Mumbai, INDIA.*

EP-471

Using deep learning techniques to analyse PET/CT images of adrenal glands to assist in the diagnosis of adrenal adenomas

R. Crawford[1], *D. Gillett*[1,2], *R. Senanayake*[2], *W. Drake*[3,4], *M. Brown*[3,5], *I. Mendichovszky*[1], *L. Aloj*[1], *H. Cheow*[1], *M. Gurnell*[2];

[1]*Cambridge University Hospitals, Cambridge, UNITED KINGDOM,* [2]*University of Cambridge, Cambridge, UNITED KINGDOM,* [3]*Queen Mary University, London, UNITED KINGDOM,* [4]*Barts Health NHS Trust, London, UNITED KINGDOM,* [5]*NIHR Barts Hospital Biomedical Research Centre, London, UNITED KINGDOM.*

EP-472

^{18}F-FDG PET Image Quality Improvement using a Pix2Pix Conditional Generative Adversarial Network Combined with The Bayesian Penalized Likelihood (BPL) Reconstruction Algorithm

A. Ghafari, *A. Monsef, P. Sheikhzadeh;
Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-473

Role of Artificial Intelligence tool in detecting recurrent Mantle cell Lymphoma (MCL)lesions compared to regular visuals assessment

D. Khan, *S. Sagar, J. Pathak, S. K. Velliangiri, S. A. Shamim, R. Kumar;
AIIMS Delhi, Delhi, INDIA.*

EP-474

Utility of AI (Artificial Intelligence) tool for automatic segmentation and calculation of quantitative PET parameters compared to conventional manual segmentation in patients of Hodgkin's Lymphoma

S. Sagar, *D. Khan, A. S. Babu, J. Pathak, A. Mahalik, S. Jha, S. A. Shamim, R. Kumar;
AIIMS, Delhi, INDIA.*

EP-51

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D3 Radiation Protection -> D31 Radiation Exposure and Protection

EP-475

The effect of a multi-isotope automatic syringe dispensing system on hand dose

I. E. J. Post, *M. Sonneborn - Bols, C. Mylvaganan - Young, D. Verwoerd, M. P. M. Stokkel, J. J. M. A. Hendrikx, E. A. Aalbersberg; Netherlands Cancer Intitute - Antoni van Leeuwenhoek, Amsterdam, NETHERLANDS.*

EP-476

Collecting Dose Indicators of Paediatric Positron Emission Tomography Examinations

M. Serrano Cuesta, *V. Álvarez Sánchez, R. Sánchez Casanueva, D. P. Córdoba Gómez, M. N. Cabrera Martín, J. M. Fernández Soto; Hospital Clínico San Carlos, Madrid, SPAIN.*

EP-477

Proposal of a Simple Method to Establish Individualized Restriction Times after Medical Discharge in Treatments with ^{177}Lu-DOTATATE

T. Monserrat Fuertes[1], *N. Montenegro Iglesias*[1], *D. San José Olmedo*[1], *C. Arroyo Sánchez*[1], *D. Álvarez Llorente*[1], *M. A. Peinado Montes*[1], *P. Mínguez Gabiña*[2];
[1]*Hospital Universitario Central de Asturias, Oviedo, SPAIN,* [2]*Hospital Universitario Gurutzeta-Cruces/Instituto de Investigación Sanitaria BioCruces, Barakaldo, SPAIN.*

EP-478

Optimising Day-Case Ablations: Whole Body Imaging to Establish Personalised Radiation Restrictions Following I^{131}Thyroid Remnant Ablation

V. Rowse, *B. Fongenie;
Barts Health NHS Trust, London, UNITED KINGDOM.*

EP-479

Estimation of radiation exposure of family members during home care of a patient after radionuclide therapy using ^{177}Lu

J. Hudzietzova[1], *M. Fülöp*[2], *A. Vondrák*[3], *P. Nemček*[3], *J. Sabol*[4], *F. Lubica*[5];
[1]*Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, CZECH REPUBLIC,* [2]*ABRS, s.r.o., Samorin, SLOVAKIA,* [3]*IZOTOPCENTRUM, s.r.o., Nitra, SLOVAKIA,* [4]*Faculty of Security Management, PACR in Prague, Prague, CZECH REPUBLIC,* [5]*Faculty of Business Management, University of Economics in Bratislava, Bratislava, SLOVAKIA.*

EP-480

Determine the absorbed dose to the embryo/fetus in the pulmonary perfusion scintigraphy in pregnant women with suspected pulmonary thromboembolism

E. Dobra, *E. Martínez Montalbán, E. Corredoira Silva, L. Arias Buendía, L. Abelenda Magarín, S. Lopez Muñoz, B. Martínez de Miguel;
Hospital Universitario La Paz, Madrid, SPAIN.*

EP-481

Effective-doses received by partners of patients treated with ^{177}Lu-DOTATATE

P. Minguez Gabiña[1], *T. Montserrat Fuertes*[2], *R. Valverde Jorge*[1], *A. Esteban Figueruelo*[1], *M. Martin Veganzones*[1], *R. Nuñez Muñoz*[1], *Y. Carreres Ortega*[1], *M. Astudillo Sarmiento*[1], *A. Peña Fuentes*[1], *E. Rodeño Ortiz de Zarate*[1];
[1]*Gurutzeta/Cruces University Hospital, Barakaldo, SPAIN,* [2]*Central University Hospital of Asturias, Oviedo, SPAIN.*

EP-482

Patient radiation exposure from low-dose CT scans in parathyroid SPECT/CT scintigraphy

S. Rep, *P. Tomse, L. Lezaic;
University Medical Centre Ljubljana, Ljubljana, SLOVENIA.*

EP-483

^{125}I Radiation protection

J. Bartl, *R. Bartlova;
Masaryk Memorial Cancer Institute, Brno, CZECH REPUBLIC.*

EP-484

Equivalent dose rate from patients undergoing nuclear medicine procedures: head to head comparison of recently - introduced prostate cancer radiopharmaceuticals

A. De Maggi[1], *F. Dalmasso*[2], *C. Zoppi*[3], *F. Bergesio*[1], *E. Roberto*[1], *S. Aimonetto*[2], *S. Chauvie*[1];
[1]*Medical Physics Divisions of Santa Croce e Carle Hospital (Cuneo), Cuneo, ITALY,* [2]*Medical Physics Divisions of Azienda USL della Valle d'Aosta (Aosta), Aosta, ITALY,* [3]*University of Turin (UNITO),Turin, Cuneo, ITALY.*

EP-485

Clinical audit on administered activities to patients undergoing 2-[18F]FDG PET/CT

I. C. Ferreira, *R. T. Ferreira, V. de Sousa, G. Cardoso, A. I. Santos; Serviço de Medicina Nuclear - Hospital Garcia de Orta, E.P.E, Almada, PORTUGAL.*

EP-486

Selective monitoring of beta and gamma exposure of hands of DNM workers handling radiopharmaceuticals

M. Fulop[1], *J. Hudzietzová*[2], *A. Vondrák*[3], *P. Nemček*[3], *J. Sabol*[4], *I. Gomola*[5], *D. Solivajs*[6];
[1]*ABRS, s.r.o., Samorin, SLOVAKIA,* [2]*Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, CZECH REPUBLIC,* [3]*IZOTOPCENTRUM, s.r.o., Nitra, SLOVAKIA,* [4]*Faculty of Security Management, PACR in Prague, Prague, CZECH REPUBLIC,* [5]*Slovak Medical University in Bratislava, Bratislava, SLOVAKIA,* [6]*Slovak legal metrology, Hviezdoslavova 31, SLOVAKIA.*

EP-52

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D41 Preclinical Dosimetry and Radiobiology

EP-487

Multicellular Dosimetry of 3D Tumor Spheroids Based on the Iodine Distribution and Cell Cycle Analysis in Human Sodium Iodide Symporter (NIS) Gene Expressing HeLa Cells

J. Lee[1,2,3], *I. Kim*[1,3,4], *S. Hong*[1,3,5], *K. Kang*[1,2,3], *G. Cheon*[1,3], *H. Youn*[1,3,6];
[1]*Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [3]*Laboratory of Molecular Imaging and Therapy, Cancer Research Institute, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [4]*Radiation Medicine Research Institute, Medical Research Center, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [5]*Center for Medical Innovation, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF,* [6]*Cancer Imaging Center, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF.*

EP-488

Similarities and differences of dosimetry between meta-[^{211}At]astatobenzylguanidine (^{211}At-MABG) and meta-[^{123}I]iodobenzylguanidine (^{123}I-MIBG) as companion diagnostic drug in PC12 pheochromocytoma model mice

N. Ukon, *S. Zhao, K. Washiyama, K. Nishijima, N. Oriuchi, S. Shimoyama, T. Joho, T. Shiga, K. Takahashi, H. Ito;*
Fukushima Medical University, Fukushima, JAPAN.

EP-489

Evaluation of patient-specific MC simulation accuracy with the XCAT phantom results in PET/CT patient dosimetry

M. Karimipourfard[1], *S. Sina*[1], *F. Khodadadi Shoshtari*[1], *H. Mahani*[2];
[1]*Department of Ray-Medical Engineering, Shiraz, IRAN, ISLAMIC REPUBLIC OF,* [2]*Nuclear Science and Technology Research Institute (NSTRI), Tehran, IRAN, ISLAMIC REPUBLIC OF.*

EP-490

Preclinical internal radiation dosimetry of [^{18}F]PSMA-1007 and its application for predicting the tumor absorbed dose of PSMA-targeting ^{177}Lu-labeled theranostic tandem

S. Kim[1,2], *H. Kim*[1,2], *H. Ko*[3], *S. Kim*[3], *I. Song*[2], *H. Park*[2,4], *M. Yun*[3], *S. Kim*[2,4,5];
[1]*Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [2]*Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF,* [3]*Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF,* [4]*Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF,* [5]*Advanced Institutes of Convergence Technology, Suwon, KOREA, REPUBLIC OF.*

EP-491

Hypoxia adapted relative biological effectiveness models for tumors in proton therapy: implementation and study with the FLUKA Monte Carlo code

G. Garrido-Hernandez[1], *H. Henjum*[2], *M. K. Høiskar*[1], *T. J. Dahle*[3], *K. R. Redalen*[1], *K. S. Ytre-Hauge*[2];
[1]*Norwegian University of Science and Technology, Trondheim, NORWAY,* [2]*University of Bergen, Bergen, NORWAY,* [3]*Haukeland University Hospital, Bergen, NORWAY.*

EP-53

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D4 Dosimetry and Radiobiology -> D42 Clinical Dosimetry

EP-492

Single time-point dosimetry for PRRT: Validation of a trained multiple linear regression model in 212 patients and 654 treatment cycles

A. Chicheportiche, *M. Sason, Y. Krausz, J. Godefroy, K. Oleinikov, A. Meirovitz, D. Gross, S. Grozinsky-Glasberg, S. Ben-Haim;*
Hadassah Ein Kerem Hospital, Jerusalem, ISRAEL.

EP-493

Iodine-124 Dosimetry for Radioactive Iodine Therapy in the Treatment of Paediatric Thyroid Cancers

C. Ng, *K. S. Loke;*
Singapore General Hospital, Singapore, SINGAPORE.

EP-494

Time-integrated activity coefficients calculated using a physiologically based pharmacokinetic model and sampling schedules for [^{177}Lu]Lu-PSMA-617 radioligand therapy

C. Orlov, *V. Vasic, A. J. Beer, G. Glatting;*
University Hospital Of Ulm, Ulm, GERMANY.

EP-495

Estimation of kidney doses from ^{177}Lu-DOTATATE using single time point SPECT/CT

S. Ballout[1], *D. Gillett*[1], *I. Harper*[1], *D. Pitfield*[2], *A. Powell*[1], *R. T. Casey*[3,2], *S. Heard*[1], *L. Aloj*[4,1];
[1]*Department of Nuclear Medicine, Cambridge University Hospital NHSFT, Cambridge, UNITED KINGDOM,* [2]*Department of Endocrinology, Cambridge University Hospitals NHSFT, Cambridge, UNITED KINGDOM,* [3]*Department of Genetics, University of Cambridge, Cambridge, UNITED KINGDOM,* [4]*Department of Radiology, University of Cambridge, Cambridge, UNITED KINGDOM.*

EP-496

Evaluation of ^{99m}Tc-MAA SPECT/CT-based dosimetry with ^{90}Y PET/MR-based dosimetry in ^{90}Y microsphere treatment

A. Namazova, *N. Yeyin, L. Uslu Besli, K. Sönmezoğlu;*
Istanbul University-Cerrahpasa, Department of Nuclear Medicine, Istanbul, TÜRKIYE.

EP-497

Lesion Quantification Accuracy of Digital ^{90}Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide Therapy

D. Kersting[1], *W. Jentzen*[1], *D. Jeromin*[1], *I. Mavroeidi*[2], *M. Conti*[3], *F. Büther*[4], *K. Herrmann*[1], *C. Rischpler*[1], *R. Hamacher*[2], *W. P. Fendler*[1], *R. Seifert*[1], *P. Fragoso Costa*[1];
[1]*Department of Nuclear Medicine, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [2]*Department of Medical Oncology, West German Cancer Center (WTZ), University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY,* [3]*Siemens Medical Solutions USA, Inc., Knoxville, TN, UNITED STATES OF AMERICA,* [4]*Department of Nuclear Medicine, University Hospital Münster, University of Münster, Münster, GERMANY.*

EP-498

Radiobiological parameters for the assessment of ^{177}Lu-PSMA-617 Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

J. Hu[1], *S. Xue*[1], *L. Mercolli*[1], *H. Sari*[2], *A. Rominger*[1], *A. Afshar-Oromieh*[1], *K. Shi*[1];
[1]*University of Bern, Department of Nuclear Medicine, Bern, SWITZERLAND,* [2]*Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.*

EP-499

Multi-Isotope SPECT-based evaluation of kidney and lesion SUV and pharmacokinetics for combined Ac-225/Lu-177-PSMA-I&T therapy

G. Liubchenko, *M. Rumiantcev, M. Zacherl, F. Gildehaus, A. Harbach, I. Berg, S. Resch, V. Wenter, P. Bartenstein, S. Ziegler, L. Beyer, G. Böning, A. Delker;*
Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY.

EP-500

The relationship between absorbed doses to normal organs and tumours in [^{177}Lu]Lu-DOTA-TATE therapy and pre-therapeutic [^{68}Ga]Ga-DOTA-TATE PET-derived quantities

A. Stenvall[1,2], *J. Gustafsson*[1], *E. Larsson*[2], *D. Roth*[1], *A. Sundlöv*[3], *L. Jönsson*[1,2], *C. Hindorf*[4,1], *T. Ohlsson*[2], *K. Sjögreen Gleisner*[1];
[1]*Medical Radiation Physics, Lund University, Lund, SWEDEN,* [2]*Radiation Physics, Skåne University Hospital, Lund, SWEDEN,* [3]*Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, SWEDEN,* [4]*Department of Radiation physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, SWEDEN.*

EP-501

^{166}Ho SIRT Imaging Quantification: Comparison between absolute and patient-relative calibration

F. Murtas[1,2], *G. Iaccarino*[1], *S. Ungania*[1], *R. Sciuto*[3], *D. Maccora*[3], *G. E. Vallati*[4], *F. Cappelli*[4], *A. Soriani*[1], *M. D'Andrea*[1], *B. Cassano*[1];
[1]*IRCCS Regina Elena National Cancer Institute, Medical Physics Laboratory, Rome, ITALY,* [2]*University of Rome "Tor Vergata", Specialization School in Medical Physics, Rome, ITALY,* [3]*IRCCS Regina Elena National Cancer Institute, Nuclear Medicine Unit, Rome, ITALY,* [4]*IRCCS Regina Elena National Cancer Institute, Interventional Radiology Unit, Rome, ITALY.*

EP-502

Proof of principle of a new system for internal radiation dosimetry

E. Solfaroli Camillocci[1,2], *B. Cassano*[2], *F. Collamati*[3], *R. Faccini*[4,3], *G. Iaccarino*[2], *C. Mancini Terracciano*[4,3], *R. Mirabelli*[4,3], *M. Pacilio*[5], *A. Soriani*[2], *S. Morganti*[3];
[1]*IRCCS Bambino Gesù Children's Hospital, Rome, ITALY,* [2]*IRCCS Regina Elena National Cancer Institute, Rome, ITALY,* [3]*National Institute of Nuclear Physics, INFN, Rome, ITALY,* [4]*Sapienza University of Rome, Rome, ITALY,* [5]*Azienda Ospedaliera-Universitaria Policlinico Umberto I, Rome, ITALY.*

EP-503

An analytical method for computing ^{177}Lu Voxel S-Values for 3D internal dosimetry

D. Pistone[1,2], *L. Auditore*[1,2], *A. Italiano*[2,3], *E. Amato*[1,2];
[1]*BIOMORF Department, University of Messina, Messina, ITALY,* [2]*INFN Section of Catania, Catania, ITALY,* [3]*MIFT Department, University of Messina, Messina, ITALY.*

EP-504

Renal Dosimetry in [^{177}Lu]Lu-DOTA-TATE Therapy Based on Multiple Small VOIs as an Alternative to Whole-Kidney Segmentation

S. Curkic[1], *J. Gustafsson*[1], *L. Jessen*[1], *M. Ljungberg*[1], *A. Sundlöv*[2], *K. Sjögreen Gleisner*[1];
[1]*Medical Radiation Physics, Lund, Lund University, Lund, SWEDEN,* [2]*Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, SWEDEN.*

EP-505

Neoadjuvant PRRT with Y-90-DOTATOC: can first cycle kidney dosimetry correctly estimate the cumulative absorbed dose?

F. Mattana[1], *F. Botta*[2], *M. Ferrari*[2], *R. Mei*[3], *M. Calabrese*[3], *A. Cascio*[4], *S. Papi*[4], *I. Clerici*[4], *F. Ceci*[1], *C. M. Grana*[1];
[1]*Nuclear Medicine Department, Radiometabolic Therapy Unit, European Institute of Oncology IRCSS, Milan, ITALY,* [2]*Medical Physics Unit, European Institute of Oncology IRCSS, Milan, ITALY,* [3]*Nuclear Medicine Department, Radiometabolic Therapy Unit, European Institute of Oncology IRCCS, Milan, ITALY,* [4]*Radiofarmacy Unit, European Institute of Oncology, Milan, ITALY.*

EP-506

Use of whole-body retention data for personalized dosimetry of radioiodine treatments of thyroid metastatic cancers: evaluation using data from an ancillary study of the MERAIODE clinical trial (NCT 03244956)

A. Pignard[1], *N. Anizan*[2,3], *S. Lamart*[1], *A. Legrand*[1], *M. Bensiali*[1], *D. Broggio*[1], *S. Lebouleux*[3,4];
[1]*French Institute for Radiological Protection and Nuclear Safety (IRSN), Internal Dose Assessment Laboratory, Fontenay-aux-Roses, FRANCE,* [2]*Gustave Roussy and Université Paris Saclay, Service de Physique médicale, Villejuif, FRANCE,* [3]*Gustave Roussy and Université Paris Saclay, Service de Médecine nucléaire, Villejuif, FRANCE,* [4]*Present workplace: Department of Endocrinology, Diabetes, Nutrition and Therapeutic Patient Education, Geneva University Hospitals, Geneva, SWITZERLAND.*

EP-507

New radionuclides for theranostic applications: a methodology for evaluating the dosimetry impact in clinics

N. Varmenot[1,2,3], *T. Pham*[4], *A. Vergara-Gil*[5], *M. Nzatsi-Nzatsi*[1,3], *C. Rousseau*[1,3], *F. Haddad*[2,6], *L. Ferrer*[1,3];
[1]*Institut de Cancérologie de l'Ouest René Gauducheau, F-44800 Saint-Herblain, FRANCE,* [2]*ARRONAX, F-44800 Saint-Herblain, FRANCE,* [3]*Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, F-44000 Nantes, FRANCE,* [4]*Laboratoire ImVia EA 7535, IFTIM, Université de Bourgogne, F-21000 Dijon, FRANCE,* [5]*CRCT, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, F-31000 Toulouse, FRANCE,* [6]*Subatech, Nantes Université, IN2P3/CNRS, IMT Atlantique, F-44000 Nantes, FRANCE.*

EP-508

Optimising Molecular Radionuclide Therapy: The Role of Patient-Led Whole-Body Retention Dosimetry

T. Alkahtani[1,2,3], *L. Livieratos*[1,2], *V. Lewington*[1,2];
[1]*King's College London, London, UNITED KINGDOM,*

[2]Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UNITED KINGDOM, [3]Princess Nourah bint Abdulrahman University, Riyadh, SAUDI ARABIA.

EP-509

Pretherapeutic I-131 Dosimetry Comparison to During Therapy Biokinetics in Thyroid Cancer Patients Prepared with rhTSH Injection

A. Al Jabri[1,2], *J. Cooke*[3], *S. Cournane*[4], *M. Healy*[5];
[1]*Trinity College Dublin, Dublin, IRELAND,* [2]*Sultan Qaboos University, Muscat, OMAN,* [3]*Children's Health Ireland at Crumlin, Dublin, IRELAND,* [4]*St Vincent's University Hospital, Dublin, IRELAND,* [5]*St James's Hospital, Dublin, IRELAND.*

EP-510

An Original Segmentation Method for Dosimetry of Refractory Meningiomas Treated by ^{177}Lu-DOTATATE based on Quantitative SPECT 360° Whole-body CZT-camera Imaging

T. Zaragori[1,2], *C. Boursier*[3,2,1], *M. Bros*[3], *E. Mairal*[3], *A. Verger*[3,2,1], *L. Imbert*[3,2,1];
[1]*IADI INSERM U1254, Vandoeuvre-lès-Nancy, FRANCE,* [2]*Nancyclotep Imaging Platform, Vandoeuvre-lès-Nancy, FRANCE,* [3]*CHRU Nancy, Vandoeuvre-lès-Nancy, FRANCE.*

EP-511

Determination Of Waiting Time After ^{166}Ho Radioembolization For An Accurate Post-treatment Dosimetrical Image In SPECT

T. Lusa Agüero, *C. Camacho López, F. Asensio Llobat, T. Marín López, C. Velasco Fernández, L. Casas Fernández, A. Sánchez Tornero;*
Hospital Clínico Universitario de Valencia, Valencia, SPAIN.

EP-512

Single ^{68}Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organ and tumour lesions in ^{177}Lu-PSMA-617 treatment

A. Nautiyal[1], *I. Pitkin*[1], *A. K. Jha*[2], *T. Srichandan*[2], *S. Mithun*[2], *A. Konuparamban*[2], *V. Rangarajan*[2];
[1]*Cromwell Hospital, London, UNITED KINGDOM,* [2]*Tata Memorial Hospital, Mumbai, INDIA.*

EP-513

Comparison of Effective Dose measurement using ICRP 128 (2015) and RADAR 2017 methods in diagnostic Nuclear Medicine studies

A. Konuparamban[1,2], *T. Srichandan*[1,2], *A. K. Jha*[1,2,3], *S. Mithun*[1,2,3], *A. Nautiyal*[4], *I. Pitkin*[4], *G. Katre*[1,2], *P. Borkar*[1,2], *N. Balip*[1,2], *V. Rangarajan*[1,2];
[1]*Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute, Mumbai, INDIA,* [3]*Maastricht University Medical Centre, Maastricht, NETHERLANDS,* [4]*Department of Physics, Cromwell Hospital, London, UNITED KINGDOM.*

EP-514

Influence of a late SPECT/CT acquisition and the selected fit model on lesion dosimetry for Lu-177-PSMA-I&T therapy in the context of clinical routine

S. Resch, *S. L. Takayama Fouladgar, G. Sheikh, G. Liubchenko, M. Rumiantcev, M. Zacherl, V. Wenter, P. Bartenstein, S. Ziegler, H. Ilhan, L. Beyer, G. Böning, A. Delker;*
Department of Nuclear Medicine, LMU Hospital, Munich, GERMANY.

EP-515

Evaluation of Concordance Between [^{99m}Tc]Tc-MAA SPECT and ^{90}Y-microsphere PET Based Dosimetry in ^{90}Y Microsphere Therapy for Primary and Metastatic Liver Malignancies

M. Mavi, *B. Volkan Salancı, M. F. Bozkurt;*
Hacettepe University, Ankara, TÜRKIYE.

EP-516

Change in activity uptake between treatment cycles in quantitative ^{177}Lu SPECT/CT

L. Bonney[1], *D. R. McGowan*[1,2];
[1]*Oxford University Hospitals Trust, Oxford, UNITED KINGDOM,* [2]*University of Oxford, Oxford, UNITED KINGDOM.*

EP-54

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D51 New Radiopharmaceuticals - SPECT

EP-517

Design, Synthesis, and biological evaluation of quinoline based Sigma-2 receptor-specific 99mTc- (DTPA)-Isoquinoline complex for SPECT Imaging of breast tumor

V. Chaudhary[1], *S. Chaturvedi*[1], *A. Anju*[2], *R. Kumar*[3], *A. K. Mishra*[1];
[1]*INMAS, DRDO Delhi, New Delhi, INDIA,* [2]*University of California, San Francisco, CA, UNITED STATES OF AMERICA,* [3]*Kirori Mal College, University of Delhi, New Delhi, INDIA.*

EP-518

A Comparison of image quality in myocardial perfusion scintigraphy with MIBI, Tetrofosmin Myoview and Tetrofosmin ROTOP radio-pharmaceuticals

O. Crossman, *M. Martins, M. Heatley, C. Gascoigne, C. Barnett, N. Hartman, J. Halcox;*
Swansea Bay University Health Board, Swansea, UNITED KINGDOM.

EP-519

Towards Early Detection of PDAC: Molecular Imaging of mutant p53 overexpression

H. Alakonya[1], *S. L. Hopkins*[2], *S. Koustoulidou*[3], *G. Dias*[1], *E. O'Neil*[1], *B. Cornelissen*[1];
[1]*University of Oxford, Oxford, UNITED KINGDOM,* [2]*PPD Inc, Wilmington, NC, UNITED STATES OF AMERICA,* [3]*Erasmus University Medical Cente, Rotterdam, NETHERLANDS.*

EP-520

Non Invasive Evaluation of Laminin-Peptide(PGPIKVAV) Hydrogel for Wound Imaging

M. Saklani[1,2], *M. Agrawal*[1], *R. Mathur*[1], *A. Tiwari*[2], *A. Mishra*[1], *R. Varshney*[*1];
[1]*Radiological Nuclear and Imaging Science,Institute of Nuclear Medicine and Allied Sciences, Delhi, INDIA,* [2]*Babasaheb Bhimrao Ambedkar University, A Central University, Lucknow, INDIA.*

EP-521

Radioactive iodine labelled mesenchymal stem cell (MSC)-exosomes and their CD73 enzymatic activities

C. Yang[1], *R. Lai*[2], *V. Phua*[1], *S. Lim*[2], *D. Ng*[1];
[1]*Singapore General Hospital, Singapore, SINGAPORE,* [2]*Institute of Molecular & Cell Biology, A*STAR, Singapore, SINGAPORE.*

EP-522

Using Non Invasive Imaging to Evaluate the Curcumin Conjugated Gold Nanoparticles (C-AuNPs) as a Potential Diagnostic Agent

C. Jha[1,2], *C. Singh*[1,3], *R. Varshney*[1], *J. Randhawa*[4], *A. Kaul*[1], *A. Mishra*[1], *K. Manna*[*2], *R. Mathur*[*1];
[1]*Institute of Nuclear Medicine and Imaging Sciences, DRDO, Delhi, INDIA,* [2]*Department of Chemistry, Indian Institute of Technology, Delhi, INDIA,* [3]*Department of Chemical Engineering, Indian Institute of Technology, Delhi, INDIA,* [4]*School of Engineering, Indian institute of Technology Mandi, Himachal Pradesh, INDIA.*

EP-55

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D52 New Radiopharmaceuticals - PET

EP-523

Automated cassette-based synthesis of [18F]FAPI-74 via [18F]AlF strategy for routine production in a GMP environment

N. Emmanuel[1], *D. Goblet*[1], *G. Decoux*[1], *V. Kramer*[2], *F. Valla*[3], *J. Agudelo*[3];
[1]*IBA, Louvain-la-Neuve, BELGIUM,* [2]*Positronpharma, Santiago, CHILE,* [3]*SOFIE, Dulles, VA, UNITED STATES OF AMERICA.*

EP-524

Novel Synthesis of [^{18}F]UCB-J

S. Forsback[1], *T. Keller*[1], *E. Kerminen*[1], *F. Lopez-Picon*[1], *J. Rajander*[2], *A. K. Kirjavainen*[1], *O. Solin*[1];
[1]*University of Turku, Turku, FINLAND,* [2]*Åbo Akademi University, Turku, FINLAND.*

EP-525

Methodological development of the intravesical injection of 89Zr-girentixumab for the trial PERTINENCE: Technical feasibility, radiation protection, dosimetry

A. Grassal[1], *C. Rousseau*[2], *C. Pitel*[1], *F. Delaunay*[1], *N. Varmenot*[2], *M. Frindel*[1], *L. Ferrer*[2], *J. Chatal*[3], *A. Rauscher*[1], *P. Baumgartner*[1];
[1]*ICO Rene Gauducheau, F-44800 St Herblain, FRANCE,* [2]*ICO René Gauducheau, F-44800 Saint-Herblain, Nantes Université, Univ Angers, INSERM, CNRS, CRCI2NA, F-44000, Nantes, FRANCE,* [3]*ATONCO SAS, F-44800, St Herblain, FRANCE.*

EP-526

Synthesis of Novel Zirconium-89 Labled Rhodamine: A Potential PET Myocardial Perfusion Imaging Agent

I. Aljammaz;
King Faisal Specialist Hospital and Research centre, Riyadh, SAUDI ARABIA.

EP-527

[^{18}F]F and [^{11}C]C kenpaullone labelling: a potential Alzheimer's disease diagnostic agent

M. Zeni[1], *J. Gambini*[1], *P. Duarte*[1], *A. Rey*[2], *J. Giglio*[1];
[1]*Centro Uruguayo de Imagenología Molecular, Montevideo, URUGUAY,* [2]*Facultad de Química, Universidad de la República, Montevideo, URUGUAY.*

EP-528

Synthesis, characterization, and radiosynthesis of fluorine-18-AVT-011 as a Pgp chemoresistance imaging marker

R. Thakur[1], *P. Kumar*[1], *P. Acharya*[2], *A. Kumar*[1], *M. Kumar*[1], *A. Mohammed*[3], *M. Krishnamurhty*[4], *P. UN*[4];
[1]*National Institute of Mental Health & Neuro Sciences, Bengaluru, INDIA,* [2]*Tripura University, Tripura, INDIA,* [3]*Esente Healthcare, Bengaluru, INDIA,* [4]*Sri Shankara cancer Hospital, Bengaluru, INDIA.*

EP-529

Efficacy of ^{18}F-DCFPyL PET/CT in patients with Biochemical Recurrence of Prostate Cancer

Á. Alonso García[1], *M. L. Bravo-Ferrer Moreno*[1], *M. A. Asensio Ruiz*[1,2], *M. T. Martínez Martínez*[1,2];
[1]*Unidad de Radiofarmacia Hospital Virgen de la Arrixaca, Murcia, SPAIN,* [2]*Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, SPAIN.*

EP-530

Optimization of Radiolabelling of 68Ga-MAA with varying incubation temperature and time

M. Babu[1,2], *P. Bhardwaj*[1,2], *N. Nisar*[1,2], *k. Chitnis*[1,2], *A. K. Jha*[1,2], *S. Mithun*[1,2], *V. Rangarajan*[1,2], *S. Mallick*[1,2];
[1]*Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA,* [2]*Homi Bhabha National Institute (HBNI), Deemed University, Mumbai, INDIA.*

EP-56

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D53 New Radiopharmaceuticals - Therapy

EP-531

Exploring the potential of high-specific activity Samarium-153 for targeted radionuclide therapy with [^{153}Sm]Sm-DOTA-TATE

C. Segers[1], *K. Vermeulen*[1], *M. Van de Voorde*[1], *N. Daems*[1], *C. Duchemin*[2], *S. Perez Rodriguez*[1], *M. Crabbé*[1], *R. Heinke*[2], *B. Ponsard*[1], *L. Geenen*[1], *J. Nonnekens*[3], *L. Lambert*[4], *C. Bernerd*[2], *A. Burgoyne*[1], *T. E. Cocolios*[2], *T. Stora*[4], *M. Ooms*[1];
[1]*SCK CEN, Mol, BELGIUM,* [2]*KU Leuven, Leuven, BELGIUM,* [3]*Erasmus MC, Rotterdam, NETHERLANDS,* [4]*CERN, Geneva, SWITZERLAND.*

EP-532

Thallium-201 (^{201}Tl) - Labelled Prussian Blue Nanoparticles for Auger-Meitner Electron-Emitter Radionuclide Therapy

K. Osytek[1], *J. Pellico*[1], *P. Blower*[1], *S. Terry*[1], *V. Abbate*[2];
[1]*School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM,* [2]*Institute of Pharmaceutical Sciences, London, UNITED KINGDOM.*

EP-533

Structure based In silico design, synthesis and preliminary assessments of Neurokinin-1 receptor (NK1R) targeted radiolabeled small molecules as potential neuroblastoma theranostic agents

P. Jha[1,2], *H. Berglund*[1], *S. Lundsten*[1], *U. Rosenström*[3], *M. Nestor*[1];
[1]*Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, SWEDEN,* [2]*Department of Radiology, University of Texas Southwestern Medical Centre, Dallas, TX, UNITED STATES OF AMERICA,* [3]*Department of Medicinal Chemistry, Biomedical Centre, Uppsala University, Uppsala, SWEDEN.*

EP-534

Study of Radioactive Progeny Recoils Release from ^{225}Ac Labelled TiO2 Nanoparticles

M. Sakmár[1,2], *J. Kozempel*[2], *L. Ondrák*[2], *K. Fialová*[2], *M. Vlk*[2], *A. Morgenstern*[3], *F. Bruchertseifer*[3];
[1]*Institute of Nuclear Medicine, First Medical Faculty, Charles University and General University Hospital Prague, Prague, CZECH REPUBLIC,* [2]*Department of Nuclear Chemistry, Czech Technical University in Prague, Faculty of Nuclear Sciences and Physical Engineering, Prague, CZECH REPUBLIC,* [3]*European Commission, Joint Research Centre, Karlsruhe, GERMANY.*

EP-535

Administration of [^{177}Lu] Lu-PSMA-617: Validation of a new method and first-experience

M. Santos Virosta, *I. Romero Zayas, F. Campos Añon, P. Paredes Barranco, J. Cordon del Pozo, A. Fritsch Medina, S. Casanueva*

Eliceiry, M. Tormo Ratera, K. Quintero Martínez, D. Fuster Pelfort, E. Agusti, J. Rochera Alba;
Hospital Clinic Barcelona, Barcelona, SPAIN.

EP-536

Post-labelling stability, human biodistribution and whole body effective dose to radiation worker from trans-arterially injected ^{188}Re-N-DEDC lipiodol for treatment of inoperable hepatocellular carcinoma (HCC) - A pilot study

N. Kumar, *P. Gupta, S. A. Shamim, S. Gamanagatti, Shalimar, C. Bal;*
All India Institute of Medical Sciences, New Delhi, INDIA.

EP-537

Develop Companion Radiopharmaceutical YKL40 Antibodies as Potential Theranostic Agents for Epithelial Ovarian Cancer

M. Chang, *C. Chen, P. Chiang, Y. Kuo, C. Peng;*
Institute of Nuclear Energy Research, Taoyuan, TAIWAN.

EP-57

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D54 New Biological Targets and Ligands

EP-538

^{99m}Tc-FGF2: A Novel Approach for the Diagnosis of Early Tumor Stages

M. Varani[1], *V. Bentivoglio*[1], *D. Ranieri*[2], *M. Serafinelli*[1], *C. Lauri*[1], *A. Signore*[1];
[1]*Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, "Sapienza" University of Rome, Rome, ITALY,* [2]*Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Rome, ITALY.*

EP-539

The Pharmacological Effects of Quinuclidine-Triazole Derivatives on the Suppression of Lung Cancer Proliferation

J. Sarasamkan[1], *S. Mangmool*[2], *O. Vajragupta*[3];
[1]*Khon Kaen University, Khon Kaen, THAILAND,*
[2]*Mahidol University, Bangkok, THAILAND,*
[3]*Chulalongkorn University, Bangkok, THAILAND.*

EP-58

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D55 Radiopharmacokinetics and Drug Development

EP-540

HER3-targeted drug delivery: preclinical characterization of (HE)3-ZHER3-ABD-mcDM1 using ^{99m}Tc

S. Rinne[1], *A. Abouzayed*[1], *W. Yin*[2], *A. Mestre Borras*[2], *C. Dahlsson Leitao*[2], *A. Vorobyeva*[1], *J. Löfblom*[2], *S. Ståhl*[2], *T. Gräslund*[2], *A. Orlova*[1];
[1]*Uppsala University, Uppsala, SWEDEN,* [2]*KTH - Royal Institute of Technology, Stockholm, SWEDEN.*

EP-541

Anti-HER2 antibody DOTA-pertuzumab conjugation and labelling studies with Ac-225

K. Fialová[1,2], *L. Ondrák*[1,3], *M. Vlk*[1,2], *J. Kozempel*[1], *M. Pruszyński*[4], *F. Bruchertseifer*[5], *A. Morgenstern*[5];
[1]*Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, CZECH REPUBLIC,* [2]*Motol University Hospital, Prague, CZECH REPUBLIC,* [3]*Institute for Clinical and Experimental Medicine, Prague, CZECH REPUBLIC,* [4]*Institute of Nuclear Chemistry and Technology, Warsaw, POLAND,* [5]*European Commission, Joint Research Centre, Karlsruhe, GERMANY.*

EP-543

The Great Potential of Long Axial Field of View PET Systems for Imaging-based Pharmacokinetic Analysis Exemplified With the Radiolabeled Antibiotic [^{18}F] Ciprofloxacin

I. Hernandez-Lozano[1], *S. Mairinger*[1], *T. Filip*[2], *M. Löbsch*[2], *J. Stanek*[3], *T. Wanek*[3], *O. Langer*[1];
[1]*Department of Clinical Pharmacology, Medical University of Vienna, Vienna, AUSTRIA,* [2]*Core Facility Laboratory Animal Breeding and Husbandry, Medical University of Vienna, Vienna, AUSTRIA,* [3]*Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.*

EP-544

Artificial intelligence and the diagnosis of neurodegenerative diseases: making the future for radiopharmaceutical development

M. Li[1], *L. Huang*[2], *Y. Huang*[1], *K. Huang*[3], *M. Chen*[4];
[1]*Radiopharmaceutical Theranostic Center, Koo foundation Sun Yat-Sen Cancer Center, Taipei, TAIWAN,* [2]*AI and Informatics Group R&D Department, Insilico Medicine Taiwan, Taipei, TAIWAN,* [3]*Department of Hematology and Medical Oncology, Koo foundation Sun Yat-Sen Cancer Center, Taipei, TAIWAN,* [4]*Manager of Theranostic R&D, Advancharis Scientific Research Co., Taipei, TAIWAN.*

EP-545

^{99m}Tc-FITC-Silk Fibroin Nanoparticles: A dual labeled probe for biodistribution studies

M. Asensio Ruiz[1,2], *Á. Alonso García*[1], *M. L. Bravo-Ferrer Moreno*[1], *A. A. Lozano-Pérez*[3,2], *M. T. Martínez Martínez*[1,2];
[1]*Unidad de Radiofarmacia Hospital Virgen de la Arrixaca, Murcia, SPAIN,* [2]*Instituto Murciano de Investigación Biosanitaria (IMIB)-Arrixaca, Murcia, SPAIN,* [3]*Instituto Murciano de Investigación y Desarrollo Agrario y Medioambiental, Murcia, SPAIN.*

EP-546

Nuclear addressing peptides of monoclonal antibodies for radioimmunotherapy

M. Bio Idrissou, *C. Diaz Garcia-Prada, A. A. Parach, J. Constanzo, S. Atis, G. Ouerdane, M. Bardiès, S. Poty, J. Pouget;*
Institute of cancer research of Montpellier, Montpellier, FRANCE.

EP-547

Hemodialysis Effect On ^{131}I Plasmatic Levels In Its Different Therapeutic Indications

S. Chamizo, *A. Cherino, A. Repetto, P. Mondejar, C. Medina, J. Amaya, L. Nieto, N. Orta, F. Vega;*
Hospital Universitario Son Espases, Palma, SPAIN.

EP-59

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D56 Radionuclide Production

EP-548

Kinetic and static study of Ac-225 sorption on the surface of α-zirconium phosphate in acidic enviroment

L. Ondrák[1,2], *K. Fialová*[1,3], *M. Sakmár*[1], *M. Vlk*[1,3], *K. Štamberg*[1], *B. Drtinová*[1], *J. Kozempel*[1], *F. Bruchertsefier*[4], *A. Morgenstern*[4];
[1]*Faculty of Nuclear Sciences and Physical Engineering, Czech Technical University in Prague, Prague, CZECH REPUBLIC,* [2]*Institute for Clinical and Experimental Medicine, Prague, CZECH REPUBLIC,* [3]*Motol University Hospital, Prague, CZECH REPUBLIC,* [4]*European Commission, Joint Research Centre, Karlsruhe, GERMANY.*

EP-549

Development of a ^{68}Ge/^{68}Ga Generator (4.45 Gbq): Pars-Gallugen 70 as Largest Commercial ^{68}Ge/^{68}Ga Generator

M. Gholamhosseini-Nazari, *A. Rahiminezhad;*
Pars Isotope company, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-550

A new workflow for the cyclotron production of ^{68}Ga

D. Szikra, *V. Forgács, A. Fekete, G. Trencsényi;*
University of Debrecen, Faculty of Medicine, Medical Imaging Department, Division of Nuclear Medicine, Debrecen, HUNGARY.

EP-551

Last year challenge of Nuclear Medicine: medical radioisotopes supply

M. Paula, *A. Fonseca, C. Marques, I. Marques, L. Pereira, L. Ribeiro, S. Sequeira, C. Capelo, H. Duarte;*
Ipo Porto, Porto, PORTUGAL.

EP-60

During Congress Opening Hours

e-Poster Area

D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control

EP-552

Therapeutic Multiple Patient Doses Formulation of a Ready-to-Use [^{177}Lu]Lu-FAPI-4 Using Carrier Added Lutetium-177 and its Pre-Clinical Efficacy

S. Lad[1], *S. Sahu*[1], *A. Chakraborty*[1], *M. Tawate*[1], *A. Mitra*[2], *T. Upadhye*[1], *S. Rakshit*[1], *K. Koundal*[3], *M. Ray*[1], *A. Damle*[1], *S. Kulkarni*[1];
[1]*RMC, BARC, Mumbai, INDIA,* [2]*RPL, BRIT, Navi Mumbai, INDIA,* [3]*HPD, BARC, Mumbai, INDIA.*

EP-553

Simplified method for Quality Control and the temperature effect on ^{99m}Tc-MAG3

A. Valin Hansen, *H. Gjerløv;*
Department of Nuclear Medicine, Zealand University hospital, Næstved, DENMARK.

EP-554

Automated synthesis of [^{18}F]AlF-NOTA-octreotride on a Synthra RNplus Research platform

J. Giglio[1], *P. Decuadra*[1], *J. Gambini*[1], *A. Rey*[2], *P. Duarte*[1], *E. Savio*[1];
[1]*Centro Uruguayo de Imagenologia Molecular, Montevideo, URUGUAY,* [2]*Área de Radiofarmacia, Facultad de Química, UdelaR, Montevideo, URUGUAY.*

EP-555

Analytical HPLC issues with a 5 kDa [^{18}F]fluoro-exendin-4 peptide

K. Heikkilä[1], *L. Uusitalo*[1], *J. Uotinen*[1], *O. Solin*[1,2,3], *S. Lahdenpohja*[1,4];
[1]*Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, FINLAND,* [2]*Department of Chemistry, University of Turku, Turku, FINLAND,* [3]*Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, FINLAND,* [4]*Service Hospitalier Frédéric Joliot, CEA, Orsay, FRANCE.*

EP-556

A Comparative study of production of [^{68}Ga]PSMA-11 with or without cassette type modules

H. Park, *H. An, H. Lee, G. Lee, B. Lee, W. Lee;*
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, KOREA, REPUBLIC OF.

EP-557

LASER-assisted 68Ga labelling of Macroaggregated of Human Serum Albumin (MAA)

L. Canziani, *C. Aprile, G. Pepe, L. Lodola;*
Fondazione IRCCS Policlinico San Matteo, Nuclear Medicine Unit, Pavia, ITALY.

EP-558

Quality Control of Therapeutic Radiopharmaceuticals: A Radio-TLC and HPLC analysis comparison, exemplified by clinical implementation of [^{177}Lu]Lu-PSMA

E. Hooijman[1], *C. M. Ntihabose*[1], *T. G. A. Reuvers*[1], *E. A. Aalbersberg*[2], *S. L. W. Koolen*[1], *J. J. M. Hendrikx*[2], *E. de Blois*[1];
[1]*Erasmus MC, Rotterdam, NETHERLANDS,* [2]*Netherlands Cancer Institute: NKI, Amsterdam, NETHERLANDS.*

EP-559

Practical aspects of [^{18}F]AlF-NOTA-octreotide quality control

O. Shamni, *G. Abourbeh Gofrit, E. Mishani, O. Press;*
Hadassah Medical Organization, Jerusalem, ISRAEL.

EP-560

Determination of TEMPO along with volatile solvents by GC for the production of radiopharmaceuticals

J. Simon[1,2], *M. Collantes*[1,3], *F. Pareja*[1,2], *G. Quincoces*[1,2], *I. Peñuelas*[1,2,3];
[1]*Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN,* [2]*Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN,* [3]*Translational Molecular Imaging Unit, University of Navarra, Navarra Institute for Health Research (IdisNA), Pamplona, SPAIN.*

EP-561

A practical method of measuring ^{68}Ge breakthrough from a ^{68}Ge/^{68}Ga generator using a PET scanner

M. Stavrinou[1], *A. G. Sherwani*[2], *L. E. Gridset*[2], *M. K. Siksjø*[3], *C. Stokke*[1,4], *L. T. G. Mikalsen*[1,5];
[1]*Section of Nuclear Medicine Physics/PET Physics, Department of Physics and Computational Radiology, Clinic of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, NORWAY,* [2]*Department of Nuclear Medicine, Clinic of Radiology and Nuclear Medicine, Oslo University Hospital Rikshospitalet, Oslo, NORWAY,* [3]*Department of Image Diagnostics, Østfold Hospital, Kalnes, NORWAY,* [4]*Department of Physics, University of Oslo, Norway, Oslo, NORWAY,* [5]*Department of Life Sciences and Health, Oslo Metropolitan University, Oslo, NORWAY.*

EP-562
Fractioning cold kits for labelling with 99mTc: our experience and outcomes
E. Lemos Pereira;
Nuclearmed - Instituto De Medicina Nuclear, Almada, PORTUGAL.

EP-563
Fast And Improved Leukocytes Labelling Procedure With ^{99m}Tc.HMPAO
P. Bueno, *R. Sánchez, M. Requena, M. Martín, F. Moreno;*
Hospital Universtario de Badajoz, Badajoz, SPAIN.

EP-564
Quality control of Ac-225 labelled peptides on the example of [^{225}Ac]Ac-DOTA-Substance-P - preliminary results
D. Pawlak, *M. Maurin, R. Mikołajczak, P. Garnuszek;*
National Centre for Nuclear Research Radioisotope Centre POLATOM, Otwock, POLAND.

EP-565
Validation of In-house Manual synthesis of 68Ga-Trivehexin and its Biodistribution for targeting the "Integrinαvβ6" expressing tumors
P. Thakral, *S. S. Das, D. Khichi, S. Dhiman, D. Manda, V. C B, D. Malik, I. Sen;*
Fortis Memorial Research Institute, Gurgaon, INDIA.

EP-566
Two Different Radiopharmaceutical Cold Kits And One Molecular Target The Prostate-Specific Membrane Antigen (PSMA)
S. Migliari[1], *B. Janota*[2], *M. Scarlattei*[1], *G. Baldari*[1], *U. Maestroni*[3], *L. Ruffini*[1];
[1]Nuclear Medicine Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY, [2]University Radioisotope Center POLATOM, Otwock, POLAND, [3]Urology Division, Azienda Ospedaliero-Universitaria of Parma, Parma, ITALY.

EP-567
One-year experience in preparation of Ga-68 tracers using cold kits in a single camera PET centre
J. Aerts, *T. Deboschere, N. Lutringer, J. Pamelard, T. Perrin, O. Dragusin, G. Gaudillot;*
Centre Hospitalier de Luxembourg, Luxembourg, LUXEMBOURG.

EP-568
Identification of [^{177}Lu]Lu-PSMA I&T, [^{177}Lu]LuCl3 and [^{177}Lu]Lu-DTPA by a single reversed-phase TLC
C. Cucchi, *A. Bogni, M. Mainente, C. Beretta, M. Kirienko, E. Seregni, C. Pascali;*
Fondazione IRCCS Istituto Nazionale Tumori - Milano, Milan, ITALY.

EP-569
Study Of The Possible Cause Of Liver And Spleen Visualization In Pulmonary Perfusion Studies With 99mTc-MAA
S. Lopez Muñoz, *E. Martinez Montalban, L. Abelenda Magarín, E. Dobra, L. Arias Buendía, B. Martinez De Miguel;*
Hospital Universitario La Paz, Madrid, SPAIN.

EP-570
Fully-automated synthesis of [^{68}Ga]Ga-FAPI-46 for clinical practice
C. Provost, *C. Schmitt, L. Trump, Q. Bruyer, J. Fouque, O. Madar;*
Institut Curie, Radiopharmacology department, Saint Cloud, FRANCE.

EP-571
Assessment of the critical points in the synthesis of carbon-11 radiopharmaceuticals
M. De Arcocha Torres, *V. Mendi-Barcina, I. Martínez-Rodríguez, J. Andrés-Pacheco, A. Gutierrez-González, N. Martínez-Amador, F. Gómez-de la Fuente, J. Jiménez-Bonilla, A. Sánchez-Salmón, A. Bota-Bota, M. Pombo-López, R. Quirce-Pisano;*
Nuclear Medicine Service. Marqués de Valdecilla University Hospital. Molecular Imaging Group (IDIVAL). University of Cantabria, Santander, SPAIN.

EP-572
Abnormal biological distribution related to normal saline among 99mTc-DMSA scans
T. Al Bulushi;
Royal Hospital, Muscat, OMAN.

EP-61

During Congress Opening Hours

e-Poster Area

E: Other Studies -> E1 Case Reports

EP-573
A rare case of congenital pulmonary venolobar syndrome with diaphragmatic hernia
M. Gulya, *Y. Varlamova, O. Yanulevich;*
Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION.

EP-574
The effects of Henne Plant (Lawsonia Inermis) on iodine thyroid uptake and its implications on radioactive iodine therapy : A Case-report study
M. Bettaieb, *A. Ezzine, A. Gorchene, W. Touila, M. Nouira, K. Chatti;*
Centre hospitalo-universitaire Sahloul, Sousse, TUNISIA.

EP-575
Metabolic Response to Rituximab Treatment in Granulomatosis with Polyangiitis
N. Filizoglu, *K. Oksuzoglu, C. O. Engur, S. Kesim, K. Niftaliyeva, T. N. Kissa, Z. C. Balaban Genc, S. Ozguven, F. Sen, T. Ones, H. T. Turoglu, T. Y. Erdil;*
Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE.

EP-576
An Unusual Case with Bilateral Breast Metastasis from Pancreatic Neuroendocrin Tumor
H. Sariyildiz Gumusgoz, *B. Karasah Erkek, U. Yararbas;*
Ege University Medical Faculty Department of Nuclear Medicine, Izmir, TÜRKIYE.

EP-577
Relevance of radioactive iodine therapy in the treatment of mixed anaplastic-papillary thyroid carcinoma
A. Missaoui, *F. Hamza, K. Ben Ahmed, H. Nooman, M. Maaloul, K. Chtourou, F. Guermazi;*
Department of Nuclear Medicine, Habib Bourguiba University Hospital, Sfax, TUNISIA.

EP-578
Atypical Onset Of A Bronchial Carcinoid Through Ocular Symptoms: Case Report
A. Ciocan[1], *A. Bajenaru*[1], *A. Lazar*[1], *M. Mutuleanu*[1], *M. Gherghe*[1,2];
[1]Institute of Oncology "Professor Doctor Alexandru Trestioreanu", Bucharest, ROMANIA, [2]University of Medicine and Pharmacy Carol Davila Bucharest, Bucharest, ROMANIA.

EP-579
Interstitial Lung Involvement of Multiple Myeloma on 18F FDG PET/CT
M. Keskin, *B. Temelli;*
Mersin City Hospital, Mersin, TÜRKIYE.

EP-580
Incidental Cardiac ^{68}Ga-FAPI-04 Uptake Related to Cardiovascular Diseases: Case Reports
D. Denizmen, *D. Has Şimşek, E. G. Işık, A. Mudun, S. Kuyumcu;*
Istanbul University, Istanbul, TÜRKIYE.

EP-581
A Rare Case: Hemangiopericytoma With Widespread Metastasis on ^{68}Ga DOTATATE PET/CT
B. Karasah Erkek, *H. Sariyildiz Gumusgoz, O. Omur;*
Ege University, İzmir, TÜRKIYE.

EP-582
An unusual presentation of Acute Myeloid Leukemia: Neuroleukemiosis on FDG PET/CT
N. Filizoglu, *K. Oksuzoglu, S. Kesim, C. O. Engur, K. Niftaliyeva, T. N. Kissa, Z. C. Balaban Genc, S. Ozguven, F. Sen, T. Ones, H. T. Turoglu, T. Y. Erdil;*
Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE.

EP-583
IgG4-related Myositis of Levator Palpebrae Superioris Muscle on 18F-FDG PET/CT
N. Filizoglu, *S. Kesim, C. O. Engur, K. Niftaliyeva, T. N. Kissa, Z. C. Balaban Genc, K. Oksuzoglu, S. Ozguven, F. Sen, T. Ones, H. T. Turoglu, T. Y. Erdil;*
Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE.

EP-584
Ventilation/Perfusion Scintigraphy In Pulmonary Venous Thrombotic Occlusion
V. Rodríguez Morales, *A. Castillo Simón, C. Martínez Ramos, G. Fdez-Cervera Fdez-Herrerin, J. Muñoz Iglesias, I. Domínguez-Prado, F. Loira Bamio, J. Nogueiras Alonso;*
Hospital Meixoeiro, Vigo, SPAIN.

EP-585
Radioguided surgery using a portable gamma camera in a patient with mediastinal parathyroid adenoma by video-assisted thoracoscopy
C. Castillo Arias[1], *I. Casans Tormo*[2], *H. Rodriguez Parra*[2], *V. Carrero Vasquez*[2], *L. Asensio Valero*[2], *M. Redal Peña*[2], *N. A. Pérez Castro*[2], *P. M. Cárcamo Ibarra*[2];
[1]Hospital Clínico Universitario de Valencia - Nuclear Medicine, Valencia, SPAIN, [2]Hospital Clínico Universitario de Valencia, Valencia, SPAIN.

EP-586
ACTH secreting neuroendocrine tumor arising from thymus with brachiocephalic vein infiltration
S. Fares, *M. Dobrenić, D. Huić;*
University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-587
Hepatic chronic veno-occlusive disease mimicking hepatic metastasis on FDG PET/CT in a patient with distal esophageal squamous cell carcinoma
A. Abdelrahman, *S. Gavane, T. Eljabbour, S. Thung;*
Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

EP-588
^{18}F-FDG PET/CT identifying rare extrapelvic localizations of endometriosis: a case report
A. Franchini, *A. Scarale, E. Gay, G. Cabrini, C. Serra, K. Shyli, S. Capitanio, C. Rossetti;*
Nuclear Medicine Unit, Dipartimento Ematologia, Oncologia e Medicina Molecolare, ASST Niguarda Hospital, Milan, ITALY.

EP-589
Intra-abdominal and pelvic splenosis: a case report representing invaluable conventional nuclear medicine
M. Pešorda, *L. Milišić Kelava, R. Petrović;*
Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-590
Incidental detection of elastofibroma dorsi on ^{18}F-FDG PET/CT: a case series
B. Seven[1], *M. O. Kartal*[2], *B. O. Tekin*[2];
[1]Department of Nuclear Medicine, Sabuncuoğlu Şerefeddin Training and Research Hospital, Amasya, TÜRKIYE, [2]Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE.

EP-591
Acute Phase of Herpes Simplex Virus-1 Encephalitis on 18F-FDG PET/CT: Hypermetabolism in the Left Temporal Lobe
N. Filizoglu, *C. O. Engur, S. Kesim, T. N. Kissa, K. Niftaliyeva, Z. C. Balaban Genc, K. Oksuzoglu, S. Ozguven, F. Sen, T. Ones, H. T. Turoglu, T. Y. Erdil;*
Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE.

EP-592
Interest of 18 FDG PET-CT in acute leukemia: about three cases
S. Cherif, *M. Somai, H. Rokbani, I. Meddeb, I. Yeddes, A. Mhiri;*
Salah azaiez institute, Tunis, TUNISIA.

EP-593
Impact Of [^{18}F]F-FDG Positron Emission Tomography In The Management Of Suspicious Relapse Of Cutaneous Squamocellular Cancer In Patient With History Of Bilateral Warthin Adenoma: A Case Report
N. Fraccascia[1], *G. Argalia*[1], *S. Damiani*[2], *E. Tabacchi*[3], *S. Fanti*[1,3];
[1]Nuclear Medicine, Alma Mater Studiorium University of Bologna, Bologna, ITALY, [2]Anatomy and Histopathology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, [3]Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-594
Importance of hybrid pulmonary scintigraphy in patients with dyspnea after COVID-19 pneumonia - case report
V. Laskov, *O. Lang;*
Third Faculty of Medicine, Charles University, Prague, CZECH REPUBLIC.

EP-595
Radioiodine diagnosis of differentiated thyroid cancer lung metastases in children: a case report
T. Geliashvili, *M.O. Goncharov, E.H. Gadzhieva, A.I. Pronin, A.S.Krylov, A.V. Parnas, V.S. Ilyakov;*
N.N. Blokhin National Medical Research Center of Oncology, Moscow, RUSSIAN FEDERATION.

EP-596
[68Ga]Ga-PSMA PET/CT Uptake in Fibrous Dysplasia of the Rib: a Pitfall to Know
M. Di Franco[1], *C. Sgro*[1], *F. Monastero*[1], *R. Mei*[1], *M. Novello*[2], *S. Fanti*[1,3], *P. Castellucci*[3];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Department of Nuclear Medicine and Molecular Imaging, Icahn School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA,* [3]*Nuclear Medicine IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-597
Why to include the brain in 18F-FDG PET/CT PET/CT scanning protocol in cancer patient ?- a case report
T. Yordanova, *A. Klisarova, B. Chaushev, Z. Dancheva, T. Stoeva, M. Dyankova, S. Chausheva;*
Medical University Prof. dr. P. Stoyanov, Deparment of nuclear medicine, Varna, BULGARIA.

EP-598
Inflammatory myofibroblastic tumor of the lung mimicking breast cancer metastasis on 18 FDG PET / CT
K. Ben Ahmed, *S. Charfeddine, G. Baazoug, K. Ayed, W. Amouri, K. Chtourou, F. Guermazi;*
Nuclear medecine department , Habib bourguiba hospital, Sfax, TUNISIA.

EP-599
Incidental finding of cervical spondylodiscitis in a patient with suspected septic aneurysm
A. Castillo Simón, *C. Martínez Ramos, V. Rodríguez Morales, G. Fernández-Cervera Fernández-Herrerín, J. Nogueiras Alonso, J. Muñoz Iglesias, D. Ruiz Hernández, O. Tabuenca Dopico, I. Domínguez Prado, F. Loira Bamio, A. Renda Alcalde, A. López López, R. Guitián Iglesias;*
Hospital Meixoeiro, Vigo, SPAIN.

EP-600
Incidental detection of an accessory salivary gland on ^{68}Ga-PSMA PET/CT imaging
B. Seven[1], *M. O. Kartal*[1], *B. O. Tekin*[2];
[1]*Department of Nuclear Medicine, Sabuncuoglu Serefeddin Training and Research Hospital, Amasya, TÜRKIYE,* [2]*Department of Nuclear Medicine, Ankara City Hospital, University of Health Sciences, Ankara, TÜRKIYE.*

EP-601
Lymphoma or splenosis, that's the question: a case report
M. Prisco, *F. Porcaro, L. Turchetta, I. Annarumma, A. Genova, R. Marano, M. Catalano;*
A.O.R.N. A.Cardarelli, Naples, ITALY.

EP-602
Intense FDG uptake in Aggressive Systemic Mastocytosis (ASM) without Associated clonal Haematological Non-Mast-cell lineage Disease (AHNMD): Unusual FDG PET/CT presentation
M. Zaman[1], *N. Fatima*[1], *A. Zaman*[2], *S. Zaman*[3], *U. Zaman*[2];
[1]*AKUH, Karachi, PAKISTAN,* [2]*Dept of Medicine SUNNY Downstate, New York, NY, UNITED STATES OF AMERICA,* [3]*DMC, Ruth Pfau Hospital, Karachi, PAKISTAN.*

EP-603
Incidental finding of a chest SPECT/ CT with iodine -131 of unrecognized lung adenocarcinoma synchronous to lung metastases of diffuse papillary thyroid carcinoma !
K. Ben Ahmed[1], *K. Chtourou*[1], *K. Ayed*[1], *H. Noomen*[1], *A. Missaoui*[2], *W. Amouri*[1], *M. Maaloul*[1], *F. Hamza*[1], *S. Charfeddine*[1], *F. Guermazi*[1];
[1]*Nuclear medicine department , Habib bourguiba hospital, Sfax, TUNISIA,* [2]*Endocrinology department , Hedi Chaker hospital, Sfax, TUNISIA.*

EP-604
Evaluation by molecular imaging with PET/CT ^{18}F-FDG of therapy and follow-up of multifocal and extranodal Rosai-Dorfman-Destombes disease
F. Lemus Ramirez[1], *Q. Pitalua Cortes*[1], *D. Hernandez Oliver*[2], *M. Castellanos Mares*[1], *A. López Méndez*[3], *K. Vite Pineda*[4];
[1]*Insitituto Nacional De Cancerología, México, MEXICO,* [2]*Hospital Angeles Universidad, México, MEXICO,* [3]*Insitituto Nacional De Cardiología, México, MEXICO,* [4]*HGZ 35 Instituto Mexicano del Seguro Social, Ciudad Juárez, MEXICO.*

EP-605
Allergic reaction after [^{18}F]-FDG administration
A. Castillo Simón, *C. Martínez Ramos, V. Rodríguez Morales, G. Fernández-Cervera Fernández-Herrerín, J. Nogueiras Alonso, J. Muñoz Iglesias, D. Ruiz Hernández, O. Tabuenca Dopico, I. Domínguez Prado, F. Loira Bamio, A. Renda Alcalde, A. López López, R. Guitián Iglesias;*
Hospital Meixoeiro, Vigo, SPAIN.

EP-606
Role of PET/CT in Multiple Subcutaneous Nodules: unusual presentation of Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
A. Cimino, *A. Mita;*
Nuclear Medicine Unit, Lecce, ITALY.

EP-607
^{68}Ga PSMA- avid Serous Cystadenoma of the Pancreas and ^{68}Ga-PSMA PET/CT negative multiple myeloma in patient with biochemical recurrence of prostate cancer
M. Dyankova[1,2], *Z. Dancheva*[3], *T. Stoeva*[3], *S. Chausheva*[3], *T. Yordanova*[3], *B. Chaushev*[3], *A. Klisarova*[3];
[1]*St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA,* [2]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Varna, BULGARIA,* [3]*St. Marina University Hospital, Varna, BULGARIA.*

EP-608
Diagnostic Goodness of 68Ga-DOTATOC PET/CT Test to Surface Gastroenteropancreatic Neuroendocrine Tumors (GEP-nets)
T. Moreno-Monsalve, *M. Castellón- Sánchez, T. Rodríguez-Lorcano, A. Leiva-Montejo, C. Ruiz-Corbalan, A. De Agrela- Serrao, L. Frutos-Esteban, J. Navarro-Fernández, R. Caceres-Silva, L. Mohamed-Salem, A. Hernández Martínez, R. Mears Baño, F. Hernandez Almagro, J. Contreras-Guitierrez;*
Hospital Universitario Virgen De La Arrixaca, Murcia, SPAIN.

EP-609
Unrecognized thymoma-associated paraneoplastic "stiff person" syndrome - a case report
N. Novoselska, *G. Mateva, P. Bochev;*
Acibadem City Clinic Mladost, Sofia, BULGARIA.

EP-610
A rare case of McCune- Albright Syndrome and use of ^{99}Tc MDP whole- body scintigraphy for the mapping of bone involvement
S. Chausheva[1], *Z. Dancheva*[1], *B. Chaushev*[1], *T. Stoeva*[1], *M. Dyankova*[1], *T. Yordanova*[1], *A. Klisarova*[1], *G. Valchev*[2];
[1]*Medical University "Prof. Dr. Paraskev Stoyanov" Department of Diagnostic Imaging, Interventional Radiology and Radiotherapy Clinic of Nuclear medicine, UMHAT "St. Marina" – Varna, Varna, BULGARIA,* [2]*Medical University "Prof. Dr. Paraskev Stoyanov" Department of Diagnostic Imaging, Interventional Radiology and Radiotherapy Clinic of Imaging Diagnostics, UMHAT "St. Marina" – Varna, Varna, BULGARIA.*

EP-611
Early diagnosis with 18F-FDG PET/CT in a case of left Ventricular Assist Device (VAD) infection
L. Burroni, *G. Biscontini, F. M. Fringuelli, C. Romagnolo, C. Cottignoli, A. Palucci;*
Dept. of Nuclear Medicine, Ospedali Riuniti di Torrette, Ancona, ITALY.

EP-612
Challenging current knowledge of metastatic prostate cancer: isolated metastasis to an adrenal gland utilizing F-18 Fluciclovine PET/CT
S. Peterson[1], *A. Patel*[1], *G. Spilberg*[1], *L. Busby*[2];
[1]*Hartford Healthcare, Hartford, CT, UNITED STATES OF AMERICA,* [2]*Jefferson Radiology, Hartford, CT, UNITED STATES OF AMERICA.*

EP-613
Clinical Value of 18F-FDG PET/CT in the Management of the Tuberculous Lymphadenitis
N. Filizoglu, *H. T. Turoglu, C. O. Engur, S. Kesim, K. Niftaliyeva, T. N. Kissa, Z. C. Balaban Genc, K. Oksuzoglu, S. Ozguven, F. Sen, T. Ones, T. Y. Erdil;*
Marmara University Pendik Training and Research Hospital, Istanbul, TÜRKIYE.

EP-613a
Prostate specific membrane antigen radioguided surgery for salvage pelvic lymph node dissection in a prostate cancer man
S. Erfani, *R. Sadeghi, A. Aghaee, V. Roshanravan, H. Ghorbani;*
Mashhad University of Medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-613b
Myositis ossificans progressive in a 13 year old boy with diffuse muscle uptake in whole body bone scan
S. Erfani, *A. Aghaee, H. Mohammadzadeh, Y. Fakhar, P. Sahafi;*
Mashhad University of Medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-613c
Identification of an unusual source of biliary leakage on a Hida scan: Liver subcapsular biloma
S. Erfani, *A. Aghaee, R. Sadeghi, E. Askari, A. Sahebkari;*
Mashhad University of Medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-62

During Congress Opening Hours

e-Poster Area

E: Other Studies -> E2 Covid Studies

EP-614
A V/Q SPECT/CT Study on Whether Persistent Reduction in Lung Diffusion Capacity after COVID-19 is Related to Restrictive or Vascular Lung Disease?
J. Mortensen, *J. Christensen, T. K. Lund, A. Kalhauge, R. M. G. Berg, T. W. Kjær, A. Lebech, T. L. Katzenstein;*
Rigshospitalet, Copenhagen, DENMARK.

EP-615
Brain FDG PET imaging of patients with persistent post-COVID-19 fatigue
E. Park, *L. L. Boles Ponto, A. C. Fietsam, J. R. Deters, P. E. Gander, T. Rudroff;*
University of Iowa Hospitals and Clinics, Iowa City, IA, UNITED STATES OF AMERICA.

EP-616
Lung VQ scan in COVID-19: Various patterns of perfusion defects
F. Karamian, *R. Sadeghi, E. Askari;*
Mashhad university of medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-617
Persistent symptoms after COVID-19 infection : place of pulmonary scintigraphy
W. Touila, *S. Mensi, A. Ezzine, H. Boudrigua, M. Bettaieb, B. Khrouf, C. Landoulsi, M. Ouachem, R. Sfar, M. Nouira, H. Charfi, M. Ben Fredj, K. Chatti;*
Nuclear medicine department of Sahloul hospital, Sousse, TUNISIA.

EP-618
Persistent dyspnea in post-COVID patients in the absence of pulmonary embolism: added value of lung perfusion scintigraphy
F. Lanfranchi[1], *S. Maggio*[2], *F. Bertoldi*[1], *C. Delucchi*[2], *F. D'Amico*[1], *T. Di Raimondo*[1], *M. I. Donegani*[1], *A. Miceli*[1], *M. Pennone*[2], *G. Villa*[2], *S. Raffa*[2], *S. Chiola*[2], *C. Marini*[3], *T. Aloè*[4], *E. Barisione*[4], *S. Morbelli*[1,2], *G. Sambuceti*[1,2], *M. Bauckneht*[1,2];
[1]*Department of Health Sciences (DISSAL), University of Genoa, Genoa, ITALY,* [2]*Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY,* [3]*CNR Institute of Molecular Bioimaging and Physiology, Milan, ITALY,* [4]*Interventional Pulmonology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, ITALY.*

EP-619
FDG-PET Brain Imaging in the Evaluation and Follow-up of COVID-19
S. Czibor[1], *L. Száraz*[2], *É. Birincsik*[2], *J. Simon*[3], *E. Zsarnóczay*[3], *B. Dombai*[4], *V. Müller*[4], *P. Maurovich-Horvat*[3], *T. Györke*[1];
[1]*Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Budapest, HUNGARY,* [2]*Faculty of Medicine, Semmelweis University, Budapest, HUNGARY,* [3]*Department of Radiology, Medical Imaging Centre, Semmelweis University, Budapest, HUNGARY,* [4]*Department of Pulmonology, Medical Imaging Centre, Semmelweis University, Budapest, HUNGARY.*

EP-620
Myocardial perfusion imaging findings of patients with history of COVID-19 infection: a single-center one-year experience
I. Armenis[1], *N. Sideris*[2], *P. Sotiriou*[2], *M. Papadelli*[2], *E. Kitziri*[2], *S. Kitziri*[2], *A. Kouzoumi*[2], *M. Koutelou*[2];
[1]*Onassis Cardiac Surgery Center, Athènes, GREECE,*
[2]*Onassis Cardiac Surgery Center, Athens, GREECE.*

EP-621
FDG-avid lymph nodes (LN) in response to vaccines for SARS-CoV-2
M. Dyankova[1,2], *Z. Dancheva*[1], *T. Stoeva*[1], *S. Chausheva*[1], *T. Yordanova*[1], *B. Chaushev*[1], *A. Klisarova*[1];
[1]*St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA,* [2]*Medical University Varna "Prof. Dr. Paraskev Stoyanov", Varna, BULGARIA.*

EP-622
Characteristics of Subacute Thyroiditis during COVID-19 Pandemic
S. Gaberscek[1,2], *T. Medved*[2], *N. Medle*[2], *K. Zaletel*[1];
[1]*Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA,* [2]*Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.*

EP-623
Contribution of low dose CT to the V/Q pulmonary scintigraphy in patients after Covid-19 virosis
O. Lang[1,2,3], *V. Laskov*[1], *I. Kuníková*[1];
[1]*Charles University, 3rd Med Fac, Prague 10, CZECH REPUBLIC,* [2]*District Hospital, Dept Nucl Med, Pribram, CZECH REPUBLIC,* [3]*PMCD Ltd, Dept Nucl Med, Prague 6, CZECH REPUBLIC.*

EP-624
Impact of the Covid-19 pandemic on the care of patients with chronic arterial disease. A nuclear medicine physician´s perspective
M. Moreno-Caballero, *E. Moratalla-Aranda, M. Sánchez Torrente, A. Castro López, M. Gallego Márquez, D. Becerra-García;*
Hospital Universitario San Cecilio, Granada, SPAIN.

EP-63

During Congress Opening Hours

e-Poster Area

E: Other Studies -> E3 Other Study (including Training, Projects)

EP-625
Prediction of BRAF gene mutation in thyroid papillary carcinoma based on 18F-FDG-PET imaging radiomics model
Z. Jiang;
Affiliated Hospital of Guilin Medical College, GuiLin, CHINA.

EP-627
Emotional state of patients with prostate cancer during PSMA-PET/CT
J. Boeser[1], *H. Faller*[2], *M. Lukasczik*[2], *J. Weisbrodt*[1], *R. A. Werner*[1], *A. Buck*[1];
[1]*University Hospital Wuerzburg, Department of Nuclear Medicine, Wuerzburg, GERMANY,* [2]*University Hospital Wuerzburg, Department of Psychology and Psychotherapy, Wuerzburg, GERMANY.*

EP-628
Referrals from the Nuclear Medicine department to the Emergency department of our hospital for incidental findings in PET-CT studies in two years of the COVID-19 pandemic
G. Cuesta Domingo[1], *P. Dauden*[1], *P. Nespral*[1], *P. Bascuñana*[1], *M. K. Meneses Navas*[1], *R. M. Couto Caro*[1], *M. García Esquinas*[2], *J. L. Carreras Delgado*[1], *M. N. Cabrera Martín*[1];
[1]*Department of Nuclear Medicine, Health Research Institute of Hospital Clínico San Carlos, Madrid, SPAIN,* [2]*Department of Radiology, Hospital Clínico San Carlos, Madrid, SPAIN.*

EP-629
Digital Technology applied to Customer Satisfaction: set-up and experience in a leading-edge Nuclear Medicine Department
A. Pisani, *F. Iuele, C. D'Alò, R. Ruta, P. Mammucci, A. Di Palo, A. Gaudiano, C. Altini, G. Rubini;*
Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University Aldo Moro, Bari, ITALY.

EP-630
Does dose reduction affect prostatic uptake in staging PSMA PET/CT scans? A single centre, retrospective analysis on 174 ISUP grade 3 and higher patients
J. Morigi, *N. Kovaleva, J. Anderson, O. Alghazo, K. duToit, A. Loughman, H. Duncan;*
Royal Darwin Hospital, Darwin, AUSTRALIA.

EP-631
FAP expression in alpha cells of Langherhans insulae claims for safety assessment when using FAP-targeting radiopharmaceuticals
M. Kirienko, *G. Centonze, G. Sabella, E. Seregni, M. Milione;*
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY.

EP-632
Standard and Delayed [68Ga]Ga-PSMA PET/CT Image Acquisition in Staging High-risk Prostate Cancer: Proposed Protocol Optimization
C. Sgro[1], *M. Moscarino*[2], *R. Mei*[1], *A. Farolfi*[2], *A. Zappacosta*[2], *L. Romagnoli*[2], *S. Civollani*[3], *P. Castellucci*[2], *S. Fanti*[1,2];
[1]*Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,* [2]*Nuclear Medicine IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY,* [3]*Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.*

EP-633
Navigating the PET DMF/ ANDA Submissions Process Recently Initiated for Academic Institutions
M. Soffing, *N. Bhatt, A. Mintz;*
Columbia University Medical Center, New York, NY, UNITED STATES OF AMERICA.

EP-635
Counseling pre-Myocardial perfusion GSPECT imaging: a good practice to improve quality of the nuclear medicine service
S. Ibba, *P. Gandolfo, M. Pozzoni, G. Zuccotti, N. D'Amico, S. Gonella, G. Fosci, S. Papa;*
Centro Diagnostico Italiano S.p.A., Milan, ITALY.

INDUSTRY EXHIBITION

The industry exhibition will be located on the ground floor of the CCIB – Barcelona International Convention Centre. It will give you an extensive overview of the latest achievements concerning pharmaceuticals and radiopharmaceuticals, as well as state-of-the-art technical equipment. Booksellers and publishers will display the most recent publications in the field of Nuclear Medicine and related sciences.

SUNDAY,	MONDAY,	TUESDAY,
OCTOBER 16, 2022	OCTOBER 17, 2022	OCTOBER 18, 2022
09:00 – 17:00	09:00 – 17:00	09:00 – 17:00

SATELLITE SYMPOSIA

Sunday, October 16 **13:15 – 14:45, Hall 114**

Symposium by Pfizer: Accelerating the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM): the role of nuclear scintigraphy and other imaging tools

Chairperson: María Nazarena Pizzi (Barcelona, Spain)

13:15–13:30	**Cardiac amyloidosis and the role of nuclear medicine** María Nazarena Pizzi (Chair), Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
13:30–13:40	**Red flags: the importance of constant vigilance** Stefano Perlini, Amyloid Diagnosis and Treatment Center, Pavia, Italy
13:40–13:50	**Long-term management of ATTR-CM** Stefano Perlini, Amyloid Diagnosis and Treatment Center, Pavia, Italy
13:50–14:05	**Non-invasive tools for the diagnosis and monitoring of ATTR-CM** Maria Koutelou, Onassis Cardiac Surgery Center, Athens, Greece
14:05–14:15	**Panel discussion and Q&A** All faculty

Sunday, October 16 **13:15 – 14:45, Hall 211**

Symposium by Telix Pharmaceuticals: Shifting Perspectives in Genitourinary Oncology through Nuclear Medicine

Chairperson: Matthias Eiber, MD, PhD, Department of Nuclear Medicine, Technische Universität München, Munich, Germany

13:15–13:35	**PSMA-ligand PET imaging: Current status and impact on patient management** Professor Matthias Eiber, Department of Nuclear Medicine, Technische Universität München, Munich, Germany
13:35–13:55	**Interventional nuclear medicine: focus on radioguided surgery in urology cancers** Professor Jochen Walz, Unit Chief, Institut Paoli Calmette, Marseille, France
13:55–14:15	**Redefining the management of Renal Cancer patients** Doctor Stijn Muselaers, Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands
14:15–14:35	**Establishing radio ligand imaging and therapy in hospital practice** Doctor Zéna Wimana, Radiopharmacy Manager, Department of Nuclear Medicine, Institut Jules Bordet, Brussels, Belgium

Sunday, October 16 **13:15 – 14:45, Hall 117**

Symposium by Boston Scientific International SA: Y-90 Glass Microspheres: Personalized Dosimetry, Guidelines and Clinical Data

Chairperson: Ken Herrmann (Barcelona, Spain)

Focus on personalized dosimetry and Simplicit90YTM Software, while discussing the TARGET study, with case examples, and an overview of radioembolization of HCC in the EANM Guidelines.

Sunday, October 16 **13:15 – 14:45, Hall 115**

Symposium by United Imaging Healthcare Poland The Future of Molecular Imaging

Chairperson: Ken Herrmann (Barcelona, Spain) Jusong Xia (CEO, International Business at United Imaging Healthcare), Łukasz Mizerka (Vice President of International Business. General Manager for Europe)

	Opening speech
	EANM Young Authors' Award Ceremony
	Special Tracers, New Technology, Best Imaging Dr. Olivari Laura and Dr. Doraku Joniada , Department of Nuclear Medicine and Radiometabolic Therapy IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) – Hospital Negrar, Italy
	Academic-Industrial Partnership for Translational Study of Advanced Molecular Imaging Prof Li Hongdi (CTO of UIH and CEO of UIH America)
	Radiopharmacy & Cyclotron Giancarlo Gorgoni (Director Radiopharmacy & Cyclotron department IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) – Hospital Negrar, Italy)

Sunday, October 16 **13:15 – 14:45, Hall 212**

Symposium by OncoBeta GmbH
Rhenium-SCT the future of treating Non-Melanoma skin cancer – A new liaison between Nuclear medicine and Dermatology

Chairperson: María Nazarena Pizzi (Barcelona, Spain)

13:15–13:30	**Non-Melanoma skin cancer and the potential of using Re188 for treatment**
13:30–13:40	**Resent Study Results from the Rhenium-SCT Rostock Triale**
13:40–13:50	**Practical Demonstration**
13:50–14:05	**Radiation protection in case of high energy beta emitter Re188**

Sunday, October 16 **13:15 – 14:45, Hall 116**

Symposium by
Monrol Nuclear Products Co
The Current and Future of Lutetium-177 Based Therapy: Uro-oncology & Radiology Perspective

Chairperson: Prof. Dr. Richard Baum, MD – Curanosticum Wiesbaden – Frankfurt

1.15 – 1.45 pm	**Uro-oncology Perspective:** Prof. Dr. Boris Hadaschik, MD – University of Essen
1.45 – 2.15 pm	**Radiology Perspective: Assoc.** Prof. Dr. Heather Jacene, MD – Dana Farber Cancer Institute
2.15 – 2.30 pm	**Closing Remarks by the Chair:** Prof. Dr. Richard Baum, MD – Curanosticum Wiesbaden – Frankfurt
2.30 – 2.45	**Q&A**

Monday, October 17 **13:15 – 14:45, Hall 211**

Symposium by
Advanced Accelerator Applications International
PSMA-targeted Theranostics: Towards Clinical Implementation in Advanced Prostate Cancer

Chairperson: Ken Herrmann

	Welcome and Introduction Ken Herrmann (Chair)
	Treatment Landscape and Future Horizons Derya Tilki
	Next Generation Imaging in Treatment Decisions Ken Herrmann
	Emerging PSMA-targeted Theranostics Joe O'Sullivan
	Panel Discussion: Multidisciplinary Approaches in Clinical Practice Valerie Lewington & Ken Herrmann
	Live Q&A Session

Monday, October 17 **13:15 – 14:45, Hall 117**

Symposium by GE Healthcare
How to make Molecular Imaging more Personalised?

Chairperson: Ben Newton PhD, General Manager Oncology at GE Healthcare

	Investing in Next Generation Radiotracers to Improve Patient Outcomes Paul Evans PhD, Head of Global R&D at GE Healthcare
	Introducing New Digital PET/CT Platform Prof. Frédéric Courbon, IUCT Oncopole, Toulouse, France
	Unlocking the Potential of Theranostics with StarGuideTM Prof. Patrick Flamen, Jules Bordet Institute, Brussels, Belgium
	Brain Motion Management with SIGNATM PET/MR Matthew Spangler-Bickell PhD, PET/MR Systems Engineer at GE Healthcare

Monday, October 17 **13:15 – 14:45, Hall 212**

Symposium by Blue Earth Diagnostics Ltd
What, How and Why of Cardiac PET

Chairperson: Dr. Tahir Saleem Sheikh, Medical Director, EU & UK Medical Affairs, Blue Earth Diagnostics Ltd

What are the fundamentals of Cardiac PET, and how do we improve patient access in Europe?
Speaker: Dr Hein Verberne MD PhD, Department of Radiology & Nuclear Medicine, University of Amsterdam, The Netherlands

How to establish your Cardiac PET service
Speaker: Jessica Williams MS CNMT, Cardiology Application Specialist, Blue Earth Diagnostics Ltd

Why perform Cardiac PET – understanding the clinical value
Speaker: Dr Parthiban Arumugam MD, Clinical Director Nuclear Medicine, Manchester University NHS FT, Manchester, UK

Monday, October 17 **13:15 – 14:45, Hall 116**

Symposium by Spectrum Dynamics Medical
Next Generation SPECT Imaging

Chairperson: Prof. Denis Agostini, MD, PhD, Head of Nuclear Medicine Normandy University, CHU Caen, France

Experience of AI application for myocardial perfusion imaging attenuation correction in obese patients with ICA correlation: Linköping University Hospital, Sweden
Dr. Miguel Ochoa Figueroa, MD, PhD, Consultant in Nuclear Medicine and Clinical Radiology

3D Dynamic Imaging Applications: Royal United Hospitals, Bath
Richard Graham, Deputy Medical Director, Consultant Radiologist
Dr. Sarah Cade, PhD, Medical Physicist

Therapy Monitoring Applications: Centre Léon-Bérard, Lyon, France
Dr. Jean-Noël Badel, PhD, Medical Physicist

Clinical Experience with Next Generation Digital SPECT/CT: University Hospital of Nancy, France
Prof. Pierre-Yves Marie, MD, Ph.D., Head Department of Nuclear Medicine
Dr. Laetitia Imbert, PhD, Medical Physicist

Tuesday, October 18 **13:15 – 14:45, Hall 117**

Symposium by Eckert & Ziegler, PentixaPharm
Theranostic Innovations in Solid and Non-Solid Tumors Targeting CXCR4, HER2, FAP, αvβ6 & more

Chairperson: Prof. Margret Schottelius (PhD), Associate Professor, Translational Radiopharmaceutical Sciences, CHUV, Lausanne University Hospital

A Theranostic Roadmap: The Long or the Short Way from Diagnostics to Therapeutics
Margret Schottelius (PhD), Associate Professor, Translational Radiopharmaceutical Sciences, CHUV, Lausanne University Hospital

CXCR4 Based Theranostic: Imaging and Clinical Implications in MZL and other Hematological Neoplasms
Andreas Buck (MD), Clinical Director Nuclear Medicine, University Hospital Würzburg

CXCR4 Based Theranostic: A Promising Approach for Accurate Imaging of Multiple Myeloma and Therapy of Leukemia
Françoise Kraeber-Bodéré (PhD, MD), Head of Nuclear Medicine Department, CHU Nantes

Radiolabeled Single-Domain Antibodies as Theranostic Tools in Oncology
Matthias D'Huyvetter (PhD), Science Director, Precirix NV, Research Professor, Vrije Universiteit Brussel

Ga-68-Trivehexin for PET-Imaging of Carcinomas: The Way To Clinics
Johannes Notni (PhD) | Co-Founder and CSO, TRIMT GmbH, Jakub Simecek (PhD) | Co-Founder and CEO, TRIMT GmbH

Tuesday, October 18 **13:15 – 14:45, Hall 115**

Symposium by
Terumo Europe Interventional Systems
Advancing SIRT dosimetry with The Holmium Platform

Chairperson: Prof Dr. C. Deroose

Introducing the EANM SIRT dosimetry guidelines & products

Recent clinical evidence & dosimetry guidance of Holmium-166 SIRT

How is individualized SIRT treatment performed in routine clinical practice?

The Clinical Program of the Holmium Platform

Tuesday, October 18 **13:15 – 14:45, Hall 212**

Symposium by Curium
Innovations in Prostate Cancer Imaging and Therapy

CURIUM™ LIFE FORWARD

Chairperson: Sakir Mutevelic, Chief Medical Officer at Curium

Results from the Python trial: A Prospective Study on [^{18}F]DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
Christoph Rischpler, University Hospital Essen, Department of Nuclear Medicine, Germany, Professor of Nuclear Medicine

One year and 500 patients later: Pylarify® ([^{18}F]DCFPyL) in the daily clinical practice
Andrei Iagaru, University of Stanford, Department of Nuclear Medicine and Molecular Imaging, USA, Professor of Radiology & Nuclear Medicine

Artificial Intelligence for Enhanced Clinical Utility of Molecular Imaging
Aseem Anand, EXINI Diagnostics AB, Sweden, Vice President

PSMA-targeted Radioligand Therapy with [^{177}Lu]Lu-PSMA-I&T: A Decade of Experience
Harshad R. Kulkarni, Zentralklinik Bad Berka, Department of Nuclear Medicine, Germany, Consultant Nuclear Medicine, Chief Medical Advisor, BAMF Health, Grand Rapids, USA

Tuesday, October 18 **13:15 – 14:45, Hall 116**

Symposium by Siemens Healthineers
Answering to clinical needs in molecular imaging

SIEMENS Healthineers

First user experiences with Symbia Pro.specta SPECT/CT
Dr. Erin Ross, Yasmin Wahid,
Department of Medical Phyiscs, University Hospital Birmingham NHS, Birmingham, Great Britain

The future of PET: Total body imaging
Prof. Juhani Knuuti, Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland

RESEARCH4LIFE© EANM


EARL SERVING THE COMMUNITY:

^{18}F, ^{68}G, ^{89}ZR for

PET/CT and PET/MR

HARMONISATIONS





We are growing to serve the needs of our community. EARL provides unparallel support for tomorrow's research needs with today's molecular imaging data.

earl.eanm.org

+43-(0)1-890 44 27 earl@eanm.org earl.eanm.org

LIST OF EXHIBITORS (A - Z)

Booth No.	Exhibitor
ABSCINT	40
ABX GmbH	110
ABX-CRO advanced pharmaceutical services CM	71
ACOM Advanced Center Oncology Macerata S.r.l.	72
Advanced Accelerator Applications, a Novartis company CM	29
Advanced Accelerator Applications, a Novartis company (meeting room) CM	W04
Advanced Cyclotron Systems	58
AIMN – Associazione Italiana di Medicina Nucleare ed imaging molecolare	W10
Alliance Medical GmbH / Life Health Care	16
ASNC – American Society of Nuclear Cardiology	W08
AtomVie Global Radiopharma Inc.	10
Augmenticon AG	108
Bayer AG	W17
Best Cyclotron Systems	50
Blue Earth Diagnostics Ltd. CM	15
BNMS - British Nuclear Medicine Society	96
Boston Scientific International CM	27
Brightonix Imaging Inc	100
Bruker BioSpin CM	9
Buy Isotope (Neonest AB)	83
BV Cyclotron VU (part of the pavillion)	35
CANM-ACNM – Canadian Association of Nuclear Medicine	W02
Casram SA	4
CHEMATECH	73
Clarity Pharmaceuticals	65
CLERAD	37
CMR – Center of Molecular Research CM	48
Comecer Group CM	45
Crystal Photonics	99
CUP Laboratorien / TRIMT GmbH	33A
CURIUM CM	25
Cyclomedica Europe Ltd.	32
DIAsource ImmunoAssays	40
diXit s.r.l.	9
DOSIsoft SA	12
DSD Pharma GmbH (part of the pavillion)	35
ec2 Software Solutions	52
Eckert & Ziegler CM	19
EFRS – European Federation of Radiographer Societies	W18
EITA – European Isotopes Transport Association	W13
Eli Lilly (meeting room) CM	W06
Elysia-raytest Gmbh	40
Epsilon Radioactive Sources - ERS (part of the pavillion)	35
Eras Labo	87
Euromedical Instruments (part of the pavillion)	35
Evergreen Theragnostics	79
Fedoruk Canadian Centre for Nuclear Innovation	95
For-Med (part of the pavillion)	35
Gamma Medical Technology	67
GE Healthcare CM	26
GE Healthcare (meeting room) CM	1
Global Morpho Pharma	28
Hermes Medical Solutions AB CM	20

Hidex Oy	42
HOY Scandinavian ApS (part of the pavillion)	35
IAEA – International Atomic Energy Agency	W13.A
IBA (Ion Beam Applications) CM	22
ICPO Foundation	W16
ImaginAb	38
Incepto Medical	104
Innogamma Co	W11
Institute of Izotopes	43
Inter Medical Medizintechnik GmbH	57
Internatinal Meetings & Announcements Desk	W03.B
INVIA Medical Imaging Solutions	3
Invicro	55
Inviscan	61
Ionetix Corporation	85
Iotron Medical Inc	92
iPHASE technologies Pty Ltd	39B
IRE ELiT	40
Isotopia Molecular Imaging Ltd. CM	80
ITEL Telecomunicazioni SRL	76
ITM Medical Isotopes GmbH CM	46
Jiangsu Huayi Technology Co. Ltd	105
Jubilant Radiopharma	56
LabLogic Systems Ltd.	42
LaCalhene	60
Lemer Pax CM	28
M&I Materials Ltd (part of the pavillion)	35
Medi-Radiopharma Ltd. CM	47
Mediso Medical Imaging Systems CM	43
Mediso Medical Imaging Systems CM	44
MEDraysintell	40

medstep.de (VIVA Software AG) - Jobboard	W03.A
MedTrace Pharma A/S	11
MiE medical imaging electronics GmbH	33C
MILabs B.V. CM	78
MIM Software CM	8
Mirion Technologies, Inc. CM	W14
MNT Saglik Hizmetleri A.S.	75
MOLECUBES NV	6
Monrol Nuclear Products Co. CM	21
MR Solutions Ltd.	103
NICESOFT (part of the pavillion)	35
NMEU - Nuclear Medicine Europe	31A
NRGI PALLAS CM	34
NSNM – Norwegian Society of Nuclear Medicine and Molecular Imaging	W05
Nuclear Shields BV	69
Nucleis	40
NUVIA (part of the pavillion)	35
OGNMB – Austrian Society of Nuclear Medicine	W15
Oncidium Foundation	84
Onco Design	74
OncoBeta GmbH	88
Oncosil Medical	70
Oncovision	39
Optimized Radiochemical Applications	81
Pars Isotope Co. CM	66
PBL SRL	101
PentixaPharm	19
Pepscan	93
PI Medical Diagnostic Equipment B.V. (part of the pavillion)	35
Piur Imaging	94
PMB-ALCEN	59

POLATOM, Radioisotope Centre of National Centre for Nuclear Research CM	31
Positrigo AG	64
Precirix	51
Qubiotech Health Intelligence, S.L	2
Radiaprot	86
RADIOPROTECH	13
RadQual - International Isotopes (RadQual Global Sources)	91
Rescuedose	91
RI-TE Radiation Imaging Technologies, Lda	54
Rotem GmbH	39A
ROTOP Pharmaka GmbH CM	33
RPO - Radiomolecular Precision Oncology	109
RQS Alexander Ruffani	102
Scannix	40
Scintomics GmbH	5
SFMN – French Society of Nuclear Medicine	W19
SHINE Medical Technologies, LLC CM	63
Siemens Healthineers CM	30
Siemens Healthineers (meeting room) CM	49
Sirtex Medical Europe GmbH CM	17
SNMMI – Society of Nuclear Medicine and Molecular Imaging	W01
Society of Nuclear Medicine, India	W12
Southern Scientific	42
Spectrum Dynamics Medical Inc. CM	23
Sumitomo Heavy Industries, Ltd.	77
SYNTHRA GmbH	97
Taiyo Nippon Sanso Corporation	98
Tecnicas Radiofisicas Sl	106
Telix – ANMI SA, a Telix Company CM	41
Tema Sinergie S.p.A. CM	24

Terumo Interventional Systems CM	14
Theragnostics Limited	107
Transrad	40
TRASIS S.A.	36
Triskem International	68
TSNM – Turkish Society of Nuclear Medicine	W09
U.S. Department of Energy Isotope Program (OAK Ridge)	62
United Imaging Healthcare	53
United Imaging Healthcare	82
United Imaging Healthcare (meeting room)	W07
vent-medis GmbH	33B
Von Gahlen Nederland B.V. CM	18
Vortal	40
Wälischmiller Engineering	89
Wallonia Export & Investment Agency (AWEX)	40
Waters Cromatografía	112
WIS - World Infinity Services	40
Xeos Medical NV	111

LIST OF EXHIBITORS (SORTED BY BOOTH NO.)

Booth No.	Exhibitor
1	GE Healthcare (meeting room) CM
2	Qubiotech Health Intelligence, S.L
3	INVIA Medical Imaging Solutions
4	Casram SA
5	Scintomics GmbH
6	MOLECUBES NV
8	MIM Software CM
9	Bruker BioSpin CM
9	diXit s.r.l.
10	AtomVie Global Radiopharma Inc.
11	MedTrace Pharma A/S
12	DOSIsoft SA
13	RADIOPROTECH
14	Terumo Interventional Systems CM
15	Blue Earth Diagnostics Ltd. CM
16	Alliance Medical GmbH / Life Health Care
17	Sirtex Medical Europe GmbH CM
18	Von Gahlen Nederland B.V. CM
19	Eckert & Ziegler CM
19	PentixaPharm
20	Hermes Medical Solutions AB CM
21	Monrol Nuclear Products Co. CM
22	IBA (Ion Beam Applications) CM
23	Spectrum Dynamics Medical Inc. CM
24	Tema Sinergie S.p.A. CM
25	CURIUM CM
26	GE Healthcare CM
27	Boston Scientific International CM
28	Global Morpho Pharma
28	Lemer Pax CM
29	Advanced Accelerator Applications, a Novartis company CM
30	Siemens Healthineers CM
31	POLATOM, Radioisotope Centre of National Centre for Nuclear Research CM
32	Cyclomedica Europe Ltd.
33	ROTOP Pharmaka GmbH CM
34	NRGI PALLAS CM
35	BV Cyclotron VU (part of the pavillion)
35	DSD Pharma GmbH (part of the pavillion)
35	Epsilon Radioactive Sources - ERS (part of the pavillion)
35	Euromedical Instruments (part of the pavillion)
35	For-Med (part of the pavillion)
35	HOY Scandinavian ApS (part of the pavillion)
35	M&I Materials Ltd (part of the pavillion)
35	NICESOFT (part of the pavillion)
35	NUVIA (part of the pavillion)
35	PI Medical Diagnostic Equipment B.V. (part of the pavillion)
36	TRASIS S.A.
37	CLERAD
38	ImaginAb
39	Oncovision
40	ABSCINT
40	DIAsource ImmunoAssays
40	Elysia-raytest Gmbh


40	IRE ELiT
40	MEDraysintell
40	Nucleis
40	Scannix
40	Transrad
40	Vortal
40	Wallonia Export & Investment Agency (AWEX)
40	WIS - World Infinity Services
41	Telix – ANMI SA, a Telix Company CM
42	Hidex Oy
42	LabLogic Systems Ltd.
42	Southern Scientific
43	Institute of Izotopes
43	Mediso Medical Imaging Systems CM
44	Mediso Medical Imaging Systems CM
45	Comecer Group CM
46	ITM Medical Isotopes GmbH CM
47	Medi-Radiopharma Ltd. CM
48	CMR – Center of Molecular Research CM
49	Siemens Healthineers (meeting room) CM
50	Best Cyclotron Systems
51	Precirix
52	ec2 Software Solutions
53	United Imaging Healthcare
54	RI-TE Radiation Imaging Technologies, Lda
55	Invicro
56	Jubilant Radiopharma
57	Inter Medical Medizintechnik GmbH
58	Advanced Cyclotron Systems
59	PMB-ALCEN

60	LaCalhene
61	Inviscan
62	U.S. Department of Energy Isotope Program (OAK Ridge)
63	SHINE Medical Technologies, LLC CM
64	Positrigo AG
65	Clarity Pharmaceuticals
66	Pars Isotope Co. CM
67	Gamma Medical Technology
68	Triskem International
69	Nuclear Shields BV
70	Oncosil Medical
71	ABX-CRO advanced pharmaceutical services CM
72	ACOM Advanced Center Oncology Macerata S.r.l.
73	CHEMATECH
74	Onco Design
75	MNT Saglik Hizmetleri A.S.
76	ITEL Telecomunicazioni SRL
77	Sumitomo Heavy Industries, Ltd.
78	MILabs B.V. CM
79	Evergreen Theragnostics
80	Isotopia Molecular Imaging Ltd. CM
81	Optimized Radiochemical Applications
82	United Imaging Healthcare
83	Buy Isotope (Neonest AB)
84	Oncidium Foundation
85	Ionetix Corporation
86	Radiaprot
87	Eras Labo
88	OncoBeta GmbH
89	Wälischmiller Engineering
91	RadQual - International Isotopes (RadQual Global Sources)

91	Rescuedose
92	Iotron Medical Inc
93	Pepscan
94	Piur Imaging
95	Fedoruk Canadian Centre for Nuclear Innovation
96	BNMS - British Nuclear Medicine Society
97	SYNTHRA GmbH
98	Taiyo Nippon Sanso Corporation
99	Crystal Photonics
100	Brightonix Imaging Inc
101	PBL SRL
102	RQS Alexander Ruffani
103	MR Solutions Ltd.
104	Incepto Medical
105	Jiangsu Huayi Technology Co. Ltd
106	Tecnicas Radiofisicas Sl
107	Theragnostics Limited
108	Augmenticon AG
109	RPO - Radiomolecular Precision Oncology
110	ABX GmbH
111	Xeos Medical NV
112	Waters Cromatografía
31A	NMEU - Nuclear Medicine Europe
33A	CUP Laboratorien / TRIMT GmbH
33B	vent-medis GmbH
33C	MiE medical imaging electronics GmbH
39A	Rotem GmbH
39B	iPHASE technologies Pty Ltd
W01	SNMMI – Society of Nuclear Medicine and Molecular Imaging
W02	CANM-ACNM – Canadian Association of Nuclear Medicine

W03.A	medstep.de (VIVA Software AG) - Jobboard
W03.B	Internatinal Meetings & Announcements Desk
W04	Advanced Accelerator Applications, a Novartis company (meeting room) CM
W05	NSNM – Norwegian Society of Nuclear Medicine and Molecular Imaging CM
W06	Eli Lilly (meeting room)
W07	United Imaging Healthcare (meeting room)
W08	ASNC – American Society of Nuclear Cardiology
W09	TSNM – Turkish Society of Nuclear Medicine
W10	AIMN – Associazione Italiana di Medicina Nucleare ed imaging molecolare
W11	Innogamma Co
W12	Society of Nuclear Medicine, India
W13	EITA – European Isotopes Transport Association
W13.A	IAEA – International Atomic Energy Agency
W14	Mirion Technologies, Inc. CM
W15	OGNMB – Austrian Society of Nuclear Medicine
W16	ICPO Foundation
W17	Bayer AG
W18	EFRS – European Federation of Radiographer Societies
W19	SFMN – French Society of Nuclear Medicine

EXHIBITION HALL



29	Advanced Accelerator Applications, a Novartis company EM
W04	Advanced Accelerator Applications, a Novartis company (meeting room) EM
40	ABSCINT
110	ABX GmbH
71	ABX-CRO advanced pharmaceutical services EM
72	ACOM Advanced Center Oncology Macerata S.r.l.
58	Advanced Cyclotron Systems
W10	AIMN – Associazione Italiana di Medicina Nucleare ed imaging molecolare
16	Alliance Medical GmbH / Life Health Care
W08	ASNC – American Society of Nuclear Cardiology
10	AtomVie Global Radiopharma Inc.
108	Augmenticon AG
W17	Bayer AG
50	Best Cyclotron Systems
93	BioSynth
15	Blue Earth Diagnostics Ltd. EM
96	BNMS - British Nuclear Medicine Society
27	Boston Scientific International EM
100	Brightonix Imaging Inc
9	Bruker BioSpin EM
83	Buy Isotope (Neonest AB)
35	BV Cyclotron VU (part of the pavillion)
W02	CANM-ACNM – Canadian Association of Nuclear Medicine
4	Casram SA
73	CHEMATECH
65	Clarity Pharmaceuticals
37	CLERAD
48	CMR – Center of Molecular Research EM
45	Comecer Group EM
99	Crystal Photonics
33A	CUP Laboratorien / TRIMT GmbH
25	CURIUM EM
32	Cyclomedica Europe Ltd.
40	DIAsource ImmunoAssays
9	diXit s.r.l.
12	DOSIsoft SA
35	DSD Pharma GmbH (part of the pavillion)
52	ec2 Software Solutions
19	Eckert & Ziegler EM
W18	EFRS – European Federation of Radiographer Societies
W13	EITA – European Isotopes Transport Association
W06	Eli Lilly (meeting room) EM
40	Elysia-raytest Gmbh
35	Epsilon Radioactive Sources - ERS (part of the pavilion)
87	Eras Labo
35	Euromedical Instruments (part of the pavillion)
79	Evergreen Theragnostics
95	Fedoruk Canadian Centre for Nuclear Innovation
35	For-Med (part of the pavillion)
67	Gamma Medical Technology
26	GE Healthcare EM
1	GE Healthcare (meeting room) EM
28	Global Morpho Pharma
20	Hermes Medical Solutions AB EM
42	Hidex Oy
35	HOY Scandinavian ApS (part of the pavillion)
W13.A	IAEA – International Atomic Energy Agency
22	IBA (Ion Beam Applications) EM
W16	ICPO Foundation
38	ImaginAb
104	Incepto Medical
W11	Innogamma Co
43	Institute of Izotopes
57	Inter Medical Medizintechnik GmbH
W03.B	Internatinal Meetings & Announcements Desk
3	INVIA Medical Imaging Solutions
55	Invicro
61	Inviscan
85	Ionetix Corporation
92	Iotron Medical Inc
39B	iPHASE technologies Pty Ltd
40	IRE ELiT
80	Isotopia Molecular Imaging Ltd. EM
76	ITEL Telecomunicazioni SRL
46	ITM Medical Isotopes GmbH EM
105	Jiangsu Huayi Technology Co. Ltd
56	Jubilant Radiopharma
42	LabLogic Systems Ltd.
60	LaCalhene
28	Lemer Pax EM
35	M&I Materials Ltd (part of the pavillion)
47	Medi-Radiopharma Ltd. EM
43	Mediso Medical Imaging Systems EM
44	Mediso Medical Imaging Systems EM
40	MEDraysintell
W03.A	medstep.de (VIVA Software AG) - Jobboard
11	MedTrace Pharma A/S
33C	MiE medical imaging electronics GmbH
78	MILabs B.V. EM
8	MIM Software EM
W14	Mirion Technologies, Inc. EM
75	MNT Saglik Hizmetleri A.S.
6	MOLECUBES NV
21	Monrol Nuclear Products Co.
103	MR Solutions Ltd.
35	NICESOFT (part of the pavillion)
31A	NMEU - Nuclear Medicine Europe
34	NRG|PALLAS EM
W05	NSNM – Norwegian Society of Nuclear Medicine and Molecular Imaging
69	Nuclear Shields BV
40	Nucleis
35	NUVIA (part of the pavillion)
W15	OGNMB – Austrian Society of Nuclear Medicine
84	Oncidium Foundation
88	OncoBeta GmbH
74	Onco Design
70	Oncosil Medical
39	Oncovision
81	Optimized Radiochemical Applications
66	Pars Isotope Co. EM
101	PBL SRL
19	PentixaPharm
35	PI Medical Diagnostic Equipment B.V. (part of the pavillion)
94	Piur Imaging
59	PMB-ALCEN
31	POLATOM, Radioisotope Centre of National Centre for Nuclear Research EM
64	Positrigo AG
51	Precirix
2	Qubiotech Health Intelligence, S.L
86	Radiaprot
13	RADIOPROTECH
91	RadQual - International Isotopes (RadQual Global Sources)
91	Rescuedose
54	RI-TE Radiation Imaging Technologies, Lda
39A	Rotem GmbH
33	ROTOP Pharmaka GmbH EM
109	RPO - Radiomolecular Precision Oncology
102	RQS Alexander Ruffani
40	Scannix
5	Scintomics GmbH
W19	SFMN – French Society of Nuclear Medicine
63	SHINE Medical Technologies, LLC EM
30	Siemens Healthineers EM
49	Siemens Healthineers (meeting room) EM
17	Sirtex Medical Europe GmbH EM
W01	SNMMI – Society of Nuclear Medicine and Molecular Imaging
W12	Society of Nuclear Medicine, India
42	Southern Scientific
23	Spectrum Dynamics Medical Inc. EM
83	Stockholm Material Hub
77	Sumitomo Heavy Industries, Ltd.
99	SurgicEye GmbH
97	SYNTHRA GmbH
98	Taiyo Nippon Sanso Corporation
106	Tecnicas Radiofisicas SI
41	Telix – ANMI SA, a Telix Company EM
24	Tema Sinergie S.p.A. EM
14	Terumo Interventional Systems EM
107	Theragnostics Limited
35	The Pavillion
40	Transrad
36	TRASIS S.A.
68	Triskem International
W09	TSNM – Turkish Society of Nuclear Medicine
62	U.S. Department of Energy Isotope Program (OAK Ridge)
53	United Imaging Healthcare
82	United Imaging Healthcare
W07	United Imaging Healthcare (meeting room)
33B	vent-medis GmbH
18	Von Gahlen Nederland B.V. EM
40	Vortal
89	Wälischmiller Engineering
40	Wallonia Export & Investment Agency (AWEX)
112	Waters Cromatografia
40	WIS - World Infinity Services
111	Xeos Medical NV

COMPANY PROFILES

ABSCINT

Avenue du Parc Industriel 89
B - 4041 Herstal, Belgium

karine.clauwaert@abscint.com

https://abscint.com/

ABSCINT is a clinical stage molecular imaging company developing in vivo diagnostics empowered by single-domain antibodies. Our name captures our essence, which is to address unmet medical needs with the development of unique antibodies (AB) providing superior performance in scintigraphy (SCINT). Our mission is to provide more precise, more specific, more convenient and safer diagnostics in the fields of oncology, cardiology and immunology.

ABX advanced biochemical compounds GmbH

Heinrich-Glaeser-Str. 10 - 14
01454 Radeberg

info@abx.de

http://www.abx.de

ABX is the leading manufacturer of high-quality radiopharmaceutical products for molecular imaging & therapy mainly used for the the detection of tumors by PET and SPECT. Our company develops, produces, tests and markets precursors/active ingredients, reagent kits and hardware cassettes. Currently ABX is constructing one of the first approved and fully automated industrial-scale production facilities for radioactive theranostics with its own sterile testing.
An excerpt from our portfolio:
• FDG reagent kits & cassettes for nearly all FDG modules , Mannose Triflate, Cryptand222
• F-PSMA-1007 precursor, reagents & cassettes for GE MX, GE FX, GE FASTlab, ORA Neptis, IBA Synthera, Synthra & Trasis AIO modules • nucleophilic & electrophilic F-DOPA precursors, reagents & cassettes
• FLT, F-Choline, F-MISO, FET & NAF precursors, reagents & cassettes • comprehensive range of "scientific" precursors for oncology and neurology
• SPECT precursors e. g. CuMIBI, MIBG, ECD • PEPTIDES e.g. PSMA-11, DOTA-TOC, DOTA-TATE & DOTA-NOC for Gallium68 labelling • Gallium-68 reagents kits & cassettes • Lutetium-177 reagents kits & cassettes
•O-18 WATER • Performance of stability studies
•Development of radiotracers & labelling as well as purification strategies
We are well experienced in GMP productions and also offer custom syntheses according to Q7 chapter 19 for clinical PET studies (APIs). Our laboratories and clean rooms are GMP certified and meet pharmaceutical standards. We are GMP and ISO13485 certified.

Advanced Accelerator Applications, A Novartis Company

Rue de la Tour de l'Ile 4
1204 Genève, Switzerland

https://www.adacap.com/

At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients' lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology.

A.C.O.M. - ADVANCED CENTER ONCOLOGY MACERATA – S.R.L.

Località Cavallino, 39/A-B,
62010 Montecosaro (MC), Italy

amministrazione@acompet.it

www.acompet.it

ACOM SRL is a company operating in the nuclear medicine sector founded in 1999.
Research is the driving force of the company, with 20 years of commitment and experience in the development of innovative radiopharmaceuticals to be included in the international market. The main area of interest and development is oncology, but the activities also involve neurodegenerative and cardiovascular diseases.
The focus of the research is theranostic medicine, and in particular the development of Copper(64Cu) Chloride as a theranostic agent: a real integration of a diagnostic method with a specific therapeutic intervention.
ACOM SRL is the first company in Europe to have brought in the market the radionuclide Copper-64 as a radiopharmaceutical precursor.
ACOM SRL has recently obtained orphan designation in Europe for the treatment of glioblastoma with Copper(64Cu)Chloride.
The professional skills of the team, the capacity to operate in critical contexts and an innovative approach demonstrated by constant investment in research and development, are just some of the distinctive features developed in these years of business. For any further information please visit our stand and our WEB page (www.acompet.it) where you can find the most updated information.

Advanced Cyclotron Systems, Inc (ACSI)

150-7280 River Road
V6X 1X5 Richmond, BC, Canada

info@advancedcyclotron.com

www.advancedcyclotron.com

Advanced Cyclotron Systems, Inc. (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 30 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada.

ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market.

The versatility, high beam current and exceptional quality of ACSI cyclotrons are some of the reasons why many of the world's most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs.

For more information, please visit www.advancedcyclotron.com.

Alliance medical / Life Healthcare Europe

Westring 168
44575 Castrop-Rauxel, Germany

nikki.polat@alliancemedical.eu

Life Healthcare Europe, consisting of Life Molecular Imaging, Life Radiopharma and Life Alliance Medical is an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allows physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.

Atomvie Global Radiopharma Inc.

c/o: CPDC, 1280 Main Street West, NRB-A316
ON L8S-4K1 Hamilton, Canada

info@atomvie.com

www.atomvie.com

Leveraging over seven years of expertise in the GMP manufacturing and global distribution of radiotherapeutics, the Centre for Probe Development and Commercialization (CPDC) is launching AtomVie Global Radiopharma Inc. (AtomVie), a global leading Contract Development and Manufacturing Organization (CDMO). AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of your radiotherapeutics from Phase 1 to the commercial marketplace. AtomVie has in-depth expertise in radiolabeling with an array of radioisotopes such as Lu-177, Ac-225, I-131 and ligands that range from small molecules, to peptides to small and large antibodies. In partnership with Isotopia, AtomVie produces Lu-177 (n.c.a.) from its own facility, offering a unique value proposition to its clients with Lu-177-based programs. Capabilities offered by AtomVie include:

- Analytical and process development
- Scale-up & stability studies
- Analytical and process validation
- Logistics to global destinations (North America, EU, Asia and more)
- Regulatory affairs (FDA, Health Canada and EMA)
- Routine clinical and commercial supply to meet the needs of our clients
- Supply of GMP-grade Lu-177 (n.c.a.)

We are building a state-of-the-art, multi-product facility that will be operational in 2024. AtomVie empowers the development of your radiotherapeutics.

Augmenticon AG

Europe 19a
CH-8152 Glattbrugg, Switzerland

c.schmidt@augmenticon.ch

www.augmenticon.ch

Augmenticon AG was founded by Dr. Matthias Friebe and Dr. Christian Schmidt in 2019 with the mission to transform and digitalize pharmaceutical manufacturing with their AR/MR, computer vision based application suite. The benefits of our application suite are optimized resource utilization, better manufacturing process control with reduced number of human errors, minimal machine down-time, and consequently reduced costs.

Our Product Portfolio:

• Augmenticon ASSYST:
Process guidance & control via: Step-by-step instructions with feedback function, Immersive AR/MR interfaces, AI and deep learning algorithms

• Augmenticon SHARE:
Live Expert-to-operator communication for remote: Training, Troubleshooting, 2nd persons verifications.

• Augmenticon DOCS:
Documentation & Analysis of: R&D lab, GMP production and QC activities, incl. deviations OOS, Integration with our other systems, ASSYST and SHARE, Orders and Invoice.
Management of: Enterprise & Users, Products, Materials, Equipment, Customers, Integration with other interfaces such as ELN, EMS, LIMS, eQMS, ERP, etc.

Our Services:

• Pilot projects: These allow you to thoroughly test our products before you enter into a license agreement.

• Training: The initial training of your staff is included in the license package you acquire. Our experts support you in training of new employees or third-party staff.

• Validation Services: System validation and assistance of customer specific documentation.

Our mission is to become your reliable partner for cGMP compliant Industry 4.0 applications in pharmaceutical manufacturing. Reach out to us (www.augmenticon.ch) and let us show you how we can jointly shape the future.

Wallonia Trade and Investment Agency (AWEX)

Place Sainctelette 2
1080 Brussels, Belgium

LIFESCIENCES@awex.be

https://www.awex.be/en

The Wallonia Foreign Trade and Investment Agency, also known as AWEX, is Wallonia - Region of Belgium's government agency in charge of foreign Trade and foreign investment.
Wallonia is home to many nuclear medicine companies of various sizes, from SMEs to large companies, such as IBA and IRE, including spinoffs, suppliers and service providers.
Our regional government supports the development of existing or newly established innovative activities with regard to R&D and production in the radiopharma and radiotherapy industry. AWEX is a one-stop shop for all foreign companies interested in setting up or expanding their business in Wallonia, as well as a partner for all Walloon companies wishing to develop their activities outside Belgium. If you're interested to know more, we will provide you with tailor-made information.
Our partner BioWIN, the Health Cluster of Wallonia since 2006, encourages innovation and international development of Walloon actors active in this sector. BIOWIN connects some 250 key players: universities, research units and centers, R&D as well as manufacturing companies, incubators, capital providers, hospitals. To find out more about BioWIN's activities, please visit https://biowin.org/.

Bayer AG

Radiology Commercial Operations EMEA
Muellerstr. 178
13342 Berlin, Germany

Ronja.reuber@bayer.com

radiology.bayer.com

As a true life-science company, Bayer understands where treatment starts: With an early and precise diagnosis. Our dedication to quality in everything we do supports Radiologists to focus on patient care.
For approximately 100 years, we have pioneered products and services to enhance medical imaging. Today, we continue to be a preferred partner to radiologists and other physicians as they work to provide the best care for patients
We provide radiologists with a portfolio of products that enhance medical imaging and facilitate greater efficiency with a focus on image acquisition, from Contrast Media, Injection and Infusion Systems, Service to Software Solutions.

Best Cyclotron Systems

413 March Rd
K2K 0E4 Kanata, Canada

clemens.schroder@theratronics.ca

Best Cyclotron Systems has been established in Springfield, Virginia, U.S.A., for the design and production of commercial cyclotrons. Our Cyclotrons are manufactured and tested at Best Theratronics in Ottawa, Ontario, Canada. BCS is currently focused on five different energy cyclotrons: the 15, 25, 30, 35 and 70 MeV negative hydrogen ion accelerators.

Biosynth (formerly PEPSCAN and Vivitide)

Zuidersluisweg 2
8243RC Lelystad, The Netherlands

order@pepscan.com

www.pepscan.com

Biosynth - Peptide and Antibody division (formerly Vivitde and Pepscan) - is showcasing its new offering across the full range of peptide products and services. From custom peptide synthesis and library production, lead discovery and optimization, large scale peptide manufacture and GMP compliant NCEs, as well as our class-leading neoantigen peptide programs.
Targeted nuclear medicine has experienced rapid growth, both in diagnostic imaging and therapy as well as the combination thereof: theranostics. Peptides play an important role in this field as they can specifically deliver both radioactive markers and therapies to a tumor.
Biosynth offers a unique CLIPS™ phage display platform to discover highly constrained de novo peptides with enhanced affinity against your target of interest, selectivity and proteolytic stability. We employ some of the industry's finest chemists to further optimize and design your lead peptides to make them fit for your purpose.
We have a proven track record in synthesizing precursors for peptide radiopharmaceuticals suitable for a wide range of applications, both following our internal peptide discovery program as well as lead peptides discovered by our customers.
Come and talk to the Biosynth team if you want to know how we can assist you in progressing your peptide project through (pre-) clinical development, application and commercialization and support you in making your project a success story!

Blue Earth Diagnostics

The Magdalen Centre, Oxford Science Park
OX4 4GA, Oxford, England

BEDCongress@blueearthdx.com

www.blueearthdiagnostics.com

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is an international molecular imaging company on a growth trajectory to develop and commercialise innovative, well-differentiated diagnostic solutions that inform patient care and drive future therapies in cancer. Formed in 2014, the Company's success is driven by its management expertise, supported by a proven track record of rapid development and commercialisation of positron emission tomography radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics' expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialisation of precision radiopharmaceuticals for potential use in diagnostic imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.

Boston Scientific International S.A.

2 rue René Caudron
78960 Voisin-le-Bretonneux, France

http://www.bostonscientific.eu/

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care.
Boston Scientific collaborates with health care professionals to develop meaningful innovations that help more people live longer, healthier lives. We invest in bringing new products to large, high-growth markets while building our unique pipeline of technologies to expand our category leadership and address unmet patient needs. Our innovative culture has enabled us to serve approximately 30 million patients annually.
Interventional Oncology is giving medical teams powerful new options and patients new hopes. We believe this is just the beginning and are committed to working with you to change the fight against cancer. Our best-in-class portfolio enables personalised interventional strategies, supported by evidence and educational partnerships.

Brightonix Imaging Inc.

#1705, SK V1 Tower, 25, Yeonmujang 5ga-gil,
Seongdong-gu
04782 Seoul, South Korea

info@brtnx.com

www.brtnx.com

Brightonix Imaging is a innovative healthcare company established with the goal to provide society with innovative biomedical imaging devices and solutions.
We are currently offering AI-powered medical imaging solutions and preclinical PET systems.
SimPET is the most compact and reliable MRI compatible SiPM PET insert for truly simultaneous PET/MRI studies in small animals, to molecular imaging scientists.
BTXBrain is AI-powered automated brain PET quantification software, and runs without the aid of 3D MR images. It is very fast and reliable, and it also provides flexible settings and user-friendly interfaces for easy interactions.
Brightonix Imaging is also developing clinical PET scanner for brain and other peripheral organs with support from Korea Medical Device Development Fund.

Bruker

Bruker BioSpin GmbH
Rudolf-Plank-Str. 23
76275 Ettlingen, Germany

pr@bruker.com

https://www.bruker.com/pci

Bruker offers advanced preclinical imaging solutions for a broad spectrum of application fields, such as oncology, neurology, cardiology, inflammation, infectious diseases, cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models.
With more than 20 years of experience in molecular imaging, we are committed to enhancing each laboratory's ability to explore cellular and molecular processes in living animal models.
This commitment drives our innovation agenda by gathering knowledge, building networks, and exploring new technologies with the goal of enabling new theranostic methods and discovering new drugs in oncology, cardiology, neuroscience, and immunology.
From floor-standing instruments to benchtops, from software to service, from academic research to applied research, Bruker brings you the world of molecular imaging and offers advanced hybrid imaging devices such as PET/CT, PET/MR and PET/SPECT/CT to help scientists and life science industry to advance their research or business.

Buyisotope (Neonest AB)

Storgatan 70C
Solna, Sweden

info@buyisotope.com

www.BuyIsotope.com

Buyisotope (Neonest AB) offers a range of high quality enriched isotopes e.g. Zn-68, Ga-68, Ga-69, Ca-44, Ca-42, Pd-102, Sr-88, Lu-176, Yb-176, Ir-191, Ba-130, Tl-203, Yb-168, Sm-152, Sr-84, Sr-88 in different chemical forms: e.g. oxide, metal, carbonate and enriched isotopic gases e.g. Xe-124, Xe-129, Xe-131. On requests: we produce monoisotopic chemical compounds e.g. cisplatin, nitrates, chlorides and convert of rare-earth oxides to metals. We can produce different structured forms of the enriched isotopes e.g. targets, foils, rods, cylinders, pins, pellets.
Buyisotope offers non enriched products e.g. Iridium pellets, Iridium discs, Iridium pins, Rubidium metal (purity 99.997%) and over 1000 High Purity Inorganic Compounds including Alkali and Rare Earth metals and compounds.
Please let us know what is your requirement and we will find a solution.

BV Cyclotron VU

Van der Boechorststraat 6 A
1081 BT Amsterdam, The Netherlands

info@cyclotron.nl

www.cyclotron.nl

BV Cyclotron VU produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Strategically located in Amsterdam next to Amsterdam UMC we produce GMP-compliant medical isotopes in our state-of-the-art manufacturing facilities.
Our long standing track record on supplying daily to the customers, our great expertise combined with strong collaborations makes us a reliable partner for hospitals, pharmaceutical companies and research centers all over the world.

Capintec (A Mirion Medical Company)

7 Vreeland Rd.
07932 Florham Park, New Jersey, United States

capintec@mirion.com

www.capintec.com

Recognized as a leader in the development and manufacturing of state-of-the-art radiation measuring and monitoring instrumentation, Capintec (A Mirion Medical Company) seeks to better the human condition by protecting people from exposure during potentially life-saving diagnosis and therapy. From dose preparation to patient administration, Capintec® nuclear medicine and molecular imaging solutions enhance safety and efficiency for technologists and physicists throughout the care continuum.

CASRAM

Via Cantonale 31
6805 Mezzovico, Switzerland

info@casram.com

www.casram.com

Casram – based in Switzerland since 70 years – is a manufacturer of tungsten heavy alloys for radiation shielding, with fully integrated specialized workshops: A Powder metallurgy workshop with high end sintering technology, a state-of-the-art machining workshop to obtain most complex dimensions with most severe tolerances, surface treatment shops and a complete QC laboratory for non-destructive testing and certifications.
Every manufacturing step is located in one single EN 9100 and ISO 9001 certified facility.
Our tungsten heavy metal alloys are used for transportation containers, syringe shieldings, collimators and all other kind of radiation shielding applications.

CHEMATECH

2 rue Pauline Kergomard
21000 Dijon, France

info@chematech-mdt.com

www.chematech-mdt.com

High quality chelators for efficient radiolabeling
CheMatech is a leading company specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labelling especially with 67/68Ga, 111In, 64/67Cu or 177Lu. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also offers custom syntheses, GMP production of chelators and bioconjugation services.

Clarity Pharmaceuticals

4 Cornwallis Street,
National Innovation Centre,
Eveleigh 2015 NSW, Sydney, Australia

bd@claritypharmaceutical.com

Claritypharmaceuticals.com

Clarity is a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer.
Clarity is a global leader in Targeted Copper Theranostics (TCTs), developed with its proprietary SAR Technology platform. TCTs are the next-generation disruptive platform in radiopharmaceuticals that employ the "perfect pairing" of copper-64 (64Cu) and copper-67 (67Cu) for diagnosis and therapy. TCTs deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as provide supply, logistical and environmental advantages over the current generation of theranostics. TCT provide a highly efficacious, scalable, sustainable and cost-effective way to expand radiopharmaceuticals into the global oncology market.
Clarity has a diverse range of products in clinical trials which address both large indications, such as prostate cancer, as well as rare and orphan indications of cancer, such as neuroblastoma. The company is actively progressing six clinical trials of its three key products, SARTATE™, SAR-bisPSMA and SAR-Bombesin. The trials are conducted in two theranostic and four diagnostic indications. In addition to the six trials, sponsored by Clarity, two investigator-initiated trials (IITs) with the company's products commenced in 2022.

CLERAD

184-186 Boulevard Gustave Flaubert
63000 Clermont-Ferrand, France

clerad@clerad.fr

www.clerad.fr

Since 2000, CLERAD has become a main leader in ionizing rays detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery.
We are operating in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other solutions in Radiology, and Radiotherapy.
Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.

CMR (Center of Molecular Research)

Office 518, Regico Offices, the Old Bank 153,
the Parade High Street
WD17 1NA, Watford, United Kingdom

info@isotope-cmr.com

CMR is one of the world's largest manufacturers and suppliers of Oxygen-18 water (GMP certified, I.E. ≥ 98%), stable and radioactive isotopes. For more than twenty years, CMR has been a reliable supplier of isotopes in different industries, mainly in nuclear medicine, science and industry. The list of enriched stable isotopes we offer for cyclotron and reactor targets includes Xe-124, Te-124, Ni-64, Tl-203 and many others. CMR is ready to accept orders for almost full range of isotope elements of Periodic Table. Industrial isotopes are also on our Product List. There are Heavy Water, Depleted Zinc Oxide and others. Furthermore, we guarantee stable supply of radioactive isotopes such as Lu-177 (n.c.a. and c.a.), I-131, I-125, etc. In addition, CMR produces peptide precursors for radiopharmaceutical preparations, for example, DOTA-TATE, DOTA-TOC, DOTA-NOC, PSMA- I&T, PSMA-1007, etc. CMR's goal is to satisfy all customers' needs therefore besides isotopes and lyophilizates we offer a wide range of reagent kits, chemicals for PET-tomography. All CMR products are produced in clean rooms and dispensed under high-level quality control conditions.

COMECER

Via Maestri del Lavoro 90
48014 Castel Bolognese, Italy

marketing@comecer.com

www.comecer.com

Comecer designs and builds systems and equipment for the safe treatment of radioactive substances used in Nuclear Medicine, guaranteeing minimum exposure to the operator, total decontamination and inalterability in any working condition. In particular, Comecer excels in the field of radiochemistry where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications. Comecer follows the product at every stage, from production to use in radiopharmaceutical laboratories and nuclear medicine facilities, certifies all its products, and all systems are tested and subjected to a wide range of validation tests according to the regulatory standards in force at the national, European and international level. In the Nuclear Medicine sector, Comecer's products are used in the most advanced and prestigious research centres, universities, hospitals and pharmaceutical companies worldwide. The ability to build customised solutions for its customers is the basis of Comecer's success. With three production sites in Castel Bolognese, Siena (Italy) and Joure (Netherlands), and offices in Chicago (USA), Dubai (UAE), Mumbai (India) and Taipei (Taiwan), Comecer employs over 300 people and markets its products in over 100 countries through a direct sales network and some technological partnerships for the joint development of new products.

Crystal Photonics GmbH

Albert-Einstein-Straße 16
12489 Berlin, Germany

info@crystal-photonics.com

www.crystal-photonics.com

Crystal Photonics and SurgicEye are engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and for intraoperative and transcutane sentinel lymph node localization (SLNE) since 20 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera "CrystalCam", the surgical Gamma Probe System "Crystal Probe - automatic" with various kinds of cable and wireless probes, the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), the very new CrystalAnalyzer for HPLC-investigation in coincidence for any PET-drugs and the 3D-free-hand-spect imaging system declipse®SPECT in various versions.
Also our CE-confirmed software DosePlan for accounting the dose rate distribution while a SIRT-treatment is now ready for using.
Additionally, we present the first time our very new mini-Laparoscopic gamma probe for robotic-assisted minimal-invasive surgeries, (Drop-in-Probe) special designed for the Da Vinci robotic operation system. This probe was developed in the course of the new PSMA-technology for Prostate Cancer and has excellent medical-technical properties. For more information, please visit our websites:
www.crystal-photonics.com
www.surgiceye.com.

CUP Laboratorien Dr. Freitag GmbH

Carl-Eschebach-Strasse 7
01454 Radeberg, Germany

office@cup-freitag.de

www.cup-freitag.de

The CUP Laboratorien Dr. Freitag GmbH is a highly specialised, GMP-certified and FDA-inspected contract laboratory. Our laboratories have also recently been audited by experts under the EANM´s Shared Audit and Supplier Assessment Initiative (SASAI) and the report will be available soon.
At our site in Radeberg/Germany, we have a state-of-the-art infrastructure with clean rooms, radiation protection areas and state-of-the-art analytical equipment.
With our almost 60 excellent employees, we offer exclusive services especially for manufacturers of radiopharmaceuticals.
These include, for example, sterility testing of radiotherapeutics with membrane filtration, "hot" leachables & extractables studies, testing of peptides and antibodies as precursors for radiopharmaceuticals and many other.
In addition, we have routinely established in our laboratories several test methods of starting materials and excipients for the production of radiopharmaceuticals.

Curium

63, avenue des Champs Elysées
75008 Paris, France

contactus@curiumpharma.com

https://www.curiumpharma.com/

Curium is the world's largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for potentially life-threatening diseases to over 14 million patients annually. The name 'Curium' honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline 'Life Forward' represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.

To learn more, visit www.curiumpharma.com

Cyclopharm Ltd

Unit 4 / 1 The Crescent
2208 Kingsgrove NSW, Australia

info@cyclomedica.com

https://www.cyclopharm.com/

We are Cyclomedica – bringing light into Molecular Imaging since 1986. We have paved the way with Molecular Imaging solutions in Australia and around the globe. From innovation, development to clinical practice applications – we are the world leaders in functional lung ventilation imaging with our proprietary technology: Technegas®.
Created and manufactured in Australie our flagship product Technegas® has revolutionised diagnostic lung imaging and today transform the lives of millions of patients in more than 61 countries around the world.

A new era in Nuclear Pulmonology continues to unlock as new innovations come to light. Technegas® currently has a wide cross-section of clinical applications and several potential new Beyond PE indications for functional lung imaging. The exciting thing about our solution is our ongoing commitment to research, clinical trials, development and innovation.

We are cultivating business partners globally to deliver cutting edge products in Molecular Imaging, PET and Theranostics. In Molecular Imaging, we offer the ability to take your project from conception to completion, validations to lifetime product support with our business partners TEMA, ROTOP, Lucerno Dynamics and Jubilant Radiopharma. As Molecular Imaging evolves, we are committed to find the right solutions for your needs.

DIAsource ImmunoAssays SA

Rue du Bosquet 2
B - 1348 Louvain-la-Neuvel, Belgium

info@diasource.be

www.diasource.be

DIAsource ImmunoAssays SA, a BioVendor Group company, is an international diagnostic company based in Belgium, who develops, manufactures and markets clinical diagnostic products in the field of endocrinology and infectious diseases.
DIAsource provides a complete range of RIA (and Elisa) kits in the fields of Autoimmunity, Biogenic Amines, Bone metabolism, Cancer markers, Cardiovascular and Salt Balance, Diabetes, Fertility, Growth factors, Thyroid kits, Gastrointestinal markers, Immunology and Infectious diseases is presented to our customers.
For automation of RIA assays we offer automates like Conext 125 (Pipetting automate) and refurbished RIAMAT systems (fully automated RIA processor).
DIAsource aims to be a world leader on the RIA market and to become a "one time shopping RIA company" by offering the most complete range of RIA kits. DIAsource is also involved in the refurbishing and sales of gamma counters Riamat's, a Stratec fully automated RIA platform and the Conext 125. Moreover, we sell radioactive decontaminating products used in clinical, pharmaceutical and research labs that use I125 as an isotope, as well as to the nuclear medicine departments. With this complete service to RIA labs we want to convince our end users that our golden standard kits are the best possible choice.
ISO certificates: ISO9001 and ISO 13485
Our kits are CE marked and available worldwide, with the exception of Canada, Japan and USA. For those countries only certain kits are available since special registration is required.

Dixit S.r.l.

Via Giuseppe Giacosa 38
10125 Torino, Italy

contact@dixitsolutions.com

www.dixitsolutions.com

Based in beautiful Turin, the first capital city of Italy and a technological hub, Dixit is a company focused on building efficient medical applications and services.

Its main product, WIDEN (www.dixitsolutions.com/widen), is a Web Service designed to make the management, quality assurance and review of imaging studies in clinical trials simpler, more effective and more reliable. Trials can then easily scale in size and statistical significance can be achieved in a short time.

Dixit works with leading international imaging and oncological societies and cooperative groups that use qualitative and quantitative imaging, especially PET/CT, in their cancer treatment protocols.

Since 2012, WIDEN has been used in more than 40 multi-centre clinical trials, whose coordinating bodies reside in Austria, France, Switzerland, UK, Poland, Italy and Australia. WIDEN users are located in 25 different countries and more than 250 clinical centres.

WIDEN is also suitable for retrospective imaging-based clinical trials, that could be simply configured and operated. Their data can be quickly analysed, to assess the results and design more ambitious, prospective trials to validate them.

DOSIsoft

45/47 Avenue Carnot
94230 Cachan, France

info@dosisoft.com

www.dosisoft.com

Spin-off between Gustave Roussy & Institut Curie, DOSIsoft was founded in 2002. It develops patient-specific imaging and dosimetry software in Radiation Oncology & Nuclear Medicine to improve patient safety & treatment quality. 20 years of innovation and R&D investments have led to world leading software used in over 300 hospital centers in 50 countries.

PLANET® Software Suite is a Patient-specific, multi-radionuclide (90Y/177Lu/131I/166Ho) & theranostics platform for Molecular Imaging & Molecular RadioTherapy dosimetry. It comprises:

PLANET® Onco: Oncology software for Molecular Imaging (MI) & Radiotherapy. It helps to optimize disease diagnosis & therapy through registration, contouring, advanced quantification & patient response from multimodal imaging. Texture analysis for diagnosis, follow-up & radiomics is provided.
PLANET® Dose: Dosimetry software for Molecular RadioTherapy (MRT) providing multiple and integrated workflow for 90Y/177Lu/131I/166Ho dosimetry. It allows to personalize patient therapy through pre/post-implementation dosimetry, automatic structure propagation, calculation of residence time & comparison between treatment planning & validation control dose maps. Consolidation of multi-treatment stages is available.

DSD Pharma GmbH

Schuhmeierstr. 24
1140 Purkersdorf, Austria

office@dsd-pharma.com

www.dsd-pharma.com

Diagnostics
In nuclear medicine diagnostics, patients are administered radioactive drugs, so-called radiopharmaceuticals. Depending on their pharmacological properties, these accumulate in varying concentrations in the organs or tissues of the person. The radiopharmaceutical then emits a weak radiation that can be detected in PET-CT, SPECT-CT or scintigraphy, depending on the type of examination.
In diagnostics, DSD Pharma offers a range of radiopharmaceuticals, peptides and labelling kits for the fields of scintigraphy, positron emission tomography (PET) and single photon emission computed tomography (SPECT).

Solutions
DSD Pharma is a competent partner in all matters relating to diagnostics, therapy and theranostics in nuclear medicine: DSD Pharma's innovative and broad product portfolio includes holistic and customized solutions for specific requirements – from the provision of radioactive substances to the handling of logistics and transport to the set-up of hot rooms.

Diversity
DSD Pharma works with national and international suppliers and manufacturers who enable us to ensure the diversity and variety of our product portfolio. In addition to diagnostics, DSD Pharma also offers therapeutics, medical devices, medical-technical equipment, synthesis modules for the production of radiopharmaceuticals, equipment for radiopharmacy and hot rooms, nuclide databases, contained sources and much more.

ec² Software Solutions

3035 E. Patrick Lane, Suite 1
89120 Las Vegas, NV, USA

Sales@ec2software.com

www.ec2software.com

ec² Software Solutions and our partner company, Numa LLC, are focused on developing and commercializing workflow and compatibility solutions for the molecular imaging community. Together, with over 60 years' experience, ec² and Numa provide innovative management solutions for cyclotrons, radiopharmacies, hot lab operations, multi-vendor connectivity, archiving and reporting. Our systems are presently installed in 6000 + facilities worldwide.
We provide Enterprise Solutions that secure ePHI patient data and consolidate installations all in a scalable architecture. The HL7 / DICOM Modality Worklist interfaces enhance scheduling and eliminate redundant data entry. NumaStatus can export patient dosimetry and dose information to the cameras, RIS/PACS or Dose Management system using DICOM secondary capture and Radiopharmaceutical Radiation Dose Structured Report (RRD SR). The HL7 export module and deliver dose information to the EMR and MAR.
Our on-line ordering (OLO) e-prescribing solutions are used by hundreds of commercial radiopharmacies and their customers in the U.S. and international markets. OLO eliminates transcription errors and enhances patient safety.
.

EITA - European Isotopes Transport Association

Vandenalotte Buro & Design Center
Esplanade 1/85
1020 Brussels, Belgium

arno.meinl@meinl-logistic.de
kristel.vermeersch@kvspartners.be

www.eita.org

EITA is a non-profit association, which was founded in 1998 by European logistics providers trained, licensed and specialized in the handling and transport by Road, Air and Sea of radioactive isotopes, which are mainly used for medical purpose.

Mission
• Establishment of harmonized regulations and standards
Aiming for harmonized national and international regulations and legislations to guarantee the free market access in every state for the EITA members.
• Compliance with applicable regulations
To ensure all EITA member activities are carried out in full compliance with all applicable legal requirements.
• Safety, Security and traceability
To ensure safety and security and full traceability at all times during the complete supply chain.
• Quality
To ensure high quality of handling, packing and transport of radioactive isotopes in accordance with required standards.
• Competence center
To provide a forum to exchange information and knowledge in order to increase awareness.

ELYSIA S.A.

Rue du Sart Tilman 375
B - 4031 Angleur, Belgium

info@elysia-raytest.com

www.elysia-raytest.com

We design, manufacture, integrate and service instruments for the measurement of radioactivity and the quality control of radiopharmaceuticals and other radioactive compounds. We work in close collaboration with radiopharmaceutical and cyclotron providers to develop new products and improve existing solutions.

Elysia is a provider of hardware and software solutions for the fully integrated quality control of your radio-pharmaceutical production. Our GINA X and SARA client/server platforms offer a user friendly and fully GMP compliant solution to your QC problems.
Radiopharmaceuticals should be easily accessible world-wide and affordable. We assist our customers accelerate their R&D and to validate QC methods for existing and new molecules.
Further our Radio-detectors are also used in TLC, HPLC and GC Radio-chromatography, Gamma Spectroscopy, Dose Calibration and well counting for the pharmaceutical, agrochemical and nuclear/PET industries.
We want to make the measurement of radioactivity and the quality control of radiopharmaceuticals, easier, faster and safer.
We are a customer-oriented team of radiochemists, engineers, IT and QA specialists.

Brands: Elysia produces the specific radio-detection instruments and software for your QC needs. In order to ensure a high level of quality and to provide state-of-the-art solutions, next to our own Elysia products we work with major and well-established brands and partners, such as IBA, Shimadzu, Agilent and Charles River.

EPSILON RADIOACTIVE SOURCES (ERS)

Ferhatpaşa Mahallesi 15.Sokak
No:126-128 Ataşehir, 34888 Istanbul, Türkei

info@epsilonsources.com

www.epsilonsources.com

ERS manufactures quality assurance sources that are compatible with the leading PET OEM manufacturers to provide high-quality products and customer satisfaction. For the calibration of PET, PET/CT, PET/MR & SPECT systems, 68Ge, 22Na, 57Co and 153Gd sources are used in different forms and activities depending on the system model. Customized sources in different forms and activities can be offered upon customer request by ERS.
Please contact your local distributor or ERS headquarters for product availability and additional information.

ERAS Labo

222 Route départementale 90
38330 Grenoble, France

eras.labo@wanadoo.fr

ERAS Labo is a GMP part II certified company specialized in the manufacturing of APIs and reagent kits mainly for the radiopharmaceutical sector. It is located at the foot of the Alps, near Grenoble (France). The chemical synthesis capabilities range from the mg scale to batches of few hundred grams. The physicochemical analyses are mostly performed inhouse thanks to the wide spectrum of analytical tools available on site (NMR, various chromatographic techniques, atomic absorption, ICP coupled with emission spectroscopy, thermal analysis, UV-vis and FT-IR spectroscopy, …).
Class C clean rooms allow the dispensing of the produced APIs in single dose vials and the preparation of complete reagent kits. In this way, ERAS Labo controls the manufacturing of reagent kits from the synthesis of the API to the final assembly of the kit including the quality control operations.
ERAS Labo has a recognized expertise in the synthesis of complex organic molecules and in analytical chemistry. These custom services are highly appreciated by our clients.

EuroMedical Intruments

13 rue Raymond Losserand
75014 Paris, France

sales@em-instruments.com

www.em-instruments.com

EuroMedical Instruments is the exclusive worldwide sales and marketing company of the Europrobe, a state-of-the-art surgical gamma probe manufactured by Eurorad SA, Strasbourg, France. Founded in 1982, Eurorad is a high technology company specialised in R&D, Service and Production of mono and polycrystalline semiconductors for radiation detectors, and one of the main manufacturers for this type of equipment in the world.
The Europrobe is designed to meet the needs of surgeons in nuclear medicine. It enables to accurately tag Sentinel Lymph Nodes (SLN) by detecting areas of increased radionucleotide uptake. The Europrobe is unsurpassed in its ability to detect a wide range of isotopes.
With a single readout module and a whole range of gamma probes, the Europrobe fulfils all the needs of per-operative and percutaneous detection within 7 major clinical fields: Breast, Gynaecology, Dermatology, Head & Neck, Endocrinology, Urology and Nuclear medicine.
We have added a new fluorescent detection modality via an add-on module. In combination to the core gamma detection, fluorescence detection enables to reach almost 100% identification of SLNs, and thus fulfils standard of care dual detection recommendation.
The Europrobe system and probes are commercialised in 67 countries worldwide, including the USA, and over 3000 systems have been placed in major cancer treatment centres.

Evergreen Theragnostics Inc.

27 Commerce Street
07081 Springfield, NJ, USA

diana.kaskiw@evergreentgn.com

www.evergreentgn.com

Evergreen Theragnostics, founded in 2019, is a US-based radiopharmaceutical CDMO dedicated to high quality & high reliability manufacturing of radiopharmaceuticals using a variety of isotopes, from early development through commercialization all under one roof in Springfield, NJ. We offer research and commercial scale, centralized production capacity for therapeutic and long-lived diagnostic products built into our brand-new state of the art manufacturing facility. The design of the facility in Springfield also allows us to expand operations within our existing walls for project-specific needs or partnership opportunities. Our combination of top industry talent, compliance with global cGMP standards, and strategic facility location uniquely position Evergreen as a premier radiopharmaceutical development, manufacturing, and distribution organization in North America.

EZAG - Eckert & Ziegler Isotope Products (EZIP)

24937 Avenue Tibbitts
91355 Valencia, CA, USA

nucmedsales@ezag.com

https://sales.isotopeproducts.com

Eckert and Ziegler Isotope Products (EZIP) offers a full range of Flood Sources, PET Sources, Specialized SPECT Sources and Multimodal Sources to meet the needs of Nuclear Medicine departments worldwide. EZIP is dedicated to serving the marketplace with high-value quality products safely constructed and delivered on time through a quality system founded on customer satisfaction, regulatory compliance and continuous improvement.

EZAG - Eckert & Ziegler Medical

Robert-Roessle-Str.10
13125 Berlin, Germany

marketing.medical@ezag.de

www.medical.ezag.com

Eckert & Ziegler Medical is one of two business segments of the Eckert & Ziegler Group, with headquarters in Berlin, Germany. With more than three decades of experience in the field, Medical represents the combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond, while always focusing customer success.
We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of versatile services such as development and contract manufacturing. With our global network of GMP suites we offer fully licensed radioisotope labs, stable supply arrangements for almost all pharmaceutical radioisotopes, a state-of-the-art infrastructure including logistics, and a highly experienced staff that can be seconded to help with your preclinical and clinical projects.
As a one-stop-shop for all your radiopharmaceutical needs, using alpha, beta or gamma emitters, our products include everything from hot cell solutions to radiochemicals (e.g., Lu-177), radiopharmaceuticals (Yttriga, GalliaPharm®), radiosynthesis technology (Modular-Lab, KitLab) and radiochromatography equipment (e.g., AR-2000).
Contact as for GMP Suites, CDMO, CMC, GalliaPharm, Ac-225, Y-90, radioisotopes, hot cell solutions, IGG100, UniFill, SWB-15, rTLC, rHPLC, Flow-Count, Mini-Scan, MiniScanPRO, FlowCountPRO, IsoSeed and more.

Ezag - PentixaPharm GmbH

Bismarkstraße 13
97080 Würzburg, Germany

info@pentixapharm.com

https://pentixapharm.com

PentixaPharm, a subsidiary of Eckert & Ziegler AG, is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. These two-small peptide-based radiopharmaceuticals specifically target the CXCR4-receptor expressed by many diseases, such as haematological and solid cancers as well as cardiovascular indications.
With PentixaFor it is the aim to develop a specific PET / CT tracer linked to Gallium-68 for accurate localization of tumors or inflamed tissues. PentixaTher binds to the same receptor as the diagnostic agent but is linked to a stronger radiating nuclide (Yttrium-90). Therefore, PentixaTher has the potential to precisely destroy the pathological surrounding tissue only in the near proximity. Both products are currently under clinical development.

Sylvia Fedoruk Canadian Centre for Nuclear Innovation

303-111 Research Drive
S7N3R2 Saskatoon, Saskatchewan, Canada

lidia.matei@fedorukcentre.ca

www.fedorukcentre.ca

Placing Saskatchewan Among Leaders of Nuclear Innovation
The Sylvia Fedoruk Canadian Centre for Nuclear Innovation was established in 2011 to help place Saskatchewan among global leaders of nuclear research, development and training. We invest in partnerships with academia and industry for maximum societal and economic benefit. We fund re-search projects in nuclear topics, support new faculty positions, operate a top-quality cyclotron facility as a user-accessible resource for nuclear imaging science and training, and provide advice on nuclear topics. The Fedoruk Centre aspires to create conditions for respectful conversations about nuclear technology, and open new opportunities for economic activity in Saskatchewan's nuclear sector.
Our offerings
- Radiopharmaceuticals
We produce a range of isotopes, radiochemicals and radiopharmaceuticals at our facilities, for applications in medicine and research:
Reliable supplier of fluorodeoxyglucose (FDG) to regional hospitals, Eight radiochemical products currently available for sale, Isotope supplier for research, Contract manufacturing opportunities, Can support trials to develop new products
- Cyclotron Lab Services
Our staff members maintain our facilities in a state of readiness for user access:
24 MeV cyclotron and accompanying labs, Professional and technical staff offer customized support and services, Reasonably priced fee-based access to fully equipped labs, Licensed by the Canadian Nuclear Safety Commission as a Class II Nuclear Facility capable to handle a wide ar-ray of radionuclides.

for-med.nl

Parallelweg-zuid 33-02
5281LB Boxtel, The Netherlands

info@for-med.nl

www.for-med.nl

For-med.nl is a design and manufacturing company for standard and custom made accessories:
- Foot support for SPECT/CT/MRI
- Breast support prone position
- Arm and headrest combination
- Knee angle
- Hand support
- Baby support
- Wedges, Blocks and Mattresses

for-med.nl is a registered trademark of VANDERWILT techniques bv an ISO 13485 engineering company of customized products for daily laboratory and clinical nuclear medicine practice as well as research purposes, using state-of-the-art and innovative production methods. Typically, our customers are universities, hospitals and nuclear medicine departments, as well as radiopharmaceutical and imaging equipment companies.
- Dedicated pinhole collimators
- Manual dispensing and dose calibrator unit PET
- High Resolution Micro phantoms for small animal systems
- Thyroid phantom
- Dynamic Heart phantom (AGATE)
- SeHCAT panels, Place resolution phantoms and NEMA calibration panels
- Shielded heating device.

Gamma Medical Technology

Friesdorfer Str. 194A
53175 Bonn, Germany

info@gamma-mt.de

www.gamma-mt.de

Gamma Medical Technology - Gamma Probe Systems for Nuclear Medicine.
Gamma Medical Technology is a young and dynamic company German Company, focused on the production and commercialization of high-quality Gamma Probe Systems for the Sentinel Lymph Node Biopsy (SLNB).
Our Gamma Probe Systems are part of what we use to advance our cause. They are designed to fit into the user's everyday life and adapt to their needs, not the other way around. After years of developing our Gamma Probe Systems our focus has always been on one aspect: supporting the user's work to make patients' lives easier.
The realization of our products, including hardware and software development, production as well as service, takes place in Germany. Through a close interlocking between these areas, Gamma Medical Technology offers our customers comprehensive competence for gamma probe systems.
The company's client base is vast and includes polyclinics, medical centers, and well-known hospitals both private and government.
Our mission is to improve people's lives and help them live healthy lives without limitations. We believe that people can reach their full potential when they are healthy and can thrive without limitations.

GE HEALTHCARE

283 rue de la Minière, BP 34
78533 Buc, France

maxime.Teisseire@ge.com

www.gehealthcare.co.uk

GE Healthcare is a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator. The company enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, GE Healthcare operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.co.uk for more information.

Global Morpho Pharma

72, rue de Lorraine
44240 La Chapelle-sur-Erdre, France

contact@morphopharma.com

https://morphopharma.com/

Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes.
We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture nca Lu-177 and other radioisotopes of interest.
We are dedicated to improving the accessibility of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem.
Radioisotopes of interest : Lu-177, Tb-161, Ac-225.

Hermes Medical Solutions

Strandbergsgatan 16
112 15 Stockholm, Sweden

info@hermesmedical.com

www.hermesmedical.com

Hermes Medical Solutions continuously innovates to enable faster and more personalized diagnosis and therapies in molecular imaging. For 45 years we empower healthcare professionals with state-of-the-art software for all clinical scenarios in Nuclear Medicine into ONE vendor-neutral platform: HERMIA. Powerful and vendor agnostic software enables clinicians to simplify their workflow, increase consistency and quality and keep pace with the fast development of scanners, tracers and therapies. The result is improved quality and outcomes for healthcare providers and their patients worldwide.
At this year's EANM we are proud to showcase groundbreaking functionality within Hermia in the areas of quantitative SUV-SPECT, organ- and voxel-based dosimetry and automatic segmentation.
The state-of-the-art software leverages the power of AI and automation, together with the latest computing technology, to accelerate your workflow and reporting for all clinical scenarios in PET/SPECT/CT/MR, onsite or remote – regardless of camera vendor.
Hermia is the software of choice for theranostics and therapies with single time point voxel dosimetry, CE-marked, FDA and Health Canada cleared for a wide range of imaging isotopes. Make personalized therapy a reality for your clinical practice.
Discover more by visiting our booth #20 at the EANM and our website at www.hermesmedical.com.

Hidex Oy

Lemminkäisenkatu 62
20520 Turku, Finland

info@hidex.com

www.hidex.com

Hidex is a world leader in detection of alpha, beta and gamma emitters. Our liquid scintillation and gamma counters are used worldwide in development and quality control of radiopharmaceuticals using Actinium, Radium, Thorium, Lutetium, Strontium, Yttrium and other isotopes. Hidex gamma counters are optimized for molecular imaging isotope energies and streamlined for workflow, sample tracking and GxP compliance.
At EANM Hidex is exhibiting solutions for:

- Automated gamma counting. Hidex AMG automatic NaI well detector with on board sample balance is ideal for metabolic studies, blood input function curves, Glucomerase filtration rate or general nuclear medicine applications.
- Hidex Radiowater Generator is an online system for preparation of Oxygen-15 H_2O infusions. With approximately 50 installation Hidex is the pioneer in Oxygen-15 water technology.
- Our Liquid scintillation counters 300SL and 600SL series are used by radiopharmaceutical production facilities for development and quality control of medical use isotopes, detection of impurities, contamination control with wipe tests as well as activity standardization.

Please book a meeting with our specialists or stop by our booth to learn more!

HOY Scandivavian ApS

Jacob Møllersgade 4
9560 Hadsund, Denmark

info@hoyscandinavian.dk

www.hoyscandinavian.dk

HOY Scandinavian was founded in 1991 as a supplier and distributor for Nuclear Medicine and radiochemistry department in Scandinavia.
The "HOY Exclusive" product range was launched in 2006. The head office is located in Hadsund Denmark, and all the HOY Exclusive product range are produced in Hadsund.
Today HOY Scandinavian is an international business that supplies products to nuclear medicine and oncology departments at hospitals and laboratories all over the world. We are known for supplying very high quality products and are now a market leader in many markets – particularly in Scandinavia and Europe.
Our home market is primarily Denmark and Sweden. We are represented in other markets by a distributor network.
Products and activities
At HOY we develops and manufactures "Hoy Exclusive", an all in-house product design - offering quality products for radiation protection in nuclear medicine and PET departments.
The "HOY Exclusive" product portfolio has a modern timeless Scandinavian design, and offers maximum ergonomic comfort aligned to European standards.
Key products are:
Vial glass Shields – Syringe Shielding – Syringe handling –
Syringe Carrier and transports - Waste Contains – Tongs for Vials.

IBA RadioPharma Solutions

Chemin du Cyclotron 3
1348 Louvain-la-Neuve, Belgium

RadioPharmaSolutions@iba-group.com

www.iba-radiopharmasolutions.com

IBA is the world leader for the supply of PET & SPECT cyclotrons for radiopharmaceuticals production. IBA also offers a wide range of radiochemistry solutions designed to be highly productive and reliable for your everyday tracer needs, as well as customizable and flexible for your research purposes. Headquartered in Belgium, IBA installed and supports over 320 cyclotrons and more than 600 Synthera family radiochemistry modules across the world.
Based on more than 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET center for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

ICPO Foundation

Humboldtstraße 29
65189 Wiesbaden, Germany

info@icpo.founfation

https://www.icpo.foundation/

The International Centers for Precision Oncology Foundation (ICPO) is a German non-profit organization established in 2019 by leading medical and industry entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO is helping build momentum to scale global patient access to Molecularly Targeted Precision Oncology to accelerate this paradigm shift. To scale patient access, ICPO aims to develop a network of International Centers for Precision Oncology organized in a social model based on shared know-how, certified education, and design and process standardization enabling validated best clinical practice. Furthermore, the ICPO Foundation empowers its centers network within a growing global, inclusive community spearheading its model and living up to the Precision Oncology promise to eventually be curative and abundantly available to all patients in need, irrespectively of region, country, or social status.

IMAGINAB

423 Hindry Ave. Suite D
90301 Inglewood, United States

info@imaginab.com

www.imaginab.com

ImaginAb is a clinical stage and revenue-generating biotech company, with offices in the United States and the United Kingdom. We focus on developing next generation imaging and therapeutic radiopharmaceuticals (RPT) based on our proprietary Minibody and Cys-diabody platform. 89Zr Crefmirlimab berdoxam (CD8 ImmunoPET agent) is currently in Phase II, and is used by numerous Pharmaceutical and Biotech companies in their clinical trials.
We have a clearly defined purpose and growth strategy, enabling us to work closely with our research and commercial partners to transform patient care, and help people live better and healthier lives. We welcome and look forward to meeting our current and potential partners at the 35th Annual Congress of the European Association of Nuclear Medicine this year.

Incepto Medical

10 boulevard de Grenelle
75015 Paris, France

info@hoyscandinavian.dk

www.hoyscandinavian.dk

Incepto is the leading European platform for artificial intelligence solutions for all medical imaging, especially nuclear medicine. Incepto has two missions: integrate AI solutions from partner AI vendors and develop AI algorithms. On one hand, it provides the full range of technical and clinical services to integrate in clinical routine AI solutions through a unified, secure and interoperable platform. On the other hand, Incepto's scientific and medical teams are developing artificial intelligence solutions on clinical needs not currently addressed by other AI vendors. Our goal is simple: help doctors to make full use of AI technologies to save time, improve diagnosis and ultimately build together with them a more precise and human radiology for the patient.

InnoGamma Co. Ltd.

Kossuth Lajos street 25.
H–2862 Aka , Hungary

tamashadas@innogamma.hu

www.innogamma.hu

Development and production of devices for Radiopharmaceutical industry.

Institute of Isotopes Co. Ltd.

Konkoly-Thege Miklós u. 29-33.
1121 Budapest, Hungary

commerce@izotop.hu

www.izotop.hu

Institute of Isotopes Co. Ltd. is on the frontline of radioisotope technology collaborating with long-term partners and customers. Over the years we have developed numerous products from diagnostic kits to radioactive sources for various radioactive applications. Our company provides varied and flexible services in this unique field.
Our Radiopharmaceutical Business Unit has been exclusively focused on supplying radiopharmaceutical products to nuclear medicine professionals serving the recovery of patients worldwide and supporting early diagnosis. Our production complies with the highest quality standards and the Quality Management System is compliant with customer standards and regulatory requirements and ensures the high-quality of our products.
Besides being key participant on the market for many years, we are also engaged in product development projects and offer contract manufacturing, OEM services for our customers. We are looking forward to new products to widen our portfolio and meet our growing customer demands.

Our main products, services:

- Thyrotop I-131 sodium iodide hard capsules
- I-131 sodium iodide sterile solution / I-131 MIBG injection for therapy and for diagnostic use
- Radiochemicals /I-125, I-131/
- Cold kits for Tc-99m-labelling: DMSA, DTPA, FYTON, PYRON, MIBITop, MDP, TECHIDA
- Sm-153 -labelling MULTIBONE kit
- Ready to take part in R&D and manufacturing of active pharmaceutical ingredients, cold kits as well as investigational products for clinical trials.
- In Vitro diagnostics (RIA, IRMA, ELISA), Research Immunoassay kits
- C-14 radiolabeled drug substances, GMP custom radiosynthesis
- Designing, installing multipurpose irradiators.

Inter Medical Medizintechnik GmbH

Daimlerstr. 34-36
32312 Lübbecke, Germany

sales@intmed.de

www.intmed.de

The Inter Medical Medizintechnik GmbH Company is specialized in medicine software and hardware with the focal point in Nuclear Medicine technique.
Long time experience in product innovations, development and production of Nuclear systems makes Inter Medical to a competent partner for all technical requirements in the Nuclear Medicine and other medical departments.
Are you looking for a special camera or software for heart and brain examinations?
With the MultiCam 3000 and our in-house software such as AutoCardio 4D, 3D rendering and the 3D neurological brain evaluation package, we offer what you are looking for.
Would you like to evaluate interdisciplinary data? With the Multimodality Fusion software, you can use data from different systems such as ultrasound, PET, MR.
We offer the possibility of merging and evaluating data from different manufacturers.
Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head Gamma Cameras.

INVIA

3025 Boardwalk Drive, Suite 200
MI 48108 Ann Arbor , United States

info@inviasolutions.com

www.inviasolutions.com

INVIA is dedicated to developing advanced non-invasive cardiac imaging software for medical professionals to optimize patient care. Physicians use our software, 4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. 4DM is available integrated with more than 25 camera, workstation, EMR and PACS manufacturers, or as a software-only solution for Windows laptops and workstations. Originating at the University of Michigan more than twenty years ago, we developed 4DM with the patient in mind – enabling physicians around the world to make accurate interpretations.
Our software is always advancing; visit us at booth to explore 4DM's latest features.

Invicro

119th Fourth Avenue
MA 02494 Needham, United States

info@invicro.com

www.invicro.com

Headquartered in Needham, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro's multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro's quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro's industry-leading software informatics platforms, VivoQuant® and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.

Inviscan SAS

23 rue du Loess, Bat. 25
67200 Strasbourg, France

info@inviscan.fr

www.inviscan.fr

Inviscan Imaging Systems is a high technology company located in France. inviscan manufactures preclinical imaging systems used in Medical Research. The products of inviscan include PET and CT systems for imaging small or large animal models. inviscan is also providing novel PET/MRI technology and developing innovative digital PET detection modules based on new photodetector components. inviscan is partner in international projects with academic partners to develop MRI compatible PET imaging instrumentation for research on the human brain and neurodegenerative diseases.
Inviscan has research offices and laboratory area located in Strasbourg, France.

Ionetix Corporation

3130 Sovereign Drive
48911 Lansing, United States

N-13Ammonia@ionetix.comm

www.ionetix.com

IONETIX is a US-based cyclotron and technology company providing full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. Utilizing its proprietary cyclotron technology platform, Ionetix has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals.

Targeted Alpha Therapy Solutions
Ionetix offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies. It's decentralized production and distribution supply chain includes contract drug manufacturing and "white glove" distribution logistics, allowing global access to these alpha-emitting isotopes and targeted radiotherapies. Ionetix will initiate GMP production of both n.c.a Ac-225 and At-211 beginning in early 2023.

Compact Cyclotron Solutions
Ionetix also offers a point-of-care cyclotron to produce positron-emitting radioisotopes used for diagnostic radiopharmaceuticals. The ION-12SC is a compact 12 MeV cyclotron that can generate N-13, F-18 and Ga-68. The ION-12SC is engineered for ease of deployment and operation for both clinical and research applications. The ION-12SC is ideally suited to support theragnostic indications with local production of the radioisotopes used for the diagnostic imaging portion of the radiopharmaceutical pairs.

For more information, please stop by our booth or visit www.IONETIX.com.

Iotron Medical Inc.

55 Madison Ave., Suite 400
NJ 07960 Morristown, United States

pat.donahue@iotronmedical.com

www.copper67.com

As the first and only commercial supplier of copper-67, Iotron Medical is committed to improving the quality and accessibility of this radioisotope for the radiopharmaceutical community.
Copper-67 is a proven and effective radioisotope for theranostics, particularly when paired with copper-64. This "perfect paring" delivers key advantages over other commonly used isotopes, including:

- Identical in-vivo behavior (imaging and therapy)
- Patient dose optimization (personalized medicine)
- Optimum half-life for small molecules
- Convenient off-site central manufacturing
- No reliance on nuclear reactors for production

Through our partnership with Canadian Isotope Innovation Corp., Iotron Medical is supplying copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostics.

IRE ELiT

Avenue de l'Espérance, 1
B - 6220 Fleurus, Belgium

info@ire.eu

www.ire.eu

IRE ELiT, IRE's innovation subsidiary, is a pharmaceutical company founded in 2010 to develop radiopharmaceutical drugs used in molecular imaging and therapy.
Our main product is a Ge-68/Ga-68 generator, Galli Ad, also called Galli Eo in the USA, in Canada and in countries without marketing authorization. This generator is inspired by the principles of use of 99mTc generators. The eluate of the generator - gallium chloride solution (68Ga) - is used for the in vitro radiolabeling of different kits/molecules of radiopharmaceutical preparations developed and authorized for positron emission tomography (PET) imaging.
Galli Ad (or Galli Eo) is a fully integrated and closed system to get rapidly highly concentrated and very pure radiopharmaceuticals preparations minimizing loss of activity. Its innovative design, specific for cold kits reconstitution, limits the risk of misuse and contamination. This generator can be used manually or connected to a synthesis module.
IRE ELiT places quality, reliability and services at the center of all its concerns to secure the supply and easy use of radiopharmaceuticals for its customers worldwide. IRE ELiT's portfolio of customer-oriented solutions includes radioisotopes for diagnosis or treatment purposes, as well as equipment dedicated to their preparation.
We work with hospitals worldwide, especially in Europe and in the US. We have the Marketing Authorization in 13 European countries for our Ge-68/Ga-68 generator, Galli Ad. DMF is available in the US & Canada.

Isotopia Molecular Imaging

39 Alexander Yannai St.
4927735 Petah Tikva, Israel

info@isotopia.co.il

https://isotopia-global.com/

Weekly global production and supply by demand of theragnostic solutions.
We understand that delivering the right treatment to the patient at the right time could be the tipping point in the patient's care.
That's where our gold standard treatment and professional service make all the difference.
We supply Lu -177 tailor-made to your requirements, and work closely with our customers, to devise the optimal solution and support their growth.
Isotopia around the globe
Patient's care and efficiency are the most precious values of Isotopia.
This is why we are working to enhance our product's global accessibility. Next to our head quarter and N. America production facilities, we have partnered with Seibersdorf laboratories to strengthen our European presence, to build a local manufacturing site, designed to:
• Reduce complex logistics.
• Upscale production, shorten delivery time and reduce material loss.
• Ensure timely and consistent delivery to all locations.
Guidance, support, and peace of mind
We are committed to meeting your acute need for round-the-clock availability and responsiveness to solve problems in real-time. As we continue to take big strides and becoming a prominent global supplier to the radiopharmaceutical industry, while maintaining the personal touch of a local partner, we remain focused on fulfilling the promise of nuclear medicine for advanced personalized cancer care.
*Marketing Authorization is coming soon

ITELPHARMA – ITEL HEALTHCARE GROUP

VIA LABRIOLA Z.I. snc
70037 Ruvo di Puglia, Italy

marketing@itelte.it

www.itelte.it

Itelpharma is the radiopharmaceutical division of the italian company Itel Group. It has been established as a GMP (Good Manufacturing Practice) certified pharmaceutical facility authorized by the Italian Drug Agency (AIFA).
We produce radiopharmaceuticals for imaging diagnostics, which detect diseases in the fields of oncology, neurology and cardiology. To achieve this goal, we rely on the availability of independent production lines that can operate simultaneously.
Itelpharma is recognized as one of the most trusted radiopharmaceutical manufacturers and suppliers.
In addition to marketing our own radiopharmaceuticals, we are also contractors in the production and distribution of radiopharmaceuticals owned by other big pharmaceutical companies (including GE Healthcare, AAA – Novartis, Life Molecular Imaging).
At Itelpharma we have completely managed the design and implementation of our radiopharmaceutical production facility with two cyclotrons and an in-house microbiological laboratory.
In over 10 years of activity, we have perfectioned our specilizations and competences along with growing our full operations not only in manufacturing but also in research and radiopharmaceutical development. Above all, throughout this time, we have enhanced our scientific, technical, regulatory and commercial skills.
We work in compliance with the best quality standards in microbiology and nuclear medicine, expanding and increasing the pipeline of molecular products and the services offer.

ITM Isotope Technologies Munich SE

Walther von Dyck Strasse 4
85748 Garching, Germany

info@itm-radiopharma.com

www.itm-radiopharma.com

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.
www.itm-radiopharma.com

Jiangsu Huayi Technology Co., Ltd.

18 Fuyu Road, Haiyu town
215500 Changshu, Jiangsu, China

antony@huayi-isotopes.com
matt@huayi-isotopes.com

www.huayitec.net

Jiangsu Huayi Technology Co., Ltd. is a fully integrated provider of radiopharmaceuticals in China. We develop, manufacture, and distribute high-quality radiopharmaceutical products. CDMO services are offered to our global clients. We support projects from initial research phase to commercial production. One of the divisions, Huayi Isotopes Co. (HIC), manufactures and distributes stable isotopes, PET and SPECT precursors, reagents kits, cassettes, and sterile vials etc. Products of HIC are supplied to clients around the world.
We are client-oriented and determined to build and foster long-term partnerships with our clients. Since the company was established in 2001, we have been dedicated to serving the nuclear medicine industry.
Since 2014, we have been setting up nuclear medicine manufacturing sites strategically. Our integrated radiopharmaceutical manufacturing and distribution network will enable us to reach most of the patients in China.

Jubilant Radiopharma, a Business division of Jubilant Pharma Limited

790 Township Line Road, Suite 325
PA 19067 Yardley, United States

Laura.Shaw@jubl.com
Lisa.Shearin@jubl.com

https://www.jubilantradiopharma.com/

Jubilant Radiopharma is an industry leading radiopharmaceutical company committed to driving the value of cardiac PET as a vital imaging modality, because we recognize the important role it plays in evaluating cardiac physiology and function. We strive to deliver better clinical outcomes as a result of our investment into our pipeline, infrastructure, and people—all of whom are driven by their uncompromised passion and dedication to the utility and sustainability of nuclear medicine.
Partnering with Cyclomedica in the EEA, we aim to provide expanded access to the next-generation PET products to enhance the way patients with known or suspected coronary artery disease are both diagnosed and managed.
So, whether you are looking to start a program or want to enhance your current practice; we are here to help. To learn more about the latest advancements in Cardiac PET imaging, visit our booth at EANM or contact customer service at customerservice@jdi.jubl.com.

LabLogic Systems Limited

Paradigm House, 3 Melbourne Avenue
S10 2QJ Broomhill, Sheffield, United Kingdom

solutions@lablogic.com

www.lablogic.com

LabLogic are a manufacturer of instruments and software to the Life Science, PET/Nuclear Medicine and Radiation Safety sectors. We have over 40 years' experience and expertise in providing solutions within highly regulated environments.
LabLogic will be showcasing its Tracer QC system at EANM'22. Developed in conjunction with TraceAbility this instrument is already being seen as the future of PET QC.
The Tracer-QC is just part of LabLogic's range of market leading products which can be found in some of the world's most prestigious PET and Nuclear Medicine laboratories. These include a range of QC equipment from innovative r-TLC, r-HPLC instruments to a single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic, just ask about the QC solution.
Furthermore Lablogic offer PETra, a purpose built PET LIMS system designed to improve efficiency and compliance. PETra directly captures data from all the equipment used, acting as a central repository for all information within PET production including batch record management, QMS, trending, inventory, instrument maintenance etc.
We also offer SPECTra, a software package based on PETra. Being a direct descendant of PETra, SPECTra utilises many of its features and a similar framework, to provide a dedicated Radiopharmacy LIMS.
Visit stand 42 at the show to see demonstrations of the Tracer QC and other products in the nuclear medicine range.

LaCalhene

1 rue du Comté de Donegal
41100 Vendôme, France

samuel.kervoern@getinge.com

www.lacalhene.com/int/

Since the 1960's, LaCalhene has been designing and supplying high-performance equipment for nuclear research centers, radiopharmacy, fuel cycle, and other nuclear activities.
LaCalhene's expertise extends from design to maintenance on a wide range of solutions for hot cells and glove boxes:

- Telemanipulation: Mechanical or robotic remote manipulators for small, medium, or large cells.
- Transfer: Transfer solutions (based on the DPTE® system) for radioactive products in a hot cell or glove box.
- Transport: Shielded containers for safe transfer and transport of highly contaminated and radioactive materials.
- Handling: Equipment for direct manipulation inside secure contaminated containment enclosures (glove boxes).

Our purpose is to preserve your operators' safety and your activities' efficiency.

LEMER PAX

72, rue de Lorraine
ZA Erdre Active - Malabry
44240 La Chapelle sur Erdre, France

contact@lemerpax.com

https://www.lemerpax.com/en/

Worldwide leader in innovation in the radiation protection sector, Lemer Pax creates, designs, and engineers efficient radiation protection solutions for medical, research, industry, and nuclear applications.
With over 50 years of innovation, Lemer Pax exports all over the world, eco-aware and cutting edge of technology radiation protection products.
Lemer Pax, protecting life, we strive for excellence to protect the most important thing: Life!

M&I Materials Ltd

M&I Materials Ltd manufactures a range of speciality products under our Wolfmet, Apiezon and Metrosil brands for nuclear medicine applications.
Wolfmet tungsten alloy has been the automatic choice for radiation shielding and collimators in nuclear medicine for many years. Over the last 9 years, Wolfmet has been opening up a world of possibilities with the introduction of Wolfmet 3D printed tungsten. This revolutionary process makes complex high-precision tungsten collimators a reality.
The Apiezon family of hydrocarbon high vacuum greases are highly regarded for their quality, consistency, and excellent performance in vacuum applications. Apiezon L and M Grease are silicone and halogen-free greases suitable for use in scientific and industrial applications – used and respected by The European Space Agency, NASA, and NATO. Apiezon N Grease is widely used in the manufacture of all types of cryogenic equipment, including Magnetic Resonance Image (MRI) magnets, cryostats, and scientific instruments (including electron microscopes).
Metrosil Quench Protection Units are silicon carbide (SiC) varistors designed to clamp voltage to a required magnitude and quickly extract energy stored in superconducting magnets during a quench. The Metrosil 12000 Series has the potential to provide quench protection for proton beam therapy machines, whereas our 4K devices have the potential to protect MRI magnets.
M&I Materials Ltd is part of the Pavilion consortium (Booth 35), come and visit us to learn more about our exciting new developments.

Medi-Radiopharma Ltd.

Szamos u. 10-12.
2030 Érd, Hungary

order@mediradiopharma.hu

www.mediradiopharma.com

Medi-Radiopharma (MRP) has more than 25 years of experience in developing, manufacturing, and supplying radiopharmaceutical products to customers around the globe. Our purpose is to serve the healthcare and improve patient outcomes through a wide portfolio of high-quality products. MRP specializes in the production and supply of generic in-vivo kits for Tc99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancer, as well as heart, brain and bone diseases, our world-class products – registered in more than 70 countries worldwide - empower our customers with effective treatment and proven patient outcomes. We are also involved in the development of therapeutic radiopharmaceuticals. MRP holds valid Manufacturer's Authorization, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesaler Distributor, GLP and ISO Certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals.

Mediso Medical Imaging

Laborc u. 3.
1037 Budapest, Hungary

info@mediso.com

https://mediso.com/

Mediso works in the field of nuclear medicine since 1990 with a profile of development, manufacturing, selling and servicing molecular imaging multi-modality devices. It offers complete solutions from hardware design to evaluation and quantification software for clinical patient care and preclinical research.
With its 30-years expertise, 1,300+ clinical cameras, Mediso is within the leaders in clinical patient care. Besides a unique triple modality clinical SPECT-CT-PET hybrid system, Mediso launched the new AnyScan® TRIO family which has a triple head SPECT detector design and dedicated multipinhole collimation technology.
Mediso has a leader position in the preclinical nuclear imaging market with 250+ commissioned preclinical cameras around the world. Beyond the market leading nanoScan® PET/CT and SPECT/CT, Mediso launched the world's first integrated PET/MRI and SPECT/MRI systems. Further on 3T and 7T cryogen-free magnets and PET insert have been added to the product line, resulting in the largest install base of integrated PET/MRI systems.
Products are sold directly or through a network of distributors with over 1500 imaging systems for clinical and preclinical imaging operating in 100+ countries around the globe.

MEDraysintell

Chemin du Cyclotron 6
B - 1348 Louvain-la-Neuve, Belgium

peg@medraysintell.com

www.medraysintell.com

In Nuclear Medicine, we provide reports and directories with an exhaustive description and analysis of marketed radiopharmaceuticals, radiopharmaceuticals under clinical development, and radiopharmaceuticals under preclinical development, thru a description of about 900 products, together with a comprehensive profile of 370 companies active in nuclear medicine. Plus a complete review of the Cyclotrons used in Nuclear Medicine worldwide.
Our reports have been highly appreciated by clients worldwide. Their feedback praised the outstanding level of our reports and our expertise. Some comments have been published under:
https://www.medraysintell.com/clients.

MedTrace Pharma A/S

Agern Allé 5A
2970 Hørsholm, Denmark

connect@medtrace.dk

www.medtrace.dk

MedTrace Pharma A/S is a development stage pharma and device company and an innovator in PET diagnostic imaging. The company is working on a solution to help healthcare professionals diagnose patients better and faster via 15O-water PET. Leading hospitals in the US, Europe and Japan are close partners.
In March 2022, MedTrace received FDA approval of the company's Investigational New Drug application and the approval to commence its RAPID-WATER-FLOW Phase 3 Clinical Trial to evaluate the use of 15O-water PET in diagnosing Coronary Artery Disease. Two months later, MedTrace announced that it had scanned the first subject. Meanwhile, the company is preparing for regulatory clearance in the EU.
Our solution consists of:
1) the P3 system, which is a point-of-care cGMP-compliant chemistry lab combining the process of manufacturing and injecting 15O-water into the patient.
2) the analytical software aQuant, which produces images combined with quantitative data of the PET scan.
At the same time, MedTrace is exploring clinical applications outside of cardiology and looking into research areas such as oncology and neurology.
MedTrace, headquartered in Hørsholm, Denmark, employs +40 people and opens its US offices in September 2022.
Brands: MedTrace Pharma, P3 System 15O-water system, aQuant cardiac analytical software

MiE medical imaging electronics GmbH

Hauptstrasse 112
23845 Seth, Germany

mie@miegermany.de

https://mie-scintron.com/

We have produced gamma camera and PET systems since 1981 for the complete nuclear imaging medical market of the nuclear medical diagnostic. We provide for the discriminating and price sensitive market.
All our systems are produced according to current medical and technical requirements. The experience and the know-how since 1974 form the development of our data and image processing unit SCINTRON. This diagnostic prospects are also available for the veterinary market.
Accredited service, constantly care of our hard- and software and time accordant design show our capacities.
Since 1995 MiE America, Inc. has been in business to provide a better service to our america customers. MiE America, Inc. is located in Elk Grove Village, IL, USA.
The MiE GmbH is in accordance with EN ISO 13485 certified and our gamma camera systems are with Annex II of Directive 93/42/EWG approved. Also, we are registered at the FDA – our systems are 510(k) approved since 1995. This extensive certification is the basis for the manufacture and distribution of medical products on the world market.

MILabs

Duwboot 7a
3991 CD Houten, The Netherlands

info@milabs.com

https://www.milabs.com/

MILabs delivers top level preclinical PET, SPECT, Bioluminescence, Fluorescence & X-ray CT imaging devices in any combination, as single integrated scalable platforms, or as standalone systems. By combining up to five modalities on a single in-line platform, MILabs has introduced the first commercial system to enable ground-breaking synergistic multi-modality imaging photons from 1eV up to 1MeV. The technology also offers:

- Down to 0.6 mm PET resolution, simultaneous multi-isotope PET-PET and PET-SPECT
- Quarter-mm diagnostic and exclusive sub-mm theranostic SPECT of alpha and beta emitters
- Sub-second 4D SPECT and PET frame rates
- Quantitative CT-guided Bioluminescence and Fluorescence Tomography
- Ultra-fast and Ultra-high resolution low dose X-ray CT
- High-throughput Bioluminescence and Fluorescence imaging

With many hundreds of global installations, MILabs collaborates with leading universities, hospitals, contract research organizations and pharmaceutical companies to contribute to the development of new diagnostic solutions and therapies as well as to basic research.
Explore how our cutting-edge preclinical imaging and clinical technologies can accelerate research discoveries at www.milabs.com.

MIM Software Inc.

25800 Science Park Dr., Suite #180
44122 Cleveland, United States

info@mimsoftware.com

www.mimsoftware.com

MIM Software Inc. offers a comprehensive suite of applications that support Radiology and Nuclear Medicine's important role in cancer care. MIM Software products excel in Theranostics and emphasize the importance of quantitation, collaboration, and data management to provide physicians with crucial information to generate confident clinical guidance and inform effective treatments.
MIM Software drives your nuclear medicine workflow with comprehensive support for standard nuclear medicine studies, emerging radiotracers, neuro and cardiac imaging. MIM SurePlanTM offers tools to support the feasibility of molecular radiotherapy dosimetry and Y90 therapy within the busy Nuclear Medicine workflow. Quantitative images are needed to calculate accurate dosimetry, and MIM SPECTRA QuantTM provides a vendor-neutral SPECT reconstruction method that pairs dynamically with existing SPECT/CT cameras.
MIM Assistant® automates traditional clinical tasks and centralizes images and related data to a single repository. Flexible deployment options allow easy access to MIM Software from anywhere. The result is greater access to critical patient information in collaborative settings like tumor boards or for use in dictated reports.

MNT Healthcare Services

19 Mayıs Mah. Dr.Şevkey Bey Sk.
No:5 Şişli 34360 Istanbul, Türkiye

info@mnt.com.tr

www.mnt.com.tr

MNT provides healthcare organizations with professional nuclear medicine and radiation oncology solutions since 1990. MNT currently renders services with 63 centers in Türkiye and 7 centers in Europe. MNT provides specialized diagnostic and therapeutic services for all processes of nuclear medicine and radiation oncology.
With its dynamic and innovative structure, MNT is among the "most experienced healthcare service providers" in the field and serves patients in many NM and RT Centers within universities, state hospitals, private hospitals. MNT also services directly to cancer patients with its own centers called Neolife.
Neolife brand is increasing its international presence, establishing itself as a strong global brand. MNT is active in Romania with 4 centers as Neolife, one center in Moldova, and 2 centers in Bulgaria. MNT is pursuing further projects in Africa, Balkans, Middle East, and Central Asia.
In line with golden standards in medicine, MNT is also pioneering theragnostic applications through Intheranostics. MNT's arsenal of leading-edge technology utilizes advanced imaging, molecular probes, and limited amounts amount of radiation for diagnosis and targeted therapies.
Smooth and timely completion of turn-key projects:
• Project Design and Installation
• Equipment Supply and Care Services
• Recruitment of Personnel
• Radiation Safety and Training
• Project Management and Operation
For more info, visit: neolife.com.tr neolife.ro
mnt.bg
petct.bg radiotherapy.bg intheranostics.com

MOLECUBES

Ottergemsesteenweg Zuid 808 bus 325
9000 Gent, Belgium

info@molecubes.com

www.molecubes.com

State-of-the-art modular bench-top solutions from MOLECUBES make molecular imaging more accessible for a wider community of researchers in the field of preclinical drug discovery and development, fundamental and translational research. The CUBE platform enables you to retrieve integrated in vivo information that cannot be derived from other individual techniques requiring samples.
At MOLECUBES, we believe that molecular imaging should be accessible to every research lab. MOLECUBES has therefore made it its mission to lower the barrier to preclinical PET, SPECT and CT imaging by providing compact, intuitive, flexible benchtop imaging solutions with the highest performance, supported by fast and simple workflows.
The X-CUBE, I -CUBE and β-CUBE are the most compact micro-CT, micro-SPECT and micro-PET scanners in the field of molecular small-animal imaging. They are designed to work both as stand-alone units and in modular combinations. Thanks to their benchtop design and total ease of use, MOLECUBES systems pave the way to the next generation of whole-body mouse and rat scanners.
With more than 100 CUBES installed worldwide, MOLECUBES is a trusted partner by your side.

MONROL NUCLEAR PRODUCTS CO.

Rüzgarlıbahçe Mahallesi, Çam Pınarı Sokak
No:3 D: 10,11 Beykoz, 34805 İstanbul, Türkiye

monrol@monrol.com

https://www.monrol.com.tr/tr

Monrol is one of the world's largest radiopharmaceuticals companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today's nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe.

MR Solutions Ltd

Ashbourne House, The Guildway
Old Portsmouth Road
GU3 1LR Guildford, United Kingdom

sales@mrsolutions.com

www.mrsolutions.com

MR SOLUTIONS GROUP develops and manufactures innovative imaging solutions for the research industry. The company offers a large range of products for MR, CT, PET and SPECT. All scanners are interchangeable between each other for multi-modality imaging.
The company is the worldwide leader in high-field cryogen-free MR based on its proprietary dry magnet technology. The MRS*DRYMAG product line delivers MR up to 9.4T and a bore size up to 42 cm. Advanced coils and software tools for pulse sequence programming are also available.
The magnet technology has exclusive features such as rotating the system to 90° and the ability to ramp the field of the magnet up and down within minutes. Helium lines and shielded rooms are not required which keep the installation costs extremely low.
PET/MR imaging is possible up to 9.4T simultaneously. PET and SPECT scanners are easily removable from the MR in minutes, and can be plugged straight onto the CT. This avoids the need for numerous scanners and large rooms. Four models of PET/CT's and CT's are available: a Benchtop, two high resolution models and a very large bore for 12 kg animals.
MR SOLUTIONS can refurbish and enhance all components from any MR system. MR Solutions also manufactures compatible gradients.
MR Solutions holds the prestigious Queen's awards 2019, 2017 & 2016, the innovation award from the Institute of Physics and is the winner in the global R&D 100 awards.

NICESOFT

79 avenue Denfert Rochereau
75014 Paris, France

sales@nicesoft.com

http://www.nicesoft.com

Since 1998, NICESOFT develops innovative software solutions for Medical Imaging departments. We combine zero-footprint Web technology with a high specialization in Nuclear Medicine and Radiology to design applications that can be used in hospitals, private practices or even from home without any installation. Our VENUS product line provides a complete range of solutions, from online appointment booking to a full-Web Viewing & Processing Application Server. Thanks to its Web design, your images and reporting tools can be securely accessed from anywhere, making VENUS the ideal partner to develop teleradiology services. We are the leading RIS provider for Nuclear Medicine departments in France and have also equipped sites across Europe, the US, China and the Middle East. Come and see why!
SOFTWAY MEDICAL is a leading cloud base provider of software and services for health institution in Europe. With more than 3,000 client institutions, SOFTWAY MEDICAL covers the entire range of healthcare services in the public and private hospital sectors, as well as in radiology and outpatient medicine, becoming the second largest European player in terms of market share in the EMR sector. Based on web technologies, the SOFTWAY MEDICAL group's solutions enable the entire patient care process to be managed and data to be shared securely between healthcare professionals. Because nothing in healthcare will ever replace the discernment of human intelligence, SOFTWAY MEDICAL considers technology and data management as a means of increasing the potential of anyone who takes it on. Its innovations have only one objective, to allow each of its users to fully exploit their capacities and make informed decisions in their daily missions, in the interest of the patient.

NUCLEAR MEDICINE EUROPE – NMEU, eeig.

Avenue Louise 65, Floor 4, Office 33
1050 Brussels, Belgium

admin@nmeu.org
Jocelyne.baldasso@nmeu.org

www.nmeu.org

Nuclear Medicine Europe (former AIPES), "the Industrial Association", represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Eu-rope.
Nuclear Medicine Europe provides a wide scope of services & partnerships on behalf of its members. We maintain close contacts with the European Union representations, politicians, EMA (the European Medicine Agency), academia & the media. We also have partnerships with key EU Patient Associations & other professional bodies in the healthcare field.
Our objective is to raise awareness of the role and benefit of the industry of nuclear medicine and collectively continue to further research into molecular healthcare and its benefits for the citizens of Europe.

NRG | PALLAS

Westerduinweg 3
1755 LE Petten, The Netherlands

den.hartog@nrg.eu

www.nrg.eu
www.pallasreactor.com

The Energy & Heatlh Campus in Petten is home to a unique combination of nuclear installations. With the knowledge developed in these nuclear research facilities and the continuous production of medical isotopes, our services and products are literally lifesaving. Numerous preparations are being made for the future and a new research laboratory is being built called FIELD-LAB, where new nuclear medicines will be developed. The production of medical isotopes is being expanded and the construction of the Nuclear Health Centre and the new PALLAS-reactor are scheduled for the near future.
We meet the need to accelerate the development of new nuclear therapies, usually hindered by high costs and the restricted availability of proper facilities and isotopes.
We take the next step by presenting the progress we have made on three innovative projects:
Lu-177 n.c.a.: the isotope for targeted therapy
Pt-195m: to increase effectivity of cisplatin chemotherapy
Pb-212: promising alpha therapeutic isotope for targeted therapy
Physical construction of FIELD-LAB has started in 2020 with supply of R&D batches expected by the 2023.
These initiatives are financially supported by the European Regional Development Fund (EU) and the Province of North Holland (NL).
Our quest for saving lives began back in the 1960. Breakthroughs in scanning technology for precise diagnosis of cancer and cardiovascular diseases, led to phenomenal growth and worldwide acceptance of radiopharmaceuticals. Preparations are being made for the construction of the PALLAS-reactor, the successor the HFR.

Nuclear-Shields

Akkervoortweg 29
5827AP Vortum-Mullem, The Netherlands

info@nuclear-shields.com

https://www.nuclear-shields.com/

Nuclear Shields is a manufacturer of radiation shielding based in the Netherlands with more than 40 years of experience. The production facility is designed to meet the requirements of long term serial production and one-off custom projects. Lines of communication are short due to our small team of sales and engineering personnel. The focus on good and fast communication with the client helps us improve our services every day and makes sure the customer is satisfied.
Nuclear Shields is part of the Van Mullekom Group which was founded in The Netherlands in 1978. All factories share a common ground in engineering and radiation shielding that can be applied to many different industries, such as the healthcare, homeland security and nuclear industry. Nuclear Shields is a seller of a wide range of products regarding the shielding of radioactivity. Our products range from hot lab necessities and radiation shielding, to radiation detection and radiation cleanup solutions.
The In-House capabilities of the Van Mullekom Group range from prototyping to full assembly, which enables us to provide a wide range of solutions for a low price, high quality and with quick customer service. These in-house departments express our capability of manufacturing a wide product range, including the creation of custom-made solutions to fit your needs.

NUCLEIS SA

Allée du Six-Août, 8
B - 4000 Liège, Belgium

info@nucleis.eu

www.nucleis.eu

Nucleis is a radiopharmaceutical company which propose and manufacture Radiopharmaceutical Drugs for Diagnostic and Therapy Monitoring.
Nucleis portfolio presents Brand name drug, IMP and CMO activities. This allows Nucleis to reach nuclear medicine services and (radio)pharmaceutical industry.
Nucleis maintains a strong partnership with CRC (Cyclotron Research Center) for the development of new tracers and R&D activities.
Marketing Authorization Holder:
GMP Certificate number BE/GMP/2018/060 for Human Medicinal Products
GMP Certificate number BE/GMP/2018/061 for Human Investigational Medicinal Products
MIA 1932H
MIA 1932 IMP

NUVIA Instruments GmbH

Dornblüthstrasse 14 A
01277 Dresden, Germany

info@nuvia-instruments.de

www@nuvia-instruments.de

With 2 sites in Dresden and Dülmen, NUVIA Instruments GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET-centres and therapy stations:
• Dose Calibrators
• Thyroid Uptake-Counters, Incorporation Counters, Well-Counters, Waste Water Counters
• Patient and Area Monitoring Systems
• Contamination Monitors (portable and hand-foot clothing monitors) Waste and Release Monitors
• Laboratory Furniture (standard and customized)
About the NUVIA Group:
NUVIA is the nuclear branch of Soletanche Freyssinet, a subsidiary of Vinci Construction Group. Even though the NUVIA name was created in 2007, its history goes back to the beginning of the French and British nuclear industry. Today, with more than 30 years of experience and approx. 3,000 employees worldwide, the NUVIA Group offers engineering, services and products at all stages of a nuclear facility's lifecycle: design, construction, operations, maintenance, decommissioning. The NUVIATECH HEALTHCARE brand was created in 2017 to offer the Group's complete portfolio of instruments, systems and solutions for healthcare applications.
For more information about the NUVIA Group and its activities in the healthcare sector, please visit www.nuviatech-healthcare.com.

Oncidium foundation

Avenue Herrmann Debroux 40
1160 Brussels, Belgium

contact@oncidium-life.org

www.oncidiumfoundation.org

The Oncidium foundation is dedicated to support and accelerate the development of radiotheranostics (RLT) for cancer care. It strives to connect patients, practitioners & experts in the nuclear medicine field by raising awareness & improving access to cancer treatments & clinical trials worldwide. The activities are based on 3 pillars:
ACCESS – Through a platform that will create cohesion between all interlocutors. Notably, for patients, to find the nearest treatment center, current clinical trials & to facilitate communication with medical experts; For practitioners to register their therapy centers; For RLT experts to help promote precision medicine & its progresses. Thus, bridging the gap between people to advance availability of this innovative & life-saving technology.
EDUCATION – Education & awareness are essential, as they help to bring a better understanding of the functioning & benefits of RLT, still unknown to some practitioners & the general public.
HOPE – When other cures are not an option. The foundation is evaluating all possibilities to support clinical developments of efficient RLT & individual cases to reduce treatment overall costs in low-income countries.
Moreover, Oncidium endeavors beyond boarders through a worldwide network of Ambassadors in each country for awareness & education campaigns, local collaborations & shared knowledge.
Together, let's commit to enhance Access, Education & Hope!

OncoBeta GmbH

Schleissheimer Str. 91
85748 Garching n. Munich, Germany

info@oncobeta.com

www.oncobeta.com

OncoBeta® GmbH is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 OncoBeta® GmbH also produces tungsten (wolfram)-188/rhenium-188 Generators for commercial use.
The Rhenium-SCT® is a painless, single session, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat. It utilizes the radioisotope Re188 in an epidermal application to treat NMSCs (non-melanoma skin cancers). The Rhenium-SCT is a precise, personalised therapy that is only applied to the area needed to treat without affecting the healthy tissue. The specially designed device ensures the Rhenium-SCT compound never comes in direct contact with the skin and the application is safe and simple for the applying physician. Most cases of NMSCs can be treated in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

ONCODESIGN

18-20 Rue Jean Mazen
21000 Dijon, France

contact@oncodesign.com

https://www.oncodesign.com/

Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 1000 clients along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, bioanalysis & pharmaco-imaging, Oncodesign orients, drives & executes the development of drug candidates from hit findings up to early clinical phases.
Oncodesign has specialties in pharmaco-imaging and molecular radiotherapies (MRT).
Our expertise & capacities enable to provide imaging solutions to monitor your drug in order to better predict its efficacy. Our multimodal platforms are an open door for non-invasive techniques to understand the pharmacology of your compound.
Finally, we have a unique offering dedicated to pre-clinical evaluation of MRT: a unique combination of our skills in radiochemistry and in vivo pharmaco-imaging in order to assess radiotherapy efficacy. Oncodesign proposes a large spectrum of expertise in nuclear medicine covering the entire Drug Discovery process of Radiopharmaceuticals, from the generation of radiolabeled compounds to the evaluation of preclinical drug candidates
Come discuss with our experts & find out about our capabilities! Oncodesign supports you in your drug discovery programs & provides molecular radiotherapy expertise for your preclinical projects.

Oncosil Medical Limited

Suite 503, Level 5, 15 Blue Street
NSW 2060 Sydney, Australia

info@oncosil.com

www.oncosil.com

OncoSil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilising selective and targeted intratumoral placement of Phosphorous 32 (32P) Microparticles.
OncoSil™ is a single-use brachytherapy device that has received breakthrough device designation in the European Union, United Kingdom and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.
OncoSil™ comprises of Phosphorous-32 (32P) Microparticles suspended in a specially formulated Diluent. The Microparticles are a permanent implant which contain Phosphorous-32 (32P), a pure beta-emitter radioisotope with a physical half-life of 14.27 days. In therapeutic use, 98% of the radiation is delivered within 81 days, which gives an absorbed does equivalent to 100 Gy.

ONCOVISION

C/ Jerónimo de Monsoriu, 92
46022 Valencia, Spain

info@oncovision.com

www.oncovision.com

Oncovision is a Spanish-based molecular vision company, founded in 2002, committed to making a difference in improving major health challenges through continued, clinically relevant innovation. Its revolutionary, IP-protected medical imaging devices have been successfully used in 100.000+ patients by nuclear physicians, radiologists, surgeons and oncologists in 35+ countries.
Oncovision is combining breakthrough interventional gamma camera systems and organ specific dedicated PET scanners:
- CareMiBrain: dedicated Brain PET in seating / reclined position, with vastly superior specifications in sensitivity, resolution and contrast vs whole body PET with ½ to 1/3 rd tracer dose, CMB is adding patient comfort, ergonomics, and dynamic stimulus capabilities.
- Mammi®: Dedicated breast PET (in prone position) generating functional 3D breast images and lesion quantification with an unprecedented clinical resolution (up to 1.6 mm), adding major clinical value in personalized breast cancer diagnosis and therapy follow up.
- Sentinella®: World's best intra-operative integrated gamma camera system (+CAD software) for radio-guided surgery with real-time imaging to detect sentinel and deep lymph nodes and small tumors, evaluating personalized tumor
extension to lymph nodes, both in and outside of "expected" nodal chains.

Optimized Radiochemical Applications

Rue de la Salette, 15
5600 Neuville, Belgium

www.oraneptis.com

We connect you with radiosynthesizers.
Radiochemistry is widely used in medicine as a diagnostic tool and has extraordinary benefits for humankind, especially in the treatment of cancer. Whether you are looking to double your output or have reliable and unmatchable synthesizers in your radiochemistry lab, look no further than NEPTIS !
For more than 15 years, ORA has been at the forefront of the radiopharmaceutical industry providing multi-purpose radiochemistry synthesizers to academic and commercial institutions. Our mission is to provide innovative solutions for your lab's research and development, and production needs. The proven expertise of ORA coupled with the NEPTIS platform's extensive regulatory documentation support make it possible for your lab to maximize the production of PET tracers and advance the development of new pharmaceuticals to market. Founded by Dr. Vincent Tadino, in 2006, ORA is headquartered in Neuville, Belgium. ORA is a certified ISO13485 manufacturer and a leading supplier of innovative radiochemistry synthesizers.
We recommend NEPTIS in your hotcells.

PARS ISOTOPE

No. 88, West 23rd St., Azadegan Blvd.
South Sheikh Bahaie Ave.,
1439955416 Tehran, Iran

n.alai@parsisotope.com

www.parsisotope.com

Pars Isotope Co. is the only producer and supplier of radiopharmaceuticals and radiopharmaceutical kits in Iran and the leading one in the Middle East.
Pars Isotope produces more than 50 different types of diagnostic and therapeutic products in the field of nuclear medicine. Based on the knowledge and experience of our specialists, we have succeeded in producing unique radiopharmaceuticals and introducing various solutions to international markets. Variety, extent and quality are the main features of our products. Among our valuable products, we can mention Tc-99m and Ge-68/Ga-68 generators, which are known under the brand names of PARS-TEC II and PARS-GalluGen, respectively. Also, the variety of our radiopharmaceutical kits reaches more than 20 different types. In order to improve the quality and quantity of medical products based on cGMP regulations, Pars Isotope participates in a project to implement new modern RRP, CKP and PET facilities in Iran. In addition, we focus on the following activities according to our profession and abilities:
• Production of more than 20 types of Tc-99m radiopharmaceutical kits • Production of 4 types of radionuclide generators to be used in PET & SPECT imaging • Production of new ready to use PET radiopharmaceuticals • Production of more than 22 ready to use theranostic, bone pain palliation and radio-synovectomy radiopharmaceuticals • Development and optimization of separation methods for different types of radioisotopes used in the production of radiopharmaceuticals. • Development and optimization of advanced methodologies in the production of new radiopharmaceuticals • Production and development of radiation protection and measurement equipment used in various industries, including the Nuclear Medicine production sites.

The pavillion (PI Medical Diagnostic Equipment B.V.)

Forellenweg 7
4941 VN Raamdonksveer, The Netherlands

john@pi-medical.nl

www.pi-medical.nl

The Pavillion offers a wide range of instruments and accessories for the nuclear medicine market. The product range includes FDG dispensing systems, dose calibrators, contamination and radiation monitors, PET and SPECT phantoms, calibration sources and other QA devices, radiation shielding materials, Surgical equipment, Breast cancer localization products, patient positioning devices, etc.
The Pavillion is stands for high quality products and a high quality service.
With our own Service department, all highly trained and educated, we can provide the best service, support and advice to our end users.
Together with our partners, we can give you the best products and service for your needs.
The Pavillion– a Medical Imaging Specialist!

P.B.L. SRL

Via Volta 8
43046 Rubbiano (Parma), Italy

info@pblsrl.it

www.pbl.it

PBL was stablished as an industry-leading custom solutions provider to global pharmaceutical corporations. The entrepreneurial mindset of Franco Serventi and Marco Serventi - father and son - started in 1979 when the first automation solutions for the beverage, chemical and pharmaceutical sectors were designed, built and installed. Four decades of extensive engineering knowledge gradually obtained from thousands of successful projects are now available to our clients. The Serventi's history and passion for excellence combined with the support of highly skilled engineers, makes PBL an unique partner for innovative and efficient solutions for leading global manufactures corporations.

PIUR IMAGING GmbH

Hamburgerstraße 11/Top7
1050 Vienna, Austria

info@piurimaging.com

www.piurimaging.com

PIUR IMAGING, an Austrian medtech company, which is active in the field of diagnostic ultrasound imaging and is specialized in acquisition and visualization of 3D ultrasound images. PIUR IMAGINGs vision is it to provide access to affordable high-quality healthcare through AI-driven tomographic ultrasound solutions – everywhere!
PIUR´s tomographic ultrasound solution PIUR tUS Infinity turns any standard ultrasound system into a tomographic 3D imaging device, enabling true AI in ultrasound. With any conventional 2D ultrasound transducer, high-resolution tomographic images can be generated. While standard ultrasound requires on-the-spot assessment of the images, PIUR´s 3D ultrasound volumes of entire structures or organs allow retrospective diagnosis at any time. In combination with smart analysis tools, explicitly designed for the evaluation of thyroid and nodules, thyroid analysis becomes less operator-dependent and diagnostic workflows can be optimized.
PIUR tUS Infinity is the only vendor-independent tomographic 3D ultrasound solution, designed to improve thyroid diagnostics.

PMB-Alcen

Route des Michels CD56
13790 Peynier, France

imigine@pmb-alcen.com

www.imigine.com

Deeply involved in the fight against cancer, PMB is a French company specializing in medical systems, from cancer diagnosis to treatment.
We have developed a versatile and automated radiopharmaceutical production system, combining a cyclotron with a robotized radiochemistry room. A 12 MeV superconducting cyclotron produces 18F, 11C and 68Ga radioisotopes, which are used to label a targeting agent in a robotized radiochemistry room. Our microfluidic synthesizer iMiDEV designed with R&D and preclinical phases in mind. It also is recommended for onsite production of small quantities of radiotracers. With low reagent consumption and low initial investment, iMiDEV can be easily installed in pre-existing or new premises. As a versatile unit and tight environment, it allows the development of several radiopharmaceuticals for diagnostics and theranostics.
iMiGiNE provides an unprecedented solution to current limitations in the radiopharmaceutical production and distribution process, by relocating the production close to the patient and expanding the spectrum of possibilities in the field of molecular imaging. Furthermore, by allowing same-day diagnosis with multiple more specific radiopharmaceuticals, iMiGiNE improves patient care.

National Centre for Nuclear Research – Radioisotope Centre POLATOM

Andrzeja Soltana 7
05-400 Otwock, Poland

polatom@polatom.pl

www.polatom.pl

Radioisotope Centre POLATOM is a world-famous supplier of high-quality radiopharmaceuticals and diagnostic kits for nuclear medicine and an important manufacturer of radiochemical products for customers all over the world. Our products are exported to more than 70 countries. POLATOM is Poland's main producer of radiopharmaceuticals and other radioactive products.
POLATOM's current commercial package includes:

- A wide range of scintigraphy kits for 99mTc labelling for the examination of organs and cancer diagnosis,
- 131I- for the diagnosis and treatment as capsules, solution, MIBG, hippurate
- 89 Sr-chloride for the palliative treatment of bone metastases,
- Radionuclide 99Mo/99mTc generator,
- Precursors for the preparation of therapeutic radiopharmaceuticals,
- R&D substances, DOTATATE, PSMA
- Accessories and service for nuclear medicine units:

o calibration and servicing of dose calibrators,
o handling and transportation of radioactive materials.

- A wide range of special customized radioactive preparations.

POLATOM's activities in all areas meet European and international standards; with regard to its quality-assurance system, POLATOM holds the PN-EN/ISO 9001:2015-10.
Its standard of radiopharmaceutical production is confirmed by the GMP Certificate and its qualifications in the area of the ionising radiation metrology laboratory are confirmed by the Accreditation Certificate of the Calibration Laboratory in compliance with PN-EN/ISO 17025.

Positrigo AG

Technoparkstrasse 1
8005 Zurich, Switzerland

info@positrigo.com

www.positrigo.com

Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Switzerland, the medical device company was founded in 2018. NeuroLF® - the company's first device - is an ultra-compact brain PET scanner which has applications in assessment of causes of dementias, such as Alzheimer's disease and other brain related disorders.

Precirix

Burgemeester Etienne Demunterlaan 1
1090 Brussels, Belgium

info@precirix.com

www.precirix.com

Precirix is a private, clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments (sdAbs).
The company's platform allows the design and development of novel radiopharmaceuticals or targeted radioligand therapies, a technology in which radionuclides are attached to ligands that direct them to their specific target on the cancer cell. The radioactive payload is delivered in a highly selective manner to the tumor, limiting radiation to the rest of the body. Our technology platform facilitates development of sdAbs for multiple targets, in combination with different isotopes and applicability in various settings. Further, the technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. Precirix is currently advancing its lead product candidate, the HER2-targeted radioligand therapy CAM-H2, through a Phase I/II clinical trial, while further progressing and broadening its oncology pipeline. Precirix' next product candidate to enter the clinic is targeting fibroblast activation protein (FAP) and is expected to initiate clinical trials in 2023.

Qubiotech

Olmos 5, 2nd floor
15003 La Coruna, Spain

hello@qubiotech.com

www.qubiotech.com

At Qubiotech we develop AI-assisted software for automatic and advanced neuroimaging analysis: Neurocloud, a CE marked tool for quantifying biomarkers in neurodegenerative diseases, which quickly, accurately and effectively helps the doctor (radiologist, neurologist and nuclear medicine doctor with PET, SPECT and MRI imaging) in the diagnosis and follow-up of the patient providing a complete report of the results in a few minutes.
Neurocloud stands out for its experience of use and its clinically validated results (CE marked and FDA in progress) that help in the early diagnosis and monitoring of neurological diseases such as Multiple Sclerosis, Epilepsy, Parkinson's, Alzheimer's, etc. It has both cloud and on-premise versions with complete PACS integration no matter your structure. Neurocloud aims for total integration within your existing workflow.
Neurocloud quantification allows you to go from subjective evaluations, which depend on the observer, to quantitative, reproducible evaluations, and therefore members of the same team can reach the same results with confidence while saving time in doing so.
Qubiotech was born in the Neuroimaging Group of the University Hospital of Santiago de Compostela with the aim of bringing innovation in molecular image analysis to real clinical practice and also at a very low cost compared to the alternatives we had until now.
Welcome to Augmented Neuroimaging. Welcome to Qubiotech.

Radiaprot, s.l.

Miguel Yuste 16
28037 Madrid, Spain

info@radiaprot.com

www.radiaprot.com

Radiaprot is a long stablished company that has a wide portfolio of products for the spanish Nuclear Medicine market, ranging from protection to specialized equipment, always offering it's customers a wide arrange of the most innovative products in the market. Anything you need for your Nuclear Medicine deparment, Radiaprot can provide, including the knowledge required to make things easy and smooth.

Radioprotech

12 Chemin des Gorges
69570 Dardilly, France

contact@radioprotech.com

www.radioprotech.com

Radiation protection equipment for nuclear medicine department.
Designed and made in France.
Our products range cover all radioprotection needs from the arrival of the radiopharmaceutical until its disposal.

RadQual Global Sources

4137 Commerce Circle
ID 83401 Idaho Falls, United States

sales@radqual.com
info@technologyimaging.com

www.radqual.com

RadQual, LLC is the premier developer of innovative quality control products for the nuclear medicine and PET imaging communities.
We are the only remaining American-owned provider of SPECT imaging radioactive sealed sources for routine quality control. Our quality products are manufactured in Idaho Falls, ID, and distributed worldwide through a select group of dealers and nuclear pharmacies.
RadQual's goals are straightforward: Quality Products, Fair Prices, Superior Service, and Fidelity to our Clients. We at RadQual are proud of who we are and what we do.

RescueDose Ltd.

4 HaTnufa st.
2066717 Yokneam, Israel

adibm@light-inst.com

www.rescuedose.co

RescueDose Ltd. is a medical device company developing compact-sized robotic devices for automated dispensing of liquid medication. Designed with patient and medical staff safety in mind, RescueDose's mission is to automate the process of medication dispensing in order to minimize human error, dispensing risks and ensure accuracy – by making the correct dosage easily accessible. RescueDose's automated compounding robots are a game changer in the way medication dispensing is handled and are about to revolutionize the Dispensing Process in pharmacies and hospitals around the world.

Radiation Imaging Technologies, Lda (RI-TE)

UA Incubator, PCI Creative Science Park
Edifício central, Via do conhecimento
3830-352 Ílhavo, Portugal

info@ri-te.pt

www.ri-te.pt

PET is a wonderful molecular imaging technology, instrumental to tackle cancer and other diseases. We believe it should be much more available and easier to use. We're a spin-out from the University of Aveiro developing uniquely compact and affordable high-resolution PET systems. Our innovative scanning method allows high performance imaging while reducing complexity, weight and costs by more than 5 times, enabling a more flexible and broader use of this powerful technology. Our mission is to widen access to PET imaging, reducing gaps and improving biomedical research and diagnostics worldwide, particularly of cancer and neurodegenerative diseases.
Discover easyPET.3D, the most compact and affordable high-resolution PET scanner, a very versatile entry-level system for preclinical research, and a unique instrument for dedicated training of medical imaging technologists.
Find out about the new iPET scanners, our latest developments to scale up easyPET technology for more advanced preclinical imaging applications and into the clinical world.

Rotem GmbH

Franz-Flemming-Str. 39A
D-04179 Leipzig, Germany

info@rotem-eu.de

www.rotem-medical.com
www.rotem-radiation.co.il

Rotem, a longtime global leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production.
Our product range focuses on Oxygen-18 enriched water, plastic cassettes, precursors and complete reagent kits for various synthesis modules. All products are manufactured in compliance with cGMP requirements according to EU & PIC/S and are produced in our US FDA-inspected facility. Rotem's cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM.
Production is supported by Rotem's in-house certified analytical laboratory which has a wide array of equipment and QC method development capabilities. Our highly skilled staff provides users with comprehensive technical and regulatory support as well as excellent customer service.
Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, which is the result of many years of close collaboration with radiopharmaceutical companies worldwide.
Rotem GmbH in Leipzig serves customers in Europe, with local representatives in the U.K. and Ireland.

ROTOP Pharmaka GmbH

Bautzner Landstr. 400
01328 Dresden, Germany

info@rotop-pharmaka.de

https://www.rotop-pharmaka.de/

ROTOP Pharmaka is a leading pharmaceutical company with over 20 years of experience that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries. Apart from the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals and the ready-to-use production of active radiopharmaceuticals ROTOP offers broad range of CDMO services.

RQS Alexander Ruffani

Kantstr. 15
01809 Heidenau, Germany

m.michaelis@rqs-ar.com

www.rqs-ar.com

RQS Alexander Ruffani (Ruffani Quality Solutions) was founded in 2017. With a growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application with many years of experience in radiochemistry, radio pharmacy and analytical instrumentation.
In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production facilities as well as their construction, for this purpose they have been involved in several projects especially on the East Coast.
The team of now 10 employees worldwide is ready to support you with all your requests and is looking forward to get in contact with you.

SCANNIX

Rue du Mont d'Orcq 3
B - 7503 Froyennes, Belgium

info@scannix.com

https://www.scannix.com/

Scannix is specialized in the development and sales of nuclear spectroscopy equipment and radioprotection systems. Scannix offers a wide range of measurement devices in order to maintain safety of staff, assess the health of nuclear facilities and safeguard the public and the environment.

Scintomics Molecular, Applied Theranostics Technologies GmbH

Lindach 4
82256 Fürstenfeldbruck, Germany

info@sci-att.com

www.sci-att.com

Scintomics Molecular, Applied Theranostics Technologies (SCI-att) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T and next generation PSMA inhibitors for radioligand therapy such as siPSMA-14.
The well-known GRP Module Series became part of SCI-att in 2020 when SCI-att took over the Module business from its parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.
To continue our strong track record of successful Synthesis Modules and expand our portfolio of tracers we are excited to launch our smartGRP. The smartGRP is a cost-effective alternative for doing standard syntheses, such as [68Ga]- and [177Lu]-labelling-peptides. In addition, it can also be used for the syntheses that the siGRP offers.
The new model is designed with the intent of offering the usual GRP feeling while also allowing for several upgrade options.
We look forward to welcoming you at our booth!

SHINE Technologies

3400 Innovation Court
53546 Janesville, Wisconsin , United States

communications@shinefusion.com

www.shinefusion.com

SHINE is a next-generation fusion company, focused on deploying state-of-the-art fusion technology to help solve global problems and create a scalable path toward practical fusion energy. SHINE deploys its safe, cost-effective and environmentally-friendly technology in a step-wise approach, beginning with our systems used for advanced industrial imaging in non-destructive testing of components used in aerospace, defense, transportation, energy and other sectors. SHINE's proprietary medical isotope production creates Molybdenum 99 and non-carrier-added Lutetium 177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. For more information, follow SHINE on Facebook, LinkedIn and Twitter.

Siemens Healthcare GmbH

Henkestraße 127
91052 Erlangen, Germany

contact@siemens-healthineers.com

http://www.siemens-healthineers.com

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.
Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world's most threatening diseases, improving the quality of outcomes, and enabling access to care.
We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what's possible in healthcare to help improve people's lives around the world.

Sirtex Medical Europe GmbH

Joseph-Schumpeter-Allee 33
53227 Bonn, Germany

Karen.nuessmeier@sirtex.com

www.sirtex.com

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer.
Our current lead product is a targeted radiation therapy called SIR-Spheres® Y-90 resin microspheres.
SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.
SIRT is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumours.
For further information please visit www.sirtex.com.
Learn more about Sirtex in our interactive virtual booth https://www.sirtexvirtualbooth-emea.com
*SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

Southern Scientific Limited

Scientific House
The Henfield Business Park, Shoreham Road
BN5 9SL Henfield, United Kingdom

info@southernscientific.co.uk

www.southernscientific.co.uk

Southern Scientific manufacture a range of contamination monitors and probes for medical applications, including the Radhound, Handhound and Care Wise C-Trak Apollo Gamma Probe System.
The Care Wise C-Trak Apollo Gamma Probe System is a wireless/wired system which provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer.
The Radhound monitor is available with a wide range of probes suitable for detecting Alpha, Gamma and Beta isotopes.
The Handhound is a voice-activated hand monitor. All measurements are logged against a user and are easily downloaded to a USB.
Southern Scientific is also the UK distributor for the Capintec range of products and the MiE range of general purpose gamma cameras.
We are looking for distributors in certain countries. If you are interested, please visit stand 42 and speak to one of our team.

Spectrum Dynamics Medical

Rue de Lausanne 31
1110 Morges, Switzerland

info@spectrum-dynamics.com

www.spectrum-dynamics.com

Spectrum Dynamics is spearheading the transformation of SPECT imaging scanners from analog to digital detection technology, enabling hospitals and clinicians to provide superior healthcare services with improved image quali-ty, efficiency, and advanced clinical applications.
Spectrum launched the world's first digital cardiac SPECT system: the D-SPECT® in 2007. The D-SPECT employs Broadview Technology: swiveling digital detectors made of Cadmium Zinc Telluride (CZT), along with ingen-ious hardware design and unique 3D algorithms for state-of-the-art imag-ing. It features TruCorr: 1st Artificial Intelligence (IA) based software to gen-erate attenuation corrected myocardial perfusion images using emission-only data.
Spectrum's SPECT/CT innovation is the VERITON-CT®: featuring a 360° CZT detector design with a full diagnostic, high-resolution 64-slice CT; the indus-try's most advanced hybrid nuclear camera. VERITON enables routine 3D total body NM/CT imaging. Its post-processing tools allow for advanced quantitative analysis of 3D data. Plus, unique TruFlow capability: 4D SPECT/CT for dynamic flow applications.

Stockholm Material Hub

Svante Arrheniusvägen 16C
10691 Stockholm, Sweden

stockholmmaterialhub@su.se

https://stockholmmaterial.com/

Stockholm material Hub is a nexus for connecting the research and infrastructure for material science with the vibrant start-ups and well-established SMEs in the greater area of Stockholm. The Hub has two main goals. The first is to leverage the strong science base provided by Stockholm University, KTH and KI, to boost economic growth. The second is to provide an arena for sharing infrastructure and providing the research collaboration to establish a knowledge center for Energy, health and sustainability ventures. Stockholm material Hub is funded by The EU regional development fund and Stockholm University

Sumitomo Heavy Industries, Ltd.

ThinkPark Tower
1-1, Osaki 2-chome, Shinagawa-ku
141-6025 Tokyo, Japan

Marketing-medical@shi-g.co

www.shi.co.jp/industrial/en/product/medical/index.html

Since its establishment, Sumitomo Heavy Industries, Ltd. has contributed to the society by providing advanced technologies related to industrial machinery and infrastructure equipment to customers in the world. In particular, we have accumulated over 50 years of experience in the manufacture of accelerators, which have been applied to scientific, industrial and medical fields and have earned a high reputation.
In the nuclear medicine, Sumitomo PET radiotracer production system (incl. cyclotron, target, synthesizer, etc.) were delivered to more than 220 sites in the world and have been contributed for the development of clinical use and new technologies (such as Theranostics).
In EANM 2022 exhibition, a concept model of "Smart & Innovative Laboratory for Clinical & Theranostics" will be highlighted. For further expansion of PET diagnosis all over the world, we have released a compact and powerful cyclotron "CYPRIS® HM-12SPC" and a next generation radiopharma platform "SmartPharm™". Also, we have released a metal target with liquid transfer technoloty, which is capable to produce 68Ga, 64Cu and 89Zr in the same target.
Additionally, CYPRIS® HM-18HC which is ultra-high beam current cyclotron for large amount of 18F production and CYPRIS® MP-30 which accelerates not only proton and deuteron, but also alpha particle for 211At will be exhibited. 211At has been researched in the world and attracting attention as promising therapeutic nuclides.
We are welcome to you at our booth!

SurgicEye GmbH

Friedenstraße 18A
81671 München, Germany

twendler@surgiceye.com

www.surgiceye.com

Crystal Photonics and SurgicEye are engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and for intraoperative and transcutane sentinel lymph node localization (SLNE) since 20 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera "CrystalCam", the surgical Gamma Probe System "Crystal Probe - automatic" with various kinds of cable and wireless probes, the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), the very new CrystalAnalyzer for HPLC-investigation in coincidence for any PET-drugs and the 3D-free-hand-spect imaging system declipse®SPECT in various versions.
Also our CE-confirmed software DosePlan for accounting the dose rate distribution while a SIRT-treatment is now ready for using.
Additionally, we present the first time our very new mini-Laparoscopic gamma probe for robotic-assisted minimal-invasive surgeries, (Drop-in-Probe) special designed for the Da Vinci robotic operation system. This probe was developed in the course of the new PSMA-technology for Prostate Cancer and has excellent medical-technical properties.
For more information, please visit our websites:
www.crystal-photonics.com
www.surgiceye.com

Synthra GmbH

Albert-Einstein-Ring 21
22761 Hamburg, Germany

info@synthra.com

www.synthra.com

Synthra is a worldwide leading and specialized manufacturer of branded radiosynthesizers and concentrates over 40 years of experiences in the field of radiopharmaceutical production, quality control and lab automation. We undertake automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of [^{11}C]- and [^{18}F]-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.
Our radiosynthesizers combine high performance and efficiency with high flexibility. Besides the attractive design, our software and synthesizer are highly user-friendly and meet the latest GMP regulations. They barely require maintenance. Commonly our modules offer an easy possibility to create own sequences for the synthesis of new radiopharmaceuticals. It also offers an automated self-cleaning system which is a unique, eco-friendly and time-efficient feature. Furthermore, we offer preventive maintenance contracts as well as full service contracts for each module on demand.
Meet us at our booth no 97.

Telix Pharmaceuticals

Telix Innovations SA, Rue de Hermée, 255
4040 Herstal, Belgium

congress@telixpharma.com

https://telixpharma.com

Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic ('theranostic') assets using Molecularly Targeted Radiation (MTR). Nuclear medicine is finally coming of age, with commercial critical mass building and commitment to late-stage product development.
Our goal is to harness this momentum for the benefit of patients, with MTR potentially offering better-informed treatment decisions and truly personalised therapy.
Telix's product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer.

TEMA SINERGIE

Via Malpighi, 120
48018 Faenza (RA), Italy

marketing@temasinergie.com

www.temasinergie.com

OUR KNOW-HOW AT THE SERVICE OF HEALTH, WELL-BEING AND SAFETY
Since it was founded in 1985, Tema Sinergie has been working on the Design, Production and Service of shielded equipment and measuring instruments for a safe handling of
radioactive materials.
Our main manufacturing activities are: PET, Nuclear Medicine, Health Physics,
Radiotherapy and Industrial Radiography equipment applications.
Sinergie to us means a strict and cooperating interaction between internal production
and distributed brands, to offer our customers a complete service according to their
needs, through a highly qualified staff.
Tema Sinergie counts more than 1,500 customers all over the world among which are
included Hospitals, Universities, Research Centres and Factories.
Come visit us at booth 24 and see what's new!

Terumo

Researchpark Haasrode 152
Interleuvenlaan 40
3001 Leuven, Belgium

sandrine.hocquel@terumo-europe.com

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Terumo Interventional Systems is working in partnership with Interventional Radiologists and Nuclear Medics within Interventional Oncology to ensure they have access to high quality tools for their patients. This partnership is based on Terumo's comprehensive range of access to therapeutic technology and services to support healthcare professionals with their patient needs.
QuiremSpheres™ Holmium-166 microspheres, QuiremScout™ Holmium-166 microspheres and Q-Suite™ imaging software make up The Holmium Platform: three integrated products which aims to individualize SIRT at its full potential.
QuiremSpheres™ is the first Holmium-166 microsphere on the market which brings a wide range of benefits from higher dose rate, to optimized imaging capabilities.
QuiremSpheres™ are also the first SIRT microsphere to be designed with scout dose technology, QuiremScout™, which for the first time utilizes the same particle for the work up and the therapy, which aims to optimize patient selection and advance treatment planning using our Q-Suite™ imaging software. This CE-marked and in-house designed treatment planning software is also used for dose verification following the SIRT treatment to ensure you have delivered the dose you planned and will help to drive treatment efficacy and improve the outcomes for liver cancer patients.

Theragnostics Limited

21 Gloucester Place
W1U8HR London, United Kingdom

hello@theragnostics.com

www.theragnostics.com

Theragnostics is a radiopharmaceutical company focused on developing new diagnostics and therapeutics for the oncology market. Our mission is to drive innovation in the fight against cancer by enhancing patients' lives with precision radiopharmaceuticals. Our lead drugs are radiolabeled PARP inhibitors where we can bring therapeutic radioactive decay directly to the DNA.
Our therapeutic is entering a Phase 1 trial later this year where we are combining our PARPi with iodine-123 to use the power of Auger electron emissions to treat cancers. Auger emissions have not been used as a therapeutic to date, however, with our drug binding directly to damaged DNA, we can use the power of Auger emission to kill cancer cells while also having a better safety profile compared to other leading radiopharmaceutical therapeutics that use Alpha or Beta emissions. Our diagnostics is entering a Phase II trial where we plan to demonstrate the advantage of PARP PET in the management of cancers where the needs are not met with current diagnostics.
Theragnostics received FDA approval in February 2022 for NephroScan™, Kit for the Preparation of Technetium Tc 99m Succimer Injection (99mTc-DMSA). In 2021, Theragnostics out licensed it's single step Ga-68 PSMA kit IP to AAA for their product LOCOMETZ®.
Please visit our booth if you are interested in learning more about Theragnostics, our pipeline or NephroScan™.

TAIYO NIPPON SANSO Corporation

Fuji Bldg., 5-30-9 Shiba, Minato-ku,
108-0014 Tokyo, Japan

Isotope.TNS@tn-sanso.co.jp

stableisotope.tn- sanso.co.jp/index.html

TAIYO NIPPON SANSO, established in 1910, is a leading global industrial gas manufacturer. We developed the most energy efficient Oxygen-18O separation process utilizing our cryogenic air separation and ultra- clean technology. Since 2004, we have been supplying Water-18O to the world PET market. To meet the growing demand we completed our three plants with capacity of 600kg/year in 2015 by using state of the art separation technology.
The largest capacity of 600kg/year with these three independent plants and GMP capability enable us to secure the stable supply of the highest and consistent quality of Water-18O, continuing to contribute to the advancement of the PET industry.

TRANSRAD

Avenue de l'Espérance 1
Site IRE – ZI Fleurus
6220 Fleurus, Belgium

info@transrad.be

http://www.transrad.be/en/

Transrad is a logistics company created in 1988, active worldwide and specialized in the field of radioactive and nuclear material. Our company works for the nuclear fuel industry among others, but our core business remains nuclear medicine. We are proud to support the whole supply chain of medical isotopes production (from research reactors to hospitals).
Next to transport, its core business, Transrad also has a storage capacity of radioactive material and its own fleet of transport packages (Transrad's own design). Transrad also offers to its customers full dismantling, decommissioning, and recycling solutions for machines such blood irradiators, linear accelerators or even cyclotrons.

Trasis

90 Rue Gilles Magnée
4430 Ans, Belgium

events_trasis@trasis.com

www.trasis.com

Trasis is specialized in the development and the manufacturing of innovative and high quality radiopharmaceutical equipment.
By carefully listening to professional users and markets trends, Trasis provides practical and reliably designed systems for automated synthesis, dispensing and packaging of radio-pharmaceuticals.
Trasis also offers custom development services for chemistry, reagents and disposables.
AllinOne is a multiple purpose radiochemistry unit featuring synthesizer, HPLC & reformulation in a single compact box, able to efficiently produce the most complex compounds such as nucleophilic FDopa, Thyrosine, FMT as well as FDG in multiple runs. AllinOne's versatility also helps researchers address the growing need for new tracers.
MiniAllinOne is designed for simpler processes and to cost efficiently produce compounds such as FDG, Ga68/Lu177- peptide conjugates or NaF and requires less space in the hot cell.
EasyOne is the latest of the AllinOne family. It has been simplified to the extreme for routine production of most radiometals labelled pharmaceuticals. Compatible with all Ga68 Generators, its ultra-compact design and ease of use are its major assets
Unidose, a high speed dose dispenser dedicated to hospitals, simplifies the procedures and reduces drastically the exposure to the technologists.

Técnicas Radiofísicas SL

C/Antonio Gil de Jasa 18, Pral.
50006 Zaragoza, Spain

info@trf.es

www.trf.es

Técnicas Radiofísicas SL (TRF) was founded in 1985 in Zaragoza, Spain, by a group of Physicists that understood and shared a common view in the radiation protection and Nuclear Medicine field. "To provide innovative and better solutions to the customer"
TRF provides with proven expertise:
- Medical Physics Consulting, (Nuclear Medicine, Radiotherapy & Radiology)
- Manufacturing of Radiation Protection Equipment
- Development of Software for Healthcare Applications

With over 250 projects around the world, TRF outstands in the following areas:
- Radiotherapy Linear Accelerators.
- Decay Tank System Projects for Radioactive Waste Management
- Cyclotron Projects for production of Radiopharmaceuticals & Radiotracers
- TRF is recognized by the IAEA as Radiation Consultants. TRF personnel are highly trained professionals in all aspects of Radiation Safety & Radiation Protection.
- Software Engineers responsible for in-house development and support of TRF software applications.

TRIMT GmbH

Carl-Eschebach-Straße 7
01454 Radeberg, Germany

info@trimt.de

www.trimt.de

TRIMT GmbH was founded near Dresden in early 2021 and is dedicated to the development and commercialization of novel radiopharmaceuticals in molecular theranostics for the benefit of cancer patients. The inventor-founded, science and data driven company, is managed and operated by experts with a strong scientific background, supported by an interdisciplinary board of advisors. Together with a consolidated network of academic and clinical collaborators and a top choice of industrial partners, TRIMT strives to exploit the full potential of a unique IP portfolio with a strategic, diversified selection of short- and long-term development goals.
The company's current focus is on a class of cellular biomarkers called integrins. There is compelling evidence that αvβ6-Integrin is found in many of the most dreadful cancers, such as pancreatic carcinoma, cervical-, head-and-neck and certain lung cancers, as well as in many kinds of fibrotic tissues, like in idiopathic pulmonary fibrosis, a slowly progressing, lethal lung disease. Ga-68-Trivehexin, the current lead compound, is a strong and selective ligand for this integrin subtype enabling early detection of the aforementioned conditions by PET imaging and helping surgeons and oncologists to optimize treatments of their patients. The therapeutic radiopharmaceutical companion exploiting the same mechanism is just on its way to the first patients.

TrisKem International

3 rue des Champs Géons
35170 Bruz, France

contact@triskem.fr

https://www.triskem-international.com

TrisKem International develops, manufactures and commercializes highly selective resins for the separation and quality control of radionuclides such as Lu-177, Tb-161, Ga-67/8, Zr-89, Cu-64/7, alpha emitters (e.g. Ac-225, Pb-212,…), Ge-68, Ti-44/5, Sc-43/4/7 and many other radionuclides for use in nuclear medicine – in diagnosis as well as in therapy.
Further to its range of resins TrisKem also provides selective chromatography paper (DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68,…).
TrisKem's resins are increasingly finding use in the production of radionuclides for radiopharmacy and are employed by leading radionuclide manufacturers worldwide.
Our R&D team is constantly working on the development of new resins and methods in order to help you with your separation needs. If you have a special separation need, need help with your method development, you are interested in participating in R&D projects or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us!

United Imaging Healthcare Poland Sp. Z o.o.

Żwirki I Wigury 14, 02-092 Warszawa
02-092 Warszawa, Poland

biuro@united-imaging.com

www.united-imaging.eu/pl

United Imaging Healthcare is dedicated to providing, developing and producing high-performance advanced medical imaging, radiotherapy equipment, and life science instruments, and offers intelligent digital solutions to customers worldwide. UIH was founded in 2011 and headquartered in Shanghai, with subsidiaries and R&D centers across China, the United States, United Arab Emirates, Australia, Poland, India and other parts of the world.
UIH has a world-class talent team including more than 140 scientists with global experience and more than 500 employees with rich R&D and management experience in the medical industry. And 39% of 5,400 employees are R&D personnel.
UIH has launched over 80 ground-breaking products, including Total-Body PET/CT, HD TOF PET/MR, 75cm Ultra-Wide Bore 3.0T MR, 640-Slice CT Scanner, and Fully Integrated CT-linac. All core technologies are developed in house and have been globally or nationally recognized for world-leading performance. Our products have been installed in more than 9,100 medical and research institutes and nearly 900 top hospitals in 53 countries, including the U.S. and Japan. UIH topped China's new market share lists in the PET/CT, PET/MR, MR, CT and Mobile DR sector in 2020.
With our mission "To Bring Equal Healthcare for All," and our vision "Leading Healthcare Innovation," we are committed to creating more value for our customers and constantly improving the global accessibility of high-end medical equipment and services through in-depth cooperation with hospitals, universities, research institutions, and industry partners.

United States Department of Energy Isotope Program

P.O. Box 2008, MS 6158
37830-6158 Oak Ridge, TN, United States

contact@isotopes.gov

Isotopes.gov

The DOE Isotope Program supports the production and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the nation and are essential for energy, medical, and national security applications and for basic research; a goal of the program is to make critical isotopes more readily available to meet domestic U.S. needs.
The National Isotope Development Center (NIDC) is funded by the U.S. Department of Energy Isotope Program (DOE IP). It serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories. These facilities produce stable and radioactive isotopes in short supply using reactors, accelerators, and other methods.

Von Gahlen Nederland B.V.

Kelvinstraat 9
6902 PW Zevenaar, The Netherlands

info@vongahlen.com

www.vongahlen.com

Come visit us in stand no. 18 to discuss your shielding needs. Von Gahlen designs and manufactures lead shielding products for the radiopharmacy and nuclear medicine industry. Our products range from transportation solutions to complete manufacturing lines, including automated dispensing systems. Since its founding over 4 decades ago, Von Gahlen has become a world leader in these industries. With our strong customer focus, we have managed to provide high quality products that meet or exceed industry standards and safety requirements. Von Gahlen hot cell installations may be found all over the world, including many of the largest turnkey installations in the field.
Due to its extensive experience, Von Gahlen is involved from the earliest planning and design stages up to and including the completed installation and qualification, working closely with the customer at all stages to ensure that every requirement is met and to produce the best equipment available for the application.
Our team of professionals includes highly qualified technical designers as well as experienced manufacturing and installation personnel. Our modern factory is equipped with the latest computerized equipment. Von Gahlen is an ISO 9001 Certified Company. Our quality assurance program has been audited and approved by numerous customers.
Von Gahlen is proud to be at the forefront of advancing technology.

VORTAL SPRL

Rue de la Belle Haie, 44
B - 1490 Court-St-Etienne, Belgium

marc.daman@vortal.pro

www.vortal.pro

Vortal is the leader in reusable TYPE A certified transport system.
We provide transport system for liquid radio pharmaceuticals and shielding material for radiopharma facilities.
We work with organizations such as Advanced Acceleration Applications, Curium, IBA, IAEA , Siemens , Europet...
Certification: TYPE A approved packaging, NF S99-700 for thermosensitive products.

Wälischmiller Engineering GmbH

Schießstattweg 16
88677 Markdorf, Germany

info@hwm.com

www.hwm.com

For over seventy years Wälischmiller has produced world-class innovative equipment for the nuclear industry. The company is certified according ISO 9001:2015, ISO 14001:2015, DIN ISO 45001:2018, KTA 1401 and ATEX. Wälischmiller has a hard earned international reputation for performance, excellence in engineering and exceptional robotic hardware. In the most difficult and challenging nuclear environments, Wälischmiller has demonstrated the ability to bring solutions and success to many of the most difficult high-radiation remediation challenges.
Wälischmiller Engineering is a full range supplier and offers products reaching from simple tools to advanced solutions, such as universal grippers, mechanical telemanipulators for a wide range of applications (models A100 and A200), remote-controlled power manipulators from the A1000 series for handling heavy loads and the robot system TELBOT® with unique capabilities which includes unlimited rotation in all axes, no wiring inside or outside the TELBOT® arm, and unlimited fast and precise movement.
By choosing products of Wälischmiller Engineering, you choose products from a single source: engineering including product design & development, high manufacturing depth including single part assembly, all required specialised staff available within the company, installation at sites and worldwide service & maintenance.

Waters Corporation

34 Maple Street
MA 01757 Milford, United States

https://www.waters.com/clinical

Waters Clinical Diagnostic Solutions - Analytical Technology for Better Care As a clinical diagnostic laboratory, quickly providing the broadest range of tests with the best accuracy and selectivity is key, but many challenges can stand in the way. Current laboratory techniques can suffer from cross-reactivity that may skew results, availability of reagent kits for new tests can be slow, and sample preparation is often too manual. Waters unlocks the potential of science by helping clinical diagnostic labs provide better patient care. Waters helps our customers enhance workflow efficiencies, improve specificity of results, and implement new diagnostic tests with LC-MS/MS solutions, so you can help provide accurate diagnosis and treatment without compromising compliance, flexibility, and performance.

WORLD INFINITY SERVICES

Rue de Hermée 255
B - 4040 Herstal, Belgium

h.vandemaele@be-wis.com

www.be-wis.com

World Infinity Services is dedicated to the worldwide transport and logistics of radioactive materials and radiopharmaceutical products.
We are focused on providing a safe and secure, compliant and high-quality customer experience.
We perform feasibility studies in terms of regulation, transport- and packaging permits.
With our dedicated partners we provide worldwide door-to-door logistics, airfreight and charter services.
Transport authorizations for radioactive products and radiopharmaceuticals in Belgium, Luxemburg, Netherlands, Germany and France.
Storage facility and import license for radioactive products in Belgium.
ISO9001 certified with GDP-compliance.

Xeos

Ottergemsesteenweg-Zuid 808 bus 358
9000 Gent, Belgium

info@xeos.care

www.xeos.care

Is it important for you as a nuclear medicine professional to improve patients' treatment outcomes, fastened recovery and avoid re-surgery?
XEOS wants to tackle the limitations of today's available imaging techniques applied in surgical oncology, by using the transformative power of molecular imaging intra-operatively.
AURA 10 is the first-ever PET-CT specimen imager for the operating room, offering surgeons and imaging specialists the sensitivity of PET imaging at submillimeter spatial resolution. Thanks to the AURA 10 mobile scanner, a specimen does no longer need to be transported to the radiology or pathology department during surgery. High-quality specimen images can now be obtained in the OR within 10 minutes after excision.
Founded in 2019 in Ghent, Belgium, XEOS is an expert in specimen imaging, and focuses on improving outcomes in surgical oncology through innovations in intraoperative imaging. The XEOS team is passionate about expanding the use of molecular imaging to optimize clinical workflows and improve patient outcomes.



CORPORATE MEMBERS

We gratefully acknowledge the support of the following companies (in alphabetical order):

- ABX-CRO advanced pharmaceutical services Forschungsgesellschaft
- Advanced Accelerator Applications International
- Alliance Medical GmbH / Life Healthcare Europe
- Blue Earth Diagnostics Ltd.
- Boston Scientific International
- Bruker BioSpin GmbH
- CIS bio international (IBA) - Curium
- Comecer Group
- Debiopharma International SA
- Eckert & Ziegler Isotope Products GmbH
- Eli Lilly
- GE Healthcare Ltd.
- Hermes Medical Solutions
- IBA SA
- Isotopia Molecular Imaging
- ITM Isotopen Technologien München AG
- JSC Isotope
- Lemer Pax
- Medi-Radiopharma Ltd.
- Mediso Medical Imaging Systems

CORPORATE MEMBERS

- MILabs
- MIM Software
- Mirion Technologies (Capintec) Inc
- Monrol Nuclear Products Co.
- National Centre for Nuclear Research Radioisotope Centre POLATOM
- NRG Advancing Nuclear Medicine
- PARS Isotope
- Pharmazac_SA
- POINT Biopharma Inc.
- ROTOP Pharmaka GmbH
- SHINE Technologies LLC
- Siemens Healthineers
- Sirtex Medical Europe GmbH
- Spectrum Dynamics Medical
- Telix Pharmaceuticals
- Tema Sinergie S.p.A.
- Terumo Europe N.V.
- von Gahlen Nederland BV



USEFUL CONTACTS

SCIENTIFIC PROGRAMME

EANM Executive Office

Ms. Susanne Koebe

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: **s.koebe@eanm.org**
Web: **eanm22.eanm.org**

INDUSTRY EXHIBITION

EANM Executive Office

Mr. Alexander Berger
Mr. Andreas Felser (Congress Manager)

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: **a.berger@eanm.org**
Web: **eanm22.eanm.org**

REGISTRATION

EANM Executive Office

Ms. Petra Neubauer

Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: **registration@eanm.org**
Web: **eanm22.eanm.org**

IMPRINT

PUBLISHER

European Association of Nuclear Medicine
Schmalzhofgasse 26,
1060 Vienna, Austria
Phone: +43 1 890 44 27
Fax: +43 1 890 44 27-9
Email: **office@eanm.org**
Web: **www.eanm.org**

EDITORS

Stefano Fanti,
EANM Congress Chair 2020-2022
Andreas Felser, Susanne Koebe,
EANM Executive Office

LAYOUT & DESIGN

Olga Dogadina, Neta Arubas
EANM Executive Office

CONTENT

No responsibility is taken for the correctness of this information. Information as per time of publication, October 2022.


Boston Scientific
Advancing science for life™

THERASPHERE™ Y-90 Glass Microspheres

TARGET STUDY

A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.

RESULTS




70.8% ORR*
for the target lesion (mRECIST)

61.7% ORR**
for all lesions (mRECIST)

20.3 months
median Overall Survival

*95% CI = 64.3 - 76.6%
**95% CI = 55.0 - 68.0%

TUMOR ABSORBED DOSE WAS PREDICTIVE OF RESPONSE[1,2]



Responders had a

17% higher

mean tumor absorbed dose (225.5 Gy*) compared with non-responders (188.3 Gy**)

*95% CI = 201.0 - 253.0 Gy
**95% CI = 164.6 - 215.3 Gy; p=0.046

1. Total perfused tumor absorbed dose and best response (61.7%) according to mRECIST
2. Non-responders (defined as stable disease, progressive disease, or non-evaluable) are not represented in the graph

JOIN BOSTON SCIENTIFIC SYMPOSIUM

16th OCTOBER - 13:15 CET, Hall 117

Y-90 Glass Microspheres: Personalised Dosimetry, Guidelines and Clinical Data

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

PI-1389903-AA © 2022 Boston Scientific Corporation or its affiliates. All rights reserved.